
<html lang="en"     class="pb-page"  data-request-id="6163524f-7e0b-4361-bbff-fe6f110fb619"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2021.64.issue-9;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.1c00173;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series" /></meta><meta name="dc.Creator" content="Michael J.  Palmer" /></meta><meta name="dc.Creator" content="Xiaoyi  Deng" /></meta><meta name="dc.Creator" content="Shawn  Watts" /></meta><meta name="dc.Creator" content="Goran  Krilov" /></meta><meta name="dc.Creator" content="Aleksey  Gerasyuto" /></meta><meta name="dc.Creator" content="Sreekanth  Kokkonda" /></meta><meta name="dc.Creator" content="Farah  El Mazouni" /></meta><meta name="dc.Creator" content="John  White" /></meta><meta name="dc.Creator" content="Karen L.  White" /></meta><meta name="dc.Creator" content="Josefine  Striepen" /></meta><meta name="dc.Creator" content="Jade  Bath" /></meta><meta name="dc.Creator" content="Kyra A.  Schindler" /></meta><meta name="dc.Creator" content="Tomas  Yeo" /></meta><meta name="dc.Creator" content="David M.  Shackleford" /></meta><meta name="dc.Creator" content="Sachel  Mok" /></meta><meta name="dc.Creator" content="Ioanna  Deni" /></meta><meta name="dc.Creator" content="Aloysus  Lawong" /></meta><meta name="dc.Creator" content="Ann  Huang" /></meta><meta name="dc.Creator" content="Gong  Chen" /></meta><meta name="dc.Creator" content="Wen  Wang" /></meta><meta name="dc.Creator" content="Jaya  Jayaseelan" /></meta><meta name="dc.Creator" content="Kasiram  Katneni" /></meta><meta name="dc.Creator" content="Rahul  Patil" /></meta><meta name="dc.Creator" content="Jessica  Saunders" /></meta><meta name="dc.Creator" content="Shatrughan P.  Shahi" /></meta><meta name="dc.Creator" content="Rajesh  Chittimalla" /></meta><meta name="dc.Creator" content="Iñigo  Angulo-Barturen" /></meta><meta name="dc.Creator" content="María Belén  Jiménez-Díaz" /></meta><meta name="dc.Creator" content="Sergio  Wittlin" /></meta><meta name="dc.Creator" content="Patrick K.  Tumwebaze" /></meta><meta name="dc.Creator" content="Philip J.  Rosenthal" /></meta><meta name="dc.Creator" content="Roland A.  Cooper" /></meta><meta name="dc.Creator" content="Anna Caroline Campos  Aguiar" /></meta><meta name="dc.Creator" content="Rafael V. C.  Guido" /></meta><meta name="dc.Creator" content="Dhelio B.  Pereira" /></meta><meta name="dc.Creator" content="Nimisha  Mittal" /></meta><meta name="dc.Creator" content="Elizabeth A.  Winzeler" /></meta><meta name="dc.Creator" content="Diana R.  Tomchick" /></meta><meta name="dc.Creator" content="Benoît  Laleu" /></meta><meta name="dc.Creator" content="Jeremy N.  Burrows" /></meta><meta name="dc.Creator" content="Pradipsinh K.  Rathod" /></meta><meta name="dc.Creator" content="David A.  Fidock" /></meta><meta name="dc.Creator" content="Susan A.  Charman" /></meta><meta name="dc.Creator" content="Margaret A.  Phillips" /></meta><meta name="dc.Description" content="Dihydroorotate dehydrogenase (DHODH) has been clinically validated as a target for the development of new antimalarials. Experience with clinical candidate triazolopyrimidine DSM265 (1) suggested t..." /></meta><meta name="Description" content="Dihydroorotate dehydrogenase (DHODH) has been clinically validated as a target for the development of new antimalarials. Experience with clinical candidate triazolopyrimidine DSM265 (1) suggested t..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 20, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00173" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00173" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00173" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00173" /></link>
        
    
    

<title>Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00173" /></meta><meta property="og:title" content="Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0032.jpeg" /></meta><meta property="og:description" content="Dihydroorotate dehydrogenase (DHODH) has been clinically validated as a target for the development of new antimalarials. Experience with clinical candidate triazolopyrimidine DSM265 (1) suggested that DHODH inhibitors have great potential for use in prophylaxis, which represents an unmet need in the malaria drug discovery portfolio for endemic countries, particularly in areas of high transmission in Africa. We describe a structure-based computationally driven lead optimization program of a pyrrole-based series of DHODH inhibitors, leading to the discovery of two candidates for potential advancement to preclinical development. These compounds have improved physicochemical properties over prior series frontrunners and they show no time-dependent CYP inhibition, characteristic of earlier compounds. Frontrunners have potent antimalarial activity in vitro against blood and liver schizont stages and show good efficacy in Plasmodium falciparum SCID mouse models. They are equally active against P. falciparum and Plasmodium vivax field isolates and are selective for Plasmodium DHODHs versus mammalian enzymes." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00173"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00173">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00173&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00173&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00173&amp;href=/doi/10.1021/acs.jmedchem.1c00173" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 6085-6136</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00156" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00206" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Michael J. Palmer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael J. Palmer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicines for Malaria Venture, 1215 Geneva, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Palmer">Michael J. Palmer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoyi Deng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoyi Deng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, Texas 75390-9135, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyi++Deng">Xiaoyi Deng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shawn Watts</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shawn Watts</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Schrodinger, Inc., 120 West 45th St, 17th Floor, New York, New York 100036-4041, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shawn++Watts">Shawn Watts</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Goran Krilov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Goran Krilov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Schrodinger, Inc., 120 West 45th St, 17th Floor, New York, New York 100036-4041, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Goran++Krilov">Goran Krilov</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aleksey Gerasyuto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aleksey Gerasyuto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Schrodinger, Inc., 120 West 45th St, 17th Floor, New York, New York 100036-4041, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aleksey++Gerasyuto">Aleksey Gerasyuto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sreekanth Kokkonda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sreekanth Kokkonda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Chemistry and Global Health, University of Washington, Seattle, Washington 98195, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sreekanth++Kokkonda">Sreekanth Kokkonda</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Farah El Mazouni</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Farah El Mazouni</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, Texas 75390-9135, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Farah++El+Mazouni">Farah El Mazouni</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John White</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John White</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Chemistry and Global Health, University of Washington, Seattle, Washington 98195, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John++White">John White</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karen L. White</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karen L. White</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karen+L.++White">Karen L. White</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Josefine Striepen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Josefine Striepen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Josefine++Striepen">Josefine Striepen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jade Bath</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jade Bath</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jade++Bath">Jade Bath</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kyra A. Schindler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kyra A. Schindler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kyra+A.++Schindler">Kyra A. Schindler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tomas Yeo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tomas Yeo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tomas++Yeo">Tomas Yeo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David M. Shackleford</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David M. Shackleford</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+M.++Shackleford">David M. Shackleford</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sachel Mok</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sachel Mok</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sachel++Mok">Sachel Mok</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9605-0154" title="Orcid link">http://orcid.org/0000-0002-9605-0154</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ioanna Deni</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ioanna Deni</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ioanna++Deni">Ioanna Deni</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aloysus Lawong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aloysus Lawong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, Texas 75390-9135, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aloysus++Lawong">Aloysus Lawong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ann Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ann Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, Texas 75390-9135, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ann++Huang">Ann Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gong Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gong++Chen">Gong Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wen Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wen Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wen++Wang">Wen Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jaya Jayaseelan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jaya Jayaseelan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jaya++Jayaseelan">Jaya Jayaseelan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kasiram Katneni</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kasiram Katneni</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kasiram++Katneni">Kasiram Katneni</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rahul Patil</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rahul Patil</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rahul++Patil">Rahul Patil</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jessica Saunders</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jessica Saunders</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jessica++Saunders">Jessica Saunders</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shatrughan P. Shahi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shatrughan P. Shahi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Syngene International Ltd, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shatrughan+P.++Shahi">Shatrughan P. Shahi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rajesh Chittimalla</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rajesh Chittimalla</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Syngene International Ltd, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rajesh++Chittimalla">Rajesh Chittimalla</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Iñigo Angulo-Barturen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Iñigo Angulo-Barturen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TAD, Biscay Science and Technology Park, Astondo Bidea, BIC Bizkaia Bd 612, Derio, 48160 Bizkaia, Basque Country, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=I%C3%B1igo++Angulo-Barturen">Iñigo Angulo-Barturen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">María Belén Jiménez-Díaz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">María Belén Jiménez-Díaz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TAD, Biscay Science and Technology Park, Astondo Bidea, BIC Bizkaia Bd 612, Derio, 48160 Bizkaia, Basque Country, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mar%C3%ADa+Bel%C3%A9n++Jim%C3%A9nez-D%C3%ADaz">María Belén Jiménez-Díaz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sergio Wittlin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sergio Wittlin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Swiss Tropical and Public Health Institute, Socinstrasse 57, 4002 Basel, Switzerland</div><div class="loa-info-affiliations-info">University of Basel, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sergio++Wittlin">Sergio Wittlin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Patrick K. Tumwebaze</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patrick K. Tumwebaze</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Infectious Diseases Research Collaboration, Kampala, Uganda</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patrick+K.++Tumwebaze">Patrick K. Tumwebaze</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philip J. Rosenthal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philip J. Rosenthal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, University of California, San Francisco, California 94143, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philip+J.++Rosenthal">Philip J. Rosenthal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roland A. Cooper</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roland A. Cooper</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California 94901, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roland+A.++Cooper">Roland A. Cooper</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna Caroline Campos Aguiar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna Caroline Campos Aguiar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">University of Sao Paulo, Sao Carlos Institute of Physics, Sáo Carlos, SP 13560-970, Brazil</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna+Caroline+Campos++Aguiar">Anna Caroline Campos Aguiar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rafael V. C. Guido</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rafael V. C. Guido</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">University of Sao Paulo, Sao Carlos Institute of Physics, Sáo Carlos, SP 13560-970, Brazil</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rafael+V.+C.++Guido">Rafael V. C. Guido</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dhelio B. Pereira</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dhelio B. Pereira</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tropical Medicine Research Center of Rondonia, Av. Guaporé, 215, Porto Velho, RO 76812-329, Brazil</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dhelio+B.++Pereira">Dhelio B. Pereira</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nimisha Mittal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nimisha Mittal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pediatrics, Division of Host-Microbe Systems and Therapeutics, School of Medicine, University of California San Diego, La Jolla, California 92093, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nimisha++Mittal">Nimisha Mittal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elizabeth A. Winzeler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elizabeth A. Winzeler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pediatrics, Division of Host-Microbe Systems and Therapeutics, School of Medicine, University of California San Diego, La Jolla, California 92093, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elizabeth+A.++Winzeler">Elizabeth A. Winzeler</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4049-2113" title="Orcid link">http://orcid.org/0000-0002-4049-2113</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Diana R. Tomchick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Diana R. Tomchick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, Texas 75390-9135, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Diana+R.++Tomchick">Diana R. Tomchick</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Benoît Laleu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Benoît Laleu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicines for Malaria Venture, 1215 Geneva, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Beno%C3%AEt++Laleu">Benoît Laleu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeremy N. Burrows</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeremy N. Burrows</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicines for Malaria Venture, 1215 Geneva, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeremy+N.++Burrows">Jeremy N. Burrows</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8448-6068" title="Orcid link">http://orcid.org/0000-0001-8448-6068</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pradipsinh K. Rathod</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pradipsinh K. Rathod</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Chemistry and Global Health, University of Washington, Seattle, Washington 98195, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pradipsinh+K.++Rathod">Pradipsinh K. Rathod</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David A. Fidock</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David A. Fidock</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States</div><div class="loa-info-affiliations-info">Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, New York 10032, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+A.++Fidock">David A. Fidock</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susan A. Charman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susan A. Charman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susan+A.++Charman">Susan A. Charman</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Margaret A. Phillips</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Margaret A. Phillips</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, Texas 75390-9135, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#cca1adbeabadbea9b8e2bca4a5a0a0a5bcbf8cb9b8bfa3b9b8a4bba9bfb8a9bea2e2a9a8b9"><span class="__cf_email__" data-cfemail="7518140712140710015b051d1c19191c0506350001061a00011d0210060110071b5b101100">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Margaret+A.++Phillips">Margaret A. Phillips</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5250-5578" title="Orcid link">http://orcid.org/0000-0001-5250-5578</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00173&amp;href=/doi/10.1021%2Facs.jmedchem.1c00173" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 6085–6136</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 20, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 January 2021</li><li><span class="item_label"><b>Published</b> online</span>20 April 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 May 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00173" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00173</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6085%26pageCount%3D52%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMichael%2BJ.%2BPalmer%252C%2BXiaoyi%2BDeng%252C%2BShawn%2BWatts%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D9%26contentID%3Dacs.jmedchem.1c00173%26title%3DPotent%2BAntimalarials%2Bwith%2BDevelopment%2BPotential%2BIdentified%2Bby%2BStructure-Guided%2BComputational%2BOptimization%2Bof%2Ba%2BPyrrole-Based%2BDihydroorotate%2BDehydrogenase%2BInhibitor%2BSeries%26numPages%3D52%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6136%26publicationDate%3DMay%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00173"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">917</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00173" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Palmer&quot;},{&quot;first_name&quot;:&quot;Xiaoyi&quot;,&quot;last_name&quot;:&quot;Deng&quot;},{&quot;first_name&quot;:&quot;Shawn&quot;,&quot;last_name&quot;:&quot;Watts&quot;},{&quot;first_name&quot;:&quot;Goran&quot;,&quot;last_name&quot;:&quot;Krilov&quot;},{&quot;first_name&quot;:&quot;Aleksey&quot;,&quot;last_name&quot;:&quot;Gerasyuto&quot;},{&quot;first_name&quot;:&quot;Sreekanth&quot;,&quot;last_name&quot;:&quot;Kokkonda&quot;},{&quot;first_name&quot;:&quot;Farah&quot;,&quot;last_name&quot;:&quot;El Mazouni&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;White&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;L. White&quot;},{&quot;first_name&quot;:&quot;Josefine&quot;,&quot;last_name&quot;:&quot;Striepen&quot;},{&quot;first_name&quot;:&quot;Jade&quot;,&quot;last_name&quot;:&quot;Bath&quot;},{&quot;first_name&quot;:&quot;Kyra&quot;,&quot;last_name&quot;:&quot;A. Schindler&quot;},{&quot;first_name&quot;:&quot;Tomas&quot;,&quot;last_name&quot;:&quot;Yeo&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;M. Shackleford&quot;},{&quot;first_name&quot;:&quot;Sachel&quot;,&quot;last_name&quot;:&quot;Mok&quot;},{&quot;first_name&quot;:&quot;Ioanna&quot;,&quot;last_name&quot;:&quot;Deni&quot;},{&quot;first_name&quot;:&quot;Aloysus&quot;,&quot;last_name&quot;:&quot;Lawong&quot;},{&quot;first_name&quot;:&quot;Ann&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Gong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Wen&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jaya&quot;,&quot;last_name&quot;:&quot;Jayaseelan&quot;},{&quot;first_name&quot;:&quot;Kasiram&quot;,&quot;last_name&quot;:&quot;Katneni&quot;},{&quot;first_name&quot;:&quot;Rahul&quot;,&quot;last_name&quot;:&quot;Patil&quot;},{&quot;first_name&quot;:&quot;Jessica&quot;,&quot;last_name&quot;:&quot;Saunders&quot;},{&quot;first_name&quot;:&quot;Shatrughan&quot;,&quot;last_name&quot;:&quot;P. Shahi&quot;},{&quot;first_name&quot;:&quot;Rajesh&quot;,&quot;last_name&quot;:&quot;Chittimalla&quot;},{&quot;first_name&quot;:&quot;Iñigo&quot;,&quot;last_name&quot;:&quot;Angulo-Barturen&quot;},{&quot;first_name&quot;:&quot;María&quot;,&quot;last_name&quot;:&quot;Belén Jiménez-Díaz&quot;},{&quot;first_name&quot;:&quot;Sergio&quot;,&quot;last_name&quot;:&quot;Wittlin&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;K. Tumwebaze&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;J. Rosenthal&quot;},{&quot;first_name&quot;:&quot;Roland&quot;,&quot;last_name&quot;:&quot;A. Cooper&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Caroline Campos Aguiar&quot;},{&quot;first_name&quot;:&quot;Rafael&quot;,&quot;last_name&quot;:&quot;V. C. Guido&quot;},{&quot;first_name&quot;:&quot;Dhelio&quot;,&quot;last_name&quot;:&quot;B. Pereira&quot;},{&quot;first_name&quot;:&quot;Nimisha&quot;,&quot;last_name&quot;:&quot;Mittal&quot;},{&quot;first_name&quot;:&quot;Elizabeth&quot;,&quot;last_name&quot;:&quot;A. Winzeler&quot;},{&quot;first_name&quot;:&quot;Diana&quot;,&quot;last_name&quot;:&quot;R. Tomchick&quot;},{&quot;first_name&quot;:&quot;Benoît&quot;,&quot;last_name&quot;:&quot;Laleu&quot;},{&quot;first_name&quot;:&quot;Jeremy&quot;,&quot;last_name&quot;:&quot;N. Burrows&quot;},{&quot;first_name&quot;:&quot;Pradipsinh&quot;,&quot;last_name&quot;:&quot;K. Rathod&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;A. Fidock&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;A. Charman&quot;},{&quot;first_name&quot;:&quot;Margaret&quot;,&quot;last_name&quot;:&quot;A. Phillips&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;6085-6136&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00173&quot;},&quot;abstract&quot;:&quot;Dihydroorotate dehydrogenase (DHODH) has been clinically validated as a target for the development of new antimalarials. Experience with clinical candidate triazolopyrimidine DSM265 (1) suggested that DHODH inhibitors have great potential for use in prophylaxis, which represents an unmet need in the malaria drug discovery portfolio for endemic countries, particularly in areas of high transmission in Africa. We describe a structure-based computationally driven lead optimization program of a pyrrole-based series of DHODH inhibitors, leading to the discovery of two candidates for potential advancement to preclinical development. These compounds have improved physicochemical properties over prior series frontrunners and they show no time-dependent CYP inhibition, characteristic of earlier compounds. Frontrunners have potent antimalarial activity in vitro against blood and liver schizont stages and show good efficacy in Plasmodium falciparum SCID mouse models. They are equally active against P. falciparum and Plas&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00173&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00173" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00173&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00173" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00173&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00173" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00173&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00173&amp;href=/doi/10.1021/acs.jmedchem.1c00173" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00173" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00173" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00173%26sid%3Dliteratum%253Aachs%26pmid%3D33876936%26genre%3Darticle%26aulast%3DPalmer%26date%3D2021%26atitle%3DPotent%2BAntimalarials%2Bwith%2BDevelopment%2BPotential%2BIdentified%2Bby%2BStructure-Guided%2BComputational%2BOptimization%2Bof%2Ba%2BPyrrole-Based%2BDihydroorotate%2BDehydrogenase%2BInhibitor%2BSeries%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D9%26spage%3D6085%26epage%3D6136%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=291528" title="Parasites">Parasites</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292444" title="Molecular structure">Molecular structure</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/jmcmar.2021.64.issue-9/20210513/jmcmar.2021.64.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0032.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Dihydroorotate dehydrogenase (DHODH) has been clinically validated as a target for the development of new antimalarials. Experience with clinical candidate triazolopyrimidine DSM265 (<b>1</b>) suggested that DHODH inhibitors have great potential for use in prophylaxis, which represents an unmet need in the malaria drug discovery portfolio for endemic countries, particularly in areas of high transmission in Africa. We describe a structure-based computationally driven lead optimization program of a pyrrole-based series of DHODH inhibitors, leading to the discovery of two candidates for potential advancement to preclinical development. These compounds have improved physicochemical properties over prior series frontrunners and they show no time-dependent CYP inhibition, characteristic of earlier compounds. Frontrunners have potent antimalarial activity <i>in vitro</i> against blood and liver schizont stages and show good efficacy in <i>Plasmodium falciparum</i> SCID mouse models. They are equally active against <i>P. falciparum</i> and <i>Plasmodium vivax</i> field isolates and are selective for <i>Plasmodium</i> DHODHs versus mammalian enzymes.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38355" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38355" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Malaria is one of the most widespread and ancient infectious diseases of humanity.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Five species of the single-celled eukaryote <i>Plasmodium</i> genus are responsible for the disease. <i>Plasmodium falciparum</i> causes the most deaths, while <i>Plasmodium vivax</i> has a wider global distribution and a dormant liver stage that can reactivate years after the primary infection. Despite the strong implementation of malaria control programs, progress toward reducing the global incidence of malaria and deaths has stalled in recent years.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Malaria, which is transmitted by the <i>Anopheles</i> mosquito causes a febrile illness, the severity of which depends on both the <i>Plasmodium</i> species and host factors such as immunity. In 2020, the World Health Organization estimated that malaria infected 229 million people worldwide, 93% in Africa, leading to over 0.4 million deaths, of which two-thirds were children under 5 years old.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Malaria control and prevention has relied on drug therapy and vector control. A wide range of effective antimalarials has been used clinically; however, resistance to robust therapies such as chloroquine left a gap in treatment options until the discovery of the current gold standard two-drug artemisinin-based combination therapies (ACTs).<a onclick="showRef(event, 'ref1 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref3">(1,3)</a> Emergence of ACT treatment failures in the Greater Mekong subregion has raised concerns that resistance to all ACTs could jeopardize malaria control programs.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> These failures are in part associated with mutations in Kelch13, which cause a delayed parasite clearance time after treatment with artemisinins.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> Fueled by the reduced activity of artemisinins, resistance to partner compounds, particularly piperaquine, has also emerged in southeast Asia.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> However, artemether-lumefantrine and pyronaridine-artesunate currently remain efficacious in all regions. Efforts to validate triple-drug ACTs are underway to combat resistance until drugs with novel mechanisms of action can be deployed.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a></div><div class="NLM_p">In the past decade, a number of high-throughput screening campaigns against either intraerythrocytic parasites or <i>P. falciparum</i> enzymes have led to the identification of several novel chemical entities that reached clinical development and to the validation of a number of new parasite targets providing different mechanisms of action from previously used antimalarials.<a onclick="showRef(event, 'ref1 ref10'); return false;" href="javascript:void(0);" class="ref ref1 ref10">(1,10)</a> The most advanced of these include two compounds in late-stage Phase II clinical studies: KAF156 (combination therapy with lumefantrine) for uncomplicated malaria<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> and spiroindolone KAE609, a fast-acting ATP4 inhibitor being developed for severe malaria.<a onclick="showRef(event, 'ref3 ref13'); return false;" href="javascript:void(0);" class="ref ref3 ref13">(3,13)</a> Additional candidates to reach Phase II clinical development include the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) inhibitor DSM265 (<b>1</b>)<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and the PI4 kinase inhibitor MMV390048.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> These Phase II development candidates have been instrumental in work to develop new strategies and assays to support malaria drug discovery programs.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> These include the policy to introduce drugs as combinations to combat resistance and the desirability of targeting all <i>Plasmodium</i> species<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and life cycle stages (blood, liver, and sexual stages).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> While many new candidates have been advanced for malaria treatment, with the exception of tafenoquine (primarily developed to prevent relapse of dormant stages of <i>P. vivax</i> and <i>Plasmodium ovale</i>),<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> no new prophylaxis compounds have reached advanced clinical development since atovaquone/proguanil more than 20 years ago. The goal of current programs would be to deliver a candidate that could ideally be dosed orally as infrequently as once monthly and, at a minimum, no more frequently than weekly and that would have acceptable tolerability and a low cost of goods.<a onclick="showRef(event, 'ref1 ref17'); return false;" href="javascript:void(0);" class="ref ref1 ref17">(1,17)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0002.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. <i>P. falciparum</i> DHODH inhibitors from the triazolopyrimidine (<b>1</b>)<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and pyrrole (<b>2</b>, <b>3</b>)<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> structural classes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Through our work on <b>1</b>, DHODH emerged as a strong target for malaria prophylaxis. In human Phase IIa clinical studies, <b>1</b>, which has a long human half-life,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> was able to provide single-dose cures of <i>P. falciparum</i> malaria in patients in Peru.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> However, it showed lower efficacy against <i>P. vivax</i>, and resistant parasites that mapped to mutations in DHODH were identified in two relapsing <i>P. falciparum</i> patients. Importantly, <b>1</b> has both potent blood and liver-stage antischizontal activity,<a onclick="showRef(event, 'ref15 ref23'); return false;" href="javascript:void(0);" class="ref ref15 ref23">(15,23)</a> which supports the use of DHODH inhibitors for prophylaxis and provides superiority over compounds with only blood-stage activity for this indication. Human sporozoite challenge studies showed that <b>1</b> prevented the emergence of <i>P. falciparum</i> infection if dosed a day prior to infection, providing a clinical proof of concept supporting the DHODH target for this indication.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Despite its good efficacy, <b>1</b> was shown to be both teratogenic and to result in testicular toxicity in certain preclinical species (unpublished) and thus was unable to meet the safety bar required for continued clinical development, particularly for use as a prophylactic over months during the transmission season in Africa, or in pregnant women. While clinical development of <b>1</b> has been terminated, the clinical data obtained on <b>1</b> has validated DHODH as a strong target for malaria prophylaxis.</div><div class="NLM_p">As the current clinical malaria portfolio now lacks a DHODH inhibitor, there is strong justification to identify new DHODH inhibitors from a different chemical class that will combine the good efficacy of <b>1</b> with a safety profile that can support its development. Importantly, there are no current drugs in use for malaria treatment that inhibit DHODH, which supports a strategy where different drugs will be used for treatment than for prophylaxis. This strategy mitigates the risk that resistance will be selected during treatment and then compromise the prophylactic indication where the low parasite burden presents a low risk for resistance to develop. Furthermore, DHODH is a well-characterized target, and the ability to directly test compounds for mammalian DHODH inhibition provides a mechanism to ensure that any selected clinical candidate does not inhibit DHODH, thus, dramatically reducing the risk of mechanism-based toxicity.</div><div class="NLM_p last">With the goal of identifying a new compound that could move forward to clinical development for malaria prophylaxis, we continued lead optimization of a pyrrole series of DHODH inhibitors that we previously reported had potent DHODH and <i>P. falciparum</i> inhibitory activity.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The strongest candidate to emerge from the earlier work, <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), showed <i>in vivo</i> efficacy in the <i>P. falciparum</i> SCID mouse model but was less potent than <b>1</b>, it was predicted to have a shorter human half-life based on reduced metabolic stability, and it was a time-dependent CYP inhibitor raising potential safety concerns. To improve the properties of this series, we expanded our lead optimization program to include structure-based computational methods. Through this effort, we report herein on compounds with improved potency, better physicochemical properties, and for which we have eliminated the liability of time-dependent CYP inhibition. These next-generation pyrroles retain the desirable properties of <b>2</b>, including strong species selectivity against mammalian enzymes, equivalent and potent activity against both <i>P. falciparum</i> and <i>P. vivax</i> parasites, activity on both blood and liver stages blocking schizont formation, and good <i>in vivo</i> activity in SCID mouse models.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05874" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05874" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The goals of our pyrrole lead optimization program were to improve the properties of <b>2</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> by identifying compounds with greater potency versus <i>P. falciparum</i> parasites, to achieve better metabolic stability and plasma exposure profiles that would be consistent with a frequency of no more than weekly dosing for prophylaxis, and to eliminate the risk of time-dependent CYP inhibition. Identified liabilities in <b>1</b> included inhibition of rodent DHODH, which complicated the development by making it more difficult to determine whether toxicities associated with <b>1</b> in preclinical rodent studies were due to on- or off-target effects, and poor solubility that required complex and costly formulations to obtain good oral bioavailablility.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Thus, based on our experience with <b>1</b>,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> we sought to identify compounds with good solubility to enable simple formulation approaches while maintaining strong species selectivity against mammalian enzymes.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Computational Approaches to Compound Design</h3><div class="NLM_p">Focusing on potency as the initial goal, X-ray structures of DHODH bound to previously described pyrroles<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> were used as a starting point for computational predictions as detailed in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. We sought first to explore the potential to replace either the benzyl group or the cyclopropylamide with more potent substituents. To that end, programmatically enumerated libraries of commercially available precursors (eMolecules Building Blocks 2015) were docked with WScore into the binding site and WaterMap was used to assess areas of the binding pocket where potency gains could be made through the displacement of water molecules. Docked compounds providing the best scores were then analyzed using the free-energy perturbation (FEP+) method to predict <i>Pf</i>DHODH potency (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Tables S1 and S2</a>). A selection of previously reported pyrrole-based DHODH inhibitors<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> were studied to test the accuracy of predictions (retrospective validation) and refine the models (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S1 and S2</a>). This work was aided by new X-ray structures as they became available, which were used to refine predictions during the course of the program. In total, 7 new pyrrole analogue-<i>Pf</i>DHODH structures were solved and are reported herein (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S3 and Figures S1 and S2</a>). The computational modeling effort supported the prioritization of compounds for synthesis (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0003.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure–activity relationships. (A) Correlation between FEP+ predicted and measured <i>Pf</i>DHODH pIC<sub>50</sub> values. Retrospective analysis of previously reported pyrrole-based compounds used as a validation set to test predictions are shown as light green triangles and compounds from this paper are shown as red circles. Both sets were included in the linear regression analysis (<i>R</i><sup>2</sup> = 0.58). Outliers (shown as green squares) with their compound ID displayed were not included in the regression analysis. Data are provided in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Tables S1 and S2</a>. (B) Correlation between <i>Pf</i>DHODH pIC<sub>50</sub> values and <i>P. falciparum</i> 3D7 cell pEC<sub>50</sub> values. All data were included in the regression analysis (<i>R</i><sup>2</sup> = 0.84). Data were taken from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds were synthesized based on our previously described strategies,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> with modifications as detailed in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch8" aria-label="8">8</a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Schemes S1–S10</a>. Compounds were first evaluated for activity against recombinant DHODH from <i>P. falciparum</i> (<i>Pf</i>DHODH) (IC<sub>50</sub> < 0.03 μM) and <i>P. vivax</i> (<i>Pv</i>DHODH) (IC<sub>50</sub> < 0.03 μM), for selectivity versus human DHODH (<i>h</i>DHODH) (IC<sub>50</sub> > 30 μM) and for efficacy against <i>P. falciparum</i> 3D7 asexual blood stage (EC<sub>50</sub> < 0.015 μM), with our target values for an optimized late lead shown in parentheses (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). Liver-stage assays were conducted later in the program because of their more limited availability. Compounds with good potency in enzyme and parasite assays were tested in human and mouse liver microsomes to assess metabolic stability and kinetic solubility at pH 6.5 to reflect the approximate pH of the upper small intestine in the fasted state (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S4A</a>). Our target for <i>in vitro</i> intrinsic clearance (CL<sub>int</sub>) was <10 μL/min/mg microsomal protein, as experience suggested this level of stability would be required to translate to a sufficiently long half-life to support clinical development in humans. Compounds with the best combined properties were advanced to more detailed pharmacologic assays, pharmacokinetic studies, and additional parasitology.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 1-propynylmagnesium bromide, tetrahydrofuran (THF), 0 °C–room temperature (RT), 2–6 h; (ii) Dess–Martin, CH<sub>2</sub>CI<sub>2</sub>, RT, 2–4 h; (iii) ethyl isocyanoacetate, Ag<sub>2</sub>CO<sub>3</sub>, <i>N</i>-methyl-2-pyrrolidinone (NMP), 80 °C, 3–6 h; (iv) NaBH<sub>4</sub>, EtOH, 0 °C–RT, 1 h; (v) trifluoroacetic acid (TFA), triethylsilane, CH<sub>2</sub>CI<sub>2</sub>, 50 °C, 1 h; (vi) amine, Me<sub>3</sub>AI, THF, MW, 100 °C, 1 h; (vii) NaOH, EtOH, RT–80 °C, 2 h; (viii) amine, HATU, Et<sub>3</sub>N, CH<sub>2</sub>CI<sub>2</sub>, RT, 4 h; (ix) TFA, triethylsilane, CH<sub>2</sub>CI<sub>2</sub>, RT, 1 h or amine, Me<sub>3</sub>AI, THF, MW, 100 °C, 1 h or TBAF, THF, RT, 2 h.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry: Compound Synthesis and Structure–Activity Relationships (SARs) of Pyrrole-Based Compounds Versus DHODH and <i>P. falciparum</i> 3D7</h3><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6"> Nonchiral Amide and Benzyl Variations</h4><div class="NLM_p">A series of analogues (<b>4</b>–<b>21</b>) that varied either the amide or benzyl group were synthesized primarily as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, plus variations as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Schemes S1, S2, and S4</a>. The chemistry detailed in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Schemes S1 and S2</a> constructed the pyrrole from a but-2-yn-1-one intermediate, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> used a Weinreb amide variation to access the but-2-yn-1-one, and S4 used Friedel–Crafts methodology. A small set of nonchiral cyclic amides (<b>4</b>–<b>6</b>) were also made to further probe the cyclopropylamide binding pocket, with the addition of an ether linkage expected to improve on the poor potency of prior 4–6-membered cyclic rings in this position.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Additionally, we tested the ability of linker methylene to improve the geometry of a pyrazole ring (<b>7</b>) in this position and to promote binding. With the exception of the 3-methyloxetane <b>4</b>, all of the remaining compounds (<b>5</b>–<b>7</b>) had poor activity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) CDI, <i>N</i>,<i>O</i>-dimethylhydroxylamine·HCI, DMF, 5 h; (ii) 1-propynylmagnesium bromide, THF, 0 °C–RT, 2 h; (iii) ethyl isocyanoacetate, Ag<sub>2</sub>CO<sub>3</sub>, NMP, RT–80 °C, 2 h; (iv) NaBH<sub>4</sub>, EtOH, 0 °C–RT, 1 h; (v) TFA, triethylsilane, CH<sub>2</sub>CI<sub>2</sub>, 0 °C, 1 h; (vi) NaOH, EtOH/H<sub>2</sub>O, RT–80 °C, 2 h; (vii) amine, HATU, Et<sub>3</sub>N, CH<sub>2</sub>CI<sub>2</sub>, RT, 4 h; and (viii) TFA, triethylsilane, CH<sub>2</sub>CI<sub>2</sub>, RT, 1 h.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Nonchiral Amide and Benzyl Variations</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0017.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0018.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last"><i>Pf</i>, <i>P. falciparum</i>; <i>Pv</i>, <i>P. vivax</i>; and <i>h</i>, human. Triplicate data were collected at each inhibitor concentration (3-fold dilution series for DHODH and 3–4-fold series for 3D7) for each EC<sub>50</sub> or IC<sub>50</sub> determination. Multiple biological replicates were performed for key compounds, and for these studies, data represent mean ± standard deviation with the number of independent experiments in parenthesis. *Data were taken from ref <a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and included in the table.</p></div></div><div></div></div><div class="NLM_p">Benzyl replacements added either an ortho fluoro to the 4-CF<sub>3</sub>-pyridinyl ring (<b>8</b>–<b>10</b>), replaced the 4-CF<sub>3</sub> with S(O<sub>2</sub>)N(Me)<sub>2</sub> (<b>11</b>), or replaced 4-CF<sub>3</sub>-pyridinyl with isoquinoline (<b>12</b>–<b>17</b>) or benzoxazole (<b>18</b>–<b>21</b>) heteroatom aromatic ring systems, as several of these compounds were predicted to improve potency to <0.01 μM based on FEP+ calculation (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S2</a>). The 4-CF<sub>3</sub>,2-F-pyridinyls and isoquinolines were made in the context of the cyclopropylamide, CH<sub>2</sub>CF<sub>3</sub>, or difluoroazetidine, all groups were previously shown to exhibit good activity in this position.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The addition of ortho F improved potency versus <i>P. falciparum</i> 3D7 by up to 6-fold (<b>8</b> and <b>10</b> versus <b>2</b>), while replacement of 4-CF<sub>3</sub> with S(O<sub>2</sub>)N(Me)<sub>2</sub> (<b>11</b>) led to a 5–10-fold reduction in potency against <i>Pf</i>DHODH and <i>Pf</i>3D7-infected cells relative to <b>2</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The isoquinolines had excellent potency as predicted by FEP+; the best analogue <b>16</b> contained a cyclopropylamide and showed a potency boost against <i>Pf</i>3D7 of 15-fold relative to <b>2</b>. With sub-nM activity, this compound was the most potent in the pyrrole series (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The synthesis of the benzoxazoles was challenging and those with the preferred 7-methyl linkage could only be made in the context of an ethylester (<b>18</b>–<b>20</b>), and while <b>18</b> was potent it would not be expected to be metabolically stable. The 2-methyl linkage (<b>21</b>) could be made as an amide but lacked potency.</div><div class="NLM_p last">Despite showing reasonably low Log <i>D</i><sub>7.4</sub> values (<3.4), none of the highly potent isoquinoline compounds (<b>12</b>–<b>17</b>) from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> had good metabolic stability (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S4A</a>). Compounds containing an ortho fluoro to the 4-CF<sub>3</sub>-pyridinyl ring (<b>8</b>–<b>10</b>) were also less stable than <b>2</b>. Benzoxazole <b>21</b> had good stability in human liver microsomes (HLM) but was unstable in mouse liver microsomes (MLM). With the exception of <b>21</b>, compounds in this set had relatively poor aqueous solubility at intestinal pH. Thus, these compounds lacked the physicochemical and metabolic characteristics to support progression.</div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8"> Replacement of Cyclopropyl with Chiral Amides</h4><div class="NLM_p">Computational modeling suggested that substitution of the cyclopropylamide with chiral amides, particularly those with 5-membered heterocyclic rings could improve potency (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S2</a>). Using the chemistry described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Scheme S3</a>, compounds <b>22</b>–<b>52</b> were synthesized and evaluated (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Three chiral amides with simple alcohol (<b>22</b> CH<sub>2</sub>OH) or amines (<b>23</b> and <b>24</b>) (NHCH<sub>3</sub> and NH<sub>2</sub>) groups were tested first, but these were poorly active and represented the compounds with the largest discrepancy between the predicted and observed potency in this study (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Chiral Amides</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0019.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0020.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Rac, racemic; ent1, enantiomer 1; and ent2, enantiomer 2. See <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> footnote for other abbreviations and error analysis information.</p></div></div><div></div></div><div class="NLM_p">We next synthesized and tested isoxazole (<b>25</b>–<b>27</b>, <b>51</b>), pyrazole (<b>28</b>, <b>32</b>–<b>37</b>, <b>42</b>–<b>50</b>), triazole (<b>29</b>–<b>31</b>, <b>38</b>, <b>40</b>), oxadiazole (<b>39</b>), and imidazole (<b>41</b>) derivatives, which also varied by the addition of methyl groups to the rings. Key compounds were analyzed as both racemic mixtures and purified enantiomers early in the program, demonstrating that DHODH binding activity resided primarily in only one of the two enantiomer pairs (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Later compounds were often only evaluated as pure enantiomer pairs. Because of concerns that undecorated pyrazole analogues would show CYP inhibition, we also made a number of 5-substituted 3-methylpyrazole analogues, including 5-methyl (<b>42</b>, <b>43</b>), 5-CN (<b>44</b>, <b>45</b>), 5-CONH<sub>2</sub> (<b>46</b>–<b>47</b>), and 5-COHNHCH<sub>3</sub> (<b>49</b>, <b>50</b>) derivatives, all of which were predicted to bind well (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S2</a>). The most potent analogues were the active stereoisomers of the isoxazole (<b>26</b>), 4-methylpyrazole (<b>33</b>), 1,3 dimethylpyrazole <b>(36</b>), 3,5-dimethylpyrazole (<b>42</b>), 3-methyl, 5-carbonitrile pyrazole (<b>44</b>), and 3-methyl, 5-carboxamide pyrazole (<b>47</b>) derivatives, with all meeting potency criteria on <i>Pf</i>DHODH (IC<sub>50</sub> < 0.030 μM) and <i>P. falciparum</i> 3D7 (EC<sub>50</sub> < 0.020 μM) (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The triazole derivative <b>30</b> was also reasonably active (EC<sub>50</sub> 0.066 μM), and because this group lowered Log <i>P</i> and improved metabolic stability, it was also incorporated into additional analogues that combined chiral amides with changes elsewhere in the molecule. When comparing enantiomer pairs, we found that the less active stereoisomer typically showed >100-fold lower potency against both <i>Pf</i>DHODH and <i>Pf</i>3D7-infected cells throughout the series. All active compounds also showed equal to more potent activity against <i>Pv</i>DHODH, and none of the analogues had any detectable activity (up to 100 μM) against <i>h</i>DHODH (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_p last">For compounds containing 4-CF<sub>3</sub>-pyridinyl in the aryl position (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), the only compounds with a human CL<sub>int</sub> within the target range contained either the triazole (the racemic <b>29</b> and its active enantiomer <b>30</b>) or the carboxamide pyrazole <b>47</b> (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S4A</a>). Four additional compounds, including the 4-methyl pyrazoles <b>28</b> and <b>33</b>, the dimethylpyrazole <b>36</b>, and the cyanopyrazole <b>44</b>, had CL<sub>int</sub> values of <20 μL/min/mg, with <b>33</b> and <b>36</b> also meeting our <i>Pf</i>3D7 potency criteria.</div></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> Combining Chiral Amides with Variation of the Aryl Group</h4><div class="NLM_p">To further optimize both potency and absorption, distribution, metabolism, and excretion (ADME) properties, the more potent chiral amide substituents were combined with variations of the more potent isoquinolines (<b>52</b>–<b>55</b>) plus a set of additionally substituted benzyl (<b>56</b>–<b>60</b>, <b>62</b>, <b>64</b>–<b>66</b>) or pyridinyl rings (<b>61, 63</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Additionally, we sought to determine whether the beneficial properties of the triazole (low LogP) could be paired with an aryl group that could boost potency in the combined molecule. Compounds were synthesized based on the chemistry depicted in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>, <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Scheme S4</a>. Two compounds (<b>52</b> and <b>53</b>) that combined the most potent chiral amide (isoxazole) with isoquinoline showed excellent potency (<i>Pf</i>3D7 EC<sub>50</sub> 0.002–0.004 μM), although they were 2–4-fold less potent than <b>16</b> (cyclopropylamide combined with the isoquinoline). However, both <b>52</b> and <b>53</b> were rapidly metabolized and poorly soluble (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S4A</a>). Combining the triazole with isoquinoline (<b>54</b>) improved potency by 7-fold over <b>30</b> (4-CF<sub>3</sub> pyridinyl), leading to potency in the target range for development (<i>Pf</i>3D7 EC<sub>50</sub> < 0.015 μM), but metabolic stability of <b>54</b> was not sufficient for advancement. Combining the isoxazole with 4-CF<sub>3</sub> benzyl (<b>56</b>) reduced potency over <b>26</b> (4-CF<sub>3</sub> pyridinyl) by 2-fold and had minimal impact on metabolic stability but led to a compound that was amenable to crystallography as <b>26</b> had failed to cocrystallize with <i>Pf</i>DHODH (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S3</a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figures S1 and S2</a>). None of the ortho- or meta-substituted benzyl (<b>59</b>, <b>62</b>, <b>64</b>, <b>66</b>) or pyridinyl (<b>61</b>, <b>63</b>) rings provided good potency in the context of the triazole, regardless of the presence of a CF<sub>3</sub> or halogen in the 4 position, although the most active of this set was the 4-CF<sub>3</sub>, 2-F-benzyl derivative <b>59</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Chiral Amides with Variation of the Aryl group</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0021.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0022.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Rac, racemic; ent1, enantiomer 1; and ent2, enantiomer 2. See <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> footnote for other abbreviations and error analysis information.</p></div></div><div></div></div></div><div id="sec2_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Substitutions on the Bridging Carbon</h4><div class="NLM_p">To explore the potential of bridging carbon modifications to impact both potency and metabolic stability, we synthesized a series of analogues containing single <i>R</i> group substitutions on this carbon (<b>67</b>–<b>72</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The decision to make this set of compounds was done primarily with the goal of blocking a potential metabolic hotspot and one that might contribute to the time-dependent CYP inhibition of some compounds in the series. FEP+ predictions for the methyl analogue <b>67</b> suggested that it would have up to 6-fold improved potency versus <b>26</b> (FEP+ predicted IC<sub>50</sub> for the pure <i>R</i>, <i>R</i> diastereomer was 0.013 μM), supporting the approach. The compound set was made in the context of the isoxazole amide group (<b>25</b>, <b>26</b>) that showed comparable potency to the best of the chiral amides. The synthesis of these analogues was achieved as shown in <a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a> and <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. The addition of a methyl to the bridging carbon (<b>67</b>) increased potency versus <i>Pf</i>3D7-infected cells by 3-fold relative to the racemic <b>25</b> as predicted by FEP+. Compound <b>67</b> also showed equivalent IC<sub>50</sub> values versus <i>Pf</i> and <i>Pv</i>DHODH compared to <b>25</b>/<b>26</b>; however, it was less metabolically stable and less soluble than <b>25</b> (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S4A</a>). Given the additional chiral center, <b>67</b> would be predicted to be 4-fold more active than measured if tested as the purified active diastereomer, demonstrating that the modification provided a potency boost. The addition of OH (<b>68</b>), OCH<sub>3</sub> (<b>69</b>), or CN (<b>70</b>) to the bridging methyl resulted in racemic compounds that were 2–3-fold less potent than <b>25</b>/<b>26</b>; therefore, the expectation is that the most active diastereomer would have an equivalent activity to <b>26</b>. Thus, all four substitutions were well tolerated. The addition of a cyano group to the bridging methyl led to an improvement in metabolic stability within the context of the isoxazole chiral amide (<b>70</b> vs <b>26)</b>. Finally, we tested the effects of deuterating the bridging carbon (<b>71</b> and <b>72</b>) as a tool to determine if an isotope effect could reduce metabolism at this position, but it had no impact (see below).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) methylmagnesium bromide, THF, 0 °C–RT, 4 h; (ii) TFA, triethylsilane, CH<sub>2</sub>CI<sub>2</sub>, 0–85 °C, 1 h; (iii) NaOH, EtOH/H<sub>2</sub>0, RT–80 °C, 2 h; (iv) amine, HATU, Et<sub>3</sub>N, CH<sub>2</sub>CI<sub>2</sub>, RT, 3–4 h; and (v) NaBD<sub>4</sub>, TFA–D, CHCI<sub>3</sub>, 0 °C–RT, 16 h.</p></p></figure><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) NaOH, EtOH/H<sub>2</sub>O, RT–80 °C, 2 h; (ii) amine, HATU, Et<sub>3</sub>N, CH<sub>2</sub>CI<sub>2</sub>, RT, 16 h; (iii) NaBH<sub>4</sub>, EtOH, 0 °C–RT, 1 h; (iv) Mel, THF, 0 °C–RT, 16 h; (v) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, DMAP, CH<sub>2</sub>CI<sub>2</sub>, RT, 4 h; (vi) TMSCN, (C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>B, MeCN, RT, 8 h; (vii) HCI in dioxane, RT, 2 h.</p></p></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Single <i>R</i> Group Substitutions on the Bridging Carbon</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0023.gif" alt="" id="fx7" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (μM)</th><th class="rowsep1 colsep0" align="center">EC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left">cmpd</th><th class="colsep0 rowsep0" align="left">cmpd ID</th><th class="colsep0 rowsep0" align="left">Stereo chem</th><th class="colsep0 rowsep0" align="left">R1</th><th class="colsep0 rowsep0" align="center"><i>Pf</i>DHODH</th><th class="colsep0 rowsep0" align="center"><i>Pv</i>DHODH</th><th class="colsep0 rowsep0" align="center"><i>h</i>DHODH</th><th class="colsep0 rowsep0" align="center"><i>Pf</i>3D7</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>67</b></td><td class="colsep0 rowsep0" align="left">DSM619</td><td class="colsep0 rowsep0" align="left">rac</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.079</td><td class="colsep0 rowsep0" align="left">0.074</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">0.0030</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68</b></td><td class="colsep0 rowsep0" align="left">DSM626</td><td class="colsep0 rowsep0" align="left">rac</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">0.18</td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">0.022 ± 0.0049 (2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69</b></td><td class="colsep0 rowsep0" align="left">DSM627</td><td class="colsep0 rowsep0" align="left">rac</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.15</td><td class="colsep0 rowsep0" align="left">0.10</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">0.040 ± 0.0021 (2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70</b></td><td class="colsep0 rowsep0" align="left">DSM631</td><td class="colsep0 rowsep0" align="left">rac</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">0.27</td><td class="colsep0 rowsep0" align="left">0.41</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">0.021</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71</b></td><td class="colsep0 rowsep0" align="left">DSM644</td><td class="colsep0 rowsep0" align="left"><i>ent1</i></td><td class="colsep0 rowsep0" align="left">D, D<a class="ref internalNav" href="#t14fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">0.0091</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">0.0047</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left">DSM645</td><td class="colsep0 rowsep0" align="left"><i>ent2</i></td><td class="colsep0 rowsep0" align="left">D, D<a class="ref internalNav" href="#t14fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">63</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Both methylene protons were replaced with deuterium.</p></div></div></div></div><div id="sec2_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Addition of Cyclopropyl to the Bridging Carbon</h4><div class="NLM_p">We next synthesized a set of analogues containing a cyclopropyl on the bridging carbon (<b>73</b>–<b>102</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) since this functional group did not add an additional chiral center (e.g., <b>67</b> and <b>70</b>) but might yield the benefits of improved potency and/or metabolic stability that were observed for the single <i>R</i> group substitutions on the bridging carbon (above). Compounds were synthesized as shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Schemes S5 and S6</a>. The bridging cyclopropyl was tested in combination with a range of both nonchiral and chiral amides, combined with either 4-CF<sub>3</sub>-pyridinyl or a handful of closely related substituted benzyl rings. As previously observed, compounds with cyclopropyl (<b>73</b>), difluoroazetidine (<b>74</b>), isoxazole (<b>75</b>), pyrazole (1<i>H</i>-4-yl) (<b>77</b>), and substituted pyrazoles (1<i>H</i>-3-yl) (<b>81</b>, <b>86</b>) at the amide position led to the best potency against <i>Pf</i>DHODH and <i>Pf</i>3D7-infected cells, with all compounds in this set showing <0.005 μM potency against <i>Pf</i>3D7. A potency gain of 3–10-fold for <i>Pf</i>3D7-infected cells was observed for these compounds (<b>2</b> vs <b>73</b>, <b>26</b> vs <b>75</b>, <b>32</b> vs <b>77</b>, <b>42</b> vs <b>81</b>, <b>44</b> vs <b>86</b>). The triazole <b>79</b> also showed good potency (<i>Pf</i>3D7 EC<sub>50</sub> = 0.013 μM), which represents a 5-fold improvement over <b>30</b>, the analogue without the cyclopropyl on the bridge. While generally, the cyclopropyl bridge substitution improved potency, this was not the case for the 5-carboxamide pyrazole amide, where <b>47</b> was 2-fold more potent than <b>83</b> against <i>Pf</i>3D7 cells. Of the compounds in this set, FEP+ calculations were only performed for <b>30</b> and <b>79</b>, and for this pair, FEP+ predicted that <b>30</b> would be more potent than <b>79</b>, while the opposite was observed experimentally (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S2</a>).</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0013.jpeg" id="gr5" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) a: NaH, TsCI, DMF, 0 °C–RT, 4.5 h or b: DMAP, Et<sub>3</sub>N, TsCI, CH<sub>2</sub>CI<sub>2</sub>, 0 °C–RT, 2 h; (ii) methylmagnesium bromide, THF, 0 °C–RT, 2–4 h; (iii) I2, toluene, RT–115 °C, 16 h; (iv) trimethylsulfoxonium iodide, <i><sup>t</sup></i>BuOK, THF, DMSO, 0 °C–RT, 4 h; (v) NaOH, EtOH/H<sub>2</sub>O, RT–80 °C, 2 h; (vi) amine, HATU, Et<sub>3</sub>N, CH<sub>2</sub>CI<sub>2</sub>, RT, 4–5 h; (vii) trityl: TFA, triethylsilane, CH<sub>2</sub>CI<sub>2</sub>, RT, 1 h; (viii) tosyl: TBAF, THF, RT–50 °C, 2 h; (ix) KCN, DMSO, RT–130 °C, 20 h.</p></p></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Cyclopropyl Addition to the Bridging Carbon<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0024.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0025.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Rac, racemic; ent1, enantiomer 1; and ent2, enantiomer 2. See <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> footnote for other abbreviations and error analysis information.</p></div></div><div></div></div><div class="NLM_p">Combinations of the beneficial triazole with different benzyl groups (<b>92</b>–<b>102</b>) were synthesized to determine if more potent analogues could be identified (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The 2-F, 4-CF<sub>3</sub>-benzyl analogue (<b>92</b>), was 12–40-fold less potent than <b>79</b> (4-CF<sub>3</sub>-pyridinyl) against <i>Pf</i>DHODH and <i>Pf</i>3D7-infected cells, respectively, mimicking the reduced activity observed for <b>59</b>–<b>61</b>. In contrast, the addition of <i>meta</i>-fluorine (<b>94</b>) yielded compounds that were ∼2-fold less potent than <b>79</b>, while the addition of <i>meta</i>-cyano improved potency by 2-fold (<b>98</b> and <b>99</b>). The active enantiomer containing 3-CF<sub>3</sub>-benzyl (<b>96</b>) instead of 4-CF<sub>3</sub>-benzyl was nearly 4-fold less potent than <b>79</b>. Replacement of 4-CF<sub>3</sub>-pyridinyl with 4-CF<sub>2</sub>-pyridinyl also led to a 10-fold drop in potency (<b>101</b> versus <b>79</b>).</div><div class="NLM_p last">The addition of the cyclopropyl to the bridging carbon improved potency in most, but not all cases, but had little impact on metabolic stability (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S4A</a>). The overall properties were best for the triazoles; for example, <b>79</b> compared favorably to <b>30</b> was more potent while retaining similar metabolic stability. Similar effects were observed for the carboxamide pyrazole <b>84</b> versus <b>47</b>, although solubility was better for <b>47</b>. While the isoxazole <b>75</b> with the bridging cyclopropyl was highly potent and improved over <b>26</b>, it was less metabolically stable, particularly versus MLM. The cyclopropyl analogue <b>73</b> had good metabolic stability in HLM and had an improved potency over <b>2</b>, but <b>73</b> showed a large species effect in MLM, suggesting that the development of this compound would be challenging. Replacement of 4-CF<sub>3</sub> of <b>79</b> with 4-CF<sub>2</sub>H (<b>101</b>) improved metabolic stability but led to reduced potency. Replacement of 4-CF<sub>3</sub>-pyridinyl of <b>73</b> with 3-cyano, 4-CF<sub>3</sub> (<b>99</b>) improved both potency and metabolic stability. Within the <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> series of compounds (cyclopropyl on the bridging carbon), the kinetic solubility was the best for compounds containing triazole (<b>79</b> and <b>101</b>) or imidazole (<b>88</b>) combined with the pyridinyl-4-CF<sub>3</sub> in the benzyl position.</div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Pyrrole Methyl Replacements Including 3,5-Disubstituted Analogues</h3><div class="NLM_p">The potential for modifications on the pyrrole ring to improve potency and/or metabolic stability was assessed by replacing either the C3 methyl (R1) with more polar groups or by adding Me or Cl substituents to the C5 methyl (R) in the presence of either C3 Me or C3 CN (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S4A</a>). These compounds were made to complete the SAR analysis of modifiable positions in the system and extensive FEP+ analysis was not performed, though a good correlation between predicted and tested activity was observed for the one example that was modeled (<b>119</b>) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S2</a>). Compounds were made in the context of a selection of the best performing amides. Compounds <b>103</b>–<b>123</b> were synthesized as described in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Schemes S7–S9</a>. Replacement of the C3 methyl with COOCH<sub>3</sub> (<b>103</b>), CONHCH<sub>3</sub> (<b>104</b>), or CONH<sub>2</sub> (<b>105</b>) all led to a substantial loss of potency for the active enantiomer ranging from 250–800-fold against <i>Pf</i>DHODH and 70–150-fold against <i>Pf</i>3D7 when compared to the matched methyl containing analogue <b>2</b>. Cyano <b>106</b> was considerably better tolerated but still led to a 10-fold drop in potency against these key parameters when compared to <b>2</b>, although similar metabolic stability was observed. The addition of Me or Cl to C5 did not have a big impact on potency, while, in general, the addition of CN to C3 led to reduced activity in most cases. For compounds with the triazole as the chiral amide, the addition of Me at C3 <b>107</b> (C3 Me, C5 Me) led to a 2-fold reduction in potency against <i>Pf</i>3D7, while inserting Cl at C5 led to 1.5-fold improvement <b>121</b> (Cl, Me) versus <b>30</b> (H, Me) and maintained good metabolic stability and solubility (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S4A</a>). In contrast, within the context of the bridging cyclopropyl, adding the Cl resulted in a 10-fold drop in potency for <b>123</b> (Cl, Me) versus <b>79</b> (H, Me). The pyrazole <b>109</b> (Me, Me) and methylpyrazole <b>114</b> (Me, Me) C5 methyl derivatives showed similar potency and comparable solubility/metabolic stability to <b>33</b> (H, Me) and <b>36</b> (H, Me), respectively, while replacement of the C5 Me with CN in the context of the C3 Me <b>118</b> (Me, CN) resulted in a 40-fold loss of potency compared to <b>33</b>, mirroring the effects of the CN observed for <b>106</b>. Similar results were observed for the isoxazole, where <b>111</b> (Me, Me) was similarly potent to <b>26</b> (H, Me), and <b>116</b> (Me, CN) was 6-fold less potent, or for the cyclopropyl amides where the <i>Pf</i>3D7 EC<sub>50</sub> of <b>119</b> was within 2-fold of <b>2</b> (H, Me).</div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0014.jpeg" id="gr6" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 3,3-diethoxyprop-1-yne, n-BuLi, THF, −78 °C, 1.25 h; (ii) Dess–Martin, CH<sub>2</sub>CI<sub>2</sub>, RT, 0.5–1 h; (iii) ethyl isocyanoacetate, Ag<sub>2</sub>CO<sub>3</sub>, NMP, 85°C, 2 h; (iv) NaOH, EtOH, 70 °C, 2 h; (v) HATU, CH<sub>2</sub>CI<sub>2</sub>, Et<sub>3</sub>N, RT, 4 h; (vi) NaCIO<sub>2</sub>, sulfamic acid, HzO, 0 °C–RT, 2 h; (vii) SOCI<sub>2</sub>, MeOH, 0 °C–RT, 16 h; (viii) NaBH<sub>4</sub>, EtOH, 0 °C–RT, 1 h; (ix) Et<sub>3</sub>SiH, TFA, RT, −85 °C; (x) NaOH, EtOH, H<sub>2</sub>O, RT, 80 °C, 2 h; and (xi) R<sub>1</sub> = CONHMe: MeNH<sub>2</sub>, HATU, Et<sub>3</sub>N, THF, 0 °C–RT, 4 h; R<sub>1</sub> = CONH<sub>2</sub>: CDI, MeCN, RT–80 °C, 2 h, then NH<sub>4</sub>OH, RT–80 °C, 4 h; R<sub>1</sub> = CN (from R<sub>1</sub> = CONH<sub>2</sub>): POCI<sub>3</sub>, MeCN, pyridine, RT, 80 °C, 2 h.</p></p></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pyrrole Methyl Replacements, Including Disubstituted Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0026.gif" alt="" id="fx10" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0027.gif" alt="" id="fx11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>*</sup></sup><p class="last">With cyclopropyl on bridge. Rac, racemic; ent1, enantiomer 1; and ent2, enantiomer 2. See <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> footnote for other abbreviations and error analysis information.</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Removal of the Bridging Carbon</h3><div class="NLM_p">A final set of compounds explored the effects of removing the bridging methyl altogether on DHODH and <i>Pf</i>3D7 potency and metabolic stability. The decision to synthesize this set of compounds was driven by the goal of reducing metabolism at a potentially susceptible position (the bridging carbon). Aryl groups most likely to provide potent binding to Plasmodium DHODHs were identified by computational modeling and compounds (<b>124</b>–<b>163</b>) were synthesized for a selection of the best previously identified amides, as shown in <a class="ref internalNav" href="#sch7" aria-label="Schemes 7">Schemes 7</a> and <a class="ref internalNav" href="#sch8" aria-label="8">8</a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Schemes S9 and S10</a> (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Of the five aryl groups that were synthesized, all of those containing an NH group in the 5-membered ring showed activity with at least one active enantiomer from each series showing <i>Pf</i>DHODH and <i>Pf</i>3D7 activity of <0.1 μM, but in general, the molecular modeling was less predictive of activity for compounds in this set (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S2</a>). These aryl ring systems included indole (<b>124</b>–<b>130</b>), indazole (<b>131</b>–<b>142</b>), pyrazolopyridine (<b>149</b>–<b>154</b>), and pyrrolopyridine (<b>155</b>–<b>163</b>). Methylation of the NH within the indazole series led to complete loss of activity (<b>145</b>, <b>146</b>), while replacement of NH with oxygen (<b>147</b>, <b>148</b>) also led to poorly active compounds demonstrating that the free NH was an important driver of potent binding. Each of the most active aryl groups also contained a CF<sub>3</sub> at C6. Replacement of CF<sub>3</sub> with F in the indole series led to 10-fold lower activity (<b>144</b> vs <b>135</b>). Within each series, the most active amide was in all cases the active enantiomer of the isoxazole (<b>127</b>, <b>135</b>, <b>154</b>, and <b>159</b>), with the best being the pyrrolopyridine analogue <b>159</b> (<i>Pf</i>3D7 EC<sub>50</sub> = 0.0049 μM), followed by pyrazolopyridine <b>154</b>. Indole <b>127</b> and indazole <b>135</b> were 3-fold less active than <b>154</b> and 10–12-fold less active than <b>159</b>.</div><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0015.jpeg" id="gr7" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) nitroethane, NH<sub>4</sub>OAc, RT–100 °C, 1–3 h; (ii) Fe, 4 N HCI, acetone, RT–50/60 °C, 3h; (iii) DMF, DMA, MW, 120 °C, 1 h; (iv) ethyi-2-(hydroxyimino)-3-oxobutanoate, Zn, NaOAc, AcOH, RT–100 °C, 3 h; (v) NaOH, EtOH/H<sub>2</sub>O, RT, 2 h; (vi) amine, HATU, Et<sub>3</sub>N, CH<sub>2</sub>CI<sub>2</sub>, RT, 3–4 h; (vii) Et<sub>3</sub>SiH, TFA, CH<sub>2</sub>CI<sub>2</sub>, RT, 1 h.</p></p></figure><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0016.jpeg" id="gr8" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) NaOH, EtOH/H<sub>2</sub>O, RT, −80 °C, 2 h; (ii) amine, HATU, Et<sub>3</sub>N, CH<sub>2</sub>CI<sub>2</sub>, RT, 2–4 h; (iii) NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, DMSO, RT, −100 °C, 2 h; (iv) R = CONH<sub>2</sub>: aq. NH<sub>3</sub>, MeOH, RT, −100 °C, 24 h; (v) R = CN: T<sub>3</sub>P, DIPEA, CH<sub>2</sub>CI<sub>2</sub>, RT, 2 h.</p></p></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Removal of the Bridging Carbon</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0028.gif" alt="" id="fx12" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0029.gif" alt="" id="fx13" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0030.gif" alt="" id="fx14" /></img><div></div></div><div class="NLM_p last">Compounds without the bridging carbon (<b>127</b>, <b>135</b>, <b>154</b>, <b>155</b>, <b>156</b>, <b>159</b>, and <b>163</b>) were poorly soluble, regardless of the nature of the amide group. Isoxazoles <b>127</b> and <b>154</b> showed good metabolic stability in HLM (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S4A</a>), and while both met our objective (CL<sub>int</sub> < 10 μL/min/mg), neither was as potent against <i>Pf</i>3D7-infected cells as desired. Both of these compounds had better metabolic stability than isoxazole derivatives with the bridging carbon (<b>127</b>, <b>154</b> vs <b>26</b>). The most potent of the compounds lacking the bridging carbon (isoxazole <b>159</b>) had a CL<sub>int</sub> of 22 μL/min/mg but was unlikely to have the required pharmacokinetic (PK) properties needed for advancement. Thus, combined with the poor solubility, compounds lacking the bridging carbon did not meet our objectives to be advanced.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> SAR Summary</h3><div class="NLM_p">We analyzed a wide array of pyrrole-based DHODH inhibitors, with the most potent compounds tending to come from a set of chiral amides (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>) that were suggested based on molecular modeling. Within these, and where tested, the racemate tended to be 2-fold less potent throughout as expected, and the active enantiomer maintained >100-fold better potency against both <i>Pf</i>DHODH and the parasite across the tested compounds, although the difference at the enzyme level tended to be greater than for the parasite.</div><div class="NLM_p last">Throughout the series, we observed a good correlation between (1) the FEP+ predicted values and inhibitory activity against <i>Pf</i>DHODH (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figures S3</a>) and (2) between <i>Pf</i>DHODH and antiplasmodial activity against <i>Pf</i>3D7 asexual blood stage (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). For a handful of the most potent antimalarial compounds (e.g., <b>79</b>), the activity against <i>Pf</i>3D7 was better than would have been expected based on <i>Pf</i>DHODH inhibitory activity (discussed below). We assessed species selectivity of compounds against other parasite enzymes and against human DHODH (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). Inhibitory activity against <i>Pv</i>DHODH paralleled trends that were observed for <i>Pf</i>DHODH, although most compounds show better potency against <i>Pv</i>DHODH than <i>Pf</i>DHODH, suggesting that efficacy against <i>P. falciparum</i> should translate to good efficacy against <i>P. vivax</i>. No activity against human DHODH was observed for any analogue; thus, this series would not be expected to show on-target toxicity in humans.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Determination of the Binding Mode of Select Pyrrole Analogues by X-ray Structure Analysis</h3><div class="NLM_p">To assess the contribution of binding interactions to inhibitor potency, we solved the X-ray structures of select compounds that contained variable substituents expected to interact with either the chiral amide binding pocket (<b>79</b>, <b>47</b>, <b>56</b>, <b>86</b>, <b>81</b>) or the aryl binding pocket (<b>18</b>, <b>127</b>). Compounds were cocrystallized with <i>Pf</i>DHODH and X-ray structures were solved as described (<a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). Data collection and refinement statistics are presented in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S3</a>. Structures were solved to high resolution and diffracted over a range of 1.6 Å (<b>86</b>) to 2.4 Å (<b>56</b>). The refinement statistics (<i>R</i><sub>work</sub> and <i>R</i><sub>free</sub>) demonstrated that all structures were well refined (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S3</a>) and strong electron density was observed for all inhibitors (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figure S1</a>).</div><div class="NLM_p">Binding modes were similar to what we observed previously for <b>3</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figure S2</a>). Inhibitors that contained an amide bond (<b>79</b>, <b>47</b>, <b>56</b>, <b>81</b>, <b>86</b>, and <b>127</b>) formed a bifurcated hydrogen (H)-bond between H185 and the pyrrole and amide NH, whereas the ester <b>18</b> was only able to form a single H-bond. All compounds also formed a H-bond interaction between their carbonyl and R265. The chiral methyl in all 6 amide-bound structures was orientated in the same direction and pointed toward I272, making its closest contact to <b>127</b> at a distance of 3.9 Å (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). This orientation establishes the <i>R</i>-enantiomers as the active configuration, allowing us to assign the stereochemistry of these compounds. The aromatic 5-membered rings of the chiral amides were bound near flavin mononucleotide (FMN) in a pocket that contains several potential H-bond interactions, whereas the aryl binding pocket was formed by a largely hydrophobic cleft between the two N-terminal helices (helix 1, residues F166-Y176; helix 2, residues G181-Y194). Compounds containing 4-CF<sub>3</sub>-pyridinyl (<b>79</b>, <b>47</b>, <b>81</b>, and <b>86</b>) in the aryl position formed a H-bond between the pyridinyl nitrogen and an ordered water molecule (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A,B and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figure S1B,C</a>). Similarly, the indole NH of <b>127</b> formed a H-bond with an ordered water molecule in the same area of the pocket (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C).</div><figure id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0004.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structures of pyrrole-based inhibitors bound to <i>Pf</i>DHODH (green). The 4 Å shell around the bound inhibitor (pink) is shown for (A) <b>79</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KZ4">7KZ4</a>), (B) <b>47</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LOK">7LOK</a>), and (C) <b>127</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYY">7KYY</a>). Hydrogen bonds are depicted by dashed lines with distances given in Å. Structures were displayed with PyMol and chemical structures are shown in each panel as rendered by Chemdraw.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Additionally, we observed a set of novel interactions between the aromatic 5-membered rings of the chiral amides and previously unexplored areas of the binding pocket. These groups bound deeper into the pocket than previously explored functionalities (e.g., cyclopropylamide of <b>3</b>,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> the CF<sub>2</sub>CH<sub>3</sub> of <b>1</b>,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> or the OEt of <b>18</b>, Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figure S2D</a>) and, in several cases, these rings were able to make H-bonds with residues in this region of the pocket. These interactions included H-bonds between the Y528 OH and the N of triazole <b>79</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) and pyrazole <b>47</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B), and as predicted, a H-bond between the NH<sub>2</sub> portion of the carboxamide of <b>47</b> and E182. Additionally, the carbonyl oxygen of the <b>47</b> carboxamide formed a H-bond with K229, a residue we had not previously observed to form binding interactions with inhibitors in other cocrystal structures. Finally, the isoxazole N of <b>56</b> formed a H-bond with the backbone NH of E182 (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figure S2A</a>), whereas in <b>127</b> the isoxazole N formed close contacts with both the NH of E182 and the carbonyl O of G181 (3.5 Å in both cases) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C).</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Identification of Potential Late Lead Compounds</h3><div class="NLM_p last">Compounds were prioritized for further studies based on the combined potency, metabolic stability, and solubility data, with an EC<sub>50</sub> < 0.015 μM against <i>Pf</i>3D7-infected human red blood cells and a human CL<sub>int</sub> < 10 μL/min/mg being key requirements for advancement. Compounds meeting these objectives included <b>33</b>, <b>36</b>, and <b>47</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) and <b>79</b>, <b>84</b>, <b>88</b>, and <b>99</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). <b>26</b> was also included to represent the best of the isoxazoles with respect to a combination of potency and metabolic stability, although the <i>in vitro</i> human CL<sub>int</sub> suggested that it would not be sufficiently stable to meet our objectives. The carboxamide pyrazoles <b>47</b> and <b>84</b> were quickly ruled out, despite their superior metabolic stability. Their structures suggested that they might have poor permeability, which was confirmed by Caco-2 cell monolayer studies and by a mouse pharmacokinetic (PK) study for <b>84</b> in which bioavailability was only 18% (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Tables S4B and S5</a>). Compound <b>88</b> was synthesized to test the hypothesis that an imidazole group in the chiral amide position would lead to potent CYP inhibition and might reduce metabolism through autoinhibition. As predicted, <b>88</b> was a potent inhibitor of the five major CYP isoforms tested (see below); however, this property did not translate to good metabolic stability <i>in vitro</i> (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S4A</a>) or to reduced clearance in a mouse <i>in vivo</i> study (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S5</a>); therefore, this compound was not profiled further. The remaining compounds (<b>26, 33, 36, 79, 99</b>) were profiled in additional ADME studies and <i>in vivo</i> in mice and rats, and in parasitology studies to evaluate their potential to advance as late-lead candidates.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Assessing Species Selectivity and Safety Pharmacology</h3><div class="NLM_p">Compounds <b>(26, 33, 36, 79</b>, and <b>99)</b> were profiled to determine if any inhibited mammalian enzymes from species that are commonly used in toxicology studies (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S6</a>). As was observed for human DHODH, none of the compounds inhibited mouse, rat, or dog DHODH up to the highest tested concentration (100 μM). The lack of mammalian DHODH inhibition by these compounds provides a point of clear superiority over <b>1</b> that should make the assessment of the mechanisms of toxicity during the development of compounds in this series more straightforward. Compounds were also tested for cytotoxicity, and none showed growth inhibition of mouse L1210 or human HepG2 cell lines (CC<sub>50</sub>’s > 20 μM; Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S6</a>).</div><div class="NLM_p">Preliminary safety pharmacology studies included characterization of effects on the hERG channel (a measure of potential cardiac toxicity), AMES (a measure of mutagenicity potential), and a human receptor panel. The hERG channel was not inhibited by <b>26, 33, 36</b>, and <b>79</b>, while <b>99</b> showed weak inhibition (IC<sub>50</sub> = 20.4 μM) that would need to be de-risked based on the free fraction safety margin relative to predicted human plasma concentrations at the efficacious dose. Both <b>79</b> and <b>99</b> were AMES negative in a 5-strain assay with and without metabolic activation. When tested against a panel of human receptors (CEREP panel), both showed inhibition of NK<sub>1</sub>, and additionally, <b>99</b> had activity against 5-HT<sub>2A</sub>, A3, and GABA-gated chloride channel receptors (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S6</a>). However, IC<sub>50</sub> studies to measure the effect of <b>99</b> as an antagonist indicated that only NK1 was significantly inhibited (IC<sub>50</sub> = 2 μM), whereas the IC<sub>50</sub> for the other receptors were not considered to be evidence of significant inhibition (IC<sub>50</sub> of 35, 34, and >30 μM, receptively).</div><div class="NLM_p">Cytochrome P450 inhibition studies were performed using a substrate-specific interaction approach<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and both direct and time-dependent inhibition were assessed. Apart from <b>88</b>, <b>33</b> showed the most significant direct CYP inhibition, with IC<sub>50</sub> values below 2 μM for CYP2C9 and CYP2D6 (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). Compound <b>36</b> showed no inhibition against any isoform with the exception of minor inhibition of CYP2D6 (IC<sub>50</sub> 12.7 μM), <b>79</b> and <b>99</b> showed modest inhibition of CYP2C19 (IC<sub>50</sub> 6.3 and 4.2 μM, respectively) and <b>99</b> showed slightly more inhibition of CYP2C9 (IC<sub>50</sub> 2.9 μM). Time-dependent inhibition studies were conducted using an “IC<sub>50</sub> shift” protocol, as described previously.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> There was no evidence of time-dependent inhibition of any isoform, except for CYP3A4/5, for which there was a marginal increase in inhibition for <b>33</b> with preincubation in the presence of NADPH (but IC<sub>50</sub> values were still >20 μM) and an IC<sub>50</sub> shift from >20 to 5.7 μM for <b>36</b> when the preincubation was conducted in the absence or presence of NADPH, respectively. These results are similar to what was observed for <b>2</b> in our previous studies.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In contrast, no evidence for time-dependent inhibition was observed for <b>79</b> or <b>99</b>.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Direct CYP Inhibition</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="rowsep1 colsep0" colspan="5" align="center">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">CYP</th><th class="colsep0 rowsep0" align="center"><b>88</b></th><th class="colsep0 rowsep0" align="center"><b>33</b></th><th class="colsep0 rowsep0" align="center"><b>36</b></th><th class="colsep0 rowsep0" align="center"><b>79</b></th><th class="colsep0 rowsep0" align="center"><b>99</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1A2</td><td class="colsep0 rowsep0" align="left"><0.25</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2B6</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2C8</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">18.3</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2C9</td><td class="colsep0 rowsep0" align="left"><0.25</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">19.0</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2C19</td><td class="colsep0 rowsep0" align="left"><0.25</td><td class="colsep0 rowsep0" align="left">4.0</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">6.3</td><td class="colsep0 rowsep0" align="left">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2D6</td><td class="colsep0 rowsep0" align="left">0.32</td><td class="colsep0 rowsep0" align="left">0.75</td><td class="colsep0 rowsep0" align="left">12.7</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3A4 (tes/mid)</td><td class="colsep0 rowsep0" align="left">1.7/0.86</td><td class="colsep0 rowsep0" align="left">>20/c.n.c</td><td class="colsep0 rowsep0" align="left">8.5/c.n.c</td><td class="colsep0 rowsep0" align="left">>20/>20</td><td class="colsep0 rowsep0" align="left">>20/>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3A4 time-dependent inhibition</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">possibly</td><td class="colsep0 rowsep0" align="left">yes</td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">no</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">nd, not determined. c.n.c. could not calculate as there was an apparent increase in the probe metabolite formation during incubations conducted in the presence of the test compound.</p></div></div></div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Assessment of <i>In Vitro</i> ADME Properties</h3><div class="NLM_p">In general, pH 6.5 kinetic solubility and metabolic stability decreased for compounds with higher LogP/D<sub>7.4</sub> values (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The target kinetic solubility was >25 μg/mL, recognizing that studies in physiological media indicated that the kinetic solubility significantly underestimated the solubility under more biorelevant conditions. To facilitate a more accurate comparison between the compounds of different Log <i>P</i>/<i>D</i><sub>7.4</sub> that might show different binding to microsomal proteins, CL<sub>int</sub> values were corrected for the microsomal binding (calculated as described previously<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>). Maintaining Log <i>D</i><sub>7.4</sub> within a range of approximately 2 to 3.5 was therefore a goal of the medicinal chemistry program to achieve the best balance of solubility and microsomal stability and avoid issues associated with poor membrane permeability and transporter interactions that can occur for highly polar, low Log <i>D</i><sub>7.4</sub> compounds.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><figure id="fig4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0005.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Correlation of Log <i>D</i><sub>7.4</sub> with (A) unbound intrinsic clearance and (B) kinetic solubility at pH 6.5. Compound <i>Pf</i>3D7 potency is indicated as depicted in the figure legend.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Advanced ADME Studies on Identified Late Leads</h3><div class="NLM_p">The physicochemical and ADME properties of key compounds (<b>26</b>, <b>33</b>, <b>36</b>, <b>79</b>, <b>99</b>) were further profiled by assessing solubility in physiological buffers and plasma protein binding and to extend <i>in vitro</i> metabolism studies to additional mammalian species. The solubility of both <b>79</b> and <b>99</b> in fasted state simulated gastric fluid (FaSSGF), fasted and fed state simulated intestinal fluid (FaSSIF and FeSSIF, respectively), and pH 7.4 phosphate buffer (PBS) was excellent (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>), with both compounds showing very significant improvements over <b>1</b>, which suggest that they could be formulated using simple approaches without the need for solubilizing excipients. Of the two compounds, <b>79</b> showed superiority over <b>99</b>, but both compounds were significantly more soluble than <b>26</b>, <b>33</b>, or <b>36</b>.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Physicochemical Properties, <i>In Vitro</i> Binding and Metabolism</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0031.gif" alt="" id="fx15" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center"><b>1</b><a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><b>26</b></th><th class="colsep0 rowsep0" align="center"><b>33</b></th><th class="colsep0 rowsep0" align="center"><b>36</b></th><th class="colsep0 rowsep0" align="center"><b>79</b></th><th class="colsep0 rowsep0" align="center"><b>99</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MW</td><td class="colsep0 rowsep0" align="left">415</td><td class="colsep0 rowsep0" align="left">392</td><td class="colsep0 rowsep0" align="left">377</td><td class="colsep0 rowsep0" align="left">391</td><td class="colsep0 rowsep0" align="left">404</td><td class="colsep0 rowsep0" align="left">428</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLog <i>D</i><sub>7.4</sub></td><td class="colsep0 rowsep0" align="left">4.0</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility (μg/mL)<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FaSSGF (pH 1.6, 1 h)</td><td class="colsep0 rowsep0" align="left">6.8</td><td class="colsep0 rowsep0" align="left">35.1</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">113</td><td class="colsep0 rowsep0" align="left">1025</td><td class="colsep0 rowsep0" align="left">185</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FaSSIF (pH 6.5, 5 h)</td><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="left">9.9</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">890</td><td class="colsep0 rowsep0" align="left">261</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FeSSIF (pH 5.8, 5 h)</td><td class="colsep0 rowsep0" align="left">27.6</td><td class="colsep0 rowsep0" align="left">47.8</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">158</td><td class="colsep0 rowsep0" align="left">>2000</td><td class="colsep0 rowsep0" align="left">>2000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PBS (pH 7.4, 5 h)</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">5.9</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="left">493</td><td class="colsep0 rowsep0" align="left">85±10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H/R/M plasma protein binding (% bound)<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">99.8/97.5/97.0</td><td class="colsep0 rowsep0" align="left">94.7/93.7/92.2</td><td class="colsep0 rowsep0" align="left">84.0/91.4/92.1</td><td class="colsep0 rowsep0" align="left">83.0/95.1/93.6</td><td class="colsep0 rowsep0" align="left">92.8/94.3/92.1</td><td class="colsep0 rowsep0" align="left">98.5/98.2/97.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H/R/M blood-to-plasma ratio</td><td class="colsep0 rowsep0" align="left">0.54/0.8/0.7</td><td class="colsep0 rowsep0" align="left">0.7/0.9/0.8<a class="ref internalNav" href="#t9fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">1.1/1.3/1.4</td><td class="colsep0 rowsep0" align="left">0.8/0.9/0.9</td><td class="colsep0 rowsep0" align="left">0.7/0.9/0.7</td><td class="colsep0 rowsep0" align="left">0.7/0.6/0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Albumax binding (% bound)<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">83.1</td><td class="colsep0 rowsep0" align="left">75.0</td><td class="colsep0 rowsep0" align="left">49.5</td><td class="colsep0 rowsep0" align="left">49.5</td><td class="colsep0 rowsep0" align="left">71.9</td><td class="colsep0 rowsep0" align="left">89.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">microsome binding (% bound)<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">71.7</td><td class="colsep0 rowsep0" align="left">43.3</td><td class="colsep0 rowsep0" align="left">40.5</td><td class="colsep0 rowsep0" align="left">44.8</td><td class="colsep0 rowsep0" align="left">34.2</td><td class="colsep0 rowsep0" align="left">66.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H/R/M microsomal CL<sub>int</sub> (μL/min/mg)</td><td class="colsep0 rowsep0" align="left"><7/<7/<7</td><td class="colsep0 rowsep0" align="left">34/29/63</td><td class="colsep0 rowsep0" align="left">20/28/31</td><td class="colsep0 rowsep0" align="left">20/21/41</td><td class="colsep0 rowsep0" align="left">9/12/11</td><td class="colsep0 rowsep0" align="left">12/15/16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H/R/M unbound microsomal CL<sub>int</sub> (μL/min/mg)</td><td class="colsep0 rowsep0" align="left"><25/<25/<25</td><td class="colsep0 rowsep0" align="left">60/51/111</td><td class="colsep0 rowsep0" align="left">33/47/52</td><td class="colsep0 rowsep0" align="left">36/38/75</td><td class="colsep0 rowsep0" align="left">14/18/17</td><td class="colsep0 rowsep0" align="left">35/44/47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">microsome predicted H/R/M plasma clearance (mL/min/kg)</td><td class="colsep0 rowsep0" align="left"><0.05/<1.1/<2.8</td><td class="colsep0 rowsep0" align="left">2.9/5.2/nd</td><td class="colsep0 rowsep0" align="left">4.9/6.6/14</td><td class="colsep0 rowsep0" align="left">4.9/3.2/15</td><td class="colsep0 rowsep0" align="left">1.1/1.8/4.8</td><td class="colsep0 rowsep0" align="left">0.6/1.4/3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 permeability A–B/B–A Papp (10<sup>–6</sup> cm/s)<a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">54, 60/49 ± 5.1</td><td class="colsep0 rowsep0" align="left">48, 59/57, 66</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">17 ± 0.3/70 ± 0.6</td><td class="colsep0 rowsep0" align="left">22, 25/45, 50</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">Data for <b>1</b> were taken from ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> with the exception of plasma protein binding data, which were remeasured using the rapid equilibrium dialysis (RED) method, biorelevant solubility, human B/P, and Caco-2 permeability; each of these were taken from our previous report.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></p></div><div class="footnote" id="t9fn2"><sup><sup>b</sup></sup><p class="last">Data represent the average of 3–4 measurements; the relative SD (RSD) of solubility measurements was <10% and RSD of fraction unbound values was <15% in all cases.</p></div><div class="footnote" id="t9fn3"><sup><sup>c</sup></sup><p class="last">Caco-2 apparent permeability in the apical to basolateral (A–B) or B–A direction; mass balance.</p></div><div class="footnote" id="t9fn4"><sup><sup>d</sup></sup><p class="last">Mouse B/P for <b>26</b> estimated using the average of the human and rat values >80% in all cases; data represent duplicate measurements or the average of 3 measurements ± SD nd, not determined.</p></div></div></div><div class="NLM_p last">Plasma protein binding was determined by ultracentrifugation or rapid equilibrium dialysis (RED) (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) and was lowest for <b>33</b> and <b>36</b> (ranging from 83 to 95% bound across the species) and highest for <b>99</b> (∼98% bound for all species). All five tested compounds showed lower protein binding than <b>1</b>, which was reassessed using rapid equilibrium dialysis (RED) methods that included a presaturation of the dialysis membrane to improve accuracy for highly protein-bound compounds of this type.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> This approach yielded similar values for <b>1</b> with human and rat plasma, but lower binding for mouse (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) compared to previous methods.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Binding for the pyrrole series compounds in Albumax-based media (used for <i>P. falciparum</i><i>in vitro</i> efficacy assays) and in microsome preparations was lower in all cases than for plasma due to the lower protein concentrations. Very little variation between species was observed for <i>in vitro</i> metabolism studies across species, although overall, compounds were more stable in human than mouse or rat microsomes (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). Correcting for microsomal binding (measured for this subset of compounds) indicated that <b>79</b> had the lowest unbound CL<sub>int</sub> across all species. <b>33</b>, <b>36</b>, and <b>99</b> all had comparable unbound CL<sub>int</sub> values, and <b>26</b> was the least stable. Compounds <b>79</b> and <b>99</b> were also profiled in human and rat hepatocytes where data suggested that there were no additional clearance pathways not accounted for by the studies in liver microsomes. Permeability across confluent Caco-2 cell monolayers suggested that permeability was high with no evidence of efflux for <b>26</b>, whereas both <b>79</b> and <b>99</b> showed some efflux (efflux ratios of 4 and 2, respectively), indicating a possible transporter involvement.</div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Pharmacokinetic (PK) Properties in Mice and Rats</h3><div class="NLM_p">The PK properties of <b>26</b>, <b>33</b>, <b>36</b>, <b>79</b>, and <b>99</b> were assessed in mice and rats using intravenous (IV) and oral (PO) dosing routes (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Tables <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figure S4</a>). After IV dosing to mice (<b>26</b>, <b>79</b>, and <b>9</b>), plasma clearance of <b>26</b> was similar to <b>1</b>, while both <b>79</b> and <b>99</b> showed values that were 2–3-fold lower. IV clearance in mice for all three compounds was lower than for <b>2</b> (CL<sub>plasma</sub> = 26),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> representing an improvement over the earlier compound from the series. Compared to the clearance values predicted from the <i>in vitro</i> microsome data (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>), <b>26, 79</b>, and <b>99</b> had measured values (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>) within approximately 3-fold of the predicted values. Bioavailability of <b>26</b>, <b>79</b>, and <b>99</b> was similar, ranging from 61 to 74%, and all 5 compounds showed good exposure after PO dosing, with <b>36</b> showing the highest <i>C</i><sub>max</sub>, while <b>79</b> demonstrated the highest AUC after oral administration. Assuming dose-proportional kinetics, <b>99</b> would be expected to have a similar AUC compared to <b>79</b> if administered at a similar dose.</div><figure id="fig5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0006.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Plasma concentration versus time profiles in mice and rats. To allow easy comparison, data were scaled to a common dose level assuming linear kinetics over the dose range. (A) Mouse profiles following oral administration of 20 mg/kg (scaled). Actual administered doses were <b>26</b>:20 mg/kg (<i>n</i> = 2), <b>33</b>:20 mg/kg (<i>n</i> = 2), <b>36</b>:20 mg/kg (<i>n</i> = 2), <b>79</b>:24 mg/kg (<i>n</i> = 3), and <b>99</b>:2.4 mg/kg (<i>n</i> = 3). Error bars show the range for multiple measurements in <i>n</i> = 2–3 individual mice at each time point. (B) Rat profiles following intravenous (IV) (scaled to 2 mg/kg) and (C) oral administration (scaled to 20 mg/kg). Actual rat IV/PO doses were <b>26</b>:1.9/28 mg/kg; <b>33:</b>2.9/31 mg/kg; <b>36:</b>2.8/32 mg/kg; <b>79</b>:1.8/17 mg/kg; and <b>99</b>:1.9/10 mg/kg. Data represent the mean ± standard deviation (SD) for <i>n</i> = 3 rats. Measured doses and pharmacokinetic (PK) parameters deriving from these studies are provided in <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Tables <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a> (data are not scaled in the tables).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Pharmacokinetic Properties after Single IV and PO Doses to Swiss Outbred Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center"><b>26</b></th><th class="colsep0 rowsep0" align="center"><b>33</b></th><th class="colsep0 rowsep0" align="center"><b>36</b></th><th class="colsep0 rowsep0" align="center"><b>79</b></th><th class="colsep0 rowsep0" align="center"><b>99</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">IV:1.0 PO:10<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">IV:2.8 PO:20</td><td class="colsep0 rowsep0" align="left">IV:nd PO:20</td><td class="colsep0 rowsep0" align="left">IV:nd PO:20</td><td class="colsep0 rowsep0" align="left">IV:2.3 PO:2.6/24</td><td class="colsep0 rowsep0" align="left">IV:0.91 PO:2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL<sub>plasma</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">8.2</td><td class="colsep0 rowsep0" align="left">7.7</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss plasma</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO <i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">4.4</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">3.4/4.5</td><td class="colsep0 rowsep0" align="left">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO <i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">1-2</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">4.0/7.5</td><td class="colsep0 rowsep0" align="left">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO <i>C</i><sub>max</sub> (μM)</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">2.6/20</td><td class="colsep0 rowsep0" align="left">2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO AUC<sub>0-∞</sub> (μM·h)</td><td class="colsep0 rowsep0" align="left">22.8</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="left">217</td><td class="colsep0 rowsep0" align="left">29/250</td><td class="colsep0 rowsep0" align="left">18.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bioavailability (%)</td><td class="colsep0 rowsep0" align="left">46</td><td class="colsep0 rowsep0" align="left">61</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">74/70</td><td class="colsep0 rowsep0" align="left">70</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">Data are taken from ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and represent the average of the two described studies. Data for <b>1</b> are based on the average from two mice per time point, whereas all other data are based on the average of three mice per time point. nd, not determined.</p></div></div></div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Plasma Pharmacokinetic Parameters after a Single IV or PO Dose to Sprague Dawley Rats</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center"><b>1</b><a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><b>26</b></th><th class="colsep0 rowsep0" align="center"><b>33</b></th><th class="colsep0 rowsep0" align="center"><b>36</b></th><th class="colsep0 rowsep0" align="center"><b>79</b></th><th class="colsep0 rowsep0" align="center"><b>99</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>IV dose (mg/kg)</b></td><td class="colsep0 rowsep0" align="left"><b>2.6</b></td><td class="colsep0 rowsep0" align="left"><b>1.9</b></td><td class="colsep0 rowsep0" align="left"><b>2.9</b></td><td class="colsep0 rowsep0" align="left"><b>2.8</b></td><td class="colsep0 rowsep0" align="left"><b>1.8</b></td><td class="colsep0 rowsep0" align="left"><b>1.9</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL<sub>plasma</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">6.5</td><td class="colsep0 rowsep0" align="left">3.2 ± 0.40</td><td class="colsep0 rowsep0" align="left">6.2 ± 1.2</td><td class="colsep0 rowsep0" align="left">2.4 ± 0.50</td><td class="colsep0 rowsep0" align="left">6.8 ± 0.70</td><td class="colsep0 rowsep0" align="left">7.0 ± 0.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss plasma</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">5.9</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.060</td><td class="colsep0 rowsep0" align="left">1.7 ± 0.11</td><td class="colsep0 rowsep0" align="left">0.87 ± 0.034</td><td class="colsep0 rowsep0" align="left">2.1 ± 0.17</td><td class="colsep0 rowsep0" align="left">2.1 ± 0.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>PO dose (mg/kg)</b></td><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left"><b>17/10</b></td><td class="colsep0 rowsep0" align="left"><b>10</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">apparent <i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">4.1 ± 2.9</td><td class="colsep0 rowsep0" align="left">3.4 ± 0.58</td><td class="colsep0 rowsep0" align="left">3.7 ± 1.7</td><td class="colsep0 rowsep0" align="left">3.7 ± 0.40/5.9 ± 1.5</td><td class="colsep0 rowsep0" align="left">3.8 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO <i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">4.3 ± 0.60</td><td class="colsep0 rowsep0" align="left">3.0 ± 0.87</td><td class="colsep0 rowsep0" align="left">3.5 ± 0.87</td><td class="colsep0 rowsep0" align="left">2.5 ± 0.0/0.70 ± 0.30</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μM)</td><td class="colsep0 rowsep0" align="left">4.0</td><td class="colsep0 rowsep0" align="left">16 ± 2.5</td><td class="colsep0 rowsep0" align="left">2.4 ± 0.38</td><td class="colsep0 rowsep0" align="left">35 ± 9.7</td><td class="colsep0 rowsep0" align="left">14 ± 2.1/6.0 ± 0.12</td><td class="colsep0 rowsep0" align="left">6.2 ± 0.95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>∞</sub> (μM·h)</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">160 ± 24</td><td class="colsep0 rowsep0" align="left">22 ± 6.3</td><td class="colsep0 rowsep0" align="left">360 ± 28</td><td class="colsep0 rowsep0" align="left">120 ± 14/47 ± 11</td><td class="colsep0 rowsep0" align="left">42 ± 5.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bioavailability (%)</td><td class="colsep0 rowsep0" align="left">57</td><td class="colsep0 rowsep0" align="left">43 ± 6.2</td><td class="colsep0 rowsep0" align="left">10 ± 2.8</td><td class="colsep0 rowsep0" align="left">61 ± 4.3Ta</td><td class="colsep0 rowsep0" align="left">110 ± 13/77 ± 19</td><td class="colsep0 rowsep0" align="left">73 ± 10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup><sup>a</sup></sup><p class="last">Data are taken from ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a>. Data for <b>1</b> represents the average of two rats; all other data represent mean ± standard deviation for 3 rats.</p></div></div></div><div class="NLM_p">After IV dosing in rats, clearance was relatively low for all 5 compounds, representing a significant improvement over <b>2</b> (CL<sub>plasma</sub> = 29)<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The lowest clearance was observed for <b>26</b> and <b>36</b>, which showed values <b>2</b> and <b>3</b>-fold lower than for <b>1</b>, whereas clearance values for <b>33</b>, <b>79</b>, and <b>99</b> were similar to <b>1</b>. Microsome predicted clearance values for <b>26</b>, <b>33</b>, and <b>36</b> (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) were similar to the measured values (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>), but predicted values were about 4–5-fold lower than the measured values for <b>1</b>, <b>79</b>, and <b>99</b>. The basis for this is not known (note that <i>in vitro</i> studies using cryopreserved hepatocytes predicted even lower clearance than microsomes). None of the compounds were significantly eliminated in urine. All 5 compounds showed similar volumes of distribution, which were 3–5-fold lower than for <b>1</b> accounting for the lower half-lives. After PO dosing, bioavailability was poor for <b>33</b>, but was otherwise good (42–100%). As was observed after dosing in mice, <b>36</b> showed the highest exposure (<i>C</i><sub>max</sub> and AUC), but <b>26</b>, <b>79</b>, and <b>99</b> also showed good exposure, and all three showed higher <i>C</i><sub>max</sub> compared to <b>1</b> (assuming linear kinetics and factoring in the differences in dose). Interestingly, in both mice and rats, a major metabolite of <b>36</b> was <b>33</b> (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figure S4</a>).</div><div class="NLM_p last">Combining the ADME and PK data with the <i>in vitro</i> potency data against both <i>Pf</i>DHODH and <i>Pf</i>3D7-infected cells suggested that <b>79</b> and <b>99</b> were the best candidates from the series for advancement. Both showed considerable improvements over the early pyrrole lead <b>2</b>,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> including the finding that they were not irreversible CYP inhibitors. Both compounds showed high solubility in physiologically relevant buffers, were superior to the other pyrrole analogues, and also represented a substantial improvement over <b>1</b>. These results suggested that <b>79</b> and <b>99</b> will be formulated much more readily without the need for complicated solubilizing agents. Predicted clearance values from in vitro microsome (and hepatocyte) studies were lowest for these compounds across all species, and both also had good PK properties in mice and rats. Of the two, <b>79</b> had better ADME properties, while <b>99</b> was more potent. Neither compound matched the PO half-life observed for <b>1</b>, suggesting that they will likely have shorter half-lives in humans. We next turned to parasitology assays to screen for additional factors that might distinguish which compound was the most appropriate for advancement.</div></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Additional Parasitology</h3><div class="NLM_p last">Key compounds were profiled on a wider range of <i>Plasmodium</i> strains, species, and stages to ensure that they would be effective if used clinically against both drug-sensitive and drug-resistant <i>P. falciparum</i> strains, to confirm that like <b>1</b> they have liver-stage activity, and to ensure that unlike <b>1</b> they would show good <i>P. vivax</i> activity. Resistance selections were undertaken for <b>26</b> and <b>79</b>, and compounds were assessed for cross-resistance with <b>1</b>. Finally, <i>in vivo</i> efficacy was profiled versus <i>P. falciparum</i> in the SCID mouse model. The blood-stage model was chosen for efficacy assessment for several reasons. First, the existing liver-stage models have not yet been fully developed for use in pharmacokinetic/pharmacodynamic (PK/PD) modeling. Second, the blood-stage model was very useful in defining the plasma exposure required for efficacy in either treatment or prophylactic clinical studies for <b>1</b>. Finally, there is extensive experience working with this model for human dose predictions, whereas there is little precedence for the current <i>in vivo</i> liver-stage models.</div></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Cross-Resistance Data and Proof of Target Killing Mechanism</h3><div class="NLM_p">Compounds were tested for activity against the chloroquine- and pyrimethamine-resistant <i>P. falciparum</i> strain Dd2 (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>). All 5 profiled compounds (<b>26</b>, <b>33</b>, <b>36</b>, <b>79</b>, and <b>99</b>) showed similar activity against Dd2, as had been observed with the drug-sensitive strain 3D7 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Several demonstrated IC<sub>50</sub> values against <i>Pf</i>DHODH that were higher than expected based on their antiplasmodial activity, and that were high enough that they should not be affected by tight-binding kinetics (e.g., <b>79</b>, <i>Pf</i>DHODH= 0.095 μM, <i>Pf</i>3D7 = 0.013 μM). To demonstrate that parasite killing was the result of on-target DHODH inhibition, we profiled compounds versus a <i>P. falciparum</i> D10 strain that has been transfected with yeast DHODH. This strain was previously reported to be resistant to both DHODH and cytochrome bc1 inhibitors; however, the two activities can be distinguished by restoration of sensitivity to bc1 inhibitors in the presence of proguanil.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> Parasites expressing yeast DHODH were resistant to all tested compounds with or without proguanil, demonstrating that killing by <b>36</b>, <b>79</b>, and <b>99</b> was driven by DHODH inhibition (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>).</div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. Cross-Resistance, Target Validation, and Liver-Stage Activity</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="center"><b>26</b></th><th class="colsep0 rowsep0" align="center"><b>33</b></th><th class="colsep0 rowsep0" align="center"><b>36</b></th><th class="colsep0 rowsep0" align="center"><b>79</b></th><th class="colsep0 rowsep0" align="center"><b>99</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left"><i>P. falciparum</i> Asexual Blood Stage (EC<sub>50</sub> μM)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>Pf</i>Dd2<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.0087 ± 0.0015 (13)</td><td class="colsep0 rowsep0" align="left">0.0024 ± 0.00060 (2)</td><td class="colsep0 rowsep0" align="left">0.0070 ± 0.0021 (3)</td><td class="colsep0 rowsep0" align="left">0.018 ± 0.0022 (9)</td><td class="colsep0 rowsep0" align="left">0.0058 ± 0.0012 (8)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left"><i>Pf</i>D10_Yeast DHODH<a class="ref internalNav" href="#t12fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no PG</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10 (3)</td><td class="colsep0 rowsep0" align="left">>20, >10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">+3 μM PG</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10 (3)</td><td class="colsep0 rowsep0" align="left">>20, >10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left"><i>Plasmodium berghei</i> Liver Stage (EC<sub>50</sub> μM)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.0083 ± 0.00064 (2)</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">0.013±0.0044 (3)</td><td class="colsep0 rowsep0" align="left">0.0022 ± 0.0016 (2)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t12fn1"><div class="footnote" id="t12fn1"><sup><sup>a</sup></sup><p class="last">Data show the mean ± standard error of the mean with the number of independent replicates in parenthesis.</p></div><div class="footnote" id="t12fn2"><sup><sup>b</sup></sup><p class="last">Atovaquone control >20 μM minus proguanil (PG), 0.00016 ± 0.000051 μM plus PG. Additionally, <b>42</b>, <b>44</b>, <b>62</b>, <b>127</b>, and <b>135</b> were also tested versus the yeast DHODH line and all showed IC<sub>50</sub> > 10 μM ± PG. nd, not determined.</p></div></div></div></div><div id="sec2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>P. berghei</i> Liver-Stage Activity</h3><div class="NLM_p last"><i>P. berghei</i> liver-stage assays were performed to test whether compounds could block the establishment of HepG2 liver-stage infection by sporozoites. All three tested compounds (<b>26</b>, <b>79</b>, and <b>99</b>) showed activity on <i>P. berghei</i> liver stage similar to that observed against <i>P. falciparum</i> asexual blood stages (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>). Importantly, as expected, these data confirm the good liver-stage activity of these compounds and the suitability of the DHODH target for the development of compounds for malaria prophylaxis.</div></div><div id="sec2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>P. vivax</i>/<i>P. falciparum</i> Field Isolates</h3><div class="NLM_p">Compound efficacy was assessed against <i>P. falciparum</i> and <i>P. vivax</i> field isolates in <i>ex vivo</i> studies. Compounds were tested against fresh <i>P. falciparum</i> parasite isolates collected from malaria patients in Uganda.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Using standard Albumax media and a 72 h SYBR Green microplate assay, compounds <b>36</b> and <b>79</b> showed potency similar to that observed for laboratory strains. Median EC<sub>50</sub> values in the study were ∼3-fold higher than those observed for <b>1</b> over a large sample size (<a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">Table <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">13</a></a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figure S5A</a>), demonstrating that both DHODH inhibitors showed good activity against African isolates from the collection region. A good correlation in results was observed between DHODH inhibitors across the sample set, including for the <b>1</b> analogue DSM421,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> with the exception that results for <b>1</b> and <b>36</b> showed a lower correlation than those for other pairs (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figure S5B</a>).</div><div class="NLM_table-wrap" id="tbl13"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 13. <i>Ex Vivo</i> Studies of <i>P. falciparum</i> and <i>P. vivax</i> Patient Isolates</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">lab strains EC<sub>50</sub> (μM)</th><th class="rowsep1 colsep0" colspan="3" align="center"><i>Pf</i> field isolates EC<sub>50</sub> (μM)</th><th class="rowsep1 colsep0" colspan="3" align="center"><i>Pv</i> field isolates EC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">3D7</th><th class="colsep0 rowsep0" align="center">Dd2</th><th class="colsep0 rowsep0" align="center">N</th><th class="colsep0 rowsep0" align="center">median (range)</th><th class="colsep0 rowsep0" align="center">median unbound</th><th class="colsep0 rowsep0" align="center">N</th><th class="colsep0 rowsep0" align="center">median (range)</th><th class="colsep0 rowsep0" align="center">median unbound</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" colspan="6" align="left">Uganda</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">0.0029 ± 0.0020 (35)</td><td class="colsep0 rowsep0" align="left">0.0029 ± 0.0016 (36)</td><td class="colsep0 rowsep0" align="left">483</td><td class="colsep0 rowsep0" align="left">0.0037 (0.00017–0.019)</td><td class="colsep0 rowsep0" align="left">0.00077*</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">0.0062 ± 0.0031 (33)</td><td class="colsep0 rowsep0" align="left">0.0059 ± 0.0023 (32)</td><td class="colsep0 rowsep0" align="left">414</td><td class="colsep0 rowsep0" align="left">0.0098 (0.00023–0.040)</td><td class="colsep0 rowsep0" align="left">0.0020*</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>79</b></td><td class="colsep0 rowsep0" align="left">0.0075 ± 0.0040 (9)</td><td class="colsep0 rowsep0" align="left">0.0069 ± 0.0026 (9)</td><td class="colsep0 rowsep0" align="left">182</td><td class="colsep0 rowsep0" align="left">0.011 (0.0011–0.028)</td><td class="colsep0 rowsep0" align="left">0.0031*</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" colspan="6" align="left">Brazilian Western Amazon Schizont maturation (SM)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>79</b></td><td class="colsep0 rowsep0" align="left">0.052 (0.015) SG, 0.086 (0.024) SM</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.12 (0.077–0.25)</td><td class="colsep0 rowsep0" align="left">0.055**</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">0.12 (0.078–0.29)</td><td class="colsep0 rowsep0" align="left">0.033**</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>99</b></td><td class="colsep0 rowsep0" align="left">0.0080 (0.00084) SG, 0.020 (0.0021) SM</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">0.060 (0.032–0.092)</td><td class="colsep0 rowsep0" align="left">0.0064**</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">0.044 (0.021–0.098)</td><td class="colsep0 rowsep0" align="left">0.0024**</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t13fn1"><div class="footnote" id="t13fn1"><sup><sup>a</sup></sup><p class="last">Median EC<sub>50</sub> data are shown in micromolar with the range in parenthesis. For lab strains, the number of independent replicates is shown in parenthesis. For field isolates, <i>N</i> = number of patient samples studied. <i>Pf</i> Uganda lab strain and field isolates were assessed by standard SYBR Green (SG) assays using Albumax-based media.<a onclick="showRef(event, 'ref32 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref34">(32,34)</a> Lab strains from the Brazilian study were assessed by either the standard SG assay or by the schizont maturation (SM) assay with lab strain parasites cultured in standard Albumax media and field isolates were cultured in 20% human serum-based media (see the <a class="ref internalNav" href="#sec5" aria-label="Experimental Methods">Experimental Methods</a>); unbound values are in parenthesis. Unbound values were calculated using the protein binding data from for *Albumax-based media (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) or based on **McCoys or RPMI human serum-based media binding (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S4C</a>).</p></div></div></div><div class="NLM_p last">A second series of studies compared efficacy against <i>P. falciparum</i> versus <i>P. vivax</i> field isolates. Because <i>P. vivax</i> cannot be cultured continuously, the alternative schizont maturation assay was used to determine compound potency. Field isolates were collected from patients in the Brazilian Amazon. The tested pyrrole-based compounds (<b>79</b>, <b>99</b>) showed equal activity against both <i>P. vivax</i> and <i>P. falciparum</i> field isolates (<a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">Table <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">13</a></a>). These results predicted that, unlike <b>1</b>, pyrroles <b>79</b> and <b>99</b> would be expected to be equally effective for the treatment of either <i>P. falciparum</i> and <i>P. vivax</i> infections. EC<sub>50</sub> values in this study were higher than those determined in Albumax-based media. When corrected for protein binding, similar potency was observed between the two assays in the study (<a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">Table <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">13</a></a>). However, values for <b>79</b> were 3–7 higher for both lab strains and clinical isolates in this study than observed in other studies, e.g., <i>P. falciparum</i> lab strains (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) or African field isolates (<a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">Table <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">13</a></a>) using the SYBR Green assay, and were still higher in the schizont maturation assay. The reason for these differences is not understood.</div></div><div id="sec2_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Selection of Drug-Resistant Parasites</h3><div class="NLM_p"><i>In vitro</i> selections were performed to generate <i>P. falciparum</i> parasites resistant to <b>26</b> and <b>79</b>. These studies evaluated both the frequency by which resistance develops (minimum inoculum for resistance (MIR)) and the mechanism of resistance. <b>1</b> was used as a control in the selections to provide a comparator. In the first study, selections were performed with <b>26</b> and <b>1</b> versus Dd2 parasites at a range of starting inocula (10<sup>6</sup>–10<sup>9</sup>) and a dose of 4 × EC<sub>50</sub> (0.030 μM for <b>1</b> and 0.025 μM for <b>26</b>). For <b>26</b> selections, recrudescent parasites were observed in all three wells or flasks that were cultured at each starting inoculum, whereas for <b>1</b>, only inoculum sizes of 10<sup>7</sup> or greater demonstrated recrudescence. In the past few studies, the MIR for <b>1</b> was between 10<sup>6</sup> and 10<sup>7</sup>; therefore, the results from these current selections show a similar resistance propensity for both compounds.<a onclick="showRef(event, 'ref15 ref35'); return false;" href="javascript:void(0);" class="ref ref15 ref35">(15,35)</a></div><div class="NLM_p">We proceeded to clone parasites by limiting dilution from nine bulk cultures and then PCR amplified and sequenced the <i>dhodh</i> gene. In total, 9 SNPs were found among the analyzed clones (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S7A</a>). Three of the four-point mutations that were selected by <b>1</b> have been previously reported (E182D, C276Y, and L531F<a onclick="showRef(event, 'ref15 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref15 ref35 ref36 ref37">(15,35−37)</a>), while I272N was novel to this study. Notably, C276Y also emerged in a clinical efficacy study after treatment with <b>1</b>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> A distinct set of mutations were identified in the <b>26</b> selections (L172F, I272F, G535C, V532A, and F188I) consistent with the different binding modes of the two inhibitors (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A).</div><figure id="fig6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0007.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Superimposed X-ray structure of <b>56</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYV">7KYV</a>) (pink) and <b>1</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RX0">4RX0</a>) (green) showing residues involved in resistance mutations. The <b>56</b> ligand is displayed in ball and stick (bright pink), and <b>1</b> is displayed in sticks (bright green). (B) Differential effects of pyrrole (<b>26</b>) versus triazolopyrimidine (<b>1</b>) selected mutations in <i>Pf</i>DHODH on parasite EC<sub>50</sub>. The plot shows a bar graph of the fold change (mean ± standard error of the mean (SEM)) in EC<sub>50</sub> for mutant strains versus wild-type Dd2 parasites. Compounds used for EC<sub>50</sub> determination are shown on the <i>X</i>-axis. The results for mutant lines that were selected using <b>1</b> are shown in green and those selected with <b>26</b> are shown in pink. Identified <i>Pf</i>DHODH mutations are defined in the figure legend. Data were taken from Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S7A</a>. Data for C276F, L531F, and R265 were taken from the previously selected clone data, but were in good agreement with the newer clones showing the same mutations (e.g., F1B9 L531F).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Resistant clones were profiled to determine the EC<sub>50</sub> shift for <b>1</b>, <b>26</b>, <b>79</b> and to test for cross-resistance to atovaquone (ATQ; <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S7A</a>). We also profiled previously reported<a onclick="showRef(event, 'ref15 ref35'); return false;" href="javascript:void(0);" class="ref ref15 ref35">(15,35)</a><b>1</b>-selected mutant Dd2 lines and C276F and C276Y CRISPR/Cas9-edited lines<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S7A</a>). Overall, we saw minimal cross-resistance between parasites selected for resistance to the triazolopyrimidine <b>1</b> versus the pyrroles <b>26</b> and <b>79</b>. Exceptions were the R265G and V532A mutations, both showing ∼10–30-fold higher EC<sub>50</sub> values for all three compounds (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S7A</a>). These findings are consistent with observations that R265 forms a key H-bond to all three inhibitors and that V532 is found in both the triazolopyrimidine and pyrrole binding pockets (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A, and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figure S2</a>). Increased sensitivity of mutant parasites to DHODH inhibitors was also observed when resistance was selected by the opposite scaffold. C276F/Y mutant parasites were 2–10-fold more sensitive to <b>26</b>, the L531F mutant was 3–4-fold more sensitive to <b>79</b>, and, most strikingly, the L172F mutant was 50-fold more sensitive to <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S7A</a>).</div><div class="NLM_p">A tolerance phenotype was also observed for C276F versus <b>26</b> and <b>79</b>, and for C276Y versus <b>79</b> in some but not all experiments (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S7 and Figure S6</a>). Tolerance was defined by the observation of only a partial dose-response, with a fraction of cells (20–50%) remaining refractory to inhibition, leading to a plateau of incomplete inhibition at higher concentrations. The reason for the variability of this effect between studies is not understood. The EC<sub>50</sub> values for <b>26</b> and <b>79</b> versus these mutants remained similar to wild-type, as determined in the studies where tolerance was not observed, or by fitting the data from the fraction of cells that remained sensitive in the case of tolerance (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figure S6</a>). These results suggested that C276F/Y mutations do not directly impact binding of <b>26</b> and <b>79</b> to DHODH and that tolerance derives from a different mechanism. This hypothesis was supported by analysis of the effects of these mutations on recombinant <i>Pf</i>DHODH. The IC<sub>50</sub> values for <b>26</b> and <b>79</b> measured on the C276F and C276Y <i>Pf</i>DHODH mutant enzymes were found to be similar to wild-type for C276Y and 2–3-fold lower (more potent) for C276F, whereas the IC<sub>50</sub> values for <b>1</b> increased by 10–20-fold, similar to our previous report<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S7B</a>).</div><div class="NLM_p">In prior studies, we showed that DHODH <b>1</b>-selected resistant lines harboring point mutations showed full sensitivity to ATQ (previously reported clones, including C276F).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> However, we also found that high-level amplification (∼12-fold) of the <i>dhodh</i> gene and surrounding regions was associated not only with resistance to DHODH inhibitors but with a tolerance phenotype toward ATQ.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> For these reasons, we extended the analysis of ATQ sensitivity to our new <b>1</b> and <b>26</b>-selected parasite lines and to our CRISPR-edited C276F and C276Y lines. All of the <b>1</b> and <b>26</b>-selected lines, as well as the CRISPR-edited C276F and C276Y lines, retained full sensitivity to ATQ (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S7A</a>). A recent study also found that a CRISPR-edited C276F line retained sensitivity to ATQ.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> However, this study also reported that a combination of <i>dhodh</i> gene amplification and the C176F mutation led to tolerance toward both ATQ and the triazolopyrimidine analogue DSM1. Thus, our studies and those of others have uncovered resistance mechanisms related to genetic changes at the <i>dhodh</i> locus that have unexpected consequences, for which a mechanistic understanding remains incomplete.</div><div class="NLM_p">Mapping the selected mutations onto the X-ray structures bound to <b>1</b> and the <b>26</b>-analogue <b>56</b> shows that <b>1</b>-selected mutations with the exception of L531F are found primarily near the FMN-side of the pocket near the triazolopyrimidine and CF<sub>2</sub>CH<sub>3</sub> portion of <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). In contrast, <b>26</b>-selected mutations tend to map to the aromatic-binding pocket of the pyrroles, although V532 is closest to the pyrrole/triazolopyrimidine ring pockets, explaining why it impacts both chemical series. On the pyrrole series, L172 forms a close interaction with the bridging carbon and or the cyclopropyl on the bridge and it is also within van der Waals interaction of the 6-position methyl on the triazolopyrimidine ring of <b>1</b>. Based on their positions, the L172F and F188I mutations could impact binding directly. Alternatively, these mutations may impact the dynamics of the mobile F188 residue that flips conformation when bound to <b>1</b>-series compounds compared to when bound to the pyrroles. F172 may stabilize F188 in the down position through extending the network of aromatic edge-to-face interactions, thus favoring binding of the triazolopyrimidines, while disfavoring the binding of the pyrroles and explaining the greater potency of <b>1</b> against cells harboring this mutation. Likewise, the F188I mutation may disrupt this dynamic equilibrium favoring the down position, thus disrupting the binding of the pyrrole-series compounds, while not impacting the binding of <b>1</b>.</div><div class="NLM_p last">In a second study, selections were performed to assess the <b>79</b> resistance profile. Selections with Dd2 parasites were performed across a range of starting inocula (10<sup>6</sup>–10<sup>9</sup>) at 4 × EC<sub>50</sub> (EC<sub>50</sub> = 0.013 μM). Parasites recrudesced in all flasks by day 30, similar to the results obtained for <b>26</b>. The <b>79</b>-selected parasites, however, showed only modest EC<sub>50</sub> shifts (3–7-fold; Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S8A</a>), and targeted sequencing of the <i>dhodh</i> gene revealed no SNPs. Whole-genome sequencing (WGS) of two bulk cultures identified a 2-fold amplification of a chromosomal segment harboring the <i>dhodh</i> locus (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S8B</a>), explaining the modest level of resistance. Selections were also performed with 3D7 parasites. Drug assays with two separately pressured bulk cultures (starting inocula 10<sup>5</sup>–10<sup>7</sup> at 3 × EC<sub>50</sub> (EC<sub>50</sub> = 0.0088 nM)) showed 9–13-fold shifts in EC<sub>50</sub> (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Tables S8A</a>). Parasites were cloned from both flasks, and three clonal lines were sent for WGS. This analysis identified a 4- or 5-fold amplification in the <i>dhodh</i> locus but no SNPs in the <i>dhodh</i> gene (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Tables S8C</a>). Both Dd2 and 3D7 parasites showed amplifications of nonidentical yet overlapping segments that in all cases included <i>dhodh</i>. We observed no SNPs common to Dd2 and 3D7 selections, arguing that the only causal resistance mediator was the <i>dhodh</i> amplification. These data were generated from Illumina sequencing with a 29- to 57-fold depth of genome sequence coverage for all clones and parental lines (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S8D</a>). The differing behavior of <b>79</b> in these selections compared to other DHODH inhibitors may suggest that it is harder to select for point mutations with <b>79</b>, resulting in smaller EC<sub>50</sub> shifts when resistance does develop. Additional studies would be needed to confirm this result.</div></div><div id="sec2_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> SCID Mouse Efficacy Studies</h3><div class="NLM_p"><i>In vivo</i> efficacy of <b>33</b>, <b>36</b>, <b>79</b>, and <b>99</b> was assessed using the previously reported <i>P. falciparum</i> SCID mouse model.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Early work on <b>33</b> and <b>36</b> used the published 4-dose once daily (QD) model, with efficacy parameters assessed one day after the final dose (Day 7). Later work on <b>79</b> and <b>99</b> used newer models that allowed parasitemia to be monitored for 60 days so that the day of recrudescence (DOR) could be determined. In this model, 6 days of twice daily (BID) dosing was employed to better mimic the human clinical setting where 8 days above the minimum inhibitory concentration (MIC) is the target to enable once weekly dosing of a prophylactic drug. Then, <b>79</b> was dosed in parallel to <b>1</b> as a comparator over an extensive dose range to establish the parameters with this newer model.</div><div class="NLM_p">In the 4-day model, <b>33</b> and <b>36</b> were dosed at 10 and 50 mg/kg and both led to a reduction in parasitemia at both dose levels, although in no case were parasites cleared to below detectable limits (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figure S7</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S9A</a>). Based on the limited dose levels, an ED<sub>90</sub> (dose that clears 90% of parasites) could not be determined, but for <b>33</b>, the 10 mg/kg dose reduced parasitemia by 85%. Both the total and free AUC at this dose were similar to the AUCs measured for <b>2</b> in a prior study<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> at the approximate ED<sub>90</sub>, although a dose of 50 mg/kg was required to achieve the same level of exposure as for <b>2 (</b>Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Tables S9A,B</a>). Thus, <b>33</b> appeared to have similar efficacy to <b>2</b>, while <b>36</b> performed less well.</div><div class="NLM_p">The 6-day BID dosing study for <b>1</b> and <b>79</b> was performed at 5 dose levels to allow efficacy parameters to be fully delineated. Doses were selected for <b>1</b> based on previous studies and for <b>79</b> based on preliminary data showing that exposure in the SCID mouse was 3–5-fold lower than in wild-type mice. Both parasite clearance and the DOR were dose dependent (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Tables S10</a>). Doses of 16.7 mg/kg/day for <b>1</b> and of 50 mg/kg/day for <b>79</b> provided the maximum rate of parasite killing and fully suppressed parasitemia by days 7–8 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S10</a>). The DOR ranged from 17 to 28 days across these same dose levels. PK sampling was taken throughout the 6 days of dosing and data were used to calculate efficacy parameters. The ED<sub>90</sub> ranged from 5.6 mg/kg/day for <b>1</b> to 25.6 mg/kg/day for <b>79</b>, while the AUC<sub>ED90</sub> and C<sub>ED90</sub> (average blood concentration that prevents net parasite growth) were similar for the two compounds (AUC<sub>ED90</sub> = 35 μM·h/day and C<sub>ED90</sub> = 1.5 μM), but when comparing free concentrations, <b>1</b> was 5-fold more potent than <b>79</b> (<a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">Table <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">14</a></a>). For <b>1</b>, both the AUC<sub>ED90</sub> and ED<sub>90</sub> were similar to the values obtained in our previous 4 dose BID study (AUC<sub>ED90</sub> = 26 μM·h/day and ED<sub>90</sub> = 3 mg/kg/day).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><figure id="fig7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0008.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. SCID mouse efficacy study of <b>1</b> (A, B) and <b>79</b> (C, D). Compounds were dosed orally twice a day (BID) for 6 days. Dose levels are expressed as mg/kg/day in the panel legends. <b>1</b> was dosed as the spray-dried dispersion formulation (SDD 25% drug load), but dose levels are reported as the free base equivalent. Panels (A) and (C) show %parasitemia of human infected red blood cells (hRBCs) versus time and panels (B) and (D) show compound blood concentrations versus time. One mouse was dosed per dose group for <b>1</b> and <b>79</b> and 2 mice were dosed for each vehicle control group. Efficacy parameters are reported in <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">Table <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">14</a></a> and SCID pharmacokinetic parameters are reported in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S10</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl14"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 14. Comparison of <i>In Vitro</i> Potency (3D7 Parasites) and (mg/kg/day) Mouse Efficacy Data for <i>Pf</i>DHODH Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center" char=".">3D7 EC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">unbound 3D7 EC<sub>50</sub> (μM)<sup>¥</sup></th><th class="colsep0 rowsep0" align="center">ED<sub>90</sub> (mg/kg/day)</th><th class="colsep0 rowsep0" align="center">blood AUC<sub>ED90</sub> (μM·h)</th><th class="colsep0 rowsep0" align="center"><sup>∧</sup>unbound AUC (μM·h)</th><th class="colsep0 rowsep0" align="center">blood C<sub>ED90</sub> (μM)</th><th class="colsep0 rowsep0" align="center">unbound C<sub>ED90</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">0.0060</td><td class="colsep0 rowsep0" align="char" char=".">0.0010</td><td class="colsep0 rowsep0" align="left">5.6 (5.4–5.9)</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">0.85</td><td class="colsep0 rowsep0" align="left">1.48</td><td class="colsep0 rowsep0" align="left">0.035</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>79</b></td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char=".">0.0034</td><td class="colsep0 rowsep0" align="left">26 (24–28)</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">4.1</td><td class="colsep0 rowsep0" align="left">1.48</td><td class="colsep0 rowsep0" align="left">0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>99</b></td><td class="colsep0 rowsep0" align="char" char=".">0.0053</td><td class="colsep0 rowsep0" align="char" char=".">0.00056</td><td class="colsep0 rowsep0" align="left"><20</td><td class="colsep0 rowsep0" align="left"><16</td><td class="colsep0 rowsep0" align="left"><0.47</td><td class="colsep0 rowsep0" align="left"><0.67</td><td class="colsep0 rowsep0" align="left"><0.020</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t14fn1"><div class="footnote" id="t14fn1"><sup><sup>a</sup></sup><p class="last">Dosing was BID using a 6-day dosing model. Parasite levels, 24 h after the final dose, were used to determine the ED<sub>90</sub>. For <b>1</b> and <b>79</b>, data in parentheses represent the 95% confidence interval of the fit. <sup>∧</sup>Unbound values were estimated based on measured mouse blood concentrations, mouse B/P, and normal mouse plasma protein binding data, with the exception of <b>1</b> where the B/P and binding were measured in infected SCID mouse blood and plasma, respectively, and found to be 1.8 and 98.3%. <sup>¥</sup>Unbound EC<sub>50</sub> was determined using the Albumax binding data from <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>. C<sub>ED90</sub> is the average concentration (Cave) at the predicted dose that provides 90% parasite clearance.</p></div></div></div><div class="NLM_p">In a separate study, the <i>in vivo</i> efficacy of <b>99</b> was assessed in this model at three dose levels (20, 50, and 100 mg/kg/day administered as 10, 25, or 50 mg/kg BID). <b>99</b> showed similar efficacy at 50 and 100 mg/kg/day compared to <b>79</b>, although it was superior at the lowest tested dose of 20 mg/kg/day (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figure S8</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S10</a>). Because all three doses led to full parasite clearance during the 6 days of dosing, we were only able to estimate efficacy parameters. One caveat was that the parasite clearance rate observed for the 20 mg/kg/day dose of <b>99</b> was higher than for the other dose levels, and the reason for this difference is not currently understood (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Figure S8</a>).</div><div class="NLM_p">Unbound AUC and Cave values were estimated based on normal mouse plasma protein binding data (<a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">Table <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">14</a></a>), with the exception of <b>1</b> for which binding data were available for SCID mouse plasma. The most potent of the pyrroles <b>99</b> showed <i>in vivo</i> efficacy in the same concentration range as <b>1</b> (unbound C<sub>ED90</sub> of <0.02 vs 0.035 μM), while <b>79</b> is about 10-fold less active based on this analysis (<a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">Table <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">14</a></a>). The remaining compounds (<b>2</b>, <b>33</b>, and <b>36</b>) were assessed in a QD model but the data suggest that <b>2</b> and <b>33</b> have similar efficacy to <b>79</b>, while <b>36</b> was least effective (<a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">Table <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">14</a></a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S9B</a>). Generally, the rank order of potency based on the <i>in vivo</i> data mirrors that of the <i>in vitro Pf</i>3D7 data when corrected for protein binding (<a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">Table <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">14</a></a>).</div><div class="NLM_p last">Significant differences in plasma exposure were observed for the pyrroles when dosed in the SCID mouse model versus wild-type Swiss OB mice (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S11</a>). Blood concentrations (as evaluated by average <i>C</i><sub>max</sub>/dose) in infected SCID mice were 3–5-fold lower than observed in the normal mouse (with the exception of <b>33</b>), with <b>79</b> showing the largest difference. These differences account for why the dose required to achieve ED<sub>90</sub> for <b>79</b> in the SCID mouse model was nearly 5-fold higher than for <b>1</b>, despite showing a similar AUC<sub>ED90</sub>. These observations suggest that clearance could be higher in the SCID mouse than in wild-type mice or that the bioavailability could be lower, but emphasize the importance of comparing effective concentrations rather than effective dose levels.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54253" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54253" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We have conducted an extensive lead optimization program to identify pyrrole-based inhibitors of <i>Pf</i>DHODH to deliver candidate drugs that could advance to preclinical development. Using a structure-based computational approach we explored modifications to all regions of the scaffold, allowing identification of a number of compounds with high potency against the <i>Plasmodium</i> enzymes and <i>P. falciparum</i> asexual blood stages. These compounds also showed species selectivity versus all tested mammalian enzymes, thus improving the properties of <b>1</b>. An additional seven coinhibitor DHODH structures were solved that supported the modeling effort. FEP+ calculations to predict potency and prioritize compounds for synthesis showed a good correlation with the measured values, validating the approach. Key compounds from the series were also tested against field isolates and unlike <b>1</b>, were shown to have equal efficacy against both <i>P. falciparum</i> and <i>P. vivax</i> isolates, representing an additional point of superiority over <b>1</b>. Finally, the frontrunners <b>79</b> and <b>99</b> had equivalent efficacy on <i>P. berghei</i> liver stages designed to assess effects on the formation of the schizont in liver cells after incubation with sporozoites, supporting their use for malaria prophylaxis.</div><div class="NLM_p">Resistance studies were performed with <b>26</b> and <b>79</b> to evaluate both the propensity for resistance to develop and to determine if resistant mutations would share overlapping resistance profiles with <b>1</b>. The MIR was similar for <b>26</b>, <b>79</b>, and <b>1</b>, however, while selections to both <b>26</b> and <b>1</b> led to 20–40-fold shifts in EC<sub>50</sub> driven by binding site mutations, selections with <b>79</b> led to only modest levels of resistance, attributed to gene amplification events. Interestingly, the set of point mutations that was selected by pressure with <b>26</b> was different compared to those selected by <b>1</b> and most mutations did not lead to cross-resistance between the two different scaffolds, reflective of their different binding modes. One <b>26</b>-derived mutation actually led to significantly increased sensitivity to <b>1</b>, in a mechanism that may involve stabilization of a normally dynamic and flexible residue (F188) into the conformation that promotes binding of <b>1</b> over <b>26</b>.</div><div class="NLM_p last">Compounds that showed good <i>in vitro</i> potency against <i>Pf</i>DHODH, <i>Pf</i>3D7 asexual blood stages, and <i>P. berghei</i> liver stages were evaluated to determine if they had the properties that would support good <i>in vivo</i> efficacy. Physicochemical properties and <i>in vitro</i> metabolic stability were evaluated first and potent analogues with good properties in these assays were advanced to further <i>in vitro</i> and <i>in vivo</i> studies, including mouse and rat PK and SCID mouse efficacy studies. Five compounds were extensively profiled and of these, three showed the liability of time-dependent CYP inhibition (<b>26</b>, <b>33</b>, and <b>36</b>), which was an issue that had previously been identified for <b>2</b>. However, two compounds were identified without this liability (<b>79</b> and <b>99</b>). The addition of the cyclopropyl on the bridging carbon was likely a factor in eliminating time-dependent CYP inhibition. Both <b>79</b> and <b>99</b> also had superior physicochemical properties and both showed good exposure <i>in vivo</i> in mice and rats. Both compounds had similar clearance in rats compared to <b>1</b> but had a lower volume of distribution, and therefore a shorter half-life, which likely suggests that they will also have a shorter half-life than <b>1</b> in humans. Further studies in other species (e.g., dogs) are needed to address this issue. <b>79</b> and <b>99</b> exhibited good solubility in simulated gastric and intestinal fluids, which represented another key superiority over <b>1</b>. This would be expected to translate to simplified formulation approaches compared to <b>1</b>. Finally, the <i>in vivo</i> SCID mouse efficacy studies also demonstrated that <b>79</b> and <b>99</b> had good <i>in vivo</i> antiparasitic activity with <b>99</b>, showing effectiveness similar to that of <b>1</b>. While <b>79</b> was less potent <i>in vivo</i>, it has a lower Log <i>P</i> and better physicochemical properties, and so also remains a promising compound.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66281" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66281" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Lead optimization of a pyrrole-based series of DHODH inhibitors identified initially by target-based screening was performed using a structure-based approach with a significant computational design. Potent analogues with good activity against parasite enzymes and parasites <i>in vitro</i> and <i>in vivo</i> were identified. These compounds also had very good species selectivity, illustrated by activity against all <i>Plasmodium</i> strains and DHODH enzymes, while not showing activity against mammalian enzymes. Additionally, no significant safety signals were identified in preliminary studies. Two compounds (<b>79</b> and <b>99</b>) showed particular promise in having improved ADME and PK properties compared to earlier compounds in the series. The overall properties of these new <i>Plasmodium</i> DHODH inhibitors support progression into advanced stages of late-lead development to assess preliminary safety and human dose predictions for prophylaxis. These data would be key to determining whether one or both have preclinical candidate quality and might move forward into preclinical development for the prevention of malaria.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30774" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30774" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Materials</h3><div class="NLM_p">Routine chemicals were sourced from Sigma-Aldrich unless otherwise stated.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> DHODH Protein Expression and Purification</h4><div class="NLM_p last">BL21-DE3 <i>E. coli</i> phage-resistant cells were used to express and purify the various DHODH proteins described in the study. Expression constructs encoding the soluble DHODH domain have been previously described: <i>Pf</i>DHODH<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> and <i>Pv</i>DHODH<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (N-terminal His<sub>6</sub>-tagged DHODH-pRSETb), human DHODH (pET22b C-terminal tag)<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and rat/mouse/dog DHODHs<a onclick="showRef(event, 'ref15 ref44'); return false;" href="javascript:void(0);" class="ref ref15 ref44">(15,44)</a> (pET28b C-terminal tag). <i>Pf</i>DHODH mutant enzymes C276F and C276Y were previously described.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Proteins were purified by HisTrap HP column chromatography, followed by gel-filtration chromatography on a Pharmacia HiLoad 16/600 Superdex 200 column, as previously described,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> yielding purity >95% based on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis. Absorbance at 280 nm was used to determine DHODH concentration based on the ProtParam in ExPASy calculated extinction coefficients as previously described.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Kinetic Analysis of DHODH Inhibition</h4><div class="NLM_p last">DHODH activity was monitored in a steady-state assay using the 2,6-dichloroindophenol (DCIP) method at 25 °C in an assay buffer (100 mM HEPES, pH 8.0, 150 mM NaCl, 10% glycerol, 0.1% Triton X-100 reduced, 20 μM CoQD, 200 μM <span class="smallcaps smallerCapital">l</span>-DHO, 120 μM DCIP, and 5–20 nM enzyme) as described<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> with the exception of the mutant enzyme analysis which was done using the direct assay as described.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The 50% inhibitory concentration (IC<sub>50</sub>) for each compound was determined over a concentration range of 0.001–100 μM in a 3-fold dilution series. A 100X dilution series was first prepared in dimethyl sulfoxide (DMSO) from an initial 100 mM stock yielding a final DMSO concentration in the assay of 1%. Triplicate rate data were collected at each inhibitor concentration. IC<sub>50</sub> values were determined by fitting the data to log (inhibitor) vs response equation <i>Y</i> = bottom + (top – bottom)/(1 + 10 <sup>∧</sup> ((<i>X</i> – Log IC<sub>50</sub>))) in GraphPad Prism.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>P. falciparum</i> Growth and Inhibition Assays</h4><div class="NLM_p last"><i>P. falciparum</i> cells were maintained in continuous culture using human blood type O+ or A+ erythrocytes (Valley Biomedical or Interstate Blood Bank, TN) at 2% hematocrit and culture media constituting of RPMI 1640 medium (Gibco-R4130) 1640+HEPES and 0.5% Albumax-I (Gibco), supplemented with sodium bicarbonate (23 mM) and hypoxanthine (92 μM). For drug-resistant <i>P. falciparum</i> lines in the Fidock lab, the drug was used during selections but was not added for routine maintenance of clonal lines after that point. In the Rathod lab, <b>1</b>-resistant parasite lines were maintained in the presence of <b>1</b> at the concentration of its selection and <b>1</b> was removed 4 days (2 culture passages) prior to the EC<sub>50</sub> study. For EC<sub>50</sub> determination, cultures were diluted to 0.5% starting parasitemia at 2% hematocrit. Compound stocks were made in DMSO (30–100 mM) and these were used to generate DMSO dilution series in triplicate for dispensing onto assay plates (either 96 or 384 well plate format), resulting in a final constant DMSO concentration of 0.2% over a range of inhibitor concentrations (0.0003–30 μM depending on the compound) in the final well. Plates were incubated for 72 h at 37 °C in 5% CO<sub>2</sub>, 5% O<sub>2</sub>, 90% N<sub>2</sub> in 80% humidity, sealed in aluminum foil, and stored at −80 °C for 24 h. Parasite growth was assessed using the SYBR Green method,<a onclick="showRef(event, 'ref34 ref46'); return false;" href="javascript:void(0);" class="ref ref34 ref46">(34,46)</a> which measures fluorescence (ex./em. 485/535nm) as the output or alternatively by labeling parasites with SYBR Green I and MitoTracker Deep Red and measuring parasitemia using an Accuri C6 flow cytometer.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Data were fitted to the log(inhibitor) vs response—Variable slope (four parameters) equation model to determine the 50% effective concentration (EC<sub>50</sub>) values for parasite growth inhibition.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Growth Assays on <i>P. falciparum</i> and <i>P. vivax</i> Clinical Isolates</h4><div id="sec5_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> Uganda Field Isolates</h5><div class="NLM_p last">Field isolates were collected and analyzed for <i>ex vivo</i> drug sensitivity using a standard 72 h SYBR Green microplate assay in Albumax-based media, as previously described.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div></div><div id="sec5_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> Human Subjects Approval</h5><div class="NLM_p last">The study was approved by the Makerere University Research and Ethics Committee, the Uganda National Council for Science and Technology, and the University of California, San Francisco Committee on Human Research. Informed consent was obtained from patients and/or primary caregivers (depending on age).</div></div><div id="sec5_1_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> Sample Collection</h5><div class="NLM_p last">Participants over 6 months of age presenting at the outpatient clinics of Tororo District Hospital, Tororo District or Masafu General Hospital, Busia District with clinical suspicion for malaria and a positive Giemsa-stained blood film for <i>P. falciparum</i> and without signs of severe disease were enrolled after written informed consent, from December 2015 through October 2020. Parents or guardians of children provided written consent on their behalf. Assent was sought from children 8–17 years old. Patients expressing the use of antimalarial treatment within the previous 30 days were excluded. Second, from December 2015–January 2018, children enrolled in a clinical trial (registered at ClinicalTrials.gov [NCT02163447]) comparing monthly versus every 3-month intermittent therapy with dihydroartemisinin-piperaquine to prevent malaria provided samples if they presented to the study clinic at the Tororo District Hospital with uncomplicated malaria. Blood was collected in a heparinized tube before initiation of therapy. Subjects were treated with artemether-lumefantrine, following national guidelines, after sample collection.</div></div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Center of Malaria Control from Rondônia, Brazilian Amazon (CEPEM): Ethical approval</h4><div class="NLM_p">The study received approval from the Ethics Committee from the Centro de Pesquisa em Medicina Tropical-CEPEM-Rondônia (CAAE 61442416.7.0000.0011) dated March 21st, 2017. All participants signed a written informed consent before blood collection.</div><div id="sec5_1_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> Sample Collection</h5><div class="NLM_p last"><i>P. falciparum</i> and <i>P. vivax</i> isolates were collected in February and July 2019 from patients recruited at the Center of Malaria Control (CEPEM) in the city of Porto Velho, state of Rondônia, in the Brazilian Western Amazon. Only monoinfected patients with either <i>P. falciparum</i> or <i>P. vivax</i>, with parasitemia between 2000 and 80 000 parasites/μL and with at least 70% of ring-stage parasites were recruited. Patients who used any antimalarial drug in the previous month and/or presented severe symptoms of malaria were excluded from this study.</div></div><div id="sec5_1_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> Schizont Maturation (SM) Assay</h5><div class="NLM_p last">For the maturation of parasites, rings to schizonts, plates containing parasites and compounds in the concentration tests were maintained in a hypoxia incubator chamber (containing 5% O<sub>2</sub>, 5% CO<sub>2</sub>, and 90% N<sub>2</sub>) at 37 °C for different incubation times (40–52 h for <i>P. vivax</i> and 40–56 h for <i>P. falciparum</i>) and assays were conducted as described.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Briefly, compound stocks were made in DMSO (20 mM) and used to generate DMSO dilution series for dispensing onto 96 wells assay plates in a range of concentrations (0.048–1 μM, depending on the compound) in the well. Purified parasites from patient isolates were maturated in complete medium RPMI 1640 medium plus 20% AB human serum for <i>P. falciparum</i> samples or McCoy’s 5A medium plus 20% AB human serum for <i>P. vivax</i> samples. Incubations were stopped when 40% of rings reached the schizont stage (at least three distinct nuclei per parasite) in inhibitor-free control wells. The number of schizonts per 200 asexual stage parasites was determined by thick blood films (stained with 5% Giemsa solution for 30 min) for each inhibitor concentration and then normalized to inhibitor-free control wells (considered as 100%). Half-maximal drug inhibitory response (EC<sub>50</sub>) was determined by curve fitting using software (OriginLab Corporation, Northampton, MA). As controls, EC<sub>50</sub>’s were also determined in standard SYBR Green assays or in the above SM assay for <i>P. falciparum</i> parasites cultured in Albumax-supplement RPMI 1640 media (described above).</div></div><div id="sec5_1_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> <i>P. berghei</i> Liver-Stage Assays</h5><div class="NLM_p last"><i>P. berghei</i> liver-stage assays were performed by the Winzeler lab, as previously described.<a onclick="showRef(event, 'ref10 ref49'); return false;" href="javascript:void(0);" class="ref ref10 ref49">(10,49)</a> Briefly, <i>P. berghei</i>-ANKA-GFP-Luc-SMCON (Pb-Luc) sporozoites were used to infect HepG2-A16-CD81EGFP cells for this assay. Assay media (DMEM without phenol Red (Life Technology, CA) supplemented with 5% FBS, 1.45 mg/mL glutamine, 500 units of penicillin, and 500 μg/mL streptomycin) was used for the <i>Pbluc</i> and <i>HepG2tox</i> assays.</div></div><div id="sec5_1_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> Selection of <b>1</b>, <b>26</b>, and <b>79</b> Resistant Parasites</h5><div class="NLM_p">The propensity for Dd2 <i>P. falciparum</i> parasites to develop resistance to <b>26</b> was evaluated by the selection of resistant parasites under continuous drug pressure at 4 × EC<sub>50</sub>, as described previously.<a onclick="showRef(event, 'ref15 ref50'); return false;" href="javascript:void(0);" class="ref ref15 ref50">(15,50)</a> Starting parasite inoculums from 10<sup>6</sup>–10<sup>9</sup> were used to allow determination of the minimum inoculum for resistance (MIR) versus <b>1</b> as a control with <i>n</i> = 3 flasks per condition. Parasites recrudesced between day 20 and 30, except for parasites seeded at 10<sup>6</sup> inoculum that took longer to come back. All flasks selected for resistance to <b>26</b> recrudesced, whereas for <b>1</b>, recrudescence was only observed with inoculum sizes of >10<sup>7</sup> recrudesced. From a total of 21 resistant bulk cultures to <b>1</b> and <b>26</b>, 9 were selected for cloning. Clones were profiled to determine the EC<sub>50</sub> shift for <b>1</b>, <b>26</b>, and <b>79</b> and to test for cross-resistance to atovaquone (ATQ). The <i>dhodh</i> gene was sequenced by PCR as described,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and 9 SNPs were found among the analyzed clones (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S6</a>).</div><div class="NLM_p last"><b>S</b>elections for 79 resistant parasites were performed similarly to above on both <i>P. falciparum</i> Dd2-B2 (EC<sub>50</sub> = 0.013 μM) and 3D7 (EC<sub>50</sub> = 0.0088 μM) cells using starting parasite inoculums Dd2 (10<sup>6</sup>–10<sup>8</sup>) and 3D7 (10<sup>5</sup>–10<sup>7</sup>) and drug concentrations of 0.055 and 0.036 μM, respectively. With the Dd2 selections, the parasites cleared by day 14 at all inocula and recrudesced in all flasks by day 30. In 3D7 selections, parasites cleared from the <b>1</b> selections in both inocula but recrudescence was only observed for the 10<sup>7</sup> inocula. For the <b>79</b> selections, 0.036 μM <b>79</b> was not sufficient to clear parasites; therefore, the concentration was increased in 20% increments until 0.11 μM was reached. Targeted Sanger sequencing of the <i>dhodh</i> gene was performed as described above but as this did not identify mutations, we performed whole-genome sequencing (WGS) to evaluate both gene copy numbers and to identify other SNPs that might contribute to the resistance phenotype. To generate these WGS data, the samples were pooled and sequenced on an Illumina MiSeq to obtain 300 bp paired-end reads.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> These reads were aligned to the <i>P. falciparum</i> 3D7 genome (PlasmoDB version 36) using BWA (Burrow-Wheeler Alignment). PCR duplicates and unmapped reads were filtered out using Samtools and Picard. The reads were realigned around indels using the GATK RealignerTargetCreator and base quality scores were recalibrated using GATK Table-Recalibration. The GATK HaplotypeCaller (version 4.1.7) was used to identify all possible single nucleotide variants (SNVs) in clones, which were filtered based on quality scores (variant quality as a function of depth QD > 1.5, mapping quality > 40, min base quality score > 18), read depth (depth of read > 5) to obtain high-quality SNPs that were annotated using snpEFF. IGV was used to visually verify the SNP’s presence in the clones. BicSeq was used to discover copy number variants (CNVs). Gene IDs are provided from PlasmoDB (<a href="https://plasmodb.org/plasmo/" class="extLink">https://plasmodb.org/plasmo/</a>).</div></div><div id="sec5_1_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> X-ray Crystallography</h5><div class="NLM_p last">Loop truncated <i>Pf</i>DHODH (pET28b-TEV- <i>Pf</i>DHOD<sub>Δ384-413</sub>) was used for crystallization based on prior findings that the truncation improves crystallization.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a><i>Pf</i>DHOD<sub>Δ384-413</sub> was expressed and purified from <i>E. coli</i> BL21 phage-resistant cells (NEB, C252H) transfected with the expression vector. The protein was purified by Ni<sup>+2</sup>-column chromatography and Gel-filtration as described above. Purified protein was concentrated to 20 mg/mL in buffer containing a detergent (20 mM HEPES pH 7.8, 20 mM NaCl, and 2 mM <i>n</i>-dodecyl-<i>N</i>,<i>N</i>-dimethylamine-<i>N</i>-oxide (LDAO, Anatrace), and 10 mM DTT), and stored at −80 °C.</div></div><div id="sec5_1_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> Crystallization and Data Collection of PfDHODH<sub>Δ384-413</sub> Cocrystallized with <b>18, 56, 127, 79, 81, 86, and 47</b></h5><div class="NLM_p">Preliminary crystallization conditions were found using random crystallization screen <i>Cryos</i> suite (Qiagen), Crystal screen 2 (Hampton Research). Hit conditions were then optimized by variation of pH, precipitant, and protein concentrations. Crystals grew in the following conditions: <b>18</b> from 0.17 M ammonium acetate, 0.085 M sodium citrate pH 5.6, 25.5% v/v PEG4000, and 15% v/v glycerol; <b>56</b> from 0.16 M Ammonium sulfate, 18% v/v PEG4000, 0.1 M sodium acetate pH 5.1, and 24% v/v glycerol; <b>127</b> from 0.085 M HEPES pH 7.5, 8.5% 2-propanol, 17% v/v PEG4000, and 15% v/v glycerol; and, <b>79</b>, <b>81</b>, <b>86</b>, and <b>47</b> from 0.05 M MgCl<sub>2</sub>, 28% v/v PEG4000, and 0.1 M Tris-HCl, pH 8.8. The later four crystals were first obtained as clusters and single crystals of these inhibitors in complex with <i>Pf</i>DHODH<sub>Δ384-413</sub> grew only after seeding. All crystallizations were setup using hanging drop vapor diffusion at 20 °C from an equal volume mixture of reservoir solution and <i>Pf</i>DHODH<sub>Δ384-413</sub> (20 mg/mL) pre-equilibrated with 1 mM inhibitor and 2 mM dihydroorotate (DHO).</div><div class="NLM_p last">Diffraction data were collected at 100 K on beamline 19ID at Advanced Photon Source (APS) using an ADSC Q315 detector. For the <i>Pf</i>DHODH<sub>Δ384-413</sub>-<b>18</b> crystal, 540 images (0.3°/image) were collected and the crystal diffracted to 2.15 Å in a space group of <i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> with the cell dimension of <i>a</i> = 92.2, <i>b</i> = 97.5, and <i>c</i> = 186.3. For <i>Pf</i>DHODH<sub>Δ384-413</sub>-<b>56</b>, 360 images (0.5°/image) were collected and the crystal diffracted to 2.4 Å in space group P64 with the cell dimension of <i>a</i> = <i>b</i> = 85.3, and <i>c</i> = 139.2. For <i>Pf</i>DHODH<sub>Δ384-413</sub>-<b>127</b>, 400 images (0.5°/image) were collected and the crystal diffracted to 2.0 Å in space group <i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> with the cell dimension of <i>a</i> = 93.1 <i>b</i> = 97.3, and <i>c</i> = 186.9. For <i>Pf</i>DHODH<sub>Δ384-413</sub>-<b>79</b>, 500 images (0.5°/image) were collected and the crystal diffracted to 1.75 Å in space group <i>P</i>2<sub>1</sub> with the cell dimension of <i>a</i> = 51.9, <i>b</i> = 158.0, and <i>c</i> = 63.2. For <i>Pf</i>DHODH<sub>Δ384-413</sub>-<b>81</b>, 400 images (0.5°/image) were collected and the crystal diffracted to 1.75 Å in space group <i>P</i>2<sub>1</sub> with the cell dimension of <i>a</i> = 51.4, <i>b</i> = 158.2, and <i>c</i> = 62.6. For <i>Pf</i>DHODH<sub>Δ384-413</sub>-<b>86</b>, 400 images (0.5°/image) were collected and the crystal diffracted to 1.60 Å in space group P2<sub>1</sub> with the cell dimension of <i>a</i> = 50.1, <i>b</i> = 158.0, and <i>c</i> = 61.1. For <i>Pf</i>DHODH<sub>Δ384-413</sub>-<b>47</b>, 400 images (0.5°/image) were collected and the crystal diffracted to 1.97 Å in space group <i>P</i>2<sub>1</sub> with the cell dimension of <i>a</i> = 52.1, <i>b</i> = 158.3, and <i>c</i> = 62.8. Diffraction data were integrated and intensities were scaled with the HKL2000 package.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div></div><div id="sec5_1_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Structure Determination and Refinement</h5><div class="NLM_p">Crystallographic phases for <i>Pf</i>DHODH inhibitor complexes were solved by molecular replacement with Phaser<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> using PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I65">3I65</a><a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> as the search model. Structures were rebuilt with COOT<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> and refined with phenix.refine.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Refinement statistics are provided in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S3</a>. For all structures, all amino acid residues were within the allowed section of the Ramachandran plot as defined by MolProbity.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><div class="NLM_p"><i>Pf</i>DHODH<sub>Δ384-413</sub>-<b>18</b> was refined to <i>R</i><sub>work</sub> and <i>R</i><sub>free</sub> of 0.182 and 0.224, respectively. Four molecules were found in an asymmetric unit. Electron density was observed for the following residues: Chain A: 158–378, 414–566, and 2 amino acids (Asp and Pro) from the N-terminal-His tag linker, Chain B: 160–378 and 414–566, Chain C: 163–378 and 414–566, and Chain D: 161–377 and 414–566. Three hundred and thirty-five water molecules were modeled into the structure using phenix.refine.</div><div class="NLM_p"><i>Pf</i>DHODH<sub>Δ384-413</sub>-<b>56</b> was refined to <i>R</i><sub>work</sub> and <i>R</i><sub>free</sub> of 0.180 and 0.199, respectively. A twinning operator (<i>h</i>,-<i>h</i>-<i>k</i>, -<i>l</i>) was applied during the refinement. One molecule was found in the asymmetric unit and the refined structure contains amino acid residues 162–383 and 414–566. Forty-two water molecules were modeled into the structure using phenix.refine.</div><div class="NLM_p"><i>Pf</i>DHODH<sub>Δ384-413</sub>-<b>127</b> was refined to <i>R</i><sub>work</sub> and <i>R</i><sub>free</sub> of 0.163and 0.207, respectively, with 4 molecules in an asymmetric unit. Electron density was observed for: Chain A: 158–377, 414–566, and 2 amino acids (Asp and Pro) from the N-terminal-His tag linker, Chain B: 167–377 and 414–566, Chain C: 160–377 and 414–566, and Chain D: 161–378 and 414–566. Four hundred and eighty-six water molecules were modeled into the structure using phenix.refine.</div><div class="NLM_p"><i>Pf</i>DHODH<sub>Δ384-413</sub>-<b>79</b> was refined to <i>R</i><sub>work</sub> and <i>R</i><sub>free</sub> of 0.172 and 0.207, respectively, with 2 molecules in an asymmetric unit. Electron density was observed for: Chain A: 159–383 and 414–566 and Chain B: 159–376, 414–566, and 7 amino acids (His, His, His, Ala, Glu, Asn, and Leu) from the N-terminal His tag linker. Four hundred and fifty-five water molecules were modeled into the structure using phenix.refine.</div><div class="NLM_p"><i>Pf</i>DHODH<sub>Δ384-413</sub>-<b>81</b> was refined to <i>R</i><sub>work</sub> and <i>R</i><sub>free</sub> of 0.165 and 0.204, respectively, with 2 molecules in an asymmetric unit. Electron density was observed for: Chain A: 159–383, 414–566, and 6 amino acids (His, His, His, Ala, Glu, and Asn) from the N-terminal His tag linker. Chain B: 159–377, 414–566, and 6 amino acids (His, His, His, Ala, Glu, and Asn) from the N-terminal His tag linker. Four hundred and seventy-two water molecules were modeled into the structure using phenix.refine.</div><div class="NLM_p"><i>Pf</i>DHODH<sub>Δ384-413</sub>-<b>86</b> was refined to <i>R</i><sub>work</sub> and <i>R</i><sub>free</sub> of 0.164 and 0.188, respectively. There are 2 molecules in an asymmetric unit. Electron density was observed for: Chain A: 159–377 and 414–566 and Chain B: 159–383, 414–566, and 6 amino acids (His, His, His, Ala, Glu, and Asn) from the N-terminal His tag linker. Six hundred and sixteen water molecules were modeled into the structure using phenix.refine.</div><div class="NLM_p last"><i>Pf</i>DHODH<sub>Δ384-413</sub>-<b>47</b> was refined to <i>R</i><sub>work</sub> and <i>R</i><sub>free</sub> of 0.179 and 0.213, respectively, with 2 molecules in an asymmetric unit. Electron density was observed for: Chain A: 159–383, 414–566, and one amino acid (Pro) from the N-terminal His tag linker. Three hundred and sixteen water molecules were modeled into the structure using phenix.refine.</div></div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Computational Modeling</h4><div id="sec5_1_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> Compound Structure Preparation</h5><div class="NLM_p last">Compound ideas considered in this work were built with Seurat, LiveDesign, Maestro (Maestro, Schrödinger, LLC, New York, NY, 2020), or generated by reaction-based enumeration scripts; tautomer enumeration and protonation state assignment at experimental pH was performed using LigPrep. When enumeration produced many candidate compounds, compounds were triaged with WScore docking, before moving to FEP+ simulations.</div></div><div id="sec5_1_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> Protein Structure Preparation</h5><div class="NLM_p last">Published in-house <i>Pf</i>DHODH structures in complex with inhibitors<a onclick="showRef(event, 'ref14 ref15 ref20 ref33 ref44 ref52 ref53 ref59'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref20 ref33 ref44 ref52 ref53 ref59">(14,15,20,33,44,52,53,59)</a> were used as the starting point for computational studies. We hypothesized that the distinctive orientation F188 side chain observed in the <b>3</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VTN">6VTN</a>) cocrystal<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> was a feature attributed to the pyrrole series that we were targeting for optimization and, thus, we biased WScore protein structure selection to proteins with that conformation (PDB files: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VTY">6VTY</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VTN">6VTN</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O8A">3O8A</a>). Initial studies and most FEP+ modeling were performed with <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VTY">6VTY</a>, bound to an ester pyrrole analogue of <b>3</b>. The structure of <b>3</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VTN">6VTN</a>) and other analogues bound to <i>Pf</i>DHODH were used as they became available to evaluate pose “fit” plausibility. As we added to the catalog of crystal structures in this series, the structure bound to <b>18</b> was considered for larger membrane-side perturbations. Protein coordinates were prepared for computational studies with the Protein Preparation Wizard. This involved adding hydrogen atoms, filling in missing side chains, assigning the proper ionization state for both the amino acids and cocrystallized ligand at physiological pH.</div></div><div id="sec5_1_6_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> WaterMap</h5><div class="NLM_p last">WaterMap<a onclick="showRef(event, 'ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62">(60−62)</a> was used to profile the location and thermodynamics of waters within <i>Pf</i>DHODH complexes. Proteins were prepared with the Protein Preparation Wizard. WaterMap was run in the default mode; the cocrystallized ligands associated with each protein were used to define the binding site area and were removed during the MD simulations of the water structure. WaterMap results were used to rationalize previously generated SAR and hypothesize new opportunities against which to design, score, and synthesize new compound ideas.</div></div><div id="sec5_1_6_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> WScore</h5><div class="NLM_p last">WScore is a docking and scoring methodology<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> that was used to incorporate the water structure from WaterMap to provide an atomic-level description of ligand and protein desolvation. The scoring function also integrates and MM-GBSA score component. An ensemble of receptors is used to take into account receptor conformation and protein reorganization. WScore ensemble docking and score were used to triage enumerated compounds and choose compounds to profile with FEP+.</div></div><div id="sec5_1_6_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> FEP+ Calculations</h5><div class="NLM_p last">FEP+, free-energy perturbation (FEP+) methodology, from Schrödinger Suite was used to predict relative binding free energies of <i>Pf</i>DHODH ligand complexes as described.<a onclick="showRef(event, 'ref60 ref65 ref66 ref67 ref68 ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref60 ref65 ref66 ref67 ref68 ref69 ref70">(60,65−70)</a> Briefly, a series/set/ensemble of molecular dynamics simulations were performed, as implemented in Desmond<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> (Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2020. Maestro-Desmond Interoperability Tools, Schrödinger, New York, NY, 2020) and running on GPU to ensure speed and accuracy. The atoms of the small molecule perturbed undergo replica exchange with solute tempering (REST) to ensure good sampling and a cycle closure correction is applied to calculate free-energy estimates relative to one or more reference compounds. Retrospective studies were used to establish baseline protocols for the simulation time and the number of lambda windows used to profile new ideas. Typically, the length of the simulation was increased to 20 ns per lambda window to improve sampling.</div></div><div id="sec5_1_6_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> Software Version</h5><div class="NLM_p last">Schrödinger Release 2015-3, Schrödinger, LLC, New York, NY, 2015, was the starting point, but we used new releases as they became available.</div></div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Structure Display and Analysis</h4><div class="NLM_p last">MacPyMOL: PyMOL v2.1 enhanced for Mac OS X (Schrödinger LLC) was used to display and render structures and the align command was used to generate structural alignments.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Protein Binding and Physicochemical Measurements</h4><div class="NLM_p last">Methods used to assess solubility in biorelevant media (FaSSIF, FeSSIF, and FaSSGF), binding to proteins in various media (plasma, microsomes, and <i>in vitro</i> assay media), and whole blood-to-plasma partitioning ratios were performed as described previously.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Log <i>D</i><sub>7.4</sub> values were calculated using the Chem Axon chemistry cartridge via JChem for Excel software (version 16.4.11).</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>In Vitro</i> Metabolism</h4><div class="NLM_p last">Compounds (1 μM) were incubated for up to 60 min at 37 °C with human, mouse, or rat liver microsomes (Xenotech LLC, Kansas City, KS) at a protein concentration of 0.4 mg/mL with an NADPH regenerating buffer system as described previously.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Selected compounds (1 μM) were also incubated with cryopreserved hepatocytes (Xenotech) suspended in Krebs–Henseleit buffer at a cell density of 0.5 × 10<sup>6</sup> viable cells/mL for up to 4 h. Cell count and viability were determined using the Trypan Blue exclusion method at the start and end of the incubation. The samples were taken from both the microsome and hepatocyte incubations periodically and quenched with acetonitrile containing internal standard and loss of substrate was monitored by liquid chromatography–mass spectrometry (LC-MS) (Waters Xevo G2QTOF coupled to a Waters Acquity UPLC operating in positive electrospray ionization under MS<sup>E</sup> mode). Degradation half-life and <i>in vitro</i> intrinsic clearance values were calculated from the apparent first-order degradation rate constants.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Caco-2 Permeability Assays</h4><div class="NLM_p last">Permeability of compounds across confluent Caco-2 cell monolayers was conducted as described previously.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Briefly, experiments were performed using pH 7.4 Hanks balanced salt solution containing 20 mM HEPES in both the apical and basolateral chambers. Donor solutions were prepared by spiking a DMSO stock solution into transport buffer (10 μM) with the final DMSO concentration maintained at 0.1% v/v. Compound flux was assessed in both the apical to basolateral (A–B) and B–A directions over 120 minutes, with samples taken from the donor chamber at the start and end of the experiment and from the acceptor chamber at multiple time points. Compound concentrations were assessed by LC/MS and control compounds were included to confirm monolayer integrity, passive permeation, and Pgp functionality. The apparent permeability coefficient was calculated from the linear slope of the flux profile, taking into account the initial donor concentration and the surface area.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Cytochrome P450 Inhibition and Time-Dependent Inhibition Studies</h4><div class="NLM_p last">CYP inhibition assays were performed utilizing a substrate-specific interaction approach as described previously.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The “IC<sub>50</sub> shift”-method was used to assess whether compounds showed time-dependent CYP inhibition in human liver microsomes also as previously described.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Animal Studies</h4><div class="NLM_p last">Ethical review of all animal studies was undertaken in accordance with either the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (mouse and rat PK studies) or European Directive 2010/63/EEC (SCID mouse efficacy studies). Human blood samples for the SCID mouse studies were sourced ethically and their research use was in accord with the terms of the informed consents under an IRB/EC approved protocol. Animal experiments performed at the Swiss Tropical and Public Health Institute (Basel, Switzerland) adhered to local and national regulations of laboratory animal welfare in Switzerland (awarded permission no. 2303). Protocols are regularly reviewed and revised following approval by the local authority (Veterinäramt Basel Stadt). Animal experiments were performed at The Art of Discovery (TAD) were approved by The Art of Discovery Institutional Animal Care and Use Committee (TAD-IACUC). This Committee is certified by the Biscay County Government (Bizkaiko Foru Aldundia, Basque Country, Spain) to evaluate animal research projects from Spanish institutions according to point 43.3 from Royal Decree 53/2013, from the 1st of February (BOE-A-2013-1337).</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Mouse and Rat Pharmacokinetic (PK) Studies</h4><div class="NLM_p">PK studies were performed in male Sprague Dawley rats and male Swiss outbred mice. Studies were reviewed and approved by the Monash Institute of Pharmaceutical Sciences Animal Ethics Committee. Intravenous dosing (IV) to rats was administered in a saline vehicle containing 5–10% (v/v) DMSO and 2–4% (v/v) Solutol HS 15 administered at a volume of 1 mL as a 10 min infusion into the jugular vein via a surgically implanted catheter. In mice, the IV dose was administered as a bolus injection (2 mL/kg) into the tail vein using the same vehicle. Oral doses to rats and mice were administered by gavage in an aqueous suspension vehicle (0.5% (w/v) carboxymethyl cellulose, 0.4% (v/v) Tween-80 and 0.5% (v/v) benzyl alcohol (10 mL/kg)). Blood was collected up to 24 h postdose into heparin-containing tubes. A maximum of three blood samples was collected from each mouse, with 2–3 mice per time point. For rats, sequential sampling over the complete time period was conducted with 3 rats per dosing group. Following centrifugation, the plasma fraction was transferred to clean tubes after centrifugation and protein was precipitated with acetonitrile (2:1 volume ratio). The supernatant was analyzed to determine plasma drug concentrations by LC-MS against calibration standards prepared in blank rat or mouse plasma and extracted in the same way. Diazepam was added as an internal standard for all plasma samples and calibration standards (prior to protein precipitation). Analysis was performed on a Waters Xevo TQ mass spectrometer coupled to a Waters Acquity UPLC operating in a positive electrospray ionization multiple-reaction monitoring mode using a Supelco Ascentis Express RP amide column (50 mm × 2.1 mm, 2.7 μm) with a mobile phase that consisted of an acetonitrile–water gradient with 0.05% formic acid, a gradient cycle of 4 min, and a flow rate of 0.4 mL/min.</div><div class="NLM_p last">For mice, noncompartmental PK data analysis was based on the mean concentration versus time profile for each dose route, given that sequential sampling (i.e., a complete concentration vs time profile) was not conducted in each animal. For rats, sequential sampling in each animal was conducted and the profile for each rat was assessed using noncompartmental analysis. Rat PK parameters were then averaged for each dosing group to provide a mean and standard deviation.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> SCID Mouse <i>P. falciparum</i><i>In Vivo</i> Efficacy Studies</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Studies Conducted at Swiss TPH</h4><div class="NLM_p last">Compound efficacy <i>in vivo</i> was evaluated in the murine <i>P. falciparum</i> SCID model essentially as described.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a><b>33</b> and <b>36</b> were formulated in a vehicle (70% Tween-80 and 30% ethanol, followed by a 10-fold dilution in water) and administered to age-matched female immunodeficient NOD-scidIL2Rγnull mice (NSG) (The Jackson Laboratory, Bar Harbor, ME) (20–22 g) that had been engrafted for 11 days with human erythrocytes (generously provided by the Blood Bank in Zürich, Switzerland). Mice were infected intravenously on day 0 with <i>P. falciparum</i> Pf3D70087/N9-infected erythrocytes (2 × 10<sup>7</sup>). On day 3 postinfection parasitemia was 0.75–1.5%, and mice (<i>n</i> = 2) were randomly distributed to treatment groups and administered compound or vehicle control once a day for 4 consecutive days by oral gavage (10 mL/kg). Parasitemia was measured by flow cytometry and the %parasitemia is expressed as the %infected human erythrocytes as determined using the previously described methods.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72,73)</a> Efficacy parameters (ED<sub>90</sub> and AUC<sub>ED90</sub>) were determined on Day 7, one day after the last dose.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Studies Conducted at the Art of Drug Discovery (TAD)</h4><div class="NLM_p">NSG mice engrafted with human erythrocytes (>40% of human erythrocytes in peripheral blood) as described above but sourced from Charles River (France) were intravenously infected with Pf3D70087/N9-parasitized red blood cells 72 h before drug treatment. On study day 1, mice had between 1–2% parasitemia on average and were randomly allocated to selected treatments. <b>1</b> and <b>79</b> were administered orally BID at six dose levels for 6 days (<b>1</b>: 0.5, 1.67, 3.3, 8.3, 16.7, and 33 mg/kg and <b>79</b>: 1.5, 5, 10, 25, 50, and 100 mg/kg). <b>99</b> was administered at three dose levels BID, 10, 25, and 50 mg/kg for 6 days. <b>1</b> was administered as an amorphous spray-dried dispersion formulation (25% DSM265 load)<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and formulated in 1% methylcellulose (w/v), 0.1% Tween-80 (v/v) in water. Dose levels are expressed as the free base equivalent. <b>79</b> and <b>99</b> were formulated in 0.5% (w/v) carboxymethyl cellulose, 0.5% (v/v) benzyl alcohol, and 0.4% (v/v) Polysorbate 80 in water and administered at 10 mL/kg. The effect of treatment on parasitemia was assessed by measuring the percentage of infected erythrocytes in peripheral blood every 24 h until parasitemia was below the selected limit of quantitation (usually 0.01%). During the study, samples of peripheral blood were taken from mice to measure drug concentration by LC/MS/MS. Parasitemia was monitored up to day 60 or until parasitemia reached levels requiring euthanasia.</div><div class="NLM_p last">Quantitative pharmacodynamic (PD) response to treatment in each individual of the study was assessed by measuring their (a) parasite net growth inhibition during three cycles of parasite replication (90% of growth inhibition at Day 7 in this study representing one day after the final dose), and (b) parasite killing (day of recrudescence, DoR). The primary PK explanatory variable of efficacy endpoints was the AUC, calculated from the drug concentrations in peripheral blood. To determine parameters of efficacy (ED<sub>90</sub> and AUC<sub>ED90</sub>), log parasitemia versus log dose and log parasitemia versus log AUC data were fitted to log (inhibitor) vs response equation in GraphPad Prism. To allow robust calculation of parameters the hillslope was fixed to −5 or −3.5, respectively, and the bottom was fixed to −2 (representing the lower limit of detection of parasitemia). These values are based on the average of data accumulated over the years for drugs with the same mechanism of action, including <b>1</b>, for which large data sets were available (at least 8 individuals per curve), in the same <i>in vivo</i> system and assay.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Chemistry Experimental</h3><div class="NLM_p last">All reagents and starting materials were obtained from commercial suppliers and used without further purification unless otherwise stated. General chemistry experimental conditions were as reported by Kokkonda et al.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Chiral purification was carried out by supercritical fluid chromatography (SFC) using a prepacked Lux A1, Chiralpak, Chiralcel, or YMC Amylose column, CO<sub>2</sub> as the mobile phase and cosolvent as specified. Yields from SFC resolution are based on the racemate, i.e., 50% maximum. Optical rotations were λ = 589, temp = 25.5 °C, concentration = 0.5, cell length = 50 mm. The purity of all tested compounds was >95% based on high-performance liquid chromatography (HPLC), <sup>1</sup>H NMR, LC-MS, and SFC purification unless stated otherwise.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Chemistry Synthetic Methods</h3><div class="NLM_p last">The reported pyrrole analogues were synthesized as shown in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch8" aria-label="8">8</a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Schemes S1–S10</a> using the following methods, which built on learnings from previous work.<a onclick="showRef(event, 'ref20 ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref20 ref74 ref75">(20,74,75)</a></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Chemistry Synthetic Methods</h3><div id="sec5_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> General Procedure A: Propynyl Grignard Reaction</h4><div class="NLM_p">1-Propynylmagnesium bromide (0.5 M in THF) (1.1 equiv) was added to the corresponding aryl aldehyde (1 equiv) in THF at 0 °C and stirred for 4 h at RT. The reaction mixture was quenched with 1.5 N HCl solution and extracted with ethyl acetate (2×). The resulting organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford the product (84–94%) as a colorless liquid. Compounds <b>164</b>–<b>167</b> were prepared using this procedure.</div><div id="sec5_5_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> 1-(6-(Trifluoromethyl)pyridin-3-yl)but-2-yn-1-ol (<b>164</b>)</h5><div class="NLM_p last">Title compound <b>164</b> was prepared from 6-(trifluoromethyl)pyridine-3-carboxaledehyde (94%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.96 (s, 1H), 8.26–8.31 (m, 1H), 8.02 (d, 1H, <i>J</i> = 8.1 Hz), 3.57 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 216.0.</div></div><div id="sec5_5_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> 1-(2-Fluoro-6-(trifluoromethyl)pyridin-3-yl)but-2-yn-1-ol (<b>164a</b>)</h5><div class="NLM_p last"><b>164a</b> was prepared from 2-fluoro-6-(trifluoromethyl)pyridine-3-carboxaldehyde (88%). ESIMS <i>m</i>/<i>z</i> (M + 1): 234.2. The product was used without further characterization.</div></div><div id="sec5_5_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> 1-(Benzo[<i>d</i>]oxazol-7-yl)but-2-yn-1-ol (<b>165</b>)</h5><div class="NLM_p last"><b>165</b> was prepared from benzo[<i>d</i>]oxazole-7-carbaldehyde (91%) and used without characterization.</div></div><div id="sec5_5_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> 1-(Benzo[<i>d</i>]oxazol-2-yl)but-2-yn-1-ol (<b>166</b>)</h5><div class="NLM_p last"><b>166</b> was prepared from benzo[<i>d</i>]oxazole-2-carbaldehyde (84%). ESIMS <i>m</i>/<i>z</i> (M + 1): 188.2. The product was used without further characterization.</div></div><div id="sec5_5_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> 1-(4-(Trifluoromethyl)phenyl)but-2-yn-1-ol (<b>167</b>)</h5><div class="NLM_p last"><b>167</b> was prepared from 4-(trifluoromethyl)benzaldehyde (94%). ESIMS <i>m</i>/<i>z</i> (M + 1): 215.2. The product was used without further characterization.</div></div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> General Procedure B: Hydroxyl Oxidation</h4><div class="NLM_p">Dess–Martin (1.5 equiv) was added to a stirred solution of but-2-yn-1-ol intermediate (1 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (150 mL) at RT and maintained for 2 h. The reaction mixture was quenched with saturated NaHCO<sub>3</sub> solution and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The concentrated product was purified by flash chromatography (silica gel, eluting with hexane:EtOAc mixtures from 100 to 80:20%) to afford the product (57–83%) as an off-white solid. Compounds <b>168</b>–<b>172</b> were prepared using this procedure and <b>257</b> by a modified procedure as described.</div><div id="sec5_5_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> 1-(6-(Trifluoromethyl)pyridin-3-yl)but-2-yn-1-one (<b>168</b>)</h5><div class="NLM_p last"><b>168</b> was prepared from <b>164</b> (83%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 10.21 (s, 1H), 8.66 (d, 1H, <i>J</i> = 8.2 Hz), 8.14 (d, 1H, <i>J</i> = 8.2 Hz), 2.21 (s, 3H). ESIMS <i>m</i>/<i>z</i> (M + 1): 214.2.</div></div><div id="sec5_5_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> 1-(2-Fluoro-6-(trifluoromethyl)pyridin-3-yl)but-2-yn-1-one (<b>169</b>)</h5><div class="NLM_p last"><b>169</b> was prepared from <b>164a</b> (75%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.61 (d, 1H, <i>J</i> = 8.0 Hz), 7.72 (d, 1H, <i>J</i> = 8.0 Hz), 2.20 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 232.2.</div></div><div id="sec5_5_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> 1-(Benzo[<i>d</i>]oxazol-7-yl)but-2-yn-1-one (<b>170</b>)</h5><div class="NLM_p last"><b>170</b> was prepared from <b>165</b> (57%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 8.27 (s, 1H), 8.20–8.24 (dd, <i>J</i> = 1.1 Hz & 7.7 Hz, 1H), 8.05–8.08 (dd, <i>J</i> = 1.2 Hz & 7.8 Hz, 1H), 7.50–7.54 (m, 1H), 2.22 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 186.2.</div></div><div id="sec5_5_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> 1-(Benzo[<i>d</i>]oxazol-2-yl)but-2-yn-1-one (<b>171</b>)</h5><div class="NLM_p last"><b>171</b> was prepared from <b>166</b> (78%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.02 (d, 1H, <i>J</i> = 8.0 Hz), 7.89–7.92 (m, 1H), 7.63–7.67 (m, 1H), 7.54 (d, 1H, <i>J</i> = 8.0 Hz), 2.27 (s, 3H). ESIMS <i>m</i>/<i>z</i> (M + 1): 186.2.</div></div><div id="sec5_5_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> 1-(4-(Trifluoromethyl)phenyl)but-2-yn-1-one (<b>172</b>)</h5><div class="NLM_p last"><b>172</b> was prepared from <b>167</b> (83%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.25 (d, 2H, <i>J</i> = 8.0 Hz), 7.98 (d, 2H, <i>J</i> = 8.0 Hz), 2.25 (s, 3H). ESIMS <i>m</i>/<i>z</i> (M + 1): 213.2.</div></div><div id="sec5_5_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> 4,4-Diethoxy-1-(6-(trifluoromethyl)pyridin-3-yl)but-2-yn-1-one (<b>257</b>)</h5><div class="NLM_p last"><i>n</i>-BuLi (1.6 M in hexane) (15.3 mL, 24.60 mmol) was added to a stirred solution of 3,3-diethoxyprop-1-yne (3 g, 23.40 mmol) in THF (40 mL) at −78 °C and maintained for 40 min. Then, 6-(trifluoromethyl)pyridine-3-carboxaldehyde was added (3.70 g, 21.06 mmol) at the same temperature and stirring was continued for 30 min. The reaction mixture was quenched with saturated NH<sub>4</sub>Cl solution and extracted with ethyl acetate (2 × 200 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The resulting product was stirred in CH<sub>2</sub>Cl<sub>2</sub> (50 mL), Dess–Martin reagent was added (14.7 g, 36.1 mmol), and the reaction was maintained for 1 h at RT. The reaction mixture was filtered through Celite and the filtrate was concentrated. The resulting concentrated product was purified by column chromatography using 0–10% ethyl acetate in petroleum ether to afford the product as a pale yellow liquid (2.5 g, 36%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 9.44 (brs, 1H), 8.55–8.58 (m, 1H), 7.88 (d, 1H, <i>J</i> = 8.0 Hz), 5.56 (s, 1H), 3.83 (q, 2H, <i>J</i> = 7.1 Hz), 3.73 (q, 2H, <i>J</i> = 7.1 Hz), 1.31 (m, 6H, <i>J</i> = 7.1 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 302.2.</div></div></div><div id="sec5_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> General Procedure C: Pyrrole Formation</h4><div class="NLM_p">But-2-yn-1-one intermediate (1 equiv) was added to a stirred solution of Ag<sub>2</sub>CO<sub>3</sub> (0.1–0.2 equiv) in NMP at RT. Ethyl isocyanoacetate (1.5 equiv) was added at room temperature and stirred for 2-–4 h at 80–85 °C. The reaction mixture was cooled to RT, quenched with water, and extracted with ethyl acetate (2×). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The concentrated product was purified by flash chromatography (silica gel, eluting with hexane:EtOAc mixtures from 100 to 60:40%) to afford compounds (27–66%) as an off-white solid. Compounds <b>173</b>–<b>177, 187, 197</b>–<b>201, 233</b>–<b>235, 258</b>, and <b>281</b> were prepared using this procedure.</div><div id="sec5_5_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> Ethyl 3-Methyl-4-(6-(trifluoromethyl)pyridine-3-carbonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>173</b>)</h5><div class="NLM_p last"><b>173</b> was prepared from <b>168</b> (44%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.43 (s, 1H), 9.00 (s, 1H), 8.33 (d, 1H, <i>J</i> = 8.1 Hz), 8.05 (d, 1H, <i>J</i> = 8.1 Hz), 7.45 (s, 1H), 4.30 (q, 2H, <i>J</i> = 7.1 Hz), 2.51 (s, 3H), 1.31 (t, 3H, <i>J</i> = 7.1 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 327.2.</div></div><div id="sec5_5_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> Ethyl 4-(2-Fluoro-6-(trifluoromethyl)pyridine-3-carbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>174</b>)</h5><div class="NLM_p last"><b>174</b> was prepared from <b>169</b> (34%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.46 (s, 1H), 8.39 (d, 1H, <i>J</i> = 7.8 Hz), 8.01 (d, 1H, <i>J</i> = 7.8 Hz), 7.51 (s, 1H), 4.29 (q, 2H, <i>J</i> = 7.2 Hz), 2.60 (s, 3H), 1.32 (t, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 345.2.</div></div><div id="sec5_5_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> Ethyl 4-(Benzo[<i>d</i>]oxazole-7-carbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>175</b>)</h5><div class="NLM_p last"><b>175</b> was prepared from <b>170</b> (52%). ESIMS <i>m</i>/<i>z</i> (M + 1): 299.2. The product was used without further characterization.</div></div><div id="sec5_5_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> Ethyl 4-(Benzo[<i>d</i>]oxazole-2-carbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>176</b>)</h5><div class="NLM_p last"><b>176</b> was prepared from <b>171</b> (27%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.51 (s, 1H), 8.44 (s, 1H), 8.02 (d, 1H, <i>J</i> = 8.0 Hz), 7.91 (d, 1H, <i>J</i> = 8.0 Hz), 7.60–7.63 (m, 1H), 7.52–7.56 (m, 1H), 4.32 (q, 2H, <i>J</i> = 7.0 Hz), 2.61 (s, 3H), 1.34 (t, 3H, <i>J</i> = 7.0 Hz). ESIMS <i>m</i>/<i>z</i> (M + 1): 299.2.</div></div><div id="sec5_5_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> Ethyl 3-Methyl-4-((4-(trifluoromethyl)phenyl)carbonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>177</b>)</h5><div class="NLM_p last"><b>177</b> was prepared from <b>172</b> (44%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.33 (s, 1H), 7.88 (bs, 4H), 7.30 (s, 1H), 4.28 (q, 2H, <i>J</i> = 6.8 Hz), 2.57 (s, 3H), 1.32 (t, 3H, <i>J</i> = 6.8 Hz); ESIMS (M + 1) <i>m</i>/<i>z</i>: 326.2.</div></div><div id="sec5_5_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> Ethyl 4-((2-Hydroxy-3-nitro-4-(trifluoromethyl)phenyl)carbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>187</b>)</h5><div class="NLM_p last"><b>187</b> was prepared from <b>186</b> (24%). ESIMS <i>m</i>/<i>z</i> (M + 1): 387.1. Product was used directly without further characterization.</div></div><div id="sec5_5_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> Ethyl 4-(5-Fluoroisoquinoline-8-carbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>197</b>)</h5><div class="NLM_p last"><b>197</b> was prepared from <b>194</b> as a brown solid (40%). ESIMS <i>m</i>/<i>z</i> (M + 1): 327.2. The product was used without further characterization.</div></div><div id="sec5_5_3_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> Ethyl 4-((2-Fluoro-4-(trifluoromethyl)phenyl)carbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>198</b>)</h5><div class="NLM_p last"><b>198</b> was prepared from <b>192</b> (64%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.41 (s, 1H), 7.83–7.85 (m, 1H), 7.69–7.75 (m, 2H), 7.26 (brs, 1H), 4.28 (q, 2H, <i>J</i> = 7.1 Hz), 2.67 (s, 3H), 1.32 (t, 3H, <i>J</i> = 7.1 Hz); ESIMS <i>m</i>/<i>z</i> (M – 1): 342.1.</div></div><div id="sec5_5_3_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> Ethyl 4-((2-Bromo-4-(trifluoromethyl)phenyl)carbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>199</b>)</h5><div class="NLM_p last"><b>199</b> was prepared from <b>193</b> (50%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.38 (s, 1H), 8.11 (s, 1H), 7.86 (d, 1H, <i>J</i> = 8.0 Hz), 7.64 (d, 1H, <i>J</i> = 8.0 Hz), 7.08 (s, 1H), 4.28 (q, 2H, <i>J</i> = 7.2 Hz), 2.68 (s. 3H), 1.31 (t, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M, M + 2): 404.2, 406.2.</div></div><div id="sec5_5_3_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> Ethyl 4-(2-Bromo-6-(trifluoromethyl)pyridine-3-carbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>200</b>)</h5><div class="NLM_p last"><b>200</b> was prepared from <b>195</b> (47%). ESIMS <i>m</i>/<i>z</i> (M, M + 2): 405.3, 407.3. The product was used without further characterization.</div></div><div id="sec5_5_3_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> Ethyl 4-((3,4-Difluorophenyl)carbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>201</b>)</h5><div class="NLM_p last"><b>201</b> was prepared from <b>196</b> (50%). ESIMS <i>m</i>/<i>z</i> (M + 1): 294.0. The product was used without further characterization.</div></div><div id="sec5_5_3_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> Ethyl 4-(3-Fluoro-4-(trifluoromethyl)phenylcarbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>233</b>)</h5><div class="NLM_p last"><b>233</b> was prepared from <b>230</b> (51%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.38 (brs, 1H), 7.90–7.95 (m, 1H), 7.66–7.77 (m, 2H), 7.40 (d, 1H, <i>J</i> = 4.8 Hz), 4.29 (q, 2H, <i>J</i> = 7.2 Hz), 2.58 (s, 3H), 1.33(t, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M – 1): 342.2.</div></div><div id="sec5_5_3_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> Ethyl 3-Methyl-4-(3-(trifluoromethyl)phenylcarbonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>234</b>)</h5><div class="NLM_p last"><b>234</b> was prepared from <b>231</b> (66%). The product was used without further characterization.</div></div><div id="sec5_5_3_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> Ethyl 4-(6-(Difluoromethyl)pyridine-3-carbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>235</b>)</h5><div class="NLM_p last"><b>235</b> was prepared from <b>232</b> (47%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.93 (d, 1H, <i>J</i> = 1.2 Hz), 8.30 (dd, 1H, <i>J</i> = 1.2 Hz & 8.4 Hz), 7.85 (d, 1H, <i>J</i> = 8.4 Hz), 7.34 (s, 1H), 6.69–6.97 (m, 1H), 4.34 (2H, q, <i>J</i> = 7.2 Hz), 2.66 (s, 3H), 1. 45 (t, 3H, <i>J</i> = 7.2 Hz). ESIMS <i>m</i>/<i>z</i> (M + 1): 309.2.</div></div><div id="sec5_5_3_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> 3-Formyl-4-(6-(trifluoromethyl)pyridine-3-carbonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>258</b>)</h5><div class="NLM_p last"><b>258</b> was prepared from <b>257</b> (54%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 10.44 (s, 1H), 9.78 (brs, 1H), 9.00 (s, 1H), 8.55–8.58 (m, 1H), 7.80 (d, 1H, <i>J</i> = 8.0 Hz), 7.45 (s, 1H), 4.52 (q, 2H, <i>J</i> = 7.1 Hz), 1.51 (t, 3H, <i>J</i> = 7.1 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 341.2.</div></div><div id="sec5_5_3_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> Ethyl 4-(2-Bromo-6-(trifluoromethyl)pyridine-3-carbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>281</b>)</h5><div class="NLM_p last"><b>281</b> was prepared from <b>280</b> (47%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.46 (s, 1H), 8.15 (d, 1H, <i>J</i> = 7.7 Hz), 8.07 (d, 1H, <i>J</i> = 7.7 Hz), 7.37 (s, 1H), 4.28 (q, 2H, <i>J</i> = 6.8 Hz), 2.61 (s, 3H), 1.33 (t, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M, M + 2): 405.2, 407.2.</div></div></div><div id="sec5_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> General Procedure D1: Carbonyl to Methylene Reduction</h4><div class="NLM_p">Sodium borohydride (2 equiv) was added portionwise to a stirred solution of carbonyl pyrrole intermediate (1 equiv) in ethanol at 0 °C. The reaction mixture was stirred for 1 h at RT and then concentrated under reduced pressure, dissolved in water, and extracted with ethyl acetate (2×). The resulting combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford an intermediate hydroxyl compound. The intermediate hydroxyl product was used in the next step without characterization. To a stirred solution of hydroxyl intermediate (1 equiv) in trifluoroacetic acid (TFA, 6 equiv) was added triethylsilane (3–4 equiv) at RT and stirred at 85 °C for 1 h. Then, saturated NaHCO<sub>3</sub> was added dropwise at 0 °C and the mixture was extracted with ethyl acetate (3×, with careful venting). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The resulting concentrated product was triturated with petroleum ether to afford the compound as a white solid (11–77%). Compounds <b>19</b>–<b>20, 103, 178</b>–<b>180, 188, 205</b>, and <b>216</b>–<b>219</b> were prepared using this procedure.</div><div id="sec5_5_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> Ethyl 4-(Benzo[<i>d</i>]oxazol-7-ylmethyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>19</b>)</h5><div class="NLM_p last"><b>19</b> was prepared from <b>175</b> (11%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm):11.35 (s, 1H), 8.74 (s, 1H), 7.62 (d, 1H, <i>J</i> = 7.2 Hz), 7.29–7.32 (m, 1H), 7.14 (d, 1H, <i>J</i> = 7.1 Hz), 6.72 (d, 1H, <i>J</i> = 3.2 Hz), 4.21 (q, 2H, <i>J</i> = 7.1 Hz), 4.00 (s, 2H), 2.18 (s, 3H), 1.27 (t, 3H, <i>J</i> = 7.1 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 285.0; LCMS: 97.99%; HPLC purity: 99.07%.</div></div><div id="sec5_5_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> Ethyl 4-(Benzo[<i>d</i>]oxazol-2-ylmethyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>20</b>)</h5><div class="NLM_p last"><b>20</b> was prepared from <b>176</b> (48%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.45 (s, 1H), 7.64–7.68 (m, 2H), 7.32–7.36 (m, 2H), 6.94 (s, 1H), 4.23 (q, 2H, <i>J</i> = 6.8 Hz), 4.10 (s, 2H), 2.23 (s, 3H), 1.28 (t, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 285.0; LCMS: 96.07%; HPLC purity: 95.33%.</div></div><div id="sec5_5_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112"> Methyl 2-(Cyclopropylcarbamoyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-3-carboxylate (<b>103</b>)</h5><div class="NLM_p last"><b>103</b> was prepared from <b>260</b> (52%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 9.76 (d, 1H, <i>J</i> = 4.0 Hz), 8.61 (brs, 1H), 7.79 (brs, 2H), 6.88 (d, 1H, <i>J</i> = 2.8 Hz), 4.09 (s, 2H), 3.69 (s, 3H), 2.82–2.86 (m, 1H), 0.73–0.77 (m, 2H), 0.46–0.50 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 367.8; LCMS:95.59%; HPLC purity:98.27%</div></div><div id="sec5_5_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> Ethyl 3-Methyl-4-((6-(trifluoromethyl) pyridin-3-yl) methyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>178</b>)</h5><div class="NLM_p last"><b>178</b> was prepared from <b>173</b> (77%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.41 (s, 1H), 8.64 (s, 1H), 7.81 (brs, 2H), 6.81 (s, 1H), 4.21 (q, 2H, <i>J</i> = 7.1 Hz), 3.87 (s, 2H), 2.15 (s, 3H), 1.27 (t, 3H, <i>J</i> = 7.1 Hz); ESIMS <i>m</i>/<i>z</i>: 312.2</div></div><div id="sec5_5_4_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114"> Ethyl 4-((2-Fluoro-6-(trifluoromethyl)pyridin-3-yl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>179</b>)</h5><div class="NLM_p last"><b>179</b> was prepared from <b>174</b> (71%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 8.89 (s, 1H), 7.63 (d, 1H, <i>J</i> = 8.0 Hz), 7.48 (d, 1H, <i>J</i> = 8.0 Hz), 6.73 (s, 1H), 4.34 (q, 2H, <i>J</i> = 7.1 Hz), 3.87 (s, 2H), 2.24 (s, 3H), 1.37 (t, 3H, <i>J</i> = 7.1 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 331.2.</div></div><div id="sec5_5_4_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> Ethyl 3-Methyl-4-((4-(trifluoromethyl)phenyl)methyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>180</b>)</h5><div class="NLM_p last"><b>180</b> was prepared from <b>177</b> (72%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.36 (s, 1H), 7.63 (d, 2H, <i>J</i> = 8.0 Hz), 7.38 (s, 2H, <i>J</i> = 8.0 Hz), 6.77 (s, 1H), 4.22 (q, 2H, <i>J</i> = 7.2 Hz), 3.83 (s, 2H), 2.13 (s, 3H), 1.23 (t, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 312.2.</div></div><div id="sec5_5_4_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i116" class="anchor-spacer"></div><h5 class="article-section__title" id="_i116"> Ethyl 4-(2-Hydroxy-3-nitro-(4-(trifluoromethyl)phenyl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>188</b>)</h5><div class="NLM_p last"><b>188</b> was prepared from <b>187</b> (35%). ESIMS <i>m</i>/<i>z</i> (M + 1): 373.2. The product was used without further characterization.</div></div><div id="sec5_5_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> Ethyl 4-((2-Bromo-6-(trifluoromethyl)pyridin-3-yl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>205</b>)</h5><div class="NLM_p last"><b>205</b> was prepared from <b>200</b> (68%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.47 (s, 1H), 7.88 (d, 1H, <i>J</i> = 7.8 Hz), 7.70 (d, 1H, <i>J</i> = 7.8 Hz), 6.73 (s, 1H), 4.20 (q, 2H, <i>J</i> = 7.1 Hz), 3.87 (s, 2H), 2.14 (s, 3H), 1.27 (t, 3H, <i>J</i> = 7.1 Hz); ESIMS <i>m</i>/<i>z</i> (M, M + 2): 391.3, 393.3.</div></div><div id="sec5_5_4_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> Ethyl 4-(4-(<i>N</i>,<i>N</i>-Dimethylsulfamoyl)benzyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>216</b>)</h5><div class="NLM_p last"><b>216</b> was prepared from <b>212</b> (45%). The product was used without further characterization.</div></div><div id="sec5_5_4_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i119" class="anchor-spacer"></div><h5 class="article-section__title" id="_i119"> Ethyl 4-(isoquinolin-8-ylmethyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>217</b>)</h5><div class="NLM_p last"><b>217</b> was prepared from <b>213</b> (50%). ESIMS <i>m</i>/<i>z</i> (M + 1): 295.4. The product was used without further characterization.</div></div><div id="sec5_5_4_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i120" class="anchor-spacer"></div><h5 class="article-section__title" id="_i120"> Ethyl 4-((5-Methoxyisoquinolin-8-yl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>218</b>)</h5><div class="NLM_p last"><b>218</b> was prepared from <b>214</b> (45%). ESIMS <i>m</i>/<i>z</i> (M + 1): 325.4. The product was used without further characterization.</div></div><div id="sec5_5_4_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121"> Ethyl 4-((3-Fluoro-2-iodophenyl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>219</b>)</h5><div class="NLM_p last"><b>219</b> was prepared from <b>215</b> (0.6 g, 62%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.36 (s, 1H), 7.29–7.35 (m, 1H), 7.06–7.11 (m, 1H), 6.90–6.97 (m, 1H), 6.54 (s, 1H), 4.23 (q, 2H, <i>J</i> = 7.2 Hz), 3.74 (s, 2H), 2.13 (s, 3H), 1.28 (t, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 388.2.</div></div></div><div id="sec5_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> General Procedure D2: Carbonyl to Methylene Reduction</h4><div class="NLM_p">Sodium borohydride (2 equiv) was added portionwise to a stirred solution of carbonyl pyrrole intermediate (1 equiv) in ethanol at 0 °C. The reaction mixture was stirred for 1 h at room temperature and then concentrated, dissolved in water, and extracted with ethyl acetate (2). The resulting combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford an intermediate hydroxyl compound. The product was used in the next step without characterization. To a stirred solution of hydroxyl intermediate (1 equiv) in TFA (6 equiv) and CH<sub>2</sub>Cl<sub>2</sub> was added triethylsilane (3–4 equiv) at 0 °C and maintained at RT for 1 h. Then, saturated NaHCO<sub>3</sub> was added dropwise at 0 °C and extracted with ethyl acetate (3×, with careful venting). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The resulting concentrated product was triturated with petroleum ether to afford the compound as a white solid (42-56%). Compounds <b>202–204, 206</b> were prepared by this method.</div><div id="sec5_5_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i123" class="anchor-spacer"></div><h5 class="article-section__title" id="_i123"> Ethyl 4-((5-Fluoroisoquinolin-8-yl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>202</b>)</h5><div class="NLM_p last">The title compound was prepared from <b>197</b> (63%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.35 (s, 1H), 9.60 (s, 1H), 8.64 (d, 1H. <i>J</i> = 5.8 Hz), 7.97 (d, 1H, <i>J</i> = 5.8 Hz), 7.54–7.59 (m, 1H), 7.33–7.37 (s, 1H), 6.75 (s, 1H), 4.30 (s, 2H), 4.22 (q, 2H, <i>J</i> = 7.2 Hz), 2.21 (s, 3H), 1.27 (t, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 313.1; LCMS: 93.68%; HPLC purity: 95.07%.</div></div><div id="sec5_5_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124"> Ethyl 4-((2-Fluoro-4-(trifluoromethyl)phenyl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>203</b>)</h5><div class="NLM_p last"><b>203</b> was prepared from <b>198</b> (42%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.40 (s, 1H), 7.62 (d, 1H, <i>J</i> = 7.6 Hz), 7.51 (d, 1H, <i>J</i> = 7.6 Hz), 7.34–7.38 (m, 1H), 6.73 (s, 1H), 4.21 (q, 2H, <i>J</i> = 7.1 Hz), 3.82 (s, 2H), 2.15 (s, 3H), 1.27 (t, 3H, <i>J</i> = 7.1 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 330.1.</div></div><div id="sec5_5_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i125" class="anchor-spacer"></div><h5 class="article-section__title" id="_i125"> Ethyl 4-((2-Bromo-4-(trifluoromethyl)phenyl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>204</b>)</h5><div class="NLM_p last">The title compound was prepared from <b>199</b> (42%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.43 (s, 1H), 7.98 (s, 1H), 7.69 (d, 1H, <i>J</i> = 8.0 Hz), 7.29 (d, 1H, <i>J</i> = 8.0 Hz), 6.68 (s, 1H), 4.24 (q, 2H, <i>J</i> = 7.2 Hz), 3.87 (s, 2H), 2.15 (s. 3H), 1.27 (t, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M, M + 2): 390.1, 392.2.</div></div><div id="sec5_5_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i126" class="anchor-spacer"></div><h5 class="article-section__title" id="_i126"> Ethyl 4-((3,4-Difluorophenyl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>206</b>)</h5><div class="NLM_p last"><b>206</b> was prepared from <b>201</b> (58%). ESIMS <i>m</i>/<i>z</i> (M + 1): 280.1. The product was used without further purification.</div></div></div><div id="sec5_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> General Procedure E: Ester Hydrolysis</h4><div class="NLM_p">Sodium hydroxide (2 equiv) was added to a stirred solution of arylmethyl-1<i>H</i>-pyrrole-2-carboxylate intermediate (1 equiv) in EtOH:H<sub>2</sub>O (4:1) at RT and heated to 80 °C for 2 h. The resulting reaction mixture was concentrated, quenched with water, and then acidified with 10% citric acid solution. The solid obtained was filtered, washed with water, and dried to afford the compound as an off-white solid (60-95%). Compounds <b>181</b>–<b>183, 207</b>–<b>209, 211, 220</b>–<b>223, 223, 251</b>–<b>255, 261, 274</b>–<b>277</b>, and <b>283</b> were prepared using this procedure and <b>210</b> by an extended procedure as described.</div><div id="sec5_5_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i128" class="anchor-spacer"></div><h5 class="article-section__title" id="_i128"> 3-Methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>181</b>)</h5><div class="NLM_p last"><b>181</b> was prepared from <b>178</b> (88%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.15 (s, 1H), 11.29 (s, 1H), 8.64 (s, 1H), 7.81 (brs, 2H), 6.75 (s, 1H), 3.86 (s, 2H), 2.14 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 285.2.</div></div><div id="sec5_5_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i129" class="anchor-spacer"></div><h5 class="article-section__title" id="_i129"> 4-(Benzo[<i>d</i>]oxazol-2-ylmethyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>182</b>)</h5><div class="NLM_p last"><b>182</b> was prepared from <b>20</b> (67%). ESIMS <i>m</i>/<i>z</i> (M + 1): 257.2. The product was used without further purification.</div></div><div id="sec5_5_6_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130"> 3-Methyl-4-(4-(trifluoromethyl)benzyl)-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>183</b>)</h5><div class="NLM_p last"><b>183</b> was prepared from <b>180</b> (88%). ESIMS <i>m</i>/z (M + 1): 284.2. The product was used without further characterization.</div></div><div id="sec5_5_6_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i131" class="anchor-spacer"></div><h5 class="article-section__title" id="_i131"> 4-((5-Fluoroisoquinolin-8-yl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>207</b>)</h5><div class="NLM_p last"><b>207</b> was prepared from <b>202</b> (95%). ESIMS <i>m</i>/z (M + 1):285.2. The product was used without further characterization.</div></div><div id="sec5_5_6_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i132" class="anchor-spacer"></div><h5 class="article-section__title" id="_i132"> 4-(2-Fluoro-4-(trifluoromethyl)benzyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>208</b>)</h5><div class="NLM_p last"><b>208</b> was prepared from <b>203</b> (82%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.11 (s, 1H), 11.27 (s, 1H), 7.62 (s, 1H), 7.50 (s, 1H), 7.35–7.38 (m, 1H), 6.69 (s, 1H), 3.80 (s, 2H), 2.14 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M–1): 300.1; LCMS: 99.45%; HPLC purity: 90.57%.</div></div><div id="sec5_5_6_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i133" class="anchor-spacer"></div><h5 class="article-section__title" id="_i133"> 4-(2-Bromo-4-(trifluoromethyl)benzyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>209</b>)</h5><div class="NLM_p last"><b>209</b> was prepared from <b>204</b> (86%). ESIMS <i>m</i>/<i>z</i> (M, M + 2): 362.2, 364.2. The product was used without further characterization.</div></div><div id="sec5_5_6_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i134" class="anchor-spacer"></div><h5 class="article-section__title" id="_i134"> 4-((2-Carbamoyl-6-(trifluoromethyl)pyridine-3-yl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>210</b>)</h5><div class="NLM_p">Zinc cyanide (0.72 g, 6.14 mmol) was added to a degassed solution of <b>205</b> (1.2 g, 3.067 mmol), Pd(dppf)Cl<sub>2</sub> (125 mg, 0.15 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub> (140 mg, 0.15 mmol) in DMA (20 mL) at RT and stirring was continued for 16 h at 115 °C. The reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (2 × 100 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The resulting concentrated product was purified by flash chromatography (silica gel, eluting with the hexane:EtOAc mixture from 100 to 60:40%) to afford ethyl 4-((2-cyano-6-(trifluoromethyl)pyridine-3-yl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (0.8 g, 78%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.52 (s, 1H), 8.17 (d, 1H, <i>J</i> = 8.3 Hz), 8.04 (d, 1H, <i>J</i> = 8.3 Hz), 6.79 (s, 1H), 4.23 (q, 2H, <i>J</i> = 6.8 Hz), 4.07 (s, 2H), 2.19 (s, 3H), 1.28 (t, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 338.0; LCMS: 99.70%; HPLC purity: 99.52%.</div><div class="NLM_p">Ethyl 4-((2-cyano-6-(trifluoromethyl)pyridine-3-yl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate was subjected to general procedure E to afford the title compound (21%).</div><div class="NLM_p last">ESIMS <i>m</i>/<i>z</i> (M + 1): 328.2. The product was used without further characterization.</div></div><div id="sec5_5_6_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i135" class="anchor-spacer"></div><h5 class="article-section__title" id="_i135"> 4-((3,4-Difluorophenyl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>211</b>)</h5><div class="NLM_p last"><b>211</b> was prepared from <b>206</b> (72%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.10 (s, 1H), 11.22 (s, 1H), 7.27–7.34 (m, 1H), 7.16–7.21 (m, 1H), 7.00 (brs, 1H), 6.70 (s, 1H), 3.71 (s, 2H), 2.12 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M – 1): 249.9; LCMS: 97.02%; HPLC purity: 98.60%.</div></div><div id="sec5_5_6_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i136" class="anchor-spacer"></div><h5 class="article-section__title" id="_i136"> 4-(4-(<i>N</i>,<i>N</i>-Dimethylsulfamoyl)benzyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>220</b>)</h5><div class="NLM_p last"><b>220</b> was prepared from <b>216</b> (70%). ESIMS <i>m</i>/<i>z</i> (M + 1): 322.9. The product was used without further characterization.</div></div><div id="sec5_5_6_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i137" class="anchor-spacer"></div><h5 class="article-section__title" id="_i137"> 4-(Isoquinolin-8-ylmethyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>221</b>)</h5><div class="NLM_p last"><b>221</b> was prepared from <b>217</b> (75%). ESIMS <i>m</i>/<i>z</i> (M + 1): 267.0. The product was used without further characterization.</div></div><div id="sec5_5_6_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i138" class="anchor-spacer"></div><h5 class="article-section__title" id="_i138"> 4-((5-Methoxyisoquinolin-8-yl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>222</b>)</h5><div class="NLM_p last"><b>222</b> was prepared from <b>218</b> (80%). The product was used without further characterization.</div></div><div id="sec5_5_6_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i139" class="anchor-spacer"></div><h5 class="article-section__title" id="_i139"> 4-((3-Fluoro-2-iodophenyl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>223</b>)</h5><div class="NLM_p last"><b>223</b> was prepared from <b>219</b> (92%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.12 (brs, 1H), 11.23 (s, 1H), 7.28–7.35 (m, 1H), 7.06–7.11 (m, 1H), 6.89–6.97 (m, 1H), 6.54 (s, 1H), 3.80 (s, 2H), 2.14 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M – 1): 358.2.</div></div><div id="sec5_5_6_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i140" class="anchor-spacer"></div><h5 class="article-section__title" id="_i140"> 3-Methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>251</b>)</h5><div class="NLM_p last"><b>251</b> was prepared from <b>246</b> (89%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.36 (s, 1H), 8.40 (s, 1H), 7.74 (d, 1H, <i>J</i> = 8.4 Hz), 7.63 (d, 1H, <i>J</i> = 8.4 Hz), 6.91 (s, 1H), 2.09 (s, 3H), 1.40 (brs, 2H), 1.28 (brs, 2H); ESIMS <i>m</i>/<i>z</i>: 311.2; LCMS: 98.02%; HPLC purity: 94.73%.</div></div><div id="sec5_5_6_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i141" class="anchor-spacer"></div><h5 class="article-section__title" id="_i141"> 4-((2-Fluoro-4-(trifluoromethyl)phenylmethyl)cyclopropyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>252</b>)</h5><div class="NLM_p last"><b>252</b> was prepared from <b>247</b> (78%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.07 (s, 1H), 11.22 (s, 1H), 7.68–7.73 (m, 1H), 7.47–7.53 (m, 2H), 6.88 (s, 1H), 2.19 (s, 3H), 1.16–1.18 (m, 2H), 1.10–1.11 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M – 1): 325.9; LCMS: 95.59%; HPLC purity: 95.80%.</div></div><div id="sec5_5_6_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i142" class="anchor-spacer"></div><h5 class="article-section__title" id="_i142"> 4-((3-Fluoro-4-(trifluoromethyl)phenylmethyl)cyclopropyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>253</b>)</h5><div class="NLM_p last"><b>253</b> was prepared from <b>248</b> (84%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.04 (brs, 1H), 7.57–7.61 (m, 1H), 6.98–7.03 (m, 2H), 6.74 (s, 1H), 2.08 (s, 3H), 1.30–1.32 (m, 2H),1.22–1.24 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M – 1): 326.1.</div></div><div id="sec5_5_6_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i143" class="anchor-spacer"></div><h5 class="article-section__title" id="_i143"> 3-Methyl-4-(1-(3-(trifluoromethyl)phenyl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>254</b>)</h5><div class="NLM_p last"><b>254</b> was prepared from <b>249</b> (60%). The product was used without further characterization.</div></div><div id="sec5_5_6_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i144" class="anchor-spacer"></div><h5 class="article-section__title" id="_i144"> 4-(1-(6-(Difluoromethyl)pyridin-3-yl)cyclopropyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>255</b>)</h5><div class="NLM_p last"><b>255</b> was prepared from <b>250</b> (68%). ESIMS (M + 1)<i>m</i>/<i>z</i>: 293.2. The product was used without further characterization.</div></div><div id="sec5_5_6_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i145" class="anchor-spacer"></div><h5 class="article-section__title" id="_i145"> 2-(Cyclopropylcarbamoyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-3-carboxylic Acid (<b>261</b>)</h5><div class="NLM_p last"><b>261</b> was prepared from <b>103</b> (78%). ESIMS <i>m</i>/<i>z</i> (M + 1): 354.2. The product was used without further characterization.</div></div><div id="sec5_5_6_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i146" class="anchor-spacer"></div><h5 class="article-section__title" id="_i146"> 3-Methyl-4-(6-(trifluoromethyl)-1<i>H</i>-indol-3-yl)-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>274</b>)</h5><div class="NLM_p last"><b>274</b> was prepared from <b>271</b> (65%). The product was used without characterization.</div></div><div id="sec5_5_6_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i147" class="anchor-spacer"></div><h5 class="article-section__title" id="_i147"> 4-(6-Fluoro-1<i>H</i>-indol-3-yl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>275</b>)</h5><div class="NLM_p last"><b>275</b> was prepared from <b>272</b> (83%). The product was used without characterization.</div></div><div id="sec5_5_6_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i148" class="anchor-spacer"></div><h5 class="article-section__title" id="_i148"> 4-(6-(Trifluoromethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>276</b>)</h5><div class="NLM_p last"><b>276</b> was prepared from <b>273</b> (92%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.25 (s, 1H), 11.6 (s, 1H), 8.20 (d, 1H, <i>J</i> = 8.0 Hz); 7.75 (s, 1H), 7.52 (d, 1H, <i>J</i> = 8.0 Hz), 7.14 (s, 1H), 2.33 (s, 3H); ESIMS <i>m</i>/<i>z</i>: 309.9.</div></div><div id="sec5_5_6_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i149" class="anchor-spacer"></div><h5 class="article-section__title" id="_i149"> 4-(2-Fluoro-4-(trifluoromethyl)benzoyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>277</b>)</h5><div class="NLM_p last"><b>277</b> was prepared from <b>198</b> (95%). The product was used without characterization.</div></div><div id="sec5_5_6_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i150" class="anchor-spacer"></div><h5 class="article-section__title" id="_i150"> 3-Methyl-4-(6-(trifluoromethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>283</b>)</h5><div class="NLM_p last"><b>283</b> was prepared from <b>282</b> (94%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.99 (s, 1H), 12.43 (s, 1H), 11.88 (s, 1H), 8.69 (d, 1H, <i>J</i> = 8.4 Hz), 7.63 (d, 1H, <i>J</i> = 8.4 Hz), 7.57 (d, 1H, <i>J</i> = 3.2 Hz), 2.56 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 311.1; LCMS: 94.77%; HPLC purity: 97.34%.</div></div></div><div id="sec5_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i151" class="anchor-spacer"></div><h4 class="article-section__title" id="_i151"> General Procedure F1: Amide Formation</h4><div class="NLM_p">Amine (1.1 equiv) and triethylamine (2 equiv) were added to pyrrole carboxylic acid intermediate (1 equiv) in CH<sub>2</sub>Cl<sub>2</sub> and stirred for 5 min at RT. Then, HATU (1.5 equiv) was added to the reaction mixture and stirring was maintained at RT for 4 h. After completion of the reaction (monitored by thin-layer chromatography (TLC)), water was added to the reaction mixture and crude product was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2×). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The resulting concentrated product was purified by column chromatography using 10–70% ethyl acetate in petroleum ether to afford compound (10–68%) as an off-white solid. Compounds <b>4</b>–<b>7, 11</b>–<b>17, 21</b>–<b>22, 24</b>–<b>28, 35</b>–<b>39, 51</b>–<b>53, 56</b>–<b>58, 73</b>–<b>76, 81</b>–<b>82, 104, 111</b>–<b>114, 124</b>–<b>130, 133, 137, 141</b>–<b>144, 149</b>–<b>160, 163, 189, 256</b>, and <b>279</b> were prepared using this procedure. Compounds <b>23</b> and <b>259</b> were prepared using procedure F1 with an additional step as described.</div><div id="sec5_5_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i152" class="anchor-spacer"></div><h5 class="article-section__title" id="_i152"> 3-Methyl-<i>N</i>-(oxetan-3-yl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>4</b>)</h5><div class="NLM_p last"><b>4</b> was prepared from 3-oxetanamine and <b>181</b> (61%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.97 (s, 1H), 8.04 (d, 1H, <i>J</i> = 6.4 Hz), 7.80 (s, 2H), 6.72 (s, 1H), 4.90–4.92 (m, 1H), 4.74 (t, 2H, <i>J</i> = 6.4 Hz), 4.49 (t, 2H, <i>J</i> = 6.4 Hz), 3.84 (s, 2H), 2.12 (s, 3H). ESIMS <i><i>m</i>/<i>z</i></i> (M + 1); 340.0; LCMS: 97.95%; HPLC purity: 98.13%.</div></div><div id="sec5_5_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i153" class="anchor-spacer"></div><h5 class="article-section__title" id="_i153"> <i>N</i>-(4-Hydroxytetrahydrofuran-3-yl)-3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-<i>H</i>-pyrrole-2-carboxamide (<b>5</b>)</h5><div class="NLM_p last"><b>5</b> was prepared from 4-aminotetrahydro-3-furanol and <b>181</b> (31%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.82 (s, 1H, D<sub>2</sub>O exch), 8.64 (s, 1H), 7.82 (brs, 2H), 7.45 (d, 1H, D<sub>2</sub>O exch), 6.62 (brs, 1H), 5.27 (d, 1H, <i>J</i> = 4.0 Hz, D<sub>2</sub>O exch), 4.11–4.12 (m, 2H), 3.93–3.97 (m, 1H), 3.88–3.86 (m, 1H), 3.85 (s, 2H), 3.57 (d, 1H, <i>J</i> = 9.2 Hz) 3.56 (d, 1H, <i>J</i> = 9.2 Hz), 2.13 (s, 3H); ESIMS <i><i>m</i>/<i>z</i></i> (M + 1); 370.0; LC-MS: 99.11%. HPLC purity: 99.90%.</div></div><div id="sec5_5_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i154" class="anchor-spacer"></div><h5 class="article-section__title" id="_i154"> <i>N</i>-(4-Methoxytetrahydrofuran-3-yl)-3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>6</b>)</h5><div class="NLM_p last"><b>6</b> was prepared from 4-methoxytetrahydro-3-furanamine and <b>181</b> (34%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.02 (s, 1H, D<sub>2</sub>O exch), 8.63 (s, 1H), 7.81 (brs, 2H), 7.56 (d, 1H, D<sub>2</sub>O exch), 6.72 (s, 1H), 4.30 (brs, 1H), 3.81–3.91 (m, 5H), 3.59–3.66 (m, 2H), 3.34 (s, 3H), 2.14 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1); 384.0; LCMS: 99.45%; HPLC purity: 99.57%.</div></div><div id="sec5_5_7_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i155" class="anchor-spacer"></div><h5 class="article-section__title" id="_i155"> <i>N</i>-((1<i>H</i>-Pyrazol-3-yl)methyl)-3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>7</b>)</h5><div class="NLM_p last"><b>7</b> was prepared from 1H-pyrazole-4-methanamine and <b>181</b> (24%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.56 (s, 1H), 7.82 (d, 1H, <i>J</i> = 8.0 Hz), 7.73 (d, 1H, <i>J</i> = 8.0 Hz), 7.58 (s, 1H), 6.73 (s, 1H), 6.31 (s, 1H), 4.58 (s, 2H), 3.95 (s, 2H), 2.21 (s, 3H); ESIMS <i><i>m</i>/<i>z</i></i> (M + 1); 364.2; LCMS: 99.86%; HPLC purity: 97.24.</div></div><div id="sec5_5_7_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i156" class="anchor-spacer"></div><h5 class="article-section__title" id="_i156"> <i>N</i>-Cyclopropyl-4-(4-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)benzyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide (<b>11</b>)</h5><div class="NLM_p last"><b>11</b>was prepared from cyclopropanamine and <b>220</b> (23%). <sup>1</sup>H NMR (300 MHz, MeOD) δ 7.68 (d, <i>J</i> = 7.8 Hz, 2H), 7.42 (d, <i>J</i> = 8.0 Hz, 2H), 6.67 (s, 1H), 3.90 (s, 2H), 2.81–2.71 (m, 1H), 2.67 (s, 6H), 2.16 (s, 3H), 0.90–0.70 (m, 2H), 0.66–0.46 (m, 2H). ESIMS <i>m</i>/<i>z</i> (M + 1): 362.2; LCMS: 96.52%.</div></div><div id="sec5_5_7_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i157" class="anchor-spacer"></div><h5 class="article-section__title" id="_i157"> <i>N</i>-Cyclopropyl-4-(isoquinolin-8-ylmethyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide (<b>12</b>)</h5><div class="NLM_p last"><b>12</b> was prepared from cyclopropanamine and <b>221</b> (25%). <sup>1</sup>H NMR (300 MHz, MeOD) δ (ppm): 9.47 (brs, 1H), 8.44 (brs, 1H), 7.83 (d, <i>J</i> = 8.0 Hz, 2H), 7.74–7.67 (m, 2H), 7.45 (d, <i>J</i> = 6.9 Hz, 2H), 6.41 (s, 1H), 4.35 (s, 2H), 2.89–2.71 (m, 1H), 2.27 (s, 3H), 0.89–0.73 (m, 2H), 0.71–0.53 (m, 2H). ESIMS <i>m</i>/<i>z</i> (M + 1): 306.0; LCMS: 97.85%.</div></div><div id="sec5_5_7_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i158" class="anchor-spacer"></div><h5 class="article-section__title" id="_i158"> (3,3-Difluoroazetidin-1-yl)(4-(isoquinolin-8-ylmethyl)-3-methyl-1<i>H</i>-pyrrol-2-yl)methanone (<b>13</b>)</h5><div class="NLM_p last"><b>13</b> was prepared from 3,3-difluoroazetidine and <b>221</b> (28%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ (ppm): 9.43 (s, 1H), 9.11 (brs, 1H), 8.42 (d, <i>J</i> = 5.7 Hz, 1H), 7.71–7.48 (m, 2H), 7.42–7.22 (m, 2H), 6.41 (s, 1H), 4.41 (t, <i>J</i> = 12.2 Hz, 4H), 4.21 (s, 2H), 2.12 (s, 3H). ESIMS <i>m</i>/<i>z</i> (M + 1): 342.2; LCMS: 97.45%.</div></div><div id="sec5_5_7_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i159" class="anchor-spacer"></div><h5 class="article-section__title" id="_i159"> 4-(Isoquinolin-8-ylmethyl)-3-methyl-<i>N</i>-(2,2,2-trifluoroethyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>14</b>)</h5><div class="NLM_p last"><b>14</b> was prepared from 2,2,2-trifluoroethylamine and <b>221</b> (35%). <sup>1</sup>H NMR (300 MHz, MeOD) δ (ppm): 9.46 (brs, 1H), 8.46 (brs, 1H), 7.96–7.80 (m, 2H), 7.80–7.67 (m, 2H), 7.59–7.39 (m, 2H), 6.46 (s, 1H), 4.37 (s, 2H), 4.08 (q, <i>J</i> = 9.4 Hz, 2H), 2.32 (s, 3H). ESIMS <i>m</i>/<i>z</i> (M + 1): 348.2; LCMS: 98.24%.</div></div><div id="sec5_5_7_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i160" class="anchor-spacer"></div><h5 class="article-section__title" id="_i160"> <i>N</i>-Cyclopropyl-4-((5-methoxyisoquinolin-8-yl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide (<b>15</b>)</h5><div class="NLM_p last"><b>15</b> was prepared from cyclopropylamine and <b>222</b> (30%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ (ppm): 9.44 (brs, 1H), 9.33 (brs, 1H), 8.54 (d, <i>J</i> = 5.5 Hz, 1H), 8.12 (d, <i>J</i> = 5.8 Hz, 1H), 7.23 (d, <i>J</i> = 7.9 Hz, 1H), 6.94 (d, <i>J</i> = 7.9 Hz, 1H), 6.44 (d, <i>J</i> = 2.4 Hz, 1H), 6.01 (s, 1H), 4.22 (s, 2H), 4.01 (s, 3H), 2.93–2.83 (m, 1H), 2.24 (s, 3H), 0.93–0.82 (m, 2H), 0.66–0.57 (m, 2H). ESIMS <i>m</i>/<i>z</i> (M + 1): 336.2; LCMS: 98.44%.</div></div><div id="sec5_5_7_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i161" class="anchor-spacer"></div><h5 class="article-section__title" id="_i161"> <i>N</i>-Cyclopropyl-4-((5-fluoroisoquinolin-8-yl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide (<b>16</b>)</h5><div class="NLM_p last"><b>16</b> was prepared from cyclopropylamine and <b>207</b> (25%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 10.82 (s, 1H), 9.57 (s, 1H), 8.63 (s, 1H), 7.93 (d, <i>J</i> = 4.9 Hz, 1H), 7.53 (d, <i>J</i> = 9.7 Hz, 1H), 7.49 (s, 1H), 7.36 (s, 1H), 6.46 (s, 1H), 4.27 (s, 2H), 2.83–2.61 (m, 1H), 2.19 (s, 3H), 0.73–0.55 (m, 2H), 0.51–0.38 (m, 2H). ESIMS <i>m</i>/<i>z</i> (M + 1): 324.2; LCMS: 97.73%.</div></div><div id="sec5_5_7_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i162" class="anchor-spacer"></div><h5 class="article-section__title" id="_i162"> (3,3-Difluoroazetidin-1-yl)(4-((5-fluoroisoquinolin-8-yl)methyl)-3-methyl-1<i>H</i>-pyrrol-2-yl)methanone (<b>17</b>)</h5><div class="NLM_p last"><b>17</b> was prepared from 3,3-difluoroazetidine and <b>207</b> (30%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ (ppm): 9.58 (s, 1H), 9.34 (brs, 1H), 8.68 (d, <i>J</i> = 5.8 Hz, 1H), 8.04 (d, <i>J</i> = 5.8 Hz, 1H), 7.55–7.37 (m, 2H), 6.57 (d, <i>J</i> = 2.8 Hz, 1H), 4.59 (t, <i>J</i> = 12.1 Hz, 4H), 4.34 (s, 2H), 2.28 (s, 3H). ESIMS <i>m</i>/<i>z</i> (M + 1): 360.3; LCMS: 98.65%.</div></div><div id="sec5_5_7_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i163" class="anchor-spacer"></div><h5 class="article-section__title" id="_i163"> 4-(Benzo[<i>d</i>]oxazol-2-ylmethyl)-<i>N</i>-cyclopropyl-3-methyl-1<i>H</i>-pyrrole-2-carboxamide (21)</h5><div class="NLM_p last"><b>21</b> was prepared from cyclopropanamine and <b>182</b> (22%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 9.20 (brs, 1H), 7.69–7.71 (m, 1H), 7.48–7.50 (s, 1H), 7.29–7.33 (m, 2H), 6.93 (s, 1H), 5.88 (brs, 1H), 4.13 (s, 2H), 2.84–2.88 (m, 1H), 2.10 (s, 3H), 0.85-0.89 (m, 2H), 0.58-0.61 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 296.2; LCMS: 98.13%; HPLC purity: 97.44%.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_4"><div id="ac_i164" class="anchor-spacer"></div><h5 class="article-section__title" id="_i164"> (<i>S</i>)-<i>N</i>-(1-Hydroxypropan-2-yl)-3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>22</b>)</h5><div class="NLM_p last"><b>22</b> was prepared from (2<i>S</i>)-2-amino-propan-1-ol and <b>181</b> (15%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.01 (s, 1H), 8.63 (s, 1H), 7.80 (s, 2H), 7.05 (d, 1H), 6.69 (d, 1H), 4.73–4.75 (m, 1H), 3.91–3.95 (m, 1H), 3.85 (s, 2H), 3.38–3.44 (m, 1H), 2.13 (s, 3H), 1.08–1.13 (d, 3H); ESIMS <i><i>m</i>/<i>z</i></i> (M + 1); 342.2; LCMS: 92.21%; HPLC purity: 97.44%.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_4"><div id="ac_i165" class="anchor-spacer"></div><h5 class="article-section__title" id="_i165"> (<i>S</i>)-3-Methyl-<i>N</i>-(1-(methylamino)-1-oxopropan-2-yl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>23</b>)</h5><div class="NLM_p last">(<i>S</i>)-Alanine methyl ester and <b>181</b> were coupled using general procedure <b>F1</b>. After purification, the intermediate methyl ester product in THF was added directly to MeNH<sub>2</sub> in methanol solution (2 M, 2 equiv), followed by the addition of Me<sub>3</sub>Al (1.0 M in toluene, 3 equiv). The reaction mixture was heated to 100 °C for 1 h in a microwave. The reaction mixture was quenched with 1.5 N HCl solution and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The resulting concentrated product was purified by column chromatography using 10–50% ethyl acetate in petroleum ether to afford the title compound as an off-white solid (19%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.55 (s, 1H), 8.02 (brs, 1H), 7.81 (d, 1H, <i>J</i> = 8.0 Hz), 7.72 (d, 1H, <i>J</i> = 8.0 Hz), 6.74 (s, 1H), 4.49 (q, 1H, <i>J</i> = 6.8 Hz), 3.95 (s, 2H), 2.76 (d, 3H, <i>J</i> = 4.0 Hz), 2.21 (s, 3H), 1.43 (d, 3H, <i>J</i> = 6.8 Hz). ESIMS <i><i>m</i>/<i>z</i></i> (M + 1); 369.2; LC-MS: 98.91%. HPLC purity: 96.76%.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_4"><div id="ac_i166" class="anchor-spacer"></div><h5 class="article-section__title" id="_i166"> (<i>S</i>)-<i>N</i>-(1-Amino-1-oxopropan-2-yl)-3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>24</b>)</h5><div class="NLM_p last"><b>24</b> was prepared from (<i>S</i>)-2-aminopropanamide and <b>181</b> (24%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.57 (s, 1H), 7.82 (d, 1H, <i>J</i> = 8.0 Hz), 7.27 (d, 1H, <i>J</i> = 8.0 Hz), 6.75 (s, 1H), 4.54 (q, 1H, <i>J</i> = 8.0), 3.96 (s, 2H), 2.22 (s, 3H), 1.46 (d, 3H, <i>J</i> = 8.0); ESIMS <i><i>m</i>/<i>z</i></i> (M + 1); 355.2; LC-MS: 99.74%. HPLC purity: 96.32%.</div></div><div id="sec9" class="NLM_sec NLM_sec_level_4"><div id="ac_i167" class="anchor-spacer"></div><h5 class="article-section__title" id="_i167"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl) ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>25</b>)</h5><div class="NLM_p last"><b>25</b> was prepared from 1-(5-methyl-isoxazol-3-yl)-ethylamine and <b>181</b> (55%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.02 (s, 1H), 8.63 (s, 1H), 7.81 (s, 2H), 7.80 (d, 1H), 6.73 (s, 1H), 6.18 (s, 1H), 5.13–5.17 (m, 1H), 3.86 (s, 2H), 2.34 (s, 3H), 2.14 (s, 3H), 1.44 (d, 3H); ESIMS <i>m</i>/<i>z</i>: 393.2; LCMS: 97.21%; HPLC purity: 98.59%.</div></div><div id="sec10" class="NLM_sec NLM_sec_level_4"><div id="ac_i168" class="anchor-spacer"></div><h5 class="article-section__title" id="_i168"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide, Enantiomer I (<b>26</b>)</h5><div class="NLM_p last">Racemic (<b>25</b>) was resolved by SFC purification using a Lux C4 column and 0.5% DEA in methanol as a cosolvent (30%) to afford the product (retention time 3.13) as an off-white solid (18%). Optical rotation (methanol): −14.797. 1H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.02 (s, 1H), 8.63 (s, 1H), 7.81 (s, 2H), 7.80 (d, 1H), 6.73 (s, 1H), 6.18 (s, 1H), 5.13–5.17 (m, 1H), 3.86 (s, 2H), 2.34 (s, 3H), 2.14 (s, 3H), 1.44 (d, 3H); ESIMS <i>m</i>/<i>z</i>: 393.2; HPLC purity: 98.57%; SFC purity: 100%.</div></div><div id="sec11" class="NLM_sec NLM_sec_level_4"><div id="ac_i169" class="anchor-spacer"></div><h5 class="article-section__title" id="_i169"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide, Enantiomer II (<b>27</b>)</h5><div class="NLM_p last">The product was obtained as for (<b>26</b>) above, (retention time 4.0) as an off-white solid (14%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.02 (s, 1H), 8.63 (s, 1H), 7.81 (s, 2H), 7.80 (d, 1H), 6.73 (s, 1H), 6.18 (s, 1H), 5.13–5.17 (m, 1H), 3.86 (s, 2H), 2.34 (s, 3H), 2.14 (s, 3H), 1.44 (d, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 393.2; HPLC purity: 98.96%; SFC purity: 100%.</div></div><div id="sec12" class="NLM_sec NLM_sec_level_4"><div id="ac_i170" class="anchor-spacer"></div><h5 class="article-section__title" id="_i170"> 3-Methyl-<i>N</i>-(1-(1<i>H</i>-pyrazol-3-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>28</b>)</h5><div class="NLM_p last"><b>28</b> was prepared from <b>1-(1<i>H</i>-pyrazol-3-yl)ethan-1-amine</b> and <b>181</b> as a white solid (15%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.56 (s, 1H), 7.82 (d, 1H), 7.72 (d, 1H), 7.60 (brs, 1H), 6.72 (s, 1H), 6.29 (s, 1H), 5.31–5.33 (m, 1H), 3.95 (s, 2H), 2.20 (s, 3H), 1.58 (m, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z (M + 1)</i>: 378.2; LCMS: 99.58%; HPLC purity: 94.56%.</div></div><div id="sec13" class="NLM_sec NLM_sec_level_4"><div id="ac_i171" class="anchor-spacer"></div><h5 class="article-section__title" id="_i171"> 3-Methyl-<i>N</i>-(1-(1-methyl-1<i>H</i>-pyrazol-4-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>35</b>)</h5><div class="NLM_p last"><b>35</b> was obtained from 1-(1-methyl-1<i>H</i>-pyrazol-4-yl)ethan-1-amine and <b>181</b> (58%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 9.19 (bs, 1H), 8.60 (s, 1H), 7.61 (m, 2H), 7.48 (s, 1H), 7.37 (s, 1H), 6.67 (s, 1H), 5.78–5.80 (m, 1H), 5.30–5.34 (m, 1 H), 3.90 (m, 5H), 2.14 (s, 3H), 1.59 (d, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 392; LCMS: 99.89%; HPLC purity: 97.61%.</div></div><div id="sec14" class="NLM_sec NLM_sec_level_4"><div id="ac_i172" class="anchor-spacer"></div><h5 class="article-section__title" id="_i172"> 3-Methyl-<i>N</i>-(1-(1-methyl-1<i>H</i>-pyrazol-4-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>36</b>)</h5><div class="NLM_p last">Racemic product <b>(35)</b> was separated by SFC purification using a Lux A1 column and methanol cosolvent (30%) to afford enantiomer I (retention time 3.13) as an off-white solid (19%). Mp 150–153 °C. Optical rotation (ethanol): 9.997. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 9.15 (bs, 1H), 8.60 (s, 1H), 7.61 (m, 2H), 7.51 (s, 1H), 7.29 (s, 1H), 6.67 (s, 1H), 5.81 (m, 1H), 5.32 (m, 1 H), 3.92–3.90 (m, 5H), 2.14 (s, 3H), 1.59 (d, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 392.2; HPLC purity: 97.58%, SFC purity: 99.19%.</div></div><div id="sec15" class="NLM_sec NLM_sec_level_4"><div id="ac_i173" class="anchor-spacer"></div><h5 class="article-section__title" id="_i173"> 3-Methyl-<i>N</i>-(1-(1-methyl-1<i>H</i>-pyrazol-4-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>37</b>)</h5><div class="NLM_p last">The product was obtained as for (<b>36</b>) above (retention time 5.07) as an off-white solid (19%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 9.23 (bs, 1H), 8.60 (s, 1H), 7.61 (m, 2H), 7.51 (s, 1H), 7.41 (s, 1H), 6.67 (s, 1H), 5.82 (m, 1H), 5.32 (m, 1 H), 3.90 (m, 5H), 2.14 (s, 3H), 1.59 (d, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 392.2; HPLC purity: 99.00%, SFC purity: 98.75%.</div></div><div id="sec16" class="NLM_sec NLM_sec_level_4"><div id="ac_i174" class="anchor-spacer"></div><h5 class="article-section__title" id="_i174"> 3-Methyl-<i>N</i>-(1-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>38</b>)</h5><div class="NLM_p last">The compound was prepared from 1-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine and <b>181</b> as (22%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.56 (s, 1H), 8.34 (s, 1H), 7.72–7.80 (m, 2H), 6.74 (s, 1H), 5.29–5.31 (m, 1H), 3.96 (s, 2H), 3.91 (s, 3H), 2.22 (s, 3H), 1.60 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 393.0; LCMS: 89.09%; HPLC purity: 80.56%.</div></div><div id="sec17" class="NLM_sec NLM_sec_level_4"><div id="ac_i175" class="anchor-spacer"></div><h5 class="article-section__title" id="_i175"> 3-Methyl-<i>N</i>-(1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>39</b>)</h5><div class="NLM_p last"><b>39</b> was prepared from 1-(5-methyl-1,2,4-oxadiazol-3-yl)ethan-1-amine and <b>181</b> (15%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.06 (s, 1H), 8.63 (s, 1H), 7.88 (d, 1H), 7.81 (s, 2H), 6.74 (s, 1H), 5.17–5.24 (m, 1H), 3.86 (s, 2H), 2.57 (s, 3H), 2.14 (s, 3H), 1.48 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 394.1; LCMS: 99.69%; HPLC purity: 98.36%.</div></div><div id="sec18" class="NLM_sec NLM_sec_level_4"><div id="ac_i176" class="anchor-spacer"></div><h5 class="article-section__title" id="_i176"> <i>N</i>-(1-(3-Bromoisoxazol-5-yl)ethyl)-3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>51</b>)</h5><div class="NLM_p last"><b>51</b> was obtained from 1-(3-bromoisoxazol-5-yl)ethan-1-amine and <b>181</b> (25%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.03 (s, 1H), 8.64 (s, 1H), 7.94 (d, 1H, <i>J</i> = 8.4 Hz), 7.81 (s, 1H), 7.80 (s, 1H), 6.73–6.76 (m, 2H), 5.25–5.29 (m, 1H), 3.86 (s, 2H), 2.14 (s, 3H), 1.49 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 2): 459.0; LCMS: 94.80%; HPLC purity: 94.87%.</div></div><div id="sec19" class="NLM_sec NLM_sec_level_4"><div id="ac_i177" class="anchor-spacer"></div><h5 class="article-section__title" id="_i177"> 4-(Isoquinolin-8-ylmethyl)-3-methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>52</b>)</h5><div class="NLM_p last">The compound was obtained from 1-(5-methylisoxazol-3-yl)ethanamine and <b>221</b> (25%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ (ppm): 9.53 (s, 1H), 9.36 (brs, 1H), 8.54 (d, <i>J</i> = 5.7 Hz, 1H), 7.77–7.56 (m, 3H), 7.34 (d, <i>J</i> = 7.0 Hz, 1H), 6.51 (s, 1H), 5.99 (s, 1H), 4.35 (s, 2H), 3.10–2.77 (m, 1H), 2.42 (s, 3H), 2.34 (s, 3H), 1.63 (d, <i>J</i> = 6.9 Hz, 3H). ESIMS <i>m</i>/<i>z</i> (M + 1): 375.0; LCMS: 96.70%.</div></div><div id="sec20" class="NLM_sec NLM_sec_level_4"><div id="ac_i178" class="anchor-spacer"></div><h5 class="article-section__title" id="_i178"> 4-((5-Fluoroisoquinolin-8-yl)methyl)-3-methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>53</b>)</h5><div class="NLM_p last">The compound was obtained from 1-(5-methylisoxazol-3-yl)ethanamine and <b>207</b> (28%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.51 (s, 1H), 9.44 (brs, 1H), 8.60 (s, 1H), 7.95 (d, <i>J</i> = 5 Hz, 1H) 7.27 (d, <i>J</i> = 4.4 Hz 1H), 6.58 (d, <i>J</i> = 7.1 Hz, 1H), 6.47 (s, 1H), 5.95 (s, 1H), 5.50–5.23 (m, 1H), 4.29 (s, 2H), 2.40 (s, 3H), 2.32 (s, 3H), 1.62 (d, <i>J</i> = 6.4 Hz, 3H). ESIMS <i>m</i>/<i>z</i> (M + 1): 393.1; LCMS: 97.65%.</div></div><div id="sec21" class="NLM_sec NLM_sec_level_4"><div id="ac_i179" class="anchor-spacer"></div><h5 class="article-section__title" id="_i179"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(4-(trifluoromethyl)phenylmethyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>56</b>)</h5><div class="NLM_p last">Racemic <b>56</b> was obtained from 1-(5-methylisoxazol-3-yl)ethan-1-amine and <b>183</b> (55%). The racemic product was separated by SFC purification using a Lux A1 column and methanol cosolvent (40%) to afford enantiomer I (retention time: 2.62) as an off-white solid (24%). 1H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.05 (s, 1H), 7.80 (d, 1H, <i>J</i> = 8.0 Hz), 7.61 (s, 2H, <i>J</i> = 8.0 Hz), 7.37 (d, 2H, <i>J</i> = 8.0 Hz), 6.70 (s, 1H), 6.17 (s, 1H), 5.14–5.17 (m, 1H), 3.81 (s, 2H), 2.36 (s, 3H), 2.12 (s, 3H), 1.44 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 392.2. HPLC purity: 98.86%. SFC purity: 100%.</div></div><div id="sec22" class="NLM_sec NLM_sec_level_4"><div id="ac_i180" class="anchor-spacer"></div><h5 class="article-section__title" id="_i180"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(4-(trifluoromethyl)phenylmethyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>57</b>)</h5><div class="NLM_p last">The product was obtained as for <b>56</b> above, (retention time: 5.04) as an off-white solid (26%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.05 (s, 1H), 7.80 (d, 1H, <i>J</i> = 7.6 Hz), 7.61 (s, 2H, <i>J</i> = 8.0 Hz), 7.37 (d, 2H, <i>J</i> = 8.0 Hz), 6.70 (d, 1H, <i>J</i> = 2.4 Hz), 6.18 (s, 1H), 5.14–5.17 (m, 1H), 3.81 (s, 2H), 2.36 (s, 3H), 2.12 (s, 3H), 1.44 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 392.2. HPLC purity: 97.54%; SFC purity: 100%.</div></div><div id="sec23" class="NLM_sec NLM_sec_level_4"><div id="ac_i181" class="anchor-spacer"></div><h5 class="article-section__title" id="_i181"> <i>N</i>-(1-(3-Bromoisoxazol-5-yl)ethyl)-3-methyl-4-(4-(trifluoromethyl)phenylmethyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>58</b>)</h5><div class="NLM_p last">Racemic <b>58</b> was obtained from 1-(3-bromoisoxazol-5-yl)ethan-1-amine and <b>183</b> as an off-white solid (24%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm):10.98, (s, 1H), 7.93 (d, 1H, <i>J</i> = 8.4 Hz), 7.62 (d, 2H, <i>J</i> = 8.4 Hz), 7.38 (d, 2H, <i>J</i> = 8.4 Hz), 6.73 (m, 2H), 5.28 (q, 1H, <i>J</i> = 7.2 Hz), 3.81 (s, 2H), 2.12 (s, 3H), 1.49 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i>: 456.0; LCMS: 96.46%; HPLC purity: 93.86%.</div></div><div id="sec24" class="NLM_sec NLM_sec_level_4"><div id="ac_i182" class="anchor-spacer"></div><h5 class="article-section__title" id="_i182"> <i>N</i>-Cyclopropyl-3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>73</b>)</h5><div class="NLM_p last"><b>73</b> was prepared from cyclopropylamine and <b>251</b> (50%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 10.95 (s, 1H), 8.39 (s, 1H), 7.73 (d, 1H, <i>J</i> = 8.4 Hz), 7.63 (d, 1H, <i>J</i> = 8.4 Hz), 7.45 (s, 1H), 6.87 (s, 1H), 2.72–2.74 (m, 1H), 2.06 (s, 3H), 1.37–1.40 (m, 2H), 1.23–1.26 (m, 2H), 0.65–0.69 (m, 2H), 0.46–0.49 (m, 2H); ESIMS <i>m</i>/<i>z</i>: 350.2; LCMS: 96.67%; HPLC purity: 96.52%.</div></div><div id="sec25" class="NLM_sec NLM_sec_level_4"><div id="ac_i183" class="anchor-spacer"></div><h5 class="article-section__title" id="_i183"> (3,3-Difluoroazetidin-1-yl)-(3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrol-2-yl)methanone (<b>74</b>)</h5><div class="NLM_p last"><b>74</b> was prepared from 3,3-difluoroazetidine hydrochloride and <b>251</b> (48%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.06 (s, 1H), 8.41 (s, 1H), 7.73 (d, 1H, <i>J</i> = 8.0 Hz), 7.64 (d, 1H, <i>J</i> = 8.0 Hz), 6.96 (s, 1H), 4.50–4.57 (m, 4H), 2.03 (s, 3H), 1.40 (brs, 2H), 1.27 (brs, 2H); ESIMS <i>m</i>/<i>z</i>: 386.1; LCMS: 99.78%; HPLC purity: 99.67%.</div></div><div id="sec26" class="NLM_sec NLM_sec_level_4"><div id="ac_i184" class="anchor-spacer"></div><h5 class="article-section__title" id="_i184"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(1-(6-(trifluoromethyl)pyridin-3-yl) cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>75</b>)</h5><div class="NLM_p last">Racemic <b>75</b> was prepared from 1-(5-methylisoxazol-3-yl)ethan-1-amine and <b>251</b> (56%). The racemic product was separated by SFC purification using a Chiralpak 1A column and methanol cosolvent (20%) to afford enantiomer I (retention time: 3.86) as an off-white solid (17%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.14 (s, 1H), 8.41 (s, 1H), 7.82 (d, 1H), 7.74 (d, 1H), 7.65 (m, 1H), 6.92 (s, 1H), 6.20 (s, 1H), 5.17 (m, 1H), 2.37 (s, 3H), 2.09 (s, 3H), 1.46 (d, 3H, <i>J</i> = 8.0 Hz), 1.41 (m, 2H), 1.26 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 419.0; HPLC purity: 99.59%; SFC purity: 100%.</div></div><div id="sec27" class="NLM_sec NLM_sec_level_4"><div id="ac_i185" class="anchor-spacer"></div><h5 class="article-section__title" id="_i185"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>76</b>)</h5><div class="NLM_p last"><b>76</b> was prepared as for <b>75</b> above to afford enantiomer II (retention time: 5.97) as an off-white solid (25%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.15 (s, 1H), 8.41 (s, 1H), 7.82 (d, 1H), 7.74 (d, 1H), 7.65 (m, 1H), 6.93 (s, 1H), 6.20 (s, 1H), 5.17 (m, 1H), 2.37 (s, 3H), 2.09 (s, 3H), 1.46 (d, 3H, <i>J</i> = 8.0 Hz), 1.41 (m, 2H), 1.26 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 419.1; HPLC purity: 99.78%; SFC purity: 100%.</div></div><div id="sec28" class="NLM_sec NLM_sec_level_4"><div id="ac_i186" class="anchor-spacer"></div><h5 class="article-section__title" id="_i186"> 3-Methyl-<i>N</i>-[1-(5-methyl-1<i>H</i>-pyrazol-3-yl)ethyl]-4-(1-[6-(trifluoromethyl) pyridine-3-yl]cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>81</b>)</h5><div class="NLM_p last">Racemic <b>81</b> was prepared from 1-(5-methyl-1<i>H</i>-pyrazol-3-yl)ethan-1-amine and <b>251</b> (52%). The racemic product was separated by SFC purification using a YMC Amylose-C column and methanol cosolvent (40%) to afford enantiomer I (retention time: 2.27) as an off-white solid (17%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.21 (s, 1H), 11.11 (s, 1H), 8.39 (s, 1H), 7.71 (d, 1H, <i>J</i> = 8.3 Hz), 7.62 (d, 1H, <i>J</i> = 8.3 Hz), 7.52 (s, 1H), 6.89 (s, 1H), 5.93 (s, 1H), 5.09 (m, 1H), 2.17 (s, 3H), 2.09 (s, 3H), 1.39–1.41 (m, 5H), 1.20–1.25 (m, 2H); ESIMS <i>m</i>/<i>z</i>: 418.2; HPLC purity: 98.63%; SFC purity: 98.96%.</div></div><div id="sec29" class="NLM_sec NLM_sec_level_4"><div id="ac_i187" class="anchor-spacer"></div><h5 class="article-section__title" id="_i187"> 3-Methyl-<i>N</i>-[1-(5-methyl-1<i>H</i>-pyrazol-3-yl)ethyl]-4-(1-[6-(trifluoromethyl) pyridine-3-yl]cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>82</b>)</h5><div class="NLM_p last"><b>82</b> was prepared as for <b>75</b> above to afford enantiomer II (retention time: 4.07) as an off-white solid (24%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.21 (s, 1H), 11.14 (s, 1H), 8.39 (s, 1H), 7.71 (d, 1H, <i>J</i> = 8.3 Hz), 7.62 (d, 1H, <i>J</i> = 8.3 Hz), 7.52 (s, 1H), 6.89 (s, 1H), 5.93 (s, 1H), 5.08 (m, 1H), 2.17 (s, 3H), 2.09 (s, 3H), 1.39–1.41 (m, 5H), 1.20–1.25 (m, 2H); ESIMS <i>m</i>/<i>z</i>: 418.2; HPLC purity: 98.56%; SFC purity: 100%.</div></div><div id="sec30" class="NLM_sec NLM_sec_level_4"><div id="ac_i188" class="anchor-spacer"></div><h5 class="article-section__title" id="_i188"> N2-Cyclopropyl-N3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2,3-dicarboxamide (<b>104</b>)</h5><div class="NLM_p last"><b>104</b> was prepared from <b>261</b> and methylamine (2 M in THF) (38%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.71 (s, 1H), 9.26 (d, 1H, <i>J</i> = 3.6 Hz), 8.53 (d, 2H, <i>J</i> = 6.0 Hz), 7.73–7.80 (m, 2H), 6.72 (s, 1H), 4.12 (s, 2H), 2.75–2.78 (m, 1H), 2.67 (s, 3H), 0.69–0.73 (m, 2H), 0.42–0.45 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 367.0; LCMS:96.88%; HPLC purity: 94.41%.</div></div><div id="sec31" class="NLM_sec NLM_sec_level_4"><div id="ac_i189" class="anchor-spacer"></div><h5 class="article-section__title" id="_i189"> 3,5-Dimethyl-<i>N</i>-(1-(5-methylisoxazol-3-yl) ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl) methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>111</b>)</h5><div class="NLM_p last">Racemic <b>111</b> was prepared from 1-(5-methylisoxazol-3-yl)ethan-1-amine and <b>262</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (48%). The racemic product was separated by SFC purification using a Lux A1 column and methanol cosolvent (30%) to afford enantiomer I (retention time: 2.73) as an off-white solid (19%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 10.87 (s, 1H), 8.56 (s, 1H), 7.77 (d, 1H), 7.68 (d, 1H), 7.61 (s, 1H), 6.16 (d, 1H, <i>J</i> = 8.4 Hz), 5.12–5.16 (m, 1H), 3.82 (s, 2H), 2.36 (s, 3H), 2.15 (s, 3H), 2.11 (s, 3H), 1.43 (d, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1<i>)</i>: 407.1; HPLC purity: 98.31%; SFC purity: 98.42%.</div></div><div id="sec32" class="NLM_sec NLM_sec_level_4"><div id="ac_i190" class="anchor-spacer"></div><h5 class="article-section__title" id="_i190"> 3,5-Dimethyl-<i>N</i>-(1-(5-methylisoxazol-3-yl) ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl) methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>112</b>)</h5><div class="NLM_p last"><b>112</b> was prepared as for <b>111</b> above to afford the product (retention time: 5.02) as an off-white solid (18%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 10.87 (s, 1H), 8.56 (s, 1H), 7.77 (d, 1H), 7.68 (d, 1H), 7.61 (s, 1H), 6.16 (d, 1H, <i>J</i> = 8.4 Hz), 5.12–5.16 (m, 1H), 3.82 (s, 2H), 2.36 (s, 3H), 2.15 (s, 3H), 2.11 (s, 3H), 1.43 (d, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1<i>)</i>: 407.1; HPLC purity: 96.72%; SFC purity: 100%.</div></div><div id="sec33" class="NLM_sec NLM_sec_level_4"><div id="ac_i191" class="anchor-spacer"></div><h5 class="article-section__title" id="_i191"> 3,5-Dimethyl-<i>N</i>-(1-(1-methyl-1<i>H</i>-pyrazol-4-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>113</b>)</h5><div class="NLM_p last">Racemic <b>113</b> was obtained from 1-(1-methyl-1<i>H</i>-pyrazol-4-yl)ethan-1-amine and <b>262</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (37%). The racemic product was resolved by SFC purification using a YMC cellulose-SC column and methanol cosolvent (40%) to afford enantiomer I (retention time: 2.12) as an off-white solid (37%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 10.82 (s, 1H), 8.56 (s, 1H), 7.77 (d, 1H, <i>J</i> = 8.0 Hz), 7.68 (d, 1H, <i>J</i> = 8.0 Hz), 7.58 (s, 1H), 7.35 (s, 1H), 7.33 (bs, 1H), 5.01–5.03 (m, 1H), 3.81 (s, 2H), 3.78 (s, 3H), 2.14 (s, 3H), 2.11 (s, 3H), 1.39 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 406.2; HPLC purity: 98.25%; SFC purity: 100%.</div></div><div id="sec34" class="NLM_sec NLM_sec_level_4"><div id="ac_i192" class="anchor-spacer"></div><h5 class="article-section__title" id="_i192"> 3,5-Dimethyl-<i>N</i>-(1-(1-methyl-1<i>H</i>-pyrazol-4-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>114</b>)</h5><div class="NLM_p last"><b>114</b> was prepared as for <b>111</b> above to afford the product (retention time: 2.5) as an off-white solid (24%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 10.83 (s, 1H), 8.56 (s, 1H), 7.77 (d, 1H, <i>J</i> = 8.0 Hz), 7.68 (d, 1H, <i>J</i> = 8.0 Hz), 7.58 (s, 1H), 7.35 (s, 1H), 7.33 (s, 1H), 5.01–5.04 (m, 1H), 3.81 (s, 2H), 3.78 (s, 3H), 2.14 (s, 3H), 2.11 (s, 3H), 1.39 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 406.2; HPLC purity: 98.14%; SFC purity: 97.69%.</div></div><div id="sec35" class="NLM_sec NLM_sec_level_4"><div id="ac_i193" class="anchor-spacer"></div><h5 class="article-section__title" id="_i193"> <i>N</i>-Cyclopropyl-3-methyl-4-(6-(trifluoromethyl)-1<i>H</i>-indol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide (<b>124</b>)</h5><div class="NLM_p last"><b>124</b> was prepared from cyclopropylamine and <b>274</b> (38%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.55 (s, 1H), 11.11 (s, 1H), 7.74 (s, 1H), 7.72–7.74 (d, 1H), 7.55 (m, 2H), 7.30 (d, 1H, <i>J</i> = 8.4 Hz), 7.06 (s, 1H, <i>J</i> = 2.8 Hz), 2.76–2.81 (m, 1H), 2.30 (s, 3H), 0.68–0.73 (m, 2H), 0.51–0.53 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 348.1; LCMS: 94.32%; HPLC purity: 95.14%.</div></div><div id="sec36" class="NLM_sec NLM_sec_level_4"><div id="ac_i194" class="anchor-spacer"></div><h5 class="article-section__title" id="_i194"> (3,3-Difluoroazetidin-1-yl)(3-methyl-4-(6-(trifluoromethyl)-1<i>H</i>-indol-3-yl)-1<i>H</i>-pyrrol-2-yl)methanone (<b>125</b>)</h5><div class="NLM_p last"><b>125</b> was prepared from 3,3-difluoroazetidine hydrochloride and <b>274</b> with 1 extra equiv of Et<sub>3</sub>N, as a white solid (45%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.60 (s, 1H), 11.26 (s, 1H), 7.76–7.78 (d, 1H), 7.76 (s, 1H), 7.61 (s, 1H), 7.31 (d, 1H, <i>J</i> = 8.2 Hz), 7.16 (s, 1H), 4.56–4.62 (m, 4H), 2.27 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 384.0; LCMS: 96.23%; HPLC purity: 96.24%.</div></div><div id="sec37" class="NLM_sec NLM_sec_level_4"><div id="ac_i195" class="anchor-spacer"></div><h5 class="article-section__title" id="_i195"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-indol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>126</b>)</h5><div class="NLM_p last"><b>126</b> was prepared from 1-(5-methylisoxazol-3-yl)ethan-1-amine and <b>274</b> as a pale yellow solid (37%). The racemic product was resolved by SFC purification using a Chiralcel OJ-H column and methanol cosolvent (40%) to afford enantiomer I (retention time: 2.58) as an off-white solid (21%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.55 (s, 1H), 11.26 (s, 1H), 7.87 (d, 1H, <i>J</i> = 8.0 Hz), 7.74 (s, 1H), 7.73 (s, 1H), 7.56 (s, 1H), 7.30 (d, 1H, <i>J</i> = 8.0 Hz), 7.11 (s, 1H), 6.22 (s, 1H), 5.20–5.23 (m, 1H), 2.38 (s, 3H), 2.32 (s, 3H), 1.49 (d, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 417.1; HPLC purity: 96.65%; SFC purity: 100%.</div></div><div id="sec38" class="NLM_sec NLM_sec_level_4"><div id="ac_i196" class="anchor-spacer"></div><h5 class="article-section__title" id="_i196"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-indol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>127</b>)</h5><div class="NLM_p last"><b>127</b> was prepared as for <b>126</b> above to afford the product (retention time: 3.18) as an off-white solid (24%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.57 (s, 1H), 11.27 (s, 1H), 7.88 (d, 1H, <i>J</i> = 8.0 Hz), 7.75 (s, 1H), 7.74 (s, 1H), 7.56 (s, 1H), 7.30 (d, 1H, <i>J</i> = 8.0 Hz), 7.12 (s, 1H), 6.23 (s, 1H), 5.19–5.26 (m, 1H), 2.39 (s, 3H), 2.33 (s, 3H), 1.50 (d, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 417.1; HPLC purity: 98.81%; SFC purity: 100%.</div></div><div id="sec39" class="NLM_sec NLM_sec_level_4"><div id="ac_i197" class="anchor-spacer"></div><h5 class="article-section__title" id="_i197"> 3-Methyl-<i>N</i>-(2,2,2-trifluoroethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-indol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide (<b>128</b>)</h5><div class="NLM_p last"><b>128</b> was prepared from 2,2,2-trifluoroethan-1-amine hydrochloride and <b>274</b> with 1 extra equiv of Et<sub>3</sub>N, as an off-white solid (25%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.71–7.72 (m, 1H), 7.68 (d, 1H, <i>J</i> = 8.4 Hz), 7.41 (s, 1H), 7.30 (d, 1H, <i>J</i> = 8.4 Hz), 7.08 (s, 1H), 4.11 (d, 2H, <i>J</i> = 9.2 Hz), 2.36 (s, 3H); ESIMS; <i>m</i>/<i>z</i> (M – 1): 388.1; LCMS: 92.96%; HPLC purity: 96.90%.</div></div><div id="sec40" class="NLM_sec NLM_sec_level_4"><div id="ac_i198" class="anchor-spacer"></div><h5 class="article-section__title" id="_i198"> 3-Methyl-<i>N</i>-(1-(1-methyl-1<i>H</i>-pyrazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-indol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>129</b>)</h5><div class="NLM_p last">Racemic <b>129</b> was prepared from 1-(1-methyl-1<i>H</i>-pyrazol-3-yl)ethan-1-amine·HCl and <b>274</b> (50%). The racemic product was resolved by SFC purification using a Chiralcel OZ-H column and IPA cosolvent (40%) to afford enantiomer I (retention time: 1.96) as an off-white solid (32%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.72 (s, 1H), 7.70 (d, 1H, <i>J</i> = 8.4 Hz), 7.53 (d, 1H, <i>J</i> = 2.2 Hz), 7.42 (s, 1H), 7.29 (d, 1H, <i>J</i> = 8.4 Hz), 7.05 (s, 1H), 6.28 (d, 1H, <i>J</i> = 2.2 Hz), 5.30 (q, 1H, <i>J</i> = 6.8 Hz), 3.89 (s, 3H), 2.38 (s, 3H), 1.60 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 416.1; HPLC purity: 99.95%; SFC purity: 99.60%.</div></div><div id="sec41" class="NLM_sec NLM_sec_level_4"><div id="ac_i199" class="anchor-spacer"></div><h5 class="article-section__title" id="_i199"> 3-Methyl-<i>N</i>-(1-(1-methyl-1<i>H</i>-pyrazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-indol-3-yl)-1<i>H</i>- pyrrole-2-carboxamide Enantiomer II (<b>130</b>)</h5><div class="NLM_p last"><b>130</b> was prepared as for <b>129</b> above to afford the product (retention time: 2.71) as an off-white solid (20%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.72 (s, 1H), 7.70 (d, 1H, <i>J</i> = 8.4 Hz), 7.53 (d, 1H, <i>J</i> = 2.2 Hz), 7.42 (s, 1H), 7.29 (d, 1H, <i>J</i> = 8.4 Hz), 7.05 (s, 1H), 6.28 (d, 1H, <i>J</i> = 2.2 Hz), 5.31 (q, 1H, <i>J</i> = 6.8 Hz), 3.89 (s, 3H), 2.38 (s, 3H), 1.60 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 416.1; HPLC purity: 99.70%; SFC purity: 100%.</div></div><div id="sec42" class="NLM_sec NLM_sec_level_4"><div id="ac_i200" class="anchor-spacer"></div><h5 class="article-section__title" id="_i200"> 3-Methyl-<i>N</i>-(2,2,2-trifluoroethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide (<b>133</b>)</h5><div class="NLM_p last"><b>133</b> was prepared from 2,2,2-trifluoroethan-1-amine hydrochloride and <b>278</b> as an off-white solid (44%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.98 (d, 1H, <i>J</i> = 8.4 Hz), 7.89 (s, 1H), 7.42 (d, 1H, <i>J</i> = 8.4 Hz), 7.36 (s, 1H), 4.10–4.17 (m, 2H), 2.52 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 391.1; LCMS: 97.86%; HPLC purity: 98.42%.</div></div><div id="sec43" class="NLM_sec NLM_sec_level_4"><div id="ac_i201" class="anchor-spacer"></div><h5 class="article-section__title" id="_i201"> 3-Methyl-<i>N</i>-(1-(5-methyl-1<i>H</i>-pyrazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>136</b>)</h5><div class="NLM_p last">Racemic <b>136</b> was prepared from 1-(5-methyl-1<i>H</i>-pyrazol-3-yl)ethan-1-amine and <b>278</b> (43%). The racemic product was resolved by SFC purification using a Chiralcel OD-H column and methanol cosolvent (40%) to afford enantiomer I (retention time: 1.72) as an off-white solid (24%). <sup>1</sup>H NMR (400 MHz, MeOD) δ (ppm): 7.96 (d, 1H), 7.88 (s, 1H), 7.41 (d, 1H), 7.31 (s, 1H), 6.08 (s, 1H), 5.27–5.30 (m, 1H), 2.51 (s, 3H), 2.28 (s, 3H), 1.59 (d, 3H); ESIMS; <i>m</i>/<i>z</i> (M + 1): 417.3; HPLC purity: 99.05; SFC purity: 100%.</div></div><div id="sec44" class="NLM_sec NLM_sec_level_4"><div id="ac_i202" class="anchor-spacer"></div><h5 class="article-section__title" id="_i202"> 3-Methyl-<i>N</i>-(1-(5-methyl-1<i>H</i>-pyrazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>137</b>)</h5><div class="NLM_p last"><b>137</b> was prepared as for <b>136</b> above to afford the product (retention time: 2.36) as an off-white solid (21%). <sup>1</sup>H NMR (400 MHz, MeOD) δ (ppm): 7.96 (d, 1H), 7.88 (s, 1H), 7.41 (d, 1H), 7.31 (s, 1H), 6.08 (s, 1H), 5.29–5.30 (m, 1H), 2.51 (s, 3H), 2.28 (s, 3H), 1.59 (d, 3H); ESIMS; <i>m</i>/<i>z</i> (M + 1): 417.2; HPLC purity: 99.02; SFC purity: 100%.</div></div><div id="sec45" class="NLM_sec NLM_sec_level_4"><div id="ac_i203" class="anchor-spacer"></div><h5 class="article-section__title" id="_i203"> 3-Methyl-<i>N</i>-(1-(1-methyl-1<i>H</i>-pyrazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>141</b>)</h5><div class="NLM_p last">Racemic <b>141</b> was prepared from 1-(1-methyl-1<i>H</i>-pyrazol-3-yl)ethan-1-amine·HCl and <b>278</b> (45%). The racemic product was resolved by SFC purification using a Chiralcel OZ-H column and methanol cosolvent (40%) to afford enantiomer I (retention time: 2.11) as a white solid (19%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.34 (s, 1H), 11.52 (s, 1H), 8.07 (d, 1H, <i>J</i> = 8.4 Hz), 7.89 (s, 1H), 7.74 (d, 1H), 7.60 (s, 1H), 7.37–7.43 (m, 2H), 6.19 (s, 1H), 5.16–5.20 (q, 1H, <i>J</i> = 6.8 Hz), 3.80 (s, 3H), 2.50 (s, 3H), 1.46 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS; <i>m</i>/<i>z</i> (M + 1): 417.1; HPLC purity: 98.06%; SFC purity: 100%.</div></div><div id="sec46" class="NLM_sec NLM_sec_level_4"><div id="ac_i204" class="anchor-spacer"></div><h5 class="article-section__title" id="_i204"> 3-Methyl-<i>N</i>-(1-(1-methyl-1<i>H</i>-pyrazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (142)</h5><div class="NLM_p last"><b>142</b> was prepared as for <b>141</b> above to afford product (retention time: 2.83) as a white solid (19%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.34 (s, 1H), 11.52 (s, 1H), 8.07 (d, 1H, <i>J</i> = 8.4 Hz), 7.89 (s, 1H), 7.74 (d, 1H), 7.60 (s, 1H), 7.37–7.43 (m, 2H), 6.19 (s, 1H), 5.16–5.20 (q, 1H, <i>J</i> = 6.8 Hz), 3.80 (s, 3H), 2.50 (s, 3H), 1.46 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS; <i>m</i>/<i>z</i> (M + 1): 417.2; HPLC purity: 99.66%; SFC purity: 100%.</div></div><div id="sec47" class="NLM_sec NLM_sec_level_4"><div id="ac_i205" class="anchor-spacer"></div><h5 class="article-section__title" id="_i205"> 4-(6-Fluoro-1<i>H</i>-indol-3-yl)-3-methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>143</b>)</h5><div class="NLM_p last">Racemic <b>143</b> was prepared from 1-(5-methylisoxazol-3-yl)ethan-1-amine and <b>275</b> as a pale yellow solid (57%). The racemic product was resolved by SFC purification using a Chiralcel OJ-H column and methanol cosolvent (40%) to afford enantiomer I (retention time: 4.62) as a pale yellow solid (19%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.23 (s, 1H), 11.18 (s, 1H), 7.88 (d, 1H, <i>J</i> = 8.0 Hz), 7.52–7.56 (m, 1H), 7.30 (s, 1H), 7.15–7.18 (d, 1H), 7.09 (s, 1H), 6.85–6.90 (m, 1H), 6.22 (s, 1H), 5.19–5.23 (m, 1H), 2.39 (s, 3H), 2.33 (s, 3H), 1.49 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 367.1; HPLC purity: 97.79%; SFC purity: 100%.</div></div><div id="sec48" class="NLM_sec NLM_sec_level_4"><div id="ac_i206" class="anchor-spacer"></div><h5 class="article-section__title" id="_i206"> 4-(6-Fluoro-1<i>H</i>-indol-3-yl)-3-methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>144</b>)</h5><div class="NLM_p last"><b>144</b> was prepared as for <b>143</b> above to afford the product (retention time: 6.26) as a pale yellow solid (25%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.27 (s, 1H), 11.17 (s, 1H), 7.90 (d, 1H, <i>J</i> = 8.0 Hz), 7.52–7.56 (m, 1H), 7.30 (s, 1H), 7.15–7.18 (d, 1H), 7.09 (s, 1H), 6.85–6.90 (m, 1H), 6.22 (s, 1H), 5.19–5.23 (m, 1H), 2.38 (s, 3H), 2.33 (s, 3H), 1.49 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 367.1; HPLC purity: 96.20%; SFC purity: 100%.</div></div><div id="sec49" class="NLM_sec NLM_sec_level_4"><div id="ac_i207" class="anchor-spacer"></div><h5 class="article-section__title" id="_i207"> 3-Methyl-<i>N</i>-(2,2,2-trifluoroethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxamide (<b>149</b>)</h5><div class="NLM_p last"><b>149</b> was prepared from 2,2,2-trifluoroethan-1-amine hydrochloride and <b>283</b> as an off-white solid (32%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.99 (s, 1H), 11.68 (s, 1H), 8.69 (d, 1H, <i>J</i> = 8.4 Hz), 8.14–8.17 (m, 1H), 7.66 (d, 1H, <i>J</i> = 8.4 Hz),7.63 (d, 1H, <i>J</i> = 3.2 Hz), 4.10–4.14 (m, 2H), 2.67 (s, 3H); ESIMS <i>m</i>/z (M + 1): 392.1; LCMS: 96.30%; HPLC purity: 98.02%.</div></div><div id="sec50" class="NLM_sec NLM_sec_level_4"><div id="ac_i208" class="anchor-spacer"></div><h5 class="article-section__title" id="_i208"> (3,3-Difluoroazetidin-1-yl)-(3-methyl-4-(6-(trifluoromethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrrol-2-yl)methanone (<b>150</b>)</h5><div class="NLM_p last"><b>150</b> was prepared from 3,3-difluoroazetidine hydrochloride and <b>283</b> as an off-white solid (28%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.99 (s, 1H), 11.58 (s, 1H), 8.72 (d, 1H, <i>J</i> = 8.0 Hz), 7.66 (s, 1H), 7.63 (d, 1H, <i>J</i> = 3.2 Hz), 4.56–4.62 (m, 4H), 2.48 (s, 3H); ESIMS <i>m</i>/z (M + 1): 386.0; LCMS: 99.16%; HPLC purity: 99.76%.</div></div><div id="sec51" class="NLM_sec NLM_sec_level_4"><div id="ac_i209" class="anchor-spacer"></div><h5 class="article-section__title" id="_i209"> 3-Methyl-<i>N</i>-(1-(1-methyl-1<i>H</i>-pyrazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>151</b>)</h5><div class="NLM_p last"><b>151</b> was prepared from 1-(1-methyl-1<i>H</i>-pyrazol-3-yl)ethan-1-amine, HCl, and <b>283</b> to afford the racemic title compound (45%). The racemic product was resolved by SFC purification using a Chiralcel OX-H column and IPA cosolvent (40%) to afford the title compound (retention time 2.4) as an off-white solid (26%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.51 (d, 1H, <i>J</i> = 8.4 Hz), 7.61 (d, 1H, <i>J</i> = 8.4 Hz), 7.54 (d, 1H, <i>J</i> = 2.0 Hz), 7.40 (s, 1H), 6.29 (d, 1H, <i>J</i> = 2.0 Hz), 5.29–5.34 (q, 1H, <i>J</i> = 6.8 Hz), 3.89 (s, 3H), 2.58 (s, 3H), 1.61 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/z (M + 1): 418.2; HPLC purity: 98.86%; SFC purity: 100%.</div></div><div id="sec52" class="NLM_sec NLM_sec_level_4"><div id="ac_i210" class="anchor-spacer"></div><h5 class="article-section__title" id="_i210"> 3-Methyl-<i>N</i>-(1-(1-methyl-1<i>H</i>-pyrazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>152</b>)</h5><div class="NLM_p last"><b>152</b> was prepared as for <b>151</b> above to afford the product (retention time: 3.23) as an off-white solid (33%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.51 (d, 1H, <i>J</i> = 8.4 Hz), 7.61 (d, 1H, <i>J</i> = 8.4 Hz), 7.54 (d, 1H, <i>J</i> = 2.0 Hz), 7.40 (s, 1H), 6.29 (d, 1H, <i>J</i> = 2.0 Hz), 5.31–5.32 (q, 1H, <i>J</i> = 6.8 Hz), 3.89 (s, 3H), 2.58 (s, 3H), 1.61 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/z (M + 1): 418.1; HPLC purity: 99.93%; SFC purity: 98.74%.</div></div><div id="sec53" class="NLM_sec NLM_sec_level_4"><div id="ac_i211" class="anchor-spacer"></div><h5 class="article-section__title" id="_i211"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>153</b>)</h5><div class="NLM_p last">Racemic <b>153</b> was prepared from 1-(5-methylisoxazol-3-yl)ethan-1-amine and <b>283</b> as a white solid (52%). The racemic product was resolved by SFC purification using a Chiralcel OD-H column and methanol cosolvent (20%) to afford the title compound (retention time 5.21) as a white solid (15%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.94 (s, 1H), 11.58 (s, 1H), 8.67 (d, 1H, <i>J</i> = 8.0 Hz), 7.98 (d, 1H, <i>J</i> = 8.0 Hz), 7.58–7.65 (m, 2H), 6.22 (s, 1H), 5.22–5.24 (m, 1H), 2.56 (s, 3H), 2.38 (s, 3H), 1.50 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 419.1; HPLC purity: 99.75%; SFC purity: 99.14%.</div></div><div id="sec54" class="NLM_sec NLM_sec_level_4"><div id="ac_i212" class="anchor-spacer"></div><h5 class="article-section__title" id="_i212"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>154</b>)</h5><div class="NLM_p last"><b>154</b> was prepared as for <b>153</b> above to afford the product (retention time: 5.90) as a white solid (16%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.94 (s, 1H), 11.57 (s, 1H), 8.67 (d, 1H, <i>J</i> = 8.0 Hz), 7.98 (d, 1H, <i>J</i> = 8.0 Hz), 7.58–7.64 (m, 2H), 6.22 (s, 1H), 5.19–5.23 (m, 1H), 2.55 (s, 3H), 2.37 (s, 3H), 1.49 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 419.1; HPLC purity: 99.80%; SFC purity: 100%.</div></div><div id="sec55" class="NLM_sec NLM_sec_level_4"><div id="ac_i213" class="anchor-spacer"></div><h5 class="article-section__title" id="_i213"> 3-Methyl-<i>N</i>-(2,2,2-trifluoroethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxamide (<b>155</b>)</h5><div class="NLM_p last"><b>155</b> was prepared from 2,2,2-trifluoroethan-1-amine hydrochloride and <b>276</b> as an off-white solid (16%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.15 (d, 1H, <i>J</i> = 8.4 Hz), 7.59 (s, 1H), 7.52 (d, 1H, <i>J</i> = 8.4 Hz), 7.14 (s, 1H), 4.09–4.16 (m, 2 H), 2.40 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 391.0; LCMS: 99.39%; HPLC purity: 95.18%.</div></div><div id="sec56" class="NLM_sec NLM_sec_level_4"><div id="ac_i214" class="anchor-spacer"></div><h5 class="article-section__title" id="_i214"> (3,3-Difluoroazetidin-1-yl)(3-methyl-4-(6-(trifluoromethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrrol-2-yl)methanone (<b>156</b>)</h5><div class="NLM_p last"><b>156</b> was prepared from 3,3-difluoroazetidine hydrochloride and <b>276</b> as a white solid (26%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.18 (d, 1H, <i>J</i> = 8.0 Hz); 7.61 (s, 1H), 7.52 (d, 1H, <i>J</i> = 8.2 Hz), 7.17 (s, 1H), 4.58–4.64 (m, 4H), 2.34 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 385.1; LCMS: 99.53%; HPLC purity: 98.31%.</div></div><div id="sec57" class="NLM_sec NLM_sec_level_4"><div id="ac_i215" class="anchor-spacer"></div><h5 class="article-section__title" id="_i215"> 3-Methyl-<i>N</i>-(1-(1-methyl-1<i>H</i>-pyrazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>157</b>)</h5><div class="NLM_p last"><b>157</b> was prepared from 1-(1-methyl-1<i>H</i>-pyrazol-3-yl)ethan-1-amine, HCl, and <b>276</b> to afford the racemic title compound as a pale yellow solid (37%). The racemic product was resolved by SFC purification using a Chiralcel OX-H column and IPA cosolvent (40%) to afford the title compound (retention time 1.75) as an off-white solid (21%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.21 (s, 1H), 11.35 (s, 1H), 8.22 (d, 1H, <i>J</i> = 8.0 Hz), 7.73 (s, 1H), 7.68 (d, 1H, <i>J</i> = 8.0 Hz), 7.61 (s, 1H), 7.54 (d, 1H, <i>J</i> = 8.0 Hz), 7.15 (s, 1H), 6.19 (s, 1H), 5.16–5.20 (m, 1H), 3.81 (s, 3H), 2.36 (s, 3H), 1.46 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 417.9; HPLC purity: 98.71%; SFC purity: 100%.</div></div><div id="sec58" class="NLM_sec NLM_sec_level_4"><div id="ac_i216" class="anchor-spacer"></div><h5 class="article-section__title" id="_i216"> 3-Methyl-<i>N</i>-(1-(1-methyl-1<i>H</i>-pyrazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>158</b>)</h5><div class="NLM_p last"><b>158</b> was prepared as for <b>157</b> above to afford the product (retention time: 2.67) as an off-white solid (10%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.21 (s, 1H), 11.35 (s, 1H), 8.22 (d, 1H, <i>J</i> = 8.0 Hz), 7.73 (s, 1H), 7.68 (d, 1H, <i>J</i> = 8.0 Hz), 7.61 (s, 1H), 7.54 (d, 1H, <i>J</i> = 8.0 Hz), 7.15 (s, 1H), 6.19 (s, 1H), 5.16–5.20 (m, 1H), 3.81 (s, 3H), 2.36 (s, 3H), 1.46 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 417.9; HPLC purity: 99.55%; SFC purity: 100%.</div></div><div id="sec59" class="NLM_sec NLM_sec_level_4"><div id="ac_i217" class="anchor-spacer"></div><h5 class="article-section__title" id="_i217"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>] pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>159</b>)</h5><div class="NLM_p last"><b>159</b> was prepared from 1-(5-methylisoxazol-3-yl)ethan-1-amine and <b>276</b> to afford the racemic title compound (45%). The racemic product was resolved by SFC purification using a Lux A1 column and methanol cosolvent (50%) to afford the title compound (retention time 1.56) as an off-white solid (17%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.12 (d, 1H, <i>J</i> = 8.0 Hz), 7.55 (s, 1H), 7.48 (d, 1H, <i>J</i> = 8.0 Hz), 7.08 (s, 1H), 6.16 (s, 1H), 5.28–5.33 (q, 1H, <i>J</i> = 7.2 Hz), 2.40 (s, 3H), 2.37 (s, 3H), 1.59 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 418.0; HPLC purity: 99.41%; SFC purity: 99.72%.</div></div><div id="sec60" class="NLM_sec NLM_sec_level_4"><div id="ac_i218" class="anchor-spacer"></div><h5 class="article-section__title" id="_i218"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>] pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>160</b>)</h5><div class="NLM_p"><b>160</b> was prepared as for <b>159</b> above to afford the product (retention time: 2.97) as an off-white solid (15%).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.12 (d, 1H, <i>J</i> = 8.0 Hz), 7.55 (s, 1H), 7.48 (d, 1H, <i>J</i> = 8.0 Hz), 7.08 (s, 1H), 6.16 (s, 1H), 5.30–5.32 (q, 1H, <i>J</i> = 7.2 Hz), 2.40 (s, 3H), 2.37 (s, 3H), 1.59 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 418.1; HPLC purity: 99.76%; SFC purity: 99.72%.</div></div><div id="sec61" class="NLM_sec NLM_sec_level_4"><div id="ac_i219" class="anchor-spacer"></div><h5 class="article-section__title" id="_i219"> <i>N</i>-Cyclopropyl-3-methyl-4-(6-(trifluoromethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxamide (<b>163</b>)</h5><div class="NLM_p last"><b>163</b> was prepared from cyclopropylamine and <b>276</b> as an off-white solid (31%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.21 (s,1H), 11.17 (s, 1H), 8.21 (d, 1H, <i>J</i> = 8.1 Hz), 7.72 (s, 1H), 7.58 (s, 1H), 7.54 (d, 1H, <i>J</i> = 8.1 Hz), 7.13 (s, 1H), 2.77–2.79 (m, 1H), 2.34 (s, 3H), 0.69–0.73 (m, 2H), 0.50–0.53 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 349.1; LCMS: 96.59%; HPLC purity: 96.22%.</div></div><div id="sec62" class="NLM_sec NLM_sec_level_4"><div id="ac_i220" class="anchor-spacer"></div><h5 class="article-section__title" id="_i220"> Ethyl 3-(1-(3-Methyl-4-((6-(trifluoromethyl)pyridine-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamido)ethyl)-1<i>H</i>-pyrazole-5-carboxylate (<b>189</b>)</h5><div class="NLM_p last"><b>189</b> was prepared from ethyl 3-(1-aminoethyl)-1<i>H</i>-pyrazole-5-carboxylate (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>181</b> as a yellow solid (28%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.38 (s, 1H), 11.01 (s, 1H), 8.61 (s, 1H), 7.77–7.80 (m, 3H), 6.62–6.73 (m, 2H), 5.17–5.19 (m, 1H), 4.18–4.21 (m, 2H), 3.84 (s, 2H), 2.37 (s, 3H), 1.44–1.48 (m, 3H), 1.18–1.21 (m, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 450.2.</div></div><div id="sec63" class="NLM_sec NLM_sec_level_4"><div id="ac_i221" class="anchor-spacer"></div><h5 class="article-section__title" id="_i221"> Ethyl 3-(1-(3-Methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamido)ethyl)-1<i>H</i>-pyrazole-5-carboxylate (<b>256</b>)</h5><div class="NLM_p last"><b>256</b> was prepared from ethyl 3-(1-aminoethyl)-1<i>H</i>-pyrazole-5-carboxylate (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>251</b> as a gummy solid (59%). The product was used directly without further purification.</div></div><div id="sec64" class="NLM_sec NLM_sec_level_4"><div id="ac_i222" class="anchor-spacer"></div><h5 class="article-section__title" id="_i222"> <i>N</i>-Cyclopropyl-3-formyl-4-(6-(trifluoromethyl)pyridine-3-carbonyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>259</b>)</h5><div class="NLM_p last">The title compound was prepared from <b>258</b> using general procedure E followed by general procedure F1 with cyclopropylamine to afford the product as an off-white solid (32%). ESIMS <i>m</i>/<i>z</i> (M + 1): 352.2. The product was used without further characterization.</div></div><div id="sec65" class="NLM_sec NLM_sec_level_4"><div id="ac_i223" class="anchor-spacer"></div><h5 class="article-section__title" id="_i223"> Ethyl 3-(1-(3-Methyl-4-(6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-1<i>H</i>-pyrrole-2-carboxamido)ethyl)-1<i>H</i>-pyrazole-5-carboxylate (<b>279</b>)</h5><div class="NLM_p last">Racemic <b>279</b> was prepared from ethyl 3-(1-aminoethyl)-1<i>H</i>-pyrazole-5-carboxylate (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>278</b> as a gummy solid (68%). The product was used directly without purification.</div></div></div><div id="sec66" class="NLM_sec NLM_sec_level_3"><div id="ac_i224" class="anchor-spacer"></div><h4 class="article-section__title" id="_i224"> General Procedure F2: Amide Formation</h4><div class="NLM_p">Me<sub>3</sub>Al (2.0 M in toluene) (1.5 equiv) was added to a stirred solution of pyrrole ester intermediate <b>(</b>1 equiv) and amine (1.1–1.5 equiv) in THF at RT and heated at 100–120 °C for 1 h in a microwave. After completion of the reaction (monitored by TLC), 1.5 N HCl solution was added to the reaction mixture and extracted with ethyl acetate (2×). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The resulting concentrated product was purified by column chromatography using 10–60% ethyl acetate in petroleum ether to afford the compound as a white solid (21–37%). Compounds <b>8</b>–<b>10</b> and <b>115</b>–<b>116</b> were prepared using this procedure.</div><div id="sec66_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i225" class="anchor-spacer"></div><h5 class="article-section__title" id="_i225"> <i>N</i>-Cyclopropyl-4-((2-fluoro-6-(trifluoromethyl)pyridin-3-yl) methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide (<b>8</b>)</h5><div class="NLM_p last"><b>8</b> was prepared from cyclopropamine and <b>179</b> (37%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 9.23 (brs, 1H), 7.60 (d, 1H, <i>J</i> = 8.0 Hz), 7.50 (d, 1H <i>J</i> = 8.0 Hz), 6.74 (s, 1H), 5.87 (brs, 1H), 3.88 (s, 2H), 2.86–2.90 (m, 1H), 2.14 (s, 3H), 0.87–0.92 (m, 2H), 0.62–0.64 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 342.2; LCMS: 93.46%; HPLC purity: 96.21%.</div></div><div id="sec66_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i226" class="anchor-spacer"></div><h5 class="article-section__title" id="_i226"> ((2-Fluoro-6-(trifluoromethyl)pyridin-3-yl)methyl)-3-methyl-<i>N</i>-(2,2,2-trifluoroethyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>9</b>)</h5><div class="NLM_p last"><b>9</b> was prepared from 2,2,2-trifluoro-ethanamine and <b>179</b> (21%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 9.18 (s, 1H), 7.60–7.64 (m, 1H), 7.50 (d, 1H <i>J</i> = 8.0 Hz), 6.78 (s, 1H), 5.90 (brs, 1H), 4.12–4.16 (m, 2H), 3.89 (s, 2H), 2.23 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M – 1): 382.0; LCMS: 95.70%; HPLC purity: 94.43%.</div></div><div id="sec66_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i227" class="anchor-spacer"></div><h5 class="article-section__title" id="_i227"> (3,3-Difluoroazetidin-1-yl)(4-((2-fluoro-6-(trifluoromethyl)pyridin-3-yl)methyl)-3-methyl-1<i>H</i>-pyrrol-2-yl)methanone (<b>10</b>)</h5><div class="NLM_p last"><b>10</b> was prepared from 3,3-difluoro-azetidine and <b>179</b> (26%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 8.84 (brs, 1H), 7.63–7.67 (m, 1H), 7.51 (d, 1H <i>J</i> = 7.6 Hz), 6.77 (s, 1H), 4.47–4.54 (m, 4H), 3.87 (s, 2H), 2.13 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 378.0; LCMS: 99.59%; HPLC purity: 99.34%.</div></div><div id="sec66_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i228" class="anchor-spacer"></div><h5 class="article-section__title" id="_i228"> 3-Cyano-5-methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>115</b>)</h5><div class="NLM_p last"><b>115</b> was prepared from 1-(5-methylisoxazol-3-yl)ethan-1-amine and <b>265</b> to afford the racemic product (40%). The racemic product was separated by SFC purification using a YMC cellulose C column and IPA cosolvent (30%) to afford enantiomer I (retention time: 1.96) as a white solid (27%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.11 (s, 1H), 8.64 (s, 1H), 8.34 (d, 1H, <i>J</i> = 8. 0 Hz), 7.79–7.86 (m, 2H), 6.21 (s, 1H), 5.14 (q, 1H, <i>J</i> = 7.2 Hz), 3.98 (s, 2H), 2.37 (s, 3H), 2.24 (s, 3H), 1.46 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 418.1; HPLC purity: 96.69%; SFC purity: 100%.</div></div><div id="sec66_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i229" class="anchor-spacer"></div><h5 class="article-section__title" id="_i229"> 3-Cyano-5-methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>116</b>)</h5><div class="NLM_p last"><b>116</b> was prepared as for <b>115</b> above to afford the product (retention time: 4.05) as an off-white solid (30%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.11 (s, 1H), 8.64 (s, 1H), 8.33 (d, 1H, <i>J</i> = 8. 0 Hz), 7.79–7.86 (m, 2H), 6.21 (s, 1H), 5.14 (q, 1H, <i>J</i> = 7.2 Hz), 3.98 (s, 2H), 2.37 (s, 3H), 2.23 (s, 3H), 1.46 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 418.1; HPLC purity: 99.28%; SFC purity: 99.34%.</div></div></div><div id="sec67" class="NLM_sec NLM_sec_level_3"><div id="ac_i230" class="anchor-spacer"></div><h4 class="article-section__title" id="_i230"> General Procedure G: Amide Coupling followed by Trityl Deprotection</h4><div class="NLM_p">Amide coupling was carried out as described in general procedure F1. The uncharacterized product in CH<sub>2</sub>Cl<sub>2</sub>, was treated with TFA (4 equiv) and triethylsilane (2 equiv) at RT and stirred for 1 h. After completion of the reaction, the reaction mixture was quenched with sat. NaHCO<sub>3</sub> by a dropwise addition at 0 °C and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The resulting concentrated product was purified by column chromatography using 0–5% methanol in CH<sub>2</sub>Cl<sub>2</sub> to afford the product as an off-white solid (3–38%). Compounds <b>29</b>–<b>34, 40, 42</b>–<b>43, 54</b>–<b>55, 59</b>–<b>60, 62</b>–<b>65, 77</b>–<b>80, 92</b>–<b>97, 101–102, 107–110, 120–123, 161–162, and 224</b> were prepared using this procedure. Examples <b>61</b> and <b>117</b>–<b>118</b> were prepared by a modified procedure as described.</div><div id="sec67_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i231" class="anchor-spacer"></div><h5 class="article-section__title" id="_i231"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl) ethyl)-3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>29</b>)</h5><div class="NLM_p last"><b>29</b> was obtained from 1-(1-(triphenylmethyl)-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>181</b> (15%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>_D<sub>2</sub>O) δ (ppm): 8.59 (s, 1H), 7.78 (s, 2H), 6.73 (s, 1H), 5.20–5.18 (m, 1H), 3.83 (s, 2H), 2.12 (s, 3H), 1.45 (d, <i>J</i> = 7.2 Hz, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 379.2; LCMS: 98.44%; HPLC purity: 98.07%.</div></div><div id="sec67_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i232" class="anchor-spacer"></div><h5 class="article-section__title" id="_i232"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl) ethyl)-3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>30</b>)</h5><div class="NLM_p last">The racemic product <b>29</b> was separated by SFC purification using a LuxA1 column and methanol cosolvent (30%) to afford Enantiomer I (retention time: 2.89) as an off-white solid (21%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.63 (s, 1H), 8.14 (bs, 1H), 7.97 (bs, 1H), 7.80 (s, 2H), 6.72 (s, 1H), 5.21–5.26 (m, 1H), 3.86 (s, 2H), 2.16 (s, 3H), 1.49 (d, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 379.2; HPLC purity: 97.75%; SFC purity: 100%.</div></div><div id="sec67_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i233" class="anchor-spacer"></div><h5 class="article-section__title" id="_i233"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl) ethyl)-3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>31</b>)</h5><div class="NLM_p last">The product was obtained as for <b>30</b> above (retention time: 4.21) to afford enantiomer II as an off-white solid (25%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.63 (s, 1H), 8.14 (bs, 1H), 7.96 (bs, 1H), 7.80 (s, 2H), 6.72 (s, 1H), 5.22–5.26 (m, 1H), 3.86 (s, 2H), 2.16 (s, 3H), 1.46 (d, <i>J</i> = 7.2 Hz, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 379.2; HPLC purity: 99.15%; SFC purity: 100%.</div></div><div id="sec67_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i234" class="anchor-spacer"></div><h5 class="article-section__title" id="_i234"> 3-Methyl-<i>N</i>-(1-(1<i>H</i>-pyrazol-4-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>32</b>)</h5><div class="NLM_p last"><b>32</b> was obtained from 1-(1-(triphenylmethyl)-1<i>H</i>-pyrazol-4-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>181</b> (19%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.40 (s, 1H), 7.65 (d, 1H, <i>J</i> = 8.2 Hz), 7.56 (d, 1H, <i>J</i> = 8.2 Hz), 7.46 (brs, 2H), 6.54 (s, 1H), 5.09 (q, 1H, <i>J</i> = 6.8 Hz), 3.79 (s, 2H), 2.04 (s, 3H), 1.41 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 378; LCMS: 99.90%; HPLC purity: 96.45%.</div></div><div id="sec67_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i235" class="anchor-spacer"></div><h5 class="article-section__title" id="_i235"> 3-Methyl-<i>N</i>-(1-(1<i>H</i>-pyrazol-4-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>33</b>)</h5><div class="NLM_p last">The racemic product <b>32</b> was separated by SFC purification using a LuxA1 column and methanol cosolvent (30%) to afford Enantiomer I (retention time: 2.94) as an off-white solid (26%). Mp 225–230 °C. Optical rotation (ethanol): 9.198. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.56 (s, 1H), 7.81 (d, 1H, <i>J</i> = 8.2 Hz), 7.71 (d, 1H, <i>J</i> = 8.2 Hz), 7.61 (brs, 2H), 6.70 (s, 1H), 5.25 (q, 1H, <i>J</i> = 6.8 Hz), 3.94 (s, 2H), 2.19 (s, 3H), 1.57 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 378.2; HPLC purity: 98.61%; SFC purity: 99.72%.</div></div><div id="sec67_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i236" class="anchor-spacer"></div><h5 class="article-section__title" id="_i236"> 3-Methyl-<i>N</i>-(1-(1<i>H</i>-pyrazol-4-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>34</b>)</h5><div class="NLM_p last">The product was obtained as for <b>33</b> above (retention time: 4.27) to afford enantiomer II as an off-white solid (26%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.56 (s, 1H), 7.81 (d, 1H, <i>J</i> = 8.2 Hz), 7.71 (d, 1H, <i>J</i> = 8.2 Hz), 7.61 (brs, 2H), 6.70 (s, 1H), 5.25 (q, 1H, <i>J</i> = 6.8 Hz), 3.94 (s, 2H), 2.19 (s, 3H), 1.57 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 378.2; HPLC purity: 98.52%; SFC purity: 99.74%.</div></div><div id="sec67_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i237" class="anchor-spacer"></div><h5 class="article-section__title" id="_i237"> 3-Methyl-<i>N</i>-(1-(5-methyl-1<i>H</i>-1,2,4-triazol-3-yl)ethyl)-4-((6-(trifluoromethyl) pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>40</b>)</h5><div class="NLM_p last"><b>40</b> was obtained from 1-(5-methyl-1-triphenymethyl-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>181</b> (36%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.56 (s, 1H), 7.83 (d, <i>J</i> = 8.2 Hz, 1H), 7.73 (d, <i>J</i> = 8.2 Hz, 1 H), 6.75 (s, 1H), 5.27–5.28 (m, 1H), 3.96 (s, 2H), 2.72 (s, 3H), 2.24 (s, 3H), 1.60 (brs, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 393.2; LCMS: 94.65%; HPLC purity: 96.64%.</div></div><div id="sec67_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i238" class="anchor-spacer"></div><h5 class="article-section__title" id="_i238"> 3-Methyl-<i>N</i>-(1-(5-methyl-1<i>H</i>-pyrazol-3-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>42</b>)</h5><div class="NLM_p last">Racemic <b>42</b> was prepared from 1-(5-methyl-1<i>H</i>-pyrazol-3-yl)ethan-1-amine and <b>181</b> (36%). The racemic product was separated by SFC purification using a LuxA1 column and methanol cosolvent (40%) to afford enantiomer I (retention time: 2.44) as an off-white solid (24%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.22 (s, 1H), 11.04 (s, 1H), 8.63 (s, 1H), 7.80 (s, 2H), 7.53 (bs, 1H), 6.69 (s, 1 H), 5.92 (s, 1H), 5.09 (m, 1H), 3.85 (s, 2H), 2.17 (s, 3H), 2.15 (s, 3H), 1.40 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 392.1; HPLC purity: 98.86%; SFC purity: 100%.</div></div><div id="sec67_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i239" class="anchor-spacer"></div><h5 class="article-section__title" id="_i239"> 3-Methyl-<i>N</i>-(1-(5-methyl-1<i>H</i>-pyrazol-3-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>43</b>)</h5><div class="NLM_p last">The product was obtained as for <b>42</b> above (retention time: 5.02) as an off-white solid (26%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.22 (s, 1H), 11.04 (s, 1H), 8.63 (s, 1H), 7.80 (s, 2H), 7.53 (bs, 1H), 6.69 (s, 1 H), 5.92 (s, 1H), 5.09 (m, 1H), 3.85 (s, 2H), 2.17 (s, 3H), 2.15 (s, 3H), 1.40 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 392.1; HPLC purity: 98.93%; SFC purity: 100%.</div></div><div id="sec67_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i240" class="anchor-spacer"></div><h5 class="article-section__title" id="_i240"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl)ethyl)-4-((5-fluoroisoquinolin-8-yl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>54</b>)</h5><div class="NLM_p last">The product was prepared from 1-(1-(triphenylmethyl)-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>207</b> (23%). The racemic product was separated by SFC purification using a LuxA1 column and methanol cosolvent (40%) to afford enantiomer I (retention time 3.73) as an off-white solid (29%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 9.49 (s, 1H), 8.54 (d, 1H, <i>J</i> = 5.9 Hz), 8.23 (s, 1H), 8.01 (d, 1H, <i>J</i> = 5.9 Hz), 7.40–7.43 (m, 2H), 6.46 (s, 1H), 5.36 (q, 1H, <i>J</i> = 7.0 Hz), 4.34 (s, 2H), 2.31 (s, 3H), 1.61 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 379.1; HPLC purity: 98.09%, SFC purity: 100%.</div></div><div id="sec67_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i241" class="anchor-spacer"></div><h5 class="article-section__title" id="_i241"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl)ethyl)-4-((5-fluoroisoquinolin-8-yl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>55</b>)</h5><div class="NLM_p last">The product was obtained as for <b>54</b> above (retention time: 5.62) as an off-white solid (31%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 9.49 (s, 1H), 8.53 (d, 1H, <i>J</i> = 5.9 Hz), 8.14 (s, 1H), 8.01 (d, 1H, <i>J</i> = 5.9 Hz), 7.40–7.45 (m, 2H), 6.45 (s, 1H), 5.36 (q, 1H, <i>J</i> = 7.0 Hz), 4.34 (s, 2H), 2.30 (s, 3H), 1.61 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 379.1; HPLC purity: 99.01%, SFC purity: 100%.</div></div><div id="sec67_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i242" class="anchor-spacer"></div><h5 class="article-section__title" id="_i242"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl)ethyl)-4-(2-fluoro-4-(trifluoromethyl)benzyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>59</b>)</h5><div class="NLM_p last">Racemic <b>59</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>208</b> (30%). The racemic product was separated by SFC purification using a Lux A1 column and methanol cosolvent (30%) to afford enantiomer I (retention time 2.16) as an off-white solid (26%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.60 (bs, 1H), 11.06 (s, 1H), 8.20 (brs, 1H), 7.76 (s, 1H), 7.60 (d, 1H, <i>J</i> = 8.0 Hz), 7.49 (d, 1H, <i>J</i> = 8.0 Hz), 7.33–7.37 (m, 1H), 6.66 (s, 1H), 5.23 (q, 1H, <i>J</i> = 7.0 Hz), 3.79 (s, 2H), 2.16 (s, 3H), 1.46 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 396.1; HPLC purity: 97.47%. SFC purity: 100%.</div></div><div id="sec67_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i243" class="anchor-spacer"></div><h5 class="article-section__title" id="_i243"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl)ethyl)-4-(2-fluoro-4-(trifluoromethyl)benzyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>60</b>)</h5><div class="NLM_p last">The product was obtained as for <b>59</b> above (retention time: 2.79) as an off-white solid (23%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.82 (bs, 1H), 11.07 (s, 1H), 8.20 (brs, 1H), 7.76 (s, 1H), 7.60 (d, 1H, <i>J</i> = 8.0 Hz), 7.49 (d, 1H, <i>J</i> = 8.0 Hz), 7.34–7.38 (m, 1H), 6.67 (s, 1H), 5.24 (q, 1H, <i>J</i> = 7.0 Hz), 3.80 (s, 2H), 2.17 (s, 3H), 1.47 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 396.1; HPLC purity: 96.32%. SFC purity: 99.19%.</div></div><div id="sec67_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i244" class="anchor-spacer"></div><h5 class="article-section__title" id="_i244"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl) ethyl)-4-((2-fluoro-6-(trifluoromethyl)pyridin-3-yl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide (<b>61</b>)</h5><div class="NLM_p last">Racemic <b>61</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>179</b> using general procedure F2 and trityl deprotection as described to afford the product as an off-white solid (3%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 10.25 (s, 1H), 8.12 (brs, 1H), 7.61 (d, 1H, <i>J</i> = 8.0 Hz), 7.48 (d, 1H, <i>J</i> = 8.0 Hz), 6.76 (s, 1H), 6.71 (bs, 1H), 5.48–5.52 (m, 1H), 3.87 (s, 2H), 2.24 (s, 3H), 1.77 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 397.1; LCMS: 94.41%; HPLC purity: 95.36%.</div></div><div id="sec67_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i245" class="anchor-spacer"></div><h5 class="article-section__title" id="_i245"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl)ethyl)-4-(2-bromo-4-(trifluoromethyl)benzyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide (<b>62</b>)</h5><div class="NLM_p last">Racemic <b>62</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>209</b> (14%). <sup>1</sup>H NMR (400 MHz, MeOD) δ (ppm): 8.44 (brs, 1H), 7.86 (s, 1H), 7.54 (d, 1H, <i>J</i> = 8.0 Hz), 7.27 (d, 1H, <i>J</i> = 8.0 Hz), 6.63 (s, 1H), 5.36–5.37 (m, 1H), 3.94 (s, 2H), 2.18 (s, 3H), 1.61 (brs, 3H); ESIMS <i>m</i>/<i>z</i> (M, M + 2): 456.1, 458.1; LCMS: 96.33%; HPLC purity: 95.93%.</div></div><div id="sec67_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i246" class="anchor-spacer"></div><h5 class="article-section__title" id="_i246"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl)ethyl)-4-((2-cyano-6-(trifluoromethyl)pyridine-3-yl) methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide (<b>63</b>)</h5><div class="NLM_p last">Racemic <b>63</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>210</b> to afford the product as a white solid (3%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.42 (brs, 1H), 7.95 (s, 2H), 6.75 (s, 1H), 5.35 (q, 1H, <i>J</i> = 6.0 Hz), 4.13 (s, 2H), 2.23 (s, 3H), 1.61 (d, 3H, <i>J</i> = 6.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 404.1; LCMS: 94.79%; HPLC purity: <u class="uu">92.83%.</u></div></div><div id="sec67_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i247" class="anchor-spacer"></div><h5 class="article-section__title" id="_i247"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl) ethyl)-4-((3,4-difluorophenyl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>64</b>)</h5><div class="NLM_p last">Racemic <b>64</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>211</b> (14%). The racemic product was separated by SFC purification using a Lux A1 column and methanol cosolvent (40%) to afford enantiomer I (retention time 2.49) as an off-white solid (23%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.81 (brs, 1H), 11.01 (bs, 1H), 8.44 (bs, 1 h), 7.74 (brs, 1H), 7.27–7.34 (m, 1H), 7.14–7.18 (m, 1H), 7.00 (s, 1H), 6.69 (s, 1H), 5.20–5.27 (m, 1H), 3.71 (s, 2H), 2.13 (s, 3H), 1.47 (d, 3H); ESIMS <i>m</i>/z (M + 1): 346.1; HPLC purity: 99.54%; SFC purity: 100%.</div></div><div id="sec67_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i248" class="anchor-spacer"></div><h5 class="article-section__title" id="_i248"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl) ethyl)-4-((3,4-difluorophenyl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>65</b>)</h5><div class="NLM_p last">The product was obtained as for <b>64</b> above (retention time: 3.61) as an off-white solid (19%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.81 (brs, 1H), 11.01 (bs, 1H), 8.48 (bs, 1 h), 7.63–7.85 (brs, 1H), 7.27–7.34 (m, 1H), 7.15–7.20 (m, 1H), 7.00 (s, 1H), 6.69 (s, 1H), 5.23 (m, 1H), 3.71 (s, 2H), 2.13 (s, 3H), 1.47 (d, 3H); ESIMS <i>m</i>/z (M + 1): 346.1; HPLC purity: 99.47%; SFC purity: 100%.</div></div><div id="sec67_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i249" class="anchor-spacer"></div><h5 class="article-section__title" id="_i249"> <i>N</i>-(1-(1<i>H</i>-Pyrazol-4-yl)ethyl)-3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>77</b>)</h5><div class="NLM_p last">Racemic <b>77</b> was prepared from 1-(1-(triphenylmethyl)-1<i>H</i>-pyrazol-4-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>251</b> to afford the racemic product (24%). The racemic product was separated by SFC purification using a Lux A1 column and methanol cosolvent (30%) to afford enantiomer I (retention time 2.41) as an off-white solid (30%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.07 (s, 1H), 8.39 (s, 1H), 7.72 (d, 1H), 7.64 (s, 1H), 7.62 (brs, 1H), 7.51 (d, 1H), 7.45 (brs, 1H), 6.87 (s, 1H), 5.05–5.11 (m, 1H), 2.09 (s, 3H), 1.39–1.43 (m, 4H), 1.24 (brs, 3H). ESIMS <i>m</i>/<i>z</i>: 404.2; HPLC purity: 96.93%, SFC purity: 98.61%.</div></div><div id="sec67_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i250" class="anchor-spacer"></div><h5 class="article-section__title" id="_i250"> <i>N</i>-(1-(1<i>H</i>-Pyrazol-4-yl)ethyl)-3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>78</b>)</h5><div class="NLM_p last">The product was obtained as for <b>77</b> above (retention time: 3.2) as an off-white solid (19%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.07 (s, 1H), 8.39 (s, 1H), 7.72 (d, 1H), 7.64 (s, 1H), 7.62 (brs, 1H), 7.51 (d, 1H), 7.45 (brs, 1H), 6.87 (s, 1H), 5.05–5.11 (m, 1H), 2.09 (s, 3H), 1.39–1.43 (m, 4H), 1.24 (brs, 3H). ESIMS <i>m</i>/<i>z</i> (M + 1): 404.2, HPLC purity: 98.54%, SFC purity: 96.02%.</div></div><div id="sec67_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i251" class="anchor-spacer"></div><h5 class="article-section__title" id="_i251"> 3-Methyl-<i>N</i>-(1-(1<i>H</i>-1,2,4-triazol-3-yl)ethyl)-4-(1-(6-(trifluoromethyl) pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>79</b>)</h5><div class="NLM_p last">Racemic <b>79</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>251</b> to afford the product (43%) as a white solid. The racemic product was separated by SFC purification using a Lux A1 column and isopropanol cosolvent (30%) to afford enantiomer I (retention time 2.07) as an off-white solid (23%). Mp 140–145°C. Optical rotation (ethanol): −15.196. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.36 (s, 2H), 7.68 (s, 2H), 6.93 (s, 1H), 5.38 (q, 1H, <i>J</i> = 6.8 Hz), 2.21 (s, 3H), 1.63 (d, 3H, <i>J</i> = 6.8 Hz), 1.42–1.45 (m, 2H), 1.36–1.39 (m, 2H); ESIMS <i>m</i>/z (M + 1): 405.2; HPLC purity: 99.39%; SFC purity: 100%.</div></div><div id="sec67_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i252" class="anchor-spacer"></div><h5 class="article-section__title" id="_i252"> 3-Methyl-<i>N</i>-(1-(1<i>H</i>-1,2,4-triazol-3-yl)ethyl)-4-(1-(6-(trifluoromethyl) pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>80</b>)</h5><div class="NLM_p last">The product was obtained as for <b>7</b>9 above (retention time: 3.81) as an off-white solid (20%). Optical rotation (ethanol): 15.596. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.36 (s, 2H), 7.68 (s, 2H), 6.93 (s, 1H), 5.38 (q, 1H, <i>J</i> = 6.8 Hz), 2.21 (s, 3H), 1.63 (d, 3H, <i>J</i> = 6.8 Hz), 1.42–1.45 (m, 2H), 1.36–1.39 (m, 2H); ESIMS <i>m</i>/<i>z</i>: 405.2; HPLC purity: 98.47%; SFC purity: 100%.</div></div><div id="sec67_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i253" class="anchor-spacer"></div><h5 class="article-section__title" id="_i253"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl) ethyl)-4-(1-(2-fluoro-4-(trifluoromethyl)phenyl)cyclopropyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>92</b>)</h5><div class="NLM_p last">Racemic <b>92</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>252</b> (36%). The racemate was resolved by SFC purification using a Lux A1 column and methanol cosolvent (30%) to afford enantiomer I <b>(</b>retention time: 2.1) as an off-white solid (18%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.45 (brs, 1H), 7.66–7.70 (m, 1H), 7.40 (d, 1H, <i>J</i> = 8.0 Hz), 7.29 (d, 1H, <i>J</i> = 8.0 Hz), 6.94 (s, 1H), 5.32 (m, 1H), 2.32 (s, 3H), 1.59 (brs, 3H), 1.28–1.31 (m, 2H), 1.18–1.19 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 422.1; LCMS 97.84%; SFC purity: 98.09%.</div></div><div id="sec67_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i254" class="anchor-spacer"></div><h5 class="article-section__title" id="_i254"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl) ethyl)-4-(1-(2-fluoro-4-(trifluoromethyl)phenyl)cyclopropyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>93</b>)</h5><div class="NLM_p last">The product was obtained as for <b>92</b> above (retention time: 2.87) as an off-white solid (17%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.45 (brs, 1H), 7.66–7.70 (m, 1H), 7.40 (d, 1H, <i>J</i> = 8.0 Hz), 7.29 (d, 1H, <i>J</i> = 8.0 Hz), 6.94 (s, 1H), 5.33 (m, 1H), 2.32 (s, 3H), 1.59 (brs, 3H), 1.27–1.31 (m, 2H), 1.17–1.19 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 422.1; LCMS 98.78%; SFC purity: 100%.</div></div><div id="sec67_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i255" class="anchor-spacer"></div><h5 class="article-section__title" id="_i255"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl)ethyl)-4-(1-(3-fluoro-4-(trifluoromethyl)phenyl)cyclopropyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>94</b>)</h5><div class="NLM_p last">Racemic <b>94</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>253</b> (39%). The racemate was resolved by SFC purification using a Lux A1 column and IPA cosolvent (40%) to afford enantiomer I <b>(</b>retention time: 1.48) as an off-white solid (28%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.47 (brs, 1H), 7.48–7.57 (m, 1H), 6.99 (d, 1H), 6.89–6.95 (m, 2H), 5.38 (brs, 1H), 2.20 (s, 3H), 1.59–1.63 (brs, 3H), 1.31–1.42 (m, 4H); ESIMS <i>m</i>/<i>z</i> (M + 1): 422.1; LCMS: 98.08%; HPLC purity: 92.20%; SFC purity: 96.07%.</div></div><div id="sec67_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i256" class="anchor-spacer"></div><h5 class="article-section__title" id="_i256"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl)ethyl)-4-(1-(3-fluoro-4-(trifluoromethyl)phenyl)cyclopropyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>95</b>)</h5><div class="NLM_p last">The product was obtained as for <b>94</b> above (retention time: 2.45) as an off-white solid (33%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.46 (brs, 1H), 7.48–7.53 (t, 1H), 6.99 (d, 1H), 6.90–6.95 (m, 2H), 5.38 (brs, 1H), 2.20 (s, 3H), 1.59–1.64 (brs, 3H), 1.31–1.42 (m, 4H); ESIMS <i>m</i>/<i>z</i> (M + 1): 422.1; LCMS: 98.53%; HPLC purity: 90.95%; SFC purity: 97.84%.</div></div><div id="sec67_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i257" class="anchor-spacer"></div><h5 class="article-section__title" id="_i257"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl) ethyl)-3-methyl-4-(1-(3-(trifluoromethyl)phenyl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>96</b>)</h5><div class="NLM_p last">Racemic <b>96</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>254</b> (32%). The racemate was resolved by SFC purification using a Lux A1 column and 0.5% isopropylamine in IPA cosolvent (40%) to afford enantiomer I <b>(</b>retention time: 1.41) as an off-white solid (15%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.40 (brs, 1H), 7.40–7.41 (m, 2H), 7.33–7.33 (m, 2H), 6.91 (s, 2H), 5.38 (q, 1H, <i>J</i> = 6.8 Hz), 2.19 (s, 3H), 1.65 (d, 3H, <i>J</i> = 6.8 Hz), 1.30–1.33 (m, 2H), 1.25–1.27 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 404.1; LCMS: 99.00%; SFC purity: 100%.</div></div><div id="sec67_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i258" class="anchor-spacer"></div><h5 class="article-section__title" id="_i258"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl) ethyl)-3-methyl-4-(1-(3-(trifluoromethyl)phenyl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>97</b>)</h5><div class="NLM_p last">The product was obtained as for <b>96</b> above (retention time: 2.45) as an off-white solid (10%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.43 (brs, 1H), 7.39–7.43 (m, 2H), 7.32–7.34 (m, 2H), 6.91 (s, 2H), 5.38 (q, 1H, <i>J</i> = 6.8 Hz), 2.19 (s, 3H), 1.65 (d, 3H, <i>J</i> = 6.8 Hz), 1.30–1.33 (m, 2H), 1.25–1.27 (m, 2H); ESIMS; <i>m</i>/<i>z</i> (M + 1): 404.1; LCMS: 97.74%; SFC purity: 100%.</div></div><div id="sec67_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i259" class="anchor-spacer"></div><h5 class="article-section__title" id="_i259"> 4-(1-(6-(Difluoromethyl)pyridin-3-yl)cyclopropyl)-3-methyl-<i>N</i>-(1-(1<i>H</i>-1,2,4-triazol-3-yl)ethyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>101</b>)</h5><div class="NLM_p last">Racemic <b>101</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>255</b> (36%). The racemate was resolved by SFC purification using a Lux A1 column and IPA cosolvent (40%) to afford enantiomer I <b>(</b>retention time: 1.29) as an off-white solid (23%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.30 (d, 1H, <i>J</i> = 2.0 Hz), 7.66 (dd, 1H, <i>J</i> = 2.0 Hz & 8.4 Hz), 7.56 (d, 1H, <i>J</i> = 8.0 Hz), 6.93 (s, 1H), 6.68 (t, 1H, <i>J</i> = 55.2 Hz), 5.38 (q, 1H, <i>J</i> = 6.8 Hz), 2.21 (s, 3H), 1.64 (d, 3H, <i>J</i> = 6.8 Hz), 1.39–1.41 (m, 2H), 1.32–1.34 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 387.2; HPLC purity: 99.50%; SFC purity: 100%.</div></div><div id="sec67_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i260" class="anchor-spacer"></div><h5 class="article-section__title" id="_i260"> 4-(1-(6-(Difluoromethyl)pyridin-3-yl)cyclopropyl)-3-methyl-<i>N</i>-(1-(1<i>H</i>-1,2,4-triazol-3-yl)ethyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>102</b>)</h5><div class="NLM_p last">The product was obtained as for <b>101</b> above (retention time: 1.99) as an off-white solid (42%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.30 (d, 1H, <i>J</i> = 2.0 Hz), 7.66 (dd, 1H, <i>J</i> = 2.0 Hz & 8.4 Hz), 7.56 (d, 1H, <i>J</i> = 8.0 Hz), 6.93 (s, 1H), 6.68 (t, 1H, <i>J</i> = 55.2 Hz), 5.38 (q, 1H, <i>J</i> = 6.8 Hz), 2.21 (s, 3H), 1.64 (d, 3H, <i>J</i> = 6.8 Hz), 1.39–1.41 (m, 2H), 1.32–1.34 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 387.2; HPLC purity: 96.03%; SFC purity: 99.16.</div></div><div id="sec67_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i261" class="anchor-spacer"></div><h5 class="article-section__title" id="_i261"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl)ethyl)-3,5-dimethyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>107</b>)</h5><div class="NLM_p last">Racemic <b>107</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>262</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (26%). The racemate was resolved by SFC purification using a YMC cellulose-SC column and methanol cosolvent (30%) to afford enantiomer I <b>(</b>retention time: 2.1) as an off-white solid (29%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.79 (s, 1H), 10.95 (s, 1H), 8.58 (s, 1H), 8.19 (brs, 1H), 7.78 (d, 1H, <i>J</i> = 8.0 Hz), 7.67 (d, 1H, <i>J</i> = 8.0 Hz), 7.62 (brs, 1H), 5.21–5.25 (m, 1H), 3.83 (s, 2H), 2.16 (s, 3H), 2.13 (s, 3H), 1.42 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 393.2; HPLC purity: 99.46%; SFC purity: 99.94%.</div></div><div id="sec67_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i262" class="anchor-spacer"></div><h5 class="article-section__title" id="_i262"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl)ethyl)-3,5-dimethyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>108</b>)</h5><div class="NLM_p last">The product was obtained as for <b>107</b> above (retention time: 3.37) as an off-white solid (27%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.81 (s, 1H), 10.95 (s, 1H), 8.58 (s, 1H), 8.19 (brs, 1H), 7.78 (d, 1H, <i>J</i> = 8.0 Hz), 7.68 (d, 1H, <i>J</i> = 8.0 Hz), 7.61 (brs, 1H), 5.21–5.25 (m, 1H), 3.83 (s, 2H), 2.16 (s, 3H), 2.13 (s, 3H), 1.47 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 393.2; HPLC purity: 97.96%; SFC purity: 99.44%.</div></div><div id="sec67_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i263" class="anchor-spacer"></div><h5 class="article-section__title" id="_i263"> <i>N</i>-(1-(1<i>H</i>-Pyrazol-4-yl)ethyl)-3,5-dimethyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>109</b>)</h5><div class="NLM_p last">Racemic <b>109</b> was prepared from 1-(1-trityl-1<i>H</i>-pyrazol-4-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>262</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (27%). The racemate was resolved by SFC purification using a Lux A1 column and methanol cosolvent (30%) to afford enantiomer I <b>(</b>retention time: 2.48) as an off-white solid (44%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.66 (bs, 1H), 10.90 (s, 1H), 8.58 (s, 1H), 7.78 (d, 1H), 7.68 (d, 1H), 7.43–7.58 (m, 2H), 7.38 (d, 1H), 5.04–5.10 (m, 1H), 3.82 (s, 2H), 2.15 (s, 3H), 2.12 (s, 3H), 1.42 (d, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 392.1; HPLC purity: 95.37%; SFC purity: 100%.</div></div><div id="sec67_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i264" class="anchor-spacer"></div><h5 class="article-section__title" id="_i264"> <i>N</i>-(1-(1<i>H</i>-Pyrazol-4-yl)ethyl)-3,5-dimethyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>110</b>)</h5><div class="NLM_p last">The product was obtained as for <b>109</b> above (retention time: 3.15) as an off-white solid (35%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.66 (bs, 1H), 10.86 (s, 1H), 8.58 (s, 1H), 7.78 (d, 1H), 7.68 (d, 1H), 7.44–7.64 (m, 2H), 7.39 (d, 1H), 5.06–5.11 (m, 1H), 3.82 (s, 2H), 2.15 (s, 3H), 2.12 (s, 3H), 1.42 (d, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 392.2; HPLC purity: 94.45%; SFC purity: 100%.</div></div><div id="sec67_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i265" class="anchor-spacer"></div><h5 class="article-section__title" id="_i265"> <i>N</i>-(1-(1<i>H</i>-Pyrazol-4-yl)ethyl)-3-cyano-5-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>117</b>)</h5><div class="NLM_p last">Racemic <b>117</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-pyrazol-4-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>265</b> using general procedure F2 and trityl deprotection to afford the product as a white solid (25%). The racemate was resolved by SFC purification using a YMC cellulose C column and IPA cosolvent (30%) to afford enantiomer I <b>(</b>retention time: 2.6) as a white solid (19%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 12.69 (s, 1H), 12.06 (brs,1H), 8.64 (s, 1H), 8.02 (d, 1H, <i>J</i> = 7.2 Hz), 7.79–7.85 (m, 2H), 7.58 (brs, 2H), 5.07 (q, 1H, <i>J</i> = 7.2 Hz), 3.97 (s, 2H), 2.21 (s, 3H), 1.44 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 403.2; HPLC purity: 99.23%; SFC purity: 100%.</div></div><div id="sec67_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i266" class="anchor-spacer"></div><h5 class="article-section__title" id="_i266"> <i>N</i>-(1-(1<i>H</i>-Pyrazol-4-yl)ethyl)-3-cyano-5-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>118</b>)</h5><div class="NLM_p last">The product was obtained as for <b>117</b> above (retention time: 3.09) as a white solid (30%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 12.69 (s, 1H), 12.08 (brs,1H), 8.63 (s, 1H), 8.02 (d, 1H, <i>J</i> = 7.2 Hz), 7.78–7.85 (m, 2H), 7.58 (brs, 2H), 5.07 (q, 1H, <i>J</i> = 7.2 Hz), 3.97 (s, 2H), 2.21 (s, 3H), 1.44 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 403.1; HPLC purity: 98.47%; SFC purity: 100%.</div></div><div id="sec67_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i267" class="anchor-spacer"></div><h5 class="article-section__title" id="_i267"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl)ethyl)-5-chloro-3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>120</b>)</h5><div class="NLM_p last">Racemic <b>120</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>266</b> (32%). The racemate was resolved by SFC purification using a Chiralcel OX-H column and 0.5% DEA in methanol cosolvent (30%) to afford enantiomer I <b>(</b>retention time: 2.05) as an off-white solid (34%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.55 (s, 1H), 8.47 (s, 1H), 7.78 (d, 1H, <i>J</i> = 8.8 Hz), 7.73 (d, 1H, <i>J</i> = 8.8 Hz), 5.36 (q, 1H, <i>J</i> = 6.9 Hz), 3.95 (s, 2H), 2.23 (s, 3H), 1.62 (brs, 3H); ESIMS <i>m</i>/<i>z</i>: 412.9; HPLC purity: 98.42%; SFC purity: 100%.</div></div><div id="sec67_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i268" class="anchor-spacer"></div><h5 class="article-section__title" id="_i268"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl)ethyl)-5-chloro-3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>121</b>)</h5><div class="NLM_p last">The product was obtained as for <b>120</b> above (retention time: 3.38) as an off-white solid (26%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.55 (s, 1H), 8.46 (bs, 1H), 7.78 (d, 1H, <i>J</i> = 8.8 Hz), 7.73 (d, 1H, <i>J</i> = 8.8 Hz), 5.36 (q, 1H, <i>J</i> = 6.9 Hz), 3.95 (s, 2H), 2.23 (s, 3H), 1.62 (brs, 3H); ESIMS <i>m</i>/<i>z</i>: 412.9; HPLC purity: 98.13%; SFC purity: 100%.</div></div><div id="sec67_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i269" class="anchor-spacer"></div><h5 class="article-section__title" id="_i269"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl) ethyl)-5-chloro-3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>122</b>)</h5><div class="NLM_p last">Racemic <b>122</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-pyrazol-4-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>267</b> (23%). The racemate was resolved by SFC purification using a YMC cellulose-SC column and methanol cosolvent (30%) to afford enantiomer I <b>(</b>retention time: 1.82) as an off-white solid (27%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.48 (s, 1H), 8.34 (s, 1H), 7.65–7.71 (m, 2H), 5.37 (brs, 1H), 2.29 (s, 3H), 1.62 (m, 3H), 1.53–1.55 (m, 2H), 1.43–1.47 (m, 2H). ESIMS <i>m</i>/<i>z</i> (M + 1): 439.1; HPLC purity: 98.38%; SFC purity: 100%.</div></div><div id="sec67_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i270" class="anchor-spacer"></div><h5 class="article-section__title" id="_i270"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl) ethyl)-5-chloro-3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>123</b>)</h5><div class="NLM_p last">The product was obtained as for <b>122</b> above (retention time: 2.43) as an off-white solid (34%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.47 (s, 1H), 8.34 (s, 1H), 7.65–7.71 (m, 2H), 5.37 (brs, 1H), 2.29 (s, 3H), 1.63 (m, 3H), 1.52–1.55 (m, 2H), 1.43–1.47 (m, 2H). ESIMS <i>m</i>/<i>z</i> (M + 1): 439.1; HPLC purity: 95.08%; SFC purity: 95.61%.</div></div><div id="sec67_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i271" class="anchor-spacer"></div><h5 class="article-section__title" id="_i271"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>] pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>161</b>)</h5><div class="NLM_p last">Racemic <b>161</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>276</b> (44%). The racemate was resolved by SFC purification using a Lux A1 column and methanol cosolvent (40%) to afford enantiomer I <b>(</b>retention time: 1.53) as an off-white solid (42%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.45 (brs, 1H), 8.12 (d, 1H, <i>J</i> = 8.0 Hz), 7.54 (s, 1H), 7.48 (d, 1H, <i>J</i> = 8.0 Hz), 7.08 (s, 1H), 5.37–5.42 (q, 1H, <i>J</i> = 6.8 Hz), 2.37 (s, 3H), 1.64 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 404.1; HPLC purity: 93.70%; SFC purity: 95.48%.</div></div><div id="sec67_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i272" class="anchor-spacer"></div><h5 class="article-section__title" id="_i272"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>] pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>162</b>)</h5><div class="NLM_p last">The product was obtained as for <b>161</b> above (retention time: 2.37) as an off-white solid (30%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.26 (brs, 1H), 8.12 (d, 1H, <i>J</i> = 8.0 Hz), 7.54 (s, 1H), 7.48 (d, 1H, <i>J</i> = 8.0 Hz), 7.08 (s, 1H), 5.37–5.42 (q, 1H, <i>J</i> = 6.8 Hz), 2.37 (s, 3H), 1.64 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 404.1; HPLC purity: 99.74%; SFC purity: 99.21%.</div></div><div id="sec67_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i273" class="anchor-spacer"></div><h5 class="article-section__title" id="_i273"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl) ethyl)-4-((3-fluoro-2-iodophenyl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide (<b>224</b>)</h5><div class="NLM_p last"><b>224</b> was prepared from 1-(1-triphenylmethyl-1<i>H</i>-1,2,4-triazol-3-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>223</b> (38%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.26 (s, 1H), 7.23–7.29 (m, 1H), 6.69–6.99 (m, 2H), 6.55 (s, 1H), 5.36–5.39 (m, 1H), 3.89 (s, 2H), 2.18 (s, 3H), 1.27–1.31 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 454.4.</div></div></div><div id="sec68" class="NLM_sec NLM_sec_level_3"><div id="ac_i274" class="anchor-spacer"></div><h4 class="article-section__title" id="_i274"> General Procedure H: Amide Coupling followed by Tosyl Deprotection</h4><div class="NLM_p">Amide coupling was carried out as described in general procedure F1. The uncharacterized product in THF was treated with TBAF (1.0 M THF) (2 equiv) at RT and continued for 2 h. After completion of the reaction, the reaction mixture was quenched with sat·NaHCO<sub>3</sub> and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The resulting concentrated product was purified by column chromatography using 0–5% methanol in CH<sub>2</sub>Cl<sub>2</sub> to afford the product (35%). Compounds <b>41</b> and <b>88–89</b> were prepared by this method.</div><div id="sec68_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i275" class="anchor-spacer"></div><h5 class="article-section__title" id="_i275"> 3-Methyl-<i>N</i>-(1-(2-methyl-1<i>H</i>-imidazol-4-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>41</b>)</h5><div class="NLM_p last">The title compound was prepared using 1-(2-methyl-1-(4-methylbenzene-1-sulphonyl)-1<i>H</i>-imidazol-4-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>181</b> as an off-white solid (35%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.55 (s, 1H), 11.06 (s, 1H), 8.63 (s, 1H), 7.80 (s, 2H), 7.44 (d, 1 H, <i>J</i> = 6.0 Hz), 6.75 (s, 1H), 6.68 (s, 1H), 5.01–5.03 (m, 1H), 3.85 (s, 2H), 2.23 (s, 3H), 2.15 (s, 3H), 1.38 (d, 3H, <i>J</i> = 6.4 Hz); ESIMS <i>m</i>/<i>z</i>: 392.2; LCMS: 98.37%; HPLC purity: 98.67%.</div></div><div id="sec68_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i276" class="anchor-spacer"></div><h5 class="article-section__title" id="_i276"> <i>N</i>-(1-(1<i>H</i>-Imidazol-4-yl)ethyl)-3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>88</b>)</h5><div class="NLM_p last">Racemic <b>88</b> was prepared from general procedure H (but heating to 50 °C for 2 h) using 1-(2-methyl-1-(4-methylbenzene-1-sulphonyl)-1<i>H</i>-imidazol-4-yl)ethan-1-amine (preparation in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Supporting Information Methods</a>) and <b>251</b> (36%). Racemic <b>88</b> was resolved by SFC purification using a Lux A1 column and IPA cosolvent (30%) to afford the product (retention time: 2.34) as a white solid (29%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.35 (s, 1H), 7.67 (brs, 3H), 7.03 (s, 1H), 6.90 (s, 1H), 5.27 (q, 1H, <i>J</i> = 6.6 Hz), 2.19 (s, 3H), 1.58 (d, 3H, <i>J</i> = 6.6 Hz), 1.42–1.43 (m, 2H), 1.37–1.38 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 404.2; HPLC purity: 99.37%; SFC purity: 100%.</div></div><div id="sec68_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i277" class="anchor-spacer"></div><h5 class="article-section__title" id="_i277"> <i>N</i>-(1-(1<i>H</i>-Imidazol-4-yl)ethyl)-3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>89</b>)</h5><div class="NLM_p last">The compound was prepared as for <b>88</b> to afford the product (retention time: 3.94) as a white solid (36%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.35 (s, 1H), 7.67 (brs, 3H), 7.03 (s, 1 H), 6.90 (s, 1H), 5.26 (q, 1H, <i>J</i> = 6.6 Hz), 2.19 (s, 3H), 1.58 (d, 3H, <i>J</i> = 6.6 Hz), 1.43 (m, 2H), 1.37 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 404.1; HPLC purity: 99.24%; SFC purity: 100%.</div></div></div><div id="sec69" class="NLM_sec NLM_sec_level_3"><div id="ac_i278" class="anchor-spacer"></div><h4 class="article-section__title" id="_i278"> General Procedure I1: Weinreb Amide Formation</h4><div class="NLM_p">1,1′-Carbonyldiimidazole (1.2 equiv) was added to a stirred solution of the aryl/heteroaryl carboxylic acid (1 equiv) in DMF at RT for 1 h. Then, <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (2.5 equiv) was added to the reaction mixture at RT and stirring continued for 4 h. The reaction mixture was poured into water and extracted with ethyl acetate (2×). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The concentrated product was purified by flash chromatography (silica gel, eluting with hexane:EtOAc mixtures from 100 to 70:30%) to afford product as a yellow liquid (91–94%). Compounds <b>190</b>–<b>191</b> were prepared by this method. Compound <b>229</b> was prepared by an alternative procedure as described.</div><div id="sec69_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i279" class="anchor-spacer"></div><h5 class="article-section__title" id="_i279"> 2-Fluoro-<i>N</i>-methoxy-<i>N</i>-methyl-4-(trifluoromethyl)benzamide (<b>190</b>)</h5><div class="NLM_p last">The compound was prepared from 2-fluoro-4-(trifluoromethyl)benzoic acid (94%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 7.83 (d, 1H, <i>J</i> = 8.0 Hz), 7.73–7.76 (m, 1H), 7.68 (d, 1H, <i>J</i> = 8.0 Hz), 3.48 (s, 3H), 3.32 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 252.1</div></div><div id="sec69_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i280" class="anchor-spacer"></div><h5 class="article-section__title" id="_i280"> 2-Bromo-<i>N</i>-methoxy-<i>N</i>-methyl-4-(trifluoromethyl)benzamide (<b>191</b>)</h5><div class="NLM_p last">The compound was prepared from 2-bromo-4-(trifluoromethyl)benzoic acid (91%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.09 (s, 1H), 7.80–7.87 (s, 1H), 7.69–7.72 (m, 1H), 3.46 (s, 3H), 3.31 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M, M + 2): 312.2, 314.2.</div></div><div id="sec69_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i281" class="anchor-spacer"></div><h5 class="article-section__title" id="_i281"> 6-(Difuoromethyl)-<i>N</i>-methoxy-<i>N</i>-methylpyridine-3-carboxamide (<b>229</b>)</h5><div class="NLM_p last">Pd(OAc)<sub>2</sub> (0.16 g, 0.72 mmol) and 4,5-bis(diphenylphosphino)-9, 9-dimethylxanthene (0.70 g, 1.2 mmol) were added to a purged solution of 5-bromo-2-(difluoromethyl)pyridine (5 g, 24.03 mmol), K3PO4 (15.3 g, 72.07 mmol), and <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (3.52 g, 36.09 mmol) in <i>m</i>-xylene (70 mL) at RT. The reaction was heated to 100 °C for 16 h under CO gas. The reaction mixture was cooled to RT, 10% NaHCO<sub>3</sub> was added, and the mixture extracted with ethyl acetate (3 × 100 mL). The concentrated product was purified by flash chromatography (silica gel, eluting with hexane:EtOAc mixtures from 100 to 60:40%) to afford product (2.5 g, 48%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.91 (s, 1H), 8.26 (dd, 1H, <i>J</i> = 2.0 Hz & 8.0 Hz), 7.81 (d, 1H, <i>J</i> = 8.0 Hz), 6.79 (t, 1H, <i>J</i> = 55.2 Hz), 3.62 (s, 3H), 3.33 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 217.1.</div></div></div><div id="sec70" class="NLM_sec NLM_sec_level_3"><div id="ac_i282" class="anchor-spacer"></div><h4 class="article-section__title" id="_i282"> General Procedure J: Propynyl Grignard on Weinreb Amide</h4><div class="NLM_p">1-Propynylmagnesium bromide (0.5 M in THF) (1.2 equiv) was added to the aryl/heteroaryl amide in THF at 0 °C and stirred for 4 h at RT. The reaction mixture was quenched with 1.5 N HCl solution and extracted with ethyl acetate (2×). The combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford the product as a yellow liquid (82–93%). Compounds <b>192</b>–<b>193</b> and <b>232</b> were prepared by this method.</div><div id="sec70_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i283" class="anchor-spacer"></div><h5 class="article-section__title" id="_i283"> 1-(2-Fluoro-4-(trifluoromethyl)phenyl)but-2-yn-1-one (<b>192</b>)</h5><div class="NLM_p last"><b>192</b> was prepared from <b>190</b> (89%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.20–8.24 (m, 1H), 7.89–7.92 (m, 1H), 7.78 (d, 1H, <i>J</i> = 8.0 Hz), 2.22 (s, 3H).</div></div><div id="sec70_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i284" class="anchor-spacer"></div><h5 class="article-section__title" id="_i284"> 1-(2-Bromo-4-(trifluoromethyl)phenyl)but-2-yn-1-one (<b>193</b>)</h5><div class="NLM_p last"><b>193</b> was prepared from <b>191</b> as a yellow solid (82%). ESIMS <i>m</i>/<i>z</i> (M, M + 2): 291.2, 293.2. The product was used without further characterization.</div></div><div id="sec70_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i285" class="anchor-spacer"></div><h5 class="article-section__title" id="_i285"> 1-(6-(Difluoromethyl)pyridin-3-yl)but-2-yn-1-one (<b>232</b>)</h5><div class="NLM_p last">The title compound was prepared from <b>229</b> (2.1 g, 93%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 9.31 (s, 1H), 8.62 (dd, 1H, <i>J</i> = 2.0 Hz & 8.4 Hz), 7.88 (d, 1H, <i>J</i> = 8.4 Hz), 6.83 (t,1H, <i>J</i> = 55.2), 2.25 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 196.0.</div></div></div><div id="sec71" class="NLM_sec NLM_sec_level_3"><div id="ac_i286" class="anchor-spacer"></div><h4 class="article-section__title" id="_i286"> General Procedure I2: Weinreb Amide Formation followed by Propynyl Grignard</h4><div class="NLM_p">1,1′<b>-</b>Carbonyldiimidazole (1.2 equiv) was added to a stirred solution of the aryl/heteroaryl carboxylic acid (1 equiv) in DMF at RT for 1 h. Then, <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (2.5 equiv) was added to the reaction mixture at RT and stirring was continued for 4 h. The reaction mixture was poured into water and extracted with ethyl acetate (2×). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The concentrated product was purified by flash chromatography (silica gel, eluting with hexane:EtOAc mixtures from 100 to 70:30%). Then, 1-propynylmagnesium bromide (0.5 M in THF) (1.2 equiv) was added to the amide product in THF at 0 °C and stirred for 4 h at RT. The reaction mixture was quenched with 1.5 N HCl solution and extracted with ethyl acetate (2×). The combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford the product as an off-white solid (54-89%). Compounds <b>194</b>–<b>196, 230</b>–<b>231</b>, and <b>280</b> were prepared by this method.</div><div id="sec71_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i287" class="anchor-spacer"></div><h5 class="article-section__title" id="_i287"> 1-(5-Fluoroisoquinolin-8-yl)but-2-yn-1-one (<b>194</b>)</h5><div class="NLM_p last"><b>194</b> was prepared from 5-fluoroisoquinoline-8-carboxylic acid (54%). ESIMS <i>m</i>/<i>z</i> (M + 1): 214.2. The product was used without further characterization.</div></div><div id="sec71_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i288" class="anchor-spacer"></div><h5 class="article-section__title" id="_i288"> 1-(2-Bromo-6-(trifluoromethyl)pyridin-3-yl) but-2-yn-1-ol (<b>195</b>)</h5><div class="NLM_p last"><b>195</b> was prepared from 2-bromo-6-(trifluoromethyl)-3-pyridinecarboxylic acid (68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 8.29 (d, 1H, <i>J</i> = 7.8 Hz), 8.09 (d, 1H, <i>J</i> = 7.8 Hz), 3.48 (s, 3H); ESIMS <i>m</i>/<i>z</i>: (M, M + 2): 291.2, 293.2.</div></div><div id="sec71_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i289" class="anchor-spacer"></div><h5 class="article-section__title" id="_i289"> 1-(3,4-Difluorophenyl)but-2-yn-1-one (<b>196</b>)</h5><div class="NLM_p last"><b>196</b> was prepared from 3,4-difluorobenzoic acid (1.6 g, 89%). ESIMS <i>m</i>/<i>z</i> (M + 1): 181.0. The product was used without further characterization.</div></div><div id="sec71_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i290" class="anchor-spacer"></div><h5 class="article-section__title" id="_i290"> 1-(3-Fluoro-4-(trifluoromethyl)phenyl)but-2-yn-1-one (<b>230</b>)</h5><div class="NLM_p last"><b>230</b> was prepared from 3-fluoro-4-(trifluoromethyl)benzoic acid as a yellow liquid (62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.01–8.10 (m, 3H), 2.26 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 230.9.</div></div><div id="sec71_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i291" class="anchor-spacer"></div><h5 class="article-section__title" id="_i291"> 1-(3-(Trifluoromethyl)phenyl)but-2-yn-1-one (<b>231</b>)</h5><div class="NLM_p last"><b>231</b> was prepared from 3-(trifluoromethyl)benzoic acid (83%). The product was used without characterization.</div></div><div id="sec71_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i292" class="anchor-spacer"></div><h5 class="article-section__title" id="_i292"> 1-(2-Bromo-6-(trifluoromethyl)pyridin-3-yl)but-2-yn-1-one (<b>280</b>)</h5><div class="NLM_p last"><b>280</b> was prepared from 2-bromo-6-(trifluoromethyl)-3-pyridinecarboxylic acid (68%). ESIMS <i>m</i>/<i>z</i> (M, M + 2): 292.2, 294.2. The product was used without further characterization.</div></div></div><div id="sec72" class="NLM_sec NLM_sec_level_3"><div id="ac_i293" class="anchor-spacer"></div><h4 class="article-section__title" id="_i293"> General Procedure K: N-Tosylation of Pyrrole Carboxylate</h4><div class="NLM_p">Sodium hydride (1.5 equiv) was added to a stirred solution of pyrrole carboxylate intermediate (1 equiv) in DMF at 0 °C for 30 min. Tosyl chloride (1.5 equiv) was added at 0 °C and the reaction mixture was stirred at RT for 4 h. Water was added and the reaction mixture was then extracted with ethyl acetate (2×). The resulting combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The concentrated product was purified by flash chromatography (silica gel, eluting with hexane:EtOAc mixtures from 100 to 60:40%) to afford the product as an off-white solid (55–81%). Compounds <b>236</b>–<b>239</b> were prepared using this procedure, compound <b>240</b> was prepared by a modified procedure.</div><div id="sec72_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i294" class="anchor-spacer"></div><h5 class="article-section__title" id="_i294"> Ethyl 3-Methyl-1-(4-methylbenzenesulfonyl)-4-(6-(trifluoromethyl)pyridine-3-carbonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>236</b>)</h5><div class="NLM_p last"><b>236</b> was prepared from <b>173</b> (55%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 9.12 (s, 1H), 8.45 (d, 1H, <i>J</i> = 8.1 Hz), 8.23 (s, 1H), 8.13 (d, 1H, <i>J</i> = 8.1 Hz), 7.98 (d, 2H, <i>J</i> = 8.4 Hz), 7.50 (d, 2H, <i>J</i> = 8.4 Hz), 4.25 (q, 2H, <i>J</i> = 7.2 Hz), 2,43 (s, 3H), 2.40 (s, 3H), 1.22 (t, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 480.9.</div></div><div id="sec72_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i295" class="anchor-spacer"></div><h5 class="article-section__title" id="_i295"> Ethyl 4-(2-Fluoro-4-(trifluoromethyl)benzoyl)-3-methyl-1-(4-methylbenzenesulfonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>237</b>)</h5><div class="NLM_p last"><b>237</b> was prepared from <b>198</b> (81%). The product was used without characterization.</div></div><div id="sec72_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i296" class="anchor-spacer"></div><h5 class="article-section__title" id="_i296"> Ethyl 4-(3-Fluoro-4-(trifluoromethyl)benzoyl)-3-methyl-1-(4-methylbenzene-1-sulfonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>238</b>)</h5><div class="NLM_p last"><b>238</b> was prepared from <b>233</b> (78%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.16 (s, 1H), 7.92–8.09 (m, 3H), 7.79–7.90 (m, 2H), 7.49–7.51 (m, 2H), 4.24 (q, 2H, <i>J</i> = 9.2 Hz), 2.43 (s, 3 H), 2.38 (s, 3H), 1.22 (t, 3H, <i>J</i> = 9.2 Hz); ESIMS <i>m</i>/<i>z</i> (M – 1): 496.2.</div></div><div id="sec72_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i297" class="anchor-spacer"></div><h5 class="article-section__title" id="_i297"> Ethyl 3-Methyl-1-(4-methylbenzene-1-sulfonyl)-4-(3-(trifluoromethyl)benzoyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>239</b>)</h5><div class="NLM_p last">The title compound was prepared from <b>234</b> (81%). The product was used without characterization.</div></div><div id="sec72_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i298" class="anchor-spacer"></div><h5 class="article-section__title" id="_i298"> Ethyl 4-(6-(Difluoromethyl)pyridine-3-carbonyl)-3-methyl-1-(4-methylbenzene-1-sulfonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>240</b>)</h5><div class="NLM_p last">4-Dimethylaminopyridine (DMAP, 56 mg, 0.49 mmol) was added to a stirred solution of <b>235</b> (1.5 g, 4.87 mmol) and Et<sub>3</sub>N (1.3 mL, 9.74 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at 0 °C for 10 min. Tosyl chloride (1.1 g, 5.84 mmol) was added at 0 °C and the reaction mixture was stirred for 2 h at room temperature. Then, 1.5 N HCl (100 mL) was added and the reaction mixture was extracted with ethyl acetate (2 × 100 mL). The resulting combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The concentrated product was purified by flash chromatography (silica gel, eluting with hexane:EtOAc mixtures from 100 to 80:20%) to afford the product (2.0 g, 89%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 9.03 (s, 1H), 8.39 (dd, 1H, <i>J</i> = 1.6 Hz & 8.0 Hz), 8.03 (s, 1H), 7.89–7.94 (m, 3H), 7.46 (d, 2H, <i>J</i> = 8.4 Hz), 6.72–6.99 (t, 1H, <i>J</i> = 55.2 Hz), 4.31 (q, 2H, <i>J</i> = 7.2 Hz), 2,47 (s, 6H), 1.31 (t, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 462.9.</div></div></div><div id="sec73" class="NLM_sec NLM_sec_level_3"><div id="ac_i299" class="anchor-spacer"></div><h4 class="article-section__title" id="_i299"> General Procedure L: Ethenyl Pyrrole Formation</h4><div class="NLM_p">Methylmagnesium bromide (2.0 M in THF) (1.2–1.5 equiv) was added to the general procedure K tosylated product (1 equiv) in THF at 0 °C and stirred for 4 h at RT. The reaction mixture was quenched with 1.5 N HCl solution and extracted with ethyl acetate (2×). The resulting organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford the methylated product. Iodine (catalytic, 0.2 equiv) was added to the methylated intermediate in toluene at RT and stirred for 16 h at 115 °C. The reaction mixture was quenched with 10% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution and extracted with ethyl acetate (2×). The resulting organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The concentrated product was purified by flash chromatography (silica gel, eluting with hexane:EtOAc from 100 to 90:10%) to afford the product as a gray solid (55–73%). Compounds <b>241</b>–<b>245</b> were prepared using this procedure.</div><div id="sec73_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i300" class="anchor-spacer"></div><h5 class="article-section__title" id="_i300"> Ethyl 3-Methyl-1-(4-methylbenzenesulfonyl)-4-(1-(6-(trifluoromethyl)pyridin-3-yl)ethenyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>241</b>)</h5><div class="NLM_p last"><b>241</b> was prepared from <b>236</b> (73%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.79 (s, 1H), 7.88–7.95 (m, 4H), 7.75 (s, 1H), 7.49 (d, 2H, <i>J</i> = 8.2 Hz), 5.99 (s, 1H), 5.66 (s, 1H), 4.19 (q, 2H, <i>J</i> = 7.1 Hz), 2.43 (s, 3H), 1.88 (s, 3H), 1.19 (t, 3H, <i>J</i> = 7.1 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 480.0.</div></div><div id="sec73_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i301" class="anchor-spacer"></div><h5 class="article-section__title" id="_i301"> Ethyl 4-(1-(2-Fluoro-4-(trifluoromethyl)phenyl)ethenyl)-3-methyl-1-(4-methylbenzenesulfonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>242</b>)</h5><div class="NLM_p last"><b>242</b> was prepared from <b>237</b> (55%). The product was used without characterization.</div></div><div id="sec73_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i302" class="anchor-spacer"></div><h5 class="article-section__title" id="_i302"> Ethyl 4-(1-(3-Fluoro-4-(trifluoromethyl)phenyl)ethenyl)-3-methyl-1-(4-methylbenzene-1-sulfonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>243</b>)</h5><div class="NLM_p last"><b>243</b> was prepared from <b>238</b> (66%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 7.90–7.92 (m, 2H), 7.72–7.79 (m, 2H), 7.47–7.51 (m, 3H), 7.26 (d, 1H, <i>J</i> = 10.8 Hz), 5.96 (s, 1H), 5.59 (s, 1H), 4.20 (q, 2H, <i>J</i> = 9.6 Hz), 2.42 (s, 3 H), 1.84 (s, 3H), 1.18 (t, 3H, <i>J</i> = 9.6 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 496.2.</div></div><div id="sec73_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i303" class="anchor-spacer"></div><h5 class="article-section__title" id="_i303"> Ethyl 3-Methyl-1-(4-methylbenzene-1-sulfonyl)-4-(1-(3-(trifluoromethyl)phenyl)ethenyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>244</b>)</h5><div class="NLM_p last"><b>244</b> was prepared from <b>239</b> (69%). The product was used without characterization.</div></div><div id="sec73_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i304" class="anchor-spacer"></div><h5 class="article-section__title" id="_i304"> Ethyl 4-(1-(6-(Difluoromethyl)pyridin-3-yl)ethenyl)-3-methyl-1-(4-methylbenzene-1-sufonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>245</b>)</h5><div class="NLM_p last"><b>245</b> was prepared from <b>240</b> (61%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.60 (d, 1H, <i>J</i> = 1.6 Hz), 7.87–7.92 (m, 3H), 7.71 (d, 1H, <i>J</i> = 8.0 Hz), 7.65 (s, 1H), 7.46 (d, 2H, <i>J</i> = 8.0 Hz), 6.76 (t, 1H, <i>J</i> = 55.2 Hz), 5.88 (s, 1H), 5.58 (s, 1H), 4.26 (q, 2H, <i>J</i> = 7.2 Hz), 2.48 (s, 3H), 1.93 (s, 3H), 1.26 (t, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M – 1): 459.2.</div></div></div><div id="sec74" class="NLM_sec NLM_sec_level_3"><div id="ac_i305" class="anchor-spacer"></div><h4 class="article-section__title" id="_i305"> General Procedure M: Cyclopropyl Formation</h4><div class="NLM_p">A solution of general procedure L ethenyl product (1 equiv) in THF (10 mL) was added to a stirred solution of trimethylsulfoxonium iodide (2 equiv) and t-BuOK (2 equiv) in DMSO at 0 °C and stirred for 4 h at RT. The reaction mixture was poured into water and extracted with ethyl acetate (2×). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The concentrated product was purified by flash chromatography (silica gel, eluting with hexane:EtOAc mixtures from 100 to 60:40%) to afford the product as an off-white solid (49–71%). Compounds <b>246</b>–<b>250</b> were prepared using this procedure.</div><div id="sec74_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i306" class="anchor-spacer"></div><h5 class="article-section__title" id="_i306"> Ethyl 3-Methyl-1-(4-methylbenzenesulfonyl)-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>246</b>)</h5><div class="NLM_p last"><b>246</b> was prepared from <b>241</b> (71%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.41 (s, 1H), 7.89 (d, 2H, <i>J</i> = 8.3 Hz), 7.80 (s, 1H), 7.77 (d, 1H, <i>J</i> = 8.3 Hz), 7.67–7.69 (m, 1H), 7.48 (d, 2H, <i>J</i> = 8.1 Hz), 4.16 (q, 2H, <i>J</i> = 7.1 Hz), 2.42 (s, 3H), 1.96 (s, 3H), 1.44–1.47 (m, 2H), 1.37–1.40 (m, 2H), 1.17 (t, 3H, <i>J</i> = 7.1 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1<i>)</i>: 494.1.</div></div><div id="sec74_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i307" class="anchor-spacer"></div><h5 class="article-section__title" id="_i307"> Ethyl 4-(1-(2-Fluoro-4-(trifluoromethyl)phenyl)cyclopropyl)-3-methyl-1-(4-methylbenzenesulfonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>247</b>)</h5><div class="NLM_p last"><b>247</b> was prepared from <b>242</b> (53%). The product was used without characterization.</div></div><div id="sec74_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i308" class="anchor-spacer"></div><h5 class="article-section__title" id="_i308"> Ethyl 4-(1-(3-Fluoro-4-(trifluoromethyl)phenyl)cyclopropyl)-3-methyl-1-(4-methylbenzene-1-sulfonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>248</b>)</h5><div class="NLM_p last"><b>248</b> was prepared from <b>243</b> (63%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 7.86–7.89 (m, 2H), 7.75 (s, 1H), 7.59–7.62 (m, 1H), 7.46–7.49 (m, 2H), 6.96–7.08 (m, 2H), 4.16 (q, 2H, <i>J</i> = 9.6 Hz), 2.28 (s, 3 H), 1.36–1.39 (m, 4H), 1.84 (s, 3H), 1.18 (t, 3H, <i>J</i> = 9.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 510.0.</div></div><div id="sec74_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i309" class="anchor-spacer"></div><h5 class="article-section__title" id="_i309"> Ethyl 4-(1-(3-(Trifluoromethyl)phenyl)cyclopropyl)-3-methyl-1-(4-methylbenzene-1-sulfonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>249</b>)</h5><div class="NLM_p last"><b>249</b> was prepared from <b>244</b> (49%). The product was used without characterization.</div></div><div id="sec74_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i310" class="anchor-spacer"></div><h5 class="article-section__title" id="_i310"> Ethyl 4-(1-(6-(Difluoromethyl)pyridin-3-yl)cyclopropyl)-3-methyl-1-(4-methylbenzene-1-sufonyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>250</b>)</h5><div class="NLM_p last"><b>250</b> was prepared from <b>245</b> (60%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 8.28 (d, 1H, <i>J</i> = 7.2 Hz), 7.85 (d, 2H, <i>J</i> = 8.4 Hz), 7.69 (s, 1H), 7.58–7.65 (m, 2H), 7.44 (d, 2H, <i>J</i> = 8.4 Hz), 6.69 (t, 1H, <i>J</i> = 55.2 Hz), 4.23 (q, 2H, <i>J</i> = 7.2 Hz), 2.47 (s, 3H), 1.44–1.45 (m, 2H), 1.38–1.40 (m, 2H), 1.25 (t, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 475.2.</div></div></div><div id="sec75" class="NLM_sec NLM_sec_level_3"><div id="ac_i311" class="anchor-spacer"></div><h4 class="article-section__title" id="_i311"> General Procedure N: Amide Coupling and Indazole Formation</h4><div class="NLM_p">The corresponding amine and pyrrole carboxylic acid intermediate were coupled together using general procedure F1. The intermediate phenylcarbonylpyrrole carboxamide (1 equiv) was used directly, stirred in DMSO, treated with NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (20 equiv), and then heated to 100 °C for 2 h. After consumption of the starting material, the reaction mixture was poured into water and stirred for 10 min. The solid obtained was filtered, washed with water, and dried to afford the title compound as an off-white solid (13–45%). Title compounds <b>131</b>–<b>132</b> and <b>134</b>–<b>135</b> were prepared using this procedure.</div><div id="sec75_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i312" class="anchor-spacer"></div><h5 class="article-section__title" id="_i312"> <i>N</i>-Cyclopropyl-3-methyl-4-(6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide (<b>131</b>)</h5><div class="NLM_p last">Cyclopropylamine and <b>277</b> were reacted together to produce the title compound (13%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.97 (d, 1H, <i>J</i> = 8.0 Hz), 7.89 (s, 1H), 7.41 (d, 1H, <i>J</i> = 8.0 Hz), 7.30 (s, 1H), 2.82–2.87 (m, 1H), 2.48 (s, 3H), 0.83–0.87 (m, 2H), 0.64–0.68 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 349.1; LCMS: 98.36%; HPLC purity: 98.13%.</div></div><div id="sec75_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i313" class="anchor-spacer"></div><h5 class="article-section__title" id="_i313"> (3,3-Difluoroazetidin-1-yl)(3-methyl-4-(6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-1<i>H</i>-pyrrol-2-yl)methanone (<b>132</b>)</h5><div class="NLM_p last">3,3-Difluoroazetidine hydrochloride and <b>277</b> were reacted together to produce the title compound (45%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.39 (s, 1H), 11.51 (s, 1H), 8.11 (d, 1H, <i>J</i> = 8.0 Hz), 7.91 (s, 1H), 7.50 (s, 1H), 7.40 (d, 1H, <i>J</i> = 8.0 Hz), 4.56–4.63 (m, 4H), 2.42 (s, 3H); ESIMS <i>m</i>/<i>z</i>: 385.1; LCMS: 91.55%; HPLC purity: 93.13%.</div></div><div id="sec75_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i314" class="anchor-spacer"></div><h5 class="article-section__title" id="_i314"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>134</b>)</h5><div class="NLM_p last">1-(5-Methylisoxazol-3-yl)ethan-1-amine and <b>277</b> were reacted together to produce the racemic title compound (32%). The racemic product was resolved by SFC using a YMC Amylose-SA column and 0.5% isopropylamine in methanol cosolvent (40%) to afford the title compound (retention time 2.95) as an off-white solid (27%). <sup>1</sup>H NMR (400 MHz, MeOD) δ (ppm): 7.97 (d, 1H, <i>J</i> = 8.0 Hz), 7.89 (s, 1H), 7.41 (d, 1H, <i>J</i> = 8.0 Hz), 7.34 (s, 1H), 6.21 (s, 1H), 5.32–5.38 (q, 1H, <i>J</i> = 7.2 Hz), 2.52 (s, 3H), 2.43 (s, 3H), 1.63 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i>: 418.1; HPLC purity: 99.06%; SFC purity: 100%.</div></div><div id="sec75_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i315" class="anchor-spacer"></div><h5 class="article-section__title" id="_i315"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>135</b>)</h5><div class="NLM_p last"><b>135</b> was prepared as for <b>134</b> above (retention time 4.62) as an off-white solid (24%). <sup>1</sup>H NMR (400 MHz, MeOD) δ (ppm): 7.97 (d, 1H, <i>J</i> = 8.0 Hz), 7.89 (s, 1H), 7.41 (d, 1H, <i>J</i> = 8.0 Hz), 7.33 (s, 1H), 6.20 (s, 1H), 5.32–5.38 (q, 1H, <i>J</i> = 7.2 Hz), 2.52 (s, 3H), 2.43 (s, 3H), 1.63 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i>: 418.1; HPLC purity: 98.32%; SFC purity: 100%.</div></div></div><div id="sec76" class="NLM_sec NLM_sec_level_3"><div id="ac_i316" class="anchor-spacer"></div><h4 class="article-section__title" id="_i316"> General Procedure O: Friedel–Crafts acetylation of pyrroles</h4><div class="NLM_p">Ethyl 3-methyl-1<i>H</i>-pyrrole-2-carboxylate (1 equiv) and 3-fluoro-2-iodobenzoyl chloride (1.5 equiv) were dissolved in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (100 mL) under argon and cooled to 0 °C in an ice/water bath. AlCl<sub>3</sub> (3 equiv) was added portionwise to the reaction mixture and stirred at 40 °C for 16 h. The reaction mixture was poured into ice water (100 mL) slowly. The resulting reaction mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 150 mL). The combined organic layer was washed with saturated sodium bicarbonate solution, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The resulting concentrated product was purified by column chromatography using 0–50% ethyl acetate in petroleum ether to afford the product (23–45%). Compounds <b>212</b>–<b>215</b> were prepared using this procedure.</div><div id="sec76_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i317" class="anchor-spacer"></div><h5 class="article-section__title" id="_i317"> Ethyl 4-(4-(<i>N</i>,<i>N</i>-Dimethylsulfamoyl)benzoyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>212</b>)</h5><div class="NLM_p last"><b>212</b> was prepared from ethyl 3-methyl-1<i>H</i>-pyrrole-2-carboxylate and 4-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)benzoyl chloride (30%). ESIMS <i>m</i>/<i>z</i> (M + 1): 365.2. The product was used without further characterization.</div></div><div id="sec76_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i318" class="anchor-spacer"></div><h5 class="article-section__title" id="_i318"> Ethyl 4-(Isoquinoline-8-carbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>213</b>)</h5><div class="NLM_p last"><b>213</b> was prepared from ethyl 3-methyl-1<i>H</i>-pyrrole-2-carboxylate and 8-isoquinolinecarbonyl chloride (45%). ESIMS <i>m</i>/<i>z</i> (M + 1): 309.3. The product was used without further characterization.</div></div><div id="sec76_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i319" class="anchor-spacer"></div><h5 class="article-section__title" id="_i319"> Ethyl 4-(5-Methoxyisoquinoline-8-carbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>214</b>)</h5><div class="NLM_p last"><b>214</b> was prepared from ethyl 3-methyl-1<i>H</i>-pyrrole-2-carboxylate and 5-methoxy-8-isoquinolinecarbonyl chloride (40%). ESIMS <i>m</i>/<i>z</i> (M + 1): 339.3. The product was used without further characterization.</div></div><div id="sec76_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i320" class="anchor-spacer"></div><h5 class="article-section__title" id="_i320"> Ethyl 4-((3-Fluoro-2-iodophenyl)carbonyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>215</b>)</h5><div class="NLM_p"><b>215</b> was prepared from ethyl 3-methyl-1<i>H</i>-pyrrole-2-carboxylate and 3-fluoro-2-iodobenzoyl chloride (23%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.52 (s, 1H), 7.50–7.57 (m, 1H), 7.38–7.43 (m, 1H), 7.24–4.26 (m, 1 H), 6.32 (s, 1H), 4.27 (q, 2H, <i>J</i> = 7.2 Hz), 2.22 (s, 3H), 1.32 (t, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 402.2.</div><div class="NLM_p last">The remaining compounds were prepared as described individually.</div></div><div id="sec76_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i321" class="anchor-spacer"></div><h5 class="article-section__title" id="_i321"> Ethyl 3-Methyl-4-((4-(trifluoromethyl)benzo[<i>d</i>]oxazol-7-yl)methyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>18</b>)</h5><div class="NLM_p last">SnCl<sub>2</sub> (0.14 g, 0.81 mmol) was added to a stirred solution of <b>188</b> (0.15 g, 0.40 mmol) in ethanol:water (8:2 mL) at RT and stirred for 4 h at 80 °C. The reaction mixture was concentrated, basified with saturated sodium bicarbonate solution (10 mL), and extracted with ethyl acetate (2 × 30 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The resulting concentrated product was dissolved in triethyl orthoformate (1 mL) and heated to 100 °C for 18 h. The reaction mixture was concentrated and purified by flash chromatography (silica gel, eluting with hexane:EtOAc mixtures from 100 to 70:30%) to afford the product (10 mg, 7%) as an off-white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ (ppm): 8.85 (bs, 1H), 8.25 (s, 1H), 7.58 (d, 1H, <i>J</i> = 8.4 Hz), 7.22 (d, 1H, <i>J</i> = 8.4 Hz), 6.71 (s, 1H), 4.33 (q, 2H, <i>J</i> = 7.1 Hz), 4.14 (s, 2H), 2.29 (s, 3H), 1.36 (t, 3H, <i>J</i> = 7.1 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 353.2 LCMS: 96.78%; HPLC purity: 98.59%.</div></div><div id="sec76_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i322" class="anchor-spacer"></div><h5 class="article-section__title" id="_i322"> <i>N</i>-(1-(5-Cyano-1<i>H</i>-pyrazol-3-yl)ethyl)-3-methyl-4-(((6-trifluoromethyl)pyridine-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>44</b>)</h5><div class="NLM_p last">To a stirred solution of racemic <b>46</b> (180 mg, 0.43 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL), <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA, 0.3 mL, 0.86 mmol) was added followed by T3P in ethyl acetate (50 wt %, 0.5 mL). The reaction mixture was then stirred for 2 h at RT. After completion of the reaction (monitored by TLC), water was added and the reaction mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 40 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The resulting concentrated product was purified by column chromatography using 30–80% ethyl acetate in petroleum ether to afford the racemic product (80 mg, 47%). The racemic product was resolved by SFC purification using a Lux A1 column eluting with methanol cosolvent (40%) to afford the product (retention time: 1.88) as an off-white solid (13 mg, 16%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.87 (s, 1H), 11.00 (s, 1H), 8.63 (s, 1H), 7.82 (m, 1H), 7.81(s, 2H), 6.85 (s, 1H,), 6.75 (s, 1H), 5.18–5.25 (m, 1H), 3.86 (s, 2H), 2.14 (s, 3H), 1.47 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 403.1; HPLC purity: 95.30%; SFC purity: 98.59%.</div></div><div id="sec76_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i323" class="anchor-spacer"></div><h5 class="article-section__title" id="_i323"> <i>N</i>-(1-(5-Cyano-1<i>H</i>-pyrazol-3-yl)ethyl)-3-methyl-4-(((6-trifluoromethyl)pyridine-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>45</b>)</h5><div class="NLM_p last"><b>45</b> was obtained by the same SFC process as described in <b>44</b> above (retention time: 2.96) as an off-white solid (18 mg, 23%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.87 (s, 1H), 11.00 (s, 1H), 8.63 (s, 1H), 7.83 (m, 1H), 7.81(s, 2H), 6.85 (s, 1H,), 6.75 (s, 1H), 5.18–5.25 (m, 1H), 3.86 (s, 2H), 2.14 (s, 3H), 1.47 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 403.1; HPLC purity: 99.90%; SFC purity: 98.73%.</div></div><div id="sec76_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i324" class="anchor-spacer"></div><h5 class="article-section__title" id="_i324"> 3-(1-(3-Methyl-4-((6-(trifluoromethyl)pyridine-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamido)ethyl)-1<i>H</i>-pyrazole-5-carboxamide (<b>46</b>)</h5><div class="NLM_p last">Aqueous ammonia (10 mL) was added to a stirred solution of <b>189</b> (400 mg, 0.90 mmol) in methanol (4 mL), and the reaction mixture was stirred for 24 h at 100 °C in a sealed tube. The reaction mixture was concentrated and purified by preparative HPLC to afford the product as a pale yellow solid (0.18 g, 48%). <sup>1</sup>H NMR (400 MHz, MeOD) δ (ppm): 8.56 (s, 1H), 7.82 (d, 1H, <i>J</i> = 8.0 Hz), 7.73 (d, 1H, <i>J</i> = 8.1 Hz), 6.71–6.74 (bs, 1H), 6.71 (s, 1H), 5.29–5.38 (m, 1H), 3.96 (s, 2H), 2.22 (s, 3H), 1.59–1.63 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 421.1; LCMS: 99.65%; HPLC purity: 98.47%.</div></div><div id="sec76_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i325" class="anchor-spacer"></div><h5 class="article-section__title" id="_i325"> 3-(1-(3-Methyl-4-((6-(trifluoromethyl)pyridine-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamido)ethyl)-1<i>H</i>-pyrazole-5-carboxamide Enantiomer I (<b>47</b>)</h5><div class="NLM_p last">Racemic <b>46</b> was resolved by SFC purification using a Chiralcel OD-H column eluting with IPA cosolvent (30%) to afford enantiomer I (retention time 3.37) as an off-white solid (22%). <sup>1</sup>H NMR (400 MHz, MeOD) δ (ppm): 8.55 (s, 1H), 7.82 (d, 1H, <i>J</i> = 8.0 Hz), 7.73 (d, 1H, <i>J</i> = 8.1 Hz), 6.70–6.73 (bs, 1H), 6.73 (s, 1H), 5.33 (m, 1H), 3.95 (s, 2H), 2.22 (s, 3H), 1.60–1.62 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 421.2; HPLC purity: 97.66%; SFC purity: 100%.</div></div><div id="sec76_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i326" class="anchor-spacer"></div><h5 class="article-section__title" id="_i326"> 3-(1-(3-Methyl-4-((6-(trifluoromethyl)pyridine-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamido)ethyl)-1<i>H</i>-pyrazole-5-carboxamide Enantiomer II (<b>48</b>)</h5><div class="NLM_p last"><b>48</b> was prepared as described for <b>47</b> above (retention time 4.61) as an off-white solid (26%). <sup>1</sup>H NMR (400 MHz, MeOD) δ (ppm): 8.56 (s, 1H), 7.83 (d, 1H, <i>J</i> = 8.0 Hz), 7.73 (d, 1H, <i>J</i> = 8.1 Hz), 6.71–6.74 (bs, 1H), 6.74 (s, 1H), 5.34 (m, 1H), 3.96 (s, 2H), 2.22 (s, 3H), 1.61–1.63 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 421.2; HPLC purity: 96.01%; SFC purity: 96.71%.</div></div><div id="sec76_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i327" class="anchor-spacer"></div><h5 class="article-section__title" id="_i327"> <i>N</i>-Methyl-3-(1-(3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl) methyl)-1<i>H</i>-pyrrole-2-carboxamido)ethyl)-1<i>H</i>-pyrazole-5-carboxamide Enantiomer I (<b>49</b>)</h5><div class="NLM_p last">Methylamine (1 M in THF; 0.5 mL, 0.52 mmol) was added to a stirred solution of <b>189</b> (200 mg, 0.45 mmol) in THF (4 mL) at RT. Then, Me<sub>3</sub>Al (1.0 M in toluene) (1.0 mL, 1.0 mmol) was added and stirred at 100 °C for 1 h in a microwave. The reaction mixture was quenched with 1.5 N HCl solution and extracted with ethyl acetate (2 × 50 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The resulting concentrated product was purified by column chromatography using 10–50% ethyl acetate in petroleum ether to afford the racemic product (0.12 g, 62%). The racemic product was resolved by SFC purification using a YMC Amylose-SA column eluting with IPA cosolvent (40%) to afford the title compound (retention time: 1.79) as an off-white solid (26 mg, 22%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.56 (s, 1H), 7.81 (d, 1H, <i>J</i> = 8.0 Hz), 7.72 (d, 1H, <i>J</i> = 8.0 Hz), 6.74 (s, 1H), 6.68 (s, 1H), 5.33 (m, 1H) 3.95 (s, 2H), 2.89 (s, 3H), 2.21 (s, 3H), 1.60 (d, 3H, <i>J</i> = 6.4 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 435.1; HPLC purity: 95.96%; SFC purity: 100%.</div></div><div id="sec76_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i328" class="anchor-spacer"></div><h5 class="article-section__title" id="_i328"> <i>N</i>-Methyl-3-(1-(3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl) methyl)-1<i>H</i>-pyrrole-2-carboxamido)ethyl)-1<i>H</i>-pyrazole-5-carboxamide Enantiomer II (<b>50</b>)</h5><div class="NLM_p last"><b>50</b> was obtained by the same SFC process as described for <b>49</b> above (retention time: 3.1) as an off-white solid (20 mg, 17%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.56 (s, 1H), 7.81 (d, 1H, <i>J</i> = 8.0 Hz), 7.72 (d, 1H, <i>J</i> = 8.0 Hz), 6.74 (s, 1H), 6.68 (s, 1H), 5.32 (m, 1H), 3.95 (s, 2H), 2.90 (s, 3H), 2.21 (s, 3H), 1.61 (d, 3H, <i>J</i> = 6.4 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 435.2; HPLC purity: 95.88%; SFC purity: 99.52%.</div></div><div id="sec76_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i329" class="anchor-spacer"></div><h5 class="article-section__title" id="_i329"> <i>N</i>-(1-(1<i>H</i>-1,2,4-Triazol-3-yl) ethyl)-4-((2-cyano-3-fluorophenyl)methyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxamide (<b>66</b>)</h5><div class="NLM_p last">To a stirred solution of <b>224</b> (0.17 g, 0.38 mmol) in DMA:H<sub>2</sub>O (9 mL:1 mL) were added zinc dust (0.05 g, 0.75 mmol), Pd(dppf)Cl<sub>2</sub> (0.015 g, 0.018 mmol), and poly(methyl hydrosiloxane) (1.0 mL) at RT. Then, zinc cyanide (0.13 g, 1.13 mmol) was added and heated to 80 °C for 16 h. The reaction mixture was then quenched with water (50 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The resulting concentrated product was purified by preparative HPLC to afford the product as a white solid (25 mg, 19%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.26 (s, 1H), 7.57–7.63 (m, 1H), 7.20 (d, 1H, <i>J</i> = 8.8 Hz), 7.15 (d, 1H, <i>J</i> = 8.0 Hz), 6.70 (s, 1H), 5.38 (q, 1H, <i>J</i> = 6.8 Hz), 4.02 (s, 2H), 2.25 (s, 3H), 1.63 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 353.1; LCMS: 99.77%; HPLC purity: 97.26%.</div></div><div id="sec76_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i330" class="anchor-spacer"></div><h5 class="article-section__title" id="_i330"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(1-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>67</b>)</h5><div class="NLM_p">Methylmagnesium bromide (2.0 M in THF) (0.37 mL, 0.74 mmol) was added to a stirred solution of <b>173</b> (0.20 g, 0.61 mmol) in THF (5 mL) at 0 °C and stirring was continued for 4 h at RT. The reaction mixture was quenched with 1.5 N HCl solution and extracted with ethyl acetate (2 × 10 mL). The resulting organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The resulting concentrated product was purified by column chromatography using 10–50% ethyl acetate in petroleum ether to afford ethyl 4-(1-hydroxy-1-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (0.15 g, 73%) as a gummy solid. The product was used without purification.</div><div class="NLM_p">To a stirred solution of the above pyrrole carboxylate intermediate (0.15 g, 0.44 mmol) in TFA (0.19 mL, 2.6 mmol) and CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added triethylsilane (0.26 g, 1.76 mmol) at RT and stirred at 85 °C for 1 h. After completion of the reaction, the reaction mixture was quenched with sat·NaHCO<sub>3</sub> (50 mL) by dropwise addition at 0 °C and extracted with ethyl acetate (3 × 10 mL, with careful venting). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The resulting concentrated product was triturated with petroleum ether to afford ethyl 3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>225</b>) (0.12 g, 83%) as a white solid. The product was used without purification.</div><div class="NLM_p">Sodium hydroxide (30 mg, 0.74 mmol) was added to a stirred solution of <b>225</b> (0.12 g, 0.37 mmol) in EtOH:water (4:1 mL) at RT and heated to 80 °C for 2 h. The resulting reaction mixture was concentrated and quenched with water (2 mL). Then, it was acidified with 10% citric acid solution. The solid obtained was filtered, washed with water, and dried to afford 3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-1<i>H</i>-pyrrole-2-carboxylic acid (80 mg, 73%) as an off-white solid. The product was used without purification.</div><div class="NLM_p last">1-(5-Methylisoxazol-3-yl)ethan-1-amine (37 mg, 0.29 mmol) and triethylamine (0.07 mL, 0.54 mmol) were added to a stirred solution of the above pyrrole carboxylic acid intermediate (80 mg, 0.27 mmol) in dichloromethane (2 mL) at RT and continued for 5 min. Then, HATU (0.15 g, 0.40 mmol) was added to the reaction mixture and stirred at RT for 3 h. After completion of the reaction (monitored by TLC), water was added to the reaction mixture and extracted with dichloromethane (2 × 10 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The resulting concentrated product was purified by column chromatography using 10–40% ethyl acetate in petroleum ether to afford the title compound (50 mg, 46%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.07, (s, 1H), 8.66 (s, 1H), 7.77–7.84 (m, 3H), 6.90 (s, 1H), 6.17 (s, 1H), 5.13–5.16 (m, 1H), 4.15 (q, 1H, <i>J</i> = 7.2 Hz), 2.36 (s, 3H), 2.02 (s, 3H), 1.54 (d, 3H, <i>J</i> = 7.2 Hz), 1.44 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M – 1): 405; LCMS: 99.74%; HPLC purity: 98.81%.</div></div><div id="sec76_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i331" class="anchor-spacer"></div><h5 class="article-section__title" id="_i331"> 4-(Hydroxy(6-(trifluoromethyl)pyridin-3-yl)methyl)-3-methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>68</b>)</h5><div class="NLM_p">Sodium hydroxide (112 mg, 3.06 mmol) was added to a stirred solution of <b>173</b> (0.50 g, 1.53 mmol) in EtOH:H<sub>2</sub>O (9:1 mL) at RT and heated to 80 °C for 4 h. The resulting reaction mixture was concentrated, water was added (4 mL), and then acidified with 10% citric acid solution. The solid obtained was filtered, washed with water, and dried to afford 3-methyl-4-(6-(trifluoromethyl)pyridine-3-carbonyl)-1<i>H</i>-pyrrole-2-carboxylic acid as an off-white solid (420 mg, 92%). ESIMS <i>m</i>/<i>z</i> (M + 1): 299.2. The product was used without purification.</div><div class="NLM_p">1-(5-Methylisoxazol-3-yl)ethan-1-amine (125 mg, 1.61 mmol) and triethylamine (0.4 mL, 2.82 mmol) were added to a stirred solution of the above pyrrole intermediate (420 mg, 1.34 mmol) in (10 mL) at RT and stirring was continued for 5 min. Then, HATU (0.8 g, 2.11 mmol) was added to the reaction mixture and stirring was continued at RT for 16 h. After completion of the reaction (monitored by TLC), water was added to the reaction mixture and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 50 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The resulting concentrated product was purified by column chromatography using 0-40% ethyl acetate in petroleum ether to afford 3-methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(6-(trifluoromethyl)pyridine-3-carbonyl)-1<i>H</i>-pyrrole-2-carboxamide <b>(227)</b> (400 mg, 70%) as an off-white solid. ESIMS <i>m</i>/<i>z</i> (M + 1): 407.2. The product was used without further purification.</div><div class="NLM_p last">Sodium borohydride (75 mg, 1.97 mmol) was added portionwise to a stirred solution of <b>227</b> (0.4 g, 0.99 mmol) in ethanol (10 mL) at 0 °C. Then, the reaction mixture was stirred for 1 h at room temperature. The reaction mixture was concentrated under reduced pressure. Water (10 mL) was added to the concentrated product and the mixture was extracted with ethyl acetate (2 × 50 mL). The resulting combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford the title compound as an off-white solid (0.4 g, 99%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.05 (s, 1H), 8.72 (s, 1H), 7.99 (d, 1H, <i>J</i> = 7.6 Hz), 7.86 (d, 1H, <i>J</i> = 8.4 Hz), 7.79 (d, 1H, <i>J</i> = 8.4 Hz), 6.66 (s, 1H), 6.62 (s, 1H), 5.80 (brs, 2H), 5.15–5.17 (m, 1H), 2.36 (s, 3H), 2.18 (s, 3H), 1.43 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 409.0; LCMS: 99.66%; HPLC purity: 98.34%.</div></div><div id="sec76_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i332" class="anchor-spacer"></div><h5 class="article-section__title" id="_i332"> 4-(Methoxy(6-(trifluoromethyl)pyridin-3-yl)methyl)-3-methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>69</b>)</h5><div class="NLM_p last">MeI (0.21 g, 0.74 mmol) was added to a stirred solution of <b>68</b> (0.15 g, 0.37 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (0.21 g, 0.74 mmol) in THF (3 mL) at 0 °C. The reaction mixture was stirred for 16 h at room temperature. Water was added and the mixture was extracted with ethyl acetate (2 × 30 mL). The resulting combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The crude product was purified by prep. HPLC to afford product (35 mg, 23%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.17 (s, 1H), 8.72 (s, 1H), 7.98 (d, 1H, <i>J</i> = 8.8 Hz), 7. 89 (d, 1H, <i>J</i> = 8.0 Hz), 7.84 (d, 1H, <i>J</i> = 8.0 Hz), 6.71 (d, 1H, <i>J</i> = 2.0 Hz), 6.18 (d, 1H, <i>J</i> = 3.8 Hz), 5.48 (s, 1H), 5.13–5.16 (m, 1H), 3.27 (s, 3H), 2.36 (brs, 3H), 2.16 (s, 3H), 1.43–1.45 (m, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 423.2; LCMS: 99.66%; HPLC purity: 94.67%.</div></div><div id="sec76_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i333" class="anchor-spacer"></div><h5 class="article-section__title" id="_i333"> 4-(Cyano(6-(trifluoromethyl)pyridin-3-yl)methyl)-3-methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl) ethyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>70</b>)</h5><div class="NLM_p">Boc anhydride (236 mg, 0.108 mmol) was added to a stirred solution of <b>227</b> (400 mg, 0.98 mmol), triethylamine (0.2 mL, 1.47 mmol), and DMAP (12 mg, 0.09 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at RT and continued for 4 h. After completion of the reaction (monitored by TLC), water was added and the reaction mixture extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 50 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The resulting concentrated product was purified by column chromatography using 0–40% ethyl acetate in petroleum ether to afford <i>tert</i>-butyl 3-methyl-2-((1-(5-methylisoxazol-3-yl)ethyl)carbamoyl)-4-(6-(trifluoromethyl)pyridine-3-carbonyl)-1<i>H</i>-pyrrole-1-carboxylate (450 mg, 90%) as a yellow liquid. ESIMS <i>m</i>/<i>z</i> (M + 1): 507.2. The product was used without purification.</div><div class="NLM_p">Sodium borohydride (67 mg, 1.78 mmol) was added portionwise to a stirred solution of the above Boc-pyrrole intermediate (0.45 g, 0.89 mmol) in ethanol (10 mL) at 0 °C, and the reaction mixture was stirred for 1 h at RT. The reaction mixture was concentrated under reduced pressure. Water (10 mL) was added to the concentrated product and the mixture was extracted with ethyl acetate (2 × 50 mL). The resulting combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford <i>tert</i>-butyl 4-(hydroxy(6-(trifluoromethyl)pyridin-3-yl)methyl)-3-methyl-2-((1-(5-methylisoxazol-3-yl)ethyl)carbamoyl)-1<i>H</i>-pyrrole-1-carboxylate (<b>228</b>) (0.4 g, 89%). ESIMS <i>m</i>/<i>z</i> (M + 1): 509.2. The product was used without further purification.</div><div class="NLM_p">TMSCN (78 mg, 0.79 mmol) was added to a stirred solution of <b>228</b> (400 mg, 0.79 mmol) and tris(pentafluorophenyl)borane (20 mg, 0.04 mmol) in acetonitrile (4 mL) at RT. Stirring was continued for 8 h at RT. After completion of the reaction (by TLC), the reaction mixture was concentrated to afford <i>ter</i>t-butyl 4-(cyano(6-(trifluoromethyl)pyridin-3-yl)methyl)-3-methyl-2-((1-(5-methylisoxazol-3-yl)ethyl) carbamoyl)-1<i>H</i>-pyrrole-1-carboxylate (100 mg, 25%). ESIMS <i>m</i>/<i>z</i> (M + 1): 518.2. The product was used without further purification.</div><div class="NLM_p last">HCl (4.5 N) in dioxane (2 mL) was added to a stirred solution of the above Boc cyano pyrrole intermediate (100 mg, 0.19 mmol) in dioxane (2 mL) at 0 °C and stirring was continued for 2 h at RT. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated and then dissolved in ethyl acetate (10 mL) and washed with sodium bicarbonate solution (10 mL). The separated organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by column chromatography using 0–60% ethyl acetate in petroleum ether to afford the title compound (20 mg, 25%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 9.54 (s, 1H), 8.75 (s, 1H), 7.91 (d, 1H, <i>J</i> = 8.4 Hz), 7.75 (d, 1H, <i>J</i> = 8.4 Hz), 6.87–6.89 (m, 1H), 6.52 (d, 1H, <i>J</i> = 7.6 Hz), 5.97 (s, 1H), 5.34–5.37 (m, 1H), 5.21 (s, 1H), 2.44 (s, 3H), 2.27 (s, 3H), 1.61 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 418.2; LCMS: 98.83%; HPLC purity: 98.24%.</div></div><div id="sec76_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i334" class="anchor-spacer"></div><h5 class="article-section__title" id="_i334"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl-d2)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>71</b>)</h5><div class="NLM_p">Sodium borodeuteride (0.51 g, 12.26 mmol) was added portionwise to a stirred solution of <b>173</b> (2 g, 6.12 mmol) and trifluoroacetic acid-<i>d</i> (10 mL) in chloroform (20 mL) at 0 °C. The reaction mixture was stirred for 16 h at RT. Saturated NaHCO<sub>3</sub> (50 mL) was then added dropwise at 0 °C and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 40 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The resulting concentrated product was purified by column chromatography using 0–40% ethyl acetate in petroleum ether to afford ethyl 3-methyl-4-((6-(trifluoromethyl) pyridin-3-yl)methyl-d2)-1<i>H</i>-pyrrole-2-carboxylate (<b>226</b>) as an off-white solid (0.8 g, 42%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.39 (s, 1H), 8.63 (s, 1H), 7.77–7.87 (m, 2H), 6.80 (s, 1H), 4.17 (q, 2H, <i>J</i> = 7.1 Hz), 2.14 (s, 3H), 1.26 (t, 3H, <i>J</i> = 7.1 Hz).</div><div class="NLM_p">Sodium hydroxide (200 mg, 5.09 mmol) was added to a stirred solution of <b>226</b> (800 mg, 2.54 mmol) in EtOH:H<sub>2</sub>O (16:4 mL) at RT and heated to 80 °C for 2 h. The reaction mixture was acidified using citric acid. The solid obtained was filtered and washed with diethyl ether to afford 3-methyl-4-((6-(trifluoromethyl) pyridin-3-yl)methyl-d2)-1<i>H</i>-pyrrole-2-carboxylic acid as a white solid (600 mg, 82%). The product was used without purification.</div><div class="NLM_p last">1-(5-Methylisoxazol-3-yl)ethan-1-amine (97 mg, 0.84 mmol) and triethylamine (0.2 mL, 1.40 mmol) were added to a stirred solution of the above deuterated pyrrole carboxylic acid intermediate (200 mg, 0.70 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) at RT and stirring continued for 5 min. Then, HATU (400 mg, 1.05 mmol) was added to the reaction mixture and stirring was continued at RT for 4 h. After completion of the reaction (monitored by TLC), water was added and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 30 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The resulting concentrated product was purified by column chromatography using 10–50% ethyl acetate in petroleum ether to afford the racemic product as an off-white solid (150 mg, 55%). The racemic product was resolved by SFC using a YMC Amylose-SA column and methanol cosolvent (30%) to afford the title compound as an off-white solid (retention time 2.6) (24 mg, 18%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.09 (s, 1H), 8.64 (s, 1H), 7.81–7.83 (m, 3H), 6.73 (s, 1H), 6.18 (s, 1H), 5.14–5.18 (m, 1H), 2.34 (s, 3H), 2.14 (s, 3H), 1.45 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 396.2; HPLC purity: 99.49%; SFC purity: 99.35%.</div></div><div id="sec76_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i335" class="anchor-spacer"></div><h5 class="article-section__title" id="_i335"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl-d2)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>72</b>)</h5><div class="NLM_p last"><b>72</b> was prepared as for <b>71</b> above to afford the product as an off-white solid (retention time 3.79) (21 mg, 15%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.13 (s, 1H), 8.63 (s, 1H), 7.85 (m, 1H), 7.80 (s, 2H), 6.72 (s, 1H), 6.17 (s, 1H), 5.13–5.17 (m, 1H), 2.35 (s, 3H), 2.13 (s, 3H), 1.44 (d, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 396.2; HPLC purity: 99.36%; SFC purity: 98.89%.</div></div><div id="sec76_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i336" class="anchor-spacer"></div><h5 class="article-section__title" id="_i336"> 3-(1-(3-Methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamido)ethyl)-1<i>H</i>-pyrazole-5-carboxamide (<b>83</b>)</h5><div class="NLM_p last">Aqueous ammonia (10 mL) was added to a stirred solution of <b>256</b> (0.45 g, 0.95 mmol) in methanol (2 mL) and the reaction heated to 100 °C for 24 h. The reaction mixture was concentrated and purified by preparative HPLC to afford the racemic title compound as a white solid (150 mg, 36%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.35 (s, 1H), 7.67 (s, 2H), 6.91 (s, 1H), 6.71 (s, 1H), 5.34–5.36 (m, 1H), 2.19 (s, 3H), 1.62 (d, 3H), 1.41–1.42 (m, 2H), 1.36–1.37 (m, 2H); ESIMS <i>m</i>/z (M + 1): 446.9; LCMS: 99.67%; HPLC purity: 98.46%.</div></div><div id="sec76_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i337" class="anchor-spacer"></div><h5 class="article-section__title" id="_i337"> 3-(1-(3-Methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamido)ethyl)-1<i>H</i>-pyrazole-5-carboxamide Enantiomer I (84)</h5><div class="NLM_p last">Racemic <b>83</b> was resolved by SFC purification using a YMC Amylose-SA column and methanol cosolvent (40%) to afford the product (retention time: 2.14) as a white solid (30%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.33 (s, 1H), 7.64 (s, 2H), 6.90 (s, 1H), 6.70 (s, 1H), 5.33–5.34 (m, 1H), 2.17 (s, 3H), 1.60 (d, 3H), 1.39–1.42 (m, 2H), 1.34–1.35 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 447.1; HPLC purity: 98.93%; SFC purity: 97.76%.</div></div><div id="sec76_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i338" class="anchor-spacer"></div><h5 class="article-section__title" id="_i338"> 3-(1-(3-Methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamido)ethyl)-1<i>H</i>-pyrazole-5-carboxamide Enantiomer II (<b>85</b>)</h5><div class="NLM_p last"><b>85</b> was prepared as for <b>84</b> above to afford the product (retention time: 3.27) as a white solid (19%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.33 (s, 1H), 7.64 (s, 2H), 6.90 (s, 1H), 6.70 (s, 1H), 5.33–5.34 (m, 1H), 2.17 (s, 3H), 1.60 (d, 3H), 1.39–1.42 (m, 2H), 1.34–1.35 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 447.1; HPLC purity: 99.43%; SFC purity: 100%.</div></div><div id="sec76_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i339" class="anchor-spacer"></div><h5 class="article-section__title" id="_i339"> <i>N</i>-(1-(5-Cyano-1<i>H</i>-pyrazol-3-yl)ethyl)-3-methyl-4-(1-(6-(trifluoromethyl) pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>86</b>)</h5><div class="NLM_p last">To a stirred solution of <b>83</b> (120 mg, 0.27 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added DIPEA (0.25 mL, 1.08 mmol) followed by T3P (50 wt % in ethyl acetate) (0.35 mL, 0.54 mmol). The reaction mixture was then stirred for 2 h at RT. After completion of the reaction (monitored by TLC), water was added to the reaction mixture and the reaction mixture was extracted with dichloromethane (2 × 40 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The resulting concentrated product was purified by column chromatography using 30–80% ethyl acetate in petroleum ether to afford the product as an off-white solid (70 mg, 61%). The racemic product was resolved by SFC purification using a Lux A1 column and methanol cosolvent (30%) to afford product (retention time: 2.52) as a white solid (17%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.87 (s, 1H), 11.08 (s, 1H), 8.40 (s, 1H), 7.83 (d, 1H, <i>J</i> = 8.0 Hz), 7.73 (d, 1H, <i>J</i> = 8.0 Hz), 7.63 (d 1H), 6.93 (s, 1H), 6.85 (s, 1H), 5.20–5.23 (m, 1H), 2.09 (s, 3H), 1.48 (d, 3H, <i>J</i> = 6.7 Hz), 1.40 (brs, 2H), 1.24 (brs, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 429.0; HPLC purity: 98.71%, SFC purity: 99.20%.</div></div><div id="sec76_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i340" class="anchor-spacer"></div><h5 class="article-section__title" id="_i340"> <i>N</i>-(1-(5-Cyano-1<i>H</i>-pyrazol-3-yl)ethyl)-3-methyl-4-(1-(6-(trifluoromethyl) pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>87</b>)</h5><div class="NLM_p last"><b>87</b> was prepared as for <b>86</b> above to afford the product (retention time: 3.51) as a white solid (24%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.87 (s, 1H), 11.09 (s, 1H), 8.40 (s, 1H), 7.84 (d, 1H, <i>J</i> = 8.0 Hz), 7.73 (d, 1H, <i>J</i> = 8.0 Hz), 7.63 (d 1H), 6.93 (s, 1H), 6.84 (s, 1H), 5.20–5.23 (m, 1H), 2.09 (s, 3H), 1.47 (d, 3H, <i>J</i> = 6.7 Hz), 1.40 (brs, 2H), 1.24 (brs, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 428.9; HPLC purity: 99.57%, SFC purity: 99.29%.</div></div><div id="sec76_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i341" class="anchor-spacer"></div><h5 class="article-section__title" id="_i341"> <i>N</i>-Methyl-3-(1-(3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl) cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamido)ethyl)-1<i>H</i>-pyrazole-5-carboxamide Enantiomer I (<b>90</b>)</h5><div class="NLM_p last">Methylamine (1.0 M in THF) (0.5 mL, 0.51 mmol) was added to a stirred solution of <b>256</b> (200 mg, 0.42 mmol) in THF (4 mL) at RT. Then, Me<sub>3</sub>Al (1.0 M in toluene) (0.8 mL, 0.82 mmol) was added to the reaction mixture and stirred at 100 °C for 2 h in a microwave. The resulting reaction mixture was quenched with 1.5 N HCl solution and extracted with ethyl acetate (2 × 40 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The resulting concentrated product was purified by column chromatography using 10–50% ethyl acetate in petroleum ether to afford the racemic product as a white solid (0.11 g, 57%). The racemic product was resolved by SFC purification using a YMC Amylose-SA column and 0.5% isopropylamine in IPA cosolvent (30%) to afford the title compound (retention time: 3.03) as a white solid (32%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.36 (s, 1H), 7.68 (s, 2H), 6.92 (s, 1H), 6.69 (s, 1H), 5.34 (m, 1H), 2.90 (s, 3H), 2.20 (s, 3H), 1.62 (d, 3H,), 1.37–1.45 (m, 4H); ESIMS <i>m</i>/<i>z</i> (M + 1): 461.2; HPLC purity: 97.78%; SFC purity: 100%.</div></div><div id="sec76_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i342" class="anchor-spacer"></div><h5 class="article-section__title" id="_i342"> <i>N</i>-Methyl-3-(1-(3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl) cyclopropyl)-1<i>H</i>-pyrrole-2-carboxamido)ethyl)-1<i>H</i>-pyrazole-5-carboxamide Enantiomer II (<b>91</b>)</h5><div class="NLM_p last"><b>91</b> was prepared as for <b>90</b> above to afford the product (retention time: 4.33) as a white solid (29%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.36 (s, 1H), 7.68 (s, 2H), 6.92 (s, 1H), 6.69 (s, 1H), 5.35 (m, 1H), 2.90 (s, 3H), 2.20 (s, 3H), 1.62 (d, 3H,), 1.37–1.45 (m, 4H); ESIMS <i>m</i>/<i>z</i> (M + 1): 461.2; HPLC purity: 95.88%; SFC purity: 100%.</div></div><div id="sec76_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i343" class="anchor-spacer"></div><h5 class="article-section__title" id="_i343"> 4-(1-[3-Cyano-4-(trifluoromethyl)phenyl]cyclopropyl)-3-methyl-<i>N</i>-[1-(1<i>H</i>-1,2,4-triazol-3-yl)ethyl]-1<i>H</i>-pyrrole-2-carboxamide (<b>98</b>)</h5><div class="NLM_p last">Potassium cyanide (1.16 g, 17.81 mmol) was added to a stirred solution of racemic <b>94</b> (3.0 g, 7.13 mmol) in DMSO (20 mL) at RT. Then, the reaction mixture was stirred for 20 h at 130 °C. The starting material was not all consumed but continuation of heating lead to side product formation. Therefore, the reaction mixture was quenched with water (200 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The resulting concentrated product was purified by preparative HPLC to afford the product as a white solid (550 mg, 18%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.34 (brs, 1H), 7.71 (d, 1H, <i>J</i> = 8.4 Hz), 7.54 (s, 1H), 7.47 (d, 1H, <i>J</i> = 8.4 Hz), 6.89 (s, 1H), 5.35–5.37 (m, 1H), 2.19 (s, 3H), 1.61 (d, 3H, <i>J</i> = 6.8 Hz), 1.41–1.42 (m, 2H), 1.34–1.36 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 429.2; LCMS: 97.67%; HPLC purity: 97.55%.</div></div><div id="sec76_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i344" class="anchor-spacer"></div><h5 class="article-section__title" id="_i344"> 4-(1-[3-Cyano-4-(trifluoromethyl)phenyl]cyclopropyl)-3-methyl-<i>N</i>-[1-(1<i>H</i>-1,2,4-triazol-3-yl)ethyl]-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>99</b>)</h5><div class="NLM_p last"><b>98</b> was resolved by SFC purification using a Lux A1 column and IPA cosolvent (30%) to afford the product (retention time: 1.70) as an off-white solid (40%). Mp 135–140 °C. Optical rotation (ethanol): −12.797. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.28 (brs, 1H), 7.75 (d, 1H, <i>J</i> = 8.4 Hz), 7.57 (s, 1H), 7.49–7.51 (d, 1H, <i>J</i> = 8.4 Hz), 6.92 (s, 1H), 5.36–5.41 (m, 1H), 2.18 (s, 3H), 1.64 (d, 3H, <i>J</i> = 6.8 Hz), 1.43–1.45 (m, 2H), 1.37–1.40 (m, 2H); ESIMS (<i>m</i>/<i>z</i>) (M + 1): 429.1; HPLC purity: 99.92; SFC purity: 100%.</div></div><div id="sec76_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i345" class="anchor-spacer"></div><h5 class="article-section__title" id="_i345"> 4-(1-[3-Cyano-4-(trifluoromethyl)phenyl]cyclopropyl)-3-methyl-<i>N</i>-[1-(1<i>H</i>-1,2,4-triazol-3-yl)ethyl]-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>100</b>)</h5><div class="NLM_p last">The title compound was prepared as for <b>99</b> above (retention time: 3.15) as an off-white solid (35%). Optical rotation (ethanol): 14.396. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 8.28 (brs, 1H), 7.75 (d, 1H, <i>J</i> = 8.4 Hz), 7.57 (s, 1H), 7.49–7.51 (d, 1H, <i>J</i> = 8.4 Hz), 6.92 (s, 1H), 5.38 (m, 1H), 2.19 (s, 3H), 1.64 (d, 3H, <i>J</i> = 6.8 Hz), 1.43–1.46 (m, 2H), 1.37–1.40 (m, 2H); ESIMS (<i>m</i>/<i>z)</i>: 429.1; HPLC purity: 99.38%; SFC purity: 100%.</div></div><div id="sec76_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i346" class="anchor-spacer"></div><h5 class="article-section__title" id="_i346"> N2-Cyclopropyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2,3-dicarboxamide (<b>105</b>)</h5><div class="NLM_p last">1,1′-Carbonyldiimidazole (44 mg, 0.27 mmol) was added to a stirred solution of <b>261</b> (80 mg, 0.23 mmol) in acetonitrile (3 mL) at RT and stirred at 80 °C for 2 h. Then, NH4OH solution was added at RT and stirred for 4 h at 80 °C. The reaction mixture was concentrated and acidified with 1.5 N HCl solution. The solid obtained was filtered, washed with water, and dried to afford the product as an off-white solid (60 mg, 76%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.72 (s, 1H), 9.50 (s, 1H), 8.58 (s, 1H), 8.01 (s, 1H), 7.76–7.81 (m, 2H), 7.51 (s, 1H), 6.68 (s, 1H), 4.14 (s, 2H), 2.69–2.74 (m, 1H), 0.70–0.72 (m, 2H), 0.42–0.44 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 352.8.</div></div><div id="sec76_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i347" class="anchor-spacer"></div><h5 class="article-section__title" id="_i347"> 3-Cyano-<i>N</i>-cyclopropyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>106</b>)</h5><div class="NLM_p last">POCl<sub>3</sub> (22 mg, 0.15 mmol) was added to a stirred solution of <b>105</b> (35 mg, 0.10 mmol) in acetonitrile (2 mL) and pyridine (15 mg, 0.20 mmol) at RT and heated to 80 °C for 2 h. The reaction mixture was cooled to RT, then acidified with 1.5 N HCl solution, and extracted with ethyl acetate (2 × 15 mL). The combined organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The resulting concentrated product was purified by column chromatography using 5–60% ethyl acetate in petroleum ether to afford the product as an off-white solid (12 mg, 36%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 9.85 (s, 1H), 8.64 (s, 1H), 7.75 (d, 1H, <i>J</i> = 8.0 Hz), 7.66 (d, 1H, <i>J</i> = 8.0 Hz), 6.74 (s, 1H), 6.52 (s, 1H), 4.04 (s, 2H), 2.89–2.92 (m, 1H), 0.90–0.94 (m, 2H), 0.67–0.71 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 334.8; LCMS: 99.31%; HPLC purity: 97.91%.</div></div><div id="sec76_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i348" class="anchor-spacer"></div><h5 class="article-section__title" id="_i348"> 5-Chloro-<i>N</i>-cyclopropyl-3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxamide (<b>119</b>)</h5><div class="NLM_p last"><i>N</i>-Chlorosuccinamide (20 mg, 0.15 mmol) was added to a stirred solution of <b>268</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (50 mg, 015 mmol) in DMF (2 mL) at room temperature and stirring was continued for 4 h. The reaction mixture was poured into water and extracted with ethyl acetate (2 × 30 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The resulting concentrated product was purified by column chromatography using 10–50% ethyl acetate in petroleum ether to afford the product as an off-white solid (25 mg, 45%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.71 (s, 1H), 8.60 (s, 1H), 7.81 (d, 1H, <i>J</i> = 8.2 Hz), 7.72 (d, 1H, <i>J</i> = 8.2 Hz), 7.49 (s, 1H), 3.85 (s, 2H), 2.71–2.73 (m, 1H), 2.12 (s, 3H), 0.65–0.68 (m, 2H), 0.43–0.47 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M + 1): 358.1; LCMS: 96.84%; HPLC purity: 99.78%.</div></div><div id="sec76_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i349" class="anchor-spacer"></div><h5 class="article-section__title" id="_i349"> 3-(1-(3-Methyl-4-(6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-1<i>H</i>-pyrrole-2-carboxamido)ethyl)-1<i>H</i>-pyrazole-5-carboxamide (<b>138</b>)</h5><div class="NLM_p last">Aqueous ammonia (10 mL) was added to a stirred solution of <b>279</b> (0.52 g, 1.10 mmol) in methanol (3 mL) and heated to 100 °C for 24 h. The reaction mixture was concentrated and purified by preparative HPLC to afford the title compound as an off-white solid (25%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.97 (d, 1H, <i>J</i> = 8.8 Hz), 7.89 (s, 1H), 7.41 (d, 1H, <i>J</i> = 8.8 Hz), 7.33 (s, 1H), 6.79 (s, 1H), 5.39–5.41 (m, 1H), 2.52 (s, 3H), 1.67 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS; <i>m</i>/<i>z</i> (M + 1): 446.9; LCMS: 97.36%; HPLC purity: 93.862%.</div></div><div id="sec76_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i350" class="anchor-spacer"></div><h5 class="article-section__title" id="_i350"> <i>N</i>-(1-(5-Cyano-1<i>H</i>-pyrazol-3-yl)ethyl)-3-methyl-4-(6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>139</b>)</h5><div class="NLM_p last">To a stirred solution of <b>138</b> (120 mg, 0.27 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added DIPEA (0.25 mL, 1.08 mmol) followed by T3P (50 wt % in ethyl acetate) (0.35 mL, 0.54 mmol). The reaction mixture was stirred for 2 h at RT. After completion of the reaction (monitored by TLC), water was added and the reaction mixture extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 40 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The resulting concentrated product was purified by column chromatography using 30–80% ethyl acetate in petroleum ether to afford the racemic product as an off-white solid (52%). The racemic product was resolved by SFC purification using a Chiralcel OJ-H column and methanol cosolvent (30%) to afford the title compound (retention time 3.02) as a white solid (26%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.97 (d, 1H, <i>J</i> = 8.4 Hz), 7.89 (s, 1H), 7.41 (d, 1H, <i>J</i> = 8.4 Hz), 7.34 (s, 1H), 6.81 (s, 1H), 5.39–5.44 (q, 1H, <i>J</i> = 6.8 Hz), 2.52 (s, 3H), 1.67 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS; <i>m</i>/<i>z</i> (M + 1): 428.2; HPLC purity: 99.05%; SFC purity: 100%.</div></div><div id="sec76_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i351" class="anchor-spacer"></div><h5 class="article-section__title" id="_i351"> <i>N</i>-(1-(5-Cyano-1<i>H</i>-pyrazol-3-yl)ethyl)-3-methyl-4-(6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>140</b>)</h5><div class="NLM_p last"><b>140</b> was prepared as for <b>139</b> above (retention time 3.74) as a white solid (23%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.97 (d, 1H, <i>J</i> = 8.4 Hz), 7.89 (s, 1H), 7.41 (d, 1H, <i>J</i> = 8.4 Hz), 7.34 (s, 1H), 6.81 (s, 1H), 5.40–5.44 (q, 1H, <i>J</i> = 6.8 Hz), 2.52 (s, 3H), 1.67 (d, 3H, <i>J</i> = 6.8 Hz); ESIMS; <i>m</i>/<i>z</i> (M + 1): 428.1; HPLC purity: 99.22%; SFC purity: 97.91%.</div></div><div id="sec76_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i352" class="anchor-spacer"></div><h5 class="article-section__title" id="_i352"> 3-Methyl-4-(1-methyl-6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-<i>N</i>-(1-(5-methylisoxazol-3-yl) ethyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>145</b>)</h5><div class="NLM_p last">1-(5-Methylisoxazol-3-yl)ethan-1-amine and <b>277</b> were reacted together using general procedure F1 to produce 4-(2-fluoro-4-(trifluoromethyl)benzoyl)-3-methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-1<i>H</i>-pyrrole-2-carboxamide as an off-white solid (60%). The intermediate carboxamide (100 mg, 0.24 mmol) was used directly and treated with methyl hydrazine (0.2 mL) with stirring in DMSO (1 mL) at RT and then heated to 100 °C for 2 h. After consumption of the starting material, the reaction mixture was poured into water and stirred for 10 min. The solid obtained was filtered, washed with water, and dried to afford the racemic product (69%). The racemic product was resolved by SFC purification using a Lux A1 column and IPA cosolvent (40%) to afford the title compound (retention time 4.30) as an off-white solid (24%). <sup>1</sup>H NMR (400 MHz, MeOD) δ (ppm): 7.94–7.96 (m, 2H), 7.40–7.43 (d, 1H, <i>J</i> = 8.0 Hz), 7.33 (s, 1H), 6.19 (s, 1H), 5.31–5.36 (q, 1H, <i>J</i> = 7.0 Hz), 4.17 (s, 3H), 2.52 (s, 3H), 2.42 (s, 3H), 1.62 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 432.2; HPLC purity: 99.23%; SFC purity: 99.69%.</div></div><div id="sec76_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i353" class="anchor-spacer"></div><h5 class="article-section__title" id="_i353"> 3-Methyl-4-(1-methyl-6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-<i>N</i>-(1-(5-methylisoxazol-3-yl) ethyl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>146</b>)</h5><div class="NLM_p last"><b>146</b> was prepared as for <b>145</b> above (retention time 5.81) as an off-white solid (20%). <sup>1</sup>H NMR (400 MHz, MeOD) δ (ppm): 7.94–7.96 (m, 2H), 7.40–7.43 (d, 1H, <i>J</i> = 8.0 Hz), 7.32 (s, 1H), 6.19 (s, 1H), 5.31–5.36 (q, 1H, <i>J</i> = 7.0 Hz), 4.17 (s, 3H), 2.52 (s, 3H), 2.42 (s, 3H), 1.62 (d, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 432.2; HPLC purity: 98.16%; SFC purity: 98.60%.</div></div><div id="sec76_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i354" class="anchor-spacer"></div><h5 class="article-section__title" id="_i354"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(6-(trifluoromethyl)benzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer I (<b>147</b>)</h5><div class="NLM_p last">The intermediate carboxamide described in <b>145</b> above (0.2 g, 0.47 mmol) was treated with NH<sub>2</sub>OH·HCl (0.13 g, 1.89 mmol) in pyridine (2 mL) at RT and then heated to 100 °C for 16 h. The resulting reaction mixture was concentrated, 1.5 N HCl was added (10 mL), and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 40 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The resulting concentrated product was purified by column chromatography using 10–50% ethyl acetate in petroleum ether to afford 4-((2-fluoro-4-(trifluoromethyl)phenyl)(hydroxyimino)methyl)-3-methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-1<i>H</i>-pyrrole-2-carboxamide as an off-white solid (0.15 g, 63%). NaOMe (40 mg, 060 mmol) was added to a stirred solution of the intermediate hydroxyimino compound (0.13 g, 0.30 mmol) in THF (4 mL) at RT and heated to 60 °C for 6 h. The resulting reaction mixture was concentrated, water was added (5 mL), and the mixture was extracted with dichloromethane (2 × 40 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The resulting concentrated product was purified by column chromatography using 10–50% ethyl acetate in petroleum ether to afford the racemic product (80 mg, 56%) as an off-white solid. The racemic product was resolved by SFC purification using a Chiralcel OZ-H column and methanol cosolvent (30%) to afford the title compound (retention time 3.0) as an off-white solid (21%). <sup>1</sup>H NMR (400 MHz, MeOD) δ (ppm): 8.17–8.19 (d, 1H), 8.07 (s, 1H), 7.71–7.73 (d, 1H) 7.67(s, 1H), 6.21 (s, 1H), 5.32–5.38 (m, 1H), 2.62 (s, 3H), 2.44 (s, 3H), 1.63 (d, 3H); ESIMS (M + 1) <i>m</i>/<i>z</i>: 419.0; HPLC purity: 98.34%; SFC purity: 99.48%.</div></div><div id="sec76_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i355" class="anchor-spacer"></div><h5 class="article-section__title" id="_i355"> 3-Methyl-<i>N</i>-(1-(5-methylisoxazol-3-yl)ethyl)-4-(6-(trifluoromethyl)benzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-pyrrole-2-carboxamide Enantiomer II (<b>148</b>)</h5><div class="NLM_p last"><b>148</b> was prepared as for <b>147</b> above (retention time 3.44) as an off-white solid (20%). <sup>1</sup>H NMR (400 MHz, MeOD) δ (ppm): 8.17–8.19 (d, 1H), 8.07 (s, 1H), 7.71–7.73 (d, 1H) 7.67(s, 1H), 6.21 (s, 1H), 5.32–5.38 (m, 1H), 2.62 (s, 3H), 2.44 (s, 3H), 1.63 (d, 3H); ESIMS (M + 1) <i>m</i>/<i>z</i>: 419.1; HPLC purity: 96.51%; SFC purity: 99.24%.</div></div><div id="sec76_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i356" class="anchor-spacer"></div><h5 class="article-section__title" id="_i356"> 2-Hydroxy-<i>N</i>-methoxy-<i>N</i>-methyl-4-(trifluoromethyl)benzamide (<b>184</b>)</h5><div class="NLM_p last">1,1′-Carbonyldiimidazole (7.65 g, 54.51 mmol) was added to a stirred solution of 2-hydroxy-4-(trifluoromethyl)benzoic acid (10.0 g, 45.42 mmol) in DMF (50 mL) at RT and stirring continued for 1 h. Then, <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (11.13 g, 113.56 mmol) was added to the reaction mixture at RT and stirring was continued for 4 h. The reaction mixture was poured into water and extracted with ethyl acetate (2 × 300 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The concentrated product was purified by flash chromatography (silica gel, eluting with hexane:EtOAc mixtures from 100 to 70:30%) to yield the product as a yellow liquid (8.0 g, 71%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ (ppm): 11.31 (s, 1H), 8.12 (d, 1H, <i>J</i> = 8.4 Hz), 7.27–7.28 (m, 1H), 7.10–7.12 (dd, 1H, <i>J</i> = 0.8 Hz & 8.4 Hz), 3.67 (s, 3H), 3.45 (s, 3H). ESIMS <i>m</i>/<i>z</i> (M + 1): 250.1.</div></div><div id="sec76_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i357" class="anchor-spacer"></div><h5 class="article-section__title" id="_i357"> 1-(2-Hydroxy-4-(trifluoromethyl)phenyl)but-2-yn-1-one (<b>185</b>)</h5><div class="NLM_p last">1-Propynylmagnesium bromide (0.5 M in THF) (71 mL, 35.30 mmol) was added to <b>184</b> (8 g, 32.10 mmol) in THF (150 mL) at 0 °C and stirred for 4 h at RT. The reaction mixture was quenched with 1.5 N HCl solution and extracted with ethyl acetate (2 × 300 mL). The resulting organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford the product as a colorless liquid (4 g, 55%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ (ppm): 11.75 (s, 1H), 8.16 (d, 1H, <i>J</i> = 8.4 Hz), 7.26 (d, 1H, <i>J</i> = 8.4 Hz), 7.19 (d, 1H), 2.24 (s, 3H). ESIMS <i>m</i>/<i>z</i> (M + 1): 229.1.</div></div><div id="sec76_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i358" class="anchor-spacer"></div><h5 class="article-section__title" id="_i358"> 1-(2-Hydroxy-3-nitro-4-(trifluoromethyl)phenyl)but-2-yn-1-one (<b>186</b>)</h5><div class="NLM_p last">Conc·HNO<sub>3</sub> (4 mL) was added to a stirred solution of <b>185</b> (4 g, 17.53 mmol) in acetic acid (20 mL) at 0 °C. Then, conc·H<sub>2</sub>SO<sub>4</sub> (4 mL) was added slowly at 0 °C and the reaction mixture was stirred for 4 h at 0 °C. After completion of the reaction (monitored by TLC), the reaction mixture was poured into ice cold water and extracted with ethyl acetate (2 × 100 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The concentrated product was purified by flash chromatography (silica gel, eluting with hexane:EtOAc mixtures from 100 to 70:30%) to afford the product as a yellow solid (1.5 g, 31%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ (ppm): 12.20 (s, 1H), 8.29 (d, 1H, <i>J</i> = 8.4 Hz), 7.32 (d, 1H, <i>J</i> = 8.2 Hz), 2.29 (s, 3H). ESIMS <i>m</i>/<i>z</i> (M – 1): 272.2.</div></div><div id="sec76_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i359" class="anchor-spacer"></div><h5 class="article-section__title" id="_i359"> Methyl 2-(Cyclopropylcarbamoyl)-4-(6-(trifluoromethyl)pyridine-3-carbonyl)-1<i>H</i>-pyrrole-3-carboxylate (<b>260</b>)</h5><div class="NLM_p last">Sodium chlorite (0.31 g, 3.42 mmol) was added to a stirred solution of <b>259</b> (0.8 g, 2.27 mmol) and sulfamic acid (0.3 g, 3.42 mmol) in methanol (5 mL) and water (2 mL) at 0 °C and stirring continued for 2 h at RT. Water was added to the reaction mixture and extracted with ethyl acetate (2 × 30 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. SOCl2 (0.3 mL, 3.41 mmol) was added to a stirred solution of the concentrated product in methanol (10 mL) at 0 °C and stirring continued for 16 h at RT. The resulting reaction mixture was concentrated, dissolved in ethyl acetate (20 mL), washed with 10% NaHCO<sub>3</sub> solution, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. The resulting concentrated product was purified by column chromatography using 5–30% ethyl acetate in petroleum ether to afford the product as an off-white solid (0.30 g, 35%). ESIMS <i>m</i>/<i>z</i> (M + 1): 382.2. The product was used without further characterization.</div></div><div id="sec76_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i360" class="anchor-spacer"></div><h5 class="article-section__title" id="_i360"> Ethyl 3-Bromo-5-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>264</b>)</h5><div class="NLM_p last"><i>N</i>-Bromosuccinimide (NBS, 0.52 g, 2.89 mmol) was added to a stirred solution of <b>263</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (0.9 g, 2.89 mmol) in DMF (10 mL) at 0 °C and stirred at RT for 2 h. The resulting reaction mixture was concentrated and quenched with water (10 mL) and stirred for 10 min. The solid obtained was filtered, washed with water, and dried to afford the product as an off-white solid (0.8 g, 71%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.99 (s, 1H), 8.60 (s, 1H), 7.79 (d, 1H, <i>J</i> = 8.0 Hz), 7.72 (d, 1H, <i>J</i> = 8.0 Hz), 4.22 (q, 2H, <i>J</i> = 7.0 Hz), 3.87 (s, 2H), 2.20 (s, 3H), 1.27 (t, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M, M + 2): 390.8, 391.8.</div></div><div id="sec76_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i361" class="anchor-spacer"></div><h5 class="article-section__title" id="_i361"> Ethyl 3-Cyano-5-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxylate (<b>265</b>)</h5><div class="NLM_p last">CuCN (0.52 g, 2.89 mmol) was added to a stirred solution of <b>264</b> (0.8 g, 2.05 mmol) in DMF (10 mL) at RT and stirred at 130 °C for 16 h. Water (20 mL) was added to reaction mixture and extracted with ethyl acetate (2 × 50 mL). The resulting combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The resulting concentrated product was purified by column chromatography using 10–50% ethyl acetate in petroleum ether to afford the product as an off-white solid (0.5 g, 72%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.66 (s, 1H), 8.63 (s, 1H), 7.77–7.83 (m, 2H), 4.27 (q, 2H, <i>J</i> = 7.0 Hz), 3.99 (s, 2H), 2.21 (s, 3H), 1.88 (t, 3H, <i>J</i> = 7.0 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 338.0; LCMS: 96.04%; HPLC purity: 97.66%.</div></div><div id="sec76_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i362" class="anchor-spacer"></div><h5 class="article-section__title" id="_i362"> 5-Chloro-3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>266</b>)</h5><div class="NLM_p last"><i>N</i>-Chlorosuccinimide (NCS, 0.23 g, 1.27 mmol) was added to a stirred solution of <b>181</b> (300 mg, 1.05 mmol) in DMF (2 mL) at RT and stirred for 16 h. The reaction mixture was poured into water and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 10 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The crude product was purified by preparative HPLC to afford as a white solid (0.16 g, 48%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.41 (s, 1H), 12.25 (s, 1H), 8.61 (s, 1H), 7.81 (d, 1H, <i>J</i> = 8.0 Hz), 7.30 (d, 1H, <i>J</i> = 8.0 Hz), 3.87 (s, 2H), 2.09 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M): 319.3</div></div><div id="sec76_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i363" class="anchor-spacer"></div><h5 class="article-section__title" id="_i363"> 5-Chloro-3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1<i>H</i>-pyrrole-2-carboxylic Acid (<b>267</b>)</h5><div class="NLM_p last">NCS (0.23 g, 1.36 mmol) was added to a stirred solution of <b>251</b> (350 mg, 1.13 mmol) in DMF (3 mL) at RT and stirred for 6 h. The reaction mixture was poured into water and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 30 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The crude product was purified by preparative HPLC to afford the product as a white solid (0.13 g, 34%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 12.42 (s, 1H), 12.28 (s, 1H), 8.63 (s, 1H), 7.83 (d, 1H, <i>J</i> = 8.0 Hz), 7.35 (d, 1H, <i>J</i> = 8.0 Hz), 2.12 (s, 3H), 1.50–1.59 (m, 2H), 1.40–1.49 (m, 2H); ESIMS <i>m</i>/<i>z</i> (M): 345.3.</div></div><div id="sec76_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i364" class="anchor-spacer"></div><h5 class="article-section__title" id="_i364"> (<i>E</i>)-3-(2-Nitroprop-1-en-1-yl)-6-(trifluoromethyl)-1<i>H</i>-pyrrolo [2,3-b]pyridine (<b>269</b>)</h5><div class="NLM_p last">Ammonium acetate (3.20 g, 42.03 mmol) was added to a stirred solution of 6-(trifluoromethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-3-carbaldehyde (3.0 g, 14.01 mmol) in nitroethane (20 mL) at RT and stirred for 1 h at 100 °C. The reaction mixture was poured into ice water (100 mL) and extracted with ethyl acetate (2 × 100 mL). The combined organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The resulting concentrated product was purified by column chromatography using 0–50% ethyl acetate in petroleum ether to afford the product as a yellow solid (3.0 g, 79%). ESIMS <i>m</i>/<i>z</i> (M + 1): 272.2. The product was used without further characterization.</div></div><div id="sec76_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i365" class="anchor-spacer"></div><h5 class="article-section__title" id="_i365"> 1-(6-(Trifluoromethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)propan-2-one (<b>270</b>)</h5><div class="NLM_p last">Iron powder (3.1 g, 55.35 mmol) was added to a stirred solution of <b>269</b> (3.0 g, 11.07 mmol) in acetone (40 mL) at RT and heated to 50 °C with stirring. Then, 4 N HCl solution (20 mL) was added dropwise at the same temperature and stirred for 3 h. The reaction mixture was concentrated under reduced pressure, 4 N HCl solution (30 mL) was poured onto the residue and the mixture extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 100 mL). The combined organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The concentrated product was purified by column chromatography using 0–40% ethyl acetate in petroleum ether to afford the product as an off-white solid (1.5 g, 56%). ESIMS <i>m</i>/<i>z</i> (M + 1): 243.2. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ (ppm): 11.26 (brs, 1H), 8.10 (d, 1H, <i>J</i> = 8.1 Hz), 7.55–7.57 (m, 2H), 3.92 (s, 2H), 2.26 (s, 3H); ESIMS <i>m</i>/<i>z</i> (M + 1): 243.6.</div></div><div id="sec76_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i366" class="anchor-spacer"></div><h5 class="article-section__title" id="_i366"> Ethyl 3-Methyl-4-(6-(trifluoromethyl)-1<i>H</i>-indol-3-yl)-pyrrole-2-carboxylate (<b>271</b>)</h5><div class="NLM_p last"><i>N</i>,<i>N</i>-Dimethylformamide dimethyl acetal (4.0 mL) was added to 1-(6-(trifluoromethyl)-1<i>H</i>-indol-3-yl)propan-2-one (commercial) (0.8 g, 3.31 mmol) and heated to 120 °C in a microwave for 1 h. The reaction mixture was concentrated under reduced pressure to afford (4-dimethylamino)-3-(6-(trifluoromethyl)-1<i>H</i>-indol-3-yl)but-3-en-2-one (1.0 g crude) as a gummy solid that was used directly. To a stirred solution of the intermediate but-en-one (1.0 g, 3.39 mmol) in acetic acid (20 mL) were added ethyl-2-(hydroxyimino)3-oxobutanoate (0.538 g, 3.39 mmol), sodium acetate (0.833 g, 10.16 mmol), and zinc (1.10 g, 16.93 mmol). The reaction mixture was heated to 100 °C for 3 h. The reaction mixture was then concentrated under reduced pressure, the residue was poured into saturated NaHCO<sub>3</sub> solution, and extracted with ethyl acetate (2 × 100 mL). The combined organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The resulting concentrated product was purified by column chromatography using 0–40% ethyl acetate in petroleum ether to afford the product as a pale yellow solid (0.7 g, 62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.68 (s, 1H), 11.61 (s, 1H), 7.71–7.76 (m, 2H); 7.61 (s, 1H), 7.32 (d, 1H, <i>J</i> = 8.4 Hz), 7.14 (d, 1H, <i>J</i> = 2.0 Hz), 4.28 (q, 2H, <i>J</i> = 6.8 Hz), 2.34 (s, 3H), 1.33 (t, 3H, <i>J</i> = 6.8 Hz); ESIMS <i>m</i>/<i>z</i> (M + 1): 337.0; LCMS: 98.58%; HPLC purity: 98.76%.</div></div><div id="sec76_51" class="NLM_sec NLM_sec_level_4"><div id="ac_i367" class="anchor-spacer"></div><h5 class="article-section__title" id="_i367"> Ethyl 4-(6-Fluoro-1<i>H</i>-indol-3-yl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylate (<b>272</b>)</h5><div class="NLM_p last"><i>N</i>,<i>N</i>-Dimethylformamide dimethyl acetal (5.0 mL) was added to 1-(6-fluoro-1<i>H</i>-indol-3-yl)propan-2-one (commercial) (1.0 g, 5.23 mmol) and heated to 120 °C in a microwave for 1 h. The reaction mixture was concentrated under reduced pressure to afford 4-(dimethylamino)-3-(6-fluoro-1<i>H</i>-indol-3-yl)but-3-en-2-one (1.1 g) as a gummy solid that was used directly. To a stirred solution of intermediate but-en-one (1.1 g, 4.47 mmol) in acetic acid (15 mL) were added ethyl-2-(hydroxyimino)3-oxobutanoate (0.538 g, 4.47 mmol), sodium acetate (1.1 g, 13.41 mmol), and zinc (1.46 g, 22.36 mmol). The reaction mixture was heated to 100 °C for 3 h. The reaction mixture was then concentrated under reduced pressure, the residue was poured into saturated NaHCO<sub>3</sub> solution, and extracted with ethyl acetate (2 × 100 mL). The combined organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The resulting concentrated product was purified by column chromatography using 0–40% ethyl acetate in petroleum ether to afford the product as a pale yellow solid (26%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 11.61 (s, 1H), 11.20 (s, 1H), 7.48–7.53 (m, 1H); 7.33 (s, 1H), 7.15–7.20 (m, 1H), 7.10 (s, 1H), 6.87–6.90 (m, 1H), 4.28 (q, 2H, <i>J</i> = 7.2 Hz), 2.33 (s, 3H), 1.32 (t, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i>: 287.2; LCMS: 99.09%; HPLC purity: 97.03%.</div></div><div id="sec76_52" class="NLM_sec NLM_sec_level_4"><div id="ac_i368" class="anchor-spacer"></div><h5 class="article-section__title" id="_i368"> Ethyl 3-Methyl-4-(6-(trifluoromethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxylate (<b>273</b>)</h5><div class="NLM_p last"><i>N</i>,<i>N</i>-Dimethylformamide dimethyl acetal (5.0 mL) was added to <b>270</b> (1.50 g, 6.20 mmol) and heated to 120 °C in a microwave for 1 h. The reaction mixture was concentrated under reduced pressure to afford (<i>Z</i>)-4-(dimethylamino)-3-(6-(trifluoromethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>] pyridin-3-yl)but-3-en-2-one (1.85 g, 100%) as a gummy solid. ESIMS <i>m</i>/<i>z</i> (M + 1): 298.2. The product was used without further purification. To a stirred solution of intermediate but-en-one (1.85 g, 6.20 mmol) in acetic acid (20 mL) were added ethyl-2-(hydroxyimino)3-oxobutanoate (0.96 g, 6.20 mmol), sodium acetate (1.50 g, 18.6 mmol), and zinc (2.0 g, 31.0 mmol). The reaction mixture was heated to 100 °C for 3 h. The reaction mixture was then concentrated under reduced pressure, residue was then poured into saturated NaHCO<sub>3</sub> solution, and extracted with ethyl acetate (2 × 200 mL). The combined organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The resulting concentrated product was purified by column chromatography using 0–40% ethyl acetate in petroleum ether to afford the product as a pale yellow solid (0.5 g, 29%). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ (ppm): 8.15 (d, 1H, <i>J</i> = 8.0 Hz); 7.59 (s, 1H), 7.52 (d, 1H, <i>J</i> = 8.0 Hz), 7.14 (s, 1H), 4.35 (q, 2H, <i>J</i> = 7.2 Hz), 2.41 (s, 3H), 1.41 (t, 3H, <i>J</i> = 7.2 Hz); ESIMS <i>m</i>/<i>z</i>: 337.9; LCMS: 98.79%; HPLC purity: 96.69%.</div></div><div id="sec76_53" class="NLM_sec NLM_sec_level_4"><div id="ac_i369" class="anchor-spacer"></div><h5 class="article-section__title" id="_i369"> 3-Methyl-4-(6-(trifluoromethyl)-1<i>H</i>-indazol-3-yl)-1<i>H</i>-pyrrole-2-carboxylic acid (<b>278</b>)</h5><div class="NLM_p last">NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (1.5 mL, 2 vol) was added to a stirred solution of <b>277</b> (0.75 g, 0.21 mmol) in DMSO (4 mL) and the reaction mixture heated to 100 °C for 1 h. After consumption of the starting material, the reaction mixture was poured into water and acidified with 1.5 N HCl solution. The solid obtained was filtered, washed with water, and dried to afford the product as a white solid (0.6 g, 82%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm): 13.38 (s, 1H), 12.36 (brs, 1H), 11.79 (s, 1H), 8.07 (d, 1H, <i>J</i> = 8.4 Hz), 7.91 (s, 1H), 7.43 (s, 1H), 7.40 (d, 1H, <i>J</i> = 8.4 Hz), 2.52 (s, 3H); ESIMS; <i>m</i>/<i>z</i> (M – 1): 308.0; LCMS: 96.01%; HPLC purity: 92.79%.</div></div><div id="sec76_54" class="NLM_sec NLM_sec_level_4"><div id="ac_i370" class="anchor-spacer"></div><h5 class="article-section__title" id="_i370"> Ethyl 3-Methyl-4-(6-(trifluoromethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrrole-2-carboxylate (<b>282</b>)</h5><div class="NLM_p last">NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (1.6 mL, 2 vol) was added to a stirred solution of <b>281</b> (800 mg, 1.98 mmol) in DMSO (4 mL) was heated to 80 °C for 30 min. After completion of the starting material, the reaction mixture was poured into water and stirred for 10 min. The solid obtained was filtered, washed with water, and dried to afford the product as an off-white solid (500 mg, 75%). ESIMS <i><i>m</i></i>/<i><i>z</i></i> (M + 1): 339.3. The product was used without further characterization.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i371"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00173" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33323" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33323" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00173?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00173</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Supporting information methods; supporting information Schemes S1–S10; FEP+ predictions for previously reported<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Pyrrole-based DHODH inhibitors (Table S1); FEP+ predictions for compounds reported in this publication (Table S2); X-ray data collection and refinement statistics for the structures of PfDHODH bound to select pyrroles (Table S3); <i>In vitro</i> metabolism and kinetic solubility data (Table S4A); Caco-2 permeability studies for carboxamide pyrazoles <b>47</b> and <b>84</b> (Table S4B); mouse PK data after (IV) and oral (PO) dosing for <b>84</b>, <b>88</b>, and <b>154</b> (Table S5); species selectivity and preliminary safety analysis (Table S6); summary of <i>P. falciparum</i> EC<sub>50</sub> values on Dd2 wild-type and DHODH inhibitor (<b>1</b> and <b>26</b>) selected resistant cell lines (Table S7A); steady-state kinetic analysis of recombinant C276F and C276Y mutant <i>Pf</i>DHODH versus <b>26</b> and <b>79</b> (Table S7B); EC<sub>50</sub> determination of 79-resistant Dd2 and 3D7 parasites (Table S8A); list of genes included in the CNV region of <b>79</b> Dd2-resistant parasites (Table S8B); list of genes included in the CNV region of <b>79</b> 3D7-resistant parasites (Table S8C); metrics of whole-genome sequencing of <b>79</b>-resistant parasites and their parental lines (Table S8D); SCID mouse efficacy studies on <b>33</b> and <b>36</b> (conducted at Swiss TPH) (Table S9); SCID mouse efficacy studies on <b>1, 79</b> and <b>99</b> (conducted at TAD) (Table S10); comparison of exposure for SCID mouse versus normal mouse (Table S11); electron density for <i>Pf</i>DHODH coinhibitor structures showing the Fo-Fc map of the bound inhibitors prior to refinement (Figure S1); X-ray structures of <i>Pf</i>DHODH (green) bound to <b>56</b>, <b>86, 81</b>, and <b>18</b> (Figure S2); FEP+ predictions correlated to measured IC<sub>50</sub> values on <i>Pf</i>DHODH (Figure S3); mouse and rat PK profiles for <b>36</b> showing concentrations <b>33</b> as a metabolite (Figure S4); Uganda <i>P. falciparum</i> field isolates. Scatterplots and Spearman Correlations (Figure S5); tolerance phenotype of C276F and C276Y mutant clones versus <b>26</b> and <b>79</b> (Figure S6); SCID mouse efficacy study of <b>33</b> and <b>36</b> showing parasitemia and drug blood concentrations over time (Figure S7); SCID mouse efficacy study of <b>99</b> showing parasitemia and drug blood concentrations over time (Figure S8); NMR and LCMS data for key compounds (<b>26</b>, <b>33</b>, <b>36</b>, <b>79</b>, and <b>99</b>) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular Formula Strings Excel Spread sheet (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf">jm1c00173_si_001.pdf (4.59 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_002.csv">jm1c00173_si_002.csv (12.41 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last"><b>PDB coordinates</b>. The coordinates for the structure of <i>Pf</i>DHODH bound to <b>18, 56, 127, 79, 81, 86</b>, and <b>47</b> have been submitted to the Protein Data Bank (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYK">7KYK</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYV">7KYV</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYY">7KYY</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KZ4">7KZ4</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KZY">7KZY</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LO1">7LO1</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LOK">7LOK</a>, respectively). The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.1c00173" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42055" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42055" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Margaret A. Phillips</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, University of Texas Southwestern
Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, Texas 75390-9135, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5250-5578" title="Orcid link">http://orcid.org/0000-0001-5250-5578</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4f222e3d282e3d2a3b613f27262323263f3c0f3a3b3c203a3b27382a3c3b2a3d21612a2b3a"><span class="__cf_email__" data-cfemail="e48985968385968190ca948c8d88888d9497a49190978b91908c9381979081968aca818091">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Palmer</span> - <span class="hlFld-Affiliation affiliation">Medicines
for Malaria Venture, 1215 Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyi Deng</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, University of Texas Southwestern
Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, Texas 75390-9135, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shawn Watts</span> - <span class="hlFld-Affiliation affiliation">Schrodinger,
Inc., 120 West 45th St,
17th Floor, New York, New
York 100036-4041, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Goran Krilov</span> - <span class="hlFld-Affiliation affiliation">Schrodinger,
Inc., 120 West 45th St,
17th Floor, New York, New
York 100036-4041, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aleksey Gerasyuto</span> - <span class="hlFld-Affiliation affiliation">Schrodinger,
Inc., 120 West 45th St,
17th Floor, New York, New
York 100036-4041, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sreekanth Kokkonda</span> - <span class="hlFld-Affiliation affiliation">Departments
of Chemistry and Global Health, University
of Washington, Seattle, Washington 98195, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Farah El Mazouni</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, University of Texas Southwestern
Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, Texas 75390-9135, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John White</span> - <span class="hlFld-Affiliation affiliation">Departments
of Chemistry and Global Health, University
of Washington, Seattle, Washington 98195, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen L. White</span> - <span class="hlFld-Affiliation affiliation">Centre
for Drug Candidate Optimisation, Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, VIC 3052, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Josefine Striepen</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Immunology, Columbia
University Irving Medical Center, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jade Bath</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Immunology, Columbia
University Irving Medical Center, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kyra A. Schindler</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Immunology, Columbia
University Irving Medical Center, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tomas Yeo</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Immunology, Columbia
University Irving Medical Center, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David M. Shackleford</span> - <span class="hlFld-Affiliation affiliation">Centre
for Drug Candidate Optimisation, Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, VIC 3052, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sachel Mok</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Immunology, Columbia
University Irving Medical Center, New York, New York 10032, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9605-0154" title="Orcid link">http://orcid.org/0000-0002-9605-0154</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ioanna Deni</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Immunology, Columbia
University Irving Medical Center, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aloysus Lawong</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, University of Texas Southwestern
Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, Texas 75390-9135, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ann Huang</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, University of Texas Southwestern
Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, Texas 75390-9135, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gong Chen</span> - <span class="hlFld-Affiliation affiliation">Centre
for Drug Candidate Optimisation, Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, VIC 3052, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wen Wang</span> - <span class="hlFld-Affiliation affiliation">Centre
for Drug Candidate Optimisation, Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, VIC 3052, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jaya Jayaseelan</span> - <span class="hlFld-Affiliation affiliation">Centre
for Drug Candidate Optimisation, Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, VIC 3052, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kasiram Katneni</span> - <span class="hlFld-Affiliation affiliation">Centre
for Drug Candidate Optimisation, Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, VIC 3052, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rahul Patil</span> - <span class="hlFld-Affiliation affiliation">Centre
for Drug Candidate Optimisation, Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, VIC 3052, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jessica Saunders</span> - <span class="hlFld-Affiliation affiliation">Centre
for Drug Candidate Optimisation, Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, VIC 3052, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shatrughan P. Shahi</span> - <span class="hlFld-Affiliation affiliation">Syngene
International Ltd, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rajesh Chittimalla</span> - <span class="hlFld-Affiliation affiliation">Syngene
International Ltd, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Iñigo Angulo-Barturen</span> - <span class="hlFld-Affiliation affiliation">TAD,
Biscay Science and Technology Park, Astondo Bidea, BIC Bizkaia Bd 612, Derio, 48160 Bizkaia, Basque
Country, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">María Belén Jiménez-Díaz</span> - <span class="hlFld-Affiliation affiliation">TAD,
Biscay Science and Technology Park, Astondo Bidea, BIC Bizkaia Bd 612, Derio, 48160 Bizkaia, Basque
Country, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sergio Wittlin</span> - <span class="hlFld-Affiliation affiliation">Swiss
Tropical and Public Health Institute, Socinstrasse 57, 4002 Basel, Switzerland</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Basel, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick K. Tumwebaze</span> - <span class="hlFld-Affiliation affiliation">Infectious Diseases Research Collaboration, Kampala, Uganda</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip J. Rosenthal</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, University of California, San Francisco, California 94143, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roland A. Cooper</span> - <span class="hlFld-Affiliation affiliation">Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California 94901, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Caroline Campos Aguiar</span> - <span class="hlFld-Affiliation affiliation">University of Sao Paulo, Sao Carlos Institute of Physics, Sáo Carlos, SP 13560-970, Brazil</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rafael V. C. Guido</span> - <span class="hlFld-Affiliation affiliation">University of Sao Paulo, Sao Carlos Institute of Physics, Sáo Carlos, SP 13560-970, Brazil</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dhelio B. Pereira</span> - <span class="hlFld-Affiliation affiliation">Tropical Medicine Research Center of Rondonia, Av. Guaporé, 215, Porto Velho, RO 76812-329, Brazil</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nimisha Mittal</span> - <span class="hlFld-Affiliation affiliation">Department
of Pediatrics, Division of Host-Microbe Systems and Therapeutics,
School of Medicine, University of California
San Diego, La Jolla, California 92093, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elizabeth A. Winzeler</span> - <span class="hlFld-Affiliation affiliation">Department
of Pediatrics, Division of Host-Microbe Systems and Therapeutics,
School of Medicine, University of California
San Diego, La Jolla, California 92093, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4049-2113" title="Orcid link">http://orcid.org/0000-0002-4049-2113</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Diana R. Tomchick</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, University of Texas Southwestern
Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, Texas 75390-9135, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benoît Laleu</span> - <span class="hlFld-Affiliation affiliation">Medicines
for Malaria Venture, 1215 Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeremy N. Burrows</span> - <span class="hlFld-Affiliation affiliation">Medicines
for Malaria Venture, 1215 Geneva, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8448-6068" title="Orcid link">http://orcid.org/0000-0001-8448-6068</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pradipsinh K. Rathod</span> - <span class="hlFld-Affiliation affiliation">Departments
of Chemistry and Global Health, University
of Washington, Seattle, Washington 98195, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David A. Fidock</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Immunology, Columbia
University Irving Medical Center, New York, New York 10032, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Division of Infectious Diseases, Department
of Medicine, Columbia University Irving
Medical Center, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan A. Charman</span> - <span class="hlFld-Affiliation affiliation">Centre
for Drug Candidate Optimisation, Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, VIC 3052, Australia</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>S.W., G.K., and A.G. performed computational structure-based modeling. M.J.P., S.W., G.K., A.G., M.A.P., and S.A.C. contributed to the compound design and determination of the compound target list. M.J.P. supervised synthetic chemistry, which was carried out by S.K., S.P.S., and R.C.; M.A.P. designed and supervised enzyme kinetic analysis and structural biology was carried out by X.D., F.E.M., and A.H., with X-ray structure determination also supervised by D.T.; M.A.P. and P.K.R. supervised blood-stage parasite assays conducted by A.L. and J.W. S.A.C. supervised all ADME and PK studies carried out by K.L.W., G.C., W.W., J.J., K.K., R.P., D.M.S., and J.S.; D.F supervised the generation of new drug-resistant lines and their analysis carried out by K.S., J.S., J.B., T.Y., S.M., and I.D.; I.A.P., M.B.J.-D., and S.W. were responsible for SCID mouse efficacy studies; A.C.C.A., R.V.C.G., and D.B.P. carried out field studies in Brazil; P.K.T., P.J.R., and R.A.C. carried out field studies in Africa; N.M. an E.W. conducted P. berghei liver-stage studies. B.L. and J.N.B. supervised M.M.V. studies and provided chemistry advise. M.J.P., S.A.C., and M.A.P. wrote the paper, which was edited and approved by all authors.</p></li><li><span class="author-information-subsection-header">Funding</span><p>This work was supported by funds from the United States National Institutes of Health (NIH), R01AI103947 (to M.A.P. and P.K.R.), from Medicines for Malaria Venture (M.M.V.). Schrödinger acknowledges support from the Bill & Melinda Gates Foundation (contract #26296). M.A.P. acknowledges the support of the Welch Foundation (I-1257). MAP holds the Sam G. Winstead and F. Andrew Bell Distinguished Chair in Biochemistry. P.K.R. acknowledges funding support from NIH (AI093380, AI139179, and AI089688), D.A.F. acknowledges funding support the Department of Defense (E01 W81XWH1910086) and the NIH (R01 AI109023).</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): B.L. and J.N.B. are employees of Medicines for Malaria Venture.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e20564-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i374">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76801" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76801" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Suraksha Gahalawat for performing melting point and optical rotation measurements on selected compounds (UT Southwestern), Heekuk Park and Anne-Cartin Uhlemann for assistance with genome sequencing (Columbia), and Christoph Fischli for technical assistance with the SCID mouse <i>P. falciparum</i><i>in vivo e</i>fficacy studies (Swiss TPH). The results shown in this report are derived from work performed at the Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source. PlasmoDB (Plasmodium genomics resource) was used during analysis of sequencing results during the study of drug-resistant clones.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">DHODH</td><td class="NLM_def"><p class="first last">dihydroorotate dehydrogenase</p></td></tr><tr><td class="NLM_term"><i>Pf</i></td><td class="NLM_def"><p class="first last"><i>Plasmodium falciparum</i></p></td></tr><tr><td class="NLM_term"><i>Pv</i></td><td class="NLM_def"><p class="first last"><i>Plasmodium vivax</i></p></td></tr><tr><td class="NLM_term"><i>h</i>DHODH</td><td class="NLM_def"><p class="first last">human DHODH</p></td></tr><tr><td class="NLM_term">mDHODH</td><td class="NLM_def"><p class="first last">mouse DHODH</p></td></tr><tr><td class="NLM_term">rDHODH</td><td class="NLM_def"><p class="first last">rat DHODH</p></td></tr><tr><td class="NLM_term">dDHODH</td><td class="NLM_def"><p class="first last">dog DHODH</p></td></tr><tr><td class="NLM_term"><i>Pf</i>3D7</td><td class="NLM_def"><p class="first last"><i>P. falciparum</i> 3D7 parasites</p></td></tr><tr><td class="NLM_term"><i>Pf</i>Dd2</td><td class="NLM_def"><p class="first last"><i>P. falciparum</i> Dd2 parasites</p></td></tr><tr><td class="NLM_term">PG</td><td class="NLM_def"><p class="first last">proguanil</p></td></tr><tr><td class="NLM_term">DSM</td><td class="NLM_def"><p class="first last">code name assigned to compounds from our team and stands for Dallas, Seattle, and Melbourne, reflecting the location of the three project groups on the team</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i376">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 75 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manyando, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Huijsduijnen, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, T. N. C.</span></span> <span> </span><span class="NLM_article-title">Malaria</span>. <i>Nat. Rev. Dis. Primers</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">17050</span> <span class="refDoi"> DOI: 10.1038/nrdp.2017.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1038%2Fnrdp.2017.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28770814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A280%3ADC%252BC1cfjvVGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&author=M.+A.+Phillipsauthor=J.+N.+Burrowsauthor=C.+Manyandoauthor=R.+H.+van+Huijsduijnenauthor=W.+C.+Van+Voorhisauthor=T.+N.+C.+Wells&title=Malaria&doi=10.1038%2Fnrdp.2017.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Malaria</span></div><div class="casAuthors">Phillips Margaret A; Burrows Jeremy N; van Huijsduijnen Rob Hooft; Wells Timothy N C; Manyando Christine; Van Voorhis Wesley C</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17050</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Malaria is caused in humans by five species of single-celled eukaryotic Plasmodium parasites (mainly Plasmodium falciparum and Plasmodium vivax) that are transmitted by the bite of Anopheles spp. mosquitoes.  Malaria remains one of the most serious infectious diseases; it threatens nearly half of the world's population and led to hundreds of thousands of deaths in 2015, predominantly among children in Africa.  Malaria is managed through a combination of vector control approaches (such as insecticide spraying and the use of insecticide-treated bed nets) and drugs for both treatment and prevention.  The widespread use of artemisinin-based combination therapies has contributed to substantial declines in the number of malaria-related deaths; however, the emergence of drug resistance threatens to reverse this progress.  Advances in our understanding of the underlying molecular basis of pathogenesis have fuelled the development of new diagnostics, drugs and insecticides.  Several new combination therapies are in clinical development that have efficacy against drug-resistant parasites and the potential to be used in single-dose regimens to improve compliance.  This ambitious programme to eliminate malaria also includes new approaches that could yield malaria vaccines or novel vector control strategies.  However, despite these achievements, a well-coordinated global effort on multiple fronts is needed if malaria elimination is to be achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcfdgTdv0RVI2y4bB4mnvYfW6udTcc2eZcWPEk_nehmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfjvVGhtg%253D%253D&md5=ec450ab6baef0a6c2b6bd6bac030771a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2017.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2017.50%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DManyando%26aufirst%3DC.%26aulast%3Dvan%2BHuijsduijnen%26aufirst%3DR.%2BH.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DWells%26aufirst%3DT.%2BN.%2BC.%26atitle%3DMalaria%26jtitle%3DNat.%2520Rev.%2520Dis.%2520Primers%26date%3D2017%26volume%3D3%26doi%3D10.1038%2Fnrdp.2017.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">World
Health Organization</span>. <span> </span><span class="NLM_article-title">World
Malaria Report.</span> <a href="https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2020" class="extLink">https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2020</a> (accessed Dec 15, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=World%0AHealth+Organization&title=World%0AMalaria+Report."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DWorld%250AMalaria%2520Report.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hien, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faiz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokuolu, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span> <span> </span><span class="NLM_article-title">Malaria</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">735</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(13)60024-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2FS0140-6736%2813%2960024-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=23953767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A280%3ADC%252BC3sbgs1Grug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2014&pages=723-735&author=N.+J.+Whiteauthor=S.+Pukrittayakameeauthor=T.+T.+Hienauthor=M.+A.+Faizauthor=O.+A.+Mokuoluauthor=A.+M.+Dondorp&title=Malaria&doi=10.1016%2FS0140-6736%2813%2960024-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Malaria</span></div><div class="casAuthors">White Nicholas J; Pukrittayakamee Sasithon; Hien Tran Tinh; Faiz M Abul; Mokuolu Olugbenga A; Dondorp Arjen M</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">9918</span>),
    <span class="NLM_cas:pages">723-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although global morbidity and mortality have decreased substantially, malaria, a parasite infection of red blood cells, still kills roughly 2000 people per day, most of whom are children in Africa.  Two factors largely account for these decreases; increased deployment of insecticide-treated bednets and increased availability of highly effective artemisinin combination treatments.  In large trials, parenteral artesunate (an artemisinin derivative) reduced severe malaria mortality by 22·5% in Africa and 34·7% in Asia compared with quinine, whereas adjunctive interventions have been uniformly unsuccessful.  Rapid tests have been an important addition to microscopy for malaria diagnosis.  Chemopreventive strategies have been increasingly deployed in Africa, notably intermittent sulfadoxine-pyrimethamine treatment in pregnancy, and monthly amodiaquine-sulfadoxine-pyrimethamine during the rainy season months in children aged between 3 months and 5 years across the sub-Sahel.  Enthusiasm for malaria elimination has resurfaced.  This ambitious but laudable goal faces many challenges, including the worldwide economic downturn, difficulties in elimination of vivax malaria, development of pyrethroid resistance in some anopheline mosquitoes, and the emergence of artemisinin resistance in Plasmodium falciparum in southeast Asia.  We review the epidemiology, clinical features, pathology, prevention, and treatment of malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUNJZs6BRXR-kdrW1FkXG-fW6udTcc2eZcWPEk_nehmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbgs1Grug%253D%253D&md5=bd84954e5e034997111401f4dcdc69fd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2960024-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252960024-0%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DHien%26aufirst%3DT.%2BT.%26aulast%3DFaiz%26aufirst%3DM.%2BA.%26aulast%3DMokuolu%26aufirst%3DO.%2BA.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26atitle%3DMalaria%26jtitle%3DLancet%26date%3D2014%26volume%3D383%26spage%3D723%26epage%3D735%26doi%3D10.1016%2FS0140-6736%2813%2960024-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A.</span></span> <span> </span><span class="NLM_article-title">Antimalarial drug resistance: a threat to malaria elimination</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">a025619</span> <span class="refDoi"> DOI: 10.1101/cshperspect.a025619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1101%2Fcshperspect.a025619" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28289248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFKqurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&author=D.+Menardauthor=A.+Dondorp&title=Antimalarial+drug+resistance%3A+a+threat+to+malaria+elimination&doi=10.1101%2Fcshperspect.a025619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial drug resistance: a threat to malaria elimination</span></div><div class="casAuthors">Menard, Didier; Dondorp, Arjen</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">a025619/1-a025619/25</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Increasing antimalarial drug resistance once again threatens effective antimalarial drug treatment, malaria control, and elimination.  Artemisinin combination therapies (ACTs) are first-line treatment for uncomplicated falciparum malaria in all endemic countries, yet partial resistance to artemisinins has emerged in the Greater Mekong Subregion.  Concomitant emergence of partner drug resistance is now causing high ACT treatment failure rates in several areas.  Genetic markers for artemisinin resistance and several of the partner drugs have been established, greatly facilitating surveillance.  Single point mutations in the gene coding for the Kelch propeller domain of the K13 protein strongly correlate with artemisinin resistance.  Novel regimens and strategies using existing antimalarial drugs will be needed until novel compds. can be deployed.  Elimination of artemisinin resistance will imply elimination of all falciparum malaria from the same areas.  In vivax malaria, chloroquine resistance is an increasing problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAcvouDhij-7Vg90H21EOLACvtfcHk0lg9p1VVVGkuJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFKqurw%253D&md5=77170984fbae885dc193c9e0c9b3f6e5</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a025619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a025619%26sid%3Dliteratum%253Aachs%26aulast%3DMenard%26aufirst%3DD.%26aulast%3DDondorp%26aufirst%3DA.%26atitle%3DAntimalarial%2520drug%2520resistance%253A%2520a%2520threat%2520to%2520malaria%2520elimination%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2017%26volume%3D7%26doi%3D10.1101%2Fcshperspect.a025619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnadig, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralph, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title">Artemisinin action and resistance in <i>Plasmodium falciparum</i></span>. <i>Trends Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">696</span>, <span class="refDoi"> DOI: 10.1016/j.pt.2016.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2Fj.pt.2016.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=27289273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC28Xoslamt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2016&pages=682-696&author=L.+Tilleyauthor=J.+Straimerauthor=N.+F.+Gnadigauthor=S.+A.+Ralphauthor=D.+A.+Fidock&title=Artemisinin+action+and+resistance+in+Plasmodium+falciparum&doi=10.1016%2Fj.pt.2016.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin Action and Resistance in Plasmodium falciparum</span></div><div class="casAuthors">Tilley, Leann; Straimer, Judith; Gnadig, Nina F.; Ralph, Stuart A.; Fidock, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Parasitology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">682-696</span>CODEN:
                <span class="NLM_cas:coden">TPRACT</span>;
        ISSN:<span class="NLM_cas:issn">1471-4922</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The worldwide use of artemisinin-based combination therapies (ACTs) has contributed in recent years to a substantial redn. in deaths resulting from Plasmodium falciparum malaria.  Resistance to artemisinins, however, has emerged in Southeast Asia.  Clin., resistance is defined as a slower rate of parasite clearance in patients treated with an artemisinin deriv. or an ACT.  These slow clearance rates assoc. with enhanced survival rates of ring-stage parasites briefly exposed in vitro to dihydroartemisinin.  We describe recent progress made in defining the mol. basis of artemisinin resistance, which has identified a primary role for the P. falciparum K13 protein.  Using K13 mutations as mol. markers, epidemiol. studies are now tracking the emergence and spread of artemisinin resistance.  Mechanistic studies suggest potential ways to overcome resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTqDTZppoE1bVg90H21EOLACvtfcHk0lg9p1VVVGkuJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xoslamt78%253D&md5=8a1cb66eab2962ca73ea6d6e2cbf8f21</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.pt.2016.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pt.2016.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DTilley%26aufirst%3DL.%26aulast%3DStraimer%26aufirst%3DJ.%26aulast%3DGnadig%26aufirst%3DN.%2BF.%26aulast%3DRalph%26aufirst%3DS.%2BA.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DArtemisinin%2520action%2520and%2520resistance%2520in%2520Plasmodium%2520falciparum%26jtitle%3DTrends%2520Parasitol.%26date%3D2016%26volume%3D32%26spage%3D682%26epage%3D696%26doi%3D10.1016%2Fj.pt.2016.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralph, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, L.</span></span> <span> </span><span class="NLM_article-title">K13, the cytostome, and artemisinin resistance</span>. <i>Trends Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1016/j.pt.2020.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2Fj.pt.2020.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=32359872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFCmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2020&pages=533-544&author=S.+C.+Xieauthor=S.+A.+Ralphauthor=L.+Tilley&title=K13%2C+the+cytostome%2C+and+artemisinin+resistance&doi=10.1016%2Fj.pt.2020.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">K13, the Cytostome, and Artemisinin Resistance</span></div><div class="casAuthors">Xie, Stanley C.; Ralph, Stuart A.; Tilley, Leann</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Parasitology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">533-544</span>CODEN:
                <span class="NLM_cas:coden">TPRACT</span>;
        ISSN:<span class="NLM_cas:issn">1471-4922</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Artemisinins the frontline antimalarial drug class are compromised by emerging resistance, putting at risk the lives of hundreds of thousands of people each year.  Resistance is assocd. with mutations in a malaria parasite protein, called Kelch 13 (K13).  Recent work suggests that K13 is located at the cytostome (cell mouth) that the parasite uses to take up Hb.  Here we explore the proposal that K13 mutations confer artemisinin resistance by dampening Hb endocytosis.  This model suggests that the resultant decrease in Hb-derived heme reduces artemisinin activation, which is sufficient to enable parasite survival in the early ring stage of infection.  A fuller understanding of the resistance mechanism will underpin efforts to develop alternative antimalarial strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5KtqLFMyUo7Vg90H21EOLACvtfcHk0lg9p1VVVGkuJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFCmt70%253D&md5=8da990185af4ac8437f78e458acdea44</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.pt.2020.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pt.2020.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DS.%2BC.%26aulast%3DRalph%26aufirst%3DS.%2BA.%26aulast%3DTilley%26aufirst%3DL.%26atitle%3DK13%252C%2520the%2520cytostome%252C%2520and%2520artemisinin%2520resistance%26jtitle%3DTrends%2520Parasitol.%26date%3D2020%26volume%3D36%26spage%3D533%26epage%3D544%26doi%3D10.1016%2Fj.pt.2020.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Pluijm, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoa, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuy-Nhien, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thanh, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanboonkunupakarn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chutasmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saelow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runjarern, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaewmok, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peto, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhorda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chotivanich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waithira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheah, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maude, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winterberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hien, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miotto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span> <span> </span><span class="NLM_article-title">Determinants of dihydroartemisinin-piperaquine treatment failure in <i>Plasmodium falciparum</i> malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">952</span>– <span class="NLM_lpage">961</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(19)30391-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2FS1473-3099%2819%2930391-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=31345710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVeltb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=952-961&author=R.+W.+van%0Ader+Pluijmauthor=M.+Imwongauthor=N.+H.+Chauauthor=N.+T.+Hoaauthor=N.+T.+Thuy-Nhienauthor=N.+V.+Thanhauthor=P.+Jittamalaauthor=B.+Hanboonkunupakarnauthor=K.+Chutasmitauthor=C.+Saelowauthor=R.+Runjarernauthor=W.+Kaewmokauthor=R.+Tripuraauthor=T.+J.+Petoauthor=S.+Yokauthor=S.+Suonauthor=S.+Srengauthor=S.+Maoauthor=S.+Ounauthor=S.+Yenauthor=C.+Amaratungaauthor=D.+Lekauthor=R.+Huyauthor=M.+Dhordaauthor=K.+Chotivanichauthor=E.+A.+Ashleyauthor=M.+Mukakaauthor=N.+Waithiraauthor=P.+Y.+Cheahauthor=R.+J.+Maudeauthor=R.+Amatoauthor=R.+D.+Pearsonauthor=S.+Goncalvesauthor=C.+G.+Jacobauthor=W.+L.+Hamiltonauthor=R.+M.+Fairhurstauthor=J.+Tarningauthor=M.+Winterbergauthor=D.+P.+Kwiatkowskiauthor=S.+Pukrittayakameeauthor=T.+T.+Hienauthor=N.+P.+Dayauthor=O.+Miottoauthor=N.+J.+Whiteauthor=A.+M.+Dondorp&title=Determinants+of+dihydroartemisinin-piperaquine+treatment+failure+in+Plasmodium+falciparum+malaria+in+Cambodia%2C+Thailand%2C+and+Vietnam%3A+a+prospective+clinical%2C+pharmacological%2C+and+genetic+study&doi=10.1016%2FS1473-3099%2819%2930391-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study</span></div><div class="casAuthors">van der Pluijm, Rob W.; Imwong, Mallika; Chau, Nguyen Hoang; Hoa, Nhu Thi; Thuy-Nhien, Nguyen Thanh; Thanh, Ngo Viet; Jittamala, Podjanee; Hanboonkunupakarn, Borimas; Chutasmit, Kitipumi; Saelow, Chalermpon; Runjarern, Ratchadaporn; Kaewmok, Weerayuth; Tripura, Rupam; Peto, Thomas J.; Yok, Sovann; Suon, Seila; Sreng, Sokunthea; Mao, Sivanna; Oun, Savuth; Yen, Sovannary; Amaratunga, Chanaki; Lek, Dysoley; Huy, Rekol; Dhorda, Mehul; Chotivanich, Kesinee; Ashley, Elizabeth A.; Mukaka, Mavuto; Waithira, Naomi; Cheah, Phaik Yeong; Maude, Richard J.; Amato, Roberto; Pearson, Richard D.; Goncalves, Sonia; Jacob, Christopher G.; Hamilton, William L.; Fairhurst, Rick M.; Tarning, Joel; Winterberg, Markus; Kwiatkowski, Dominic P.; Pukrittayakamee, Sasithon; Hien, Tran Tinh; Day, Nicholas P. J.; Miotto, Olivo; White, Nicholas J.; Dondorp, Arjen M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">952-961</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The current study is part of a multi-country, open-label, randomised clin. trial (TRACII, 2015-18) evaluating the efficacy, safety, and tolerability of triple artemisinin combination therapies.  A very high rate of treatment failure after treatment with dihydroartemisinin-piperaquine was obsd. in Thailand, Cambodia, and Vietnam.  Patients aged between 2 and 65 years presenting with uncomplicated P falciparum or mixed species malaria at seven sites in Thailand, Cambodia, and Vietnam were randomly assigned to receive dihydroartemisinin-piperaquine with or without mefloquine, as part of the TRACII trial.  The primary outcome was the PCR-cor. efficacy at day 42.  Next-generation sequencing was used to assess the prevalence of mol. markers assocd. with artemisinin resistance (kelch13 mutations, in particular Cys580Tyr) and piperaquine resistance (plasmepsin-2 and plasmepsin-3 amplifications and crt mutations).  Between Sept 28, 2015, and Jan 18, 2018, 539 patients with acute P falciparum malaria were screened for eligibility, 292 were enrolled, and 140 received dihydroartemisinin-piperaquine.  The overall Kaplan-Meier est. of PCR-cor. efficacy of dihydroartemisinin-piperaquine at day 42 was 50·0% (95% CI 41·1-58·3).  Treatment failure was assocd. independently with plasmepsin2/3 amplification status and four mutations in the crt gene (Thr93Ser, His97Tyr, Phe145Ile, and Ile218Phe).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpscjzMhmc-97Vg90H21EOLACvtfcHk0lhswTm48jFB1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVeltb%252FJ&md5=e2c8bf51cf812518a46186a49a07894f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2819%2930391-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252819%252930391-3%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BPluijm%26aufirst%3DR.%2BW.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DChau%26aufirst%3DN.%2BH.%26aulast%3DHoa%26aufirst%3DN.%2BT.%26aulast%3DThuy-Nhien%26aufirst%3DN.%2BT.%26aulast%3DThanh%26aufirst%3DN.%2BV.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DHanboonkunupakarn%26aufirst%3DB.%26aulast%3DChutasmit%26aufirst%3DK.%26aulast%3DSaelow%26aufirst%3DC.%26aulast%3DRunjarern%26aufirst%3DR.%26aulast%3DKaewmok%26aufirst%3DW.%26aulast%3DTripura%26aufirst%3DR.%26aulast%3DPeto%26aufirst%3DT.%2BJ.%26aulast%3DYok%26aufirst%3DS.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DOun%26aufirst%3DS.%26aulast%3DYen%26aufirst%3DS.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DLek%26aufirst%3DD.%26aulast%3DHuy%26aufirst%3DR.%26aulast%3DDhorda%26aufirst%3DM.%26aulast%3DChotivanich%26aufirst%3DK.%26aulast%3DAshley%26aufirst%3DE.%2BA.%26aulast%3DMukaka%26aufirst%3DM.%26aulast%3DWaithira%26aufirst%3DN.%26aulast%3DCheah%26aufirst%3DP.%2BY.%26aulast%3DMaude%26aufirst%3DR.%2BJ.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DPearson%26aufirst%3DR.%2BD.%26aulast%3DGoncalves%26aufirst%3DS.%26aulast%3DJacob%26aufirst%3DC.%2BG.%26aulast%3DHamilton%26aufirst%3DW.%2BL.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DWinterberg%26aufirst%3DM.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BP.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DHien%26aufirst%3DT.%2BT.%26aulast%3DDay%26aufirst%3DN.%2BP.%26aulast%3DMiotto%26aufirst%3DO.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26atitle%3DDeterminants%2520of%2520dihydroartemisinin-piperaquine%2520treatment%2520failure%2520in%2520Plasmodium%2520falciparum%2520malaria%2520in%2520Cambodia%252C%2520Thailand%252C%2520and%2520Vietnam%253A%2520a%2520prospective%2520clinical%252C%2520pharmacological%252C%2520and%2520genetic%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2019%26volume%3D19%26spage%3D952%26epage%3D961%26doi%3D10.1016%2FS1473-3099%2819%2930391-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Pluijm, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoglund, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyae
Phyo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ul Islam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anvikar, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satpathi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satpathi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behera, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baidya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onyamboko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sovann, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chutasmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saelow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runcharern, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaewmok, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoa, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thanh, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanboonkunupakarn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callery, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohanty, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gantait, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waithira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grobusch, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Vugt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheah, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peto, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Seidlein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhorda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maude, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winterberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuy-Nhien, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hlaing, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chotivanich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayxay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hien, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valecha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithuis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miotto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Tracking Resistance to Artemisinin, C., Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated <i>Plasmodium falciparum</i> malaria: a multicentre, open-label, randomised clinical trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1360</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(20)30552-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2FS0140-6736%2820%2930552-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=32171078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVGkt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1345-1360&author=R.+W.+van%0Ader+Pluijmauthor=R.+Tripuraauthor=R.+M.+Hoglundauthor=A.+Pyae%0APhyoauthor=D.+Lekauthor=A.+Ul+Islamauthor=A.+R.+Anvikarauthor=P.+Satpathiauthor=S.+Satpathiauthor=P.+K.+Beheraauthor=A.+Tripuraauthor=S.+Baidyaauthor=M.+Onyambokoauthor=N.+H.+Chauauthor=Y.+Sovannauthor=S.+Suonauthor=S.+Srengauthor=S.+Maoauthor=S.+Ounauthor=S.+Yenauthor=C.+Amaratungaauthor=K.+Chutasmitauthor=C.+Saelowauthor=R.+Runcharernauthor=W.+Kaewmokauthor=N.+T.+Hoaauthor=N.+V.+Thanhauthor=B.+Hanboonkunupakarnauthor=J.+J.+Calleryauthor=A.+K.+Mohantyauthor=J.+Heatonauthor=M.+Thantauthor=K.+Gantaitauthor=T.+Ghoshauthor=R.+Amatoauthor=R.+D.+Pearsonauthor=C.+G.+Jacobauthor=S.+Goncalvesauthor=M.+Mukakaauthor=N.+Waithiraauthor=C.+J.+Woodrowauthor=M.+P.+Grobuschauthor=M.+van+Vugtauthor=R.+M.+Fairhurstauthor=P.+Y.+Cheahauthor=T.+J.+Petoauthor=L.+von+Seidleinauthor=M.+Dhordaauthor=R.+J.+Maudeauthor=M.+Winterbergauthor=N.+T.+Thuy-Nhienauthor=D.+P.+Kwiatkowskiauthor=M.+Imwongauthor=P.+Jittamalaauthor=K.+Linauthor=T.+M.+Hlaingauthor=K.+Chotivanichauthor=R.+Huyauthor=C.+Fanelloauthor=E.+Ashleyauthor=M.+Mayxayauthor=P.+N.+Newtonauthor=T.+T.+Hienauthor=N.+Valechaauthor=F.+Smithuisauthor=S.+Pukrittayakameeauthor=A.+Faizauthor=O.+Miottoauthor=J.+Tarningauthor=N.+P.+J.+Dayauthor=N.+J.+Whiteauthor=A.+M.+Dondorp&title=Tracking+Resistance+to+Artemisinin%2C+C.%2C+Triple+artemisinin-based+combination+therapies+versus+artemisinin-based+combination+therapies+for+uncomplicated+Plasmodium+falciparum+malaria%3A+a+multicentre%2C+open-label%2C+randomised+clinical+trial&doi=10.1016%2FS0140-6736%2820%2930552-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial</span></div><div class="casAuthors">van der Pluijm, Rob W.; Tripura, Rupam; Hoglund, Richard M.; Pyae Phyo, Aung; Lek, Dysoley; ul Islam, Akhter; Anvikar, Anupkumar R.; Satpathi, Parthasarathi; Satpathi, Sanghamitra; Behera, Prativa Kumari; Tripura, Amar; Baidya, Subrata; Onyamboko, Marie; Nguyen, Hoang Chau; Sovann, Yok; Suon, Seila; Sreng, Sokunthea; Mao, Sivanna; Oun, Savuth; Yen, Sovannary; Amaratunga, Chanaki; Chutasmit, Kitipumi; Saelow, Chalermpon; Runcharern, Ratchadaporn; Kaewmok, Weerayuth; Hoa, Nhu Thi; Thanh, Ngo Viet; Hanboonkunupakarn, Borimas; Callery, James J.; Mohanty, Akshaya Kumar; Heaton, James; Thant, Myo; Gantait, Kripasindhu; Ghosh, Tarapada; Amato, Roberto; Pearson, Richard D.; Jacob, Christopher G.; Goncalves, Sonia; Mukaka, Mavuto; Waithira, Naomi; Woodrow, Charles J.; Grobusch, Martin P.; van Vugt, Michele; Fairhurst, Rick M.; Cheah, Phaik Yeong; Peto, Thomas J.; von Seidlein, Lorenz; Dhorda, Mehul; Maude, Richard J.; Winterberg, Markus; Thuy-Nhien, Nguyen Thanh; Kwiatkowski, Dominic P.; Imwong, Mallika; Jittamala, Podjanee; Lin, Khin; Hlaing, Tin Maung; Chotivanich, Kesinee; Huy, Rekol; Fanello, Caterina; Ashley, Elizabeth; Mayxay, Mayfong; Newton, Paul N.; Hien, Tran Tinh; Valecha, Neena; Smithuis, Frank; Pukrittayakamee, Sasithon; Faiz, Abul; Miotto, Olivo; Tarning, Joel; Day, Nicholas P. J.; White, Nicholas J.; Dondorp, Arjen M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10233</span>),
    <span class="NLM_cas:pages">1345-1360</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination.  Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance.  In this multicentre, open-label, randomised trial, we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in eight countries.  Eligible patients were aged 2-65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum species, and a temp. of 37·5°C or higher, or a history of fever in the past 24 h.  Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin-piperaquine or dihydroartemisinin-piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate-mefloquine or dihydroartemisinin-piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether-lumefantrine or artemether-lumefantrine plus amodiaquine.  All drugs were administered orally and doses varied by drug combination and site.  Patients were followed-up weekly for 42 days.  The primary endpoint was efficacy, defined by 42-day PCR-cor. adequate clin. and parasitol. response.  Primary anal. was by intention to treat.  A detailed assessment of safety and tolerability of the study drugs was done in all patients randomly assigned to treatment.  This study is registered at ClinicalTrials.gov, NCT02453308, and is complete.  Between Aug 7, 2015, and Feb 8, 2018, 1100 patients were given either dihydroartemisinin-piperaquine (183 [17%]), dihydroartemisinin-piperaquine plus mefloquine (269 [25%]), artesunate-mefloquine (73 [7%]), artemether-lumefantrine (289 [26%]), or artemether-lumefantrine plus amodiaquine (286 [26%]).  The median age was 23 years (IQR 13 to 34) and 854 (78%) of 1100 patients were male.  In Cambodia, Thailand, and Vietnam the 42-day PCR-cor. efficacy after dihydroartemisinin-piperaquine plus mefloquine was 98% (149 of 152; 95% CI 94 to 100) and after dihydroartemisinin-piperaquine was 48% (67 of 141; 95% CI 39 to 56; risk difference 51%, 95% CI 42 to 59; p<0·0001).  Efficacy of dihydroartemisinin-piperaquine plus mefloquine in the three sites in Myanmar was 91% (42 of 46; 95% CI 79 to 98) vs. 100% (42 of 42; 95% CI 92 to 100) after dihydroartemisinin-piperaquine (risk difference 9%, 95% CI 1 to 17; p=0·12).  The 42-day PCR cor. efficacy of dihydroartemisinin-piperaquine plus mefloquine (96% [68 of 71; 95% CI 88 to 99]) was non-inferior to that of artesunate-mefloquine (95% [69 of 73; 95% CI 87 to 99]) in three sites in Cambodia (risk difference 1%; 95% CI -6 to 8; p=1·00).  The overall 42-day PCR-cor. efficacy of artemether-lumefantrine plus amodiaquine (98% [281 of 286; 95% CI 97 to 99]) was similar to that of artemether-lumefantrine (97% [279 of 289; 95% CI 94 to 98]; risk difference 2%, 95% CI -1 to 4; p=0·30).  Both TACTs were well tolerated, although early vomiting (within 1 h) was more frequent after dihydroartemisinin-piperaquine plus mefloquine (30 [3·8%] of 794) than after dihydroartemisinin-piperaquine (eight [1·5%] of 543; p=0·012).  Vomiting after artemether-lumefantrine plus amodiaquine (22 [1·3%] of 1703) and artemether-lumefantrine (11 [0·6%] of 1721) was infrequent.  Adding amodiaquine to artemether-lumefantrine extended the ECG cor. QT interval (mean increase at 52 h compared with baseline of 8·8 ms [SD 18·6] vs 0·9 ms [16·1]; p<0·01) but adding mefloquine to dihydroartemisinin-piperaquine did not (mean increase of 22·1 ms [SD 19·2] for dihydroartemisinin-piperaquine vs 20·8 ms [SD 17·8] for dihydroartemisinin-piperaquine plus mefloquine; p=0·50).  Dihydroartemisinin-piperaquine plus mefloquine and artemether-lumefantrine plus amodiaquine TACTs are efficacious, well tolerated, and safe treatments of uncomplicated P falciparum malaria, including in areas with artemisinin and ACT partner-drug resistance.  UK Department for International Development, Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and US National Institutes of Health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaU1eueIUvTrVg90H21EOLACvtfcHk0ljiXZNAYtL4-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVGkt7k%253D&md5=2de86af293b6d2dcfe2474b045ecca2e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930552-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930552-3%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BPluijm%26aufirst%3DR.%2BW.%26aulast%3DTripura%26aufirst%3DR.%26aulast%3DHoglund%26aufirst%3DR.%2BM.%26aulast%3DPyae%2BPhyo%26aufirst%3DA.%26aulast%3DLek%26aufirst%3DD.%26aulast%3DUl%2BIslam%26aufirst%3DA.%26aulast%3DAnvikar%26aufirst%3DA.%2BR.%26aulast%3DSatpathi%26aufirst%3DP.%26aulast%3DSatpathi%26aufirst%3DS.%26aulast%3DBehera%26aufirst%3DP.%2BK.%26aulast%3DTripura%26aufirst%3DA.%26aulast%3DBaidya%26aufirst%3DS.%26aulast%3DOnyamboko%26aufirst%3DM.%26aulast%3DChau%26aufirst%3DN.%2BH.%26aulast%3DSovann%26aufirst%3DY.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DOun%26aufirst%3DS.%26aulast%3DYen%26aufirst%3DS.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DChutasmit%26aufirst%3DK.%26aulast%3DSaelow%26aufirst%3DC.%26aulast%3DRuncharern%26aufirst%3DR.%26aulast%3DKaewmok%26aufirst%3DW.%26aulast%3DHoa%26aufirst%3DN.%2BT.%26aulast%3DThanh%26aufirst%3DN.%2BV.%26aulast%3DHanboonkunupakarn%26aufirst%3DB.%26aulast%3DCallery%26aufirst%3DJ.%2BJ.%26aulast%3DMohanty%26aufirst%3DA.%2BK.%26aulast%3DHeaton%26aufirst%3DJ.%26aulast%3DThant%26aufirst%3DM.%26aulast%3DGantait%26aufirst%3DK.%26aulast%3DGhosh%26aufirst%3DT.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DPearson%26aufirst%3DR.%2BD.%26aulast%3DJacob%26aufirst%3DC.%2BG.%26aulast%3DGoncalves%26aufirst%3DS.%26aulast%3DMukaka%26aufirst%3DM.%26aulast%3DWaithira%26aufirst%3DN.%26aulast%3DWoodrow%26aufirst%3DC.%2BJ.%26aulast%3DGrobusch%26aufirst%3DM.%2BP.%26aulast%3Dvan%2BVugt%26aufirst%3DM.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DCheah%26aufirst%3DP.%2BY.%26aulast%3DPeto%26aufirst%3DT.%2BJ.%26aulast%3Dvon%2BSeidlein%26aufirst%3DL.%26aulast%3DDhorda%26aufirst%3DM.%26aulast%3DMaude%26aufirst%3DR.%2BJ.%26aulast%3DWinterberg%26aufirst%3DM.%26aulast%3DThuy-Nhien%26aufirst%3DN.%2BT.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BP.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DHlaing%26aufirst%3DT.%2BM.%26aulast%3DChotivanich%26aufirst%3DK.%26aulast%3DHuy%26aufirst%3DR.%26aulast%3DFanello%26aufirst%3DC.%26aulast%3DAshley%26aufirst%3DE.%26aulast%3DMayxay%26aufirst%3DM.%26aulast%3DNewton%26aufirst%3DP.%2BN.%26aulast%3DHien%26aufirst%3DT.%2BT.%26aulast%3DValecha%26aufirst%3DN.%26aulast%3DSmithuis%26aufirst%3DF.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DFaiz%26aufirst%3DA.%26aulast%3DMiotto%26aufirst%3DO.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DDay%26aufirst%3DN.%2BP.%2BJ.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26atitle%3DTracking%2520Resistance%2520to%2520Artemisinin%252C%2520C.%252C%2520Triple%2520artemisinin-based%2520combination%2520therapies%2520versus%2520artemisinin-based%2520combination%2520therapies%2520for%2520uncomplicated%2520Plasmodium%2520falciparum%2520malaria%253A%2520a%2520multicentre%252C%2520open-label%252C%2520randomised%2520clinical%2520trial%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1345%26epage%3D1360%26doi%3D10.1016%2FS0140-6736%2820%2930552-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>, <span class="NLM_elocation-id">338</span> <span class="refDoi"> DOI: 10.1186/s12936-019-2955-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1186%2Fs12936-019-2955-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=31581941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A280%3ADC%252BB3MnkvValug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&author=N.+J.+White&title=Triple+artemisinin-containing+combination+anti-malarial+treatments+should+be+implemented+now+to+delay+the+emergence+of+resistance&doi=10.1186%2Fs12936-019-2955-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance</span></div><div class="casAuthors">White Nicholas J</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">338</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Resistance threatens all our currently available anti-malarial drugs.  Triple artemisinin-containing combination anti-malarial treatments (TACTs) combine an artemisinin derivative with two slowly eliminated partner drugs.  TACTs are undergoing large-scale trials.  If they prove safe, well-tolerated and efficacious then they should be deployed.  This is in order to protect and extend the useful therapeutic life of the current generation of anti-malarial drugs, which are so essential for malaria control and elimination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzFiwiIEVgEeqrn-c4Of3KfW6udTcc2eZue8wFmK6z_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnkvValug%253D%253D&md5=4795985d6928aaabeda72efe5187fed5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1186%2Fs12936-019-2955-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-019-2955-z%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DTriple%2520artemisinin-containing%2520combination%2520anti-malarial%2520treatments%2520should%2520be%2520implemented%2520now%2520to%2520delay%2520the%2520emergence%2520of%2520resistance%26jtitle%3DMalar.%2520J.%26date%3D2019%26volume%3D18%26doi%3D10.1186%2Fs12936-019-2955-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laleu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creek, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleebs, B. E.</span></span> <span> </span><span class="NLM_article-title">The Development process for discovery and clinical advancement of modern antimalarials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10526</span>– <span class="NLM_lpage">10562</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00761</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00761" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFamsrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10526-10562&author=T.+D.+Ashtonauthor=S.+M.+Devineauthor=J.+J.+Mohrleauthor=B.+Laleuauthor=J.+N.+Burrowsauthor=S.+A.+Charmanauthor=D.+J.+Creekauthor=B.+E.+Sleebs&title=The+Development+process+for+discovery+and+clinical+advancement+of+modern+antimalarials&doi=10.1021%2Facs.jmedchem.9b00761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Development Process for Discovery and Clinical Advancement of Modern Antimalarials</span></div><div class="casAuthors">Ashton, Trent D.; Devine, Shane M.; Mohrle, Jorg J.; Laleu, Benoit; Burrows, Jeremy N.; Charman, Susan A.; Creek, Darren J.; Sleebs, Brad E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10526-10562</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Malaria is a devastating disease caused by Plasmodium parasites resulting in approx. 435,000 deaths in 2018.  The impact of malaria is compounded by the emergence of widespread resistance to current antimalarial therapies.  Recently a new strategy was initiated to screen small mol. collections against the Plasmodium parasite enabling the identification of new antimalarial chemotypes with novel modes of action.  This initiative ushered in the modern era of antimalarial drug development and as a result, numerous lead candidates are advancing towards or are currently in human clin. trials.  In this perspective, we describe the development pathway of four of the most clin. advanced modern antimalarials, KAE609, KAF156, DSM265 and MMV048.  Addnl., the mechanism of action and lifecycle stage-specificity of the four antimalarials is discussed in relation to aligning with global strategies to treat and eliminate malaria.  This perspective serves as a guide to the expectations of modern antimalarial drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy-Wsk49dMLrVg90H21EOLACvtfcHk0lhAgG1bBHKK5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFamsrvL&md5=767c459a589507f646fdbd2816030d8d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00761%26sid%3Dliteratum%253Aachs%26aulast%3DAshton%26aufirst%3DT.%2BD.%26aulast%3DDevine%26aufirst%3DS.%2BM.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DLaleu%26aufirst%3DB.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DCreek%26aufirst%3DD.%2BJ.%26aulast%3DSleebs%26aufirst%3DB.%2BE.%26atitle%3DThe%2520Development%2520process%2520for%2520discovery%2520and%2520clinical%2520advancement%2520of%2520modern%2520antimalarials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10526%26epage%3D10562%26doi%3D10.1021%2Facs.jmedchem.9b00761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buenviaje, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graumans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Vegte-Bolmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gemert, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirjanata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebayang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marfurt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwanarusk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tungtaeng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettayacamin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattabongkot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tully, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patra, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinetz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span> <span> </span><span class="NLM_article-title">KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5060</span>– <span class="NLM_lpage">5067</span>, <span class="refDoi"> DOI: 10.1128/AAC.02727-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1128%2FAAC.02727-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=24913172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1eqs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=5060-5067&author=K.+L.+Kuhenauthor=A.+K.+Chatterjeeauthor=M.+Rottmannauthor=K.+Gagaringauthor=R.+Borboaauthor=J.+Buenviajeauthor=Z.+Chenauthor=C.+Francekauthor=T.+Wuauthor=A.+Nagleauthor=S.+W.+Barnesauthor=D.+Plouffeauthor=M.+C.+Leeauthor=D.+A.+Fidockauthor=W.+Graumansauthor=M.+van+de+Vegte-Bolmerauthor=G.+J.+van+Gemertauthor=G.+Wirjanataauthor=B.+Sebayangauthor=J.+Marfurtauthor=B.+Russellauthor=R.+Suwanaruskauthor=R.+N.+Priceauthor=F.+Nostenauthor=A.+Tungtaengauthor=M.+Gettayacaminauthor=J.+Sattabongkotauthor=J.+Taylorauthor=J.+R.+Walkerauthor=D.+Tullyauthor=K.+P.+Patraauthor=E.+L.+Flanneryauthor=J.+M.+Vinetzauthor=L.+Reniaauthor=R.+W.+Sauerweinauthor=E.+A.+Winzelerauthor=R.+J.+Glynneauthor=T.+T.+Diagana&title=KAF156+is+an+antimalarial+clinical+candidate+with+potential+for+use+in+prophylaxis%2C+treatment%2C+and+prevention+of+disease+transmission&doi=10.1128%2FAAC.02727-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">KAf156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission</span></div><div class="casAuthors">Kuhen, Kelli L.; Chatterjee, Arnab K.; Rottmann, Matthias; Gagaring, Kerstin; Borboa, Rachel; Buenviaje, Jennifer; Chen, Zhong; Francek, Carolyn; Wu, Tao; Nagle, Advait; Barnes, S. Whitney; Plouffe, David; Lee, Marcus C. S.; Fidock, David A.; Graumans, Wouter; van de Vegte-Bolmer, Marga; van Gemert, Geert J.; Wirjanata, Grennady; Sebayang, Boni; Marfurt, Jutta; Russell, Bruce; Suwanarusk, Rossarin; Price, Ric N.; Nosten, Francois; Tungtaeng, Anchalee; Gettayacamin, Montip; Sattabongkot, Jetsumon; Taylor, Jennifer; Walker, John R.; Tully, David; Patra, Kailash P.; Flannery, Erika L.; Vinetz, Joseph M.; Renia, Laurent; Sauerwein, Robert W.; Winzeler, Elizabeth A.; Glynne, Richard J.; Diagana, Thierry T.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5060-5067, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Renewed global efforts toward malaria eradication have highlighted the need for novel antimalarial agents with activity against multiple stages of the parasite life cycle.  We have previously reported the discovery of a novel class of antimalarial compds. in the imidazolopiperazine series that have activity in the prevention and treatment of blood stage infection in a mouse model of malaria.  Consistent with the previously reported activity profile of this series, the clin. candidate KAF156 shows blood schizonticidal activity with 50% inhibitory concns. of 6 to 17.4 nM against P. falciparum drug-sensitive and drug-resistant strains, as well as potent therapeutic activity in a mouse models of malaria with 50, 90, and 99 % EDs of 0.6, 0.9, and 1.4 mg/kg, resp.  When administered prophylactically in a sporozoite challenge mouse model, KAF156 is completely protective as a single oral dose of 10 mg/kg.  Finally, KAF156 displays potent Plasmodium transmission blocking activities both in vitro and in vivo.  Collectively, our data suggest that KAF156, currently under evaluation in clin. trials, has the potential to treat, prevent, and block the transmission of malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QluxrWtdq7Vg90H21EOLACvtfcHk0lhmZt3ZeCcNAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1eqs7fK&md5=c97e07e4832e871885546880084be5ca</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FAAC.02727-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02727-13%26sid%3Dliteratum%253Aachs%26aulast%3DKuhen%26aufirst%3DK.%2BL.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DBorboa%26aufirst%3DR.%26aulast%3DBuenviaje%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DFrancek%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DGraumans%26aufirst%3DW.%26aulast%3Dvan%2Bde%2BVegte-Bolmer%26aufirst%3DM.%26aulast%3Dvan%2BGemert%26aufirst%3DG.%2BJ.%26aulast%3DWirjanata%26aufirst%3DG.%26aulast%3DSebayang%26aufirst%3DB.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DB.%26aulast%3DSuwanarusk%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DTungtaeng%26aufirst%3DA.%26aulast%3DGettayacamin%26aufirst%3DM.%26aulast%3DSattabongkot%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DTully%26aufirst%3DD.%26aulast%3DPatra%26aufirst%3DK.%2BP.%26aulast%3DFlannery%26aufirst%3DE.%2BL.%26aulast%3DVinetz%26aufirst%3DJ.%2BM.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DSauerwein%26aufirst%3DR.%2BW.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26atitle%3DKAF156%2520is%2520an%2520antimalarial%2520clinical%2520candidate%2520with%2520potential%2520for%2520use%2520in%2520prophylaxis%252C%2520treatment%252C%2520and%2520prevention%2520of%2520disease%2520transmission%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D5060%26epage%3D5067%26doi%3D10.1128%2FAAC.02727-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uthaisin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanboonkunupakarn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuthasmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, F. J.</span></span> <span> </span><span class="NLM_article-title">Antimalarial activity of KAF156 in falciparum and vivax Malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">1152</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1602250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1056%2FNEJMoa1602250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=27653565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=1152-1160&author=N.+J.+Whiteauthor=T.+T.+Duongauthor=C.+Uthaisinauthor=F.+Nostenauthor=A.+P.+Phyoauthor=B.+Hanboonkunupakarnauthor=S.+Pukrittayakameeauthor=P.+Jittamalaauthor=K.+Chuthasmitauthor=M.+S.+Cheungauthor=Y.+Fengauthor=R.+Liauthor=B.+Magnussonauthor=M.+Sultanauthor=D.+Wieserauthor=X.+Xunauthor=R.+Zhaoauthor=T.+T.+Diaganaauthor=P.+Pertelauthor=F.+J.+Leong&title=Antimalarial+activity+of+KAF156+in+falciparum+and+vivax+Malaria&doi=10.1056%2FNEJMoa1602250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of KAF156 in falciparum and vivax malaria</span></div><div class="casAuthors">White, Nicholas J.; Duong, Tran T.; Uthaisin, Chirapong; Nosten, Francois; Phyo, Aung P.; Hanboonkunupakarn, Borimas; Pukrittayakamee, Sasithon; Jittamala, Podjanee; Chuthasmit, Kittiphum; Cheung, Ming S.; Feng, Yiyan; Li, Ruobing; Magnusson, Baldur; Sultan, Marc; Wieser, Daniela; Xun, Xiaolei; Zhao, Rong; Diagana, Thierry T.; Pertel, Peter; Leong, F. Joel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1152-1160</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: KAF156 belongs to a new class of antimalarial agents (imidazolopiperazines), with activity against asexual and sexual blood stages and the preerythrocytic liver stages of malarial parasites.  METHODS: We conducted a phase 2, open-label, two-part study at five centers in Thailand and Vietnam to assess the antimalarial efficacy, safety, and pharmacokinetic profile of KAF156 in adults with acute Plasmodium vivax or P. falciparum malaria.  Assessment of parasite clearance rates in cohorts of patients with vivax or falciparum malaria who were treated with multiple doses (400 mg once daily for 3 days) was followed by assessment of the cure rate at 28 days in a sep. cohort of patients with falciparum malaria who received a single dose (800 mg).  RESULTS: Median parasite clearance times were 45 h (interquartile range, 42 to 48) in 10 patients with falciparum malaria and 24 h (interquartile range, 20 to 30) in 10 patients with vivax malaria after treatment with the multiple-dose regimen and 49 h (interquartile range, 42 to 54) in 21 patients with falciparum malaria after treatment with the single dose.  Among the 21 patients who received the single dose and were followed for 28 days, 1 had reinfection and 7 had recrudescent infections (cure rate, 67%; 95% credible interval, 46 to 84).  The mean (±SD) KAF156 terminal elimination half-life was 44.1±8.9 h.  There were no serious adverse events in this small study.  The most common adverse events included sinus bradycardia, thrombocytopenia, hypokalemia, anemia, and hyperbilirubinemia.  Vomiting of grade 2 or higher occurred in 2 patients, 1 of whom discontinued treatment because of repeated vomiting after receiving the single 800-mg dose.  More adverse events were reported in the single-dose cohort, which had longer follow-up, than in the multiple-dose cohorts.  CONCLUSIONS: KAF156 showed antimalarial activity without evident safety concerns in a small no. of adults with uncomplicated P. vivax or P. falciparum malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHzWNldN2RLbVg90H21EOLACvtfcHk0lhmZt3ZeCcNAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrnN&md5=24d0943da6d583f8c0fe4fe9f380ec99</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1602250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1602250%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDuong%26aufirst%3DT.%2BT.%26aulast%3DUthaisin%26aufirst%3DC.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DHanboonkunupakarn%26aufirst%3DB.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DChuthasmit%26aufirst%3DK.%26aulast%3DCheung%26aufirst%3DM.%2BS.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DSultan%26aufirst%3DM.%26aulast%3DWieser%26aufirst%3DD.%26aulast%3DXun%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DPertel%26aufirst%3DP.%26aulast%3DLeong%26aufirst%3DF.%2BJ.%26atitle%3DAntimalarial%2520activity%2520of%2520KAF156%2520in%2520falciparum%2520and%2520vivax%2520Malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D1152%26epage%3D1160%26doi%3D10.1056%2FNEJMoa1602250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharia, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Paez, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwanarusk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jegla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span> <span> </span><span class="NLM_article-title">Spiroindolones, a potent compound class for the treatment of malaria</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>329</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1180</span>, <span class="refDoi"> DOI: 10.1126/science.1193225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1126%2Fscience.1193225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=20813948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2hsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2010&pages=1175-1180&author=M.+Rottmannauthor=C.+McNamaraauthor=B.+K.+Yeungauthor=M.+C.+Leeauthor=B.+Zouauthor=B.+Russellauthor=P.+Seitzauthor=D.+M.+Plouffeauthor=N.+V.+Dhariaauthor=J.+Tanauthor=S.+B.+Cohenauthor=K.+R.+Spencerauthor=G.+E.+Gonzalez-Paezauthor=S.+B.+Lakshminarayanaauthor=A.+Gohauthor=R.+Suwanaruskauthor=T.+Jeglaauthor=E.+K.+Schmittauthor=H.+P.+Beckauthor=R.+Brunauthor=F.+Nostenauthor=L.+Reniaauthor=V.+Dartoisauthor=T.+H.+Kellerauthor=D.+A.+Fidockauthor=E.+A.+Winzelerauthor=T.+T.+Diagana&title=Spiroindolones%2C+a+potent+compound+class+for+the+treatment+of+malaria&doi=10.1126%2Fscience.1193225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Spiroindolones, a Potent Compound Class for the Treatment of Malaria</span></div><div class="casAuthors">Rottmann, Matthias; McNamara, Case; Yeung, Bryan K. S.; Lee, Marcus C. S.; Zou, Bin; Russell, Bruce; Seitz, Patrick; Plouffe, David M.; Dharia, Neekesh V.; Tan, Jocelyn; Cohen, Steven B.; Spencer, Kathryn R.; Gonzalez-Paez, Gonzalo E.; Lakshminarayana, Suresh B.; Goh, Anne; Suwanarusk, Rossarin; Jegla, Timothy; Schmitt, Esther K.; Beck, Hans-Peter; Brun, Reto; Nosten, Francois; Renia, Laurent; Dartois, Veronique; Keller, Thomas H.; Fidock, David A.; Winzeler, Elizabeth A.; Diagana, Thierry T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">5996</span>),
    <span class="NLM_cas:pages">1175-1180</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Recent reports of increased tolerance to artemisinin derivs.-the most recently adopted class of antimalarials-have prompted a need for new treatments.  The spirotetrahydro-β-carbolines, or spiroindolones, are potent drugs that kill the blood stages of Plasmodium falciparum and Plasmodium vivax clin. isolates at low nanomolar concn.  Spiroindolones rapidly inhibit protein synthesis in P. falciparum, an effect that is ablated in parasites bearing nonsynonymous mutations in the gene encoding the P-type cation-transporter ATPase4 (PfATP4).  The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI6O1WaX-1b7Vg90H21EOLACvtfcHk0li0Qh3V2B57_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2hsr%252FJ&md5=239bc9babd5cb5f07e2be38741038e2c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.1193225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1193225%26sid%3Dliteratum%253Aachs%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DMcNamara%26aufirst%3DC.%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DZou%26aufirst%3DB.%26aulast%3DRussell%26aufirst%3DB.%26aulast%3DSeitz%26aufirst%3DP.%26aulast%3DPlouffe%26aufirst%3DD.%2BM.%26aulast%3DDharia%26aufirst%3DN.%2BV.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DSpencer%26aufirst%3DK.%2BR.%26aulast%3DGonzalez-Paez%26aufirst%3DG.%2BE.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DGoh%26aufirst%3DA.%26aulast%3DSuwanarusk%26aufirst%3DR.%26aulast%3DJegla%26aufirst%3DT.%26aulast%3DSchmitt%26aufirst%3DE.%2BK.%26aulast%3DBeck%26aufirst%3DH.%2BP.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26atitle%3DSpiroindolones%252C%2520a%2520potent%2520compound%2520class%2520for%2520the%2520treatment%2520of%2520malaria%26jtitle%3DScience%26date%3D2010%26volume%3D329%26spage%3D1175%26epage%3D1180%26doi%3D10.1126%2Fscience.1193225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coteron, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquivias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katneni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhamidipati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathurst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase inhibitors with clinical candidate potential</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5540</span>– <span class="NLM_lpage">5561</span>, <span class="refDoi"> DOI: 10.1021/jm200592f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200592f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVehsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5540-5561&author=J.+M.+Coteronauthor=M.+Marcoauthor=J.+Esquiviasauthor=X.+Dengauthor=K.+L.+Whiteauthor=J.+Whiteauthor=M.+Koltunauthor=F.+El+Mazouniauthor=S.+Kokkondaauthor=K.+Katneniauthor=R.+Bhamidipatiauthor=D.+M.+Shacklefordauthor=I.+Angulo-Barturenauthor=S.+B.+Ferrerauthor=M.+B.+Jimenez-Diazauthor=F.+J.+Gamoauthor=E.+J.+Goldsmithauthor=W.+N.+Charmanauthor=I.+Bathurstauthor=D.+Floydauthor=D.+Matthewsauthor=J.+N.+Burrowsauthor=P.+K.+Rathodauthor=S.+A.+Charmanauthor=M.+A.+Phillips&title=Structure-guided+lead+optimization+of+triazolopyrimidine-ring+substituents+identifies+potent+Plasmodium+falciparum+dihydroorotate+dehydrogenase+inhibitors+with+clinical+candidate+potential&doi=10.1021%2Fjm200592f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential</span></div><div class="casAuthors">Coteron, Jose M.; Marco, Maria; Esquivias, Jorge; Deng, Xiaoyi; White, Karen L.; White, John; Koltun, Maria; El Mazouni, Farah; Kokkonda, Sreekanth; Katneni, Kasiram; Bhamidipati, Ravi; Shackleford, David M.; Angulo-Barturen, Inigo; Ferrer, Santiago B.; Jimenez-Diaz, Maria Belen; Gamo, Francisco-Javier; Goldsmith, Elizabeth J.; Charman, William N.; Bathurst, Ian; Floyd, David; Matthews, David; Burrows, Jeremy N.; Rathod, Pradipsinh K.; Charman, Susan A.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5540-5561</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug therapy is the mainstay of antimalarial therapy, yet current drugs are threatened by the development of resistance.  In an effort to identify new potential antimalarials, we have undertaken a lead optimization program around our previously identified triazolopyrimidine-based series of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors.  The X-ray structure of PfDHODH was used to inform the medicinal chem. program allowing the identification of a potent and selective inhibitor (DSM265) that acts through DHODH inhibition to kill both sensitive and drug resistant strains of the parasite.  This compd. has similar potency to chloroquine in the humanized SCID mouse P. falciparum model, can be synthesized by a simple route, and rodent pharmacokinetic studies demonstrated it has excellent oral bioavailability, a long half-life and low clearance.  These studies have identified the first candidate in the triazolopyrimidine series to meet previously established progression criteria for efficacy and ADME properties, justifying further development of this compd. toward clin. candidate status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVpPPR2Tcs9rVg90H21EOLACvtfcHk0li0Qh3V2B57_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVehsbg%253D&md5=d92f71aeda04fbbbbcd8905a657df011</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm200592f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200592f%26sid%3Dliteratum%253Aachs%26aulast%3DCoteron%26aufirst%3DJ.%2BM.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DEsquivias%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DKoltun%26aufirst%3DM.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DKatneni%26aufirst%3DK.%26aulast%3DBhamidipati%26aufirst%3DR.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DFerrer%26aufirst%3DS.%2BB.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DGoldsmith%26aufirst%3DE.%2BJ.%26aulast%3DCharman%26aufirst%3DW.%2BN.%26aulast%3DBathurst%26aufirst%3DI.%26aulast%3DFloyd%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DStructure-guided%2520lead%2520optimization%2520of%2520triazolopyrimidine-ring%2520substituents%2520identifies%2520potent%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520inhibitors%2520with%2520clinical%2520candidate%2520potential%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5540%26epage%3D5561%26doi%3D10.1021%2Fjm200592f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotharius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benito, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazaga, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haselden, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louttit, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechering, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinden, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickham, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gahagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirsalis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathhurst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span> <span> </span><span class="NLM_article-title">A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">296ra111</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aaa6645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1126%2Fscitranslmed.aaa6645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=26180101" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&author=M.+A.+Phillipsauthor=J.+Lothariusauthor=K.+Marshauthor=J.+Whiteauthor=A.+Dayanauthor=K.+L.+Whiteauthor=J.+W.+Njorogeauthor=F.+El+Mazouniauthor=Y.+Laoauthor=S.+Kokkondaauthor=D.+R.+Tomchickauthor=X.+Dengauthor=T.+Lairdauthor=S.+N.+Bhatiaauthor=S.+Marchauthor=C.+L.+Ngauthor=D.+A.+Fidockauthor=S.+Wittlinauthor=M.+Lafuente-Monasterioauthor=F.+J.+Benitoauthor=L.+M.+Alonsoauthor=M.+S.+Martinezauthor=M.+B.+Jimenez-Diazauthor=S.+F.+Bazagaauthor=I.+Angulo-Barturenauthor=J.+N.+Haseldenauthor=J.+Louttitauthor=Y.+Cuiauthor=A.+Sridharauthor=A.+M.+Zeemanauthor=C.+Kockenauthor=R.+Sauerweinauthor=K.+Decheringauthor=V.+M.+Averyauthor=S.+Duffyauthor=M.+Delvesauthor=R.+Sindenauthor=A.+Rueckerauthor=K.+S.+Wickhamauthor=R.+Rochfordauthor=J.+Gahagenauthor=L.+Iyerauthor=E.+Riccioauthor=J.+Mirsalisauthor=I.+Bathhurstauthor=T.+Rueckleauthor=X.+Dingauthor=B.+Campoauthor=D.+Leroyauthor=M.+J.+Rogersauthor=P.+K.+Rathodauthor=J.+N.+Burrowsauthor=S.+A.+Charman&title=A+long-duration+dihydroorotate+dehydrogenase+inhibitor+%28DSM265%29+for+prevention+and+treatment+of+malaria&doi=10.1126%2Fscitranslmed.aaa6645"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaa6645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaa6645%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DLotharius%26aufirst%3DJ.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DDayan%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DNjoroge%26aufirst%3DJ.%2BW.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DLao%26aufirst%3DY.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DTomchick%26aufirst%3DD.%2BR.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DLaird%26aufirst%3DT.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26aulast%3DMarch%26aufirst%3DS.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%26aulast%3DBenito%26aufirst%3DF.%2BJ.%26aulast%3DAlonso%26aufirst%3DL.%2BM.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DBazaga%26aufirst%3DS.%2BF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DHaselden%26aufirst%3DJ.%2BN.%26aulast%3DLouttit%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DKocken%26aufirst%3DC.%26aulast%3DSauerwein%26aufirst%3DR.%26aulast%3DDechering%26aufirst%3DK.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DDelves%26aufirst%3DM.%26aulast%3DSinden%26aufirst%3DR.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DWickham%26aufirst%3DK.%2BS.%26aulast%3DRochford%26aufirst%3DR.%26aulast%3DGahagen%26aufirst%3DJ.%26aulast%3DIyer%26aufirst%3DL.%26aulast%3DRiccio%26aufirst%3DE.%26aulast%3DMirsalis%26aufirst%3DJ.%26aulast%3DBathhurst%26aufirst%3DI.%26aulast%3DRueckle%26aufirst%3DT.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DRogers%26aufirst%3DM.%2BJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26atitle%3DA%2520long-duration%2520dihydroorotate%2520dehydrogenase%2520inhibitor%2520%2528DSM265%2529%2520for%2520prevention%2520and%2520treatment%2520of%2520malaria%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26doi%3D10.1126%2Fscitranslmed.aaa6645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paquet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Manach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrera, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrich, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagborough, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakutansky, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morizzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheurer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechering, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tungtaeng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanachayangkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witty, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodenreider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solapure, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkholtz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">eaad9735</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aad9735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1126%2Fscitranslmed.aad9735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28446690" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&author=T.+Paquetauthor=C.+Le+Manachauthor=D.+G.+Cabreraauthor=Y.+Younisauthor=P.+P.+Henrichauthor=T.+S.+Abrahamauthor=M.+C.+S.+Leeauthor=R.+Basakauthor=S.+Ghidelli-Disseauthor=M.+J.+Lafuente-Monasterioauthor=M.+Bantscheffauthor=A.+Rueckerauthor=A.+M.+Blagboroughauthor=S.+E.+Zakutanskyauthor=A.+M.+Zeemanauthor=K.+L.+Whiteauthor=D.+M.+Shacklefordauthor=J.+Mannilaauthor=J.+Morizziauthor=C.+Scheurerauthor=I.+Angulo-Barturenauthor=M.+S.+Martinezauthor=S.+Ferrerauthor=L.+M.+Sanzauthor=F.+J.+Gamoauthor=J.+Readerauthor=M.+Bothaauthor=K.+J.+Decheringauthor=R.+W.+Sauerweinauthor=A.+Tungtaengauthor=P.+Vanachayangkulauthor=C.+S.+Limauthor=J.+Burrowsauthor=M.+J.+Wittyauthor=K.+C.+Marshauthor=C.+Bodenreiderauthor=R.+Rochfordauthor=S.+M.+Solapureauthor=M.+B.+Jimenez-Diazauthor=S.+Wittlinauthor=S.+A.+Charmanauthor=C.+Doniniauthor=B.+Campoauthor=L.+M.+Birkholtzauthor=K.+K.+Hansonauthor=G.+Drewesauthor=C.+H.+M.+Kockenauthor=M.+J.+Delvesauthor=D.+Leroyauthor=D.+A.+Fidockauthor=D.+Watersonauthor=L.+J.+Streetauthor=K.+Chibale&title=Antimalarial+efficacy+of+MMV390048%2C+an+inhibitor+of+Plasmodium+phosphatidylinositol+4-kinase&doi=10.1126%2Fscitranslmed.aad9735"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aad9735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aad9735%26sid%3Dliteratum%253Aachs%26aulast%3DPaquet%26aufirst%3DT.%26aulast%3DLe%2BManach%26aufirst%3DC.%26aulast%3DCabrera%26aufirst%3DD.%2BG.%26aulast%3DYounis%26aufirst%3DY.%26aulast%3DHenrich%26aufirst%3DP.%2BP.%26aulast%3DAbraham%26aufirst%3DT.%2BS.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DBasak%26aufirst%3DR.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DBlagborough%26aufirst%3DA.%2BM.%26aulast%3DZakutansky%26aufirst%3DS.%2BE.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DMannila%26aufirst%3DJ.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DScheurer%26aufirst%3DC.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DSanz%26aufirst%3DL.%2BM.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DReader%26aufirst%3DJ.%26aulast%3DBotha%26aufirst%3DM.%26aulast%3DDechering%26aufirst%3DK.%2BJ.%26aulast%3DSauerwein%26aufirst%3DR.%2BW.%26aulast%3DTungtaeng%26aufirst%3DA.%26aulast%3DVanachayangkul%26aufirst%3DP.%26aulast%3DLim%26aufirst%3DC.%2BS.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DWitty%26aufirst%3DM.%2BJ.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DBodenreider%26aufirst%3DC.%26aulast%3DRochford%26aufirst%3DR.%26aulast%3DSolapure%26aufirst%3DS.%2BM.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DDonini%26aufirst%3DC.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DBirkholtz%26aufirst%3DL.%2BM.%26aulast%3DHanson%26aufirst%3DK.%2BK.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DKocken%26aufirst%3DC.%2BH.%2BM.%26aulast%3DDelves%26aufirst%3DM.%2BJ.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DAntimalarial%2520efficacy%2520of%2520MMV390048%252C%2520an%2520inhibitor%2520of%2520Plasmodium%2520phosphatidylinositol%25204-kinase%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26doi%3D10.1126%2Fscitranslmed.aad9735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutteridge, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooft van Huijsduijnen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaszubska, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, T. N. C.</span></span> <span> </span><span class="NLM_article-title">New developments in anti-malarial target candidate and product profiles</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>, <span class="NLM_elocation-id">26</span> <span class="refDoi"> DOI: 10.1186/s12936-016-1675-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1186%2Fs12936-016-1675-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28086874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsFCqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&author=J.+N.+Burrowsauthor=S.+Duparcauthor=W.+E.+Gutteridgeauthor=R.+Hooft+van+Huijsduijnenauthor=W.+Kaszubskaauthor=F.+Macintyreauthor=S.+Mazzuriauthor=J.+J.+Mohrleauthor=T.+N.+C.+Wells&title=New+developments+in+anti-malarial+target+candidate+and+product+profiles&doi=10.1186%2Fs12936-016-1675-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">New developments in anti-malarial target candidate and product profiles</span></div><div class="casAuthors">Burrows, Jeremy N.; Duparc, Stephan; Gutteridge, Winston E.; Hooft van Huijsduijnen, Rob; Kaszubska, Wiweka; MacIntyre, Fiona; Mazzuri, Sebastien; Mohrle, Jorg J.; Wells, Timothy N. C.</div><div class="citationInfo"><span class="NLM_cas:title">Malaria Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26/1-26/29</span>CODEN:
                <span class="NLM_cas:coden">MJAOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-2875</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  A decade of discovery and development of new anti-malarial medicines has led to a renewed focus on malaria elimination and eradication.  Changes in the way new anti-malarial drugs are discovered and developed have led to a dramatic increase in the no. and diversity of new mols. presently in pre-clin. and early clin. development.  The twin challenges faced can be summarized by multi-drug resistant malaria from the Greater Mekong Subregion, and the need to provide simplified medicines.  This review lists changes in anti-malarial target candidate and target product profiles over the last 4 years.  As well as new medicines to treat disease and prevent transmission, there has been increased focus on the longer term goal of finding new medicines for chemoprotection, potentially with long-acting mols., or parenteral formulations.  Other gaps in the malaria armamentarium, such as drugs to treat severe malaria and endectocides (that kill mosquitoes which feed on people who have taken the drug), are defined here.  Ultimately the elimination of malaria requires medicines that are safe and well-tolerated to be used in vulnerable populations: in pregnancy, esp. the first trimester, and in those suffering from malnutrition or co-infection with other pathogens.  These updates reflect the maturing of an understanding of the key challenges in producing the next generation of medicines to control, eliminate and ultimately eradicate malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjgdhMYAylM7Vg90H21EOLACvtfcHk0lil5IQGby8OVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsFCqu7g%253D&md5=17984994f7a29c9fb184faa5214d4d35</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Fs12936-016-1675-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-016-1675-x%26sid%3Dliteratum%253Aachs%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DGutteridge%26aufirst%3DW.%2BE.%26aulast%3DHooft%2Bvan%2BHuijsduijnen%26aufirst%3DR.%26aulast%3DKaszubska%26aufirst%3DW.%26aulast%3DMacintyre%26aufirst%3DF.%26aulast%3DMazzuri%26aufirst%3DS.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DWells%26aufirst%3DT.%2BN.%2BC.%26atitle%3DNew%2520developments%2520in%2520anti-malarial%2520target%2520candidate%2520and%2520product%2520profiles%26jtitle%3DMalar.%2520J.%26date%3D2017%26volume%3D16%26doi%3D10.1186%2Fs12936-016-1675-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lover, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span> <span> </span><span class="NLM_article-title">Malaria Elimination: Time to Target All Species</span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.17-0869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.4269%2Fajtmh.17-0869" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=29761762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A280%3ADC%252BC1Mfjtlaitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2018&pages=17-23&author=A.+A.+Loverauthor=J.+K.+Bairdauthor=R.+Goslingauthor=R.+N.+Price&title=Malaria+Elimination%3A+Time+to+Target+All+Species&doi=10.4269%2Fajtmh.17-0869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Malaria Elimination: Time to Target All Species</span></div><div class="casAuthors">Lover Andrew A; Gosling Roly; Baird J Kevin; Price Ric N; Baird J Kevin; Price Ric N</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of tropical medicine and hygiene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Important strides have been made within the past decade toward malaria elimination in many regions, and with this progress, the feasibility of eradication is once again under discussion.  If the ambitious goal of eradication is to be achieved by 2040, all species of Plasmodium infecting humans will need to be targeted with evidence-based and concerted interventions.  In this perspective, the potential barriers to achieving global malaria elimination are discussed with respect to the related diversities in host, parasite, and vector populations.  We argue that control strategies need to be reorientated from a sequential attack on each species, dominated by Plasmodium falciparum to one that targets all species in parallel.  A set of research themes is proposed to mitigate the potential setbacks on the pathway to a malaria-free world.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgausn-8JY9n6CEoQgWY10fW6udTcc2eZfWmolNYmfeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mfjtlaitg%253D%253D&md5=f1fad1867951725cd089f4cf9b9161e8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.17-0869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.17-0869%26sid%3Dliteratum%253Aachs%26aulast%3DLover%26aufirst%3DA.%2BA.%26aulast%3DBaird%26aufirst%3DJ.%2BK.%26aulast%3DGosling%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26atitle%3DMalaria%2520Elimination%253A%2520Time%2520to%2520Target%2520All%2520Species%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D2018%26volume%3D99%26spage%3D17%26epage%3D23%26doi%3D10.4269%2Fajtmh.17-0869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haston, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, K. R.</span></span> <span> </span><span class="NLM_article-title">Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria — United States</span>. <i>MMWR. Morb. Mortal. Wkly. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1062</span>– <span class="NLM_lpage">1068</span>, <span class="refDoi"> DOI: 10.15585/mmwr.mm6846a4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.15585%2Fmmwr.mm6846a4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=31751320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmslOqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2019&pages=1062-1068&author=J.+C.+Hastonauthor=J.+Hwangauthor=K.+R.+Tan&title=Guidance+for+Using+Tafenoquine+for+Prevention+and+Antirelapse+Therapy+for+Malaria+%E2%80%94+United+States&doi=10.15585%2Fmmwr.mm6846a4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Guidance for using tafenoquine for prevention and antirelapse therapy for Malaria - United States, 2019</span></div><div class="casAuthors">Haston, Julia C.; Hwang, Jimee; Tan, Kathrine R.</div><div class="citationInfo"><span class="NLM_cas:title">Morbidity and Mortality Weekly Report</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">1062-1068</span>CODEN:
                <span class="NLM_cas:coden">MMWRC7</span>;
        ISSN:<span class="NLM_cas:issn">1545-861X</span>.
    
            (<span class="NLM_cas:orgname">Centers for Disease Control and Prevention</span>)
        </div><div class="casAbstract">What is already known about this topic.  Malaria can be prevented by taking antimalarials when traveling to an area with malaria.  Treatment of malaria caused by Plasmodium vivax and Plasmodium ovale requires antirelapse therapy to kill the dormant liver-stage parasite.  What is added by this report.  Adults aged ≥18 years can take tafenoquine (Arakoda 100 mg tablets) to prevent malaria.  Persons aged ≥16 years requiring antirelapse therapy for P. vivax or P. ovale can take tafenoquine (Krintafel 150 mg tablets).  Before using tafenoquine, quant. testing to rule out glucose-6-phosphate dehydrogenase deficiency is required.  What are the implications for public health practice.  Tafenoquine is another option for malaria chemoprophylaxis and for antirelapse therapy.  The simplified dosing regimen has the potential to improve adherence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSfel4DO7vTbVg90H21EOLACvtfcHk0lgibfKzPVASeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmslOqtLs%253D&md5=789750eb53c53b9455d6e3460ea15c71</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.15585%2Fmmwr.mm6846a4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15585%252Fmmwr.mm6846a4%26sid%3Dliteratum%253Aachs%26aulast%3DHaston%26aufirst%3DJ.%2BC.%26aulast%3DHwang%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DK.%2BR.%26atitle%3DGuidance%2520for%2520Using%2520Tafenoquine%2520for%2520Prevention%2520and%2520Antirelapse%2520Therapy%2520for%2520Malaria%2520%25E2%2580%2594%2520United%2520States%26jtitle%3DMMWR.%2520Morb.%2520Mortal.%2520Wkly.%2520Rep.%26date%3D2019%26volume%3D68%26spage%3D1062%26epage%3D1068%26doi%3D10.15585%2Fmmwr.mm6846a4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katneni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, F. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crighton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huertas-Valentin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chittimalla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahi, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Lead optimization of a pyrrole-based dihydroorotate dehydrogenase inhibitor series for the treatment of malaria</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4929</span>– <span class="NLM_lpage">4956</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00311</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00311" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtl2lu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4929-4956&author=S.+Kokkondaauthor=X.+Dengauthor=K.+L.+Whiteauthor=F.+El+Mazouniauthor=J.+Whiteauthor=D.+M.+Shacklefordauthor=K.+Katneniauthor=F.+C.+K.+Chiuauthor=H.+Barkerauthor=J.+McLarenauthor=E.+Crightonauthor=G.+Chenauthor=I.+Angulo-Barturenauthor=M.+B.+Jimenez-Diazauthor=S.+Ferrerauthor=L.+Huertas-Valentinauthor=M.+S.+Martinez-Martinezauthor=M.+J.+Lafuente-Monasterioauthor=R.+Chittimallaauthor=S.+P.+Shahiauthor=S.+Wittlinauthor=D.+Watersonauthor=J.+N.+Burrowsauthor=D.+Matthewsauthor=D.+Tomchickauthor=P.+K.+Rathodauthor=M.+J.+Palmerauthor=S.+A.+Charmanauthor=M.+A.+Phillips&title=Lead+optimization+of+a+pyrrole-based+dihydroorotate+dehydrogenase+inhibitor+series+for+the+treatment+of+malaria&doi=10.1021%2Facs.jmedchem.0c00311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria</span></div><div class="casAuthors">Kokkonda, Sreekanth; Deng, Xiaoyi; White, Karen L.; El Mazouni, Farah; White, John; Shackleford, David M.; Katneni, Kasiram; Chiu, Francis C. K.; Barker, Helena; McLaren, Jenna; Crighton, Elly; Chen, Gong; Angulo-Barturen, Inigo; Jimenez-Diaz, Maria Belen; Ferrer, Santiago; Huertas-Valentin, Leticia; Martinez-Martinez, Maria Santos; Lafuente-Monasterio, Maria Jose; Chittimalla, Rajesh; Shahi, Shatrughan P.; Wittlin, Sergio; Waterson, David; Burrows, Jeremy N.; Matthews, Dave; Tomchick, Diana; Rathod, Pradipsinh K.; Palmer, Michael J.; Charman, Susan A.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4929-4956</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Malaria puts at risk nearly half the world's population and causes high mortality in sub-Saharan Africa, while drug resistance threatens current therapies.  The pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) is a validated target for malaria treatment based on our finding that triazolopyrimidine DSM265 (1) showed efficacy in clin. studies.  Herein, we describe optimization of a pyrrole-based series identified using a target-based DHODH screen.  Compds. with nanomolar potency vs. Plasmodium DHODH and Plasmodium parasites were identified with good pharmacol. properties.  X-ray studies showed that the pyrroles bind an alternative enzyme conformation from 1 leading to improved species selectivity vs. mammalian enzymes and equiv. activity on Plasmodium falciparum and Plasmodium vivax DHODH.  The best lead DSM502 (37)(I) showed in vivo efficacy at similar levels of blood exposure to 1, although metabolic stability was reduced.  Overall, the pyrrole-based DHODH inhibitors provide an attractive alternative scaffold for the development of new antimalarial compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxKUG8uEm6XLVg90H21EOLACvtfcHk0lgibfKzPVASeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtl2lu7o%253D&md5=33fcfe54e02132d8fd9a4816d40212b3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00311%26sid%3Dliteratum%253Aachs%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DKatneni%26aufirst%3DK.%26aulast%3DChiu%26aufirst%3DF.%2BC.%2BK.%26aulast%3DBarker%26aufirst%3DH.%26aulast%3DMcLaren%26aufirst%3DJ.%26aulast%3DCrighton%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DHuertas-Valentin%26aufirst%3DL.%26aulast%3DMartinez-Martinez%26aufirst%3DM.%2BS.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DChittimalla%26aufirst%3DR.%26aulast%3DShahi%26aufirst%3DS.%2BP.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DTomchick%26aufirst%3DD.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPalmer%26aufirst%3DM.%2BJ.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DLead%2520optimization%2520of%2520a%2520pyrrole-based%2520dihydroorotate%2520dehydrogenase%2520inhibitor%2520series%2520for%2520the%2520treatment%2520of%2520malaria%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4929%26epage%3D4956%26doi%3D10.1021%2Facs.jmedchem.0c00311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotharius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rückle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekuloski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobeau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebrevska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosario, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möhrle, J. J.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30171-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2FS1473-3099%2817%2930171-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28363636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlWmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=626-635&author=J.+S.+McCarthyauthor=J.+Lothariusauthor=T.+R%C3%BCckleauthor=S.+Chalonauthor=M.+A.+Phillipsauthor=S.+Elliottauthor=S.+Sekuloskiauthor=P.+Griffinauthor=C.+L.+Ngauthor=D.+A.+Fidockauthor=L.+Marquartauthor=N.+S.+Williamsauthor=N.+Gobeauauthor=L.+Bebrevskaauthor=M.+Rosarioauthor=K.+Marshauthor=J.+J.+M%C3%B6hrle&title=Safety%2C+tolerability%2C+pharmacokinetics%2C+and+activity+of+the+novel+long-acting+antimalarial+DSM265%3A+a+two-part+first-in-human+phase+1a%2F1b+randomised+study&doi=10.1016%2FS1473-3099%2817%2930171-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study</span></div><div class="casAuthors">McCarthy, James S.; Lotharius, Julie; Ruckle, Thomas; Chalon, Stephan; Phillips, Margaret A.; Elliott, Suzanne; Sekuloski, Silvana; Griffin, Paul; Ng, Caroline L.; Fidock, David A.; Marquart, Louise; Williams, Noelle S.; Gobeau, Nathalie; Bebrevska, Lidiya; Rosario, Maria; Marsh, Kennan; Mohrle, Jorg J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">626-635</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">DSM265 is a novel antimalarial that inhibits plasmodial dihydroorotate dehydrogenase, an enzyme essential for pyrimidine biosynthesis.  We investigated the safety, tolerability, and pharmacokinetics of DSM265, and tested its antimalarial activity.  Healthy participants aged 18-55 years were enrolled in a two-part study: part 1, a single ascending dose (25-1200 mg), double-blind, randomised, placebo-controlled study, and part 2, an open-label, randomised, active-comparator controlled study, in which participants were inoculated with Plasmodium falciparum induced blood-stage malaria (IBSM) and treated with DSM265 (150 mg) or mefloquine (10 mg/kg).  Primary endpoints were DSM265 safety, tolerability, and pharmacokinetics.  Randomisation lists were created using a validated, automated system.  Both parts were registered with the Australian New Zealand Clin. Trials Registry, no. ACTRN12613000522718 (part 1) and no. ACTRN12613000527763 (part 2).  In part 1, 73 participants were enrolled between Apr. 12, 2013, and July 14, 2015 (DSM265, n = 55; placebo, n = 18).  In part 2, nine participants were enrolled between Sept 30 and Nov 25, 2013 (150 mg DSM265, n = 7; 10 mg/kg mefloquine, n = 2).  In part 1, 117 adverse events were reported; no drug-related serious or severe events were reported.  The most common drug-related adverse event was headache.  The mean DSM265 peak plasma concn. (Cmax) ranged between 1310 ng/mL and 34 800 ng/mL and was reached in a median time (tmax) between 1.5 h and 4 h, with a mean elimination half-life between 86 h and 118 h.  In part 2, the log10 parasite redn. ratio at 48 h in the DSM265 (150 mg) group was 1.55 (95% CI 1.42-1.67) and in the mefloquine (10 mg/kg) group was 2.34 (2.17-2.52), corresponding to a parasite clearance half-life of 9.4 h (8.7-10.2) and 6.2 h (5.7-6.7), resp.  The median min. inhibitory concn. of DSM265 in blood was estd. as 1040 ng/mL (range 552-1500), resulting in a predicted single efficacious dose of 340 mg.  Parasite clearance was significantly faster in participants who received mefloquine than in participants who received DSM265 (p<0.0001).  The good safety profile, long elimination half-life, and antimalarial effect of DSM265 supports its development as a partner drug in a single-dose antimalarial combination treatment.  Wellcome Trust, UK Department for International Development, Global Health Innovative Technol. Fund, Bill & Melinda Gates Foundation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc6SKwiEAKqbVg90H21EOLACvtfcHk0ljrKjAE4X2BmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlWmur8%253D&md5=144cece3cf70a64af921f7f37df7c72d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930171-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930171-8%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DJ.%2BS.%26aulast%3DLotharius%26aufirst%3DJ.%26aulast%3DR%25C3%25BCckle%26aufirst%3DT.%26aulast%3DChalon%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DElliott%26aufirst%3DS.%26aulast%3DSekuloski%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DP.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DMarquart%26aufirst%3DL.%26aulast%3DWilliams%26aufirst%3DN.%2BS.%26aulast%3DGobeau%26aufirst%3DN.%26aulast%3DBebrevska%26aufirst%3DL.%26aulast%3DRosario%26aufirst%3DM.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DM%25C3%25B6hrle%26aufirst%3DJ.%2BJ.%26atitle%3DSafety%252C%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520activity%2520of%2520the%2520novel%2520long-acting%2520antimalarial%2520DSM265%253A%2520a%2520two-part%2520first-in-human%2520phase%25201a%252F1b%2520randomised%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2017%26volume%3D17%26spage%3D626%26epage%3D635%26doi%3D10.1016%2FS1473-3099%2817%2930171-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llanos-Cuentas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casapia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuquiyauri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinojosa, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosario, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toovey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arch, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozenberg, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowell, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooft
van Huijsduijnen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobeau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araeipour, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andenmatten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span> <span> </span><span class="NLM_article-title">Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated <i>Plasmodium falciparum</i> or <i>Plasmodium vivax</i> malaria infection: a proof-of-concept, open-label, phase 2a study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">883</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(18)30309-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2FS1473-3099%2818%2930309-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=29909069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFyqurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=874-883&author=A.+Llanos-Cuentasauthor=M.+Casapiaauthor=R.+Chuquiyauriauthor=J.+C.+Hinojosaauthor=N.+Kerrauthor=M.+Rosarioauthor=S.+Tooveyauthor=R.+H.+Archauthor=M.+A.+Phillipsauthor=F.+D.+Rozenbergauthor=J.+Bathauthor=C.+L.+Ngauthor=A.+N.+Cowellauthor=E.+A.+Winzelerauthor=D.+A.+Fidockauthor=M.+Bakerauthor=J.+J.+Mohrleauthor=R.+Hooft%0Avan+Huijsduijnenauthor=N.+Gobeauauthor=N.+Araeipourauthor=N.+Andenmattenauthor=T.+Ruckleauthor=S.+Duparc&title=Antimalarial+activity+of+single-dose+DSM265%2C+a+novel+plasmodium+dihydroorotate+dehydrogenase+inhibitor%2C+in+patients+with+uncomplicated+Plasmodium+falciparum+or+Plasmodium+vivax+malaria+infection%3A+a+proof-of-concept%2C+open-label%2C+phase+2a+study&doi=10.1016%2FS1473-3099%2818%2930309-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study</span></div><div class="casAuthors">Llanos-Cuentas, Alejandro; Casapia, Martin; Chuquiyauri, Raul; Hinojosa, Juan-Carlos; Kerr, Nicola; Rosario, Maria; Toovey, Stephen; Arch, Robert H.; Phillips, Margaret A.; Rozenberg, Felix D.; Bath, Jade; Ng, Caroline L.; Cowell, Annie N.; Winzeler, Elizabeth A.; Fidock, David A.; Baker, Mark; Mohrle, Jorg J.; Hooft van Huijsduijnen, Rob; Gobeau, Nathalie; Araeipour, Nada; Andenmatten, Nicole; Ruckle, Thomas; Duparc, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">874-883</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against blood and liver stages of Plasmodium falciparum.  This study aimed to assess the efficacy of DSM265 in patients with P falciparum or Plasmodium vivax malaria infection.  This proof-of-concept, open-label, phase 2a study was conducted at the Asociacio´n Civil Selva Amazo´nica in Iquitos, Peru.  Patients aged 18-70 years, weighing 45-90 kg, who had clin. malaria (P falciparum or P vivax monoinfection) and fever within the previous 24 h were eligible.  Exclusion criteria were clin. or lab. signs of severe malaria, inability to take oral medicine, and use of other antimalarial treatment in the preceding 14 days.  Patients were divided into cohorts of those with P falciparum (cohort a) or P vivax (cohort b) infection.  Two initial cohorts received single oral doses of 400 mg DSM265.  Patients were followed up for efficacy for 28 days and safety for 35 days.  Further cohorts received escalated or de-escalated doses of DSM265, after safety and efficacy assessment of the initial dose.  The primary endpoints were the proportion of patients achieving PCR-adjusted adequate clin. and parasitol. response (ACPR) by day 14 for patients infected with P falciparum and the proportion of patients achieving a crude cure by day 14 for those infected with P vivax.  Cohort success, the criteria for dose escalation, was defined as ACPR (P falciparum) or crude cure (P vivax) in at least 80% of patients in the cohort.  The primary anal. was done in the intention-to-treat population (ITT) and the per-protocol population, and safety analyses were done in all patients who received the study drug.  This study is registered at ClinicalTrials.gov (NCT02123290).  Between Jan 12, 2015, and Dec 2, 2015, 45 Peruvian patients (24 with P falciparum [cohort a] and 21 with P vivax [cohort b] infection) were sequentially enrolled.  For patients with P falciparum malaria in the per-protocol population, all 11 (100%) in the 400 mg group and eight (80%) of ten in the 250 mg group achieved ACPR on day 14.  In the ITT anal., 11 (85%) of 13 in the 400 mg group and eight (73%) of 11 in the 250 mg group achieved ACPR at day 14.  For the patients with P vivax malaria, the primary endpoint was not met.  In the per-protocol anal., none of four patients who had 400 mg, three (50%) of six who had 600 mg, and one (25%) of four who had 800 mg DSM265 achieved crude cure at day 14.  In the ITT anal., none of five in the 400 mg group, three (33%) of nine in the 600 mg group, and one (14%) of seven in the 800 mg group achieved crude cure at day 14.  During the 28-day extended observation of P falciparum patients, a resistance-assocd. mutation in the gene encoding the DSM265 target DHODH was obsd. in two of four recurring patients.  DSM265 was well tolerated.  The most common adverse events were pyrexia (20 [44%] of 45) and headache (18 [40%] of 45), which are both common symptoms of malaria, and no patients had any treatment-related serious adverse events or adverse events leading to study discontinuation.  After a single dose of DSM265, P falciparum parasitemia was rapidly cleared, whereas against P vivax, DSM265 showed less effective clearance kinetics.  Its long duration of action provides the potential to prevent recurrence of P falciparum after treatment with a single dose, which should be further assessed in future combination studies.  The Global Health Innovative Technol. Fund, the Bill & Melinda Gates Foundation, the National Institutes of Health (R01 AI103058), the Wellcome Trust, and the UK Department of International Development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgJbUWoNq8m7Vg90H21EOLACvtfcHk0ljrKjAE4X2BmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFyqurnI&md5=05eacd75b07eee65fca20ec28ea3c1c4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2818%2930309-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252818%252930309-8%26sid%3Dliteratum%253Aachs%26aulast%3DLlanos-Cuentas%26aufirst%3DA.%26aulast%3DCasapia%26aufirst%3DM.%26aulast%3DChuquiyauri%26aufirst%3DR.%26aulast%3DHinojosa%26aufirst%3DJ.%2BC.%26aulast%3DKerr%26aufirst%3DN.%26aulast%3DRosario%26aufirst%3DM.%26aulast%3DToovey%26aufirst%3DS.%26aulast%3DArch%26aufirst%3DR.%2BH.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRozenberg%26aufirst%3DF.%2BD.%26aulast%3DBath%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DCowell%26aufirst%3DA.%2BN.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DBaker%26aufirst%3DM.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DHooft%2Bvan%2BHuijsduijnen%26aufirst%3DR.%26aulast%3DGobeau%26aufirst%3DN.%26aulast%3DAraeipour%26aufirst%3DN.%26aulast%3DAndenmatten%26aufirst%3DN.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DDuparc%26aufirst%3DS.%26atitle%3DAntimalarial%2520activity%2520of%2520single-dose%2520DSM265%252C%2520a%2520novel%2520plasmodium%2520dihydroorotate%2520dehydrogenase%2520inhibitor%252C%2520in%2520patients%2520with%2520uncomplicated%2520Plasmodium%2520falciparum%2520or%2520Plasmodium%2520vivax%2520malaria%2520infection%253A%2520a%2520proof-of-concept%252C%2520open-label%252C%2520phase%25202a%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2018%26volume%3D18%26spage%3D874%26epage%3D883%26doi%3D10.1016%2FS1473-3099%2818%2930309-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foquet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuenchob, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishbaugher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camargo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bial, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappe, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikolajczak, S. A.</span></span> <span> </span><span class="NLM_article-title">Assessing drug efficacy against <i>Plasmodium falciparum</i> liver stages in vivo</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e92587</span> <span class="refDoi"> DOI: 10.1172/jci.insight.92587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1172%2Fjci.insight.92587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=29321371" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&author=E.+L.+Flanneryauthor=L.+Foquetauthor=V.+Chuenchobauthor=M.+Fishbaugherauthor=Z.+Billmanauthor=M.+J.+Navarroauthor=W.+Betzauthor=T.+M.+Olsenauthor=J.+Leeauthor=N.+Camargoauthor=T.+Nguyenauthor=C.+Schaferauthor=B.+K.+Sackauthor=E.+M.+Wilsonauthor=J.+Saundersauthor=J.+Bialauthor=B.+Campoauthor=S.+A.+Charmanauthor=S.+C.+Murphyauthor=M.+A.+Phillipsauthor=S.+H.+Kappeauthor=S.+A.+Mikolajczak&title=Assessing+drug+efficacy+against+Plasmodium+falciparum+liver+stages+in+vivo&doi=10.1172%2Fjci.insight.92587"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.92587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.92587%26sid%3Dliteratum%253Aachs%26aulast%3DFlannery%26aufirst%3DE.%2BL.%26aulast%3DFoquet%26aufirst%3DL.%26aulast%3DChuenchob%26aufirst%3DV.%26aulast%3DFishbaugher%26aufirst%3DM.%26aulast%3DBillman%26aufirst%3DZ.%26aulast%3DNavarro%26aufirst%3DM.%2BJ.%26aulast%3DBetz%26aufirst%3DW.%26aulast%3DOlsen%26aufirst%3DT.%2BM.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DCamargo%26aufirst%3DN.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DSchafer%26aufirst%3DC.%26aulast%3DSack%26aufirst%3DB.%2BK.%26aulast%3DWilson%26aufirst%3DE.%2BM.%26aulast%3DSaunders%26aufirst%3DJ.%26aulast%3DBial%26aufirst%3DJ.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DMurphy%26aufirst%3DS.%2BC.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DKappe%26aufirst%3DS.%2BH.%26aulast%3DMikolajczak%26aufirst%3DS.%2BA.%26atitle%3DAssessing%2520drug%2520efficacy%2520against%2520Plasmodium%2520falciparum%2520liver%2520stages%2520in%2520vivo%26jtitle%3DJCI%2520Insight%26date%3D2018%26volume%3D3%26doi%3D10.1172%2Fjci.insight.92587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duke, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seilie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanron, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishbaugher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VonGoedert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritzen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappe, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcsisin, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andenmatten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kublin, J. G.</span></span> <span> </span><span class="NLM_article-title">A Randomized Trial Evaluating the Prophylactic Activity of DSM265 against preerythrocytic <i>Plasmodium falciparum</i> infection during controlled human malarial infection by mosquito bites and direct venous inoculation</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>217</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">702</span>, <span class="refDoi"> DOI: 10.1093/infdis/jix613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1093%2Finfdis%2Fjix613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=29216395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=2018&pages=693-702&author=S.+C.+Murphyauthor=E.+R.+Dukeauthor=K.+J.+Shipmanauthor=R.+L.+Jensenauthor=Y.+Fongauthor=S.+Fergusonauthor=H.+E.+Janesauthor=K.+Gillespieauthor=A.+M.+Seilieauthor=A.+E.+Hanronauthor=L.+Rinnauthor=M.+Fishbaugherauthor=T.+VonGoedertauthor=E.+Fritzenauthor=S.+H.+Kappeauthor=M.+Changauthor=J.+C.+Sousaauthor=S.+R.+Marcsisinauthor=S.+Chalonauthor=S.+Duparcauthor=N.+Kerrauthor=J.+J.+Mohrleauthor=N.+Andenmattenauthor=T.+Rueckleauthor=J.+G.+Kublin&title=A+Randomized+Trial+Evaluating+the+Prophylactic+Activity+of+DSM265+against+preerythrocytic+Plasmodium+falciparum+infection+during+controlled+human+malarial+infection+by+mosquito+bites+and+direct+venous+inoculation&doi=10.1093%2Finfdis%2Fjix613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized trial evaluating the prophylactic activity of DSM265 against preerythrocytic Plasmodium falciparum infection during controlled human malarial infection by mosquito bites and direct venous inoculation</span></div><div class="casAuthors">Murphy, Sean C.; Duke, Elizabeth R.; Shipman, Kelly J.; Jensen, Ryan L.; Fong, Youyi; Ferguson, Sue; Janes, Holly E.; Gillespie, Kevin; Seilie, Annette M.; Hanron, Amelia E.; Rinn, Laurie; Fishbaugher, Matthew; VonGoedert, Tracie; Fritzen, Emma; Kappe, Stefan H.; Chang, Ming; Sousa, Jason C.; Marcsisin, Sean R.; Chalon, Stephan; Duparc, Stephan; Kerr, Nicola; Mohrle, Jorg J.; Andenmatten, Nicole; Rueckle, Thomas; Kublin, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">693-702</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">1537-6613</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  DSM265 is a selective inhibitor of Plasmodium dihydroorotate dehydrogenase that fully protected against controlled human malarial infection (CHMI) by direct venous inoculation of Plasmodium falciparum sporozoites when administered 1 day before challenge and provided partial protection when administered 7 days before challenge.  Methods.  A double-blinded, randomized, placebo-controlled trial was performed to assess safety, tolerability, pharmacokinetics, and efficacy of 1 oral dose of 400 mg of DSM265 before CHMI.  Three cohorts were studied, with DSM265 administered 3 or 7 days before direct venous inoculation of sporozoites or 7 days before 5 bites from infected mosquitoes.  Results.  DSM265-related adverse events consisted of mild-to-moderate headache and gastrointestinal symptoms.  DSM265 concns. were consistent with pharmacokinetic models (mean area under the curve extrapolated to infinity, 1707 μg*h/mL).  Placebo-treated participants became pos. by quant. reverse transcription-polymerase chain reaction (qRT-PCR) and were treated 7-10 days after CHMI.  Among DSM265-treated subjects, 2 of 6 in each cohort were sterilely protected.  DSM265-treated recipients had longer times to development of parasitemia than placebo-treated participants (P < .004).  Conclusions.  This was the first CHMI study of a novel antimalarial compd. to compare direct venous inoculation of sporozoites and mosquito bites.  Times to qRT-PCR positivity and treatment were comparable for both routes.  DSM265 given 3 or 7 days before CHMI was safe and well tolerated but sterilely protected only one third of participants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMZHT578xgCrVg90H21EOLACvtfcHk0lgnScAlS2r07g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsFGlsL8%253D&md5=09ad9e8ac99393967ca57e475f2f52bb</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjix613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjix613%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DS.%2BC.%26aulast%3DDuke%26aufirst%3DE.%2BR.%26aulast%3DShipman%26aufirst%3DK.%2BJ.%26aulast%3DJensen%26aufirst%3DR.%2BL.%26aulast%3DFong%26aufirst%3DY.%26aulast%3DFerguson%26aufirst%3DS.%26aulast%3DJanes%26aufirst%3DH.%2BE.%26aulast%3DGillespie%26aufirst%3DK.%26aulast%3DSeilie%26aufirst%3DA.%2BM.%26aulast%3DHanron%26aufirst%3DA.%2BE.%26aulast%3DRinn%26aufirst%3DL.%26aulast%3DFishbaugher%26aufirst%3DM.%26aulast%3DVonGoedert%26aufirst%3DT.%26aulast%3DFritzen%26aufirst%3DE.%26aulast%3DKappe%26aufirst%3DS.%2BH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DSousa%26aufirst%3DJ.%2BC.%26aulast%3DMarcsisin%26aufirst%3DS.%2BR.%26aulast%3DChalon%26aufirst%3DS.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DKerr%26aufirst%3DN.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DAndenmatten%26aufirst%3DN.%26aulast%3DRueckle%26aufirst%3DT.%26aulast%3DKublin%26aufirst%3DJ.%2BG.%26atitle%3DA%2520Randomized%2520Trial%2520Evaluating%2520the%2520Prophylactic%2520Activity%2520of%2520DSM265%2520against%2520preerythrocytic%2520Plasmodium%2520falciparum%2520infection%2520during%2520controlled%2520human%2520malarial%2520infection%2520by%2520mosquito%2520bites%2520and%2520direct%2520venous%2520inoculation%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2018%26volume%3D217%26spage%3D693%26epage%3D702%26doi%3D10.1093%2Finfdis%2Fjix613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulyok, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murbeth, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samec, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobeau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calle, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulyok, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebru, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granados, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruckner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguetse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalremruata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, B. K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsner, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordmuller, B.</span></span> <span> </span><span class="NLM_article-title">DSM265 for <i>Plasmodium falciparum</i> chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30139-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2FS1473-3099%2817%2930139-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28363637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlWmtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=636-644&author=M.+Sulyokauthor=T.+Ruckleauthor=A.+Rothauthor=R.+E.+Murbethauthor=S.+Chalonauthor=N.+Kerrauthor=S.+S.+Samecauthor=N.+Gobeauauthor=C.+L.+Calleauthor=J.+Ibanezauthor=Z.+Sulyokauthor=J.+Heldauthor=T.+Gebruauthor=P.+Granadosauthor=S.+Brucknerauthor=C.+Nguetseauthor=J.+Mengueauthor=A.+Lalremruataauthor=B.+K.+L.+Simauthor=S.+L.+Hoffmanauthor=J.+J.+Mohrleauthor=P.+G.+Kremsnerauthor=B.+Mordmuller&title=DSM265+for+Plasmodium+falciparum+chemoprophylaxis%3A+a+randomised%2C+double+blinded%2C+phase+1+trial+with+controlled+human+malaria+infection&doi=10.1016%2FS1473-3099%2817%2930139-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection</span></div><div class="casAuthors">Sulyok, Mihaly; Rueckle, Thomas; Roth, Alexandra; Muerbeth, Raymund E.; Chalon, Stephan; Kerr, Nicola; Samec, Sonia Schnieper; Gobeau, Nathalie; Calle, Carlos Lamsfus; Ibanez, Javier; Sulyok, Zita; Held, Jana; Gebru, Tamirat; Granados, Patricia; Brueckner, Sina; Nguetse, Christian; Mengue, Juliana; Lalremruata, Albert; Sim, Kim Lee; Hoffman, Stephen L.; Moehrle, Joerg J.; Kremsner, Peter G.; Mordmueller, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">636-644</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A drug for causal (ie, pre-erythrocytic) prophylaxis of Plasmodium falciparum malaria with prolonged activity would substantially advance malaria control.  DSM265 is an exptl. antimalarial that selectively inhibits the parasite dihydroorotate dehydrogenase.  DSM265 shows in vitro activity against liver and blood stages of P falciparum.  We assessed the prophylactic activity of DSM265 against controlled human malaria infection (CHMI).  At the Institute of Tropical Medicine, Eberhard Karls University (Tubingen, Germany), healthy, malaria-naive adults were allocated to receive 400 mg DSM265 or placebo either 1 day (cohort 1A) or 7 days (cohort 2) before CHMI by direct venous inoculation (DVI) of 3200 aseptic, purified, cryopreserved P falciparum sporozoites (PfSPZ Challenge; Sanaria Inc, Rockville, MD, USA).  An addnl. group received daily atovaquone-proguanil (250-100 mg) for 9 days, starting 1 day before CHMI (cohort 1B).  Allocation to DSM265, atovaquone-proguanil, or placebo was randomised by an interactive web response system.  Allocation to cohort 1A and 1B was open-label, within cohorts 1A and 2, allocation to DSM265 and placebo was double-blinded.  All treatments were given orally.  Volunteers were treated with an antimalarial on day 28, or when parasitemic, as detected by thick blood smear (TBS) microscopy.  The primary efficacy endpoint was time-to-parasitemia, assessed by TBS.  All participants receiving at least one dose of chemoprophylaxis or placebo were considered for safety, those receiving PfSPZ Challenge for efficacy analyzes.  Log-rank test was used to compare time-to-parasitemia between interventions.  The trial was registered with ClinicalTrials.gov, no. NCT02450578.22 participants were enrolled between Oct 23, 2015, and Jan 18, 2016.  Five participants received 400 mg DSM265 and two participants received placebo 1 day before CHMI (cohort 1A), six participants received daily atovaquone-proguanil 1 day before CHMI (cohort 1B), and six participants received 400 mg DSM265 and two participants received placebo 7 days before CHMI (cohort 2).  Five of five participants receiving DSM265 1 day before CHMI and six of six in the atovaquone-proguanil cohort were protected, whereas placebo recipients (two of two) developed malaria on days 11 and 14.  When given 7 days before CHMI, three of six volunteers receiving DSM265 became TBS pos. on days 11, 13, and 24.  The remaining three DSM265-treated, TBS-neg. participants of cohort 2 developed transient submicroscopic parasitemia.  Both participants receiving placebo 7 days before CHMI became TBS pos. on day 11.  The only possible DSM265-related adverse event was a moderate transient elevation in serum bilirubin in one participant.  A single dose of 400 mg DSM265 was well tolerated and had causal prophylactic activity when given 1 day before CHMI.  Future trials are needed to investigate further the use of DSM265 for the prophylaxis of malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Qz_g361v_rVg90H21EOLACvtfcHk0lgnScAlS2r07g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlWmtbY%253D&md5=17e414f86bbefda108b858930ae28bfc</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930139-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930139-1%26sid%3Dliteratum%253Aachs%26aulast%3DSulyok%26aufirst%3DM.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DA.%26aulast%3DMurbeth%26aufirst%3DR.%2BE.%26aulast%3DChalon%26aufirst%3DS.%26aulast%3DKerr%26aufirst%3DN.%26aulast%3DSamec%26aufirst%3DS.%2BS.%26aulast%3DGobeau%26aufirst%3DN.%26aulast%3DCalle%26aufirst%3DC.%2BL.%26aulast%3DIbanez%26aufirst%3DJ.%26aulast%3DSulyok%26aufirst%3DZ.%26aulast%3DHeld%26aufirst%3DJ.%26aulast%3DGebru%26aufirst%3DT.%26aulast%3DGranados%26aufirst%3DP.%26aulast%3DBruckner%26aufirst%3DS.%26aulast%3DNguetse%26aufirst%3DC.%26aulast%3DMengue%26aufirst%3DJ.%26aulast%3DLalremruata%26aufirst%3DA.%26aulast%3DSim%26aufirst%3DB.%2BK.%2BL.%26aulast%3DHoffman%26aufirst%3DS.%2BL.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DKremsner%26aufirst%3DP.%2BG.%26aulast%3DMordmuller%26aufirst%3DB.%26atitle%3DDSM265%2520for%2520Plasmodium%2520falciparum%2520chemoprophylaxis%253A%2520a%2520randomised%252C%2520double%2520blinded%252C%2520phase%25201%2520trial%2520with%2520controlled%2520human%2520malaria%2520infection%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2017%26volume%3D17%26spage%3D636%26epage%3D644%26doi%3D10.1016%2FS1473-3099%2817%2930139-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austin, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockroft, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenlock, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, R. J.</span></span> <span> </span><span class="NLM_article-title">The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1497</span>– <span class="NLM_lpage">1503</span>, <span class="refDoi"> DOI: 10.1124/dmd.30.12.1497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1124%2Fdmd.30.12.1497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=12433825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD38XptVyisbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=1497-1503&author=R.+P.+Austinauthor=P.+Bartonauthor=S.+L.+Cockroftauthor=M.+C.+Wenlockauthor=R.+J.+Riley&title=The+influence+of+nonspecific+microsomal+binding+on+apparent+intrinsic+clearance%2C+and+its+prediction+from+physicochemical+properties&doi=10.1124%2Fdmd.30.12.1497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties</span></div><div class="casAuthors">Austin, Rupert P.; Barton, Patrick; Cockroft, Scott L.; Wenlock, Mark C.; Riley, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1497-1503</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The apparent intrinsic clearance of 13 drugs has been detd. using rat liver microsomes at three different concns. of microsomal protein.  The kinetics was studied using the in vitro half-life method.  The nonspecific binding of these drugs to the microsomes was also studied under the same conditions, except for cofactor removal, using equil. dialysis.  The intrinsic clearances are shown to be dependent on the microsomal concn., but are approx. const. when cor. for the extent of nonspecific binding to the microsomes.  The large difference between obsd. intrinsic clearance and unbound intrinsic clearance that exists for some compds., particularly lipophilic bases, is highlighted.  A simple model has been developed for understanding the binding of compds. to microsomes and is demonstrated to accurately predict the extent of microsomal binding at one concn. of microsomes from measurement at another.  The binding of a further 25 drugs to rat liver microsomes at a microsomal concn. of 1 mg/mL was also studied, along with measurements of lipophilicity using octanol-water partition coeffs.  It is shown that the extent of microsomal binding is correlated with lipophilicity, but that basic compds. show a different behavior to acidic and neutral compds.  Microsomal binding is shown to be best predicted using a model where logP is used for basic compds., and logD7.4 is used for acidic and neutral compds.  This model has been developed further so that the extent of binding to microsomes of any given concn. can be estd. purely from a knowledge of lipophilicity and ionization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGril7K_-q51KLVg90H21EOLACvtfcHk0lhThgPAkFDFXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptVyisbg%253D&md5=8ff465ee407bf503e38862da9d2fbdc6</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.12.1497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.12.1497%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%26aufirst%3DR.%2BP.%26aulast%3DBarton%26aufirst%3DP.%26aulast%3DCockroft%26aufirst%3DS.%2BL.%26aulast%3DWenlock%26aufirst%3DM.%2BC.%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520influence%2520of%2520nonspecific%2520microsomal%2520binding%2520on%2520apparent%2520intrinsic%2520clearance%252C%2520and%2520its%2520prediction%2520from%2520physicochemical%2520properties%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D1497%26epage%3D1503%26doi%3D10.1124%2Fdmd.30.12.1497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Clearance in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2245</span>– <span class="NLM_lpage">2255</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVCru7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2245-2255&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Clearance+in+Drug+Design&doi=10.1021%2Facs.jmedchem.8b01263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Clearance in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2245-2255</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Due to its implications for both dose level and frequency, clearance rate is one of the most important pharmacokinetic parameters to consider in the design of drug candidates.  Clearance can be classified into three general categories, namely, metabolic transformation, renal excretion, and hepatobiliary excretion.  Within each category, there are a host of biochem. and physiol. mechanisms that ultimately det. the clearance rate.  Physiochem. properties are often indicative of the rate-detg. mechanism, with lipophilic mols. tending toward metab. and hydrophilic, polar mols. tending toward passive or active excretion.  Optimization of clearance requires recognition of the major clearance mechanisms and use of the most relevant in vitro and in vivo tools to develop structure-clearance relationships.  The reliability of methods to detect and predict human clearance varies across mechanisms.  While methods for metabolic and passive renal clearance have proven reasonably robust, there is a clear need for better tools to support the optimization of transporter-mediated clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8nvv_L3pL-LVg90H21EOLACvtfcHk0lhThgPAkFDFXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVCru7fO&md5=e4a4d72056ed9b41842a11934fa4bffc</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01263%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DClearance%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2245%26epage%3D2255%26doi%3D10.1021%2Facs.jmedchem.8b01263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, F. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crighton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katneni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morizzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almond, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moehrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abla, N.</span></span> <span> </span><span class="NLM_article-title">An in vitro toolbox to accelerate anti-malarial drug discovery and development</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>, <span class="NLM_elocation-id">1</span> <span class="refDoi"> DOI: 10.1186/s12936-019-3075-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1186%2Fs12936-019-3075-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=31898492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltlKisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&author=S.+A.+Charmanauthor=A.+Andreuauthor=H.+Barkerauthor=S.+Blundellauthor=A.+Campbellauthor=M.+Campbellauthor=G.+Chenauthor=F.+C.+K.+Chiuauthor=E.+Crightonauthor=K.+Katneniauthor=J.+Morizziauthor=R.+Patilauthor=T.+Phamauthor=E.+Ryanauthor=J.+Saundersauthor=D.+M.+Shacklefordauthor=K.+L.+Whiteauthor=L.+Almondauthor=M.+Dickinsauthor=D.+A.+Smithauthor=J.+J.+Moehrleauthor=J.+N.+Burrowsauthor=N.+Abla&title=An+in+vitro+toolbox+to+accelerate+anti-malarial+drug+discovery+and+development&doi=10.1186%2Fs12936-019-3075-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">An in vitro toolbox to accelerate anti-malarial drug discovery and development</span></div><div class="casAuthors">Charman, Susan A.; Andreu, Alice; Barker, Helena; Blundell, Scott; Campbell, Anna; Campbell, Michael; Chen, Gong; Chiu, Francis C. K.; Crighton, Elly; Katneni, Kasiram; Morizzi, Julia; Patil, Rahul; Pham, Thao; Ryan, Eileen; Saunders, Jessica; Shackleford, David M.; White, Karen L.; Almond, Lisa; Dickins, Maurice; Smith, Dennis A.; Moehrle, Joerg J.; Burrows, Jeremy N.; Abla, Nada</div><div class="citationInfo"><span class="NLM_cas:title">Malaria Journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1</span>CODEN:
                <span class="NLM_cas:coden">MJAOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-2875</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Modeling and simulation are being increasingly utilized to support the discovery and development of new anti-malarial drugs.  These approaches require reliable in vitro data for physicochem. properties, permeability, binding, intrinsic clearance and cytochrome P 450 inhibition.  This work was conducted to generate an in vitro data toolbox using standardized methods for a set of 45 anti-malarial drugs and to assess changes in physicochem. properties in relation to changing target product and candidate profiles.  Methods: Ionization consts. were detd. by potentiometric titrn. and partition coeffs. were measured using a shake-flask method.  Soly. was assessed in biorelevant media and permeability coeffs. and efflux ratios were detd. using Caco-2 cell monolayers.  Binding to plasma and media proteins was measured using either ultracentrifugation or rapid equil. dialysis.  Metabolic stability and cytochrome P 450 inhibition were assessed using human liver microsomes.  Sample anal. was conducted by LC-MS/MS.  Results: Both soly. and fraction unbound decreased, and permeability and unbound intrinsic clearance increased, with increasing Log D7.4.  In general, development compds. were somewhat more lipophilic than legacy drugs.  For many compds., permeability and protein binding were challenging to assess and both required the use of exptl. conditions that minimized the impact of non-specific binding.  Intrinsic clearance in human liver microsomes was varied across the data set and several compds. exhibited no measurable substrate loss under the conditions used.  Inhibition of cytochrome P 450 enzymes was minimal for most compds.  Conclusions: This is the first data set to describe in vitro properties for 45 legacy and development anti-malarial drugs.  The studies identified several practical methodol. issues common to many of the more lipophilic compds. and highlighted areas which require more work to customize exptl. conditions for compds. being designed to meet the new target product profiles.  The dataset will be a valuable tool for malaria researchers aiming to develop PBPK models for the prediction of human PK properties and/or drug-drug interactions.  Furthermore, generation of this comprehensive data set within a single lab. allows direct comparison of properties across a large dataset and evaluation of changing property trends that have occurred over time with changing target product and candidate profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz-G7Yo6U877Vg90H21EOLACvtfcHk0lhThgPAkFDFXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltlKisQ%253D%253D&md5=a996cd5a032c9042bc957d0bddecbd3b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1186%2Fs12936-019-3075-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-019-3075-5%26sid%3Dliteratum%253Aachs%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DAndreu%26aufirst%3DA.%26aulast%3DBarker%26aufirst%3DH.%26aulast%3DBlundell%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DChiu%26aufirst%3DF.%2BC.%2BK.%26aulast%3DCrighton%26aufirst%3DE.%26aulast%3DKatneni%26aufirst%3DK.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DPatil%26aufirst%3DR.%26aulast%3DPham%26aufirst%3DT.%26aulast%3DRyan%26aufirst%3DE.%26aulast%3DSaunders%26aufirst%3DJ.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DAlmond%26aufirst%3DL.%26aulast%3DDickins%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DMoehrle%26aufirst%3DJ.%2BJ.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DAbla%26aufirst%3DN.%26atitle%3DAn%2520in%2520vitro%2520toolbox%2520to%2520accelerate%2520anti-malarial%2520drug%2520discovery%2520and%2520development%26jtitle%3DMalar.%2520J.%26date%3D2020%26volume%3D19%26doi%3D10.1186%2Fs12936-019-3075-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckley, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harradine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalvass, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamek-Gliszczynski, M. J.</span></span> <span> </span><span class="NLM_article-title">Industry perspective on contemporary protein-binding methodologies: considerations for regulatory drug-drug interaction and related guidelines on highly bound drugs</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">3442</span>– <span class="NLM_lpage">3452</span>, <span class="refDoi"> DOI: 10.1016/j.xphs.2017.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2Fj.xphs.2017.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28927987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Gmu7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2017&pages=3442-3452&author=L.+Diauthor=C.+Breenauthor=R.+Chambersauthor=S.+T.+Eckleyauthor=R.+Frickeauthor=A.+Ghoshauthor=P.+Harradineauthor=J.+C.+Kalvassauthor=S.+Hoauthor=C.+A.+Leeauthor=P.+Maratheauthor=E.+J.+Perkinsauthor=M.+Qianauthor=S.+Tseauthor=Z.+Yanauthor=M.+J.+Zamek-Gliszczynski&title=Industry+perspective+on+contemporary+protein-binding+methodologies%3A+considerations+for+regulatory+drug-drug+interaction+and+related+guidelines+on+highly+bound+drugs&doi=10.1016%2Fj.xphs.2017.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Industry Perspective on Contemporary Protein-Binding Methodologies: Considerations for Regulatory Drug-Drug Interaction and Related Guidelines on Highly Bound Drugs</span></div><div class="casAuthors">Di, Li; Breen, Christopher; Chambers, Rob; Eckley, Sean T.; Fricke, Robert; Ghosh, Avijit; Harradine, Paul; Kalvass, J. Cory; Ho, Stacy; Lee, Caroline A.; Marathe, Punit; Perkins, Everett J.; Qian, Mark; Tse, Susanna; Yan, Zhengyin; Zamek-Gliszczynski, Maciej J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3442-3452</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Regulatory agencies have recently issued drug-drug interaction guidelines, which require detn. of plasma protein binding (PPB).  To err on the conservative side, the agencies recommend that a 0.01 lower limit of fraction unbound (fu) be used for highly bound compds. (>99%), irresp. of the actual measured values.  While this may avoid false negatives, the recommendation would likely result in a high rate of false pos. predictions, resulting in unnecessary clin. studies and more stringent inclusion/exclusion criteria, which may add cost and time in delivery of new medicines to patients.  In this perspective, the authors provide a review of current approaches to measure PPB, and important determinants in enabling the accuracy and precision in these measurements.  The ability to measure fu is further illustrated by a cross-company data comparison of PPB for warfarin and itraconazole, demonstrating good concordance of the measured fu values.  The data indicate that fu values of ≤0.01 may be detd. accurately across labs. when appropriate methods are used.  These data, along with numerous other examples presented in the literature, support the use of exptl. measured fu values for drug-drug interaction predictions, rather than using the arbitrary cutoff value of 0.01 as recommended in current regulatory guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCMgObUz2ZArVg90H21EOLACvtfcHk0lg4YhZY4qyEwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Gmu7nO&md5=316d6854cc04968107b609a9ccae6eed</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.xphs.2017.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.xphs.2017.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DBreen%26aufirst%3DC.%26aulast%3DChambers%26aufirst%3DR.%26aulast%3DEckley%26aufirst%3DS.%2BT.%26aulast%3DFricke%26aufirst%3DR.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DHarradine%26aufirst%3DP.%26aulast%3DKalvass%26aufirst%3DJ.%2BC.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DPerkins%26aufirst%3DE.%2BJ.%26aulast%3DQian%26aufirst%3DM.%26aulast%3DTse%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26atitle%3DIndustry%2520perspective%2520on%2520contemporary%2520protein-binding%2520methodologies%253A%2520considerations%2520for%2520regulatory%2520drug-drug%2520interaction%2520and%2520related%2520guidelines%2520on%2520highly%2520bound%2520drugs%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D106%26spage%3D3442%26epage%3D3452%26doi%3D10.1016%2Fj.xphs.2017.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrisey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laroiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mather, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. B.</span></span> <span> </span><span class="NLM_article-title">Yeast dihydroorotate dehydrogenase as a new selectable marker for <i>Plasmodium falciparum</i> transfection</span>. <i>Mol. Biochem. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.molbiopara.2011.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2Fj.molbiopara.2011.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=21251930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsV2gtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2011&pages=29-34&author=S.+M.+Ganesanauthor=J.+M.+Morriseyauthor=H.+Keauthor=H.+J.+Painterauthor=K.+Laroiyaauthor=M.+A.+Phillipsauthor=P.+K.+Rathodauthor=M.+W.+Matherauthor=A.+B.+Vaidya&title=Yeast+dihydroorotate+dehydrogenase+as+a+new+selectable+marker+for+Plasmodium+falciparum+transfection&doi=10.1016%2Fj.molbiopara.2011.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Yeast dihydroorotate dehydrogenase as a new selectable marker for Plasmodium falciparum transfection</span></div><div class="casAuthors">Ganesan, Suresh M.; Morrisey, Joanne M.; Ke, Hangjun; Painter, Heather J.; Laroiya, Kamal; Phillips, Margaret A.; Rathod, Pradipsinh K.; Mather, Michael W.; Vaidya, Akhil B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Biochemical Parasitology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-34</span>CODEN:
                <span class="NLM_cas:coden">MBIPDP</span>;
        ISSN:<span class="NLM_cas:issn">0166-6851</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Genetic manipulation of Plasmodium falciparum in culture through transfection has provided numerous insights into the mol. and cell biol. of this parasite.  The procedure is rather cumbersome, and is limited by the no. of drug-resistant markers that can be used for selecting transfected parasites.  Here, the authors report a new selectable marker that could allow multiple transfections.  They have taken advantage of the finding that a crit. function of the mitochondrial electron transport chain (mtETC) in the erythrocytic stages of P. falciparum is the regeneration of ubiquinone as co-substrate of dihydroorotate dehydrogenase (DHODH), and that transgenic P. falciparum expressing ubiquinone-independent DHODH from yeast (yDHODH) are resistant to all mtETC inhibitors.  The authors assessed the possibility of using yDHODH as a pos. selectable marker for transfections of P. falciparum, including its use in gene disruption strategies.  They constructed a transfection vector designed for gene disruption, termed pUF-1, contg. the yDHODH gene as the pos. selection marker in combination with a previously described fused yeast cytosine deaminase-uracil phosphoribosyl transferase gene as a neg. selection marker.  Transfection of the D10 strain followed by selection with atovaquone yielded pos. selected parasites contg. the plasmid, demonstrating that yDHODH can be used as a selective marker.  Atovaquone, however, could not be used for such selection with the Dd2 strain of P. falciparum.  On the other hand, we demonstrated that yDHODH transgenic parasites could be selected in both strains by Plasmodium DHODH-specific triazolopyrimidine-based inhibitors.  Thus, selection with DHODH inhibitors was superior in that it successfully selected transgenic Dd2 parasites, as well as yielded transgenic parasites after a shorter period of selection.  As a proof of concept, the authors have successfully disrupted the type II vacuolar proton-pumping pyrophosphatase gene (PfVP2) in P. falciparum by double crossover recombination, showing that this gene is not essential for the survival of blood stage parasites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbgajAbUgQWLVg90H21EOLACvtfcHk0lg4YhZY4qyEwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsV2gtbg%253D&md5=f0a91cd88063879be3854c7aaff0ed72</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.molbiopara.2011.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molbiopara.2011.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DS.%2BM.%26aulast%3DMorrisey%26aufirst%3DJ.%2BM.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DPainter%26aufirst%3DH.%2BJ.%26aulast%3DLaroiya%26aufirst%3DK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DMather%26aufirst%3DM.%2BW.%26aulast%3DVaidya%26aufirst%3DA.%2BB.%26atitle%3DYeast%2520dihydroorotate%2520dehydrogenase%2520as%2520a%2520new%2520selectable%2520marker%2520for%2520Plasmodium%2520falciparum%2520transfection%26jtitle%3DMol.%2520Biochem.%2520Parasitol.%26date%3D2011%26volume%3D177%26spage%3D29%26epage%3D34%26doi%3D10.1016%2Fj.molbiopara.2011.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Painter, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrisey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mather, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. B.</span></span> <span> </span><span class="NLM_article-title">Specific role of mitochondrial electron transport in blood-stage <i>Plasmodium falciparum</i></span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>446</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1038/nature05572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1038%2Fnature05572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=17330044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1arsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=446&publication_year=2007&pages=88-91&author=H.+J.+Painterauthor=J.+M.+Morriseyauthor=M.+W.+Matherauthor=A.+B.+Vaidya&title=Specific+role+of+mitochondrial+electron+transport+in+blood-stage+Plasmodium+falciparum&doi=10.1038%2Fnature05572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum</span></div><div class="casAuthors">Painter, Heather J.; Morrisey, Joanne M.; Mather, Michael W.; Vaidya, Akhil B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">446</span>
        (<span class="NLM_cas:issue">7131</span>),
    <span class="NLM_cas:pages">88-91</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The origin of all mitochondria can be traced to the symbiotic arrangement that resulted in the emergence of eukaryotes in a world that was exclusively populated by prokaryotes.  This arrangement, however, has been in continuous genetic flux: the varying degrees of gene loss and transfer from the mitochondrial genome in different eukaryotic lineages seem to signify an ongoing 'conflict' between the host and the symbiont.  Eukaryotic parasites belonging to the phylum Apicomplexa provide an excellent example to support this view.  These organisms contain the smallest mitochondrial genomes known, with an organization that differs among various genera; one genus, Cryptosporidium, seems to have lost the entire mitochondrial genome.  Erythrocytic stages of the human malaria parasite Plasmodium falciparum seem to maintain an active mitochondrial electron transport chain to serve just one metabolic function: regeneration of ubiquinone required as the electron acceptor for dihydroorotate dehydrogenase, an essential enzyme for pyrimidine biosynthesis.  Transgenic P. falciparum parasites expressing Saccharomyces cerevisiae dihydroorotate dehydrogenase, which does not require ubiquinone as an electron acceptor, were completely resistant to inhibitors of mitochondrial electron transport.  Maintenance of mitochondrial membrane potential, however, was essential in these parasites, as indicated by their hypersensitivity to proguanil, a drug that collapsed the membrane potential in the presence of electron transport inhibitors.  Thus, acquisition of just one enzyme can render mitochondrial electron transport nonessential in erythrocytic stages of P. falciparum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb4_LLvNdFmLVg90H21EOLACvtfcHk0lhwvnNhtqH9Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1arsLc%253D&md5=9d0e94ce26c6711961f4245226bea858</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnature05572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05572%26sid%3Dliteratum%253Aachs%26aulast%3DPainter%26aufirst%3DH.%2BJ.%26aulast%3DMorrisey%26aufirst%3DJ.%2BM.%26aulast%3DMather%26aufirst%3DM.%2BW.%26aulast%3DVaidya%26aufirst%3DA.%2BB.%26atitle%3DSpecific%2520role%2520of%2520mitochondrial%2520electron%2520transport%2520in%2520blood-stage%2520Plasmodium%2520falciparum%26jtitle%3DNature%26date%3D2007%26volume%3D446%26spage%3D88%26epage%3D91%26doi%3D10.1038%2Fnature05572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceja, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrad, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumwebaze, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byaruhanga, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katairo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nsobya, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, R. A.</span></span> <span> </span><span class="NLM_article-title">Changing antimalarial drug sensitivities in uganda</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">e01516</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1128/AAC.01516-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1128%2FAAC.01516-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28923866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Crtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&pages=e01516-17&author=S.+A.+Rasmussenauthor=F.+G.+Cejaauthor=M.+D.+Conradauthor=P.+K.+Tumwebazeauthor=O.+Byaruhangaauthor=T.+Katairoauthor=S.+L.+Nsobyaauthor=P.+J.+Rosenthalauthor=R.+A.+Cooper&title=Changing+antimalarial+drug+sensitivities+in+uganda&doi=10.1128%2FAAC.01516-17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Changing Antimalarial Drug Sensitivities in Uganda</span></div><div class="casAuthors">Rasmussen, Stephanie A.; Ceja, Frida G.; Conrad, Melissa D.; Tumwebaze, Patrick K.; Byaruhanga, Oswald; Katairo, Thomas; Nsobya, Samuel L.; Rosenthal, Philip J.; Cooper, Roland A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e01516-17/1-e01516-17/11</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Dihydroartemisinin-piperaquine (DP) has demonstrated excellent efficacy for the treatment and prevention of malaria in Uganda.  However, resistance to both components of this regimen has emerged in Southeast Asia.  The efficacy of artemether-lumefantrine, the first-line regimen to treat malaria in Uganda, has also been excellent, but continued pressure may select for parasites with decreased sensitivity to lumefantrine.  To gain insight into current drug sensitivity patterns, ex vivo sensitivities were assessed and genotypes previously assocd. with altered drug sensitivity were characterized for 58 isolates collected in Tororo, Uganda, from subjects presenting in 2016 with malaria from the community or as part of a clin. trial comparing DP chemoprevention regimens.  Compared to community isolates, those from trial subjects had lower sensitivities to the aminoquinolines chloroquine, monodesethyl amodiaquine, and piperaquine and greater sensitivities to lumefantrine and mefloquine, an observation consistent with DP selection pressure.  Compared to results for isolates from 2010 to 2013, the sensitivities of 2016 community isolates to chloroquine, amodiaquine, and piperaquine improved (geometric mean 50% inhibitory concns. [IC50] = 248, 76.9, and 19.1 nM in 2010 to 2013 and 33.4, 14.9, and 7.5 nM in 2016, resp. [P < 0.001 for all comparisons]), the sensitivity to lumefantrine decreased (IC50 = 3.0 nM in 2010 to 2013 and 5.4 nM in 2016 [P < 0.001]), and the sensitivity to dihydroartemisinin was unchanged (IC50 = 1.4 nM).  These changes were accompanied by decreased prevalence of transporter mutations assocd. with aminoquinoline resistance and low prevalence of polymorphisms recently assocd. with resistance to artemisinins or piperaquine.  Antimalarial drug sensitivities are changing in Uganda, but novel genotypes assocd. with DP treatment failure in Asia are not prevalent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLcmYAqeEnqLVg90H21EOLACvtfcHk0lhwvnNhtqH9Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Crtb7M&md5=fb8a53f991d000575149db4b026359b4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1128%2FAAC.01516-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01516-17%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DS.%2BA.%26aulast%3DCeja%26aufirst%3DF.%2BG.%26aulast%3DConrad%26aufirst%3DM.%2BD.%26aulast%3DTumwebaze%26aufirst%3DP.%2BK.%26aulast%3DByaruhanga%26aufirst%3DO.%26aulast%3DKatairo%26aufirst%3DT.%26aulast%3DNsobya%26aufirst%3DS.%2BL.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DCooper%26aufirst%3DR.%2BA.%26atitle%3DChanging%2520antimalarial%2520drug%2520sensitivities%2520in%2520uganda%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2017%26volume%3D61%26spage%3De01516%26epage%3D17%26doi%3D10.1128%2FAAC.01516-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjalanagara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudra, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirjanata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noviyanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marfurt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazaga, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossignol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span> <span> </span><span class="NLM_article-title">A Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with improved drug-like properties for treatment and prevention of malaria</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">945</span>– <span class="NLM_lpage">957</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.6b00144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.6b00144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWmtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=945-957&author=M.+A.+Phillipsauthor=K.+L.+Whiteauthor=S.+Kokkondaauthor=X.+Dengauthor=J.+Whiteauthor=F.+El+Mazouniauthor=K.+Marshauthor=D.+R.+Tomchickauthor=K.+Manjalanagaraauthor=K.+R.+Rudraauthor=G.+Wirjanataauthor=R.+Noviyantiauthor=R.+N.+Priceauthor=J.+Marfurtauthor=D.+M.+Shacklefordauthor=F.+C.+Chiuauthor=M.+Campbellauthor=M.+B.+Jimenez-Diazauthor=S.+F.+Bazagaauthor=I.+Angulo-Barturenauthor=M.+S.+Martinezauthor=M.+Lafuente-Monasterioauthor=W.+Kaminskyauthor=K.+Silueauthor=A.+M.+Zeemanauthor=C.+Kockenauthor=D.+Leroyauthor=B.+Blascoauthor=E.+Rossignolauthor=T.+Rueckleauthor=D.+Matthewsauthor=J.+N.+Burrowsauthor=D.+Watersonauthor=M.+J.+Palmerauthor=P.+K.+Rathodauthor=S.+A.+Charman&title=A+Triazolopyrimidine-based+dihydroorotate+dehydrogenase+inhibitor+with+improved+drug-like+properties+for+treatment+and+prevention+of+malaria&doi=10.1021%2Facsinfecdis.6b00144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria</span></div><div class="casAuthors">Phillips, Margaret A.; White, Karen L.; Kokkonda, Sreekanth; Deng, Xiaoyi; White, John; El Mazouni, Farah; Marsh, Kennan; Tomchick, Diana R.; Manjalanagara, Krishne; Rudra, Kakali Rani; Wirjanata, Grennady; Noviyanti, Rintis; Price, Ric N.; Marfurt, Jutta; Shackleford, David M.; Chiu, Francis C. K.; Campbell, Michael; Jimenez-Diaz, Maria Belen; Bazaga, Santiago Ferrer; Angulo-Barturen, Inigo; Martinez, Maria Santos; Lafuente-Monasterio, Maria; Kaminsky, Werner; Silue, Kigbafori; Zeeman, Anne-Marie; Kocken, Clemens; Leroy, Didier; Blasco, Benjamin; Rossignol, Emilie; Rueckle, Thomas; Matthews, Dave; Burrows, Jeremy N.; Waterson, David; Palmer, Michael J.; Rathod, Pradipsinh K.; Charman, Susan A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">945-957</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The emergence of drug resistant malaria parasites continues to hamper efforts to control this lethal disease.  Dihydroorotate dehydrogenase has recently been validated as a new target for the treatment of malaria and a selective inhibitor I of the Plasmodium enzyme is currently in clin. development.  With the goal of identifying a backup compd. to I, the authors explored replacement of the SF5-aniline moiety of I with a series of CF3-pyridinyls, while maintaining the core triazolopyrimidine scaffold.  This effort led to the identification of II, which has improved soly., lower intrinsic clearance and increased plasma exposure after oral dosing compared to I, while maintaining a long predicted human half-life.  Its improved phys. and chem. properties will allow it to be formulated more readily than I.  II showed excellent efficacy in the SCID mouse model of P. falciparum malaria that supports the prediction of a low human dose (<200 mg).  Importantly II showed equal activity against both P. falciparum and P. vivax field isolates, while I was more active on P. falciparum.  II has the potential to be developed as a single dose cure or once-weekly chemopreventative for both P. falciparum and P. vivax malaria leading to its advancement as a preclin. development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE-Pm5_CT2LrVg90H21EOLACvtfcHk0lhwvnNhtqH9Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWmtbjJ&md5=df58b9d21b75ad84d6181d42a2341e60</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.6b00144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.6b00144%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DTomchick%26aufirst%3DD.%2BR.%26aulast%3DManjalanagara%26aufirst%3DK.%26aulast%3DRudra%26aufirst%3DK.%2BR.%26aulast%3DWirjanata%26aufirst%3DG.%26aulast%3DNoviyanti%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DChiu%26aufirst%3DF.%2BC.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DBazaga%26aufirst%3DS.%2BF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%26aulast%3DKaminsky%26aufirst%3DW.%26aulast%3DSilue%26aufirst%3DK.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DKocken%26aufirst%3DC.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DBlasco%26aufirst%3DB.%26aulast%3DRossignol%26aufirst%3DE.%26aulast%3DRueckle%26aufirst%3DT.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DPalmer%26aufirst%3DM.%2BJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26atitle%3DA%2520Triazolopyrimidine-based%2520dihydroorotate%2520dehydrogenase%2520inhibitor%2520with%2520improved%2520drug-like%2520properties%2520for%2520treatment%2520and%2520prevention%2520of%2520malaria%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2016%26volume%3D2%26spage%3D945%26epage%3D957%26doi%3D10.1021%2Facsinfecdis.6b00144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smilkstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriwilaijaroen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilairat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riscoe, M.</span></span> <span> </span><span class="NLM_article-title">Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1803</span>– <span class="NLM_lpage">1806</span>, <span class="refDoi"> DOI: 10.1128/AAC.48.5.1803-1806.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1128%2FAAC.48.5.1803-1806.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=15105138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjslGltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=1803-1806&author=M.+Smilksteinauthor=N.+Sriwilaijaroenauthor=J.+X.+Kellyauthor=P.+Wilairatauthor=M.+Riscoe&title=Simple+and+inexpensive+fluorescence-based+technique+for+high-throughput+antimalarial+drug+screening&doi=10.1128%2FAAC.48.5.1803-1806.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening</span></div><div class="casAuthors">Smilkstein, Martin; Sriwilaijaroen, Nongluk; Kelly, Jane Xu; Wilairat, Prapon; Riscoe, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1803-1806</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Radioisotopic assays involve expense, multistep protocols, equipment, and radioactivity safety requirements which are problematic in high-throughput drug testing.  This study reports an alternative, simple, robust, inexpensive, one-step fluorescence assay for use in antimalarial drug screening.  Parasite growth is detd. by using SYBR Green 1, a dye with marked fluorescence enhancement upon contact with Plasmodium DNA.  A side-by-side comparison of this fluorescence assay and a std. radioisotopic method was performed by testing known antimalarial agents against Plasmodium falciparum strain D6.  Both assay methods were used to det. the effective concn. of drug that resulted in a 50% redn. in the obsd. counts (EC50) after 48 h of parasite growth in the presence of each drug.  The EC50s of chloroquine, quinine, mefloquine, artemisinin, and 3,6-bis-.vepsiln.-(N,N-diethylamino)-amyloxyanthone were similar or identical by both techniques.  The results obtained with this new fluorescence assay suggest that it may be an ideal method for high-throughput antimalarial drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzXZZP9UWQ27Vg90H21EOLACvtfcHk0lhizWU8K7GdKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjslGltLw%253D&md5=84a9721da1d873dfca16d1f2570ed304</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.5.1803-1806.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.5.1803-1806.2004%26sid%3Dliteratum%253Aachs%26aulast%3DSmilkstein%26aufirst%3DM.%26aulast%3DSriwilaijaroen%26aufirst%3DN.%26aulast%3DKelly%26aufirst%3DJ.%2BX.%26aulast%3DWilairat%26aufirst%3DP.%26aulast%3DRiscoe%26aufirst%3DM.%26atitle%3DSimple%2520and%2520inexpensive%2520fluorescence-based%2520technique%2520for%2520high-throughput%2520antimalarial%2520drug%2520screening%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D1803%26epage%3D1806%26doi%3D10.1128%2FAAC.48.5.1803-1806.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhingra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afanador, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in <i>Plasmodium falciparum</i> that confer in vitro resistance to the clinical candidate DSM265</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.8b00211</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.8b00211" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVarurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=90-101&author=J.+Whiteauthor=S.+K.+Dhingraauthor=X.+Dengauthor=F.+El+Mazouniauthor=M.+C.+S.+Leeauthor=G.+A.+Afanadorauthor=A.+Lawongauthor=D.+R.+Tomchickauthor=C.+L.+Ngauthor=J.+Bathauthor=P.+K.+Rathodauthor=D.+A.+Fidockauthor=M.+A.+Phillips&title=Identification+and+mechanistic+understanding+of+dihydroorotate+dehydrogenase+point+mutations+in+Plasmodium+falciparum+that+confer+in+vitro+resistance+to+the+clinical+candidate+DSM265&doi=10.1021%2Facsinfecdis.8b00211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in Plasmodium falciparum that confer in vitro resistance to the clinical candidate DSM265</span></div><div class="casAuthors">White, John; Dhingra, Satish K.; Deng, Xiaoyi; El Mazouni, Farah; Lee, Marcus C. S.; Afanador, Gustavo A.; Lawong, Aloysus; Tomchick, Diana R.; Ng, Caroline L.; Bath, Jade; Rathod, Pradipsinh K.; Fidock, David A.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-101</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Malaria is one of the most challenging human infectious diseases, and both prevention and control have been hindered by the development of Plasmodium falciparum resistance to existing therapies.  Several new compds. with novel mechanisms are in clin. development for the treatment of malaria, including DSM265, an inhibitor of Plasmodium dihydroorotate dehydrogenase.  To explore the mechanisms by which resistance might develop to DSM265 in the field, we selected for DSM265-resistant P. falciparum parasites in vitro.  Any of five different amino acid changes led to reduced efficacy on the parasite and to decreased DSM265 binding to P. falciparum DHODH.  The DSM265-resistant parasites retained full sensitivity to atovaquone.  All but one of the obsd. mutations were in the DSM265 binding site, and the remaining C276F was in the adjacent flavin cofactor site.  The C276F mutation was previously identified in a recrudescent parasite during a Phase IIa clin. study.  We confirmed that this mutation (and the related C276Y) accounted for the full level of obsd. DSM265 resistance by regenerating the mutation using CRISPR/Cas9 genome editing.  X-ray structure anal. of the C276F mutant enzyme showed that conformational changes of nearby residues were required to accommodate the larger F276 residue, which in turn led to a restriction in the size of the DSM265 binding pocket.  These findings underscore the importance of developing DSM265 as part of a combination therapy with other agents for successful use against malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQMMzkCwd_zrVg90H21EOLACvtfcHk0lhizWU8K7GdKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVarurzN&md5=6b9001020d2332016c7f189a6dbe9380</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.8b00211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.8b00211%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DDhingra%26aufirst%3DS.%2BK.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DAfanador%26aufirst%3DG.%2BA.%26aulast%3DLawong%26aufirst%3DA.%26aulast%3DTomchick%26aufirst%3DD.%2BR.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DBath%26aufirst%3DJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DIdentification%2520and%2520mechanistic%2520understanding%2520of%2520dihydroorotate%2520dehydrogenase%2520point%2520mutations%2520in%2520Plasmodium%2520falciparum%2520that%2520confer%2520in%2520vitro%2520resistance%2520to%2520the%2520clinical%2520candidate%2520DSM265%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2019%26volume%3D5%26spage%3D90%26epage%3D101%26doi%3D10.1021%2Facsinfecdis.8b00211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mandt, R. E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata-Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luth, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segura, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pablos-Tanarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottilie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukens, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span> <span> </span><span class="NLM_article-title">In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">eaav1636</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aav1636</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1126%2Fscitranslmed.aav1636" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=31801884" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=R.+E.+K.+Mandtauthor=M.+J.+Lafuente-Monasterioauthor=T.+Sakata-Katoauthor=M.+R.+Luthauthor=D.+Seguraauthor=A.+Pablos-Tanarroauthor=S.+Vieraauthor=N.+Maganauthor=S.+Ottilieauthor=E.+A.+Winzelerauthor=A.+K.+Lukensauthor=F.+J.+Gamoauthor=D.+F.+Wirth&title=In+vitro+selection+predicts+malaria+parasite+resistance+to+dihydroorotate+dehydrogenase+inhibitors+in+a+mouse+infection+model&doi=10.1126%2Fscitranslmed.aav1636"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aav1636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aav1636%26sid%3Dliteratum%253Aachs%26aulast%3DMandt%26aufirst%3DR.%2BE.%2BK.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DSakata-Kato%26aufirst%3DT.%26aulast%3DLuth%26aufirst%3DM.%2BR.%26aulast%3DSegura%26aufirst%3DD.%26aulast%3DPablos-Tanarro%26aufirst%3DA.%26aulast%3DViera%26aufirst%3DS.%26aulast%3DMagan%26aufirst%3DN.%26aulast%3DOttilie%26aufirst%3DS.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DLukens%26aufirst%3DA.%2BK.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26atitle%3DIn%2520vitro%2520selection%2520predicts%2520malaria%2520parasite%2520resistance%2520to%2520dihydroorotate%2520dehydrogenase%2520inhibitors%2520in%2520a%2520mouse%2520infection%2520model%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26doi%3D10.1126%2Fscitranslmed.aav1636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegand, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span> <span> </span><span class="NLM_article-title">In vitro resistance selections for <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">17980</span>– <span class="NLM_lpage">17995</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.558353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1074%2Fjbc.M114.558353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=24782313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=17980-17995&author=L.+S.+Rossauthor=F.+J.+Gamoauthor=M.+J.+Lafuente-Monasterioauthor=O.+M.+Singhauthor=P.+Rowlandauthor=R.+C.+Wiegandauthor=D.+F.+Wirth&title=In+vitro+resistance+selections+for+Plasmodium+falciparum+dihydroorotate+dehydrogenase+inhibitors+give+mutants+with+multiple+point+mutations+in+the+drug-binding+site+and+altered+growth&doi=10.1074%2Fjbc.M114.558353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Resistance Selections for Plasmodium Falciparum Dihydroorotate Dehydrogenase Inhibitors Give Mutants with Multiple Point Mutations in the Drug-binding Site and Altered Growth</span></div><div class="casAuthors">Ross, Leila S.; Gamo, Francisco Javier; Lafuente-Monasterio, Maria Jose; Singh, Onkar M. P.; Rowland, Paul; Wiegand, Roger C.; Wirth, Dyann F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">17980-17995</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Malaria is a preventable and treatable disease; yet half of the world's population lives at risk of infection, and an estd. 660,000 people die of malaria-related causes every year.  Rising drug resistance threatens to make malaria untreatable, necessitating both the discovery of new antimalarial agents and the development of strategies to identify and suppress the emergence and spread of drug resistance.  We focused on in-development dihydroorotate dehydrogenase (DHODH) inhibitors.  Characterizing resistance pathways for antimalarial agents not yet in clin. use will increase our understanding of the potential for resistance.  We identified resistance mechanisms of Plasmodium falciparum (Pf) DHODH inhibitors via in vitro resistance selections.  We found 11 point mutations in the PfDHODH target.  Target gene amplification and unknown mechanisms also contributed to resistance, albeit to a lesser extent.  These mutant parasites were often hypersensitive to other PfDHODH inhibitors, which immediately suggested a novel combination therapy approach to preventing resistance.  Indeed, a combination of wild-type and mutant-type selective inhibitors led to resistance far less often than either drug alone.  The effects of point mutations in PfDHODH were corroborated with purified recombinant wild-type and mutant-type PfDHODH proteins, which showed the same trends in drug response as the cognate cell lines.  Comparative growth assays demonstrated that two mutant parasites grew less robustly than their wild-type parent, and the purified protein of those mutants showed a decrease in catalytic efficiency, thereby suggesting a reason for the diminished growth rate.  Co-crystallog. of PfDHODH with three inhibitors suggested that hydrophobic interactions are important for drug binding and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro56dX8r--uLVg90H21EOLACvtfcHk0lhUeUdKf0PMpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsL%252FO&md5=35ea613c4223241c76a7bc0436cf9adb</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.558353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.558353%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DL.%2BS.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DSingh%26aufirst%3DO.%2BM.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DWiegand%26aufirst%3DR.%2BC.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26atitle%3DIn%2520vitro%2520resistance%2520selections%2520for%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520inhibitors%2520give%2520mutants%2520with%2520multiple%2520point%2520mutations%2520in%2520the%2520drug-binding%2520site%2520and%2520altered%2520growth%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D17980%26epage%3D17995%26doi%3D10.1074%2Fjbc.M114.558353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guler, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span> <span> </span><span class="NLM_article-title">Atovaquone tolerance in <i>Plasmodium falciparum</i> parasites selected for high-level resistance to a dihydroorotate dehydrogenase inhibitor</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">686</span>– <span class="NLM_lpage">689</span>, <span class="refDoi"> DOI: 10.1128/AAC.02347-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1128%2FAAC.02347-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=25331708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=686-689&author=J.+L.+Gulerauthor=J.+Whiteauthor=M.+A.+Phillipsauthor=P.+K.+Rathod&title=Atovaquone+tolerance+in+Plasmodium+falciparum+parasites+selected+for+high-level+resistance+to+a+dihydroorotate+dehydrogenase+inhibitor&doi=10.1128%2FAAC.02347-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Atovaquone tolerance in Plasmodium falciparum parasites selected for high-level resistance to a dihydroorotate dehydrogenase inhibitor</span></div><div class="casAuthors">Guler, Jennifer L.; White, John; Phillips, Margaret A.; Rathod, Pradipsinh K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">686-689/1-686-689/4, 4 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Atovaquone is a component of Malarone, a widely prescribed antimalarial combination, that targets malaria respiration.  Here we show that parasites with high-level resistance to an inhibitor of dihydroorotate dehydrogenase demonstrate unexpected atovaquone tolerance.  Fortunately, the tolerance is diminished with proguanil, the second partner in Malarone.  It is important to understand such "genetic cross talk" between respiration and pyrimidine biosynthesis since many antimalarial drug development programs target these two seemingly independent pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpExQ7kAbojnLVg90H21EOLACvtfcHk0liLe_4NHo2D3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wqtr4%253D&md5=060c47a284f0c5ce0a9101d723954f47</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1128%2FAAC.02347-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02347-14%26sid%3Dliteratum%253Aachs%26aulast%3DGuler%26aufirst%3DJ.%2BL.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26atitle%3DAtovaquone%2520tolerance%2520in%2520Plasmodium%2520falciparum%2520parasites%2520selected%2520for%2520high-level%2520resistance%2520to%2520a%2520dihydroorotate%2520dehydrogenase%2520inhibitor%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D686%26epage%3D689%26doi%3D10.1128%2FAAC.02347-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guler, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahyong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patrapuvich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gujjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRisi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span> <span> </span><span class="NLM_article-title">Asexual populations of the human malaria parasite, <i>Plasmodium falciparum</i>, use a two-step genomic strategy to acquire accurate, beneficial DNA amplifications</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e1003375</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1003375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1371%2Fjournal.ppat.1003375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=23717205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslOhtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&author=J.+L.+Gulerauthor=D.+L.+Freemanauthor=V.+Ahyongauthor=R.+Patrapuvichauthor=J.+Whiteauthor=R.+Gujjarauthor=M.+A.+Phillipsauthor=J.+DeRisiauthor=P.+K.+Rathod&title=Asexual+populations+of+the+human+malaria+parasite%2C+Plasmodium+falciparum%2C+use+a+two-step+genomic+strategy+to+acquire+accurate%2C+beneficial+DNA+amplifications&doi=10.1371%2Fjournal.ppat.1003375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Asexual populations of the human malaria parasite, Plasmodium falciparum, use a two-step genomic strategy to acquire accurate, beneficial DNA amplifications</span></div><div class="casAuthors">Guler, Jennifer L.; Freeman, Daniel L.; Ahyong, Vida; Patrapuvich, Rapatbhorn; White, John; Gujjar, Ramesh; Phillips, Margaret A.; DeRisi, Joseph; Rathod, Pradipsinh K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e1003375</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Malaria drug resistance contributes to up to a million annual deaths.  Judicious deployment of new antimalarials and vaccines could benefit from an understanding of early mol. events that promote the evolution of parasites.  Continuous in vitro challenge of Plasmodium falciparum parasites with a novel dihydroorotate dehydrogenase (DHODH) inhibitor reproducibly selected for resistant parasites.  Genome-wide anal. of independently-derived resistant clones revealed a two-step strategy to evolutionary success.  Some haploid blood-stage parasites first survive antimalarial pressure through fortuitous DNA duplications that always included the DHODH gene.  Independently-selected parasites had different sized amplification units but they were always flanked by distant A/T tracks.  Higher level amplification and resistance was attained using a second, more efficient and more accurate, mechanism for head-to-tail expansion of the founder unit.  This second homol.-based process could faithfully tune DNA copy nos. in either direction, always retaining the unique DNA amplification sequence from the original A/T-mediated duplication for that parasite line.  Pseudo-polyploidy at relevant genomic loci sets the stage for gaining addnl. mutations at the locus of interest.  Overall, we reveal a population-based genomic strategy for mutagenesis that operates in human stages of P. falciparum to efficiently yield resistance-causing genetic changes at the correct locus in a successful parasite.  Importantly, these founding events arise with precision; no other new amplifications are seen in the resistant haploid blood stage parasite.  This minimizes the need for meiotic genetic cleansing that can only occur in sexual stage development of the parasite in mosquitoes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre-k9Fm0WQKrVg90H21EOLACvtfcHk0liLe_4NHo2D3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslOhtb8%253D&md5=9b2ad216a436922860c7f29aa5402c52</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1003375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1003375%26sid%3Dliteratum%253Aachs%26aulast%3DGuler%26aufirst%3DJ.%2BL.%26aulast%3DFreeman%26aufirst%3DD.%2BL.%26aulast%3DAhyong%26aufirst%3DV.%26aulast%3DPatrapuvich%26aufirst%3DR.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DGujjar%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DDeRisi%26aufirst%3DJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26atitle%3DAsexual%2520populations%2520of%2520the%2520human%2520malaria%2520parasite%252C%2520Plasmodium%2520falciparum%252C%2520use%2520a%2520two-step%2520genomic%2520strategy%2520to%2520acquire%2520accurate%252C%2520beneficial%2520DNA%2520amplifications%26jtitle%3DPLoS%2520Pathog.%26date%3D2013%26volume%3D9%26doi%3D10.1371%2Fjournal.ppat.1003375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Painter, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrisey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mather, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orchard, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smilkstein, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riscoe, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, M.</span></span> <span> </span><span class="NLM_article-title">Atypical molecular basis for drug resistance to mitochondrial function inhibitors in <i>Plasmodium falciparum</i></span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">e02143</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1101/2020.10.08.330241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1101%2F2020.10.08.330241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=33361312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BB3MXmvVaju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2021&pages=e02143-20&author=H.+J.+Painterauthor=J.+M.+Morriseyauthor=M.+W.+Matherauthor=L.+M.+Orchardauthor=C.+Luckauthor=M.+J.+Smilksteinauthor=M.+K.+Riscoeauthor=A.+B.+Vaidyaauthor=M.+Llinas&title=Atypical+molecular+basis+for+drug+resistance+to+mitochondrial+function+inhibitors+in+Plasmodium+falciparum&doi=10.1101%2F2020.10.08.330241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Atypical molecular basis for drug resistance to mitochondrial function inhibitors in Plasmodium falciparum</span></div><div class="casAuthors">Painter, Heather J.; Morrisey, Joanne M.; Mather, Michael W.; Orchard, Lindsey M.; Luck, Cuyler; Smilkstein, Martin J.; Riscoe, Michael K.; Vaidya, Akhil B.; Llinasa, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e02143</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The continued emergence of drug-resistant Plasmodium falciparum parasites hinders global attempts to eradicate malaria, emphasizing the need to identify new antimalarial drugs.  Attractive targets for chemotherapeutic intervention are the cytochrome (cyt) bc1 complex, which is an essential component of the mitochondrial electron transport chain (mtETC) required for ubiquinone recycling and mitochondrially localized dihydroorotate dehydrogenase (DHODH) crit. for de novo pyrimidine synthesis.  Despite the essentiality of this complex, resistance to a novel acridone class of compds. targeting cyt bc1 was readily attained, resulting in a parasite strain (SB1-A6) that was panresistant to both mtETC and DHODH inhibitors.  Here, we describe the mol. mechanism behind the resistance of the SB1-A6 parasite line, which lacks the common cyt bc1 point mutations characteristic of resistance to mtETC inhibitors.  Using Illumina whole-genome sequencing, we have identified both a copy no. variation (~ 2x) and a single-nucleotide polymorphism (C276F) assocd. with pfdhodh in SB1-A6.  We have characterized the role of both genetic lesions by mimicking the copy no. variation via episomal expression of pfdhodh and introducing the identified single nucleotide polymorphism (SNP) using CRISPR-Cas9 and assessed their contributions to drug resistance.  Although both of these genetic polymorphisms have been previously identified as contributing to both DSM-1 and atovaquone resistance, SB1-A6 represents a unique genotype in which both alterations are present in a single line, suggesting that the combination contributes to the panresistant phenotype.  This novel mechanism of resistance to mtETC inhibition has crit. implications for the development of future drugs targeting the bc1 complex or de novo pyrimidine synthesis that could help guide future antimalarial combination therapies and reduce the rapid development of drug resistance in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooNevLFxOEG7Vg90H21EOLACvtfcHk0liLe_4NHo2D3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXmvVaju7s%253D&md5=6005d1992b5507d5576cff8e26c34173</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1101%2F2020.10.08.330241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.10.08.330241%26sid%3Dliteratum%253Aachs%26aulast%3DPainter%26aufirst%3DH.%2BJ.%26aulast%3DMorrisey%26aufirst%3DJ.%2BM.%26aulast%3DMather%26aufirst%3DM.%2BW.%26aulast%3DOrchard%26aufirst%3DL.%2BM.%26aulast%3DLuck%26aufirst%3DC.%26aulast%3DSmilkstein%26aufirst%3DM.%2BJ.%26aulast%3DRiscoe%26aufirst%3DM.%2BK.%26aulast%3DVaidya%26aufirst%3DA.%2BB.%26aulast%3DLlinas%26aufirst%3DM.%26atitle%3DAtypical%2520molecular%2520basis%2520for%2520drug%2520resistance%2520to%2520mitochondrial%2520function%2520inhibitors%2520in%2520Plasmodium%2520falciparum%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2021%26volume%3D65%26spage%3De02143%26epage%3D20%26doi%3D10.1101%2F2020.10.08.330241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garuti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Doval, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargallo-Viola, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span> <span> </span><span class="NLM_article-title">Improved murine model of malaria using <i>Plasmodium falciparum</i> competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4533</span>– <span class="NLM_lpage">4536</span>, <span class="refDoi"> DOI: 10.1128/AAC.00519-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1128%2FAAC.00519-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=19596869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KkurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=4533-4536&author=M.+B.+Jimenez-Diazauthor=T.+Muletauthor=S.+Vieraauthor=V.+Gomezauthor=H.+Garutiauthor=J.+Ibanezauthor=A.+Alvarez-Dovalauthor=L.+D.+Shultzauthor=A.+Martinezauthor=D.+Gargallo-Violaauthor=I.+Angulo-Barturen&title=Improved+murine+model+of+malaria+using+Plasmodium+falciparum+competent+strains+and+non-myelodepleted+NOD-scid+IL2Rgammanull+mice+engrafted+with+human+erythrocytes&doi=10.1128%2FAAC.00519-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rγnull mice engrafted with human erythrocytes</span></div><div class="casAuthors">Jimenez-Diaz, Maria Belen; Mulet, Teresa; Viera, Sara; Gomez, Vanessa; Garuti, Helen; Ibanez, Javier; Alvarez-Doval, Angela; Shultz, Leonard D.; Martinez, Antonio; Gargallo-Viola, Domingo; Angulo-Barturen, Inigo</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4533-4536</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Murine models of Plasmodium falciparum malaria may become crucial tools in drug discovery.  Here we show that non-myelodepleted NOD-scid IL2Rγnull mice engrafted with human erythrocytes support an infectious burden up to tenfold higher than that supported by engrafted NOD-scid β2microglobulinnull mice.  The new model was validated for drug discovery and was used to assess the therapeutic efficacy of 4-pyridones, selective inhibitors of P. falciparum cytochrome bc1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoGw5NKfthdbVg90H21EOLACvtfcHk0lhpLjAfn-UMGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KkurbO&md5=df25f5f7382b0b422a9e9b2137a66093</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1128%2FAAC.00519-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00519-09%26sid%3Dliteratum%253Aachs%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DMulet%26aufirst%3DT.%26aulast%3DViera%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DV.%26aulast%3DGaruti%26aufirst%3DH.%26aulast%3DIbanez%26aufirst%3DJ.%26aulast%3DAlvarez-Doval%26aufirst%3DA.%26aulast%3DShultz%26aufirst%3DL.%2BD.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DGargallo-Viola%26aufirst%3DD.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26atitle%3DImproved%2520murine%2520model%2520of%2520malaria%2520using%2520Plasmodium%2520falciparum%2520competent%2520strains%2520and%2520non-myelodepleted%2520NOD-scid%2520IL2Rgammanull%2520mice%2520engrafted%2520with%2520human%2520erythrocytes%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D4533%26epage%3D4536%26doi%3D10.1128%2FAAC.00519-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hurt, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Structure of <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase with a bound inhibitor</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1107/S0907444905042642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1107%2FS0907444905042642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=16510978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvVKnt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=312-323&author=D.+E.+Hurtauthor=J.+Widomauthor=J.+Clardy&title=Structure+of+Plasmodium+falciparum+dihydroorotate+dehydrogenase+with+a+bound+inhibitor&doi=10.1107%2FS0907444905042642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor</span></div><div class="casAuthors">Hurt, Darrell E.; Widom, Joanne; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">D62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">312-323</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Membrane-assocd. dihydroorotate dehydrogenase (DHODH) is an antimalarial therapeutic target without an effective inhibitor.  Studies on human DHODH (HsDHODH) led to a structural mechanistic model in which respiratory quinones bind in a tunnel formed by the highly variable N-terminus that leads to the FMN-binding site.  The therapeutic agents leflunomide (Arava) and brequinar sodium inhibit HsDHODH by binding in this tunnel.  Plasmodium falciparum DHODH (PfDHODH) and HsDHODH have markedly different sensitivities to the two drugs.  To understand the structural basis of this differential sensitivity and begin a structure-based drug-design cycle for PfDHODH inhibitors, the three-dimensional structure (2.4 Å, R = 20.1%) of PfDHODH bound to the active metabolite of leflunomide was detd. by x-ray crystallog.  Comparison of the structures of HsDHODH and PfDHODH reveals a completely different binding mode for the same inhibitor in these two catalytically identical enzymes and explains the previously obsd. species-specific preferential binding.  Because no effective inhibitors have been described for PfDHODH, this structure provides crit. insight for the design of potential antimalarials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmXjioMQpSWrVg90H21EOLACvtfcHk0lhpLjAfn-UMGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvVKnt7w%253D&md5=5dcf54ce84e9802be9bcbafe78e5a8cb</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0907444905042642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444905042642%26sid%3Dliteratum%253Aachs%26aulast%3DHurt%26aufirst%3DD.%2BE.%26aulast%3DWidom%26aufirst%3DJ.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520with%2520a%2520bound%2520inhibitor%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2006%26volume%3D62%26spage%3D312%26epage%3D323%26doi%3D10.1107%2FS0907444905042642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farajallah, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmquist, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Malarial dihydroorotate dehydrogenase: substrate and inhibitor specificity</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">41827</span>– <span class="NLM_lpage">41834</span>, <span class="refDoi"> DOI: 10.1074/jbc.M206854200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1074%2Fjbc.M206854200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=12189151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD38XotF2gsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=41827-41834&author=J.+Baldwinauthor=A.+M.+Farajallahauthor=N.+A.+Malmquistauthor=P.+K.+Rathodauthor=M.+A.+Phillips&title=Malarial+dihydroorotate+dehydrogenase%3A+substrate+and+inhibitor+specificity&doi=10.1074%2Fjbc.M206854200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Malarial Dihydroorotate Dehydrogenase</span></div><div class="casAuthors">Baldwin, Jeffrey; Farajallah, Azizeh M.; Malmquist, Nicholas A.; Rathod, Pradipsinh K.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">41827-41834</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The malarial parasite relies on de novo pyrimidine biosynthesis to maintain its pyrimidine pools, and unlike the human host cell it is unable to scavenge preformed pyrimidines.  Dihydroorotate dehydrogenase (DHODH) catalyzes the oxidn. of dihydroorotate (DHO) to produce orotate, a key step in pyrimidine biosynthesis.  The enzyme is located in the outer membrane of the mitochondria of the malarial parasite.  To characterize the biochem. properties of the malarial enzyme, an N-terminally truncated version of P. falciparum DHODH has been expressed as a sol., active enzyme in E. coli.  The recombinant enzyme binds 0.9 molar equivalents of the cofactor FMN and it has a pH max. of 8.0 (kcat 8 s-1, Km DHO (40-80 μM)).  The substrate specificity of the ubiquinone cofactor (CoQn) that is required for the oxidn. of FMN in the second step of the reaction was also detd.  The isoprenoid (n) length of CoQn was a determinant of reaction efficiency; CoQ4, CoQ6 and decylubiquinone (CoQD) were efficiently utilized in the reaction while cofactors lacking an isoprenoid tail (CoQ0 and vitamin K3) showed decreased catalytic efficiency, resulting from a 4 to 7-fold increase in K.  Five potent inhibitors of mammalian DHODH (Redoxal, dichloroallyl lawsone or DCL, and three analogs of A77 1726) were tested as inhibitors of the malarial enzyme.  All five compds. were poor inhibitors of the malarial enzyme, with IC50 values ranging from 0.1-1.0 mM.  The IC50 values for inhibition of the malarial enzyme are 102-104-fold higher than the values reported for the mammalian enzyme, demonstrating that inhibitor binding to DHODH is species specific.  These studies provide direct evidence that the malarial DHODH active site is different from the host enzyme, and that it is an attractive target for the development of new anti-malarial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU1l-Kjs9vvbVg90H21EOLACvtfcHk0lhpLjAfn-UMGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotF2gsLk%253D&md5=99d23bd543c70017914cb2fdebc779da</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M206854200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M206854200%26sid%3Dliteratum%253Aachs%26aulast%3DBaldwin%26aufirst%3DJ.%26aulast%3DFarajallah%26aufirst%3DA.%2BM.%26aulast%3DMalmquist%26aufirst%3DN.%2BA.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DMalarial%2520dihydroorotate%2520dehydrogenase%253A%2520substrate%2520and%2520inhibitor%2520specificity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D41827%26epage%3D41834%26doi%3D10.1074%2Fjbc.M206854200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine modulates species selectivity in the triazolopyrimidine class of <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5381</span>– <span class="NLM_lpage">5394</span>, <span class="refDoi"> DOI: 10.1021/jm500481t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500481t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns1Chs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5381-5394&author=X.+Dengauthor=S.+Kokkondaauthor=F.+El+Mazouniauthor=J.+Whiteauthor=J.+N.+Burrowsauthor=W.+Kaminskyauthor=S.+A.+Charmanauthor=D.+Matthewsauthor=P.+K.+Rathodauthor=M.+A.+Phillips&title=Fluorine+modulates+species+selectivity+in+the+triazolopyrimidine+class+of+Plasmodium+falciparum+dihydroorotate+dehydrogenase+inhibitors&doi=10.1021%2Fjm500481t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors</span></div><div class="casAuthors">Deng, Xiaoyi; Kokkonda, Sreekanth; El Mazouni, Farah; White, John; Burrows, Jeremy N.; Kaminsky, Werner; Charman, Susan A.; Matthews, David; Rathod, Pradipsinh K.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5381-5394</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Malaria is one of the most serious global infectious diseases.  The pyrimidine biosynthetic enzyme Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) is an important target for antimalarial chemotherapy.  The authors describe a detailed anal. of protein-ligand interactions between DHODH and a triazolopyrimidine-based inhibitor series to explore the effects of fluorine on affinity and species selectivity.  The authors show that increasing fluorination dramatically increases binding to mammalian DHODHs, leading to a loss of species selectivity.  Triazolopyrimidines bind Plasmodium and mammalian DHODHs in overlapping but distinct binding sites.  Key hydrogen-bond and stacking interactions underlying strong binding to PfDHODH are absent in the mammalian enzymes.  Increasing fluorine substitution leads to an increase in the entropic contribution to binding, suggesting that strong binding to mammalian DHODH is a consequence of an enhanced hydrophobic effect upon binding to an apolar pocket.  The authors conclude that hydrophobic interactions between fluorine and hydrocarbons provide significant binding energy to protein-ligand interactions.  The authors' studies define the requirements for species-selective binding to PfDHODH and show that the triazolopyrimidine scaffold can alternatively be tuned to inhibit human DHODH, an important target for autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFg5a-YaPFpLVg90H21EOLACvtfcHk0lg50PYJedxMaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns1Chs74%253D&md5=abfc8df6c8510665049e65338732acf0</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm500481t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500481t%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DKaminsky%26aufirst%3DW.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DFluorine%2520modulates%2520species%2520selectivity%2520in%2520the%2520triazolopyrimidine%2520class%2520of%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5381%26epage%3D5394%26doi%3D10.1021%2Fjm500481t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malmquist, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gujjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Analysis of flavin oxidation and electron-transfer inhibition in <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2466</span>– <span class="NLM_lpage">2475</span>, <span class="refDoi"> DOI: 10.1021/bi702218c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi702218c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFamsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=2466-2475&author=N.+A.+Malmquistauthor=R.+Gujjarauthor=P.+K.+Rathodauthor=M.+A.+Phillips&title=Analysis+of+flavin+oxidation+and+electron-transfer+inhibition+in+Plasmodium+falciparum+dihydroorotate+dehydrogenase&doi=10.1021%2Fbi702218c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Flavin Oxidation and Electron-Transfer Inhibition in Plasmodium falciparum Dihydroorotate Dehydrogenase</span></div><div class="casAuthors">Malmquist, Nicholas A.; Gujjar, Ramesh; Rathod, Pradipsinh K.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2466-2475</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Plasmodium falciparum dihydroorotate dehydrogenase (pfDHODH) is a flavin-dependent mitochondrial enzyme that provides the only route to pyrimidine biosynthesis in the parasite.  Clin. significant inhibitors of human DHODH (e.g., A77 1726) bind to a pocket on the opposite face of the flavin cofactor from dihydroorotate (DHO).  This pocket demonstrates considerable sequence variability, which has allowed species-specific inhibitors of the malarial enzyme to be identified.  Ubiquinone (CoQ), the physiol. oxidant in the reaction, has been postulated to bind this site despite a lack of structural evidence.  To more clearly define the residues involved in CoQ binding and catalysis, we undertook site-directed mutagenesis of seven residues in the structurally defined A77 1726 binding site, which we term the species-selective inhibitor site.  Mutation of several of these residues (H185, F188, and F227) to Ala substantially decreased the affinity of pfDHODH-specific inhibitors (40-240-fold).  In contrast, only a modest increase in the Kmapp for CoQ was obsd., although mutation of Y528 in particular caused a substantial redn. in kcat (40-100-fold decrease).  Pre-steady-state kinetic anal. by single wavelength stopped-flow spectroscopy showed that the mutations had no effect on the rate of the DHO-dependent reductive half-reaction, but most reduced the rate of the CoQ-dependent flavin oxidn. step (3-20-fold decrease), while not significantly altering the Kdox for CoQ.  As with the mutants, inhibitors that bind this site block the CoQ-dependent oxidative half-reaction without affecting the DHO-dependent step.  These results identify residues involved in inhibitor binding and electron transfer to CoQ.  Importantly, the data provide compelling evidence that the binding sites for CoQ and species-selective site inhibitors do not overlap, and they suggest instead that inhibitors act either by blocking the electron path between flavin and CoQ or by stabilizing a conformation that excludes CoQ binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo26Ps1PRGyuLVg90H21EOLACvtfcHk0lg50PYJedxMaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFamsbs%253D&md5=970f3a06d7e2e658aa7134e78f67c1c5</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fbi702218c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi702218c%26sid%3Dliteratum%253Aachs%26aulast%3DMalmquist%26aufirst%3DN.%2BA.%26aulast%3DGujjar%26aufirst%3DR.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DAnalysis%2520of%2520flavin%2520oxidation%2520and%2520electron-transfer%2520inhibition%2520in%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%26jtitle%3DBiochemistry%26date%3D2008%26volume%3D47%26spage%3D2466%26epage%3D2475%26doi%3D10.1021%2Fbi702218c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paguio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gligorijevic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seudieu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosar, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roepe, P. D.</span></span> <span> </span><span class="NLM_article-title">Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1810</span>, <span class="refDoi"> DOI: 10.1128/AAC.48.5.1807-1810.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1128%2FAAC.48.5.1807-1810.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=15105139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjslCks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=1807-1810&author=T.+N.+Bennettauthor=M.+Paguioauthor=B.+Gligorijevicauthor=C.+Seudieuauthor=A.+D.+Kosarauthor=E.+Davidsonauthor=P.+D.+Roepe&title=Novel%2C+rapid%2C+and+inexpensive+cell-based+quantification+of+antimalarial+drug+efficacy&doi=10.1128%2FAAC.48.5.1807-1810.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy</span></div><div class="casAuthors">Bennett, Tyler N.; Paguio, Michelle; Gligorijevic, Bojana; Seudieu, Clement; Kosar, Andrew D.; Davidson, Eugene; Roepe, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1807-1810</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We report on the development of a new SYBR Green I-based plate assay for analyzing the activities of antimalarial drugs against intraerythrocytic Plasmodium falciparum.  This assay is considerably faster, less labor-intensive, and less expensive than conventional radiotracer (e.g., [3H]hypoxanthine and [3H]ethanolamine)-based assays or P. falciparum lactate dehydrogenase activity-based assays.  The assay significantly improves the pace at which antimalarial drug discovery efforts may proceed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFhAlJNQSwX7Vg90H21EOLACvtfcHk0lg50PYJedxMaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjslCks7o%253D&md5=87ee6c113aefaf11160624c8fe8c8354</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.5.1807-1810.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.5.1807-1810.2004%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DT.%2BN.%26aulast%3DPaguio%26aufirst%3DM.%26aulast%3DGligorijevic%26aufirst%3DB.%26aulast%3DSeudieu%26aufirst%3DC.%26aulast%3DKosar%26aufirst%3DA.%2BD.%26aulast%3DDavidson%26aufirst%3DE.%26aulast%3DRoepe%26aufirst%3DP.%2BD.%26atitle%3DNovel%252C%2520rapid%252C%2520and%2520inexpensive%2520cell-based%2520quantification%2520of%2520antimalarial%2520drug%2520efficacy%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D1807%26epage%3D1810%26doi%3D10.1128%2FAAC.48.5.1807-1810.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekland, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title">Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3583</span>– <span class="NLM_lpage">3593</span>, <span class="refDoi"> DOI: 10.1096/fj.11-187401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1096%2Ffj.11-187401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=21746861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSru7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=3583-3593&author=E.+H.+Eklandauthor=J.+Schneiderauthor=D.+A.+Fidock&title=Identifying+apicoplast-targeting+antimalarials+using+high-throughput+compatible+approaches&doi=10.1096%2Ffj.11-187401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches</span></div><div class="casAuthors">Ekland, Eric H.; Schneider, Jessica; Fidock, David A.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3583-3593, 10.1096/fj.11-187401</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Malarial parasites have evolved resistance to all previously used therapies, and recent evidence suggests emerging resistance to the first-line artemisinins.  To identify antimalarials with novel mechanisms of action, we have developed a high-throughput screen targeting the apicoplast organelle of Plasmodium falciparum.  Antibiotics known to interfere with this organelle, such as azithromycin, exhibit an unusual phenotype whereby the progeny of drug-treated parasites die.  Our screen exploits this phenomenon by assaying for "delayed death" compds. that exhibit a higher potency after two cycles of intraerythrocytic development compared to one.  We report a primary assay employing parasites with an integrated copy of a firefly luciferase reporter gene and a secondary flow cytometry-based assay using a nucleic acid stain paired with a mitochondrial vital dye.  Screening of the U.S. National Institutes of Health Clin. Collection identified known and novel antimalarials including kitasamycin.  This inexpensive macrolide, used for agricultural applications, exhibited an in vitro IC50 in the 50 nM range, comparable to the 30 nM activity of our control drug, azithromycin.  Imaging and pharmacol. studies confirmed kitasamycin action against the apicoplast, and in vivo activity was obsd. in a murine malaria model.  These assays provide the foundation for high-throughput campaigns to identify novel chemotypes for combination therapies to treat multidrug-resistant malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03kNR99YnDbVg90H21EOLACvtfcHk0lhLLY6y30anYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSru7rI&md5=f02c6a8e25576da8537cf0e6332aa7c9</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1096%2Ffj.11-187401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.11-187401%26sid%3Dliteratum%253Aachs%26aulast%3DEkland%26aufirst%3DE.%2BH.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DIdentifying%2520apicoplast-targeting%2520antimalarials%2520using%2520high-throughput%2520compatible%2520approaches%26jtitle%3DFASEB%2520J.%26date%3D2011%26volume%3D25%26spage%3D3583%26epage%3D3593%26doi%3D10.1096%2Ffj.11-187401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udomsangpetch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieckmann, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotecka, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattabongkot, J.</span></span> <span> </span><span class="NLM_article-title">Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1128/AAC.47.1.170-173.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1128%2FAAC.47.1.170-173.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=12499187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis12gtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2003&pages=170-173&author=B.+M.+Russellauthor=R.+Udomsangpetchauthor=K.+H.+Rieckmannauthor=B.+M.+Koteckaauthor=R.+E.+Colemanauthor=J.+Sattabongkot&title=Simple+in+vitro+assay+for+determining+the+sensitivity+of+Plasmodium+vivax+isolates+from+fresh+human+blood+to+antimalarials+in+areas+where+P.+vivax+is+endemic&doi=10.1128%2FAAC.47.1.170-173.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic</span></div><div class="casAuthors">Russell, Bruce M.; Udomsangpetch, Rachanee; Rieckmann, Karl H.; Kotecka, Barbara M.; Coleman, Russell E.; Sattabongkot, Jetsumon</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">170-173</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The aim of this study was to develop a simple, field-practical, and effective in vitro method for detg. the sensitivity of fresh erythrocytic Plasmodium vivax isolates to a range of antimalarials.  The method used is a modification of the std. World Health Organization (WHO) microtest for detn. of P. falciparum drug sensitivity.  The WHO method was modified by removing leukocytes and using a growth medium supplemented with AB+ serum.  The authors successfully carried out 34 in vitro drug assays on 39 P. vivax isolates collected from the Mae Sod malaria clinic, Tak Province, Thailand.  The mean percentage of parasites maturing to schizonts (six or more merozoites) in control wells was 66.5% ± 5.9% (std. deviation).  This level of growth in the control wells enabled rapid microscopic detn. (5 min per isolate per drug) of the MICs of chloroquine, dihydroartemisinin, WR238605 (tafenoquine), and sulfadoxine.  P. vivax was relatively sensitive to chloroquine (MIC = 160 ng/mL, 50% inhibitory concn. [IC50] = 49.8 ng/mL) and dihydroartemisinin (MIC = 0.5 ng/mL, IC50 = 0.47 ng/mL).  The poor response of P. vivax to both tafenoquine (MIC = 14,000 ng/mL, IC50 = 9,739 ng/mL) and sulfadoxine (MIC = 500,000 ng/mL, IC50 = 249,000 ng/mL) was due to the slow action of these drugs and the innate resistance of P. vivax to sulfadoxine.  The in vitro assay developed in this study should be useful both for assessing the antimalarial sensitivity of P. vivax populations and for screening new antimalarials in the absence of long-term P. vivax cultures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM41fKL7ehYrVg90H21EOLACvtfcHk0lhLLY6y30anYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis12gtg%253D%253D&md5=204ad517dfe4fd66f0e30553628d55ba</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1128%2FAAC.47.1.170-173.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.47.1.170-173.2003%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DB.%2BM.%26aulast%3DUdomsangpetch%26aufirst%3DR.%26aulast%3DRieckmann%26aufirst%3DK.%2BH.%26aulast%3DKotecka%26aufirst%3DB.%2BM.%26aulast%3DColeman%26aufirst%3DR.%2BE.%26aulast%3DSattabongkot%26aufirst%3DJ.%26atitle%3DSimple%2520in%2520vitro%2520assay%2520for%2520determining%2520the%2520sensitivity%2520of%2520Plasmodium%2520vivax%2520isolates%2520from%2520fresh%2520human%2520blood%2520to%2520antimalarials%2520in%2520areas%2520where%2520P.%2520vivax%2520is%2520endemic%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2003%26volume%3D47%26spage%3D170%26epage%3D173%26doi%3D10.1128%2FAAC.47.1.170-173.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonova-Koch, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luth, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottilie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukens, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata-Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanaerschot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jado, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaumeau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eribez, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taggard, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lincoln, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambachew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouillier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Open-source discovery of chemical leads for next-generation chemoprotective antimalarials</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>362</i></span>, <span class="NLM_elocation-id">eaat9446</span> <span class="refDoi"> DOI: 10.1126/science.aat9446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1126%2Fscience.aat9446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=30523084" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2018&author=Y.+Antonova-Kochauthor=S.+Meisterauthor=M.+Abrahamauthor=M.+R.+Luthauthor=S.+Ottilieauthor=A.+K.+Lukensauthor=T.+Sakata-Katoauthor=M.+Vanaerschotauthor=E.+Owenauthor=J.+C.+Jadoauthor=S.+P.+Maherauthor=J.+Callaauthor=D.+Plouffeauthor=Y.+Zhongauthor=K.+Chenauthor=V.+Chaumeauauthor=A.+J.+Conwayauthor=C.+W.+McNamaraauthor=M.+Ibanezauthor=K.+Gagaringauthor=F.+N.+Serranoauthor=K.+Eribezauthor=C.+M.+Taggardauthor=A.+L.+Cheungauthor=C.+Lincolnauthor=B.+Ambachewauthor=M.+Rouillierauthor=D.+Siegelauthor=F.+Nostenauthor=D.+E.+Kyleauthor=F.+J.+Gamoauthor=Y.+Zhouauthor=M.+Llinasauthor=D.+A.+Fidockauthor=D.+F.+Wirthauthor=J.+Burrowsauthor=B.+Campoauthor=E.+A.+Winzeler&title=Open-source+discovery+of+chemical+leads+for+next-generation+chemoprotective+antimalarials&doi=10.1126%2Fscience.aat9446"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1126%2Fscience.aat9446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aat9446%26sid%3Dliteratum%253Aachs%26aulast%3DAntonova-Koch%26aufirst%3DY.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DAbraham%26aufirst%3DM.%26aulast%3DLuth%26aufirst%3DM.%2BR.%26aulast%3DOttilie%26aufirst%3DS.%26aulast%3DLukens%26aufirst%3DA.%2BK.%26aulast%3DSakata-Kato%26aufirst%3DT.%26aulast%3DVanaerschot%26aufirst%3DM.%26aulast%3DOwen%26aufirst%3DE.%26aulast%3DJado%26aufirst%3DJ.%2BC.%26aulast%3DMaher%26aufirst%3DS.%2BP.%26aulast%3DCalla%26aufirst%3DJ.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DChaumeau%26aufirst%3DV.%26aulast%3DConway%26aufirst%3DA.%2BJ.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DIbanez%26aufirst%3DM.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DSerrano%26aufirst%3DF.%2BN.%26aulast%3DEribez%26aufirst%3DK.%26aulast%3DTaggard%26aufirst%3DC.%2BM.%26aulast%3DCheung%26aufirst%3DA.%2BL.%26aulast%3DLincoln%26aufirst%3DC.%26aulast%3DAmbachew%26aufirst%3DB.%26aulast%3DRouillier%26aufirst%3DM.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DKyle%26aufirst%3DD.%2BE.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLlinas%26aufirst%3DM.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DOpen-source%2520discovery%2520of%2520chemical%2520leads%2520for%2520next-generation%2520chemoprotective%2520antimalarials%26jtitle%3DScience%26date%3D2018%26volume%3D362%26doi%3D10.1126%2Fscience.aat9446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span>; <span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title"><i>Plasmodium falciparum</i> In Vitro Drug Resistance Selections and Gene Editing</span>.  <i>Malaria Control and Elimination</i>; <span class="NLM_series">Methods in Molecular Biology</span>; <span class="NLM_publisher-name">Humana</span>, <span class="NLM_year">2019</span>; Vol.  <span class="NLM_volume">2013</span>, pp  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">140</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1007%2F978-1-4939-9550-9_9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=123-140&author=C.+L.+Ng&author=D.+A.+Fidock&title=Malaria+Control+and+Elimination"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-9550-9_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-9550-9_9%26sid%3Dliteratum%253Aachs%26aulast%3DNg%26aufirst%3DC.%2BL.%26atitle%3DPlasmodium%2520falciparum%2520In%2520Vitro%2520Drug%2520Resistance%2520Selections%2520and%2520Gene%2520Editing%26btitle%3DMalaria%2520Control%2520and%2520Elimination%26pub%3DHumana%26date%3D2019%26volume%3D2013%26spage%3D123%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanaerschot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murithi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasaje, C. F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwomoh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spottiswoode, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendse, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicht, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siciliano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, T. R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giddins, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottilie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlemann, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niles, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of resistance-refractory <i>P. falciparum</i> kinase pkg delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">806</span>– <span class="NLM_lpage">816.e8</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2020.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2Fj.chembiol.2020.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=32359426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosF2rtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2020&pages=806-816.e8&author=M.+Vanaerschotauthor=J.+M.+Murithiauthor=C.+F.+A.+Pasajeauthor=S.+Ghidelli-Disseauthor=L.+Dwomohauthor=M.+Birdauthor=N.+Spottiswoodeauthor=N.+Mittalauthor=L.+B.+Arendseauthor=E.+S.+Owenauthor=K.+J.+Wichtauthor=G.+Sicilianoauthor=M.+Boscheauthor=T.+Yeoauthor=T.+R.+S.+Kumarauthor=S.+Mokauthor=E.+F.+Carpenterauthor=M.+J.+Giddinsauthor=O.+Sanzauthor=S.+Ottilieauthor=P.+Alanoauthor=K.+Chibaleauthor=M.+Llinasauthor=A.+C.+Uhlemannauthor=M.+Delvesauthor=A.+B.+Tobinauthor=C.+Doerigauthor=E.+A.+Winzelerauthor=M.+C.+S.+Leeauthor=J.+C.+Nilesauthor=D.+A.+Fidock&title=Inhibition+of+resistance-refractory+P.+falciparum+kinase+pkg+delivers+prophylactic%2C+blood+stage%2C+and+transmission-blocking+antiplasmodial+activity&doi=10.1016%2Fj.chembiol.2020.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Resistance-Refractory P. falciparum Kinase PKG Delivers Prophylactic, Blood Stage, and Transmission-Blocking Antiplasmodial Activity</span></div><div class="casAuthors">Vanaerschot, Manu; Murithi, James M.; Pasaje, Charisse Flerida A.; Ghidelli-Disse, Sonja; Dwomoh, Louis; Bird, Megan; Spottiswoode, Natasha; Mittal, Nimisha; Arendse, Lauren B.; Owen, Edward S.; Wicht, Kathryn J.; Siciliano, Giulia; Bosche, Markus; Yeo, Tomas; Kumar, T. R. Santha; Mok, Sachel; Carpenter, Emma F.; Giddins, Marla J.; Sanz, Olalla; Ottilie, Sabine; Alano, Pietro; Chibale, Kelly; Llinas, Manuel; Uhlemann, Anne-Catrin; Delves, Michael; Tobin, Andrew B.; Doerig, Christian; Winzeler, Elizabeth A.; Lee, Marcus C. S.; Niles, Jacquin C.; Fidock, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">806-816.e8</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The search for antimalarial chemotypes with modes of action unrelated to existing drugs has intensified with the recent failure of first-line therapies across Southeast Asia.  Here, we show that the trisubstituted imidazole MMV030084 potently inhibits hepatocyte invasion by Plasmodium sporozoites, merozoite egress from asexual blood stage schizonts, and male gamete exflagellation.  Metabolomic, phosphoproteomic, and chemoproteomic studies, validated with conditional knockdown parasites, mol. docking, and recombinant kinase assays, identified cGMP-dependent protein kinase (PKG) as the primary target of MMV030084.  PKG is known to play essential roles in Plasmodium invasion of and egress from host cells, matching MMV030084's activity profile.  Resistance selections and gene editing identified tyrosine kinase-like protein 3 as a low-level resistance mediator for PKG inhibitors, while PKG itself never mutated under pressure.  These studies highlight PKG as a resistance-refractory antimalarial target throughout the Plasmodium life cycle and promote MMV030084 as a promising Plasmodium PKG-targeting chemotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUFtSi3NQKI7Vg90H21EOLACvtfcHk0liUWAYwuC83KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosF2rtbk%253D&md5=fa3b9fdf545a973c1f71500f1d530ffe</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2020.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2020.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DVanaerschot%26aufirst%3DM.%26aulast%3DMurithi%26aufirst%3DJ.%2BM.%26aulast%3DPasaje%26aufirst%3DC.%2BF.%2BA.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DDwomoh%26aufirst%3DL.%26aulast%3DBird%26aufirst%3DM.%26aulast%3DSpottiswoode%26aufirst%3DN.%26aulast%3DMittal%26aufirst%3DN.%26aulast%3DArendse%26aufirst%3DL.%2BB.%26aulast%3DOwen%26aufirst%3DE.%2BS.%26aulast%3DWicht%26aufirst%3DK.%2BJ.%26aulast%3DSiciliano%26aufirst%3DG.%26aulast%3DBosche%26aufirst%3DM.%26aulast%3DYeo%26aufirst%3DT.%26aulast%3DKumar%26aufirst%3DT.%2BR.%2BS.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DCarpenter%26aufirst%3DE.%2BF.%26aulast%3DGiddins%26aufirst%3DM.%2BJ.%26aulast%3DSanz%26aufirst%3DO.%26aulast%3DOttilie%26aufirst%3DS.%26aulast%3DAlano%26aufirst%3DP.%26aulast%3DChibale%26aufirst%3DK.%26aulast%3DLlinas%26aufirst%3DM.%26aulast%3DUhlemann%26aufirst%3DA.%2BC.%26aulast%3DDelves%26aufirst%3DM.%26aulast%3DTobin%26aufirst%3DA.%2BB.%26aulast%3DDoerig%26aufirst%3DC.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DNiles%26aufirst%3DJ.%2BC.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DInhibition%2520of%2520resistance-refractory%2520P.%2520falciparum%2520kinase%2520pkg%2520delivers%2520prophylactic%252C%2520blood%2520stage%252C%2520and%2520transmission-blocking%2520antiplasmodial%2520activity%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2020%26volume%3D27%26spage%3D806%26epage%3D816.e8%26doi%3D10.1016%2Fj.chembiol.2020.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Booker, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastos, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, R. H.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerlj, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidhu, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celatka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortese, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero
Bravo, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo Llado, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garuti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papastogiannidis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janse, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duraisingh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinger, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegand, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sybertz, E.</span></span> <span> </span><span class="NLM_article-title">Novel inhibitors of <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase with anti-malarial activity in the mouse model</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">33054</span>– <span class="NLM_lpage">33064</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.162081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1074%2Fjbc.M110.162081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=20702404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12nu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=33054-33064&author=M.+L.+Bookerauthor=C.+M.+Bastosauthor=M.+L.+Kramerauthor=R.+H.+Barkerauthor=R.+Skerljauthor=A.+B.+Sidhuauthor=X.+Dengauthor=C.+Celatkaauthor=J.+F.+Corteseauthor=J.+E.+Guerrero%0ABravoauthor=K.+N.+Crespo+Lladoauthor=A.+E.+Serranoauthor=I.+Angulo-Barturenauthor=M.+B.+Jimenez-Diazauthor=S.+Vieraauthor=H.+Garutiauthor=S.+Wittlinauthor=P.+Papastogiannidisauthor=J.+W.+Linauthor=C.+J.+Janseauthor=S.+M.+Khanauthor=M.+Duraisinghauthor=B.+Colemanauthor=E.+J.+Goldsmithauthor=M.+A.+Phillipsauthor=B.+Munozauthor=D.+F.+Wirthauthor=J.+D.+Klingerauthor=R.+Wiegandauthor=E.+Sybertz&title=Novel+inhibitors+of+Plasmodium+falciparum+dihydroorotate+dehydrogenase+with+anti-malarial+activity+in+the+mouse+model&doi=10.1074%2Fjbc.M110.162081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Anti-malarial Activity in the Mouse Model</span></div><div class="casAuthors">Booker, Michael L.; Bastos, Cecilia M.; Kramer, Martin L.; Barker, Robert H., Jr.; Skerlj, Renato; Sidhu, Amar Bir; Deng, Xiao-Yi; Celatka, Cassandra; Cortese, Joseph F.; Guerrero Bravo, Jose E.; Crespo Llado, Keila N.; Serrano, Adelfa E.; Angulo-Barturen, Inigo; Jimenez-Diaz, Maria Belen; Viera, Sara; Garuti, Helen; Wittlin, Sergio; Papastogiannidis, Petros; Lin, Jing-Wen; Janse, Chris J.; Khan, Shahid M.; Duraisingh, Manoj; Coleman, Bradley; Goldsmith, Elizabeth J.; Phillips, Margaret A.; Munoz, Benito; Wirth, Dyann F.; Klinger, Jeffrey D.; Wiegand, Roger; Sybertz, Edmund</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">33054-33064</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Plasmodium falciparum, the causative agent of the most deadly form of human malaria, is unable to salvage pyrimidines and must rely on de novo biosynthesis for survival.  Dihydroorotate dehydrogenase (DHODH) catalyzes the rate-limiting step in the pyrimidine biosynthetic pathway and represents a potential target for anti-malarial therapy.  A high throughput screen and subsequent medicinal chem. program identified a series of N-alkyl-5-(1H-benzimidazol-1-yl)thiophene-2-carboxamides with low nanomolar in vitro potency against DHODH from P. falciparum, P. vivax, and P. berghei.  The compds. were selective for the parasite enzymes over human DHODH, and x-ray structural data on the analog Genz-667348, demonstrated that species selectivity could be attributed to amino acid differences in the inhibitor-binding site.  Compds. from this series demonstrated in vitro potency against the 3D7 and Dd2 strains of P. falciparum, good tolerability and oral exposure in the mouse, and ED50 values in the 4-day murine P. berghei efficacy model of 13-21 mg/kg/day with oral twice-daily dosing.  In particular, treatment with Genz-667348 at 100 mg/kg/day resulted in sterile cure.  Two recent analogs of Genz-667348 are currently undergoing pilot toxicity testing to det. suitability as clin. development candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF5On22AaGp7Vg90H21EOLACvtfcHk0liUWAYwuC83KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12nu7rL&md5=c94713a85af27461b3593bff5e4aa955</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.162081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.162081%26sid%3Dliteratum%253Aachs%26aulast%3DBooker%26aufirst%3DM.%2BL.%26aulast%3DBastos%26aufirst%3DC.%2BM.%26aulast%3DKramer%26aufirst%3DM.%2BL.%26aulast%3DBarker%26aufirst%3DR.%2BH.%26aulast%3DSkerlj%26aufirst%3DR.%26aulast%3DSidhu%26aufirst%3DA.%2BB.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DCelatka%26aufirst%3DC.%26aulast%3DCortese%26aufirst%3DJ.%2BF.%26aulast%3DGuerrero%2BBravo%26aufirst%3DJ.%2BE.%26aulast%3DCrespo%2BLlado%26aufirst%3DK.%2BN.%26aulast%3DSerrano%26aufirst%3DA.%2BE.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DViera%26aufirst%3DS.%26aulast%3DGaruti%26aufirst%3DH.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DPapastogiannidis%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DJ.%2BW.%26aulast%3DJanse%26aufirst%3DC.%2BJ.%26aulast%3DKhan%26aufirst%3DS.%2BM.%26aulast%3DDuraisingh%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DB.%26aulast%3DGoldsmith%26aufirst%3DE.%2BJ.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DMunoz%26aufirst%3DB.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26aulast%3DKlinger%26aufirst%3DJ.%2BD.%26aulast%3DWiegand%26aufirst%3DR.%26aulast%3DSybertz%26aufirst%3DE.%26atitle%3DNovel%2520inhibitors%2520of%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520with%2520anti-malarial%2520activity%2520in%2520the%2520mouse%2520model%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D33054%26epage%3D33064%26doi%3D10.1074%2Fjbc.M110.162081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gujjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmquist, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">26999</span>– <span class="NLM_lpage">27009</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.028589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1074%2Fjbc.M109.028589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=19640844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCgsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=26999-27009&author=X.+Dengauthor=R.+Gujjarauthor=F.+El+Mazouniauthor=W.+Kaminskyauthor=N.+A.+Malmquistauthor=E.+J.+Goldsmithauthor=P.+K.+Rathodauthor=M.+A.+Phillips&title=Structural+plasticity+of+malaria+dihydroorotate+dehydrogenase+allows+selective+binding+of+diverse+chemical+scaffolds&doi=10.1074%2Fjbc.M109.028589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds</span></div><div class="casAuthors">Deng, Xiaoyi; Gujjar, Ramesh; El Mazouni, Farah; Kaminsky, Werner; Malmquist, Nicholas A.; Goldsmith, Elizabeth J.; Rathod, Pradipsinh K.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">26999-27009</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Malaria remains a major global health burden and current drug therapies are compromised by resistance.  Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) was validated as a new drug target through the identification of potent and selective triazolopyrimidine-based DHODH inhibitors with anti-malarial activity in vivo.  Here we report x-ray structure detn. of PfDHODH bound to three inhibitors from this series, representing the first of the enzyme bound to malaria specific inhibitors.  We demonstrate that conformational flexibility results in an unexpected binding mode identifying a new hydrophobic pocket on the enzyme.  Importantly this plasticity allows PfDHODH to bind inhibitors from different chem. classes and to accommodate inhibitor modifications during lead optimization, increasing the value of PfDHODH as a drug target.  A second discovery, based on small mol. crystallog., is that the triazolopyrimidines populate a resonance form that promotes charge sepn.  These intrinsic dipoles allow formation of energetically favorable H-bond interactions with the enzyme.  The importance of delocalization to binding affinity was supported by site-directed mutagenesis and the demonstration that triazolopyrimidine analogs that lack this intrinsic dipole are inactive.  Finally, the PfDHODH-triazolopyrimidine bound structures provide considerable new insight into species-selective inhibitor binding in this enzyme family.  Together, these studies will directly impact efforts to exploit PfDHODH for the development of anti-malarial chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRiLeJ8tO72bVg90H21EOLACvtfcHk0lgaNQJ1mksHLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCgsL%252FM&md5=0b6b089104abafd748010651b964494e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.028589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.028589%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DGujjar%26aufirst%3DR.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DKaminsky%26aufirst%3DW.%26aulast%3DMalmquist%26aufirst%3DN.%2BA.%26aulast%3DGoldsmith%26aufirst%3DE.%2BJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DStructural%2520plasticity%2520of%2520malaria%2520dihydroorotate%2520dehydrogenase%2520allows%2520selective%2520binding%2520of%2520diverse%2520chemical%2520scaffolds%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D26999%26epage%3D27009%26doi%3D10.1074%2Fjbc.M109.028589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otwinowski, Z.</span>; <span class="NLM_string-name">Minor, W.</span></span> <span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span>. In  <i>Methods in Enzymology</i>; <span class="NLM_publisher-name">Elsevier Inc.</span>, <span class="NLM_year">1997</span>; Vol.  <span class="NLM_volume">276</span>, pp  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">326</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&pages=307-326&author=Z.+Otwinowski&author=W.+Minor&title=Methods+in+Enzymology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26btitle%3DMethods%2520in%2520Enzymology%26pub%3DElsevier%2520Inc%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R.</span></span> <span> </span><span class="NLM_article-title">Phaser crystallographic software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+McCoyauthor=R.+Grosse-Kunstleveauthor=P.+Adamsauthor=M.+Winnauthor=L.+Storoniauthor=R.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lgaNQJ1mksHLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%26aulast%3DAdams%26aufirst%3DP.%26aulast%3DWinn%26aufirst%3DM.%26aulast%3DStoroni%26aufirst%3DL.%26aulast%3DRead%26aufirst%3DR.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lgaNQJ1mksHLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkóczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P.</span></span> <span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+Adamsauthor=P.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+Chenauthor=I.+Davisauthor=N.+Echolsauthor=J.+Headdauthor=L.+Hungauthor=G.+Kapralauthor=R.+Grosse-Kunstleveauthor=A.+McCoyauthor=N.+Moriartyauthor=R.+Oeffnerauthor=R.+Readauthor=D.+Richardsonauthor=J.+Richardsonauthor=T.+Terwilligerauthor=P.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0ljThKyHMaGiZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%26aulast%3DAfonine%26aufirst%3DP.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DI.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%26aulast%3DHung%26aufirst%3DL.%26aulast%3DKapral%26aufirst%3DG.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMoriarty%26aufirst%3DN.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DD.%26aulast%3DRichardson%26aufirst%3DJ.%26aulast%3DTerwilliger%26aufirst%3DT.%26aulast%3DZwart%26aufirst%3DP.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendall, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Immormino, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span> <span> </span><span class="NLM_article-title">MolProbity: all-atom structure validation for macromolecular crystallography</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1107/S0907444909042073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1107%2FS0907444909042073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=20057044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=12-21&author=V.+B.+Chenauthor=W.+B.+Arendallauthor=J.+J.+Headdauthor=D.+A.+Keedyauthor=R.+M.+Immorminoauthor=G.+J.+Kapralauthor=L.+W.+Murrayauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+structure+validation+for+macromolecular+crystallography&doi=10.1107%2FS0907444909042073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom structure validation for macromolecular crystallography</span></div><div class="casAuthors">Chen, Vincent B.; Arendall, W. Bryan, III; Headd, Jeffrey J.; Keedy, Daniel A.; Immormino, Robert M.; Kapral, Gary J.; Murray, Laura W.; Richardson, Jane S.; Richardson, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-21</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">MolProbity is a structure-validation web service that provides broad-spectrum solidly based evaluation of model quality at both the global and local levels for both proteins and nucleic acids.  It relies heavily on the power and sensitivity provided by optimized hydrogen placement and all-atom contact anal., complemented by updated versions of covalent-geometry and torsion-angle criteria.  Some of the local corrections can be performed automatically in MolProbity and all of the diagnostics are presented in chart and graphical forms that help guide manual rebuilding.  X-ray crystallog. provides a wealth of biol. important mol. data in the form of at. three-dimensional structures of proteins, nucleic acids and increasingly large complexes in multiple forms and states.  Advances in automation, in everything from crystn. to data collection to phasing to model building to refinement, have made solving a structure using crystallog. easier than ever.  However, despite these improvements, local errors that can affect biol. interpretation are widespread at low resoln. and even high-resoln. structures nearly all contain at least a few local errors such as Ramachandran outliers, flipped branched protein side chains and incorrect sugar puckers.  It is crit. both for the crystallographer and for the end user that there are easy and reliable methods to diagnose and correct these sorts of errors in structures.  MolProbity is the authors' contribution to helping solve this problem and this article reviews its general capabilities, reports on recent enhancements and usage, and presents evidence that the resulting improvements are now beneficially affecting the global database.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIjgsh59dO-7Vg90H21EOLACvtfcHk0ljThKyHMaGiZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D&md5=b5fc7574f43f01dd6e43c3663ca4f779</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1107%2FS0907444909042073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909042073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DKeedy%26aufirst%3DD.%2BA.%26aulast%3DImmormino%26aufirst%3DR.%2BM.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520structure%2520validation%2520for%2520macromolecular%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D12%26epage%3D21%26doi%3D10.1107%2FS0907444909042073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coteron, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Las Heras, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjalanagara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudra, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morizzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazaga, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span> <span> </span><span class="NLM_article-title">Tetrahydro-2-naphthyl and 2-indanyl triazolopyrimidines targeting <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase display potent and selective antimalarial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5416</span>– <span class="NLM_lpage">5431</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00275</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00275" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFShtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5416-5431&author=S.+Kokkondaauthor=X.+Dengauthor=K.+L.+Whiteauthor=J.+M.+Coteronauthor=M.+Marcoauthor=L.+de+Las+Herasauthor=J.+Whiteauthor=F.+El+Mazouniauthor=D.+R.+Tomchickauthor=K.+Manjalanagaraauthor=K.+R.+Rudraauthor=G.+Chenauthor=J.+Morizziauthor=E.+Ryanauthor=W.+Kaminskyauthor=D.+Leroyauthor=M.+S.+Martinez-Martinezauthor=M.+B.+Jimenez-Diazauthor=S.+F.+Bazagaauthor=I.+Angulo-Barturenauthor=D.+Watersonauthor=J.+N.+Burrowsauthor=D.+Matthewsauthor=S.+A.+Charmanauthor=M.+A.+Phillipsauthor=P.+K.+Rathod&title=Tetrahydro-2-naphthyl+and+2-indanyl+triazolopyrimidines+targeting+Plasmodium+falciparum+dihydroorotate+dehydrogenase+display+potent+and+selective+antimalarial+activity&doi=10.1021%2Facs.jmedchem.6b00275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity</span></div><div class="casAuthors">Kokkonda, Sreekanth; Deng, Xiaoyi; White, Karen L.; Coteron, Jose M.; Marco, Maria; de las Heras, Laura; White, John; El Mazouni, Farah; Tomchick, Diana R.; Manjalanagara, Krishne; Rudra, Kakali Rani; Chen, Gong; Morizzi, Julia; Ryan, Eileen; Kaminsky, Werner; Leroy, Didier; Martinez-Martinez, Maria Santos; Jimenez-Diaz, Maria Belen; Bazaga, Santiago Ferrer; Angulo-Barturen, Inigo; Waterson, David; Burrows, Jeremy N.; Matthews, Dave; Charman, Susan A.; Phillips, Margaret A.; Rathod, Pradipsinh K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5416-5431</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Malaria persists as one of the most devastating global infectious diseases.  The pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) has been identified as a new malaria drug target, and a triazolopyrimidine-based DHODH inhibitor 1 (DSM265) is in clin. development.  We sought to identify compds. with higher potency against Plasmodium DHODH while showing greater selectivity toward animal DHODHs.  Herein we describe a series of novel triazolopyrimidines wherein the p-SF5-aniline was replaced with substituted 1,2,3,4-tetrahydro-2-naphthyl or 2-indanyl amines.  These compds. showed strong species selectivity, and several highly potent tetrahydro-2-naphthyl derivs. were identified.  Compds. with halogen substitutions displayed sustained plasma levels after oral dosing in rodents leading to efficacy in the P. falciparum SCID mouse malaria model.  These data suggest that tetrahydro-2-naphthyl derivs. have the potential to be efficacious for the treatment of malaria, but due to higher metabolic clearance than 1, they most likely would need to be part of a multidose regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYADLrWooUCbVg90H21EOLACvtfcHk0ljl4dVStovNVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFShtro%253D&md5=4a6dcc57849971a406f0f6338a53fecb</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00275%26sid%3Dliteratum%253Aachs%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DCoteron%26aufirst%3DJ.%2BM.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3Dde%2BLas%2BHeras%26aufirst%3DL.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DTomchick%26aufirst%3DD.%2BR.%26aulast%3DManjalanagara%26aufirst%3DK.%26aulast%3DRudra%26aufirst%3DK.%2BR.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DRyan%26aufirst%3DE.%26aulast%3DKaminsky%26aufirst%3DW.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DMartinez-Martinez%26aufirst%3DM.%2BS.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DBazaga%26aufirst%3DS.%2BF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26atitle%3DTetrahydro-2-naphthyl%2520and%25202-indanyl%2520triazolopyrimidines%2520targeting%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520display%2520potent%2520and%2520selective%2520antimalarial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5416%26epage%3D5431%26doi%3D10.1021%2Facs.jmedchem.6b00275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harder, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">Advancing Drug Discovery through Enhanced Free Energy Calculations</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1632</span>, <span class="refDoi"> DOI: 10.1021/acs.accounts.7b00083</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.accounts.7b00083" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSiur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2017&pages=1625-1632&author=R.+Abelauthor=L.+Wangauthor=E.+D.+Harderauthor=B.+J.+Berneauthor=R.+A.+Friesner&title=Advancing+Drug+Discovery+through+Enhanced+Free+Energy+Calculations&doi=10.1021%2Facs.accounts.7b00083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing Drug Discovery through Enhanced Free Energy Calculations</span></div><div class="casAuthors">Abel, Robert; Wang, Lingle; Harder, Edward D.; Berne, B. J.; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1625-1632</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A principal goal of drug discovery project is to design mols. that can tightly and selectively bind to the target protein receptor.  Accurate prediction of protein-ligand binding free energies is therefore of central importance in computational chem. and computer aided drug design.  Multiple recent improvements in computing power, classical force field accuracy, enhanced sampling methods, and simulation setup, have enabled accurate and reliable calcns. of protein-ligands binding free energies, and position free energy calcns. to play a guiding role in small mol. drug discovery.  In this accounts, the authors outline the relevant methodol. advances, including the REST2 (Replica Exchange with Solute Temperting) enhanced sampling, the incorporation of REST2 sampling with conventional FEP (Free Energy Perturbation) through FEP/REST, the OPLS3 force fields, and the advanced simulation set up that constitute the authors' FEP+ approach, followed by the presentation of extensive comparisons with expt., demonstrating sufficient accuracy in potency prediction (better than 1 kcal/mol) to substantially impact lead optimization campaigns.  The limitations of the current FEP+ implementation and best practices in drug discovery applications are also discussed followed by the future methodol. development plans to address those limitations.  The authors then report results from a recent drug discovery project, in which several thousand FEP+ calcns. were successfully deployed to simultaneously optimize potency, selectivity, and soly., illustrating the power of the approach to solve challenging drug design problems.  The capabilities of free energy calcns. to accurately predict potency and selectivity have led to the advance of ongoing drug discovery projects, in challenging situations where alternative approaches would have great difficulties.  The ability to effectively carry out projects evaluating tens of thousands, or hundreds of thousands, of proposed drug candidates, is potentially transformative in enabling hard to drug targets to be attacked, and in facilitating the development of superior compds., in various dimensions, for a wide range of targets.  More effective integration of FEP+ calcns. into the drug discovery process will ensure that the results are deployed in an optimal fashion for yielding the best possible compds. entering the clinic; this is where the greatest payoff is in the exploitation of computer driven design capabilities.  A key conclusion from the work described is the surprisingly robust and accurate results that are attainable within the conventional classical simulation, fixed charge paradigm.  No doubt there are individual cases that would benefit from a more sophisticated energy model or dynamical treatment, and properties other than protein-ligand binding energies may be more sensitive to these approxns.  The authors conclude that an inflection point in the ability of MD simulations to impact drug discovery has now been attained, due to the confluence of hardware and software development along with the formulation of "good enough" theor. methods and models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_VeCPmDRlf7Vg90H21EOLACvtfcHk0ljl4dVStovNVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSiur3K&md5=46d07ee6f6f129a126f0fde40a62ffe2</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.accounts.7b00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.accounts.7b00083%26sid%3Dliteratum%253Aachs%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHarder%26aufirst%3DE.%2BD.%26aulast%3DBerne%26aufirst%3DB.%2BJ.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DAdvancing%2520Drug%2520Discovery%2520through%2520Enhanced%2520Free%2520Energy%2520Calculations%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2017%26volume%3D50%26spage%3D1625%26epage%3D1632%26doi%3D10.1021%2Facs.accounts.7b00083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">Role of the active-site solvent in the thermodynamics of factor Xa ligand binding</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">2817</span>– <span class="NLM_lpage">2831</span>, <span class="refDoi"> DOI: 10.1021/ja0771033</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0771033" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvFWgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=2817-2831&author=R.+Abelauthor=T.+Youngauthor=R.+Faridauthor=B.+J.+Berneauthor=R.+A.+Friesner&title=Role+of+the+active-site+solvent+in+the+thermodynamics+of+factor+Xa+ligand+binding&doi=10.1021%2Fja0771033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the Active-Site Solvent in the Thermodynamics of Factor Xa Ligand Binding</span></div><div class="casAuthors">Abel, Robert; Young, Tom; Farid, Ramy; Berne, Bruce J.; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2817-2831</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Understanding the underlying physics of the binding of small-mol. ligands to protein active sites is a key objective of computational chem. and biol.  It is widely believed that displacement of water mols. from the active site by the ligand is a principal (if not the dominant) source of binding free energy.  Although continuum theories of hydration are routinely used to describe the contributions of the solvent to the binding affinity of the complex, it is still an unsettled question as to whether or not these continuum solvation theories describe the underlying mol. physics with sufficient accuracy to reliably rank the binding affinities of a set of ligands for a given protein.  Here we develop a novel, computationally efficient descriptor of the contribution of the solvent to the binding free energy of a small mol. and its assocd. receptor that captures the effects of the ligand displacing the solvent from the protein active site with at. detail.  This descriptor quant. predicts (R2 = 0.81) the binding free energy differences between congeneric ligand pairs for the test system factor Xa, elucidates phys. properties of the active site solvent that appear to be missing in most continuum theories of hydration, and identifies several features of the hydration of the factor Xa active site relevant to the structure-activity relationship of its inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS42r59nNXH7Vg90H21EOLACvtfcHk0ljl4dVStovNVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvFWgurk%253D&md5=8eefe76547a82bccaea38f2c84e6cd5f</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fja0771033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0771033%26sid%3Dliteratum%253Aachs%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DT.%26aulast%3DFarid%26aufirst%3DR.%26aulast%3DBerne%26aufirst%3DB.%2BJ.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DRole%2520of%2520the%2520active-site%2520solvent%2520in%2520the%2520thermodynamics%2520of%2520factor%2520Xa%2520ligand%2520binding%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D2817%26epage%3D2831%26doi%3D10.1021%2Fja0771033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">808</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1073/pnas.0610202104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1073%2Fpnas.0610202104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=17204562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVegtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=808-813&author=T.+Youngauthor=R.+Abelauthor=B.+Kimauthor=B.+J.+Berneauthor=R.+A.+Friesner&title=Motifs+for+molecular+recognition+exploiting+hydrophobic+enclosure+in+protein-ligand+binding&doi=10.1073%2Fpnas.0610202104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding</span></div><div class="casAuthors">Young, Tom; Abel, Robert; Kim, Byungchan; Berne, Bruce J.; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">808-813</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The thermodn. properties and phase behavior of water in confined regions can vary significantly from that obsd. in the bulk.  This is particularly true for systems in which the confinement is on the mol.-length scale.  In this study, we use mol. dynamics simulations and a powerful solvent anal. technique based on inhomogeneous solvation theory to investigate the properties of water mols. that solvate the confined regions of protein active sites.  Our simulations and anal. indicate that the solvation of protein active sites that are characterized by hydrophobic enclosure and correlated hydrogen bonds induce atypical entropic and enthalpic penalties of hydration.  These penalties apparently stabilize the protein-ligand complex with respect to the independently solvated ligand and protein, which leads to enhanced binding affinities.  Our anal. elucidates several challenging cases, including the super affinity of the streptavidin-biotin system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWumQ61YTqILVg90H21EOLACvtfcHk0ljl4dVStovNVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVegtr4%253D&md5=1109e3f48670cd910885f7fd527eb880</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0610202104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0610202104%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DT.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DB.%26aulast%3DBerne%26aufirst%3DB.%2BJ.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DMotifs%2520for%2520molecular%2520recognition%2520exploiting%2520hydrophobic%2520enclosure%2520in%2520protein-ligand%2520binding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D808%26epage%3D813%26doi%3D10.1073%2Fpnas.0610202104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubert-Brohman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerome, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annabhimoju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyles, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">WScore: a flexible and accurate treatment of explicit water molecules in ligand-receptor docking</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4364</span>– <span class="NLM_lpage">4384</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00131</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00131" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Gqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4364-4384&author=R.+B.+Murphyauthor=M.+P.+Repaskyauthor=J.+R.+Greenwoodauthor=I.+Tubert-Brohmanauthor=S.+Jeromeauthor=R.+Annabhimojuauthor=N.+A.+Boylesauthor=C.+D.+Schmitzauthor=R.+Abelauthor=R.+Faridauthor=R.+A.+Friesner&title=WScore%3A+a+flexible+and+accurate+treatment+of+explicit+water+molecules+in+ligand-receptor+docking&doi=10.1021%2Facs.jmedchem.6b00131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">WScore: A Flexible and Accurate Treatment of Explicit Water Molecules in Ligand-Receptor Docking</span></div><div class="casAuthors">Murphy, Robert B.; Repasky, Matthew P.; Greenwood, Jeremy R.; Tubert-Brohman, Ivan; Jerome, Steven; Annabhimoju, Ramakrishna; Boyles, Nicholas A.; Schmitz, Christopher D.; Abel, Robert; Farid, Ramy; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4364-4384</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have developed a new methodol. for protein-ligand docking and scoring, WScore, incorporating a flexible description of explicit water mols.  The locations and thermodn. of the waters are derived from a WaterMap mol. dynamics simulation.  The water structure is employed to provide an at. level description of ligand and protein desolvation.  WScore also contains a detailed model for localized ligand and protein strain energy and integrates an MM-GBSA scoring component with these terms to assess delocalized strain of the complex.  Ensemble docking is used to take into account induced fit effects on the receptor conformation, and protein reorganization free energies are assigned via fitting to exptl. data.  The performance of the method is evaluated for pose prediction, rank ordering of self-docked complexes, and enrichment in virtual screening, using a large data set of PDB complexes and compared with the Glide SP and Glide XP models; significant improvements are obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonCVRxlzARBbVg90H21EOLACvtfcHk0ljAPIFJ1u-VJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Gqtr4%253D&md5=dcb2bc320a1bffe608531c4aa01666bb</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00131%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DTubert-Brohman%26aufirst%3DI.%26aulast%3DJerome%26aufirst%3DS.%26aulast%3DAnnabhimoju%26aufirst%3DR.%26aulast%3DBoyles%26aufirst%3DN.%2BA.%26aulast%3DSchmitz%26aufirst%3DC.%2BD.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFarid%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DWScore%253A%2520a%2520flexible%2520and%2520accurate%2520treatment%2520of%2520explicit%2520water%2520molecules%2520in%2520ligand-receptor%2520docking%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4364%26epage%3D4384%26doi%3D10.1021%2Facs.jmedchem.6b00131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubert-Brohman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">Docking performance of the glide program as evaluated on the Astex and DUD datasets: a complete set of glide SP results and selected results for a new scoring function integrating WaterMap and glide</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1007/s10822-012-9575-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1007%2Fs10822-012-9575-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=22576241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVelu7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=787-799&author=M.+P.+Repaskyauthor=R.+B.+Murphyauthor=J.+L.+Banksauthor=J.+R.+Greenwoodauthor=I.+Tubert-Brohmanauthor=S.+Bhatauthor=R.+A.+Friesner&title=Docking+performance+of+the+glide+program+as+evaluated+on+the+Astex+and+DUD+datasets%3A+a+complete+set+of+glide+SP+results+and+selected+results+for+a+new+scoring+function+integrating+WaterMap+and+glide&doi=10.1007%2Fs10822-012-9575-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Docking performance of the glide program as evaluated on the Astex and DUD datasets: a complete set of glide SP results and selected results for a new scoring function integrating WaterMap and glide</span></div><div class="casAuthors">Repasky, Matthew P.; Murphy, Robert B.; Banks, Jay L.; Greenwood, Jeremy R.; Tubert-Brohman, Ivan; Bhat, Sathesh; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">787-799</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Glide SP mode enrichment results for two prepns. of the DUD dataset and native ligand docking RMSDs for two prepns. of the Astex dataset are presented.  Following a best-practices prepn. scheme, an av. RMSD of 1.140 Å for native ligand docking with Glide SP is computed.  Following the same best-practices prepn. scheme for the DUD dataset an av. area under the ROC curve (AUC) of 0.80 and av. early enrichment via the ROC (0.1 %) metric of 0.12 were obsd. 74 and 56 % of the 39 best-practices prepd. targets showed AUC over 0.7 and 0.8, resp.  Av. AUC was greater than 0.7 for all best-practices protein families demonstrating consistent enrichment performance across a broad range of proteins and ligand chemotypes.  In both Astex and DUD datasets, docking performance is significantly improved employing a best-practices prepn. scheme over using minimally-prepd. structures from the PDB.  Enrichment results for WScore, a new scoring function and sampling methodol. integrating WaterMap and Glide, are presented for four DUD targets, hivrt, hsp90, cdk2, and fxa.  WScore performance in early enrichment is consistently strong and all systems examd. show AUC > 0.9 and superior early enrichment to DUD best-practices Glide SP results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHCCMQs2lTrLVg90H21EOLACvtfcHk0ljAPIFJ1u-VJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVelu7nI&md5=9eb2c6feb24177c81bb5c06b947893fc</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2Fs10822-012-9575-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-012-9575-9%26sid%3Dliteratum%253Aachs%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DTubert-Brohman%26aufirst%3DI.%26aulast%3DBhat%26aufirst%3DS.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DDocking%2520performance%2520of%2520the%2520glide%2520program%2520as%2520evaluated%2520on%2520the%2520Astex%2520and%2520DUD%2520datasets%253A%2520a%2520complete%2520set%2520of%2520glide%2520SP%2520results%2520and%2520selected%2520results%2520for%2520a%2520new%2520scoring%2520function%2520integrating%2520WaterMap%2520and%2520glide%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2012%26volume%3D26%26spage%3D787%26epage%3D799%26doi%3D10.1007%2Fs10822-012-9575-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span> <span> </span><span class="NLM_article-title">Accurate calculation of relative binding free energies between ligands with different net charges</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">6346</span>– <span class="NLM_lpage">6358</span>, <span class="refDoi"> DOI: 10.1021/acs.jctc.8b00825</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.8b00825" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVarurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=6346-6358&author=W.+Chenauthor=Y.+Dengauthor=E.+Russellauthor=Y.+Wuauthor=R.+Abelauthor=L.+Wang&title=Accurate+calculation+of+relative+binding+free+energies+between+ligands+with+different+net+charges&doi=10.1021%2Facs.jctc.8b00825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Accurate Calculation of Relative Binding Free Energies between Ligands with Different Net Charges</span></div><div class="casAuthors">Chen, Wei; Deng, Yuqing; Russell, Ellery; Wu, Yujie; Abel, Robert; Wang, Lingle</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6346-6358</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In drug discovery programs, modifications that change the net charge of the ligands are often considered to improve the binding potency and soly., or to address other ADME/Tox problems.  Accurate calcn. of the binding free-energy changes assocd. with charge-changing perturbations remains a great challenge of central importance in computational drug discovery.  The finite size effects assocd. with periodic boundary condition and lattice summation employed in common mol. dynamics simulations introduce artifacts in the electrostatic potential energy calcns., which need to be carefully handled for accurate free-energy calcns. between systems with different net charges.  The salts in the buffer soln. of exptl. binding affinity assays also have a strong effect on the binding free energies between charged species, which further complicates the modeling of the charge-changing perturbations.  Here, we extend our free-energy perturbation (FEP) algorithm, which has been extensively applied to many drug discovery programs for relative binding free-energy calcns. between ligands with the same net charge (charge-conserving perturbation), to enable charge-changing perturbations.  We have investigated three different approaches to correct the finite size effects and tested them on 10 protein targets and 31 charge-changing perturbations.  We have found that all three methods are able to successfully eliminate the box-size dependence of calcd. binding free energies assocd. with brute force FEP.  Moreover, inclusion of salts matching the ionic strength of exptl. buffer soln. significantly improves the calcd. binding free energies.  For ligands with multiple possible protonation states, we applied the pKa correction to account for the ionization equil. of the ligands and the results are significantly improved.  Finally, the calcd. binding free energies from these methods agree with each other, and also agree well with the exptl. results.  The root-mean-square error between the calcd. binding free energies and exptl. data is 1.1 kcal/mol, which is on par with the accuracy of charge-conserving perturbations.  We anticipate that the outstanding accuracy demonstrated here across a broad range of target classes may have significant implications for drug discovery projects, where charge-changing modifications must be considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPN1nqGGUR9rVg90H21EOLACvtfcHk0ljAPIFJ1u-VJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVarurjL&md5=bc0f54d3836f2525f90164e4b6b38b25</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.8b00825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.8b00825%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DRussell%26aufirst%3DE.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26atitle%3DAccurate%2520calculation%2520of%2520relative%2520binding%2520free%2520energies%2520between%2520ligands%2520with%2520different%2520net%2520charges%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2018%26volume%3D14%26spage%3D6346%26epage%3D6358%26doi%3D10.1021%2Facs.jctc.8b00825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinbrecher, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlgren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krilov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, W.</span></span> <span> </span><span class="NLM_article-title">Accurate binding free energy predictions in fragment optimization</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2411</span>– <span class="NLM_lpage">2420</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.5b00538</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.5b00538" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1eku7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=2411-2420&author=T.+B.+Steinbrecherauthor=M.+Dahlgrenauthor=D.+Cappelauthor=T.+Linauthor=L.+Wangauthor=G.+Krilovauthor=R.+Abelauthor=R.+Friesnerauthor=W.+Sherman&title=Accurate+binding+free+energy+predictions+in+fragment+optimization&doi=10.1021%2Facs.jcim.5b00538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Accurate Binding Free Energy Predictions in Fragment Optimization</span></div><div class="casAuthors">Steinbrecher, Thomas B.; Dahlgren, Markus; Cappel, Daniel; Lin, Teng; Wang, Lingle; Krilov, Goran; Abel, Robert; Friesner, Richard; Sherman, Woody</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2411-2420</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Predicting protein-ligand binding free energies is a central aim of computational structure-based drug design (SBDD) - improved accuracy in binding free energy predictions could significantly reduce costs and accelerate project timelines in lead discovery and optimization.  The recent development and validation of advanced free energy calcn. methods represents a major step toward this goal.  Accurately predicting the relative binding free energy changes of modifications to ligands is esp. valuable in the field of fragment-based drug design, since fragment screens tend to deliver initial hits of low binding affinity that require multiple rounds of synthesis to gain the requisite potency for a project.  A free energy perturbation protocol, FEP+, which was previously validated on drug-like lead compds., is suitable for the calcn. of relative binding strengths of fragment-sized compds. as well.  The authors study several pharmaceutically relevant targets with a total of >90 fragments and find that the FEP+ methodol., which uses explicit solvent mol. dynamics and physics-based scoring with no parameters adjusted, can accurately predict relative fragment binding affinities.  The calcns. afford R2-values on av. >0.5 compared to exptl. data and root-mean-square errors of ∼1.1 kcal/mol overall, demonstrating significant improvements over the docking and MM-GBSA methods tested in this work and indicating that FEP+ has the requisite predictive power to impact fragment-based affinity optimization projects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2OM1KfoQE4bVg90H21EOLACvtfcHk0lje_FxTu0EIVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1eku7%252FI&md5=116425dcc073d2907c888555e9061aa8</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.5b00538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.5b00538%26sid%3Dliteratum%253Aachs%26aulast%3DSteinbrecher%26aufirst%3DT.%2BB.%26aulast%3DDahlgren%26aufirst%3DM.%26aulast%3DCappel%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DKrilov%26aufirst%3DG.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%26aulast%3DSherman%26aufirst%3DW.%26atitle%3DAccurate%2520binding%2520free%2520energy%2520predictions%2520in%2520fragment%2520optimization%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26spage%3D2411%26epage%3D2420%26doi%3D10.1021%2Facs.jcim.5b00538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, B. J.</span></span> <span> </span><span class="NLM_article-title">Efficient sampling of puckering states of monosaccharides through replica exchange with solute tempering and bond softening</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>149</i></span>, <span class="NLM_elocation-id">072306</span> <span class="refDoi"> DOI: 10.1063/1.5024389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1063%2F1.5024389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=30134707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptlamtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2018&author=L.+Wangauthor=B.+J.+Berne&title=Efficient+sampling+of+puckering+states+of+monosaccharides+through+replica+exchange+with+solute+tempering+and+bond+softening&doi=10.1063%2F1.5024389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient sampling of puckering states of monosaccharides through replica exchange with solute tempering and bond softening</span></div><div class="casAuthors">Wang, Lingle; Berne, B. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">072306/1-072306/10</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    
            (<span class="NLM_cas:orgname">American Institute of Physics</span>)
        </div><div class="casAbstract">A mol.-level understanding of the structure, dynamics, and reactivity of carbohydrates is fundamental to the understanding of a range of key biol. processes.  The six-membered pyranose ring, a central component of biol. monosaccharides and carbohydrates, has many different puckering conformations, and the conformational free energy landscape of these biol. important monosaccharides remains elusive.  The puckering conformations of monosaccharides are sepd. by high energy barriers, which pose a great challenge for the complete sampling of these important conformations and accurate modeling of these systems.  While metadynamics or umbrella sampling methods have been used to study the conformational space of monosaccharides, these methods might be difficult to generalize to other complex ring systems with more degrees of freedom.  In this paper, the authors introduce a new enhanced sampling method for the rapid sampling over high energy barriers that combines the previously developed enhanced sampling method REST (replica exchange with solute tempering) with a bond softening (BOS) scheme that makes a chem. bond in the ring weaker as one ascends the replica ladder.  The authors call this new method replica exchange with solute tempering and bond softening (REST/BOS).  The authors demonstrate the superior sampling efficiency of REST/BOS over other commonly used enhanced sampling methods, including temp. replica exchange method and REST.  The conformational free energy landscape of four biol. important monosaccharides, namely, α-glucose, β-glucose, β-mannose, and β-xylose, is studied using REST/BOS, and results are compared with previous exptl. and theor. studies.  (c) 2018 American Institute of Physics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy9zuewHjbd7Vg90H21EOLACvtfcHk0lje_FxTu0EIVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptlamtrk%253D&md5=a5ad01e503c19c821c92c97da477583f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1063%2F1.5024389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.5024389%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBerne%26aufirst%3DB.%2BJ.%26atitle%3DEfficient%2520sampling%2520of%2520puckering%2520states%2520of%2520monosaccharides%2520through%2520replica%2520exchange%2520with%2520solute%2520tempering%2520and%2520bond%2520softening%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D2018%26volume%3D149%26doi%3D10.1063%2F1.5024389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damm, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maple, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reboul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupyan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlgren, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaus, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerutti, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krilov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">OPLS3: A force field providing broad coverage of drug-like small molecules and proteins</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1021/acs.jctc.5b00864</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.5b00864" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=281-296&author=E.+Harderauthor=W.+Dammauthor=J.+Mapleauthor=C.+Wuauthor=M.+Reboulauthor=J.+Y.+Xiangauthor=L.+Wangauthor=D.+Lupyanauthor=M.+K.+Dahlgrenauthor=J.+L.+Knightauthor=J.+W.+Kausauthor=D.+S.+Ceruttiauthor=G.+Krilovauthor=W.+L.+Jorgensenauthor=R.+Abelauthor=R.+A.+Friesner&title=OPLS3%3A+A+force+field+providing+broad+coverage+of+drug-like+small+molecules+and+proteins&doi=10.1021%2Facs.jctc.5b00864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins</span></div><div class="casAuthors">Harder, Edward; Damm, Wolfgang; Maple, Jon; Wu, Chuanjie; Reboul, Mark; Xiang, Jin Yu; Wang, Lingle; Lupyan, Dmitry; Dahlgren, Markus K.; Knight, Jennifer L.; Kaus, Joseph W.; Cerutti, David S.; Krilov, Goran; Jorgensen, William L.; Abel, Robert; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">281-296</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The parametrization and validation of the OPLS3 force field for small mols. and proteins are reported.  Enhancements with respect to the previous version (OPLS2.1) include the addn. of off-atom charge sites to represent halogen bonding and aryl nitrogen lone pairs as well as a complete refit of peptide dihedral parameters to better model the native structure of proteins.  To adequately cover medicinal chem. space, OPLS3 employs over an order of magnitude more ref. data and assocd. parameter types relative to other commonly used small mol. force fields (e.g., MMFF and OPLS_2005).  As a consequence, OPLS3 achieves a high level of accuracy across performance benchmarks that assess small mol. conformational propensities and solvation.  The newly fitted peptide dihedrals lead to significant improvements in the representation of secondary structure elements in simulated peptides and native structure stability over a no. of proteins.  Together, the improvements made to both the small mol. and protein force field lead to a high level of accuracy in predicting protein-ligand binding measured over a wide range of targets and ligands (less than 1 kcal/mol RMS error) representing a 30% improvement over earlier variants of the OPLS force field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY_jrOhcBRgrVg90H21EOLACvtfcHk0lje_FxTu0EIVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE&md5=42663f8cfa84b80a67132bbb13b9b7ce</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.5b00864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.5b00864%26sid%3Dliteratum%253Aachs%26aulast%3DHarder%26aufirst%3DE.%26aulast%3DDamm%26aufirst%3DW.%26aulast%3DMaple%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DReboul%26aufirst%3DM.%26aulast%3DXiang%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLupyan%26aufirst%3DD.%26aulast%3DDahlgren%26aufirst%3DM.%2BK.%26aulast%3DKnight%26aufirst%3DJ.%2BL.%26aulast%3DKaus%26aufirst%3DJ.%2BW.%26aulast%3DCerutti%26aufirst%3DD.%2BS.%26aulast%3DKrilov%26aufirst%3DG.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DOPLS3%253A%2520A%2520force%2520field%2520providing%2520broad%2520coverage%2520of%2520drug-like%2520small%2520molecules%2520and%2520proteins%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2016%26volume%3D12%26spage%3D281%26epage%3D296%26doi%3D10.1021%2Facs.jctc.5b00864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damm, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reboul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlgren, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harder, E. D.</span></span> <span> </span><span class="NLM_article-title">OPLS3e: Extending force field coverage for drug-like small molecules</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1863</span>– <span class="NLM_lpage">1874</span>, <span class="refDoi"> DOI: 10.1021/acs.jctc.8b01026</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.8b01026" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFKlsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=1863-1874&author=K.+Roosauthor=C.+Wuauthor=W.+Dammauthor=M.+Reboulauthor=J.+M.+Stevensonauthor=C.+Luauthor=M.+K.+Dahlgrenauthor=S.+Mondalauthor=W.+Chenauthor=L.+Wangauthor=R.+Abelauthor=R.+A.+Friesnerauthor=E.+D.+Harder&title=OPLS3e%3A+Extending+force+field+coverage+for+drug-like+small+molecules&doi=10.1021%2Facs.jctc.8b01026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">OPLS3e: Extending Force Field Coverage for Drug-Like Small Molecules</span></div><div class="casAuthors">Roos, Katarina; Wu, Chuanjie; Damm, Wolfgang; Reboul, Mark; Stevenson, James M.; Lu, Chao; Dahlgren, Markus K.; Mondal, Sayan; Chen, Wei; Wang, Lingle; Abel, Robert; Friesner, Richard A.; Harder, Edward D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1863-1874</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Building upon the OPLS3 force field we report on an enhanced model, OPLS3e, that further extends its coverage of medicinally relevant chem. space by addressing limitations in chemotype transferability.  OPLS3e accomplishes this by incorporating new parameter types that recognize moieties with greater chem. specificity and integrating an on-the-fly parametrization approach to the assignment of partial charges.  As a consequence, OPLS3e leads to greater accuracy against performance benchmarks that assess small mol. conformational propensities, solvation, and protein-ligand binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWzxgqjMQBLLVg90H21EOLACvtfcHk0lgAHVUhbONkzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFKlsrs%253D&md5=5c91547ddc0c975f9616cfba56a5454f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.8b01026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.8b01026%26sid%3Dliteratum%253Aachs%26aulast%3DRoos%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DDamm%26aufirst%3DW.%26aulast%3DReboul%26aufirst%3DM.%26aulast%3DStevenson%26aufirst%3DJ.%2BM.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DDahlgren%26aufirst%3DM.%2BK.%26aulast%3DMondal%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DHarder%26aufirst%3DE.%2BD.%26atitle%3DOPLS3e%253A%2520Extending%2520force%2520field%2520coverage%2520for%2520drug-like%2520small%2520molecules%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2019%26volume%3D15%26spage%3D1863%26epage%3D1874%26doi%3D10.1021%2Facs.jctc.8b01026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krilov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupyan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlgren, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbrecher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damm, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murcko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span> <span> </span><span class="NLM_article-title">Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">2695</span>– <span class="NLM_lpage">2703</span>, <span class="refDoi"> DOI: 10.1021/ja512751q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja512751q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2iuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=2695-2703&author=L.+Wangauthor=Y.+Wuauthor=Y.+Dengauthor=B.+Kimauthor=L.+Pierceauthor=G.+Krilovauthor=D.+Lupyanauthor=S.+Robinsonauthor=M.+K.+Dahlgrenauthor=J.+Greenwoodauthor=D.+L.+Romeroauthor=C.+Masseauthor=J.+L.+Knightauthor=T.+Steinbrecherauthor=T.+Beumingauthor=W.+Dammauthor=E.+Harderauthor=W.+Shermanauthor=M.+Brewerauthor=R.+Westerauthor=M.+Murckoauthor=L.+Fryeauthor=R.+Faridauthor=T.+Linauthor=D.+L.+Mobleyauthor=W.+L.+Jorgensenauthor=B.+J.+Berneauthor=R.+A.+Friesnerauthor=R.+Abel&title=Accurate+and+reliable+prediction+of+relative+ligand+binding+potency+in+prospective+drug+discovery+by+way+of+a+modern+free-energy+calculation+protocol+and+force+field&doi=10.1021%2Fja512751q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Accurate and Reliable Prediction of Relative Ligand Binding Potency in Prospective Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and Force Field</span></div><div class="casAuthors">Wang, Lingle; Wu, Yujie; Deng, Yuqing; Kim, Byungchan; Pierce, Levi; Krilov, Goran; Lupyan, Dmitry; Robinson, Shaughnessy; Dahlgren, Markus K.; Greenwood, Jeremy; Romero, Donna L.; Masse, Craig; Knight, Jennifer L.; Steinbrecher, Thomas; Beuming, Thijs; Damm, Wolfgang; Harder, Ed; Sherman, Woody; Brewer, Mark; Wester, Ron; Murcko, Mark; Frye, Leah; Farid, Ramy; Lin, Teng; Mobley, David L.; Jorgensen, William L.; Berne, Bruce J.; Friesner, Richard A.; Abel, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2695-2703</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing tight-binding ligands is a primary objective of small-mol. drug discovery.  Over the past few decades, free-energy calcns. have benefited from improved force fields and sampling algorithms, as well as the advent of low-cost parallel computing.  However, it has proven to be challenging to reliably achieve the level of accuracy that would be needed to guide lead optimization (∼5× in binding affinity) for a wide range of ligands and protein targets.  Not surprisingly, widespread com. application of free-energy simulations has been limited due to the lack of large-scale validation coupled with the tech. challenges traditionally assocd. with running these types of calcns.  Here, we report an approach that achieves an unprecedented level of accuracy across a broad range of target classes and ligands, with retrospective results encompassing 200 ligands and a wide variety of chem. perturbations, many of which involve significant changes in ligand chem. structures.  In addn., we have applied the method in prospective drug discovery projects and found a significant improvement in the quality of the compds. synthesized that have been predicted to be potent.  Compds. predicted to be potent by this approach have a substantial redn. in false positives relative to compds. synthesized on the basis of other computational or medicinal chem. approaches.  Furthermore, the results are consistent with those obtained from our retrospective studies, demonstrating the robustness and broad range of applicability of this approach, which can be used to drive decisions in lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor9UtXEyLPpLVg90H21EOLACvtfcHk0lgAHVUhbONkzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2iuro%253D&md5=37a4f4a6c085f47ed531342643b6c33b</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fja512751q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja512751q%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DB.%26aulast%3DPierce%26aufirst%3DL.%26aulast%3DKrilov%26aufirst%3DG.%26aulast%3DLupyan%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DDahlgren%26aufirst%3DM.%2BK.%26aulast%3DGreenwood%26aufirst%3DJ.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DMasse%26aufirst%3DC.%26aulast%3DKnight%26aufirst%3DJ.%2BL.%26aulast%3DSteinbrecher%26aufirst%3DT.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DDamm%26aufirst%3DW.%26aulast%3DHarder%26aufirst%3DE.%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DBrewer%26aufirst%3DM.%26aulast%3DWester%26aufirst%3DR.%26aulast%3DMurcko%26aufirst%3DM.%26aulast%3DFrye%26aufirst%3DL.%26aulast%3DFarid%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DMobley%26aufirst%3DD.%2BL.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DBerne%26aufirst%3DB.%2BJ.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DAbel%26aufirst%3DR.%26atitle%3DAccurate%2520and%2520reliable%2520prediction%2520of%2520relative%2520ligand%2520binding%2520potency%2520in%2520prospective%2520drug%2520discovery%2520by%2520way%2520of%2520a%2520modern%2520free-energy%2520calculation%2520protocol%2520and%2520force%2520field%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D2695%26epage%3D2703%26doi%3D10.1021%2Fja512751q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, K. J.</span>; <span class="NLM_string-name">Chow, E.</span>; <span class="NLM_string-name">Xu, H.</span>; <span class="NLM_string-name">Dror, R. O.</span>; <span class="NLM_string-name">Eastwood, M. P.</span>; <span class="NLM_string-name">Gregersen, B. A.</span>; <span class="NLM_string-name">Klepeis, J. L.</span>; <span class="NLM_string-name">Kolossvary, I.</span>; <span class="NLM_string-name">Moraes, M. A.</span>; <span class="NLM_string-name">Sacerdoti, F. D.</span>; <span class="NLM_string-name">Salmon, J. K.</span>; <span class="NLM_string-name">Shan, Y.</span>; <span class="NLM_string-name">Shaw, D. E.</span></span> In  <i>Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters</i>, Proceedings of the ACM/IEEE Conference on Supercomputing (SC06), <span class="NLM_publisher-loc">Tampa, Florida</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=K.+J.+Bowers&author=E.+Chow&author=H.+Xu&author=R.+O.+Dror&author=M.+P.+Eastwood&author=B.+A.+Gregersen&author=J.+L.+Klepeis&author=I.+Kolossvary&author=M.+A.+Moraes&author=F.+D.+Sacerdoti&author=J.+K.+Salmon&author=Y.+Shan&author=D.+E.+Shaw&title=Scalable+Algorithms+for+Molecular+Dynamics+Simulations+on+Commodity+Clusters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBowers%26aufirst%3DK.%2BJ.%26jtitle%3DScalable%2520Algorithms%2520for%2520Molecular%2520Dynamics%2520Simulations%2520on%2520Commodity%2520Clusters%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez-Díaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garuti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargallo-Viola, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span> <span> </span><span class="NLM_article-title">Quantitative measurement of Plasmodium-infected erythrocytes in murine models of malaria by flow cytometry using bidimensional assessment of SYTO-16 fluorescence</span>. <i>Cytometry, Part A</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>75A</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1002/cyto.a.20647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1002%2Fcyto.a.20647" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75A&publication_year=2009&pages=225-235&author=M.+B.+Jim%C3%A9nez-D%C3%ADazauthor=T.+Muletauthor=V.+Gomezauthor=S.+Vieraauthor=A.+Alvarezauthor=H.+Garutiauthor=Y.+Vazquezauthor=A.+Fernandezauthor=J.+Ibanezauthor=M.+Jimenezauthor=D.+Gargallo-Violaauthor=I.+Angulo-Barturen&title=Quantitative+measurement+of+Plasmodium-infected+erythrocytes+in+murine+models+of+malaria+by+flow+cytometry+using+bidimensional+assessment+of+SYTO-16+fluorescence&doi=10.1002%2Fcyto.a.20647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fcyto.a.20647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcyto.a.20647%26sid%3Dliteratum%253Aachs%26aulast%3DJim%25C3%25A9nez-D%25C3%25ADaz%26aufirst%3DM.%2BB.%26aulast%3DMulet%26aufirst%3DT.%26aulast%3DGomez%26aufirst%3DV.%26aulast%3DViera%26aufirst%3DS.%26aulast%3DAlvarez%26aufirst%3DA.%26aulast%3DGaruti%26aufirst%3DH.%26aulast%3DVazquez%26aufirst%3DY.%26aulast%3DFernandez%26aufirst%3DA.%26aulast%3DIbanez%26aufirst%3DJ.%26aulast%3DJimenez%26aufirst%3DM.%26aulast%3DGargallo-Viola%26aufirst%3DD.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26atitle%3DQuantitative%2520measurement%2520of%2520Plasmodium-infected%2520erythrocytes%2520in%2520murine%2520models%2520of%2520malaria%2520by%2520flow%2520cytometry%2520using%2520bidimensional%2520assessment%2520of%2520SYTO-16%2520fluorescence%26jtitle%3DCytometry%252C%2520Part%2520A%26date%3D2009%26volume%3D75A%26spage%3D225%26epage%3D235%26doi%3D10.1002%2Fcyto.a.20647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez-Díaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magan-Marchal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garuti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Gil, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraile, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Bustos, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span> <span> </span><span class="NLM_article-title">A new in vivo screening paradigm to accelerate antimalarial drug discovery</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e66967</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0066967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1371%2Fjournal.pone.0066967" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=23825598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2qtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=M.+B.+Jim%C3%A9nez-D%C3%ADazauthor=S.+Vieraauthor=J.+Ibanezauthor=T.+Muletauthor=N.+Magan-Marchalauthor=H.+Garutiauthor=V.+Gomezauthor=L.+Cortes-Gilauthor=A.+Martinezauthor=S.+Ferrerauthor=M.+T.+Fraileauthor=F.+Calderonauthor=E.+Fernandezauthor=L.+D.+Shultzauthor=D.+Leroyauthor=D.+M.+Wilsonauthor=J.+F.+Garcia-Bustosauthor=F.+J.+Gamoauthor=I.+Angulo-Barturen&title=A+new+in+vivo+screening+paradigm+to+accelerate+antimalarial+drug+discovery&doi=10.1371%2Fjournal.pone.0066967"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">A new in vivo screening paradigm to accelerate antimalarial drug discovery</span></div><div class="casAuthors">Jimenez-Diaz, Maria Belen; Viera, Sara; Ibanez, Javier; Mulet, Teresa; Magan-Marchal, Noemi; Garuti, Helen; Gomez, Vanessa; Cortes-Gil, Lorena; Martiez, Antonio; Ferrer, Santiago; Fraile, Maria Teresa; Caldero, Felix; Fernandez, Esther; Shultz, Leonard D.; Leroy, Didier; Wilson, David M.; Garcia-Bustos, Jose Francisco; Gamo, Francisco Javier; Angulo-Barturen, Inigo</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e66967</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The emergence of resistance to available antimalarials requires the urgent development of new medicines.  The recent disclosure of several thousand compds. active in vitro against the erythrocyte stage of Plasmodium falciparum has been a major breakthrough, though converting these hits into new medicines challenges current strategies.  A new in vivo screening concept was evaluated as a strategy to increase the speed and efficiency of drug discovery projects in malaria.  The new in vivo screening concept was developed based on human disease parameters, i.e. parasitemia in the peripheral blood of patients on hospital admission and parasite redn. ratio (PRR), which were allometrically down-scaled into P. berghei-infected mice.  Mice with an initial parasitemia (P0) of 1.5% were treated orally for two consecutive days and parasitemia measured 24 h after the second dose.  The assay was optimized for detection of compds. able to stop parasite replication (PRR = 1) or induce parasite clearance (PRR >1) with statistical power >99% using only two mice per exptl. group.  In the P. berghei in vivo screening assay, the PRR of a set of eleven antimalarials with different mechanisms of action correlated with human-equiv. data.  Subsequently, 590 compds. from the Tres Cantos Antimalarial Set with activity in vitro against P. falciparum were tested at 50 mg/kg (orally) in an assay format that allowed the evaluation of hundreds of compds. per mo.  The rate of compds. with detectable efficacy was 11.2% and about one third of active compds. showed in vivo efficacy comparable with the most potent antimalarials used clin.  High-throughput, high-content in vivo screening could rapidly select new compds., dramatically speeding up the discovery of new antimalarial medicines.  A global multilateral collaborative project aimed at screening the significant chem. diversity within the antimalarial in vitro hits described in the literature is a feasible task.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXKzdqs7h8k7Vg90H21EOLACvtfcHk0ljjsgRgOYG55g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2qtbjJ&md5=35d24cc0f14f22be828f36714752ac78</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0066967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0066967%26sid%3Dliteratum%253Aachs%26aulast%3DJim%25C3%25A9nez-D%25C3%25ADaz%26aufirst%3DM.%2BB.%26aulast%3DViera%26aufirst%3DS.%26aulast%3DIbanez%26aufirst%3DJ.%26aulast%3DMulet%26aufirst%3DT.%26aulast%3DMagan-Marchal%26aufirst%3DN.%26aulast%3DGaruti%26aufirst%3DH.%26aulast%3DGomez%26aufirst%3DV.%26aulast%3DCortes-Gil%26aufirst%3DL.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DFraile%26aufirst%3DM.%2BT.%26aulast%3DCalderon%26aufirst%3DF.%26aulast%3DFernandez%26aufirst%3DE.%26aulast%3DShultz%26aufirst%3DL.%2BD.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DGarcia-Bustos%26aufirst%3DJ.%2BF.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26atitle%3DA%2520new%2520in%2520vivo%2520screening%2520paradigm%2520to%2520accelerate%2520antimalarial%2520drug%2520discovery%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0066967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaieda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mototani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanzaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terauchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchikawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kori, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel, highly potent, and selective matrix metalloproteinase (mmp)-13 inhibitors with a 1,2,4-triazol-3-yl moiety as a zinc binding group using a structure-based design approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2nurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=608-626&author=H.+Naraauthor=A.+Kaiedaauthor=K.+Satoauthor=T.+Naitoauthor=H.+Mototaniauthor=H.+Okiauthor=Y.+Yamamotoauthor=H.+Kunoauthor=T.+Santouauthor=N.+Kanzakiauthor=J.+Terauchiauthor=O.+Uchikawaauthor=M.+Kori&title=Discovery+of+novel%2C+highly+potent%2C+and+selective+matrix+metalloproteinase+%28mmp%29-13+inhibitors+with+a+1%2C2%2C4-triazol-3-yl+moiety+as+a+zinc+binding+group+using+a+structure-based+design+approach&doi=10.1021%2Facs.jmedchem.6b01007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach</span></div><div class="casAuthors">Nara, Hiroshi; Kaieda, Akira; Sato, Kenjiro; Naito, Takako; Mototani, Hideyuki; Oki, Hideyuki; Yamamoto, Yoshio; Kuno, Haruhiko; Santou, Takashi; Kanzaki, Naoyuki; Terauchi, Jun; Uchikawa, Osamu; Kori, Masakuni</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">608-626</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of a superposition study of x-ray crystal structures of complexes of quinazoline deriv. I and triazole deriv. II with matrix metalloproteinase (MMP)-13 catalytic domain, a novel series of fused pyrimidine compds. which possess a 1,2,4-triazol-3-yl group as a zinc binding group (ZBG) was designed.  Among the herein described and evaluated compds., 5-(3-fluorophenyl)-4-oxo-N-{3-[2-[1H-1,2,4-triazol-3-yloxy]ethoxy]benzyl}-3,4-dihydrothieno[2,3-d]-pyrimidine-2-carboxamide (31f) exhibited excellent potency for MMP-13 (IC50 = 0.036 nM) and selectivities (greater than 1500-fold) over other MMPs (MMP-1, 2, 3, 7, 8, 9, 10, and 14) and tumor necrosis factor-α converting enzyme (TACE).  Furthermore, the inhibitor was shown to protect bovine nasal cartilage explants against degrdn. induced by interleukin-1 and oncostatin M.  In this article, the authors report the discovery of extremely potent, highly selective, and orally bioavailable fused pyrimidine derivs. that possess a 1,2,4-triazol-3-yl group as a novel ZBG for selective MMP-13 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ8Gj9214XrLVg90H21EOLACvtfcHk0ljjsgRgOYG55g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2nurvE&md5=2965566ea0c85df0bc5f806ef5650627</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01007%26sid%3Dliteratum%253Aachs%26aulast%3DNara%26aufirst%3DH.%26aulast%3DKaieda%26aufirst%3DA.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DNaito%26aufirst%3DT.%26aulast%3DMototani%26aufirst%3DH.%26aulast%3DOki%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKuno%26aufirst%3DH.%26aulast%3DSantou%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DTerauchi%26aufirst%3DJ.%26aulast%3DUchikawa%26aufirst%3DO.%26aulast%3DKori%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520novel%252C%2520highly%2520potent%252C%2520and%2520selective%2520matrix%2520metalloproteinase%2520%2528mmp%2529-13%2520inhibitors%2520with%2520a%25201%252C2%252C4-triazol-3-yl%2520moiety%2520as%2520a%2520zinc%2520binding%2520group%2520using%2520a%2520structure-based%2520design%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D608%26epage%3D626%26doi%3D10.1021%2Facs.jmedchem.6b01007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanaya, N. I. T.</span>; <span class="NLM_string-name">Muto, R.</span>; <span class="NLM_string-name">Watanabe, T.</span>; <span class="NLM_string-name">Ochiai, Y.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1-(3-pyridyl or 3-pyridazinyl)-5-heterocyclylpyrazole derivatives as platelet aggregation inhibitors</span>. <span class="NLM_patent">WO2006014005 20060209A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=N.+I.+T.+Kanaya&author=R.+Muto&author=T.+Watanabe&author=Y.+Ochiai&title=Preparation+of+1-%283-pyridyl+or+3-pyridazinyl%29-5-heterocyclylpyrazole+derivatives+as+platelet+aggregation+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKanaya%26aufirst%3DN.%2BI.%2BT.%26atitle%3DPreparation%2520of%25201-%25283-pyridyl%2520or%25203-pyridazinyl%2529-5-heterocyclylpyrazole%2520derivatives%2520as%2520platelet%2520aggregation%2520inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0032.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0002.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. <i>P. falciparum</i> DHODH inhibitors from the triazolopyrimidine (<b>1</b>)<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and pyrrole (<b>2</b>, <b>3</b>)<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> structural classes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0003.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure–activity relationships. (A) Correlation between FEP+ predicted and measured <i>Pf</i>DHODH pIC<sub>50</sub> values. Retrospective analysis of previously reported pyrrole-based compounds used as a validation set to test predictions are shown as light green triangles and compounds from this paper are shown as red circles. Both sets were included in the linear regression analysis (<i>R</i><sup>2</sup> = 0.58). Outliers (shown as green squares) with their compound ID displayed were not included in the regression analysis. Data are provided in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Tables S1 and S2</a>. (B) Correlation between <i>Pf</i>DHODH pIC<sub>50</sub> values and <i>P. falciparum</i> 3D7 cell pEC<sub>50</sub> values. All data were included in the regression analysis (<i>R</i><sup>2</sup> = 0.84). Data were taken from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 1-propynylmagnesium bromide, tetrahydrofuran (THF), 0 °C–room temperature (RT), 2–6 h; (ii) Dess–Martin, CH<sub>2</sub>CI<sub>2</sub>, RT, 2–4 h; (iii) ethyl isocyanoacetate, Ag<sub>2</sub>CO<sub>3</sub>, <i>N</i>-methyl-2-pyrrolidinone (NMP), 80 °C, 3–6 h; (iv) NaBH<sub>4</sub>, EtOH, 0 °C–RT, 1 h; (v) trifluoroacetic acid (TFA), triethylsilane, CH<sub>2</sub>CI<sub>2</sub>, 50 °C, 1 h; (vi) amine, Me<sub>3</sub>AI, THF, MW, 100 °C, 1 h; (vii) NaOH, EtOH, RT–80 °C, 2 h; (viii) amine, HATU, Et<sub>3</sub>N, CH<sub>2</sub>CI<sub>2</sub>, RT, 4 h; (ix) TFA, triethylsilane, CH<sub>2</sub>CI<sub>2</sub>, RT, 1 h or amine, Me<sub>3</sub>AI, THF, MW, 100 °C, 1 h or TBAF, THF, RT, 2 h.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) CDI, <i>N</i>,<i>O</i>-dimethylhydroxylamine·HCI, DMF, 5 h; (ii) 1-propynylmagnesium bromide, THF, 0 °C–RT, 2 h; (iii) ethyl isocyanoacetate, Ag<sub>2</sub>CO<sub>3</sub>, NMP, RT–80 °C, 2 h; (iv) NaBH<sub>4</sub>, EtOH, 0 °C–RT, 1 h; (v) TFA, triethylsilane, CH<sub>2</sub>CI<sub>2</sub>, 0 °C, 1 h; (vi) NaOH, EtOH/H<sub>2</sub>O, RT–80 °C, 2 h; (vii) amine, HATU, Et<sub>3</sub>N, CH<sub>2</sub>CI<sub>2</sub>, RT, 4 h; and (viii) TFA, triethylsilane, CH<sub>2</sub>CI<sub>2</sub>, RT, 1 h.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) methylmagnesium bromide, THF, 0 °C–RT, 4 h; (ii) TFA, triethylsilane, CH<sub>2</sub>CI<sub>2</sub>, 0–85 °C, 1 h; (iii) NaOH, EtOH/H<sub>2</sub>0, RT–80 °C, 2 h; (iv) amine, HATU, Et<sub>3</sub>N, CH<sub>2</sub>CI<sub>2</sub>, RT, 3–4 h; and (v) NaBD<sub>4</sub>, TFA–D, CHCI<sub>3</sub>, 0 °C–RT, 16 h.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) NaOH, EtOH/H<sub>2</sub>O, RT–80 °C, 2 h; (ii) amine, HATU, Et<sub>3</sub>N, CH<sub>2</sub>CI<sub>2</sub>, RT, 16 h; (iii) NaBH<sub>4</sub>, EtOH, 0 °C–RT, 1 h; (iv) Mel, THF, 0 °C–RT, 16 h; (v) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, DMAP, CH<sub>2</sub>CI<sub>2</sub>, RT, 4 h; (vi) TMSCN, (C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>B, MeCN, RT, 8 h; (vii) HCI in dioxane, RT, 2 h.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0013.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) a: NaH, TsCI, DMF, 0 °C–RT, 4.5 h or b: DMAP, Et<sub>3</sub>N, TsCI, CH<sub>2</sub>CI<sub>2</sub>, 0 °C–RT, 2 h; (ii) methylmagnesium bromide, THF, 0 °C–RT, 2–4 h; (iii) I2, toluene, RT–115 °C, 16 h; (iv) trimethylsulfoxonium iodide, <i><sup>t</sup></i>BuOK, THF, DMSO, 0 °C–RT, 4 h; (v) NaOH, EtOH/H<sub>2</sub>O, RT–80 °C, 2 h; (vi) amine, HATU, Et<sub>3</sub>N, CH<sub>2</sub>CI<sub>2</sub>, RT, 4–5 h; (vii) trityl: TFA, triethylsilane, CH<sub>2</sub>CI<sub>2</sub>, RT, 1 h; (viii) tosyl: TBAF, THF, RT–50 °C, 2 h; (ix) KCN, DMSO, RT–130 °C, 20 h.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0014.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 3,3-diethoxyprop-1-yne, n-BuLi, THF, −78 °C, 1.25 h; (ii) Dess–Martin, CH<sub>2</sub>CI<sub>2</sub>, RT, 0.5–1 h; (iii) ethyl isocyanoacetate, Ag<sub>2</sub>CO<sub>3</sub>, NMP, 85°C, 2 h; (iv) NaOH, EtOH, 70 °C, 2 h; (v) HATU, CH<sub>2</sub>CI<sub>2</sub>, Et<sub>3</sub>N, RT, 4 h; (vi) NaCIO<sub>2</sub>, sulfamic acid, HzO, 0 °C–RT, 2 h; (vii) SOCI<sub>2</sub>, MeOH, 0 °C–RT, 16 h; (viii) NaBH<sub>4</sub>, EtOH, 0 °C–RT, 1 h; (ix) Et<sub>3</sub>SiH, TFA, RT, −85 °C; (x) NaOH, EtOH, H<sub>2</sub>O, RT, 80 °C, 2 h; and (xi) R<sub>1</sub> = CONHMe: MeNH<sub>2</sub>, HATU, Et<sub>3</sub>N, THF, 0 °C–RT, 4 h; R<sub>1</sub> = CONH<sub>2</sub>: CDI, MeCN, RT–80 °C, 2 h, then NH<sub>4</sub>OH, RT–80 °C, 4 h; R<sub>1</sub> = CN (from R<sub>1</sub> = CONH<sub>2</sub>): POCI<sub>3</sub>, MeCN, pyridine, RT, 80 °C, 2 h.</p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0015.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) nitroethane, NH<sub>4</sub>OAc, RT–100 °C, 1–3 h; (ii) Fe, 4 N HCI, acetone, RT–50/60 °C, 3h; (iii) DMF, DMA, MW, 120 °C, 1 h; (iv) ethyi-2-(hydroxyimino)-3-oxobutanoate, Zn, NaOAc, AcOH, RT–100 °C, 3 h; (v) NaOH, EtOH/H<sub>2</sub>O, RT, 2 h; (vi) amine, HATU, Et<sub>3</sub>N, CH<sub>2</sub>CI<sub>2</sub>, RT, 3–4 h; (vii) Et<sub>3</sub>SiH, TFA, CH<sub>2</sub>CI<sub>2</sub>, RT, 1 h.</p></p></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0016.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) NaOH, EtOH/H<sub>2</sub>O, RT, −80 °C, 2 h; (ii) amine, HATU, Et<sub>3</sub>N, CH<sub>2</sub>CI<sub>2</sub>, RT, 2–4 h; (iii) NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, DMSO, RT, −100 °C, 2 h; (iv) R = CONH<sub>2</sub>: aq. NH<sub>3</sub>, MeOH, RT, −100 °C, 24 h; (v) R = CN: T<sub>3</sub>P, DIPEA, CH<sub>2</sub>CI<sub>2</sub>, RT, 2 h.</p></p></figure><figure data-id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0004.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structures of pyrrole-based inhibitors bound to <i>Pf</i>DHODH (green). The 4 Å shell around the bound inhibitor (pink) is shown for (A) <b>79</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KZ4">7KZ4</a>), (B) <b>47</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LOK">7LOK</a>), and (C) <b>127</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYY">7KYY</a>). Hydrogen bonds are depicted by dashed lines with distances given in Å. Structures were displayed with PyMol and chemical structures are shown in each panel as rendered by Chemdraw.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0005.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Correlation of Log <i>D</i><sub>7.4</sub> with (A) unbound intrinsic clearance and (B) kinetic solubility at pH 6.5. Compound <i>Pf</i>3D7 potency is indicated as depicted in the figure legend.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0006.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Plasma concentration versus time profiles in mice and rats. To allow easy comparison, data were scaled to a common dose level assuming linear kinetics over the dose range. (A) Mouse profiles following oral administration of 20 mg/kg (scaled). Actual administered doses were <b>26</b>:20 mg/kg (<i>n</i> = 2), <b>33</b>:20 mg/kg (<i>n</i> = 2), <b>36</b>:20 mg/kg (<i>n</i> = 2), <b>79</b>:24 mg/kg (<i>n</i> = 3), and <b>99</b>:2.4 mg/kg (<i>n</i> = 3). Error bars show the range for multiple measurements in <i>n</i> = 2–3 individual mice at each time point. (B) Rat profiles following intravenous (IV) (scaled to 2 mg/kg) and (C) oral administration (scaled to 20 mg/kg). Actual rat IV/PO doses were <b>26</b>:1.9/28 mg/kg; <b>33:</b>2.9/31 mg/kg; <b>36:</b>2.8/32 mg/kg; <b>79</b>:1.8/17 mg/kg; and <b>99</b>:1.9/10 mg/kg. Data represent the mean ± standard deviation (SD) for <i>n</i> = 3 rats. Measured doses and pharmacokinetic (PK) parameters deriving from these studies are provided in <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Tables <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a> (data are not scaled in the tables).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0007.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Superimposed X-ray structure of <b>56</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYV">7KYV</a>) (pink) and <b>1</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RX0">4RX0</a>) (green) showing residues involved in resistance mutations. The <b>56</b> ligand is displayed in ball and stick (bright pink), and <b>1</b> is displayed in sticks (bright green). (B) Differential effects of pyrrole (<b>26</b>) versus triazolopyrimidine (<b>1</b>) selected mutations in <i>Pf</i>DHODH on parasite EC<sub>50</sub>. The plot shows a bar graph of the fold change (mean ± standard error of the mean (SEM)) in EC<sub>50</sub> for mutant strains versus wild-type Dd2 parasites. Compounds used for EC<sub>50</sub> determination are shown on the <i>X</i>-axis. The results for mutant lines that were selected using <b>1</b> are shown in green and those selected with <b>26</b> are shown in pink. Identified <i>Pf</i>DHODH mutations are defined in the figure legend. Data were taken from Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S7A</a>. Data for C276F, L531F, and R265 were taken from the previously selected clone data, but were in good agreement with the newer clones showing the same mutations (e.g., F1B9 L531F).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/medium/jm1c00173_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0008.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. SCID mouse efficacy study of <b>1</b> (A, B) and <b>79</b> (C, D). Compounds were dosed orally twice a day (BID) for 6 days. Dose levels are expressed as mg/kg/day in the panel legends. <b>1</b> was dosed as the spray-dried dispersion formulation (SDD 25% drug load), but dose levels are reported as the free base equivalent. Panels (A) and (C) show %parasitemia of human infected red blood cells (hRBCs) versus time and panels (B) and (D) show compound blood concentrations versus time. One mouse was dosed per dose group for <b>1</b> and <b>79</b> and 2 mice were dosed for each vehicle control group. Efficacy parameters are reported in <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">Table <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">14</a></a> and SCID pharmacokinetic parameters are reported in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf" class="ext-link">Table S10</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00173/20210506/images/large/jm1c00173_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00173&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i376">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21148" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21148" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 75 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manyando, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Huijsduijnen, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, T. N. C.</span></span> <span> </span><span class="NLM_article-title">Malaria</span>. <i>Nat. Rev. Dis. Primers</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">17050</span> <span class="refDoi"> DOI: 10.1038/nrdp.2017.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1038%2Fnrdp.2017.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28770814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A280%3ADC%252BC1cfjvVGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&author=M.+A.+Phillipsauthor=J.+N.+Burrowsauthor=C.+Manyandoauthor=R.+H.+van+Huijsduijnenauthor=W.+C.+Van+Voorhisauthor=T.+N.+C.+Wells&title=Malaria&doi=10.1038%2Fnrdp.2017.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Malaria</span></div><div class="casAuthors">Phillips Margaret A; Burrows Jeremy N; van Huijsduijnen Rob Hooft; Wells Timothy N C; Manyando Christine; Van Voorhis Wesley C</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17050</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Malaria is caused in humans by five species of single-celled eukaryotic Plasmodium parasites (mainly Plasmodium falciparum and Plasmodium vivax) that are transmitted by the bite of Anopheles spp. mosquitoes.  Malaria remains one of the most serious infectious diseases; it threatens nearly half of the world's population and led to hundreds of thousands of deaths in 2015, predominantly among children in Africa.  Malaria is managed through a combination of vector control approaches (such as insecticide spraying and the use of insecticide-treated bed nets) and drugs for both treatment and prevention.  The widespread use of artemisinin-based combination therapies has contributed to substantial declines in the number of malaria-related deaths; however, the emergence of drug resistance threatens to reverse this progress.  Advances in our understanding of the underlying molecular basis of pathogenesis have fuelled the development of new diagnostics, drugs and insecticides.  Several new combination therapies are in clinical development that have efficacy against drug-resistant parasites and the potential to be used in single-dose regimens to improve compliance.  This ambitious programme to eliminate malaria also includes new approaches that could yield malaria vaccines or novel vector control strategies.  However, despite these achievements, a well-coordinated global effort on multiple fronts is needed if malaria elimination is to be achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcfdgTdv0RVI2y4bB4mnvYfW6udTcc2eYnnfKB3Ewm27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfjvVGhtg%253D%253D&md5=ec450ab6baef0a6c2b6bd6bac030771a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2017.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2017.50%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DManyando%26aufirst%3DC.%26aulast%3Dvan%2BHuijsduijnen%26aufirst%3DR.%2BH.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DWells%26aufirst%3DT.%2BN.%2BC.%26atitle%3DMalaria%26jtitle%3DNat.%2520Rev.%2520Dis.%2520Primers%26date%3D2017%26volume%3D3%26doi%3D10.1038%2Fnrdp.2017.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">World
Health Organization</span>. <span> </span><span class="NLM_article-title">World
Malaria Report.</span> <a href="https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2020" class="extLink">https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2020</a> (accessed Dec 15, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=World%0AHealth+Organization&title=World%0AMalaria+Report."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DWorld%250AMalaria%2520Report.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hien, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faiz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokuolu, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span> <span> </span><span class="NLM_article-title">Malaria</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">735</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(13)60024-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2FS0140-6736%2813%2960024-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=23953767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A280%3ADC%252BC3sbgs1Grug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2014&pages=723-735&author=N.+J.+Whiteauthor=S.+Pukrittayakameeauthor=T.+T.+Hienauthor=M.+A.+Faizauthor=O.+A.+Mokuoluauthor=A.+M.+Dondorp&title=Malaria&doi=10.1016%2FS0140-6736%2813%2960024-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Malaria</span></div><div class="casAuthors">White Nicholas J; Pukrittayakamee Sasithon; Hien Tran Tinh; Faiz M Abul; Mokuolu Olugbenga A; Dondorp Arjen M</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">9918</span>),
    <span class="NLM_cas:pages">723-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although global morbidity and mortality have decreased substantially, malaria, a parasite infection of red blood cells, still kills roughly 2000 people per day, most of whom are children in Africa.  Two factors largely account for these decreases; increased deployment of insecticide-treated bednets and increased availability of highly effective artemisinin combination treatments.  In large trials, parenteral artesunate (an artemisinin derivative) reduced severe malaria mortality by 22·5% in Africa and 34·7% in Asia compared with quinine, whereas adjunctive interventions have been uniformly unsuccessful.  Rapid tests have been an important addition to microscopy for malaria diagnosis.  Chemopreventive strategies have been increasingly deployed in Africa, notably intermittent sulfadoxine-pyrimethamine treatment in pregnancy, and monthly amodiaquine-sulfadoxine-pyrimethamine during the rainy season months in children aged between 3 months and 5 years across the sub-Sahel.  Enthusiasm for malaria elimination has resurfaced.  This ambitious but laudable goal faces many challenges, including the worldwide economic downturn, difficulties in elimination of vivax malaria, development of pyrethroid resistance in some anopheline mosquitoes, and the emergence of artemisinin resistance in Plasmodium falciparum in southeast Asia.  We review the epidemiology, clinical features, pathology, prevention, and treatment of malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUNJZs6BRXR-kdrW1FkXG-fW6udTcc2eYnKS4NVjgBs7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbgs1Grug%253D%253D&md5=bd84954e5e034997111401f4dcdc69fd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2960024-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252960024-0%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DHien%26aufirst%3DT.%2BT.%26aulast%3DFaiz%26aufirst%3DM.%2BA.%26aulast%3DMokuolu%26aufirst%3DO.%2BA.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26atitle%3DMalaria%26jtitle%3DLancet%26date%3D2014%26volume%3D383%26spage%3D723%26epage%3D735%26doi%3D10.1016%2FS0140-6736%2813%2960024-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A.</span></span> <span> </span><span class="NLM_article-title">Antimalarial drug resistance: a threat to malaria elimination</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">a025619</span> <span class="refDoi"> DOI: 10.1101/cshperspect.a025619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1101%2Fcshperspect.a025619" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28289248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFKqurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&author=D.+Menardauthor=A.+Dondorp&title=Antimalarial+drug+resistance%3A+a+threat+to+malaria+elimination&doi=10.1101%2Fcshperspect.a025619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial drug resistance: a threat to malaria elimination</span></div><div class="casAuthors">Menard, Didier; Dondorp, Arjen</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">a025619/1-a025619/25</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Increasing antimalarial drug resistance once again threatens effective antimalarial drug treatment, malaria control, and elimination.  Artemisinin combination therapies (ACTs) are first-line treatment for uncomplicated falciparum malaria in all endemic countries, yet partial resistance to artemisinins has emerged in the Greater Mekong Subregion.  Concomitant emergence of partner drug resistance is now causing high ACT treatment failure rates in several areas.  Genetic markers for artemisinin resistance and several of the partner drugs have been established, greatly facilitating surveillance.  Single point mutations in the gene coding for the Kelch propeller domain of the K13 protein strongly correlate with artemisinin resistance.  Novel regimens and strategies using existing antimalarial drugs will be needed until novel compds. can be deployed.  Elimination of artemisinin resistance will imply elimination of all falciparum malaria from the same areas.  In vivax malaria, chloroquine resistance is an increasing problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAcvouDhij-7Vg90H21EOLACvtfcHk0ljo_N40fK59YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFKqurw%253D&md5=77170984fbae885dc193c9e0c9b3f6e5</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a025619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a025619%26sid%3Dliteratum%253Aachs%26aulast%3DMenard%26aufirst%3DD.%26aulast%3DDondorp%26aufirst%3DA.%26atitle%3DAntimalarial%2520drug%2520resistance%253A%2520a%2520threat%2520to%2520malaria%2520elimination%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2017%26volume%3D7%26doi%3D10.1101%2Fcshperspect.a025619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnadig, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralph, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title">Artemisinin action and resistance in <i>Plasmodium falciparum</i></span>. <i>Trends Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">696</span>, <span class="refDoi"> DOI: 10.1016/j.pt.2016.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2Fj.pt.2016.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=27289273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC28Xoslamt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2016&pages=682-696&author=L.+Tilleyauthor=J.+Straimerauthor=N.+F.+Gnadigauthor=S.+A.+Ralphauthor=D.+A.+Fidock&title=Artemisinin+action+and+resistance+in+Plasmodium+falciparum&doi=10.1016%2Fj.pt.2016.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin Action and Resistance in Plasmodium falciparum</span></div><div class="casAuthors">Tilley, Leann; Straimer, Judith; Gnadig, Nina F.; Ralph, Stuart A.; Fidock, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Parasitology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">682-696</span>CODEN:
                <span class="NLM_cas:coden">TPRACT</span>;
        ISSN:<span class="NLM_cas:issn">1471-4922</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The worldwide use of artemisinin-based combination therapies (ACTs) has contributed in recent years to a substantial redn. in deaths resulting from Plasmodium falciparum malaria.  Resistance to artemisinins, however, has emerged in Southeast Asia.  Clin., resistance is defined as a slower rate of parasite clearance in patients treated with an artemisinin deriv. or an ACT.  These slow clearance rates assoc. with enhanced survival rates of ring-stage parasites briefly exposed in vitro to dihydroartemisinin.  We describe recent progress made in defining the mol. basis of artemisinin resistance, which has identified a primary role for the P. falciparum K13 protein.  Using K13 mutations as mol. markers, epidemiol. studies are now tracking the emergence and spread of artemisinin resistance.  Mechanistic studies suggest potential ways to overcome resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTqDTZppoE1bVg90H21EOLACvtfcHk0ljo_N40fK59YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xoslamt78%253D&md5=8a1cb66eab2962ca73ea6d6e2cbf8f21</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.pt.2016.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pt.2016.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DTilley%26aufirst%3DL.%26aulast%3DStraimer%26aufirst%3DJ.%26aulast%3DGnadig%26aufirst%3DN.%2BF.%26aulast%3DRalph%26aufirst%3DS.%2BA.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DArtemisinin%2520action%2520and%2520resistance%2520in%2520Plasmodium%2520falciparum%26jtitle%3DTrends%2520Parasitol.%26date%3D2016%26volume%3D32%26spage%3D682%26epage%3D696%26doi%3D10.1016%2Fj.pt.2016.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralph, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, L.</span></span> <span> </span><span class="NLM_article-title">K13, the cytostome, and artemisinin resistance</span>. <i>Trends Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1016/j.pt.2020.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2Fj.pt.2020.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=32359872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFCmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2020&pages=533-544&author=S.+C.+Xieauthor=S.+A.+Ralphauthor=L.+Tilley&title=K13%2C+the+cytostome%2C+and+artemisinin+resistance&doi=10.1016%2Fj.pt.2020.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">K13, the Cytostome, and Artemisinin Resistance</span></div><div class="casAuthors">Xie, Stanley C.; Ralph, Stuart A.; Tilley, Leann</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Parasitology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">533-544</span>CODEN:
                <span class="NLM_cas:coden">TPRACT</span>;
        ISSN:<span class="NLM_cas:issn">1471-4922</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Artemisinins the frontline antimalarial drug class are compromised by emerging resistance, putting at risk the lives of hundreds of thousands of people each year.  Resistance is assocd. with mutations in a malaria parasite protein, called Kelch 13 (K13).  Recent work suggests that K13 is located at the cytostome (cell mouth) that the parasite uses to take up Hb.  Here we explore the proposal that K13 mutations confer artemisinin resistance by dampening Hb endocytosis.  This model suggests that the resultant decrease in Hb-derived heme reduces artemisinin activation, which is sufficient to enable parasite survival in the early ring stage of infection.  A fuller understanding of the resistance mechanism will underpin efforts to develop alternative antimalarial strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5KtqLFMyUo7Vg90H21EOLACvtfcHk0ljo_N40fK59YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFCmt70%253D&md5=8da990185af4ac8437f78e458acdea44</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.pt.2020.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pt.2020.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DS.%2BC.%26aulast%3DRalph%26aufirst%3DS.%2BA.%26aulast%3DTilley%26aufirst%3DL.%26atitle%3DK13%252C%2520the%2520cytostome%252C%2520and%2520artemisinin%2520resistance%26jtitle%3DTrends%2520Parasitol.%26date%3D2020%26volume%3D36%26spage%3D533%26epage%3D544%26doi%3D10.1016%2Fj.pt.2020.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Pluijm, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoa, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuy-Nhien, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thanh, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanboonkunupakarn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chutasmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saelow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runjarern, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaewmok, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peto, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhorda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chotivanich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waithira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheah, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maude, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winterberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hien, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miotto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span> <span> </span><span class="NLM_article-title">Determinants of dihydroartemisinin-piperaquine treatment failure in <i>Plasmodium falciparum</i> malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">952</span>– <span class="NLM_lpage">961</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(19)30391-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2FS1473-3099%2819%2930391-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=31345710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVeltb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=952-961&author=R.+W.+van%0Ader+Pluijmauthor=M.+Imwongauthor=N.+H.+Chauauthor=N.+T.+Hoaauthor=N.+T.+Thuy-Nhienauthor=N.+V.+Thanhauthor=P.+Jittamalaauthor=B.+Hanboonkunupakarnauthor=K.+Chutasmitauthor=C.+Saelowauthor=R.+Runjarernauthor=W.+Kaewmokauthor=R.+Tripuraauthor=T.+J.+Petoauthor=S.+Yokauthor=S.+Suonauthor=S.+Srengauthor=S.+Maoauthor=S.+Ounauthor=S.+Yenauthor=C.+Amaratungaauthor=D.+Lekauthor=R.+Huyauthor=M.+Dhordaauthor=K.+Chotivanichauthor=E.+A.+Ashleyauthor=M.+Mukakaauthor=N.+Waithiraauthor=P.+Y.+Cheahauthor=R.+J.+Maudeauthor=R.+Amatoauthor=R.+D.+Pearsonauthor=S.+Goncalvesauthor=C.+G.+Jacobauthor=W.+L.+Hamiltonauthor=R.+M.+Fairhurstauthor=J.+Tarningauthor=M.+Winterbergauthor=D.+P.+Kwiatkowskiauthor=S.+Pukrittayakameeauthor=T.+T.+Hienauthor=N.+P.+Dayauthor=O.+Miottoauthor=N.+J.+Whiteauthor=A.+M.+Dondorp&title=Determinants+of+dihydroartemisinin-piperaquine+treatment+failure+in+Plasmodium+falciparum+malaria+in+Cambodia%2C+Thailand%2C+and+Vietnam%3A+a+prospective+clinical%2C+pharmacological%2C+and+genetic+study&doi=10.1016%2FS1473-3099%2819%2930391-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study</span></div><div class="casAuthors">van der Pluijm, Rob W.; Imwong, Mallika; Chau, Nguyen Hoang; Hoa, Nhu Thi; Thuy-Nhien, Nguyen Thanh; Thanh, Ngo Viet; Jittamala, Podjanee; Hanboonkunupakarn, Borimas; Chutasmit, Kitipumi; Saelow, Chalermpon; Runjarern, Ratchadaporn; Kaewmok, Weerayuth; Tripura, Rupam; Peto, Thomas J.; Yok, Sovann; Suon, Seila; Sreng, Sokunthea; Mao, Sivanna; Oun, Savuth; Yen, Sovannary; Amaratunga, Chanaki; Lek, Dysoley; Huy, Rekol; Dhorda, Mehul; Chotivanich, Kesinee; Ashley, Elizabeth A.; Mukaka, Mavuto; Waithira, Naomi; Cheah, Phaik Yeong; Maude, Richard J.; Amato, Roberto; Pearson, Richard D.; Goncalves, Sonia; Jacob, Christopher G.; Hamilton, William L.; Fairhurst, Rick M.; Tarning, Joel; Winterberg, Markus; Kwiatkowski, Dominic P.; Pukrittayakamee, Sasithon; Hien, Tran Tinh; Day, Nicholas P. J.; Miotto, Olivo; White, Nicholas J.; Dondorp, Arjen M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">952-961</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The current study is part of a multi-country, open-label, randomised clin. trial (TRACII, 2015-18) evaluating the efficacy, safety, and tolerability of triple artemisinin combination therapies.  A very high rate of treatment failure after treatment with dihydroartemisinin-piperaquine was obsd. in Thailand, Cambodia, and Vietnam.  Patients aged between 2 and 65 years presenting with uncomplicated P falciparum or mixed species malaria at seven sites in Thailand, Cambodia, and Vietnam were randomly assigned to receive dihydroartemisinin-piperaquine with or without mefloquine, as part of the TRACII trial.  The primary outcome was the PCR-cor. efficacy at day 42.  Next-generation sequencing was used to assess the prevalence of mol. markers assocd. with artemisinin resistance (kelch13 mutations, in particular Cys580Tyr) and piperaquine resistance (plasmepsin-2 and plasmepsin-3 amplifications and crt mutations).  Between Sept 28, 2015, and Jan 18, 2018, 539 patients with acute P falciparum malaria were screened for eligibility, 292 were enrolled, and 140 received dihydroartemisinin-piperaquine.  The overall Kaplan-Meier est. of PCR-cor. efficacy of dihydroartemisinin-piperaquine at day 42 was 50·0% (95% CI 41·1-58·3).  Treatment failure was assocd. independently with plasmepsin2/3 amplification status and four mutations in the crt gene (Thr93Ser, His97Tyr, Phe145Ile, and Ile218Phe).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpscjzMhmc-97Vg90H21EOLACvtfcHk0lgZQ16CE4FxQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVeltb%252FJ&md5=e2c8bf51cf812518a46186a49a07894f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2819%2930391-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252819%252930391-3%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BPluijm%26aufirst%3DR.%2BW.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DChau%26aufirst%3DN.%2BH.%26aulast%3DHoa%26aufirst%3DN.%2BT.%26aulast%3DThuy-Nhien%26aufirst%3DN.%2BT.%26aulast%3DThanh%26aufirst%3DN.%2BV.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DHanboonkunupakarn%26aufirst%3DB.%26aulast%3DChutasmit%26aufirst%3DK.%26aulast%3DSaelow%26aufirst%3DC.%26aulast%3DRunjarern%26aufirst%3DR.%26aulast%3DKaewmok%26aufirst%3DW.%26aulast%3DTripura%26aufirst%3DR.%26aulast%3DPeto%26aufirst%3DT.%2BJ.%26aulast%3DYok%26aufirst%3DS.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DOun%26aufirst%3DS.%26aulast%3DYen%26aufirst%3DS.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DLek%26aufirst%3DD.%26aulast%3DHuy%26aufirst%3DR.%26aulast%3DDhorda%26aufirst%3DM.%26aulast%3DChotivanich%26aufirst%3DK.%26aulast%3DAshley%26aufirst%3DE.%2BA.%26aulast%3DMukaka%26aufirst%3DM.%26aulast%3DWaithira%26aufirst%3DN.%26aulast%3DCheah%26aufirst%3DP.%2BY.%26aulast%3DMaude%26aufirst%3DR.%2BJ.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DPearson%26aufirst%3DR.%2BD.%26aulast%3DGoncalves%26aufirst%3DS.%26aulast%3DJacob%26aufirst%3DC.%2BG.%26aulast%3DHamilton%26aufirst%3DW.%2BL.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DWinterberg%26aufirst%3DM.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BP.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DHien%26aufirst%3DT.%2BT.%26aulast%3DDay%26aufirst%3DN.%2BP.%26aulast%3DMiotto%26aufirst%3DO.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26atitle%3DDeterminants%2520of%2520dihydroartemisinin-piperaquine%2520treatment%2520failure%2520in%2520Plasmodium%2520falciparum%2520malaria%2520in%2520Cambodia%252C%2520Thailand%252C%2520and%2520Vietnam%253A%2520a%2520prospective%2520clinical%252C%2520pharmacological%252C%2520and%2520genetic%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2019%26volume%3D19%26spage%3D952%26epage%3D961%26doi%3D10.1016%2FS1473-3099%2819%2930391-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Pluijm, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoglund, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyae
Phyo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ul Islam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anvikar, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satpathi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satpathi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behera, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baidya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onyamboko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sovann, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chutasmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saelow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runcharern, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaewmok, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoa, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thanh, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanboonkunupakarn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callery, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohanty, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gantait, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waithira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grobusch, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Vugt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheah, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peto, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Seidlein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhorda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maude, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winterberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuy-Nhien, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hlaing, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chotivanich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayxay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hien, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valecha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithuis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miotto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Tracking Resistance to Artemisinin, C., Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated <i>Plasmodium falciparum</i> malaria: a multicentre, open-label, randomised clinical trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1360</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(20)30552-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2FS0140-6736%2820%2930552-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=32171078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVGkt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1345-1360&author=R.+W.+van%0Ader+Pluijmauthor=R.+Tripuraauthor=R.+M.+Hoglundauthor=A.+Pyae%0APhyoauthor=D.+Lekauthor=A.+Ul+Islamauthor=A.+R.+Anvikarauthor=P.+Satpathiauthor=S.+Satpathiauthor=P.+K.+Beheraauthor=A.+Tripuraauthor=S.+Baidyaauthor=M.+Onyambokoauthor=N.+H.+Chauauthor=Y.+Sovannauthor=S.+Suonauthor=S.+Srengauthor=S.+Maoauthor=S.+Ounauthor=S.+Yenauthor=C.+Amaratungaauthor=K.+Chutasmitauthor=C.+Saelowauthor=R.+Runcharernauthor=W.+Kaewmokauthor=N.+T.+Hoaauthor=N.+V.+Thanhauthor=B.+Hanboonkunupakarnauthor=J.+J.+Calleryauthor=A.+K.+Mohantyauthor=J.+Heatonauthor=M.+Thantauthor=K.+Gantaitauthor=T.+Ghoshauthor=R.+Amatoauthor=R.+D.+Pearsonauthor=C.+G.+Jacobauthor=S.+Goncalvesauthor=M.+Mukakaauthor=N.+Waithiraauthor=C.+J.+Woodrowauthor=M.+P.+Grobuschauthor=M.+van+Vugtauthor=R.+M.+Fairhurstauthor=P.+Y.+Cheahauthor=T.+J.+Petoauthor=L.+von+Seidleinauthor=M.+Dhordaauthor=R.+J.+Maudeauthor=M.+Winterbergauthor=N.+T.+Thuy-Nhienauthor=D.+P.+Kwiatkowskiauthor=M.+Imwongauthor=P.+Jittamalaauthor=K.+Linauthor=T.+M.+Hlaingauthor=K.+Chotivanichauthor=R.+Huyauthor=C.+Fanelloauthor=E.+Ashleyauthor=M.+Mayxayauthor=P.+N.+Newtonauthor=T.+T.+Hienauthor=N.+Valechaauthor=F.+Smithuisauthor=S.+Pukrittayakameeauthor=A.+Faizauthor=O.+Miottoauthor=J.+Tarningauthor=N.+P.+J.+Dayauthor=N.+J.+Whiteauthor=A.+M.+Dondorp&title=Tracking+Resistance+to+Artemisinin%2C+C.%2C+Triple+artemisinin-based+combination+therapies+versus+artemisinin-based+combination+therapies+for+uncomplicated+Plasmodium+falciparum+malaria%3A+a+multicentre%2C+open-label%2C+randomised+clinical+trial&doi=10.1016%2FS0140-6736%2820%2930552-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial</span></div><div class="casAuthors">van der Pluijm, Rob W.; Tripura, Rupam; Hoglund, Richard M.; Pyae Phyo, Aung; Lek, Dysoley; ul Islam, Akhter; Anvikar, Anupkumar R.; Satpathi, Parthasarathi; Satpathi, Sanghamitra; Behera, Prativa Kumari; Tripura, Amar; Baidya, Subrata; Onyamboko, Marie; Nguyen, Hoang Chau; Sovann, Yok; Suon, Seila; Sreng, Sokunthea; Mao, Sivanna; Oun, Savuth; Yen, Sovannary; Amaratunga, Chanaki; Chutasmit, Kitipumi; Saelow, Chalermpon; Runcharern, Ratchadaporn; Kaewmok, Weerayuth; Hoa, Nhu Thi; Thanh, Ngo Viet; Hanboonkunupakarn, Borimas; Callery, James J.; Mohanty, Akshaya Kumar; Heaton, James; Thant, Myo; Gantait, Kripasindhu; Ghosh, Tarapada; Amato, Roberto; Pearson, Richard D.; Jacob, Christopher G.; Goncalves, Sonia; Mukaka, Mavuto; Waithira, Naomi; Woodrow, Charles J.; Grobusch, Martin P.; van Vugt, Michele; Fairhurst, Rick M.; Cheah, Phaik Yeong; Peto, Thomas J.; von Seidlein, Lorenz; Dhorda, Mehul; Maude, Richard J.; Winterberg, Markus; Thuy-Nhien, Nguyen Thanh; Kwiatkowski, Dominic P.; Imwong, Mallika; Jittamala, Podjanee; Lin, Khin; Hlaing, Tin Maung; Chotivanich, Kesinee; Huy, Rekol; Fanello, Caterina; Ashley, Elizabeth; Mayxay, Mayfong; Newton, Paul N.; Hien, Tran Tinh; Valecha, Neena; Smithuis, Frank; Pukrittayakamee, Sasithon; Faiz, Abul; Miotto, Olivo; Tarning, Joel; Day, Nicholas P. J.; White, Nicholas J.; Dondorp, Arjen M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10233</span>),
    <span class="NLM_cas:pages">1345-1360</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination.  Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance.  In this multicentre, open-label, randomised trial, we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in eight countries.  Eligible patients were aged 2-65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum species, and a temp. of 37·5°C or higher, or a history of fever in the past 24 h.  Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin-piperaquine or dihydroartemisinin-piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate-mefloquine or dihydroartemisinin-piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether-lumefantrine or artemether-lumefantrine plus amodiaquine.  All drugs were administered orally and doses varied by drug combination and site.  Patients were followed-up weekly for 42 days.  The primary endpoint was efficacy, defined by 42-day PCR-cor. adequate clin. and parasitol. response.  Primary anal. was by intention to treat.  A detailed assessment of safety and tolerability of the study drugs was done in all patients randomly assigned to treatment.  This study is registered at ClinicalTrials.gov, NCT02453308, and is complete.  Between Aug 7, 2015, and Feb 8, 2018, 1100 patients were given either dihydroartemisinin-piperaquine (183 [17%]), dihydroartemisinin-piperaquine plus mefloquine (269 [25%]), artesunate-mefloquine (73 [7%]), artemether-lumefantrine (289 [26%]), or artemether-lumefantrine plus amodiaquine (286 [26%]).  The median age was 23 years (IQR 13 to 34) and 854 (78%) of 1100 patients were male.  In Cambodia, Thailand, and Vietnam the 42-day PCR-cor. efficacy after dihydroartemisinin-piperaquine plus mefloquine was 98% (149 of 152; 95% CI 94 to 100) and after dihydroartemisinin-piperaquine was 48% (67 of 141; 95% CI 39 to 56; risk difference 51%, 95% CI 42 to 59; p<0·0001).  Efficacy of dihydroartemisinin-piperaquine plus mefloquine in the three sites in Myanmar was 91% (42 of 46; 95% CI 79 to 98) vs. 100% (42 of 42; 95% CI 92 to 100) after dihydroartemisinin-piperaquine (risk difference 9%, 95% CI 1 to 17; p=0·12).  The 42-day PCR cor. efficacy of dihydroartemisinin-piperaquine plus mefloquine (96% [68 of 71; 95% CI 88 to 99]) was non-inferior to that of artesunate-mefloquine (95% [69 of 73; 95% CI 87 to 99]) in three sites in Cambodia (risk difference 1%; 95% CI -6 to 8; p=1·00).  The overall 42-day PCR-cor. efficacy of artemether-lumefantrine plus amodiaquine (98% [281 of 286; 95% CI 97 to 99]) was similar to that of artemether-lumefantrine (97% [279 of 289; 95% CI 94 to 98]; risk difference 2%, 95% CI -1 to 4; p=0·30).  Both TACTs were well tolerated, although early vomiting (within 1 h) was more frequent after dihydroartemisinin-piperaquine plus mefloquine (30 [3·8%] of 794) than after dihydroartemisinin-piperaquine (eight [1·5%] of 543; p=0·012).  Vomiting after artemether-lumefantrine plus amodiaquine (22 [1·3%] of 1703) and artemether-lumefantrine (11 [0·6%] of 1721) was infrequent.  Adding amodiaquine to artemether-lumefantrine extended the ECG cor. QT interval (mean increase at 52 h compared with baseline of 8·8 ms [SD 18·6] vs 0·9 ms [16·1]; p<0·01) but adding mefloquine to dihydroartemisinin-piperaquine did not (mean increase of 22·1 ms [SD 19·2] for dihydroartemisinin-piperaquine vs 20·8 ms [SD 17·8] for dihydroartemisinin-piperaquine plus mefloquine; p=0·50).  Dihydroartemisinin-piperaquine plus mefloquine and artemether-lumefantrine plus amodiaquine TACTs are efficacious, well tolerated, and safe treatments of uncomplicated P falciparum malaria, including in areas with artemisinin and ACT partner-drug resistance.  UK Department for International Development, Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and US National Institutes of Health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaU1eueIUvTrVg90H21EOLACvtfcHk0lh67eP7RSG5Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVGkt7k%253D&md5=2de86af293b6d2dcfe2474b045ecca2e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930552-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930552-3%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BPluijm%26aufirst%3DR.%2BW.%26aulast%3DTripura%26aufirst%3DR.%26aulast%3DHoglund%26aufirst%3DR.%2BM.%26aulast%3DPyae%2BPhyo%26aufirst%3DA.%26aulast%3DLek%26aufirst%3DD.%26aulast%3DUl%2BIslam%26aufirst%3DA.%26aulast%3DAnvikar%26aufirst%3DA.%2BR.%26aulast%3DSatpathi%26aufirst%3DP.%26aulast%3DSatpathi%26aufirst%3DS.%26aulast%3DBehera%26aufirst%3DP.%2BK.%26aulast%3DTripura%26aufirst%3DA.%26aulast%3DBaidya%26aufirst%3DS.%26aulast%3DOnyamboko%26aufirst%3DM.%26aulast%3DChau%26aufirst%3DN.%2BH.%26aulast%3DSovann%26aufirst%3DY.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DOun%26aufirst%3DS.%26aulast%3DYen%26aufirst%3DS.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DChutasmit%26aufirst%3DK.%26aulast%3DSaelow%26aufirst%3DC.%26aulast%3DRuncharern%26aufirst%3DR.%26aulast%3DKaewmok%26aufirst%3DW.%26aulast%3DHoa%26aufirst%3DN.%2BT.%26aulast%3DThanh%26aufirst%3DN.%2BV.%26aulast%3DHanboonkunupakarn%26aufirst%3DB.%26aulast%3DCallery%26aufirst%3DJ.%2BJ.%26aulast%3DMohanty%26aufirst%3DA.%2BK.%26aulast%3DHeaton%26aufirst%3DJ.%26aulast%3DThant%26aufirst%3DM.%26aulast%3DGantait%26aufirst%3DK.%26aulast%3DGhosh%26aufirst%3DT.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DPearson%26aufirst%3DR.%2BD.%26aulast%3DJacob%26aufirst%3DC.%2BG.%26aulast%3DGoncalves%26aufirst%3DS.%26aulast%3DMukaka%26aufirst%3DM.%26aulast%3DWaithira%26aufirst%3DN.%26aulast%3DWoodrow%26aufirst%3DC.%2BJ.%26aulast%3DGrobusch%26aufirst%3DM.%2BP.%26aulast%3Dvan%2BVugt%26aufirst%3DM.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DCheah%26aufirst%3DP.%2BY.%26aulast%3DPeto%26aufirst%3DT.%2BJ.%26aulast%3Dvon%2BSeidlein%26aufirst%3DL.%26aulast%3DDhorda%26aufirst%3DM.%26aulast%3DMaude%26aufirst%3DR.%2BJ.%26aulast%3DWinterberg%26aufirst%3DM.%26aulast%3DThuy-Nhien%26aufirst%3DN.%2BT.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BP.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DHlaing%26aufirst%3DT.%2BM.%26aulast%3DChotivanich%26aufirst%3DK.%26aulast%3DHuy%26aufirst%3DR.%26aulast%3DFanello%26aufirst%3DC.%26aulast%3DAshley%26aufirst%3DE.%26aulast%3DMayxay%26aufirst%3DM.%26aulast%3DNewton%26aufirst%3DP.%2BN.%26aulast%3DHien%26aufirst%3DT.%2BT.%26aulast%3DValecha%26aufirst%3DN.%26aulast%3DSmithuis%26aufirst%3DF.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DFaiz%26aufirst%3DA.%26aulast%3DMiotto%26aufirst%3DO.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DDay%26aufirst%3DN.%2BP.%2BJ.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26atitle%3DTracking%2520Resistance%2520to%2520Artemisinin%252C%2520C.%252C%2520Triple%2520artemisinin-based%2520combination%2520therapies%2520versus%2520artemisinin-based%2520combination%2520therapies%2520for%2520uncomplicated%2520Plasmodium%2520falciparum%2520malaria%253A%2520a%2520multicentre%252C%2520open-label%252C%2520randomised%2520clinical%2520trial%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1345%26epage%3D1360%26doi%3D10.1016%2FS0140-6736%2820%2930552-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>, <span class="NLM_elocation-id">338</span> <span class="refDoi"> DOI: 10.1186/s12936-019-2955-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1186%2Fs12936-019-2955-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=31581941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A280%3ADC%252BB3MnkvValug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&author=N.+J.+White&title=Triple+artemisinin-containing+combination+anti-malarial+treatments+should+be+implemented+now+to+delay+the+emergence+of+resistance&doi=10.1186%2Fs12936-019-2955-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance</span></div><div class="casAuthors">White Nicholas J</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">338</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Resistance threatens all our currently available anti-malarial drugs.  Triple artemisinin-containing combination anti-malarial treatments (TACTs) combine an artemisinin derivative with two slowly eliminated partner drugs.  TACTs are undergoing large-scale trials.  If they prove safe, well-tolerated and efficacious then they should be deployed.  This is in order to protect and extend the useful therapeutic life of the current generation of anti-malarial drugs, which are so essential for malaria control and elimination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzFiwiIEVgEeqrn-c4Of3KfW6udTcc2eYwlTLx199DF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnkvValug%253D%253D&md5=4795985d6928aaabeda72efe5187fed5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1186%2Fs12936-019-2955-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-019-2955-z%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DTriple%2520artemisinin-containing%2520combination%2520anti-malarial%2520treatments%2520should%2520be%2520implemented%2520now%2520to%2520delay%2520the%2520emergence%2520of%2520resistance%26jtitle%3DMalar.%2520J.%26date%3D2019%26volume%3D18%26doi%3D10.1186%2Fs12936-019-2955-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laleu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creek, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleebs, B. E.</span></span> <span> </span><span class="NLM_article-title">The Development process for discovery and clinical advancement of modern antimalarials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10526</span>– <span class="NLM_lpage">10562</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00761</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00761" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFamsrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10526-10562&author=T.+D.+Ashtonauthor=S.+M.+Devineauthor=J.+J.+Mohrleauthor=B.+Laleuauthor=J.+N.+Burrowsauthor=S.+A.+Charmanauthor=D.+J.+Creekauthor=B.+E.+Sleebs&title=The+Development+process+for+discovery+and+clinical+advancement+of+modern+antimalarials&doi=10.1021%2Facs.jmedchem.9b00761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Development Process for Discovery and Clinical Advancement of Modern Antimalarials</span></div><div class="casAuthors">Ashton, Trent D.; Devine, Shane M.; Mohrle, Jorg J.; Laleu, Benoit; Burrows, Jeremy N.; Charman, Susan A.; Creek, Darren J.; Sleebs, Brad E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10526-10562</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Malaria is a devastating disease caused by Plasmodium parasites resulting in approx. 435,000 deaths in 2018.  The impact of malaria is compounded by the emergence of widespread resistance to current antimalarial therapies.  Recently a new strategy was initiated to screen small mol. collections against the Plasmodium parasite enabling the identification of new antimalarial chemotypes with novel modes of action.  This initiative ushered in the modern era of antimalarial drug development and as a result, numerous lead candidates are advancing towards or are currently in human clin. trials.  In this perspective, we describe the development pathway of four of the most clin. advanced modern antimalarials, KAE609, KAF156, DSM265 and MMV048.  Addnl., the mechanism of action and lifecycle stage-specificity of the four antimalarials is discussed in relation to aligning with global strategies to treat and eliminate malaria.  This perspective serves as a guide to the expectations of modern antimalarial drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy-Wsk49dMLrVg90H21EOLACvtfcHk0lh67eP7RSG5Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFamsrvL&md5=767c459a589507f646fdbd2816030d8d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00761%26sid%3Dliteratum%253Aachs%26aulast%3DAshton%26aufirst%3DT.%2BD.%26aulast%3DDevine%26aufirst%3DS.%2BM.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DLaleu%26aufirst%3DB.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DCreek%26aufirst%3DD.%2BJ.%26aulast%3DSleebs%26aufirst%3DB.%2BE.%26atitle%3DThe%2520Development%2520process%2520for%2520discovery%2520and%2520clinical%2520advancement%2520of%2520modern%2520antimalarials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10526%26epage%3D10562%26doi%3D10.1021%2Facs.jmedchem.9b00761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buenviaje, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graumans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Vegte-Bolmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gemert, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirjanata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebayang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marfurt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwanarusk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tungtaeng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettayacamin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattabongkot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tully, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patra, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinetz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span> <span> </span><span class="NLM_article-title">KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5060</span>– <span class="NLM_lpage">5067</span>, <span class="refDoi"> DOI: 10.1128/AAC.02727-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1128%2FAAC.02727-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=24913172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1eqs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=5060-5067&author=K.+L.+Kuhenauthor=A.+K.+Chatterjeeauthor=M.+Rottmannauthor=K.+Gagaringauthor=R.+Borboaauthor=J.+Buenviajeauthor=Z.+Chenauthor=C.+Francekauthor=T.+Wuauthor=A.+Nagleauthor=S.+W.+Barnesauthor=D.+Plouffeauthor=M.+C.+Leeauthor=D.+A.+Fidockauthor=W.+Graumansauthor=M.+van+de+Vegte-Bolmerauthor=G.+J.+van+Gemertauthor=G.+Wirjanataauthor=B.+Sebayangauthor=J.+Marfurtauthor=B.+Russellauthor=R.+Suwanaruskauthor=R.+N.+Priceauthor=F.+Nostenauthor=A.+Tungtaengauthor=M.+Gettayacaminauthor=J.+Sattabongkotauthor=J.+Taylorauthor=J.+R.+Walkerauthor=D.+Tullyauthor=K.+P.+Patraauthor=E.+L.+Flanneryauthor=J.+M.+Vinetzauthor=L.+Reniaauthor=R.+W.+Sauerweinauthor=E.+A.+Winzelerauthor=R.+J.+Glynneauthor=T.+T.+Diagana&title=KAF156+is+an+antimalarial+clinical+candidate+with+potential+for+use+in+prophylaxis%2C+treatment%2C+and+prevention+of+disease+transmission&doi=10.1128%2FAAC.02727-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">KAf156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission</span></div><div class="casAuthors">Kuhen, Kelli L.; Chatterjee, Arnab K.; Rottmann, Matthias; Gagaring, Kerstin; Borboa, Rachel; Buenviaje, Jennifer; Chen, Zhong; Francek, Carolyn; Wu, Tao; Nagle, Advait; Barnes, S. Whitney; Plouffe, David; Lee, Marcus C. S.; Fidock, David A.; Graumans, Wouter; van de Vegte-Bolmer, Marga; van Gemert, Geert J.; Wirjanata, Grennady; Sebayang, Boni; Marfurt, Jutta; Russell, Bruce; Suwanarusk, Rossarin; Price, Ric N.; Nosten, Francois; Tungtaeng, Anchalee; Gettayacamin, Montip; Sattabongkot, Jetsumon; Taylor, Jennifer; Walker, John R.; Tully, David; Patra, Kailash P.; Flannery, Erika L.; Vinetz, Joseph M.; Renia, Laurent; Sauerwein, Robert W.; Winzeler, Elizabeth A.; Glynne, Richard J.; Diagana, Thierry T.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5060-5067, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Renewed global efforts toward malaria eradication have highlighted the need for novel antimalarial agents with activity against multiple stages of the parasite life cycle.  We have previously reported the discovery of a novel class of antimalarial compds. in the imidazolopiperazine series that have activity in the prevention and treatment of blood stage infection in a mouse model of malaria.  Consistent with the previously reported activity profile of this series, the clin. candidate KAF156 shows blood schizonticidal activity with 50% inhibitory concns. of 6 to 17.4 nM against P. falciparum drug-sensitive and drug-resistant strains, as well as potent therapeutic activity in a mouse models of malaria with 50, 90, and 99 % EDs of 0.6, 0.9, and 1.4 mg/kg, resp.  When administered prophylactically in a sporozoite challenge mouse model, KAF156 is completely protective as a single oral dose of 10 mg/kg.  Finally, KAF156 displays potent Plasmodium transmission blocking activities both in vitro and in vivo.  Collectively, our data suggest that KAF156, currently under evaluation in clin. trials, has the potential to treat, prevent, and block the transmission of malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QluxrWtdq7Vg90H21EOLACvtfcHk0lhFwXX7srphtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1eqs7fK&md5=c97e07e4832e871885546880084be5ca</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FAAC.02727-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02727-13%26sid%3Dliteratum%253Aachs%26aulast%3DKuhen%26aufirst%3DK.%2BL.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DBorboa%26aufirst%3DR.%26aulast%3DBuenviaje%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DFrancek%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DGraumans%26aufirst%3DW.%26aulast%3Dvan%2Bde%2BVegte-Bolmer%26aufirst%3DM.%26aulast%3Dvan%2BGemert%26aufirst%3DG.%2BJ.%26aulast%3DWirjanata%26aufirst%3DG.%26aulast%3DSebayang%26aufirst%3DB.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DB.%26aulast%3DSuwanarusk%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DTungtaeng%26aufirst%3DA.%26aulast%3DGettayacamin%26aufirst%3DM.%26aulast%3DSattabongkot%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DTully%26aufirst%3DD.%26aulast%3DPatra%26aufirst%3DK.%2BP.%26aulast%3DFlannery%26aufirst%3DE.%2BL.%26aulast%3DVinetz%26aufirst%3DJ.%2BM.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DSauerwein%26aufirst%3DR.%2BW.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26atitle%3DKAF156%2520is%2520an%2520antimalarial%2520clinical%2520candidate%2520with%2520potential%2520for%2520use%2520in%2520prophylaxis%252C%2520treatment%252C%2520and%2520prevention%2520of%2520disease%2520transmission%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D5060%26epage%3D5067%26doi%3D10.1128%2FAAC.02727-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uthaisin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanboonkunupakarn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuthasmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, F. J.</span></span> <span> </span><span class="NLM_article-title">Antimalarial activity of KAF156 in falciparum and vivax Malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">1152</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1602250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1056%2FNEJMoa1602250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=27653565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=1152-1160&author=N.+J.+Whiteauthor=T.+T.+Duongauthor=C.+Uthaisinauthor=F.+Nostenauthor=A.+P.+Phyoauthor=B.+Hanboonkunupakarnauthor=S.+Pukrittayakameeauthor=P.+Jittamalaauthor=K.+Chuthasmitauthor=M.+S.+Cheungauthor=Y.+Fengauthor=R.+Liauthor=B.+Magnussonauthor=M.+Sultanauthor=D.+Wieserauthor=X.+Xunauthor=R.+Zhaoauthor=T.+T.+Diaganaauthor=P.+Pertelauthor=F.+J.+Leong&title=Antimalarial+activity+of+KAF156+in+falciparum+and+vivax+Malaria&doi=10.1056%2FNEJMoa1602250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of KAF156 in falciparum and vivax malaria</span></div><div class="casAuthors">White, Nicholas J.; Duong, Tran T.; Uthaisin, Chirapong; Nosten, Francois; Phyo, Aung P.; Hanboonkunupakarn, Borimas; Pukrittayakamee, Sasithon; Jittamala, Podjanee; Chuthasmit, Kittiphum; Cheung, Ming S.; Feng, Yiyan; Li, Ruobing; Magnusson, Baldur; Sultan, Marc; Wieser, Daniela; Xun, Xiaolei; Zhao, Rong; Diagana, Thierry T.; Pertel, Peter; Leong, F. Joel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1152-1160</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: KAF156 belongs to a new class of antimalarial agents (imidazolopiperazines), with activity against asexual and sexual blood stages and the preerythrocytic liver stages of malarial parasites.  METHODS: We conducted a phase 2, open-label, two-part study at five centers in Thailand and Vietnam to assess the antimalarial efficacy, safety, and pharmacokinetic profile of KAF156 in adults with acute Plasmodium vivax or P. falciparum malaria.  Assessment of parasite clearance rates in cohorts of patients with vivax or falciparum malaria who were treated with multiple doses (400 mg once daily for 3 days) was followed by assessment of the cure rate at 28 days in a sep. cohort of patients with falciparum malaria who received a single dose (800 mg).  RESULTS: Median parasite clearance times were 45 h (interquartile range, 42 to 48) in 10 patients with falciparum malaria and 24 h (interquartile range, 20 to 30) in 10 patients with vivax malaria after treatment with the multiple-dose regimen and 49 h (interquartile range, 42 to 54) in 21 patients with falciparum malaria after treatment with the single dose.  Among the 21 patients who received the single dose and were followed for 28 days, 1 had reinfection and 7 had recrudescent infections (cure rate, 67%; 95% credible interval, 46 to 84).  The mean (±SD) KAF156 terminal elimination half-life was 44.1±8.9 h.  There were no serious adverse events in this small study.  The most common adverse events included sinus bradycardia, thrombocytopenia, hypokalemia, anemia, and hyperbilirubinemia.  Vomiting of grade 2 or higher occurred in 2 patients, 1 of whom discontinued treatment because of repeated vomiting after receiving the single 800-mg dose.  More adverse events were reported in the single-dose cohort, which had longer follow-up, than in the multiple-dose cohorts.  CONCLUSIONS: KAF156 showed antimalarial activity without evident safety concerns in a small no. of adults with uncomplicated P. vivax or P. falciparum malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHzWNldN2RLbVg90H21EOLACvtfcHk0lifXz4UQG24Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrnN&md5=24d0943da6d583f8c0fe4fe9f380ec99</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1602250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1602250%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDuong%26aufirst%3DT.%2BT.%26aulast%3DUthaisin%26aufirst%3DC.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DHanboonkunupakarn%26aufirst%3DB.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DChuthasmit%26aufirst%3DK.%26aulast%3DCheung%26aufirst%3DM.%2BS.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DSultan%26aufirst%3DM.%26aulast%3DWieser%26aufirst%3DD.%26aulast%3DXun%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DPertel%26aufirst%3DP.%26aulast%3DLeong%26aufirst%3DF.%2BJ.%26atitle%3DAntimalarial%2520activity%2520of%2520KAF156%2520in%2520falciparum%2520and%2520vivax%2520Malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D1152%26epage%3D1160%26doi%3D10.1056%2FNEJMoa1602250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharia, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Paez, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwanarusk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jegla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span> <span> </span><span class="NLM_article-title">Spiroindolones, a potent compound class for the treatment of malaria</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>329</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1180</span>, <span class="refDoi"> DOI: 10.1126/science.1193225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1126%2Fscience.1193225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=20813948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2hsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2010&pages=1175-1180&author=M.+Rottmannauthor=C.+McNamaraauthor=B.+K.+Yeungauthor=M.+C.+Leeauthor=B.+Zouauthor=B.+Russellauthor=P.+Seitzauthor=D.+M.+Plouffeauthor=N.+V.+Dhariaauthor=J.+Tanauthor=S.+B.+Cohenauthor=K.+R.+Spencerauthor=G.+E.+Gonzalez-Paezauthor=S.+B.+Lakshminarayanaauthor=A.+Gohauthor=R.+Suwanaruskauthor=T.+Jeglaauthor=E.+K.+Schmittauthor=H.+P.+Beckauthor=R.+Brunauthor=F.+Nostenauthor=L.+Reniaauthor=V.+Dartoisauthor=T.+H.+Kellerauthor=D.+A.+Fidockauthor=E.+A.+Winzelerauthor=T.+T.+Diagana&title=Spiroindolones%2C+a+potent+compound+class+for+the+treatment+of+malaria&doi=10.1126%2Fscience.1193225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Spiroindolones, a Potent Compound Class for the Treatment of Malaria</span></div><div class="casAuthors">Rottmann, Matthias; McNamara, Case; Yeung, Bryan K. S.; Lee, Marcus C. S.; Zou, Bin; Russell, Bruce; Seitz, Patrick; Plouffe, David M.; Dharia, Neekesh V.; Tan, Jocelyn; Cohen, Steven B.; Spencer, Kathryn R.; Gonzalez-Paez, Gonzalo E.; Lakshminarayana, Suresh B.; Goh, Anne; Suwanarusk, Rossarin; Jegla, Timothy; Schmitt, Esther K.; Beck, Hans-Peter; Brun, Reto; Nosten, Francois; Renia, Laurent; Dartois, Veronique; Keller, Thomas H.; Fidock, David A.; Winzeler, Elizabeth A.; Diagana, Thierry T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">5996</span>),
    <span class="NLM_cas:pages">1175-1180</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Recent reports of increased tolerance to artemisinin derivs.-the most recently adopted class of antimalarials-have prompted a need for new treatments.  The spirotetrahydro-β-carbolines, or spiroindolones, are potent drugs that kill the blood stages of Plasmodium falciparum and Plasmodium vivax clin. isolates at low nanomolar concn.  Spiroindolones rapidly inhibit protein synthesis in P. falciparum, an effect that is ablated in parasites bearing nonsynonymous mutations in the gene encoding the P-type cation-transporter ATPase4 (PfATP4).  The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI6O1WaX-1b7Vg90H21EOLACvtfcHk0lj3KF5rpFw61g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2hsr%252FJ&md5=239bc9babd5cb5f07e2be38741038e2c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.1193225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1193225%26sid%3Dliteratum%253Aachs%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DMcNamara%26aufirst%3DC.%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DZou%26aufirst%3DB.%26aulast%3DRussell%26aufirst%3DB.%26aulast%3DSeitz%26aufirst%3DP.%26aulast%3DPlouffe%26aufirst%3DD.%2BM.%26aulast%3DDharia%26aufirst%3DN.%2BV.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DSpencer%26aufirst%3DK.%2BR.%26aulast%3DGonzalez-Paez%26aufirst%3DG.%2BE.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DGoh%26aufirst%3DA.%26aulast%3DSuwanarusk%26aufirst%3DR.%26aulast%3DJegla%26aufirst%3DT.%26aulast%3DSchmitt%26aufirst%3DE.%2BK.%26aulast%3DBeck%26aufirst%3DH.%2BP.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26atitle%3DSpiroindolones%252C%2520a%2520potent%2520compound%2520class%2520for%2520the%2520treatment%2520of%2520malaria%26jtitle%3DScience%26date%3D2010%26volume%3D329%26spage%3D1175%26epage%3D1180%26doi%3D10.1126%2Fscience.1193225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coteron, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquivias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katneni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhamidipati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathurst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase inhibitors with clinical candidate potential</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5540</span>– <span class="NLM_lpage">5561</span>, <span class="refDoi"> DOI: 10.1021/jm200592f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200592f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVehsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5540-5561&author=J.+M.+Coteronauthor=M.+Marcoauthor=J.+Esquiviasauthor=X.+Dengauthor=K.+L.+Whiteauthor=J.+Whiteauthor=M.+Koltunauthor=F.+El+Mazouniauthor=S.+Kokkondaauthor=K.+Katneniauthor=R.+Bhamidipatiauthor=D.+M.+Shacklefordauthor=I.+Angulo-Barturenauthor=S.+B.+Ferrerauthor=M.+B.+Jimenez-Diazauthor=F.+J.+Gamoauthor=E.+J.+Goldsmithauthor=W.+N.+Charmanauthor=I.+Bathurstauthor=D.+Floydauthor=D.+Matthewsauthor=J.+N.+Burrowsauthor=P.+K.+Rathodauthor=S.+A.+Charmanauthor=M.+A.+Phillips&title=Structure-guided+lead+optimization+of+triazolopyrimidine-ring+substituents+identifies+potent+Plasmodium+falciparum+dihydroorotate+dehydrogenase+inhibitors+with+clinical+candidate+potential&doi=10.1021%2Fjm200592f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential</span></div><div class="casAuthors">Coteron, Jose M.; Marco, Maria; Esquivias, Jorge; Deng, Xiaoyi; White, Karen L.; White, John; Koltun, Maria; El Mazouni, Farah; Kokkonda, Sreekanth; Katneni, Kasiram; Bhamidipati, Ravi; Shackleford, David M.; Angulo-Barturen, Inigo; Ferrer, Santiago B.; Jimenez-Diaz, Maria Belen; Gamo, Francisco-Javier; Goldsmith, Elizabeth J.; Charman, William N.; Bathurst, Ian; Floyd, David; Matthews, David; Burrows, Jeremy N.; Rathod, Pradipsinh K.; Charman, Susan A.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5540-5561</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug therapy is the mainstay of antimalarial therapy, yet current drugs are threatened by the development of resistance.  In an effort to identify new potential antimalarials, we have undertaken a lead optimization program around our previously identified triazolopyrimidine-based series of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors.  The X-ray structure of PfDHODH was used to inform the medicinal chem. program allowing the identification of a potent and selective inhibitor (DSM265) that acts through DHODH inhibition to kill both sensitive and drug resistant strains of the parasite.  This compd. has similar potency to chloroquine in the humanized SCID mouse P. falciparum model, can be synthesized by a simple route, and rodent pharmacokinetic studies demonstrated it has excellent oral bioavailability, a long half-life and low clearance.  These studies have identified the first candidate in the triazolopyrimidine series to meet previously established progression criteria for efficacy and ADME properties, justifying further development of this compd. toward clin. candidate status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVpPPR2Tcs9rVg90H21EOLACvtfcHk0lj3KF5rpFw61g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVehsbg%253D&md5=d92f71aeda04fbbbbcd8905a657df011</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm200592f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200592f%26sid%3Dliteratum%253Aachs%26aulast%3DCoteron%26aufirst%3DJ.%2BM.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DEsquivias%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DKoltun%26aufirst%3DM.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DKatneni%26aufirst%3DK.%26aulast%3DBhamidipati%26aufirst%3DR.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DFerrer%26aufirst%3DS.%2BB.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DGoldsmith%26aufirst%3DE.%2BJ.%26aulast%3DCharman%26aufirst%3DW.%2BN.%26aulast%3DBathurst%26aufirst%3DI.%26aulast%3DFloyd%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DStructure-guided%2520lead%2520optimization%2520of%2520triazolopyrimidine-ring%2520substituents%2520identifies%2520potent%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520inhibitors%2520with%2520clinical%2520candidate%2520potential%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5540%26epage%3D5561%26doi%3D10.1021%2Fjm200592f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotharius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benito, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazaga, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haselden, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louttit, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechering, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinden, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickham, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gahagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirsalis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathhurst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span> <span> </span><span class="NLM_article-title">A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">296ra111</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aaa6645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1126%2Fscitranslmed.aaa6645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=26180101" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&author=M.+A.+Phillipsauthor=J.+Lothariusauthor=K.+Marshauthor=J.+Whiteauthor=A.+Dayanauthor=K.+L.+Whiteauthor=J.+W.+Njorogeauthor=F.+El+Mazouniauthor=Y.+Laoauthor=S.+Kokkondaauthor=D.+R.+Tomchickauthor=X.+Dengauthor=T.+Lairdauthor=S.+N.+Bhatiaauthor=S.+Marchauthor=C.+L.+Ngauthor=D.+A.+Fidockauthor=S.+Wittlinauthor=M.+Lafuente-Monasterioauthor=F.+J.+Benitoauthor=L.+M.+Alonsoauthor=M.+S.+Martinezauthor=M.+B.+Jimenez-Diazauthor=S.+F.+Bazagaauthor=I.+Angulo-Barturenauthor=J.+N.+Haseldenauthor=J.+Louttitauthor=Y.+Cuiauthor=A.+Sridharauthor=A.+M.+Zeemanauthor=C.+Kockenauthor=R.+Sauerweinauthor=K.+Decheringauthor=V.+M.+Averyauthor=S.+Duffyauthor=M.+Delvesauthor=R.+Sindenauthor=A.+Rueckerauthor=K.+S.+Wickhamauthor=R.+Rochfordauthor=J.+Gahagenauthor=L.+Iyerauthor=E.+Riccioauthor=J.+Mirsalisauthor=I.+Bathhurstauthor=T.+Rueckleauthor=X.+Dingauthor=B.+Campoauthor=D.+Leroyauthor=M.+J.+Rogersauthor=P.+K.+Rathodauthor=J.+N.+Burrowsauthor=S.+A.+Charman&title=A+long-duration+dihydroorotate+dehydrogenase+inhibitor+%28DSM265%29+for+prevention+and+treatment+of+malaria&doi=10.1126%2Fscitranslmed.aaa6645"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaa6645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaa6645%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DLotharius%26aufirst%3DJ.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DDayan%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DNjoroge%26aufirst%3DJ.%2BW.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DLao%26aufirst%3DY.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DTomchick%26aufirst%3DD.%2BR.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DLaird%26aufirst%3DT.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26aulast%3DMarch%26aufirst%3DS.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%26aulast%3DBenito%26aufirst%3DF.%2BJ.%26aulast%3DAlonso%26aufirst%3DL.%2BM.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DBazaga%26aufirst%3DS.%2BF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DHaselden%26aufirst%3DJ.%2BN.%26aulast%3DLouttit%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DKocken%26aufirst%3DC.%26aulast%3DSauerwein%26aufirst%3DR.%26aulast%3DDechering%26aufirst%3DK.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DDelves%26aufirst%3DM.%26aulast%3DSinden%26aufirst%3DR.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DWickham%26aufirst%3DK.%2BS.%26aulast%3DRochford%26aufirst%3DR.%26aulast%3DGahagen%26aufirst%3DJ.%26aulast%3DIyer%26aufirst%3DL.%26aulast%3DRiccio%26aufirst%3DE.%26aulast%3DMirsalis%26aufirst%3DJ.%26aulast%3DBathhurst%26aufirst%3DI.%26aulast%3DRueckle%26aufirst%3DT.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DRogers%26aufirst%3DM.%2BJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26atitle%3DA%2520long-duration%2520dihydroorotate%2520dehydrogenase%2520inhibitor%2520%2528DSM265%2529%2520for%2520prevention%2520and%2520treatment%2520of%2520malaria%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26doi%3D10.1126%2Fscitranslmed.aaa6645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paquet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Manach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrera, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrich, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagborough, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakutansky, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morizzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheurer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechering, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tungtaeng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanachayangkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witty, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodenreider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solapure, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkholtz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">eaad9735</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aad9735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1126%2Fscitranslmed.aad9735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28446690" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&author=T.+Paquetauthor=C.+Le+Manachauthor=D.+G.+Cabreraauthor=Y.+Younisauthor=P.+P.+Henrichauthor=T.+S.+Abrahamauthor=M.+C.+S.+Leeauthor=R.+Basakauthor=S.+Ghidelli-Disseauthor=M.+J.+Lafuente-Monasterioauthor=M.+Bantscheffauthor=A.+Rueckerauthor=A.+M.+Blagboroughauthor=S.+E.+Zakutanskyauthor=A.+M.+Zeemanauthor=K.+L.+Whiteauthor=D.+M.+Shacklefordauthor=J.+Mannilaauthor=J.+Morizziauthor=C.+Scheurerauthor=I.+Angulo-Barturenauthor=M.+S.+Martinezauthor=S.+Ferrerauthor=L.+M.+Sanzauthor=F.+J.+Gamoauthor=J.+Readerauthor=M.+Bothaauthor=K.+J.+Decheringauthor=R.+W.+Sauerweinauthor=A.+Tungtaengauthor=P.+Vanachayangkulauthor=C.+S.+Limauthor=J.+Burrowsauthor=M.+J.+Wittyauthor=K.+C.+Marshauthor=C.+Bodenreiderauthor=R.+Rochfordauthor=S.+M.+Solapureauthor=M.+B.+Jimenez-Diazauthor=S.+Wittlinauthor=S.+A.+Charmanauthor=C.+Doniniauthor=B.+Campoauthor=L.+M.+Birkholtzauthor=K.+K.+Hansonauthor=G.+Drewesauthor=C.+H.+M.+Kockenauthor=M.+J.+Delvesauthor=D.+Leroyauthor=D.+A.+Fidockauthor=D.+Watersonauthor=L.+J.+Streetauthor=K.+Chibale&title=Antimalarial+efficacy+of+MMV390048%2C+an+inhibitor+of+Plasmodium+phosphatidylinositol+4-kinase&doi=10.1126%2Fscitranslmed.aad9735"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aad9735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aad9735%26sid%3Dliteratum%253Aachs%26aulast%3DPaquet%26aufirst%3DT.%26aulast%3DLe%2BManach%26aufirst%3DC.%26aulast%3DCabrera%26aufirst%3DD.%2BG.%26aulast%3DYounis%26aufirst%3DY.%26aulast%3DHenrich%26aufirst%3DP.%2BP.%26aulast%3DAbraham%26aufirst%3DT.%2BS.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DBasak%26aufirst%3DR.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DBlagborough%26aufirst%3DA.%2BM.%26aulast%3DZakutansky%26aufirst%3DS.%2BE.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DMannila%26aufirst%3DJ.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DScheurer%26aufirst%3DC.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DSanz%26aufirst%3DL.%2BM.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DReader%26aufirst%3DJ.%26aulast%3DBotha%26aufirst%3DM.%26aulast%3DDechering%26aufirst%3DK.%2BJ.%26aulast%3DSauerwein%26aufirst%3DR.%2BW.%26aulast%3DTungtaeng%26aufirst%3DA.%26aulast%3DVanachayangkul%26aufirst%3DP.%26aulast%3DLim%26aufirst%3DC.%2BS.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DWitty%26aufirst%3DM.%2BJ.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DBodenreider%26aufirst%3DC.%26aulast%3DRochford%26aufirst%3DR.%26aulast%3DSolapure%26aufirst%3DS.%2BM.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DDonini%26aufirst%3DC.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DBirkholtz%26aufirst%3DL.%2BM.%26aulast%3DHanson%26aufirst%3DK.%2BK.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DKocken%26aufirst%3DC.%2BH.%2BM.%26aulast%3DDelves%26aufirst%3DM.%2BJ.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DAntimalarial%2520efficacy%2520of%2520MMV390048%252C%2520an%2520inhibitor%2520of%2520Plasmodium%2520phosphatidylinositol%25204-kinase%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26doi%3D10.1126%2Fscitranslmed.aad9735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutteridge, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooft van Huijsduijnen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaszubska, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, T. N. C.</span></span> <span> </span><span class="NLM_article-title">New developments in anti-malarial target candidate and product profiles</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>, <span class="NLM_elocation-id">26</span> <span class="refDoi"> DOI: 10.1186/s12936-016-1675-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1186%2Fs12936-016-1675-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28086874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsFCqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&author=J.+N.+Burrowsauthor=S.+Duparcauthor=W.+E.+Gutteridgeauthor=R.+Hooft+van+Huijsduijnenauthor=W.+Kaszubskaauthor=F.+Macintyreauthor=S.+Mazzuriauthor=J.+J.+Mohrleauthor=T.+N.+C.+Wells&title=New+developments+in+anti-malarial+target+candidate+and+product+profiles&doi=10.1186%2Fs12936-016-1675-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">New developments in anti-malarial target candidate and product profiles</span></div><div class="casAuthors">Burrows, Jeremy N.; Duparc, Stephan; Gutteridge, Winston E.; Hooft van Huijsduijnen, Rob; Kaszubska, Wiweka; MacIntyre, Fiona; Mazzuri, Sebastien; Mohrle, Jorg J.; Wells, Timothy N. C.</div><div class="citationInfo"><span class="NLM_cas:title">Malaria Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26/1-26/29</span>CODEN:
                <span class="NLM_cas:coden">MJAOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-2875</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  A decade of discovery and development of new anti-malarial medicines has led to a renewed focus on malaria elimination and eradication.  Changes in the way new anti-malarial drugs are discovered and developed have led to a dramatic increase in the no. and diversity of new mols. presently in pre-clin. and early clin. development.  The twin challenges faced can be summarized by multi-drug resistant malaria from the Greater Mekong Subregion, and the need to provide simplified medicines.  This review lists changes in anti-malarial target candidate and target product profiles over the last 4 years.  As well as new medicines to treat disease and prevent transmission, there has been increased focus on the longer term goal of finding new medicines for chemoprotection, potentially with long-acting mols., or parenteral formulations.  Other gaps in the malaria armamentarium, such as drugs to treat severe malaria and endectocides (that kill mosquitoes which feed on people who have taken the drug), are defined here.  Ultimately the elimination of malaria requires medicines that are safe and well-tolerated to be used in vulnerable populations: in pregnancy, esp. the first trimester, and in those suffering from malnutrition or co-infection with other pathogens.  These updates reflect the maturing of an understanding of the key challenges in producing the next generation of medicines to control, eliminate and ultimately eradicate malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjgdhMYAylM7Vg90H21EOLACvtfcHk0liakFG3rYmSfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsFCqu7g%253D&md5=17984994f7a29c9fb184faa5214d4d35</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Fs12936-016-1675-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-016-1675-x%26sid%3Dliteratum%253Aachs%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DGutteridge%26aufirst%3DW.%2BE.%26aulast%3DHooft%2Bvan%2BHuijsduijnen%26aufirst%3DR.%26aulast%3DKaszubska%26aufirst%3DW.%26aulast%3DMacintyre%26aufirst%3DF.%26aulast%3DMazzuri%26aufirst%3DS.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DWells%26aufirst%3DT.%2BN.%2BC.%26atitle%3DNew%2520developments%2520in%2520anti-malarial%2520target%2520candidate%2520and%2520product%2520profiles%26jtitle%3DMalar.%2520J.%26date%3D2017%26volume%3D16%26doi%3D10.1186%2Fs12936-016-1675-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lover, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span> <span> </span><span class="NLM_article-title">Malaria Elimination: Time to Target All Species</span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.17-0869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.4269%2Fajtmh.17-0869" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=29761762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A280%3ADC%252BC1Mfjtlaitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2018&pages=17-23&author=A.+A.+Loverauthor=J.+K.+Bairdauthor=R.+Goslingauthor=R.+N.+Price&title=Malaria+Elimination%3A+Time+to+Target+All+Species&doi=10.4269%2Fajtmh.17-0869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Malaria Elimination: Time to Target All Species</span></div><div class="casAuthors">Lover Andrew A; Gosling Roly; Baird J Kevin; Price Ric N; Baird J Kevin; Price Ric N</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of tropical medicine and hygiene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Important strides have been made within the past decade toward malaria elimination in many regions, and with this progress, the feasibility of eradication is once again under discussion.  If the ambitious goal of eradication is to be achieved by 2040, all species of Plasmodium infecting humans will need to be targeted with evidence-based and concerted interventions.  In this perspective, the potential barriers to achieving global malaria elimination are discussed with respect to the related diversities in host, parasite, and vector populations.  We argue that control strategies need to be reorientated from a sequential attack on each species, dominated by Plasmodium falciparum to one that targets all species in parallel.  A set of research themes is proposed to mitigate the potential setbacks on the pathway to a malaria-free world.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgausn-8JY9n6CEoQgWY10fW6udTcc2eboflEt3tbywbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mfjtlaitg%253D%253D&md5=f1fad1867951725cd089f4cf9b9161e8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.17-0869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.17-0869%26sid%3Dliteratum%253Aachs%26aulast%3DLover%26aufirst%3DA.%2BA.%26aulast%3DBaird%26aufirst%3DJ.%2BK.%26aulast%3DGosling%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26atitle%3DMalaria%2520Elimination%253A%2520Time%2520to%2520Target%2520All%2520Species%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D2018%26volume%3D99%26spage%3D17%26epage%3D23%26doi%3D10.4269%2Fajtmh.17-0869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haston, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, K. R.</span></span> <span> </span><span class="NLM_article-title">Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria — United States</span>. <i>MMWR. Morb. Mortal. Wkly. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1062</span>– <span class="NLM_lpage">1068</span>, <span class="refDoi"> DOI: 10.15585/mmwr.mm6846a4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.15585%2Fmmwr.mm6846a4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=31751320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmslOqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2019&pages=1062-1068&author=J.+C.+Hastonauthor=J.+Hwangauthor=K.+R.+Tan&title=Guidance+for+Using+Tafenoquine+for+Prevention+and+Antirelapse+Therapy+for+Malaria+%E2%80%94+United+States&doi=10.15585%2Fmmwr.mm6846a4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Guidance for using tafenoquine for prevention and antirelapse therapy for Malaria - United States, 2019</span></div><div class="casAuthors">Haston, Julia C.; Hwang, Jimee; Tan, Kathrine R.</div><div class="citationInfo"><span class="NLM_cas:title">Morbidity and Mortality Weekly Report</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">1062-1068</span>CODEN:
                <span class="NLM_cas:coden">MMWRC7</span>;
        ISSN:<span class="NLM_cas:issn">1545-861X</span>.
    
            (<span class="NLM_cas:orgname">Centers for Disease Control and Prevention</span>)
        </div><div class="casAbstract">What is already known about this topic.  Malaria can be prevented by taking antimalarials when traveling to an area with malaria.  Treatment of malaria caused by Plasmodium vivax and Plasmodium ovale requires antirelapse therapy to kill the dormant liver-stage parasite.  What is added by this report.  Adults aged ≥18 years can take tafenoquine (Arakoda 100 mg tablets) to prevent malaria.  Persons aged ≥16 years requiring antirelapse therapy for P. vivax or P. ovale can take tafenoquine (Krintafel 150 mg tablets).  Before using tafenoquine, quant. testing to rule out glucose-6-phosphate dehydrogenase deficiency is required.  What are the implications for public health practice.  Tafenoquine is another option for malaria chemoprophylaxis and for antirelapse therapy.  The simplified dosing regimen has the potential to improve adherence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSfel4DO7vTbVg90H21EOLACvtfcHk0liakFG3rYmSfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmslOqtLs%253D&md5=789750eb53c53b9455d6e3460ea15c71</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.15585%2Fmmwr.mm6846a4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15585%252Fmmwr.mm6846a4%26sid%3Dliteratum%253Aachs%26aulast%3DHaston%26aufirst%3DJ.%2BC.%26aulast%3DHwang%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DK.%2BR.%26atitle%3DGuidance%2520for%2520Using%2520Tafenoquine%2520for%2520Prevention%2520and%2520Antirelapse%2520Therapy%2520for%2520Malaria%2520%25E2%2580%2594%2520United%2520States%26jtitle%3DMMWR.%2520Morb.%2520Mortal.%2520Wkly.%2520Rep.%26date%3D2019%26volume%3D68%26spage%3D1062%26epage%3D1068%26doi%3D10.15585%2Fmmwr.mm6846a4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katneni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, F. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crighton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huertas-Valentin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chittimalla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahi, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Lead optimization of a pyrrole-based dihydroorotate dehydrogenase inhibitor series for the treatment of malaria</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4929</span>– <span class="NLM_lpage">4956</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00311</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00311" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtl2lu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4929-4956&author=S.+Kokkondaauthor=X.+Dengauthor=K.+L.+Whiteauthor=F.+El+Mazouniauthor=J.+Whiteauthor=D.+M.+Shacklefordauthor=K.+Katneniauthor=F.+C.+K.+Chiuauthor=H.+Barkerauthor=J.+McLarenauthor=E.+Crightonauthor=G.+Chenauthor=I.+Angulo-Barturenauthor=M.+B.+Jimenez-Diazauthor=S.+Ferrerauthor=L.+Huertas-Valentinauthor=M.+S.+Martinez-Martinezauthor=M.+J.+Lafuente-Monasterioauthor=R.+Chittimallaauthor=S.+P.+Shahiauthor=S.+Wittlinauthor=D.+Watersonauthor=J.+N.+Burrowsauthor=D.+Matthewsauthor=D.+Tomchickauthor=P.+K.+Rathodauthor=M.+J.+Palmerauthor=S.+A.+Charmanauthor=M.+A.+Phillips&title=Lead+optimization+of+a+pyrrole-based+dihydroorotate+dehydrogenase+inhibitor+series+for+the+treatment+of+malaria&doi=10.1021%2Facs.jmedchem.0c00311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria</span></div><div class="casAuthors">Kokkonda, Sreekanth; Deng, Xiaoyi; White, Karen L.; El Mazouni, Farah; White, John; Shackleford, David M.; Katneni, Kasiram; Chiu, Francis C. K.; Barker, Helena; McLaren, Jenna; Crighton, Elly; Chen, Gong; Angulo-Barturen, Inigo; Jimenez-Diaz, Maria Belen; Ferrer, Santiago; Huertas-Valentin, Leticia; Martinez-Martinez, Maria Santos; Lafuente-Monasterio, Maria Jose; Chittimalla, Rajesh; Shahi, Shatrughan P.; Wittlin, Sergio; Waterson, David; Burrows, Jeremy N.; Matthews, Dave; Tomchick, Diana; Rathod, Pradipsinh K.; Palmer, Michael J.; Charman, Susan A.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4929-4956</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Malaria puts at risk nearly half the world's population and causes high mortality in sub-Saharan Africa, while drug resistance threatens current therapies.  The pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) is a validated target for malaria treatment based on our finding that triazolopyrimidine DSM265 (1) showed efficacy in clin. studies.  Herein, we describe optimization of a pyrrole-based series identified using a target-based DHODH screen.  Compds. with nanomolar potency vs. Plasmodium DHODH and Plasmodium parasites were identified with good pharmacol. properties.  X-ray studies showed that the pyrroles bind an alternative enzyme conformation from 1 leading to improved species selectivity vs. mammalian enzymes and equiv. activity on Plasmodium falciparum and Plasmodium vivax DHODH.  The best lead DSM502 (37)(I) showed in vivo efficacy at similar levels of blood exposure to 1, although metabolic stability was reduced.  Overall, the pyrrole-based DHODH inhibitors provide an attractive alternative scaffold for the development of new antimalarial compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxKUG8uEm6XLVg90H21EOLACvtfcHk0liBOjgVySISHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtl2lu7o%253D&md5=33fcfe54e02132d8fd9a4816d40212b3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00311%26sid%3Dliteratum%253Aachs%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DKatneni%26aufirst%3DK.%26aulast%3DChiu%26aufirst%3DF.%2BC.%2BK.%26aulast%3DBarker%26aufirst%3DH.%26aulast%3DMcLaren%26aufirst%3DJ.%26aulast%3DCrighton%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DHuertas-Valentin%26aufirst%3DL.%26aulast%3DMartinez-Martinez%26aufirst%3DM.%2BS.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DChittimalla%26aufirst%3DR.%26aulast%3DShahi%26aufirst%3DS.%2BP.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DTomchick%26aufirst%3DD.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPalmer%26aufirst%3DM.%2BJ.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DLead%2520optimization%2520of%2520a%2520pyrrole-based%2520dihydroorotate%2520dehydrogenase%2520inhibitor%2520series%2520for%2520the%2520treatment%2520of%2520malaria%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4929%26epage%3D4956%26doi%3D10.1021%2Facs.jmedchem.0c00311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotharius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rückle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekuloski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobeau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebrevska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosario, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möhrle, J. J.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30171-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2FS1473-3099%2817%2930171-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28363636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlWmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=626-635&author=J.+S.+McCarthyauthor=J.+Lothariusauthor=T.+R%C3%BCckleauthor=S.+Chalonauthor=M.+A.+Phillipsauthor=S.+Elliottauthor=S.+Sekuloskiauthor=P.+Griffinauthor=C.+L.+Ngauthor=D.+A.+Fidockauthor=L.+Marquartauthor=N.+S.+Williamsauthor=N.+Gobeauauthor=L.+Bebrevskaauthor=M.+Rosarioauthor=K.+Marshauthor=J.+J.+M%C3%B6hrle&title=Safety%2C+tolerability%2C+pharmacokinetics%2C+and+activity+of+the+novel+long-acting+antimalarial+DSM265%3A+a+two-part+first-in-human+phase+1a%2F1b+randomised+study&doi=10.1016%2FS1473-3099%2817%2930171-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study</span></div><div class="casAuthors">McCarthy, James S.; Lotharius, Julie; Ruckle, Thomas; Chalon, Stephan; Phillips, Margaret A.; Elliott, Suzanne; Sekuloski, Silvana; Griffin, Paul; Ng, Caroline L.; Fidock, David A.; Marquart, Louise; Williams, Noelle S.; Gobeau, Nathalie; Bebrevska, Lidiya; Rosario, Maria; Marsh, Kennan; Mohrle, Jorg J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">626-635</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">DSM265 is a novel antimalarial that inhibits plasmodial dihydroorotate dehydrogenase, an enzyme essential for pyrimidine biosynthesis.  We investigated the safety, tolerability, and pharmacokinetics of DSM265, and tested its antimalarial activity.  Healthy participants aged 18-55 years were enrolled in a two-part study: part 1, a single ascending dose (25-1200 mg), double-blind, randomised, placebo-controlled study, and part 2, an open-label, randomised, active-comparator controlled study, in which participants were inoculated with Plasmodium falciparum induced blood-stage malaria (IBSM) and treated with DSM265 (150 mg) or mefloquine (10 mg/kg).  Primary endpoints were DSM265 safety, tolerability, and pharmacokinetics.  Randomisation lists were created using a validated, automated system.  Both parts were registered with the Australian New Zealand Clin. Trials Registry, no. ACTRN12613000522718 (part 1) and no. ACTRN12613000527763 (part 2).  In part 1, 73 participants were enrolled between Apr. 12, 2013, and July 14, 2015 (DSM265, n = 55; placebo, n = 18).  In part 2, nine participants were enrolled between Sept 30 and Nov 25, 2013 (150 mg DSM265, n = 7; 10 mg/kg mefloquine, n = 2).  In part 1, 117 adverse events were reported; no drug-related serious or severe events were reported.  The most common drug-related adverse event was headache.  The mean DSM265 peak plasma concn. (Cmax) ranged between 1310 ng/mL and 34 800 ng/mL and was reached in a median time (tmax) between 1.5 h and 4 h, with a mean elimination half-life between 86 h and 118 h.  In part 2, the log10 parasite redn. ratio at 48 h in the DSM265 (150 mg) group was 1.55 (95% CI 1.42-1.67) and in the mefloquine (10 mg/kg) group was 2.34 (2.17-2.52), corresponding to a parasite clearance half-life of 9.4 h (8.7-10.2) and 6.2 h (5.7-6.7), resp.  The median min. inhibitory concn. of DSM265 in blood was estd. as 1040 ng/mL (range 552-1500), resulting in a predicted single efficacious dose of 340 mg.  Parasite clearance was significantly faster in participants who received mefloquine than in participants who received DSM265 (p<0.0001).  The good safety profile, long elimination half-life, and antimalarial effect of DSM265 supports its development as a partner drug in a single-dose antimalarial combination treatment.  Wellcome Trust, UK Department for International Development, Global Health Innovative Technol. Fund, Bill & Melinda Gates Foundation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc6SKwiEAKqbVg90H21EOLACvtfcHk0liBOjgVySISHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlWmur8%253D&md5=144cece3cf70a64af921f7f37df7c72d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930171-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930171-8%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DJ.%2BS.%26aulast%3DLotharius%26aufirst%3DJ.%26aulast%3DR%25C3%25BCckle%26aufirst%3DT.%26aulast%3DChalon%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DElliott%26aufirst%3DS.%26aulast%3DSekuloski%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DP.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DMarquart%26aufirst%3DL.%26aulast%3DWilliams%26aufirst%3DN.%2BS.%26aulast%3DGobeau%26aufirst%3DN.%26aulast%3DBebrevska%26aufirst%3DL.%26aulast%3DRosario%26aufirst%3DM.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DM%25C3%25B6hrle%26aufirst%3DJ.%2BJ.%26atitle%3DSafety%252C%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520activity%2520of%2520the%2520novel%2520long-acting%2520antimalarial%2520DSM265%253A%2520a%2520two-part%2520first-in-human%2520phase%25201a%252F1b%2520randomised%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2017%26volume%3D17%26spage%3D626%26epage%3D635%26doi%3D10.1016%2FS1473-3099%2817%2930171-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llanos-Cuentas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casapia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuquiyauri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinojosa, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosario, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toovey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arch, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozenberg, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowell, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooft
van Huijsduijnen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobeau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araeipour, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andenmatten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span> <span> </span><span class="NLM_article-title">Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated <i>Plasmodium falciparum</i> or <i>Plasmodium vivax</i> malaria infection: a proof-of-concept, open-label, phase 2a study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">883</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(18)30309-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2FS1473-3099%2818%2930309-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=29909069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFyqurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=874-883&author=A.+Llanos-Cuentasauthor=M.+Casapiaauthor=R.+Chuquiyauriauthor=J.+C.+Hinojosaauthor=N.+Kerrauthor=M.+Rosarioauthor=S.+Tooveyauthor=R.+H.+Archauthor=M.+A.+Phillipsauthor=F.+D.+Rozenbergauthor=J.+Bathauthor=C.+L.+Ngauthor=A.+N.+Cowellauthor=E.+A.+Winzelerauthor=D.+A.+Fidockauthor=M.+Bakerauthor=J.+J.+Mohrleauthor=R.+Hooft%0Avan+Huijsduijnenauthor=N.+Gobeauauthor=N.+Araeipourauthor=N.+Andenmattenauthor=T.+Ruckleauthor=S.+Duparc&title=Antimalarial+activity+of+single-dose+DSM265%2C+a+novel+plasmodium+dihydroorotate+dehydrogenase+inhibitor%2C+in+patients+with+uncomplicated+Plasmodium+falciparum+or+Plasmodium+vivax+malaria+infection%3A+a+proof-of-concept%2C+open-label%2C+phase+2a+study&doi=10.1016%2FS1473-3099%2818%2930309-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study</span></div><div class="casAuthors">Llanos-Cuentas, Alejandro; Casapia, Martin; Chuquiyauri, Raul; Hinojosa, Juan-Carlos; Kerr, Nicola; Rosario, Maria; Toovey, Stephen; Arch, Robert H.; Phillips, Margaret A.; Rozenberg, Felix D.; Bath, Jade; Ng, Caroline L.; Cowell, Annie N.; Winzeler, Elizabeth A.; Fidock, David A.; Baker, Mark; Mohrle, Jorg J.; Hooft van Huijsduijnen, Rob; Gobeau, Nathalie; Araeipour, Nada; Andenmatten, Nicole; Ruckle, Thomas; Duparc, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">874-883</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against blood and liver stages of Plasmodium falciparum.  This study aimed to assess the efficacy of DSM265 in patients with P falciparum or Plasmodium vivax malaria infection.  This proof-of-concept, open-label, phase 2a study was conducted at the Asociacio´n Civil Selva Amazo´nica in Iquitos, Peru.  Patients aged 18-70 years, weighing 45-90 kg, who had clin. malaria (P falciparum or P vivax monoinfection) and fever within the previous 24 h were eligible.  Exclusion criteria were clin. or lab. signs of severe malaria, inability to take oral medicine, and use of other antimalarial treatment in the preceding 14 days.  Patients were divided into cohorts of those with P falciparum (cohort a) or P vivax (cohort b) infection.  Two initial cohorts received single oral doses of 400 mg DSM265.  Patients were followed up for efficacy for 28 days and safety for 35 days.  Further cohorts received escalated or de-escalated doses of DSM265, after safety and efficacy assessment of the initial dose.  The primary endpoints were the proportion of patients achieving PCR-adjusted adequate clin. and parasitol. response (ACPR) by day 14 for patients infected with P falciparum and the proportion of patients achieving a crude cure by day 14 for those infected with P vivax.  Cohort success, the criteria for dose escalation, was defined as ACPR (P falciparum) or crude cure (P vivax) in at least 80% of patients in the cohort.  The primary anal. was done in the intention-to-treat population (ITT) and the per-protocol population, and safety analyses were done in all patients who received the study drug.  This study is registered at ClinicalTrials.gov (NCT02123290).  Between Jan 12, 2015, and Dec 2, 2015, 45 Peruvian patients (24 with P falciparum [cohort a] and 21 with P vivax [cohort b] infection) were sequentially enrolled.  For patients with P falciparum malaria in the per-protocol population, all 11 (100%) in the 400 mg group and eight (80%) of ten in the 250 mg group achieved ACPR on day 14.  In the ITT anal., 11 (85%) of 13 in the 400 mg group and eight (73%) of 11 in the 250 mg group achieved ACPR at day 14.  For the patients with P vivax malaria, the primary endpoint was not met.  In the per-protocol anal., none of four patients who had 400 mg, three (50%) of six who had 600 mg, and one (25%) of four who had 800 mg DSM265 achieved crude cure at day 14.  In the ITT anal., none of five in the 400 mg group, three (33%) of nine in the 600 mg group, and one (14%) of seven in the 800 mg group achieved crude cure at day 14.  During the 28-day extended observation of P falciparum patients, a resistance-assocd. mutation in the gene encoding the DSM265 target DHODH was obsd. in two of four recurring patients.  DSM265 was well tolerated.  The most common adverse events were pyrexia (20 [44%] of 45) and headache (18 [40%] of 45), which are both common symptoms of malaria, and no patients had any treatment-related serious adverse events or adverse events leading to study discontinuation.  After a single dose of DSM265, P falciparum parasitemia was rapidly cleared, whereas against P vivax, DSM265 showed less effective clearance kinetics.  Its long duration of action provides the potential to prevent recurrence of P falciparum after treatment with a single dose, which should be further assessed in future combination studies.  The Global Health Innovative Technol. Fund, the Bill & Melinda Gates Foundation, the National Institutes of Health (R01 AI103058), the Wellcome Trust, and the UK Department of International Development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgJbUWoNq8m7Vg90H21EOLACvtfcHk0lj9sM2efTI0iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFyqurnI&md5=05eacd75b07eee65fca20ec28ea3c1c4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2818%2930309-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252818%252930309-8%26sid%3Dliteratum%253Aachs%26aulast%3DLlanos-Cuentas%26aufirst%3DA.%26aulast%3DCasapia%26aufirst%3DM.%26aulast%3DChuquiyauri%26aufirst%3DR.%26aulast%3DHinojosa%26aufirst%3DJ.%2BC.%26aulast%3DKerr%26aufirst%3DN.%26aulast%3DRosario%26aufirst%3DM.%26aulast%3DToovey%26aufirst%3DS.%26aulast%3DArch%26aufirst%3DR.%2BH.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRozenberg%26aufirst%3DF.%2BD.%26aulast%3DBath%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DCowell%26aufirst%3DA.%2BN.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DBaker%26aufirst%3DM.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DHooft%2Bvan%2BHuijsduijnen%26aufirst%3DR.%26aulast%3DGobeau%26aufirst%3DN.%26aulast%3DAraeipour%26aufirst%3DN.%26aulast%3DAndenmatten%26aufirst%3DN.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DDuparc%26aufirst%3DS.%26atitle%3DAntimalarial%2520activity%2520of%2520single-dose%2520DSM265%252C%2520a%2520novel%2520plasmodium%2520dihydroorotate%2520dehydrogenase%2520inhibitor%252C%2520in%2520patients%2520with%2520uncomplicated%2520Plasmodium%2520falciparum%2520or%2520Plasmodium%2520vivax%2520malaria%2520infection%253A%2520a%2520proof-of-concept%252C%2520open-label%252C%2520phase%25202a%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2018%26volume%3D18%26spage%3D874%26epage%3D883%26doi%3D10.1016%2FS1473-3099%2818%2930309-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foquet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuenchob, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishbaugher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camargo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bial, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappe, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikolajczak, S. A.</span></span> <span> </span><span class="NLM_article-title">Assessing drug efficacy against <i>Plasmodium falciparum</i> liver stages in vivo</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e92587</span> <span class="refDoi"> DOI: 10.1172/jci.insight.92587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1172%2Fjci.insight.92587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=29321371" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&author=E.+L.+Flanneryauthor=L.+Foquetauthor=V.+Chuenchobauthor=M.+Fishbaugherauthor=Z.+Billmanauthor=M.+J.+Navarroauthor=W.+Betzauthor=T.+M.+Olsenauthor=J.+Leeauthor=N.+Camargoauthor=T.+Nguyenauthor=C.+Schaferauthor=B.+K.+Sackauthor=E.+M.+Wilsonauthor=J.+Saundersauthor=J.+Bialauthor=B.+Campoauthor=S.+A.+Charmanauthor=S.+C.+Murphyauthor=M.+A.+Phillipsauthor=S.+H.+Kappeauthor=S.+A.+Mikolajczak&title=Assessing+drug+efficacy+against+Plasmodium+falciparum+liver+stages+in+vivo&doi=10.1172%2Fjci.insight.92587"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.92587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.92587%26sid%3Dliteratum%253Aachs%26aulast%3DFlannery%26aufirst%3DE.%2BL.%26aulast%3DFoquet%26aufirst%3DL.%26aulast%3DChuenchob%26aufirst%3DV.%26aulast%3DFishbaugher%26aufirst%3DM.%26aulast%3DBillman%26aufirst%3DZ.%26aulast%3DNavarro%26aufirst%3DM.%2BJ.%26aulast%3DBetz%26aufirst%3DW.%26aulast%3DOlsen%26aufirst%3DT.%2BM.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DCamargo%26aufirst%3DN.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DSchafer%26aufirst%3DC.%26aulast%3DSack%26aufirst%3DB.%2BK.%26aulast%3DWilson%26aufirst%3DE.%2BM.%26aulast%3DSaunders%26aufirst%3DJ.%26aulast%3DBial%26aufirst%3DJ.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DMurphy%26aufirst%3DS.%2BC.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DKappe%26aufirst%3DS.%2BH.%26aulast%3DMikolajczak%26aufirst%3DS.%2BA.%26atitle%3DAssessing%2520drug%2520efficacy%2520against%2520Plasmodium%2520falciparum%2520liver%2520stages%2520in%2520vivo%26jtitle%3DJCI%2520Insight%26date%3D2018%26volume%3D3%26doi%3D10.1172%2Fjci.insight.92587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duke, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seilie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanron, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishbaugher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VonGoedert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritzen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappe, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcsisin, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andenmatten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kublin, J. G.</span></span> <span> </span><span class="NLM_article-title">A Randomized Trial Evaluating the Prophylactic Activity of DSM265 against preerythrocytic <i>Plasmodium falciparum</i> infection during controlled human malarial infection by mosquito bites and direct venous inoculation</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>217</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">702</span>, <span class="refDoi"> DOI: 10.1093/infdis/jix613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1093%2Finfdis%2Fjix613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=29216395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=2018&pages=693-702&author=S.+C.+Murphyauthor=E.+R.+Dukeauthor=K.+J.+Shipmanauthor=R.+L.+Jensenauthor=Y.+Fongauthor=S.+Fergusonauthor=H.+E.+Janesauthor=K.+Gillespieauthor=A.+M.+Seilieauthor=A.+E.+Hanronauthor=L.+Rinnauthor=M.+Fishbaugherauthor=T.+VonGoedertauthor=E.+Fritzenauthor=S.+H.+Kappeauthor=M.+Changauthor=J.+C.+Sousaauthor=S.+R.+Marcsisinauthor=S.+Chalonauthor=S.+Duparcauthor=N.+Kerrauthor=J.+J.+Mohrleauthor=N.+Andenmattenauthor=T.+Rueckleauthor=J.+G.+Kublin&title=A+Randomized+Trial+Evaluating+the+Prophylactic+Activity+of+DSM265+against+preerythrocytic+Plasmodium+falciparum+infection+during+controlled+human+malarial+infection+by+mosquito+bites+and+direct+venous+inoculation&doi=10.1093%2Finfdis%2Fjix613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized trial evaluating the prophylactic activity of DSM265 against preerythrocytic Plasmodium falciparum infection during controlled human malarial infection by mosquito bites and direct venous inoculation</span></div><div class="casAuthors">Murphy, Sean C.; Duke, Elizabeth R.; Shipman, Kelly J.; Jensen, Ryan L.; Fong, Youyi; Ferguson, Sue; Janes, Holly E.; Gillespie, Kevin; Seilie, Annette M.; Hanron, Amelia E.; Rinn, Laurie; Fishbaugher, Matthew; VonGoedert, Tracie; Fritzen, Emma; Kappe, Stefan H.; Chang, Ming; Sousa, Jason C.; Marcsisin, Sean R.; Chalon, Stephan; Duparc, Stephan; Kerr, Nicola; Mohrle, Jorg J.; Andenmatten, Nicole; Rueckle, Thomas; Kublin, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">693-702</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">1537-6613</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  DSM265 is a selective inhibitor of Plasmodium dihydroorotate dehydrogenase that fully protected against controlled human malarial infection (CHMI) by direct venous inoculation of Plasmodium falciparum sporozoites when administered 1 day before challenge and provided partial protection when administered 7 days before challenge.  Methods.  A double-blinded, randomized, placebo-controlled trial was performed to assess safety, tolerability, pharmacokinetics, and efficacy of 1 oral dose of 400 mg of DSM265 before CHMI.  Three cohorts were studied, with DSM265 administered 3 or 7 days before direct venous inoculation of sporozoites or 7 days before 5 bites from infected mosquitoes.  Results.  DSM265-related adverse events consisted of mild-to-moderate headache and gastrointestinal symptoms.  DSM265 concns. were consistent with pharmacokinetic models (mean area under the curve extrapolated to infinity, 1707 μg*h/mL).  Placebo-treated participants became pos. by quant. reverse transcription-polymerase chain reaction (qRT-PCR) and were treated 7-10 days after CHMI.  Among DSM265-treated subjects, 2 of 6 in each cohort were sterilely protected.  DSM265-treated recipients had longer times to development of parasitemia than placebo-treated participants (P < .004).  Conclusions.  This was the first CHMI study of a novel antimalarial compd. to compare direct venous inoculation of sporozoites and mosquito bites.  Times to qRT-PCR positivity and treatment were comparable for both routes.  DSM265 given 3 or 7 days before CHMI was safe and well tolerated but sterilely protected only one third of participants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMZHT578xgCrVg90H21EOLACvtfcHk0lj9sM2efTI0iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsFGlsL8%253D&md5=09ad9e8ac99393967ca57e475f2f52bb</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjix613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjix613%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DS.%2BC.%26aulast%3DDuke%26aufirst%3DE.%2BR.%26aulast%3DShipman%26aufirst%3DK.%2BJ.%26aulast%3DJensen%26aufirst%3DR.%2BL.%26aulast%3DFong%26aufirst%3DY.%26aulast%3DFerguson%26aufirst%3DS.%26aulast%3DJanes%26aufirst%3DH.%2BE.%26aulast%3DGillespie%26aufirst%3DK.%26aulast%3DSeilie%26aufirst%3DA.%2BM.%26aulast%3DHanron%26aufirst%3DA.%2BE.%26aulast%3DRinn%26aufirst%3DL.%26aulast%3DFishbaugher%26aufirst%3DM.%26aulast%3DVonGoedert%26aufirst%3DT.%26aulast%3DFritzen%26aufirst%3DE.%26aulast%3DKappe%26aufirst%3DS.%2BH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DSousa%26aufirst%3DJ.%2BC.%26aulast%3DMarcsisin%26aufirst%3DS.%2BR.%26aulast%3DChalon%26aufirst%3DS.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DKerr%26aufirst%3DN.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DAndenmatten%26aufirst%3DN.%26aulast%3DRueckle%26aufirst%3DT.%26aulast%3DKublin%26aufirst%3DJ.%2BG.%26atitle%3DA%2520Randomized%2520Trial%2520Evaluating%2520the%2520Prophylactic%2520Activity%2520of%2520DSM265%2520against%2520preerythrocytic%2520Plasmodium%2520falciparum%2520infection%2520during%2520controlled%2520human%2520malarial%2520infection%2520by%2520mosquito%2520bites%2520and%2520direct%2520venous%2520inoculation%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2018%26volume%3D217%26spage%3D693%26epage%3D702%26doi%3D10.1093%2Finfdis%2Fjix613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulyok, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murbeth, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samec, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobeau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calle, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulyok, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebru, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granados, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruckner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguetse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalremruata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, B. K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsner, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordmuller, B.</span></span> <span> </span><span class="NLM_article-title">DSM265 for <i>Plasmodium falciparum</i> chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30139-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2FS1473-3099%2817%2930139-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28363637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlWmtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=636-644&author=M.+Sulyokauthor=T.+Ruckleauthor=A.+Rothauthor=R.+E.+Murbethauthor=S.+Chalonauthor=N.+Kerrauthor=S.+S.+Samecauthor=N.+Gobeauauthor=C.+L.+Calleauthor=J.+Ibanezauthor=Z.+Sulyokauthor=J.+Heldauthor=T.+Gebruauthor=P.+Granadosauthor=S.+Brucknerauthor=C.+Nguetseauthor=J.+Mengueauthor=A.+Lalremruataauthor=B.+K.+L.+Simauthor=S.+L.+Hoffmanauthor=J.+J.+Mohrleauthor=P.+G.+Kremsnerauthor=B.+Mordmuller&title=DSM265+for+Plasmodium+falciparum+chemoprophylaxis%3A+a+randomised%2C+double+blinded%2C+phase+1+trial+with+controlled+human+malaria+infection&doi=10.1016%2FS1473-3099%2817%2930139-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection</span></div><div class="casAuthors">Sulyok, Mihaly; Rueckle, Thomas; Roth, Alexandra; Muerbeth, Raymund E.; Chalon, Stephan; Kerr, Nicola; Samec, Sonia Schnieper; Gobeau, Nathalie; Calle, Carlos Lamsfus; Ibanez, Javier; Sulyok, Zita; Held, Jana; Gebru, Tamirat; Granados, Patricia; Brueckner, Sina; Nguetse, Christian; Mengue, Juliana; Lalremruata, Albert; Sim, Kim Lee; Hoffman, Stephen L.; Moehrle, Joerg J.; Kremsner, Peter G.; Mordmueller, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">636-644</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A drug for causal (ie, pre-erythrocytic) prophylaxis of Plasmodium falciparum malaria with prolonged activity would substantially advance malaria control.  DSM265 is an exptl. antimalarial that selectively inhibits the parasite dihydroorotate dehydrogenase.  DSM265 shows in vitro activity against liver and blood stages of P falciparum.  We assessed the prophylactic activity of DSM265 against controlled human malaria infection (CHMI).  At the Institute of Tropical Medicine, Eberhard Karls University (Tubingen, Germany), healthy, malaria-naive adults were allocated to receive 400 mg DSM265 or placebo either 1 day (cohort 1A) or 7 days (cohort 2) before CHMI by direct venous inoculation (DVI) of 3200 aseptic, purified, cryopreserved P falciparum sporozoites (PfSPZ Challenge; Sanaria Inc, Rockville, MD, USA).  An addnl. group received daily atovaquone-proguanil (250-100 mg) for 9 days, starting 1 day before CHMI (cohort 1B).  Allocation to DSM265, atovaquone-proguanil, or placebo was randomised by an interactive web response system.  Allocation to cohort 1A and 1B was open-label, within cohorts 1A and 2, allocation to DSM265 and placebo was double-blinded.  All treatments were given orally.  Volunteers were treated with an antimalarial on day 28, or when parasitemic, as detected by thick blood smear (TBS) microscopy.  The primary efficacy endpoint was time-to-parasitemia, assessed by TBS.  All participants receiving at least one dose of chemoprophylaxis or placebo were considered for safety, those receiving PfSPZ Challenge for efficacy analyzes.  Log-rank test was used to compare time-to-parasitemia between interventions.  The trial was registered with ClinicalTrials.gov, no. NCT02450578.22 participants were enrolled between Oct 23, 2015, and Jan 18, 2016.  Five participants received 400 mg DSM265 and two participants received placebo 1 day before CHMI (cohort 1A), six participants received daily atovaquone-proguanil 1 day before CHMI (cohort 1B), and six participants received 400 mg DSM265 and two participants received placebo 7 days before CHMI (cohort 2).  Five of five participants receiving DSM265 1 day before CHMI and six of six in the atovaquone-proguanil cohort were protected, whereas placebo recipients (two of two) developed malaria on days 11 and 14.  When given 7 days before CHMI, three of six volunteers receiving DSM265 became TBS pos. on days 11, 13, and 24.  The remaining three DSM265-treated, TBS-neg. participants of cohort 2 developed transient submicroscopic parasitemia.  Both participants receiving placebo 7 days before CHMI became TBS pos. on day 11.  The only possible DSM265-related adverse event was a moderate transient elevation in serum bilirubin in one participant.  A single dose of 400 mg DSM265 was well tolerated and had causal prophylactic activity when given 1 day before CHMI.  Future trials are needed to investigate further the use of DSM265 for the prophylaxis of malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Qz_g361v_rVg90H21EOLACvtfcHk0liFwbNTeixEjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlWmtbY%253D&md5=17e414f86bbefda108b858930ae28bfc</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930139-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930139-1%26sid%3Dliteratum%253Aachs%26aulast%3DSulyok%26aufirst%3DM.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DA.%26aulast%3DMurbeth%26aufirst%3DR.%2BE.%26aulast%3DChalon%26aufirst%3DS.%26aulast%3DKerr%26aufirst%3DN.%26aulast%3DSamec%26aufirst%3DS.%2BS.%26aulast%3DGobeau%26aufirst%3DN.%26aulast%3DCalle%26aufirst%3DC.%2BL.%26aulast%3DIbanez%26aufirst%3DJ.%26aulast%3DSulyok%26aufirst%3DZ.%26aulast%3DHeld%26aufirst%3DJ.%26aulast%3DGebru%26aufirst%3DT.%26aulast%3DGranados%26aufirst%3DP.%26aulast%3DBruckner%26aufirst%3DS.%26aulast%3DNguetse%26aufirst%3DC.%26aulast%3DMengue%26aufirst%3DJ.%26aulast%3DLalremruata%26aufirst%3DA.%26aulast%3DSim%26aufirst%3DB.%2BK.%2BL.%26aulast%3DHoffman%26aufirst%3DS.%2BL.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DKremsner%26aufirst%3DP.%2BG.%26aulast%3DMordmuller%26aufirst%3DB.%26atitle%3DDSM265%2520for%2520Plasmodium%2520falciparum%2520chemoprophylaxis%253A%2520a%2520randomised%252C%2520double%2520blinded%252C%2520phase%25201%2520trial%2520with%2520controlled%2520human%2520malaria%2520infection%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2017%26volume%3D17%26spage%3D636%26epage%3D644%26doi%3D10.1016%2FS1473-3099%2817%2930139-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austin, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockroft, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenlock, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, R. J.</span></span> <span> </span><span class="NLM_article-title">The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1497</span>– <span class="NLM_lpage">1503</span>, <span class="refDoi"> DOI: 10.1124/dmd.30.12.1497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1124%2Fdmd.30.12.1497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=12433825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD38XptVyisbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=1497-1503&author=R.+P.+Austinauthor=P.+Bartonauthor=S.+L.+Cockroftauthor=M.+C.+Wenlockauthor=R.+J.+Riley&title=The+influence+of+nonspecific+microsomal+binding+on+apparent+intrinsic+clearance%2C+and+its+prediction+from+physicochemical+properties&doi=10.1124%2Fdmd.30.12.1497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties</span></div><div class="casAuthors">Austin, Rupert P.; Barton, Patrick; Cockroft, Scott L.; Wenlock, Mark C.; Riley, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1497-1503</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The apparent intrinsic clearance of 13 drugs has been detd. using rat liver microsomes at three different concns. of microsomal protein.  The kinetics was studied using the in vitro half-life method.  The nonspecific binding of these drugs to the microsomes was also studied under the same conditions, except for cofactor removal, using equil. dialysis.  The intrinsic clearances are shown to be dependent on the microsomal concn., but are approx. const. when cor. for the extent of nonspecific binding to the microsomes.  The large difference between obsd. intrinsic clearance and unbound intrinsic clearance that exists for some compds., particularly lipophilic bases, is highlighted.  A simple model has been developed for understanding the binding of compds. to microsomes and is demonstrated to accurately predict the extent of microsomal binding at one concn. of microsomes from measurement at another.  The binding of a further 25 drugs to rat liver microsomes at a microsomal concn. of 1 mg/mL was also studied, along with measurements of lipophilicity using octanol-water partition coeffs.  It is shown that the extent of microsomal binding is correlated with lipophilicity, but that basic compds. show a different behavior to acidic and neutral compds.  Microsomal binding is shown to be best predicted using a model where logP is used for basic compds., and logD7.4 is used for acidic and neutral compds.  This model has been developed further so that the extent of binding to microsomes of any given concn. can be estd. purely from a knowledge of lipophilicity and ionization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGril7K_-q51KLVg90H21EOLACvtfcHk0liFwbNTeixEjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptVyisbg%253D&md5=8ff465ee407bf503e38862da9d2fbdc6</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.12.1497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.12.1497%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%26aufirst%3DR.%2BP.%26aulast%3DBarton%26aufirst%3DP.%26aulast%3DCockroft%26aufirst%3DS.%2BL.%26aulast%3DWenlock%26aufirst%3DM.%2BC.%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520influence%2520of%2520nonspecific%2520microsomal%2520binding%2520on%2520apparent%2520intrinsic%2520clearance%252C%2520and%2520its%2520prediction%2520from%2520physicochemical%2520properties%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D1497%26epage%3D1503%26doi%3D10.1124%2Fdmd.30.12.1497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Clearance in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2245</span>– <span class="NLM_lpage">2255</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVCru7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2245-2255&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Clearance+in+Drug+Design&doi=10.1021%2Facs.jmedchem.8b01263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Clearance in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2245-2255</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Due to its implications for both dose level and frequency, clearance rate is one of the most important pharmacokinetic parameters to consider in the design of drug candidates.  Clearance can be classified into three general categories, namely, metabolic transformation, renal excretion, and hepatobiliary excretion.  Within each category, there are a host of biochem. and physiol. mechanisms that ultimately det. the clearance rate.  Physiochem. properties are often indicative of the rate-detg. mechanism, with lipophilic mols. tending toward metab. and hydrophilic, polar mols. tending toward passive or active excretion.  Optimization of clearance requires recognition of the major clearance mechanisms and use of the most relevant in vitro and in vivo tools to develop structure-clearance relationships.  The reliability of methods to detect and predict human clearance varies across mechanisms.  While methods for metabolic and passive renal clearance have proven reasonably robust, there is a clear need for better tools to support the optimization of transporter-mediated clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8nvv_L3pL-LVg90H21EOLACvtfcHk0liFwbNTeixEjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVCru7fO&md5=e4a4d72056ed9b41842a11934fa4bffc</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01263%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DClearance%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2245%26epage%3D2255%26doi%3D10.1021%2Facs.jmedchem.8b01263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, F. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crighton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katneni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morizzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almond, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moehrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abla, N.</span></span> <span> </span><span class="NLM_article-title">An in vitro toolbox to accelerate anti-malarial drug discovery and development</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>, <span class="NLM_elocation-id">1</span> <span class="refDoi"> DOI: 10.1186/s12936-019-3075-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1186%2Fs12936-019-3075-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=31898492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltlKisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&author=S.+A.+Charmanauthor=A.+Andreuauthor=H.+Barkerauthor=S.+Blundellauthor=A.+Campbellauthor=M.+Campbellauthor=G.+Chenauthor=F.+C.+K.+Chiuauthor=E.+Crightonauthor=K.+Katneniauthor=J.+Morizziauthor=R.+Patilauthor=T.+Phamauthor=E.+Ryanauthor=J.+Saundersauthor=D.+M.+Shacklefordauthor=K.+L.+Whiteauthor=L.+Almondauthor=M.+Dickinsauthor=D.+A.+Smithauthor=J.+J.+Moehrleauthor=J.+N.+Burrowsauthor=N.+Abla&title=An+in+vitro+toolbox+to+accelerate+anti-malarial+drug+discovery+and+development&doi=10.1186%2Fs12936-019-3075-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">An in vitro toolbox to accelerate anti-malarial drug discovery and development</span></div><div class="casAuthors">Charman, Susan A.; Andreu, Alice; Barker, Helena; Blundell, Scott; Campbell, Anna; Campbell, Michael; Chen, Gong; Chiu, Francis C. K.; Crighton, Elly; Katneni, Kasiram; Morizzi, Julia; Patil, Rahul; Pham, Thao; Ryan, Eileen; Saunders, Jessica; Shackleford, David M.; White, Karen L.; Almond, Lisa; Dickins, Maurice; Smith, Dennis A.; Moehrle, Joerg J.; Burrows, Jeremy N.; Abla, Nada</div><div class="citationInfo"><span class="NLM_cas:title">Malaria Journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1</span>CODEN:
                <span class="NLM_cas:coden">MJAOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-2875</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Modeling and simulation are being increasingly utilized to support the discovery and development of new anti-malarial drugs.  These approaches require reliable in vitro data for physicochem. properties, permeability, binding, intrinsic clearance and cytochrome P 450 inhibition.  This work was conducted to generate an in vitro data toolbox using standardized methods for a set of 45 anti-malarial drugs and to assess changes in physicochem. properties in relation to changing target product and candidate profiles.  Methods: Ionization consts. were detd. by potentiometric titrn. and partition coeffs. were measured using a shake-flask method.  Soly. was assessed in biorelevant media and permeability coeffs. and efflux ratios were detd. using Caco-2 cell monolayers.  Binding to plasma and media proteins was measured using either ultracentrifugation or rapid equil. dialysis.  Metabolic stability and cytochrome P 450 inhibition were assessed using human liver microsomes.  Sample anal. was conducted by LC-MS/MS.  Results: Both soly. and fraction unbound decreased, and permeability and unbound intrinsic clearance increased, with increasing Log D7.4.  In general, development compds. were somewhat more lipophilic than legacy drugs.  For many compds., permeability and protein binding were challenging to assess and both required the use of exptl. conditions that minimized the impact of non-specific binding.  Intrinsic clearance in human liver microsomes was varied across the data set and several compds. exhibited no measurable substrate loss under the conditions used.  Inhibition of cytochrome P 450 enzymes was minimal for most compds.  Conclusions: This is the first data set to describe in vitro properties for 45 legacy and development anti-malarial drugs.  The studies identified several practical methodol. issues common to many of the more lipophilic compds. and highlighted areas which require more work to customize exptl. conditions for compds. being designed to meet the new target product profiles.  The dataset will be a valuable tool for malaria researchers aiming to develop PBPK models for the prediction of human PK properties and/or drug-drug interactions.  Furthermore, generation of this comprehensive data set within a single lab. allows direct comparison of properties across a large dataset and evaluation of changing property trends that have occurred over time with changing target product and candidate profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz-G7Yo6U877Vg90H21EOLACvtfcHk0ljdSADnvemUOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltlKisQ%253D%253D&md5=a996cd5a032c9042bc957d0bddecbd3b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1186%2Fs12936-019-3075-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-019-3075-5%26sid%3Dliteratum%253Aachs%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DAndreu%26aufirst%3DA.%26aulast%3DBarker%26aufirst%3DH.%26aulast%3DBlundell%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DChiu%26aufirst%3DF.%2BC.%2BK.%26aulast%3DCrighton%26aufirst%3DE.%26aulast%3DKatneni%26aufirst%3DK.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DPatil%26aufirst%3DR.%26aulast%3DPham%26aufirst%3DT.%26aulast%3DRyan%26aufirst%3DE.%26aulast%3DSaunders%26aufirst%3DJ.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DAlmond%26aufirst%3DL.%26aulast%3DDickins%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DMoehrle%26aufirst%3DJ.%2BJ.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DAbla%26aufirst%3DN.%26atitle%3DAn%2520in%2520vitro%2520toolbox%2520to%2520accelerate%2520anti-malarial%2520drug%2520discovery%2520and%2520development%26jtitle%3DMalar.%2520J.%26date%3D2020%26volume%3D19%26doi%3D10.1186%2Fs12936-019-3075-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckley, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harradine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalvass, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamek-Gliszczynski, M. J.</span></span> <span> </span><span class="NLM_article-title">Industry perspective on contemporary protein-binding methodologies: considerations for regulatory drug-drug interaction and related guidelines on highly bound drugs</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">3442</span>– <span class="NLM_lpage">3452</span>, <span class="refDoi"> DOI: 10.1016/j.xphs.2017.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2Fj.xphs.2017.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28927987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Gmu7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2017&pages=3442-3452&author=L.+Diauthor=C.+Breenauthor=R.+Chambersauthor=S.+T.+Eckleyauthor=R.+Frickeauthor=A.+Ghoshauthor=P.+Harradineauthor=J.+C.+Kalvassauthor=S.+Hoauthor=C.+A.+Leeauthor=P.+Maratheauthor=E.+J.+Perkinsauthor=M.+Qianauthor=S.+Tseauthor=Z.+Yanauthor=M.+J.+Zamek-Gliszczynski&title=Industry+perspective+on+contemporary+protein-binding+methodologies%3A+considerations+for+regulatory+drug-drug+interaction+and+related+guidelines+on+highly+bound+drugs&doi=10.1016%2Fj.xphs.2017.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Industry Perspective on Contemporary Protein-Binding Methodologies: Considerations for Regulatory Drug-Drug Interaction and Related Guidelines on Highly Bound Drugs</span></div><div class="casAuthors">Di, Li; Breen, Christopher; Chambers, Rob; Eckley, Sean T.; Fricke, Robert; Ghosh, Avijit; Harradine, Paul; Kalvass, J. Cory; Ho, Stacy; Lee, Caroline A.; Marathe, Punit; Perkins, Everett J.; Qian, Mark; Tse, Susanna; Yan, Zhengyin; Zamek-Gliszczynski, Maciej J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3442-3452</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Regulatory agencies have recently issued drug-drug interaction guidelines, which require detn. of plasma protein binding (PPB).  To err on the conservative side, the agencies recommend that a 0.01 lower limit of fraction unbound (fu) be used for highly bound compds. (>99%), irresp. of the actual measured values.  While this may avoid false negatives, the recommendation would likely result in a high rate of false pos. predictions, resulting in unnecessary clin. studies and more stringent inclusion/exclusion criteria, which may add cost and time in delivery of new medicines to patients.  In this perspective, the authors provide a review of current approaches to measure PPB, and important determinants in enabling the accuracy and precision in these measurements.  The ability to measure fu is further illustrated by a cross-company data comparison of PPB for warfarin and itraconazole, demonstrating good concordance of the measured fu values.  The data indicate that fu values of ≤0.01 may be detd. accurately across labs. when appropriate methods are used.  These data, along with numerous other examples presented in the literature, support the use of exptl. measured fu values for drug-drug interaction predictions, rather than using the arbitrary cutoff value of 0.01 as recommended in current regulatory guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCMgObUz2ZArVg90H21EOLACvtfcHk0ljdSADnvemUOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Gmu7nO&md5=316d6854cc04968107b609a9ccae6eed</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.xphs.2017.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.xphs.2017.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DBreen%26aufirst%3DC.%26aulast%3DChambers%26aufirst%3DR.%26aulast%3DEckley%26aufirst%3DS.%2BT.%26aulast%3DFricke%26aufirst%3DR.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DHarradine%26aufirst%3DP.%26aulast%3DKalvass%26aufirst%3DJ.%2BC.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DPerkins%26aufirst%3DE.%2BJ.%26aulast%3DQian%26aufirst%3DM.%26aulast%3DTse%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26atitle%3DIndustry%2520perspective%2520on%2520contemporary%2520protein-binding%2520methodologies%253A%2520considerations%2520for%2520regulatory%2520drug-drug%2520interaction%2520and%2520related%2520guidelines%2520on%2520highly%2520bound%2520drugs%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D106%26spage%3D3442%26epage%3D3452%26doi%3D10.1016%2Fj.xphs.2017.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrisey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laroiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mather, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. B.</span></span> <span> </span><span class="NLM_article-title">Yeast dihydroorotate dehydrogenase as a new selectable marker for <i>Plasmodium falciparum</i> transfection</span>. <i>Mol. Biochem. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.molbiopara.2011.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2Fj.molbiopara.2011.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=21251930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsV2gtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2011&pages=29-34&author=S.+M.+Ganesanauthor=J.+M.+Morriseyauthor=H.+Keauthor=H.+J.+Painterauthor=K.+Laroiyaauthor=M.+A.+Phillipsauthor=P.+K.+Rathodauthor=M.+W.+Matherauthor=A.+B.+Vaidya&title=Yeast+dihydroorotate+dehydrogenase+as+a+new+selectable+marker+for+Plasmodium+falciparum+transfection&doi=10.1016%2Fj.molbiopara.2011.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Yeast dihydroorotate dehydrogenase as a new selectable marker for Plasmodium falciparum transfection</span></div><div class="casAuthors">Ganesan, Suresh M.; Morrisey, Joanne M.; Ke, Hangjun; Painter, Heather J.; Laroiya, Kamal; Phillips, Margaret A.; Rathod, Pradipsinh K.; Mather, Michael W.; Vaidya, Akhil B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Biochemical Parasitology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-34</span>CODEN:
                <span class="NLM_cas:coden">MBIPDP</span>;
        ISSN:<span class="NLM_cas:issn">0166-6851</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Genetic manipulation of Plasmodium falciparum in culture through transfection has provided numerous insights into the mol. and cell biol. of this parasite.  The procedure is rather cumbersome, and is limited by the no. of drug-resistant markers that can be used for selecting transfected parasites.  Here, the authors report a new selectable marker that could allow multiple transfections.  They have taken advantage of the finding that a crit. function of the mitochondrial electron transport chain (mtETC) in the erythrocytic stages of P. falciparum is the regeneration of ubiquinone as co-substrate of dihydroorotate dehydrogenase (DHODH), and that transgenic P. falciparum expressing ubiquinone-independent DHODH from yeast (yDHODH) are resistant to all mtETC inhibitors.  The authors assessed the possibility of using yDHODH as a pos. selectable marker for transfections of P. falciparum, including its use in gene disruption strategies.  They constructed a transfection vector designed for gene disruption, termed pUF-1, contg. the yDHODH gene as the pos. selection marker in combination with a previously described fused yeast cytosine deaminase-uracil phosphoribosyl transferase gene as a neg. selection marker.  Transfection of the D10 strain followed by selection with atovaquone yielded pos. selected parasites contg. the plasmid, demonstrating that yDHODH can be used as a selective marker.  Atovaquone, however, could not be used for such selection with the Dd2 strain of P. falciparum.  On the other hand, we demonstrated that yDHODH transgenic parasites could be selected in both strains by Plasmodium DHODH-specific triazolopyrimidine-based inhibitors.  Thus, selection with DHODH inhibitors was superior in that it successfully selected transgenic Dd2 parasites, as well as yielded transgenic parasites after a shorter period of selection.  As a proof of concept, the authors have successfully disrupted the type II vacuolar proton-pumping pyrophosphatase gene (PfVP2) in P. falciparum by double crossover recombination, showing that this gene is not essential for the survival of blood stage parasites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbgajAbUgQWLVg90H21EOLACvtfcHk0ljdSADnvemUOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsV2gtbg%253D&md5=f0a91cd88063879be3854c7aaff0ed72</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.molbiopara.2011.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molbiopara.2011.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DS.%2BM.%26aulast%3DMorrisey%26aufirst%3DJ.%2BM.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DPainter%26aufirst%3DH.%2BJ.%26aulast%3DLaroiya%26aufirst%3DK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DMather%26aufirst%3DM.%2BW.%26aulast%3DVaidya%26aufirst%3DA.%2BB.%26atitle%3DYeast%2520dihydroorotate%2520dehydrogenase%2520as%2520a%2520new%2520selectable%2520marker%2520for%2520Plasmodium%2520falciparum%2520transfection%26jtitle%3DMol.%2520Biochem.%2520Parasitol.%26date%3D2011%26volume%3D177%26spage%3D29%26epage%3D34%26doi%3D10.1016%2Fj.molbiopara.2011.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Painter, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrisey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mather, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. B.</span></span> <span> </span><span class="NLM_article-title">Specific role of mitochondrial electron transport in blood-stage <i>Plasmodium falciparum</i></span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>446</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1038/nature05572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1038%2Fnature05572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=17330044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1arsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=446&publication_year=2007&pages=88-91&author=H.+J.+Painterauthor=J.+M.+Morriseyauthor=M.+W.+Matherauthor=A.+B.+Vaidya&title=Specific+role+of+mitochondrial+electron+transport+in+blood-stage+Plasmodium+falciparum&doi=10.1038%2Fnature05572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum</span></div><div class="casAuthors">Painter, Heather J.; Morrisey, Joanne M.; Mather, Michael W.; Vaidya, Akhil B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">446</span>
        (<span class="NLM_cas:issue">7131</span>),
    <span class="NLM_cas:pages">88-91</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The origin of all mitochondria can be traced to the symbiotic arrangement that resulted in the emergence of eukaryotes in a world that was exclusively populated by prokaryotes.  This arrangement, however, has been in continuous genetic flux: the varying degrees of gene loss and transfer from the mitochondrial genome in different eukaryotic lineages seem to signify an ongoing 'conflict' between the host and the symbiont.  Eukaryotic parasites belonging to the phylum Apicomplexa provide an excellent example to support this view.  These organisms contain the smallest mitochondrial genomes known, with an organization that differs among various genera; one genus, Cryptosporidium, seems to have lost the entire mitochondrial genome.  Erythrocytic stages of the human malaria parasite Plasmodium falciparum seem to maintain an active mitochondrial electron transport chain to serve just one metabolic function: regeneration of ubiquinone required as the electron acceptor for dihydroorotate dehydrogenase, an essential enzyme for pyrimidine biosynthesis.  Transgenic P. falciparum parasites expressing Saccharomyces cerevisiae dihydroorotate dehydrogenase, which does not require ubiquinone as an electron acceptor, were completely resistant to inhibitors of mitochondrial electron transport.  Maintenance of mitochondrial membrane potential, however, was essential in these parasites, as indicated by their hypersensitivity to proguanil, a drug that collapsed the membrane potential in the presence of electron transport inhibitors.  Thus, acquisition of just one enzyme can render mitochondrial electron transport nonessential in erythrocytic stages of P. falciparum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb4_LLvNdFmLVg90H21EOLACvtfcHk0liejI-umx0GpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1arsLc%253D&md5=9d0e94ce26c6711961f4245226bea858</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnature05572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05572%26sid%3Dliteratum%253Aachs%26aulast%3DPainter%26aufirst%3DH.%2BJ.%26aulast%3DMorrisey%26aufirst%3DJ.%2BM.%26aulast%3DMather%26aufirst%3DM.%2BW.%26aulast%3DVaidya%26aufirst%3DA.%2BB.%26atitle%3DSpecific%2520role%2520of%2520mitochondrial%2520electron%2520transport%2520in%2520blood-stage%2520Plasmodium%2520falciparum%26jtitle%3DNature%26date%3D2007%26volume%3D446%26spage%3D88%26epage%3D91%26doi%3D10.1038%2Fnature05572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceja, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrad, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumwebaze, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byaruhanga, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katairo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nsobya, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, R. A.</span></span> <span> </span><span class="NLM_article-title">Changing antimalarial drug sensitivities in uganda</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">e01516</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1128/AAC.01516-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1128%2FAAC.01516-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=28923866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Crtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&pages=e01516-17&author=S.+A.+Rasmussenauthor=F.+G.+Cejaauthor=M.+D.+Conradauthor=P.+K.+Tumwebazeauthor=O.+Byaruhangaauthor=T.+Katairoauthor=S.+L.+Nsobyaauthor=P.+J.+Rosenthalauthor=R.+A.+Cooper&title=Changing+antimalarial+drug+sensitivities+in+uganda&doi=10.1128%2FAAC.01516-17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Changing Antimalarial Drug Sensitivities in Uganda</span></div><div class="casAuthors">Rasmussen, Stephanie A.; Ceja, Frida G.; Conrad, Melissa D.; Tumwebaze, Patrick K.; Byaruhanga, Oswald; Katairo, Thomas; Nsobya, Samuel L.; Rosenthal, Philip J.; Cooper, Roland A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e01516-17/1-e01516-17/11</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Dihydroartemisinin-piperaquine (DP) has demonstrated excellent efficacy for the treatment and prevention of malaria in Uganda.  However, resistance to both components of this regimen has emerged in Southeast Asia.  The efficacy of artemether-lumefantrine, the first-line regimen to treat malaria in Uganda, has also been excellent, but continued pressure may select for parasites with decreased sensitivity to lumefantrine.  To gain insight into current drug sensitivity patterns, ex vivo sensitivities were assessed and genotypes previously assocd. with altered drug sensitivity were characterized for 58 isolates collected in Tororo, Uganda, from subjects presenting in 2016 with malaria from the community or as part of a clin. trial comparing DP chemoprevention regimens.  Compared to community isolates, those from trial subjects had lower sensitivities to the aminoquinolines chloroquine, monodesethyl amodiaquine, and piperaquine and greater sensitivities to lumefantrine and mefloquine, an observation consistent with DP selection pressure.  Compared to results for isolates from 2010 to 2013, the sensitivities of 2016 community isolates to chloroquine, amodiaquine, and piperaquine improved (geometric mean 50% inhibitory concns. [IC50] = 248, 76.9, and 19.1 nM in 2010 to 2013 and 33.4, 14.9, and 7.5 nM in 2016, resp. [P < 0.001 for all comparisons]), the sensitivity to lumefantrine decreased (IC50 = 3.0 nM in 2010 to 2013 and 5.4 nM in 2016 [P < 0.001]), and the sensitivity to dihydroartemisinin was unchanged (IC50 = 1.4 nM).  These changes were accompanied by decreased prevalence of transporter mutations assocd. with aminoquinoline resistance and low prevalence of polymorphisms recently assocd. with resistance to artemisinins or piperaquine.  Antimalarial drug sensitivities are changing in Uganda, but novel genotypes assocd. with DP treatment failure in Asia are not prevalent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLcmYAqeEnqLVg90H21EOLACvtfcHk0liejI-umx0GpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Crtb7M&md5=fb8a53f991d000575149db4b026359b4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1128%2FAAC.01516-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01516-17%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DS.%2BA.%26aulast%3DCeja%26aufirst%3DF.%2BG.%26aulast%3DConrad%26aufirst%3DM.%2BD.%26aulast%3DTumwebaze%26aufirst%3DP.%2BK.%26aulast%3DByaruhanga%26aufirst%3DO.%26aulast%3DKatairo%26aufirst%3DT.%26aulast%3DNsobya%26aufirst%3DS.%2BL.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DCooper%26aufirst%3DR.%2BA.%26atitle%3DChanging%2520antimalarial%2520drug%2520sensitivities%2520in%2520uganda%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2017%26volume%3D61%26spage%3De01516%26epage%3D17%26doi%3D10.1128%2FAAC.01516-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjalanagara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudra, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirjanata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noviyanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marfurt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazaga, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossignol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span> <span> </span><span class="NLM_article-title">A Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with improved drug-like properties for treatment and prevention of malaria</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">945</span>– <span class="NLM_lpage">957</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.6b00144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.6b00144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWmtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=945-957&author=M.+A.+Phillipsauthor=K.+L.+Whiteauthor=S.+Kokkondaauthor=X.+Dengauthor=J.+Whiteauthor=F.+El+Mazouniauthor=K.+Marshauthor=D.+R.+Tomchickauthor=K.+Manjalanagaraauthor=K.+R.+Rudraauthor=G.+Wirjanataauthor=R.+Noviyantiauthor=R.+N.+Priceauthor=J.+Marfurtauthor=D.+M.+Shacklefordauthor=F.+C.+Chiuauthor=M.+Campbellauthor=M.+B.+Jimenez-Diazauthor=S.+F.+Bazagaauthor=I.+Angulo-Barturenauthor=M.+S.+Martinezauthor=M.+Lafuente-Monasterioauthor=W.+Kaminskyauthor=K.+Silueauthor=A.+M.+Zeemanauthor=C.+Kockenauthor=D.+Leroyauthor=B.+Blascoauthor=E.+Rossignolauthor=T.+Rueckleauthor=D.+Matthewsauthor=J.+N.+Burrowsauthor=D.+Watersonauthor=M.+J.+Palmerauthor=P.+K.+Rathodauthor=S.+A.+Charman&title=A+Triazolopyrimidine-based+dihydroorotate+dehydrogenase+inhibitor+with+improved+drug-like+properties+for+treatment+and+prevention+of+malaria&doi=10.1021%2Facsinfecdis.6b00144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria</span></div><div class="casAuthors">Phillips, Margaret A.; White, Karen L.; Kokkonda, Sreekanth; Deng, Xiaoyi; White, John; El Mazouni, Farah; Marsh, Kennan; Tomchick, Diana R.; Manjalanagara, Krishne; Rudra, Kakali Rani; Wirjanata, Grennady; Noviyanti, Rintis; Price, Ric N.; Marfurt, Jutta; Shackleford, David M.; Chiu, Francis C. K.; Campbell, Michael; Jimenez-Diaz, Maria Belen; Bazaga, Santiago Ferrer; Angulo-Barturen, Inigo; Martinez, Maria Santos; Lafuente-Monasterio, Maria; Kaminsky, Werner; Silue, Kigbafori; Zeeman, Anne-Marie; Kocken, Clemens; Leroy, Didier; Blasco, Benjamin; Rossignol, Emilie; Rueckle, Thomas; Matthews, Dave; Burrows, Jeremy N.; Waterson, David; Palmer, Michael J.; Rathod, Pradipsinh K.; Charman, Susan A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">945-957</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The emergence of drug resistant malaria parasites continues to hamper efforts to control this lethal disease.  Dihydroorotate dehydrogenase has recently been validated as a new target for the treatment of malaria and a selective inhibitor I of the Plasmodium enzyme is currently in clin. development.  With the goal of identifying a backup compd. to I, the authors explored replacement of the SF5-aniline moiety of I with a series of CF3-pyridinyls, while maintaining the core triazolopyrimidine scaffold.  This effort led to the identification of II, which has improved soly., lower intrinsic clearance and increased plasma exposure after oral dosing compared to I, while maintaining a long predicted human half-life.  Its improved phys. and chem. properties will allow it to be formulated more readily than I.  II showed excellent efficacy in the SCID mouse model of P. falciparum malaria that supports the prediction of a low human dose (<200 mg).  Importantly II showed equal activity against both P. falciparum and P. vivax field isolates, while I was more active on P. falciparum.  II has the potential to be developed as a single dose cure or once-weekly chemopreventative for both P. falciparum and P. vivax malaria leading to its advancement as a preclin. development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE-Pm5_CT2LrVg90H21EOLACvtfcHk0lhLQVBoi--cLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWmtbjJ&md5=df58b9d21b75ad84d6181d42a2341e60</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.6b00144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.6b00144%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DTomchick%26aufirst%3DD.%2BR.%26aulast%3DManjalanagara%26aufirst%3DK.%26aulast%3DRudra%26aufirst%3DK.%2BR.%26aulast%3DWirjanata%26aufirst%3DG.%26aulast%3DNoviyanti%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DChiu%26aufirst%3DF.%2BC.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DBazaga%26aufirst%3DS.%2BF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%26aulast%3DKaminsky%26aufirst%3DW.%26aulast%3DSilue%26aufirst%3DK.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DKocken%26aufirst%3DC.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DBlasco%26aufirst%3DB.%26aulast%3DRossignol%26aufirst%3DE.%26aulast%3DRueckle%26aufirst%3DT.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DPalmer%26aufirst%3DM.%2BJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26atitle%3DA%2520Triazolopyrimidine-based%2520dihydroorotate%2520dehydrogenase%2520inhibitor%2520with%2520improved%2520drug-like%2520properties%2520for%2520treatment%2520and%2520prevention%2520of%2520malaria%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2016%26volume%3D2%26spage%3D945%26epage%3D957%26doi%3D10.1021%2Facsinfecdis.6b00144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smilkstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriwilaijaroen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilairat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riscoe, M.</span></span> <span> </span><span class="NLM_article-title">Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1803</span>– <span class="NLM_lpage">1806</span>, <span class="refDoi"> DOI: 10.1128/AAC.48.5.1803-1806.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1128%2FAAC.48.5.1803-1806.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=15105138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjslGltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=1803-1806&author=M.+Smilksteinauthor=N.+Sriwilaijaroenauthor=J.+X.+Kellyauthor=P.+Wilairatauthor=M.+Riscoe&title=Simple+and+inexpensive+fluorescence-based+technique+for+high-throughput+antimalarial+drug+screening&doi=10.1128%2FAAC.48.5.1803-1806.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening</span></div><div class="casAuthors">Smilkstein, Martin; Sriwilaijaroen, Nongluk; Kelly, Jane Xu; Wilairat, Prapon; Riscoe, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1803-1806</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Radioisotopic assays involve expense, multistep protocols, equipment, and radioactivity safety requirements which are problematic in high-throughput drug testing.  This study reports an alternative, simple, robust, inexpensive, one-step fluorescence assay for use in antimalarial drug screening.  Parasite growth is detd. by using SYBR Green 1, a dye with marked fluorescence enhancement upon contact with Plasmodium DNA.  A side-by-side comparison of this fluorescence assay and a std. radioisotopic method was performed by testing known antimalarial agents against Plasmodium falciparum strain D6.  Both assay methods were used to det. the effective concn. of drug that resulted in a 50% redn. in the obsd. counts (EC50) after 48 h of parasite growth in the presence of each drug.  The EC50s of chloroquine, quinine, mefloquine, artemisinin, and 3,6-bis-.vepsiln.-(N,N-diethylamino)-amyloxyanthone were similar or identical by both techniques.  The results obtained with this new fluorescence assay suggest that it may be an ideal method for high-throughput antimalarial drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzXZZP9UWQ27Vg90H21EOLACvtfcHk0lhLQVBoi--cLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjslGltLw%253D&md5=84a9721da1d873dfca16d1f2570ed304</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.5.1803-1806.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.5.1803-1806.2004%26sid%3Dliteratum%253Aachs%26aulast%3DSmilkstein%26aufirst%3DM.%26aulast%3DSriwilaijaroen%26aufirst%3DN.%26aulast%3DKelly%26aufirst%3DJ.%2BX.%26aulast%3DWilairat%26aufirst%3DP.%26aulast%3DRiscoe%26aufirst%3DM.%26atitle%3DSimple%2520and%2520inexpensive%2520fluorescence-based%2520technique%2520for%2520high-throughput%2520antimalarial%2520drug%2520screening%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D1803%26epage%3D1806%26doi%3D10.1128%2FAAC.48.5.1803-1806.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhingra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afanador, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in <i>Plasmodium falciparum</i> that confer in vitro resistance to the clinical candidate DSM265</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.8b00211</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.8b00211" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVarurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=90-101&author=J.+Whiteauthor=S.+K.+Dhingraauthor=X.+Dengauthor=F.+El+Mazouniauthor=M.+C.+S.+Leeauthor=G.+A.+Afanadorauthor=A.+Lawongauthor=D.+R.+Tomchickauthor=C.+L.+Ngauthor=J.+Bathauthor=P.+K.+Rathodauthor=D.+A.+Fidockauthor=M.+A.+Phillips&title=Identification+and+mechanistic+understanding+of+dihydroorotate+dehydrogenase+point+mutations+in+Plasmodium+falciparum+that+confer+in+vitro+resistance+to+the+clinical+candidate+DSM265&doi=10.1021%2Facsinfecdis.8b00211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in Plasmodium falciparum that confer in vitro resistance to the clinical candidate DSM265</span></div><div class="casAuthors">White, John; Dhingra, Satish K.; Deng, Xiaoyi; El Mazouni, Farah; Lee, Marcus C. S.; Afanador, Gustavo A.; Lawong, Aloysus; Tomchick, Diana R.; Ng, Caroline L.; Bath, Jade; Rathod, Pradipsinh K.; Fidock, David A.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-101</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Malaria is one of the most challenging human infectious diseases, and both prevention and control have been hindered by the development of Plasmodium falciparum resistance to existing therapies.  Several new compds. with novel mechanisms are in clin. development for the treatment of malaria, including DSM265, an inhibitor of Plasmodium dihydroorotate dehydrogenase.  To explore the mechanisms by which resistance might develop to DSM265 in the field, we selected for DSM265-resistant P. falciparum parasites in vitro.  Any of five different amino acid changes led to reduced efficacy on the parasite and to decreased DSM265 binding to P. falciparum DHODH.  The DSM265-resistant parasites retained full sensitivity to atovaquone.  All but one of the obsd. mutations were in the DSM265 binding site, and the remaining C276F was in the adjacent flavin cofactor site.  The C276F mutation was previously identified in a recrudescent parasite during a Phase IIa clin. study.  We confirmed that this mutation (and the related C276Y) accounted for the full level of obsd. DSM265 resistance by regenerating the mutation using CRISPR/Cas9 genome editing.  X-ray structure anal. of the C276F mutant enzyme showed that conformational changes of nearby residues were required to accommodate the larger F276 residue, which in turn led to a restriction in the size of the DSM265 binding pocket.  These findings underscore the importance of developing DSM265 as part of a combination therapy with other agents for successful use against malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQMMzkCwd_zrVg90H21EOLACvtfcHk0lhLQVBoi--cLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVarurzN&md5=6b9001020d2332016c7f189a6dbe9380</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.8b00211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.8b00211%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DDhingra%26aufirst%3DS.%2BK.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DAfanador%26aufirst%3DG.%2BA.%26aulast%3DLawong%26aufirst%3DA.%26aulast%3DTomchick%26aufirst%3DD.%2BR.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DBath%26aufirst%3DJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DIdentification%2520and%2520mechanistic%2520understanding%2520of%2520dihydroorotate%2520dehydrogenase%2520point%2520mutations%2520in%2520Plasmodium%2520falciparum%2520that%2520confer%2520in%2520vitro%2520resistance%2520to%2520the%2520clinical%2520candidate%2520DSM265%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2019%26volume%3D5%26spage%3D90%26epage%3D101%26doi%3D10.1021%2Facsinfecdis.8b00211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mandt, R. E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata-Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luth, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segura, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pablos-Tanarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottilie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukens, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span> <span> </span><span class="NLM_article-title">In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">eaav1636</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aav1636</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1126%2Fscitranslmed.aav1636" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=31801884" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=R.+E.+K.+Mandtauthor=M.+J.+Lafuente-Monasterioauthor=T.+Sakata-Katoauthor=M.+R.+Luthauthor=D.+Seguraauthor=A.+Pablos-Tanarroauthor=S.+Vieraauthor=N.+Maganauthor=S.+Ottilieauthor=E.+A.+Winzelerauthor=A.+K.+Lukensauthor=F.+J.+Gamoauthor=D.+F.+Wirth&title=In+vitro+selection+predicts+malaria+parasite+resistance+to+dihydroorotate+dehydrogenase+inhibitors+in+a+mouse+infection+model&doi=10.1126%2Fscitranslmed.aav1636"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aav1636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aav1636%26sid%3Dliteratum%253Aachs%26aulast%3DMandt%26aufirst%3DR.%2BE.%2BK.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DSakata-Kato%26aufirst%3DT.%26aulast%3DLuth%26aufirst%3DM.%2BR.%26aulast%3DSegura%26aufirst%3DD.%26aulast%3DPablos-Tanarro%26aufirst%3DA.%26aulast%3DViera%26aufirst%3DS.%26aulast%3DMagan%26aufirst%3DN.%26aulast%3DOttilie%26aufirst%3DS.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DLukens%26aufirst%3DA.%2BK.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26atitle%3DIn%2520vitro%2520selection%2520predicts%2520malaria%2520parasite%2520resistance%2520to%2520dihydroorotate%2520dehydrogenase%2520inhibitors%2520in%2520a%2520mouse%2520infection%2520model%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26doi%3D10.1126%2Fscitranslmed.aav1636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegand, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span> <span> </span><span class="NLM_article-title">In vitro resistance selections for <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">17980</span>– <span class="NLM_lpage">17995</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.558353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1074%2Fjbc.M114.558353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=24782313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=17980-17995&author=L.+S.+Rossauthor=F.+J.+Gamoauthor=M.+J.+Lafuente-Monasterioauthor=O.+M.+Singhauthor=P.+Rowlandauthor=R.+C.+Wiegandauthor=D.+F.+Wirth&title=In+vitro+resistance+selections+for+Plasmodium+falciparum+dihydroorotate+dehydrogenase+inhibitors+give+mutants+with+multiple+point+mutations+in+the+drug-binding+site+and+altered+growth&doi=10.1074%2Fjbc.M114.558353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Resistance Selections for Plasmodium Falciparum Dihydroorotate Dehydrogenase Inhibitors Give Mutants with Multiple Point Mutations in the Drug-binding Site and Altered Growth</span></div><div class="casAuthors">Ross, Leila S.; Gamo, Francisco Javier; Lafuente-Monasterio, Maria Jose; Singh, Onkar M. P.; Rowland, Paul; Wiegand, Roger C.; Wirth, Dyann F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">17980-17995</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Malaria is a preventable and treatable disease; yet half of the world's population lives at risk of infection, and an estd. 660,000 people die of malaria-related causes every year.  Rising drug resistance threatens to make malaria untreatable, necessitating both the discovery of new antimalarial agents and the development of strategies to identify and suppress the emergence and spread of drug resistance.  We focused on in-development dihydroorotate dehydrogenase (DHODH) inhibitors.  Characterizing resistance pathways for antimalarial agents not yet in clin. use will increase our understanding of the potential for resistance.  We identified resistance mechanisms of Plasmodium falciparum (Pf) DHODH inhibitors via in vitro resistance selections.  We found 11 point mutations in the PfDHODH target.  Target gene amplification and unknown mechanisms also contributed to resistance, albeit to a lesser extent.  These mutant parasites were often hypersensitive to other PfDHODH inhibitors, which immediately suggested a novel combination therapy approach to preventing resistance.  Indeed, a combination of wild-type and mutant-type selective inhibitors led to resistance far less often than either drug alone.  The effects of point mutations in PfDHODH were corroborated with purified recombinant wild-type and mutant-type PfDHODH proteins, which showed the same trends in drug response as the cognate cell lines.  Comparative growth assays demonstrated that two mutant parasites grew less robustly than their wild-type parent, and the purified protein of those mutants showed a decrease in catalytic efficiency, thereby suggesting a reason for the diminished growth rate.  Co-crystallog. of PfDHODH with three inhibitors suggested that hydrophobic interactions are important for drug binding and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro56dX8r--uLVg90H21EOLACvtfcHk0lik0fnOcs0Rdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsL%252FO&md5=35ea613c4223241c76a7bc0436cf9adb</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.558353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.558353%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DL.%2BS.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DSingh%26aufirst%3DO.%2BM.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DWiegand%26aufirst%3DR.%2BC.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26atitle%3DIn%2520vitro%2520resistance%2520selections%2520for%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520inhibitors%2520give%2520mutants%2520with%2520multiple%2520point%2520mutations%2520in%2520the%2520drug-binding%2520site%2520and%2520altered%2520growth%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D17980%26epage%3D17995%26doi%3D10.1074%2Fjbc.M114.558353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guler, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span> <span> </span><span class="NLM_article-title">Atovaquone tolerance in <i>Plasmodium falciparum</i> parasites selected for high-level resistance to a dihydroorotate dehydrogenase inhibitor</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">686</span>– <span class="NLM_lpage">689</span>, <span class="refDoi"> DOI: 10.1128/AAC.02347-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1128%2FAAC.02347-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=25331708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=686-689&author=J.+L.+Gulerauthor=J.+Whiteauthor=M.+A.+Phillipsauthor=P.+K.+Rathod&title=Atovaquone+tolerance+in+Plasmodium+falciparum+parasites+selected+for+high-level+resistance+to+a+dihydroorotate+dehydrogenase+inhibitor&doi=10.1128%2FAAC.02347-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Atovaquone tolerance in Plasmodium falciparum parasites selected for high-level resistance to a dihydroorotate dehydrogenase inhibitor</span></div><div class="casAuthors">Guler, Jennifer L.; White, John; Phillips, Margaret A.; Rathod, Pradipsinh K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">686-689/1-686-689/4, 4 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Atovaquone is a component of Malarone, a widely prescribed antimalarial combination, that targets malaria respiration.  Here we show that parasites with high-level resistance to an inhibitor of dihydroorotate dehydrogenase demonstrate unexpected atovaquone tolerance.  Fortunately, the tolerance is diminished with proguanil, the second partner in Malarone.  It is important to understand such "genetic cross talk" between respiration and pyrimidine biosynthesis since many antimalarial drug development programs target these two seemingly independent pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpExQ7kAbojnLVg90H21EOLACvtfcHk0lik0fnOcs0Rdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wqtr4%253D&md5=060c47a284f0c5ce0a9101d723954f47</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1128%2FAAC.02347-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02347-14%26sid%3Dliteratum%253Aachs%26aulast%3DGuler%26aufirst%3DJ.%2BL.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26atitle%3DAtovaquone%2520tolerance%2520in%2520Plasmodium%2520falciparum%2520parasites%2520selected%2520for%2520high-level%2520resistance%2520to%2520a%2520dihydroorotate%2520dehydrogenase%2520inhibitor%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D686%26epage%3D689%26doi%3D10.1128%2FAAC.02347-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guler, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahyong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patrapuvich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gujjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRisi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span> <span> </span><span class="NLM_article-title">Asexual populations of the human malaria parasite, <i>Plasmodium falciparum</i>, use a two-step genomic strategy to acquire accurate, beneficial DNA amplifications</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e1003375</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1003375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1371%2Fjournal.ppat.1003375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=23717205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslOhtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&author=J.+L.+Gulerauthor=D.+L.+Freemanauthor=V.+Ahyongauthor=R.+Patrapuvichauthor=J.+Whiteauthor=R.+Gujjarauthor=M.+A.+Phillipsauthor=J.+DeRisiauthor=P.+K.+Rathod&title=Asexual+populations+of+the+human+malaria+parasite%2C+Plasmodium+falciparum%2C+use+a+two-step+genomic+strategy+to+acquire+accurate%2C+beneficial+DNA+amplifications&doi=10.1371%2Fjournal.ppat.1003375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Asexual populations of the human malaria parasite, Plasmodium falciparum, use a two-step genomic strategy to acquire accurate, beneficial DNA amplifications</span></div><div class="casAuthors">Guler, Jennifer L.; Freeman, Daniel L.; Ahyong, Vida; Patrapuvich, Rapatbhorn; White, John; Gujjar, Ramesh; Phillips, Margaret A.; DeRisi, Joseph; Rathod, Pradipsinh K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e1003375</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Malaria drug resistance contributes to up to a million annual deaths.  Judicious deployment of new antimalarials and vaccines could benefit from an understanding of early mol. events that promote the evolution of parasites.  Continuous in vitro challenge of Plasmodium falciparum parasites with a novel dihydroorotate dehydrogenase (DHODH) inhibitor reproducibly selected for resistant parasites.  Genome-wide anal. of independently-derived resistant clones revealed a two-step strategy to evolutionary success.  Some haploid blood-stage parasites first survive antimalarial pressure through fortuitous DNA duplications that always included the DHODH gene.  Independently-selected parasites had different sized amplification units but they were always flanked by distant A/T tracks.  Higher level amplification and resistance was attained using a second, more efficient and more accurate, mechanism for head-to-tail expansion of the founder unit.  This second homol.-based process could faithfully tune DNA copy nos. in either direction, always retaining the unique DNA amplification sequence from the original A/T-mediated duplication for that parasite line.  Pseudo-polyploidy at relevant genomic loci sets the stage for gaining addnl. mutations at the locus of interest.  Overall, we reveal a population-based genomic strategy for mutagenesis that operates in human stages of P. falciparum to efficiently yield resistance-causing genetic changes at the correct locus in a successful parasite.  Importantly, these founding events arise with precision; no other new amplifications are seen in the resistant haploid blood stage parasite.  This minimizes the need for meiotic genetic cleansing that can only occur in sexual stage development of the parasite in mosquitoes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre-k9Fm0WQKrVg90H21EOLACvtfcHk0lik0fnOcs0Rdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslOhtb8%253D&md5=9b2ad216a436922860c7f29aa5402c52</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1003375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1003375%26sid%3Dliteratum%253Aachs%26aulast%3DGuler%26aufirst%3DJ.%2BL.%26aulast%3DFreeman%26aufirst%3DD.%2BL.%26aulast%3DAhyong%26aufirst%3DV.%26aulast%3DPatrapuvich%26aufirst%3DR.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DGujjar%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DDeRisi%26aufirst%3DJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26atitle%3DAsexual%2520populations%2520of%2520the%2520human%2520malaria%2520parasite%252C%2520Plasmodium%2520falciparum%252C%2520use%2520a%2520two-step%2520genomic%2520strategy%2520to%2520acquire%2520accurate%252C%2520beneficial%2520DNA%2520amplifications%26jtitle%3DPLoS%2520Pathog.%26date%3D2013%26volume%3D9%26doi%3D10.1371%2Fjournal.ppat.1003375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Painter, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrisey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mather, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orchard, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smilkstein, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riscoe, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, M.</span></span> <span> </span><span class="NLM_article-title">Atypical molecular basis for drug resistance to mitochondrial function inhibitors in <i>Plasmodium falciparum</i></span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">e02143</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1101/2020.10.08.330241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1101%2F2020.10.08.330241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=33361312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BB3MXmvVaju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2021&pages=e02143-20&author=H.+J.+Painterauthor=J.+M.+Morriseyauthor=M.+W.+Matherauthor=L.+M.+Orchardauthor=C.+Luckauthor=M.+J.+Smilksteinauthor=M.+K.+Riscoeauthor=A.+B.+Vaidyaauthor=M.+Llinas&title=Atypical+molecular+basis+for+drug+resistance+to+mitochondrial+function+inhibitors+in+Plasmodium+falciparum&doi=10.1101%2F2020.10.08.330241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Atypical molecular basis for drug resistance to mitochondrial function inhibitors in Plasmodium falciparum</span></div><div class="casAuthors">Painter, Heather J.; Morrisey, Joanne M.; Mather, Michael W.; Orchard, Lindsey M.; Luck, Cuyler; Smilkstein, Martin J.; Riscoe, Michael K.; Vaidya, Akhil B.; Llinasa, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e02143</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The continued emergence of drug-resistant Plasmodium falciparum parasites hinders global attempts to eradicate malaria, emphasizing the need to identify new antimalarial drugs.  Attractive targets for chemotherapeutic intervention are the cytochrome (cyt) bc1 complex, which is an essential component of the mitochondrial electron transport chain (mtETC) required for ubiquinone recycling and mitochondrially localized dihydroorotate dehydrogenase (DHODH) crit. for de novo pyrimidine synthesis.  Despite the essentiality of this complex, resistance to a novel acridone class of compds. targeting cyt bc1 was readily attained, resulting in a parasite strain (SB1-A6) that was panresistant to both mtETC and DHODH inhibitors.  Here, we describe the mol. mechanism behind the resistance of the SB1-A6 parasite line, which lacks the common cyt bc1 point mutations characteristic of resistance to mtETC inhibitors.  Using Illumina whole-genome sequencing, we have identified both a copy no. variation (~ 2x) and a single-nucleotide polymorphism (C276F) assocd. with pfdhodh in SB1-A6.  We have characterized the role of both genetic lesions by mimicking the copy no. variation via episomal expression of pfdhodh and introducing the identified single nucleotide polymorphism (SNP) using CRISPR-Cas9 and assessed their contributions to drug resistance.  Although both of these genetic polymorphisms have been previously identified as contributing to both DSM-1 and atovaquone resistance, SB1-A6 represents a unique genotype in which both alterations are present in a single line, suggesting that the combination contributes to the panresistant phenotype.  This novel mechanism of resistance to mtETC inhibition has crit. implications for the development of future drugs targeting the bc1 complex or de novo pyrimidine synthesis that could help guide future antimalarial combination therapies and reduce the rapid development of drug resistance in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooNevLFxOEG7Vg90H21EOLACvtfcHk0lizzdKcx_G2qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXmvVaju7s%253D&md5=6005d1992b5507d5576cff8e26c34173</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1101%2F2020.10.08.330241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.10.08.330241%26sid%3Dliteratum%253Aachs%26aulast%3DPainter%26aufirst%3DH.%2BJ.%26aulast%3DMorrisey%26aufirst%3DJ.%2BM.%26aulast%3DMather%26aufirst%3DM.%2BW.%26aulast%3DOrchard%26aufirst%3DL.%2BM.%26aulast%3DLuck%26aufirst%3DC.%26aulast%3DSmilkstein%26aufirst%3DM.%2BJ.%26aulast%3DRiscoe%26aufirst%3DM.%2BK.%26aulast%3DVaidya%26aufirst%3DA.%2BB.%26aulast%3DLlinas%26aufirst%3DM.%26atitle%3DAtypical%2520molecular%2520basis%2520for%2520drug%2520resistance%2520to%2520mitochondrial%2520function%2520inhibitors%2520in%2520Plasmodium%2520falciparum%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2021%26volume%3D65%26spage%3De02143%26epage%3D20%26doi%3D10.1101%2F2020.10.08.330241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garuti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Doval, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargallo-Viola, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span> <span> </span><span class="NLM_article-title">Improved murine model of malaria using <i>Plasmodium falciparum</i> competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4533</span>– <span class="NLM_lpage">4536</span>, <span class="refDoi"> DOI: 10.1128/AAC.00519-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1128%2FAAC.00519-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=19596869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KkurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=4533-4536&author=M.+B.+Jimenez-Diazauthor=T.+Muletauthor=S.+Vieraauthor=V.+Gomezauthor=H.+Garutiauthor=J.+Ibanezauthor=A.+Alvarez-Dovalauthor=L.+D.+Shultzauthor=A.+Martinezauthor=D.+Gargallo-Violaauthor=I.+Angulo-Barturen&title=Improved+murine+model+of+malaria+using+Plasmodium+falciparum+competent+strains+and+non-myelodepleted+NOD-scid+IL2Rgammanull+mice+engrafted+with+human+erythrocytes&doi=10.1128%2FAAC.00519-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rγnull mice engrafted with human erythrocytes</span></div><div class="casAuthors">Jimenez-Diaz, Maria Belen; Mulet, Teresa; Viera, Sara; Gomez, Vanessa; Garuti, Helen; Ibanez, Javier; Alvarez-Doval, Angela; Shultz, Leonard D.; Martinez, Antonio; Gargallo-Viola, Domingo; Angulo-Barturen, Inigo</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4533-4536</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Murine models of Plasmodium falciparum malaria may become crucial tools in drug discovery.  Here we show that non-myelodepleted NOD-scid IL2Rγnull mice engrafted with human erythrocytes support an infectious burden up to tenfold higher than that supported by engrafted NOD-scid β2microglobulinnull mice.  The new model was validated for drug discovery and was used to assess the therapeutic efficacy of 4-pyridones, selective inhibitors of P. falciparum cytochrome bc1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoGw5NKfthdbVg90H21EOLACvtfcHk0lizzdKcx_G2qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KkurbO&md5=df25f5f7382b0b422a9e9b2137a66093</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1128%2FAAC.00519-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00519-09%26sid%3Dliteratum%253Aachs%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DMulet%26aufirst%3DT.%26aulast%3DViera%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DV.%26aulast%3DGaruti%26aufirst%3DH.%26aulast%3DIbanez%26aufirst%3DJ.%26aulast%3DAlvarez-Doval%26aufirst%3DA.%26aulast%3DShultz%26aufirst%3DL.%2BD.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DGargallo-Viola%26aufirst%3DD.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26atitle%3DImproved%2520murine%2520model%2520of%2520malaria%2520using%2520Plasmodium%2520falciparum%2520competent%2520strains%2520and%2520non-myelodepleted%2520NOD-scid%2520IL2Rgammanull%2520mice%2520engrafted%2520with%2520human%2520erythrocytes%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D4533%26epage%3D4536%26doi%3D10.1128%2FAAC.00519-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hurt, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Structure of <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase with a bound inhibitor</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1107/S0907444905042642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1107%2FS0907444905042642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=16510978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvVKnt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=312-323&author=D.+E.+Hurtauthor=J.+Widomauthor=J.+Clardy&title=Structure+of+Plasmodium+falciparum+dihydroorotate+dehydrogenase+with+a+bound+inhibitor&doi=10.1107%2FS0907444905042642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor</span></div><div class="casAuthors">Hurt, Darrell E.; Widom, Joanne; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">D62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">312-323</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Membrane-assocd. dihydroorotate dehydrogenase (DHODH) is an antimalarial therapeutic target without an effective inhibitor.  Studies on human DHODH (HsDHODH) led to a structural mechanistic model in which respiratory quinones bind in a tunnel formed by the highly variable N-terminus that leads to the FMN-binding site.  The therapeutic agents leflunomide (Arava) and brequinar sodium inhibit HsDHODH by binding in this tunnel.  Plasmodium falciparum DHODH (PfDHODH) and HsDHODH have markedly different sensitivities to the two drugs.  To understand the structural basis of this differential sensitivity and begin a structure-based drug-design cycle for PfDHODH inhibitors, the three-dimensional structure (2.4 Å, R = 20.1%) of PfDHODH bound to the active metabolite of leflunomide was detd. by x-ray crystallog.  Comparison of the structures of HsDHODH and PfDHODH reveals a completely different binding mode for the same inhibitor in these two catalytically identical enzymes and explains the previously obsd. species-specific preferential binding.  Because no effective inhibitors have been described for PfDHODH, this structure provides crit. insight for the design of potential antimalarials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmXjioMQpSWrVg90H21EOLACvtfcHk0lizzdKcx_G2qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvVKnt7w%253D&md5=5dcf54ce84e9802be9bcbafe78e5a8cb</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0907444905042642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444905042642%26sid%3Dliteratum%253Aachs%26aulast%3DHurt%26aufirst%3DD.%2BE.%26aulast%3DWidom%26aufirst%3DJ.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520with%2520a%2520bound%2520inhibitor%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2006%26volume%3D62%26spage%3D312%26epage%3D323%26doi%3D10.1107%2FS0907444905042642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farajallah, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmquist, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Malarial dihydroorotate dehydrogenase: substrate and inhibitor specificity</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">41827</span>– <span class="NLM_lpage">41834</span>, <span class="refDoi"> DOI: 10.1074/jbc.M206854200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1074%2Fjbc.M206854200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=12189151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD38XotF2gsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=41827-41834&author=J.+Baldwinauthor=A.+M.+Farajallahauthor=N.+A.+Malmquistauthor=P.+K.+Rathodauthor=M.+A.+Phillips&title=Malarial+dihydroorotate+dehydrogenase%3A+substrate+and+inhibitor+specificity&doi=10.1074%2Fjbc.M206854200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Malarial Dihydroorotate Dehydrogenase</span></div><div class="casAuthors">Baldwin, Jeffrey; Farajallah, Azizeh M.; Malmquist, Nicholas A.; Rathod, Pradipsinh K.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">41827-41834</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The malarial parasite relies on de novo pyrimidine biosynthesis to maintain its pyrimidine pools, and unlike the human host cell it is unable to scavenge preformed pyrimidines.  Dihydroorotate dehydrogenase (DHODH) catalyzes the oxidn. of dihydroorotate (DHO) to produce orotate, a key step in pyrimidine biosynthesis.  The enzyme is located in the outer membrane of the mitochondria of the malarial parasite.  To characterize the biochem. properties of the malarial enzyme, an N-terminally truncated version of P. falciparum DHODH has been expressed as a sol., active enzyme in E. coli.  The recombinant enzyme binds 0.9 molar equivalents of the cofactor FMN and it has a pH max. of 8.0 (kcat 8 s-1, Km DHO (40-80 μM)).  The substrate specificity of the ubiquinone cofactor (CoQn) that is required for the oxidn. of FMN in the second step of the reaction was also detd.  The isoprenoid (n) length of CoQn was a determinant of reaction efficiency; CoQ4, CoQ6 and decylubiquinone (CoQD) were efficiently utilized in the reaction while cofactors lacking an isoprenoid tail (CoQ0 and vitamin K3) showed decreased catalytic efficiency, resulting from a 4 to 7-fold increase in K.  Five potent inhibitors of mammalian DHODH (Redoxal, dichloroallyl lawsone or DCL, and three analogs of A77 1726) were tested as inhibitors of the malarial enzyme.  All five compds. were poor inhibitors of the malarial enzyme, with IC50 values ranging from 0.1-1.0 mM.  The IC50 values for inhibition of the malarial enzyme are 102-104-fold higher than the values reported for the mammalian enzyme, demonstrating that inhibitor binding to DHODH is species specific.  These studies provide direct evidence that the malarial DHODH active site is different from the host enzyme, and that it is an attractive target for the development of new anti-malarial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU1l-Kjs9vvbVg90H21EOLACvtfcHk0lgvxpZFIloERA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotF2gsLk%253D&md5=99d23bd543c70017914cb2fdebc779da</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M206854200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M206854200%26sid%3Dliteratum%253Aachs%26aulast%3DBaldwin%26aufirst%3DJ.%26aulast%3DFarajallah%26aufirst%3DA.%2BM.%26aulast%3DMalmquist%26aufirst%3DN.%2BA.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DMalarial%2520dihydroorotate%2520dehydrogenase%253A%2520substrate%2520and%2520inhibitor%2520specificity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D41827%26epage%3D41834%26doi%3D10.1074%2Fjbc.M206854200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine modulates species selectivity in the triazolopyrimidine class of <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5381</span>– <span class="NLM_lpage">5394</span>, <span class="refDoi"> DOI: 10.1021/jm500481t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500481t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns1Chs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5381-5394&author=X.+Dengauthor=S.+Kokkondaauthor=F.+El+Mazouniauthor=J.+Whiteauthor=J.+N.+Burrowsauthor=W.+Kaminskyauthor=S.+A.+Charmanauthor=D.+Matthewsauthor=P.+K.+Rathodauthor=M.+A.+Phillips&title=Fluorine+modulates+species+selectivity+in+the+triazolopyrimidine+class+of+Plasmodium+falciparum+dihydroorotate+dehydrogenase+inhibitors&doi=10.1021%2Fjm500481t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors</span></div><div class="casAuthors">Deng, Xiaoyi; Kokkonda, Sreekanth; El Mazouni, Farah; White, John; Burrows, Jeremy N.; Kaminsky, Werner; Charman, Susan A.; Matthews, David; Rathod, Pradipsinh K.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5381-5394</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Malaria is one of the most serious global infectious diseases.  The pyrimidine biosynthetic enzyme Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) is an important target for antimalarial chemotherapy.  The authors describe a detailed anal. of protein-ligand interactions between DHODH and a triazolopyrimidine-based inhibitor series to explore the effects of fluorine on affinity and species selectivity.  The authors show that increasing fluorination dramatically increases binding to mammalian DHODHs, leading to a loss of species selectivity.  Triazolopyrimidines bind Plasmodium and mammalian DHODHs in overlapping but distinct binding sites.  Key hydrogen-bond and stacking interactions underlying strong binding to PfDHODH are absent in the mammalian enzymes.  Increasing fluorine substitution leads to an increase in the entropic contribution to binding, suggesting that strong binding to mammalian DHODH is a consequence of an enhanced hydrophobic effect upon binding to an apolar pocket.  The authors conclude that hydrophobic interactions between fluorine and hydrocarbons provide significant binding energy to protein-ligand interactions.  The authors' studies define the requirements for species-selective binding to PfDHODH and show that the triazolopyrimidine scaffold can alternatively be tuned to inhibit human DHODH, an important target for autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFg5a-YaPFpLVg90H21EOLACvtfcHk0lgvxpZFIloERA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns1Chs74%253D&md5=abfc8df6c8510665049e65338732acf0</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm500481t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500481t%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DKaminsky%26aufirst%3DW.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DFluorine%2520modulates%2520species%2520selectivity%2520in%2520the%2520triazolopyrimidine%2520class%2520of%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5381%26epage%3D5394%26doi%3D10.1021%2Fjm500481t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malmquist, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gujjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Analysis of flavin oxidation and electron-transfer inhibition in <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2466</span>– <span class="NLM_lpage">2475</span>, <span class="refDoi"> DOI: 10.1021/bi702218c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi702218c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFamsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=2466-2475&author=N.+A.+Malmquistauthor=R.+Gujjarauthor=P.+K.+Rathodauthor=M.+A.+Phillips&title=Analysis+of+flavin+oxidation+and+electron-transfer+inhibition+in+Plasmodium+falciparum+dihydroorotate+dehydrogenase&doi=10.1021%2Fbi702218c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Flavin Oxidation and Electron-Transfer Inhibition in Plasmodium falciparum Dihydroorotate Dehydrogenase</span></div><div class="casAuthors">Malmquist, Nicholas A.; Gujjar, Ramesh; Rathod, Pradipsinh K.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2466-2475</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Plasmodium falciparum dihydroorotate dehydrogenase (pfDHODH) is a flavin-dependent mitochondrial enzyme that provides the only route to pyrimidine biosynthesis in the parasite.  Clin. significant inhibitors of human DHODH (e.g., A77 1726) bind to a pocket on the opposite face of the flavin cofactor from dihydroorotate (DHO).  This pocket demonstrates considerable sequence variability, which has allowed species-specific inhibitors of the malarial enzyme to be identified.  Ubiquinone (CoQ), the physiol. oxidant in the reaction, has been postulated to bind this site despite a lack of structural evidence.  To more clearly define the residues involved in CoQ binding and catalysis, we undertook site-directed mutagenesis of seven residues in the structurally defined A77 1726 binding site, which we term the species-selective inhibitor site.  Mutation of several of these residues (H185, F188, and F227) to Ala substantially decreased the affinity of pfDHODH-specific inhibitors (40-240-fold).  In contrast, only a modest increase in the Kmapp for CoQ was obsd., although mutation of Y528 in particular caused a substantial redn. in kcat (40-100-fold decrease).  Pre-steady-state kinetic anal. by single wavelength stopped-flow spectroscopy showed that the mutations had no effect on the rate of the DHO-dependent reductive half-reaction, but most reduced the rate of the CoQ-dependent flavin oxidn. step (3-20-fold decrease), while not significantly altering the Kdox for CoQ.  As with the mutants, inhibitors that bind this site block the CoQ-dependent oxidative half-reaction without affecting the DHO-dependent step.  These results identify residues involved in inhibitor binding and electron transfer to CoQ.  Importantly, the data provide compelling evidence that the binding sites for CoQ and species-selective site inhibitors do not overlap, and they suggest instead that inhibitors act either by blocking the electron path between flavin and CoQ or by stabilizing a conformation that excludes CoQ binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo26Ps1PRGyuLVg90H21EOLACvtfcHk0lgvxpZFIloERA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFamsbs%253D&md5=970f3a06d7e2e658aa7134e78f67c1c5</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fbi702218c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi702218c%26sid%3Dliteratum%253Aachs%26aulast%3DMalmquist%26aufirst%3DN.%2BA.%26aulast%3DGujjar%26aufirst%3DR.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DAnalysis%2520of%2520flavin%2520oxidation%2520and%2520electron-transfer%2520inhibition%2520in%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%26jtitle%3DBiochemistry%26date%3D2008%26volume%3D47%26spage%3D2466%26epage%3D2475%26doi%3D10.1021%2Fbi702218c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paguio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gligorijevic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seudieu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosar, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roepe, P. D.</span></span> <span> </span><span class="NLM_article-title">Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1810</span>, <span class="refDoi"> DOI: 10.1128/AAC.48.5.1807-1810.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1128%2FAAC.48.5.1807-1810.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=15105139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjslCks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=1807-1810&author=T.+N.+Bennettauthor=M.+Paguioauthor=B.+Gligorijevicauthor=C.+Seudieuauthor=A.+D.+Kosarauthor=E.+Davidsonauthor=P.+D.+Roepe&title=Novel%2C+rapid%2C+and+inexpensive+cell-based+quantification+of+antimalarial+drug+efficacy&doi=10.1128%2FAAC.48.5.1807-1810.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy</span></div><div class="casAuthors">Bennett, Tyler N.; Paguio, Michelle; Gligorijevic, Bojana; Seudieu, Clement; Kosar, Andrew D.; Davidson, Eugene; Roepe, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1807-1810</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We report on the development of a new SYBR Green I-based plate assay for analyzing the activities of antimalarial drugs against intraerythrocytic Plasmodium falciparum.  This assay is considerably faster, less labor-intensive, and less expensive than conventional radiotracer (e.g., [3H]hypoxanthine and [3H]ethanolamine)-based assays or P. falciparum lactate dehydrogenase activity-based assays.  The assay significantly improves the pace at which antimalarial drug discovery efforts may proceed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFhAlJNQSwX7Vg90H21EOLACvtfcHk0lgCbvtQkm8ZEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjslCks7o%253D&md5=87ee6c113aefaf11160624c8fe8c8354</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.5.1807-1810.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.5.1807-1810.2004%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DT.%2BN.%26aulast%3DPaguio%26aufirst%3DM.%26aulast%3DGligorijevic%26aufirst%3DB.%26aulast%3DSeudieu%26aufirst%3DC.%26aulast%3DKosar%26aufirst%3DA.%2BD.%26aulast%3DDavidson%26aufirst%3DE.%26aulast%3DRoepe%26aufirst%3DP.%2BD.%26atitle%3DNovel%252C%2520rapid%252C%2520and%2520inexpensive%2520cell-based%2520quantification%2520of%2520antimalarial%2520drug%2520efficacy%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D1807%26epage%3D1810%26doi%3D10.1128%2FAAC.48.5.1807-1810.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekland, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title">Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3583</span>– <span class="NLM_lpage">3593</span>, <span class="refDoi"> DOI: 10.1096/fj.11-187401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1096%2Ffj.11-187401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=21746861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSru7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=3583-3593&author=E.+H.+Eklandauthor=J.+Schneiderauthor=D.+A.+Fidock&title=Identifying+apicoplast-targeting+antimalarials+using+high-throughput+compatible+approaches&doi=10.1096%2Ffj.11-187401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches</span></div><div class="casAuthors">Ekland, Eric H.; Schneider, Jessica; Fidock, David A.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3583-3593, 10.1096/fj.11-187401</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Malarial parasites have evolved resistance to all previously used therapies, and recent evidence suggests emerging resistance to the first-line artemisinins.  To identify antimalarials with novel mechanisms of action, we have developed a high-throughput screen targeting the apicoplast organelle of Plasmodium falciparum.  Antibiotics known to interfere with this organelle, such as azithromycin, exhibit an unusual phenotype whereby the progeny of drug-treated parasites die.  Our screen exploits this phenomenon by assaying for "delayed death" compds. that exhibit a higher potency after two cycles of intraerythrocytic development compared to one.  We report a primary assay employing parasites with an integrated copy of a firefly luciferase reporter gene and a secondary flow cytometry-based assay using a nucleic acid stain paired with a mitochondrial vital dye.  Screening of the U.S. National Institutes of Health Clin. Collection identified known and novel antimalarials including kitasamycin.  This inexpensive macrolide, used for agricultural applications, exhibited an in vitro IC50 in the 50 nM range, comparable to the 30 nM activity of our control drug, azithromycin.  Imaging and pharmacol. studies confirmed kitasamycin action against the apicoplast, and in vivo activity was obsd. in a murine malaria model.  These assays provide the foundation for high-throughput campaigns to identify novel chemotypes for combination therapies to treat multidrug-resistant malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03kNR99YnDbVg90H21EOLACvtfcHk0lgCbvtQkm8ZEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSru7rI&md5=f02c6a8e25576da8537cf0e6332aa7c9</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1096%2Ffj.11-187401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.11-187401%26sid%3Dliteratum%253Aachs%26aulast%3DEkland%26aufirst%3DE.%2BH.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DIdentifying%2520apicoplast-targeting%2520antimalarials%2520using%2520high-throughput%2520compatible%2520approaches%26jtitle%3DFASEB%2520J.%26date%3D2011%26volume%3D25%26spage%3D3583%26epage%3D3593%26doi%3D10.1096%2Ffj.11-187401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udomsangpetch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieckmann, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotecka, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattabongkot, J.</span></span> <span> </span><span class="NLM_article-title">Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1128/AAC.47.1.170-173.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1128%2FAAC.47.1.170-173.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=12499187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis12gtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2003&pages=170-173&author=B.+M.+Russellauthor=R.+Udomsangpetchauthor=K.+H.+Rieckmannauthor=B.+M.+Koteckaauthor=R.+E.+Colemanauthor=J.+Sattabongkot&title=Simple+in+vitro+assay+for+determining+the+sensitivity+of+Plasmodium+vivax+isolates+from+fresh+human+blood+to+antimalarials+in+areas+where+P.+vivax+is+endemic&doi=10.1128%2FAAC.47.1.170-173.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic</span></div><div class="casAuthors">Russell, Bruce M.; Udomsangpetch, Rachanee; Rieckmann, Karl H.; Kotecka, Barbara M.; Coleman, Russell E.; Sattabongkot, Jetsumon</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">170-173</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The aim of this study was to develop a simple, field-practical, and effective in vitro method for detg. the sensitivity of fresh erythrocytic Plasmodium vivax isolates to a range of antimalarials.  The method used is a modification of the std. World Health Organization (WHO) microtest for detn. of P. falciparum drug sensitivity.  The WHO method was modified by removing leukocytes and using a growth medium supplemented with AB+ serum.  The authors successfully carried out 34 in vitro drug assays on 39 P. vivax isolates collected from the Mae Sod malaria clinic, Tak Province, Thailand.  The mean percentage of parasites maturing to schizonts (six or more merozoites) in control wells was 66.5% ± 5.9% (std. deviation).  This level of growth in the control wells enabled rapid microscopic detn. (5 min per isolate per drug) of the MICs of chloroquine, dihydroartemisinin, WR238605 (tafenoquine), and sulfadoxine.  P. vivax was relatively sensitive to chloroquine (MIC = 160 ng/mL, 50% inhibitory concn. [IC50] = 49.8 ng/mL) and dihydroartemisinin (MIC = 0.5 ng/mL, IC50 = 0.47 ng/mL).  The poor response of P. vivax to both tafenoquine (MIC = 14,000 ng/mL, IC50 = 9,739 ng/mL) and sulfadoxine (MIC = 500,000 ng/mL, IC50 = 249,000 ng/mL) was due to the slow action of these drugs and the innate resistance of P. vivax to sulfadoxine.  The in vitro assay developed in this study should be useful both for assessing the antimalarial sensitivity of P. vivax populations and for screening new antimalarials in the absence of long-term P. vivax cultures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM41fKL7ehYrVg90H21EOLACvtfcHk0lgCbvtQkm8ZEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis12gtg%253D%253D&md5=204ad517dfe4fd66f0e30553628d55ba</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1128%2FAAC.47.1.170-173.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.47.1.170-173.2003%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DB.%2BM.%26aulast%3DUdomsangpetch%26aufirst%3DR.%26aulast%3DRieckmann%26aufirst%3DK.%2BH.%26aulast%3DKotecka%26aufirst%3DB.%2BM.%26aulast%3DColeman%26aufirst%3DR.%2BE.%26aulast%3DSattabongkot%26aufirst%3DJ.%26atitle%3DSimple%2520in%2520vitro%2520assay%2520for%2520determining%2520the%2520sensitivity%2520of%2520Plasmodium%2520vivax%2520isolates%2520from%2520fresh%2520human%2520blood%2520to%2520antimalarials%2520in%2520areas%2520where%2520P.%2520vivax%2520is%2520endemic%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2003%26volume%3D47%26spage%3D170%26epage%3D173%26doi%3D10.1128%2FAAC.47.1.170-173.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonova-Koch, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luth, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottilie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukens, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata-Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanaerschot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jado, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaumeau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eribez, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taggard, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lincoln, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambachew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouillier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Open-source discovery of chemical leads for next-generation chemoprotective antimalarials</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>362</i></span>, <span class="NLM_elocation-id">eaat9446</span> <span class="refDoi"> DOI: 10.1126/science.aat9446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1126%2Fscience.aat9446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=30523084" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2018&author=Y.+Antonova-Kochauthor=S.+Meisterauthor=M.+Abrahamauthor=M.+R.+Luthauthor=S.+Ottilieauthor=A.+K.+Lukensauthor=T.+Sakata-Katoauthor=M.+Vanaerschotauthor=E.+Owenauthor=J.+C.+Jadoauthor=S.+P.+Maherauthor=J.+Callaauthor=D.+Plouffeauthor=Y.+Zhongauthor=K.+Chenauthor=V.+Chaumeauauthor=A.+J.+Conwayauthor=C.+W.+McNamaraauthor=M.+Ibanezauthor=K.+Gagaringauthor=F.+N.+Serranoauthor=K.+Eribezauthor=C.+M.+Taggardauthor=A.+L.+Cheungauthor=C.+Lincolnauthor=B.+Ambachewauthor=M.+Rouillierauthor=D.+Siegelauthor=F.+Nostenauthor=D.+E.+Kyleauthor=F.+J.+Gamoauthor=Y.+Zhouauthor=M.+Llinasauthor=D.+A.+Fidockauthor=D.+F.+Wirthauthor=J.+Burrowsauthor=B.+Campoauthor=E.+A.+Winzeler&title=Open-source+discovery+of+chemical+leads+for+next-generation+chemoprotective+antimalarials&doi=10.1126%2Fscience.aat9446"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1126%2Fscience.aat9446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aat9446%26sid%3Dliteratum%253Aachs%26aulast%3DAntonova-Koch%26aufirst%3DY.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DAbraham%26aufirst%3DM.%26aulast%3DLuth%26aufirst%3DM.%2BR.%26aulast%3DOttilie%26aufirst%3DS.%26aulast%3DLukens%26aufirst%3DA.%2BK.%26aulast%3DSakata-Kato%26aufirst%3DT.%26aulast%3DVanaerschot%26aufirst%3DM.%26aulast%3DOwen%26aufirst%3DE.%26aulast%3DJado%26aufirst%3DJ.%2BC.%26aulast%3DMaher%26aufirst%3DS.%2BP.%26aulast%3DCalla%26aufirst%3DJ.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DChaumeau%26aufirst%3DV.%26aulast%3DConway%26aufirst%3DA.%2BJ.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DIbanez%26aufirst%3DM.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DSerrano%26aufirst%3DF.%2BN.%26aulast%3DEribez%26aufirst%3DK.%26aulast%3DTaggard%26aufirst%3DC.%2BM.%26aulast%3DCheung%26aufirst%3DA.%2BL.%26aulast%3DLincoln%26aufirst%3DC.%26aulast%3DAmbachew%26aufirst%3DB.%26aulast%3DRouillier%26aufirst%3DM.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DKyle%26aufirst%3DD.%2BE.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLlinas%26aufirst%3DM.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DOpen-source%2520discovery%2520of%2520chemical%2520leads%2520for%2520next-generation%2520chemoprotective%2520antimalarials%26jtitle%3DScience%26date%3D2018%26volume%3D362%26doi%3D10.1126%2Fscience.aat9446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span>; <span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title"><i>Plasmodium falciparum</i> In Vitro Drug Resistance Selections and Gene Editing</span>.  <i>Malaria Control and Elimination</i>; <span class="NLM_series">Methods in Molecular Biology</span>; <span class="NLM_publisher-name">Humana</span>, <span class="NLM_year">2019</span>; Vol.  <span class="NLM_volume">2013</span>, pp  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">140</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1007%2F978-1-4939-9550-9_9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=123-140&author=C.+L.+Ng&author=D.+A.+Fidock&title=Malaria+Control+and+Elimination"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-9550-9_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-9550-9_9%26sid%3Dliteratum%253Aachs%26aulast%3DNg%26aufirst%3DC.%2BL.%26atitle%3DPlasmodium%2520falciparum%2520In%2520Vitro%2520Drug%2520Resistance%2520Selections%2520and%2520Gene%2520Editing%26btitle%3DMalaria%2520Control%2520and%2520Elimination%26pub%3DHumana%26date%3D2019%26volume%3D2013%26spage%3D123%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanaerschot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murithi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasaje, C. F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwomoh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spottiswoode, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendse, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicht, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siciliano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, T. R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giddins, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottilie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlemann, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niles, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of resistance-refractory <i>P. falciparum</i> kinase pkg delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">806</span>– <span class="NLM_lpage">816.e8</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2020.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2Fj.chembiol.2020.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=32359426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosF2rtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2020&pages=806-816.e8&author=M.+Vanaerschotauthor=J.+M.+Murithiauthor=C.+F.+A.+Pasajeauthor=S.+Ghidelli-Disseauthor=L.+Dwomohauthor=M.+Birdauthor=N.+Spottiswoodeauthor=N.+Mittalauthor=L.+B.+Arendseauthor=E.+S.+Owenauthor=K.+J.+Wichtauthor=G.+Sicilianoauthor=M.+Boscheauthor=T.+Yeoauthor=T.+R.+S.+Kumarauthor=S.+Mokauthor=E.+F.+Carpenterauthor=M.+J.+Giddinsauthor=O.+Sanzauthor=S.+Ottilieauthor=P.+Alanoauthor=K.+Chibaleauthor=M.+Llinasauthor=A.+C.+Uhlemannauthor=M.+Delvesauthor=A.+B.+Tobinauthor=C.+Doerigauthor=E.+A.+Winzelerauthor=M.+C.+S.+Leeauthor=J.+C.+Nilesauthor=D.+A.+Fidock&title=Inhibition+of+resistance-refractory+P.+falciparum+kinase+pkg+delivers+prophylactic%2C+blood+stage%2C+and+transmission-blocking+antiplasmodial+activity&doi=10.1016%2Fj.chembiol.2020.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Resistance-Refractory P. falciparum Kinase PKG Delivers Prophylactic, Blood Stage, and Transmission-Blocking Antiplasmodial Activity</span></div><div class="casAuthors">Vanaerschot, Manu; Murithi, James M.; Pasaje, Charisse Flerida A.; Ghidelli-Disse, Sonja; Dwomoh, Louis; Bird, Megan; Spottiswoode, Natasha; Mittal, Nimisha; Arendse, Lauren B.; Owen, Edward S.; Wicht, Kathryn J.; Siciliano, Giulia; Bosche, Markus; Yeo, Tomas; Kumar, T. R. Santha; Mok, Sachel; Carpenter, Emma F.; Giddins, Marla J.; Sanz, Olalla; Ottilie, Sabine; Alano, Pietro; Chibale, Kelly; Llinas, Manuel; Uhlemann, Anne-Catrin; Delves, Michael; Tobin, Andrew B.; Doerig, Christian; Winzeler, Elizabeth A.; Lee, Marcus C. S.; Niles, Jacquin C.; Fidock, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">806-816.e8</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The search for antimalarial chemotypes with modes of action unrelated to existing drugs has intensified with the recent failure of first-line therapies across Southeast Asia.  Here, we show that the trisubstituted imidazole MMV030084 potently inhibits hepatocyte invasion by Plasmodium sporozoites, merozoite egress from asexual blood stage schizonts, and male gamete exflagellation.  Metabolomic, phosphoproteomic, and chemoproteomic studies, validated with conditional knockdown parasites, mol. docking, and recombinant kinase assays, identified cGMP-dependent protein kinase (PKG) as the primary target of MMV030084.  PKG is known to play essential roles in Plasmodium invasion of and egress from host cells, matching MMV030084's activity profile.  Resistance selections and gene editing identified tyrosine kinase-like protein 3 as a low-level resistance mediator for PKG inhibitors, while PKG itself never mutated under pressure.  These studies highlight PKG as a resistance-refractory antimalarial target throughout the Plasmodium life cycle and promote MMV030084 as a promising Plasmodium PKG-targeting chemotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUFtSi3NQKI7Vg90H21EOLACvtfcHk0lhVJPNrgR7GiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosF2rtbk%253D&md5=fa3b9fdf545a973c1f71500f1d530ffe</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2020.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2020.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DVanaerschot%26aufirst%3DM.%26aulast%3DMurithi%26aufirst%3DJ.%2BM.%26aulast%3DPasaje%26aufirst%3DC.%2BF.%2BA.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DDwomoh%26aufirst%3DL.%26aulast%3DBird%26aufirst%3DM.%26aulast%3DSpottiswoode%26aufirst%3DN.%26aulast%3DMittal%26aufirst%3DN.%26aulast%3DArendse%26aufirst%3DL.%2BB.%26aulast%3DOwen%26aufirst%3DE.%2BS.%26aulast%3DWicht%26aufirst%3DK.%2BJ.%26aulast%3DSiciliano%26aufirst%3DG.%26aulast%3DBosche%26aufirst%3DM.%26aulast%3DYeo%26aufirst%3DT.%26aulast%3DKumar%26aufirst%3DT.%2BR.%2BS.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DCarpenter%26aufirst%3DE.%2BF.%26aulast%3DGiddins%26aufirst%3DM.%2BJ.%26aulast%3DSanz%26aufirst%3DO.%26aulast%3DOttilie%26aufirst%3DS.%26aulast%3DAlano%26aufirst%3DP.%26aulast%3DChibale%26aufirst%3DK.%26aulast%3DLlinas%26aufirst%3DM.%26aulast%3DUhlemann%26aufirst%3DA.%2BC.%26aulast%3DDelves%26aufirst%3DM.%26aulast%3DTobin%26aufirst%3DA.%2BB.%26aulast%3DDoerig%26aufirst%3DC.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DNiles%26aufirst%3DJ.%2BC.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DInhibition%2520of%2520resistance-refractory%2520P.%2520falciparum%2520kinase%2520pkg%2520delivers%2520prophylactic%252C%2520blood%2520stage%252C%2520and%2520transmission-blocking%2520antiplasmodial%2520activity%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2020%26volume%3D27%26spage%3D806%26epage%3D816.e8%26doi%3D10.1016%2Fj.chembiol.2020.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Booker, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastos, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, R. H.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerlj, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidhu, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celatka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortese, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero
Bravo, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo Llado, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garuti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papastogiannidis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janse, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duraisingh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinger, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegand, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sybertz, E.</span></span> <span> </span><span class="NLM_article-title">Novel inhibitors of <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase with anti-malarial activity in the mouse model</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">33054</span>– <span class="NLM_lpage">33064</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.162081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1074%2Fjbc.M110.162081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=20702404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12nu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=33054-33064&author=M.+L.+Bookerauthor=C.+M.+Bastosauthor=M.+L.+Kramerauthor=R.+H.+Barkerauthor=R.+Skerljauthor=A.+B.+Sidhuauthor=X.+Dengauthor=C.+Celatkaauthor=J.+F.+Corteseauthor=J.+E.+Guerrero%0ABravoauthor=K.+N.+Crespo+Lladoauthor=A.+E.+Serranoauthor=I.+Angulo-Barturenauthor=M.+B.+Jimenez-Diazauthor=S.+Vieraauthor=H.+Garutiauthor=S.+Wittlinauthor=P.+Papastogiannidisauthor=J.+W.+Linauthor=C.+J.+Janseauthor=S.+M.+Khanauthor=M.+Duraisinghauthor=B.+Colemanauthor=E.+J.+Goldsmithauthor=M.+A.+Phillipsauthor=B.+Munozauthor=D.+F.+Wirthauthor=J.+D.+Klingerauthor=R.+Wiegandauthor=E.+Sybertz&title=Novel+inhibitors+of+Plasmodium+falciparum+dihydroorotate+dehydrogenase+with+anti-malarial+activity+in+the+mouse+model&doi=10.1074%2Fjbc.M110.162081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Anti-malarial Activity in the Mouse Model</span></div><div class="casAuthors">Booker, Michael L.; Bastos, Cecilia M.; Kramer, Martin L.; Barker, Robert H., Jr.; Skerlj, Renato; Sidhu, Amar Bir; Deng, Xiao-Yi; Celatka, Cassandra; Cortese, Joseph F.; Guerrero Bravo, Jose E.; Crespo Llado, Keila N.; Serrano, Adelfa E.; Angulo-Barturen, Inigo; Jimenez-Diaz, Maria Belen; Viera, Sara; Garuti, Helen; Wittlin, Sergio; Papastogiannidis, Petros; Lin, Jing-Wen; Janse, Chris J.; Khan, Shahid M.; Duraisingh, Manoj; Coleman, Bradley; Goldsmith, Elizabeth J.; Phillips, Margaret A.; Munoz, Benito; Wirth, Dyann F.; Klinger, Jeffrey D.; Wiegand, Roger; Sybertz, Edmund</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">33054-33064</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Plasmodium falciparum, the causative agent of the most deadly form of human malaria, is unable to salvage pyrimidines and must rely on de novo biosynthesis for survival.  Dihydroorotate dehydrogenase (DHODH) catalyzes the rate-limiting step in the pyrimidine biosynthetic pathway and represents a potential target for anti-malarial therapy.  A high throughput screen and subsequent medicinal chem. program identified a series of N-alkyl-5-(1H-benzimidazol-1-yl)thiophene-2-carboxamides with low nanomolar in vitro potency against DHODH from P. falciparum, P. vivax, and P. berghei.  The compds. were selective for the parasite enzymes over human DHODH, and x-ray structural data on the analog Genz-667348, demonstrated that species selectivity could be attributed to amino acid differences in the inhibitor-binding site.  Compds. from this series demonstrated in vitro potency against the 3D7 and Dd2 strains of P. falciparum, good tolerability and oral exposure in the mouse, and ED50 values in the 4-day murine P. berghei efficacy model of 13-21 mg/kg/day with oral twice-daily dosing.  In particular, treatment with Genz-667348 at 100 mg/kg/day resulted in sterile cure.  Two recent analogs of Genz-667348 are currently undergoing pilot toxicity testing to det. suitability as clin. development candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF5On22AaGp7Vg90H21EOLACvtfcHk0lh8Qr3jA6wFYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12nu7rL&md5=c94713a85af27461b3593bff5e4aa955</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.162081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.162081%26sid%3Dliteratum%253Aachs%26aulast%3DBooker%26aufirst%3DM.%2BL.%26aulast%3DBastos%26aufirst%3DC.%2BM.%26aulast%3DKramer%26aufirst%3DM.%2BL.%26aulast%3DBarker%26aufirst%3DR.%2BH.%26aulast%3DSkerlj%26aufirst%3DR.%26aulast%3DSidhu%26aufirst%3DA.%2BB.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DCelatka%26aufirst%3DC.%26aulast%3DCortese%26aufirst%3DJ.%2BF.%26aulast%3DGuerrero%2BBravo%26aufirst%3DJ.%2BE.%26aulast%3DCrespo%2BLlado%26aufirst%3DK.%2BN.%26aulast%3DSerrano%26aufirst%3DA.%2BE.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DViera%26aufirst%3DS.%26aulast%3DGaruti%26aufirst%3DH.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DPapastogiannidis%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DJ.%2BW.%26aulast%3DJanse%26aufirst%3DC.%2BJ.%26aulast%3DKhan%26aufirst%3DS.%2BM.%26aulast%3DDuraisingh%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DB.%26aulast%3DGoldsmith%26aufirst%3DE.%2BJ.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DMunoz%26aufirst%3DB.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26aulast%3DKlinger%26aufirst%3DJ.%2BD.%26aulast%3DWiegand%26aufirst%3DR.%26aulast%3DSybertz%26aufirst%3DE.%26atitle%3DNovel%2520inhibitors%2520of%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520with%2520anti-malarial%2520activity%2520in%2520the%2520mouse%2520model%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D33054%26epage%3D33064%26doi%3D10.1074%2Fjbc.M110.162081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gujjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmquist, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">26999</span>– <span class="NLM_lpage">27009</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.028589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1074%2Fjbc.M109.028589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=19640844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCgsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=26999-27009&author=X.+Dengauthor=R.+Gujjarauthor=F.+El+Mazouniauthor=W.+Kaminskyauthor=N.+A.+Malmquistauthor=E.+J.+Goldsmithauthor=P.+K.+Rathodauthor=M.+A.+Phillips&title=Structural+plasticity+of+malaria+dihydroorotate+dehydrogenase+allows+selective+binding+of+diverse+chemical+scaffolds&doi=10.1074%2Fjbc.M109.028589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds</span></div><div class="casAuthors">Deng, Xiaoyi; Gujjar, Ramesh; El Mazouni, Farah; Kaminsky, Werner; Malmquist, Nicholas A.; Goldsmith, Elizabeth J.; Rathod, Pradipsinh K.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">26999-27009</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Malaria remains a major global health burden and current drug therapies are compromised by resistance.  Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) was validated as a new drug target through the identification of potent and selective triazolopyrimidine-based DHODH inhibitors with anti-malarial activity in vivo.  Here we report x-ray structure detn. of PfDHODH bound to three inhibitors from this series, representing the first of the enzyme bound to malaria specific inhibitors.  We demonstrate that conformational flexibility results in an unexpected binding mode identifying a new hydrophobic pocket on the enzyme.  Importantly this plasticity allows PfDHODH to bind inhibitors from different chem. classes and to accommodate inhibitor modifications during lead optimization, increasing the value of PfDHODH as a drug target.  A second discovery, based on small mol. crystallog., is that the triazolopyrimidines populate a resonance form that promotes charge sepn.  These intrinsic dipoles allow formation of energetically favorable H-bond interactions with the enzyme.  The importance of delocalization to binding affinity was supported by site-directed mutagenesis and the demonstration that triazolopyrimidine analogs that lack this intrinsic dipole are inactive.  Finally, the PfDHODH-triazolopyrimidine bound structures provide considerable new insight into species-selective inhibitor binding in this enzyme family.  Together, these studies will directly impact efforts to exploit PfDHODH for the development of anti-malarial chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRiLeJ8tO72bVg90H21EOLACvtfcHk0lh8Qr3jA6wFYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCgsL%252FM&md5=0b6b089104abafd748010651b964494e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.028589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.028589%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DGujjar%26aufirst%3DR.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DKaminsky%26aufirst%3DW.%26aulast%3DMalmquist%26aufirst%3DN.%2BA.%26aulast%3DGoldsmith%26aufirst%3DE.%2BJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DStructural%2520plasticity%2520of%2520malaria%2520dihydroorotate%2520dehydrogenase%2520allows%2520selective%2520binding%2520of%2520diverse%2520chemical%2520scaffolds%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D26999%26epage%3D27009%26doi%3D10.1074%2Fjbc.M109.028589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otwinowski, Z.</span>; <span class="NLM_string-name">Minor, W.</span></span> <span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span>. In  <i>Methods in Enzymology</i>; <span class="NLM_publisher-name">Elsevier Inc.</span>, <span class="NLM_year">1997</span>; Vol.  <span class="NLM_volume">276</span>, pp  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">326</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&pages=307-326&author=Z.+Otwinowski&author=W.+Minor&title=Methods+in+Enzymology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26btitle%3DMethods%2520in%2520Enzymology%26pub%3DElsevier%2520Inc%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R.</span></span> <span> </span><span class="NLM_article-title">Phaser crystallographic software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+McCoyauthor=R.+Grosse-Kunstleveauthor=P.+Adamsauthor=M.+Winnauthor=L.+Storoniauthor=R.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lgwLM9eNuD-KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%26aulast%3DAdams%26aufirst%3DP.%26aulast%3DWinn%26aufirst%3DM.%26aulast%3DStoroni%26aufirst%3DL.%26aulast%3DRead%26aufirst%3DR.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lgwLM9eNuD-KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkóczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P.</span></span> <span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+Adamsauthor=P.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+Chenauthor=I.+Davisauthor=N.+Echolsauthor=J.+Headdauthor=L.+Hungauthor=G.+Kapralauthor=R.+Grosse-Kunstleveauthor=A.+McCoyauthor=N.+Moriartyauthor=R.+Oeffnerauthor=R.+Readauthor=D.+Richardsonauthor=J.+Richardsonauthor=T.+Terwilligerauthor=P.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lgwLM9eNuD-KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%26aulast%3DAfonine%26aufirst%3DP.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DI.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%26aulast%3DHung%26aufirst%3DL.%26aulast%3DKapral%26aufirst%3DG.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMoriarty%26aufirst%3DN.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DD.%26aulast%3DRichardson%26aufirst%3DJ.%26aulast%3DTerwilliger%26aufirst%3DT.%26aulast%3DZwart%26aufirst%3DP.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendall, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Immormino, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span> <span> </span><span class="NLM_article-title">MolProbity: all-atom structure validation for macromolecular crystallography</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1107/S0907444909042073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1107%2FS0907444909042073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=20057044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=12-21&author=V.+B.+Chenauthor=W.+B.+Arendallauthor=J.+J.+Headdauthor=D.+A.+Keedyauthor=R.+M.+Immorminoauthor=G.+J.+Kapralauthor=L.+W.+Murrayauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+structure+validation+for+macromolecular+crystallography&doi=10.1107%2FS0907444909042073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom structure validation for macromolecular crystallography</span></div><div class="casAuthors">Chen, Vincent B.; Arendall, W. Bryan, III; Headd, Jeffrey J.; Keedy, Daniel A.; Immormino, Robert M.; Kapral, Gary J.; Murray, Laura W.; Richardson, Jane S.; Richardson, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-21</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">MolProbity is a structure-validation web service that provides broad-spectrum solidly based evaluation of model quality at both the global and local levels for both proteins and nucleic acids.  It relies heavily on the power and sensitivity provided by optimized hydrogen placement and all-atom contact anal., complemented by updated versions of covalent-geometry and torsion-angle criteria.  Some of the local corrections can be performed automatically in MolProbity and all of the diagnostics are presented in chart and graphical forms that help guide manual rebuilding.  X-ray crystallog. provides a wealth of biol. important mol. data in the form of at. three-dimensional structures of proteins, nucleic acids and increasingly large complexes in multiple forms and states.  Advances in automation, in everything from crystn. to data collection to phasing to model building to refinement, have made solving a structure using crystallog. easier than ever.  However, despite these improvements, local errors that can affect biol. interpretation are widespread at low resoln. and even high-resoln. structures nearly all contain at least a few local errors such as Ramachandran outliers, flipped branched protein side chains and incorrect sugar puckers.  It is crit. both for the crystallographer and for the end user that there are easy and reliable methods to diagnose and correct these sorts of errors in structures.  MolProbity is the authors' contribution to helping solve this problem and this article reviews its general capabilities, reports on recent enhancements and usage, and presents evidence that the resulting improvements are now beneficially affecting the global database.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIjgsh59dO-7Vg90H21EOLACvtfcHk0lih8uh3aprPEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D&md5=b5fc7574f43f01dd6e43c3663ca4f779</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1107%2FS0907444909042073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909042073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DKeedy%26aufirst%3DD.%2BA.%26aulast%3DImmormino%26aufirst%3DR.%2BM.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520structure%2520validation%2520for%2520macromolecular%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D12%26epage%3D21%26doi%3D10.1107%2FS0907444909042073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coteron, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Las Heras, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjalanagara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudra, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morizzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazaga, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span> <span> </span><span class="NLM_article-title">Tetrahydro-2-naphthyl and 2-indanyl triazolopyrimidines targeting <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase display potent and selective antimalarial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5416</span>– <span class="NLM_lpage">5431</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00275</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00275" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFShtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5416-5431&author=S.+Kokkondaauthor=X.+Dengauthor=K.+L.+Whiteauthor=J.+M.+Coteronauthor=M.+Marcoauthor=L.+de+Las+Herasauthor=J.+Whiteauthor=F.+El+Mazouniauthor=D.+R.+Tomchickauthor=K.+Manjalanagaraauthor=K.+R.+Rudraauthor=G.+Chenauthor=J.+Morizziauthor=E.+Ryanauthor=W.+Kaminskyauthor=D.+Leroyauthor=M.+S.+Martinez-Martinezauthor=M.+B.+Jimenez-Diazauthor=S.+F.+Bazagaauthor=I.+Angulo-Barturenauthor=D.+Watersonauthor=J.+N.+Burrowsauthor=D.+Matthewsauthor=S.+A.+Charmanauthor=M.+A.+Phillipsauthor=P.+K.+Rathod&title=Tetrahydro-2-naphthyl+and+2-indanyl+triazolopyrimidines+targeting+Plasmodium+falciparum+dihydroorotate+dehydrogenase+display+potent+and+selective+antimalarial+activity&doi=10.1021%2Facs.jmedchem.6b00275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity</span></div><div class="casAuthors">Kokkonda, Sreekanth; Deng, Xiaoyi; White, Karen L.; Coteron, Jose M.; Marco, Maria; de las Heras, Laura; White, John; El Mazouni, Farah; Tomchick, Diana R.; Manjalanagara, Krishne; Rudra, Kakali Rani; Chen, Gong; Morizzi, Julia; Ryan, Eileen; Kaminsky, Werner; Leroy, Didier; Martinez-Martinez, Maria Santos; Jimenez-Diaz, Maria Belen; Bazaga, Santiago Ferrer; Angulo-Barturen, Inigo; Waterson, David; Burrows, Jeremy N.; Matthews, Dave; Charman, Susan A.; Phillips, Margaret A.; Rathod, Pradipsinh K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5416-5431</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Malaria persists as one of the most devastating global infectious diseases.  The pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) has been identified as a new malaria drug target, and a triazolopyrimidine-based DHODH inhibitor 1 (DSM265) is in clin. development.  We sought to identify compds. with higher potency against Plasmodium DHODH while showing greater selectivity toward animal DHODHs.  Herein we describe a series of novel triazolopyrimidines wherein the p-SF5-aniline was replaced with substituted 1,2,3,4-tetrahydro-2-naphthyl or 2-indanyl amines.  These compds. showed strong species selectivity, and several highly potent tetrahydro-2-naphthyl derivs. were identified.  Compds. with halogen substitutions displayed sustained plasma levels after oral dosing in rodents leading to efficacy in the P. falciparum SCID mouse malaria model.  These data suggest that tetrahydro-2-naphthyl derivs. have the potential to be efficacious for the treatment of malaria, but due to higher metabolic clearance than 1, they most likely would need to be part of a multidose regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYADLrWooUCbVg90H21EOLACvtfcHk0lih8uh3aprPEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFShtro%253D&md5=4a6dcc57849971a406f0f6338a53fecb</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00275%26sid%3Dliteratum%253Aachs%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DCoteron%26aufirst%3DJ.%2BM.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3Dde%2BLas%2BHeras%26aufirst%3DL.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DTomchick%26aufirst%3DD.%2BR.%26aulast%3DManjalanagara%26aufirst%3DK.%26aulast%3DRudra%26aufirst%3DK.%2BR.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DRyan%26aufirst%3DE.%26aulast%3DKaminsky%26aufirst%3DW.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DMartinez-Martinez%26aufirst%3DM.%2BS.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DBazaga%26aufirst%3DS.%2BF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26atitle%3DTetrahydro-2-naphthyl%2520and%25202-indanyl%2520triazolopyrimidines%2520targeting%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520display%2520potent%2520and%2520selective%2520antimalarial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5416%26epage%3D5431%26doi%3D10.1021%2Facs.jmedchem.6b00275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harder, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">Advancing Drug Discovery through Enhanced Free Energy Calculations</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1632</span>, <span class="refDoi"> DOI: 10.1021/acs.accounts.7b00083</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.accounts.7b00083" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSiur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2017&pages=1625-1632&author=R.+Abelauthor=L.+Wangauthor=E.+D.+Harderauthor=B.+J.+Berneauthor=R.+A.+Friesner&title=Advancing+Drug+Discovery+through+Enhanced+Free+Energy+Calculations&doi=10.1021%2Facs.accounts.7b00083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing Drug Discovery through Enhanced Free Energy Calculations</span></div><div class="casAuthors">Abel, Robert; Wang, Lingle; Harder, Edward D.; Berne, B. J.; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1625-1632</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A principal goal of drug discovery project is to design mols. that can tightly and selectively bind to the target protein receptor.  Accurate prediction of protein-ligand binding free energies is therefore of central importance in computational chem. and computer aided drug design.  Multiple recent improvements in computing power, classical force field accuracy, enhanced sampling methods, and simulation setup, have enabled accurate and reliable calcns. of protein-ligands binding free energies, and position free energy calcns. to play a guiding role in small mol. drug discovery.  In this accounts, the authors outline the relevant methodol. advances, including the REST2 (Replica Exchange with Solute Temperting) enhanced sampling, the incorporation of REST2 sampling with conventional FEP (Free Energy Perturbation) through FEP/REST, the OPLS3 force fields, and the advanced simulation set up that constitute the authors' FEP+ approach, followed by the presentation of extensive comparisons with expt., demonstrating sufficient accuracy in potency prediction (better than 1 kcal/mol) to substantially impact lead optimization campaigns.  The limitations of the current FEP+ implementation and best practices in drug discovery applications are also discussed followed by the future methodol. development plans to address those limitations.  The authors then report results from a recent drug discovery project, in which several thousand FEP+ calcns. were successfully deployed to simultaneously optimize potency, selectivity, and soly., illustrating the power of the approach to solve challenging drug design problems.  The capabilities of free energy calcns. to accurately predict potency and selectivity have led to the advance of ongoing drug discovery projects, in challenging situations where alternative approaches would have great difficulties.  The ability to effectively carry out projects evaluating tens of thousands, or hundreds of thousands, of proposed drug candidates, is potentially transformative in enabling hard to drug targets to be attacked, and in facilitating the development of superior compds., in various dimensions, for a wide range of targets.  More effective integration of FEP+ calcns. into the drug discovery process will ensure that the results are deployed in an optimal fashion for yielding the best possible compds. entering the clinic; this is where the greatest payoff is in the exploitation of computer driven design capabilities.  A key conclusion from the work described is the surprisingly robust and accurate results that are attainable within the conventional classical simulation, fixed charge paradigm.  No doubt there are individual cases that would benefit from a more sophisticated energy model or dynamical treatment, and properties other than protein-ligand binding energies may be more sensitive to these approxns.  The authors conclude that an inflection point in the ability of MD simulations to impact drug discovery has now been attained, due to the confluence of hardware and software development along with the formulation of "good enough" theor. methods and models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_VeCPmDRlf7Vg90H21EOLACvtfcHk0lih8uh3aprPEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSiur3K&md5=46d07ee6f6f129a126f0fde40a62ffe2</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.accounts.7b00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.accounts.7b00083%26sid%3Dliteratum%253Aachs%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHarder%26aufirst%3DE.%2BD.%26aulast%3DBerne%26aufirst%3DB.%2BJ.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DAdvancing%2520Drug%2520Discovery%2520through%2520Enhanced%2520Free%2520Energy%2520Calculations%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2017%26volume%3D50%26spage%3D1625%26epage%3D1632%26doi%3D10.1021%2Facs.accounts.7b00083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">Role of the active-site solvent in the thermodynamics of factor Xa ligand binding</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">2817</span>– <span class="NLM_lpage">2831</span>, <span class="refDoi"> DOI: 10.1021/ja0771033</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0771033" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvFWgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=2817-2831&author=R.+Abelauthor=T.+Youngauthor=R.+Faridauthor=B.+J.+Berneauthor=R.+A.+Friesner&title=Role+of+the+active-site+solvent+in+the+thermodynamics+of+factor+Xa+ligand+binding&doi=10.1021%2Fja0771033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the Active-Site Solvent in the Thermodynamics of Factor Xa Ligand Binding</span></div><div class="casAuthors">Abel, Robert; Young, Tom; Farid, Ramy; Berne, Bruce J.; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2817-2831</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Understanding the underlying physics of the binding of small-mol. ligands to protein active sites is a key objective of computational chem. and biol.  It is widely believed that displacement of water mols. from the active site by the ligand is a principal (if not the dominant) source of binding free energy.  Although continuum theories of hydration are routinely used to describe the contributions of the solvent to the binding affinity of the complex, it is still an unsettled question as to whether or not these continuum solvation theories describe the underlying mol. physics with sufficient accuracy to reliably rank the binding affinities of a set of ligands for a given protein.  Here we develop a novel, computationally efficient descriptor of the contribution of the solvent to the binding free energy of a small mol. and its assocd. receptor that captures the effects of the ligand displacing the solvent from the protein active site with at. detail.  This descriptor quant. predicts (R2 = 0.81) the binding free energy differences between congeneric ligand pairs for the test system factor Xa, elucidates phys. properties of the active site solvent that appear to be missing in most continuum theories of hydration, and identifies several features of the hydration of the factor Xa active site relevant to the structure-activity relationship of its inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS42r59nNXH7Vg90H21EOLACvtfcHk0lgeHRilHJo_fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvFWgurk%253D&md5=8eefe76547a82bccaea38f2c84e6cd5f</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fja0771033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0771033%26sid%3Dliteratum%253Aachs%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DT.%26aulast%3DFarid%26aufirst%3DR.%26aulast%3DBerne%26aufirst%3DB.%2BJ.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DRole%2520of%2520the%2520active-site%2520solvent%2520in%2520the%2520thermodynamics%2520of%2520factor%2520Xa%2520ligand%2520binding%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D2817%26epage%3D2831%26doi%3D10.1021%2Fja0771033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">808</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1073/pnas.0610202104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1073%2Fpnas.0610202104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=17204562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVegtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=808-813&author=T.+Youngauthor=R.+Abelauthor=B.+Kimauthor=B.+J.+Berneauthor=R.+A.+Friesner&title=Motifs+for+molecular+recognition+exploiting+hydrophobic+enclosure+in+protein-ligand+binding&doi=10.1073%2Fpnas.0610202104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding</span></div><div class="casAuthors">Young, Tom; Abel, Robert; Kim, Byungchan; Berne, Bruce J.; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">808-813</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The thermodn. properties and phase behavior of water in confined regions can vary significantly from that obsd. in the bulk.  This is particularly true for systems in which the confinement is on the mol.-length scale.  In this study, we use mol. dynamics simulations and a powerful solvent anal. technique based on inhomogeneous solvation theory to investigate the properties of water mols. that solvate the confined regions of protein active sites.  Our simulations and anal. indicate that the solvation of protein active sites that are characterized by hydrophobic enclosure and correlated hydrogen bonds induce atypical entropic and enthalpic penalties of hydration.  These penalties apparently stabilize the protein-ligand complex with respect to the independently solvated ligand and protein, which leads to enhanced binding affinities.  Our anal. elucidates several challenging cases, including the super affinity of the streptavidin-biotin system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWumQ61YTqILVg90H21EOLACvtfcHk0lgeHRilHJo_fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVegtr4%253D&md5=1109e3f48670cd910885f7fd527eb880</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0610202104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0610202104%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DT.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DB.%26aulast%3DBerne%26aufirst%3DB.%2BJ.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DMotifs%2520for%2520molecular%2520recognition%2520exploiting%2520hydrophobic%2520enclosure%2520in%2520protein-ligand%2520binding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D808%26epage%3D813%26doi%3D10.1073%2Fpnas.0610202104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubert-Brohman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerome, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annabhimoju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyles, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">WScore: a flexible and accurate treatment of explicit water molecules in ligand-receptor docking</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4364</span>– <span class="NLM_lpage">4384</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00131</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00131" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Gqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4364-4384&author=R.+B.+Murphyauthor=M.+P.+Repaskyauthor=J.+R.+Greenwoodauthor=I.+Tubert-Brohmanauthor=S.+Jeromeauthor=R.+Annabhimojuauthor=N.+A.+Boylesauthor=C.+D.+Schmitzauthor=R.+Abelauthor=R.+Faridauthor=R.+A.+Friesner&title=WScore%3A+a+flexible+and+accurate+treatment+of+explicit+water+molecules+in+ligand-receptor+docking&doi=10.1021%2Facs.jmedchem.6b00131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">WScore: A Flexible and Accurate Treatment of Explicit Water Molecules in Ligand-Receptor Docking</span></div><div class="casAuthors">Murphy, Robert B.; Repasky, Matthew P.; Greenwood, Jeremy R.; Tubert-Brohman, Ivan; Jerome, Steven; Annabhimoju, Ramakrishna; Boyles, Nicholas A.; Schmitz, Christopher D.; Abel, Robert; Farid, Ramy; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4364-4384</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have developed a new methodol. for protein-ligand docking and scoring, WScore, incorporating a flexible description of explicit water mols.  The locations and thermodn. of the waters are derived from a WaterMap mol. dynamics simulation.  The water structure is employed to provide an at. level description of ligand and protein desolvation.  WScore also contains a detailed model for localized ligand and protein strain energy and integrates an MM-GBSA scoring component with these terms to assess delocalized strain of the complex.  Ensemble docking is used to take into account induced fit effects on the receptor conformation, and protein reorganization free energies are assigned via fitting to exptl. data.  The performance of the method is evaluated for pose prediction, rank ordering of self-docked complexes, and enrichment in virtual screening, using a large data set of PDB complexes and compared with the Glide SP and Glide XP models; significant improvements are obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonCVRxlzARBbVg90H21EOLACvtfcHk0lgeHRilHJo_fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Gqtr4%253D&md5=dcb2bc320a1bffe608531c4aa01666bb</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00131%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DTubert-Brohman%26aufirst%3DI.%26aulast%3DJerome%26aufirst%3DS.%26aulast%3DAnnabhimoju%26aufirst%3DR.%26aulast%3DBoyles%26aufirst%3DN.%2BA.%26aulast%3DSchmitz%26aufirst%3DC.%2BD.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFarid%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DWScore%253A%2520a%2520flexible%2520and%2520accurate%2520treatment%2520of%2520explicit%2520water%2520molecules%2520in%2520ligand-receptor%2520docking%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4364%26epage%3D4384%26doi%3D10.1021%2Facs.jmedchem.6b00131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubert-Brohman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">Docking performance of the glide program as evaluated on the Astex and DUD datasets: a complete set of glide SP results and selected results for a new scoring function integrating WaterMap and glide</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1007/s10822-012-9575-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1007%2Fs10822-012-9575-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=22576241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVelu7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=787-799&author=M.+P.+Repaskyauthor=R.+B.+Murphyauthor=J.+L.+Banksauthor=J.+R.+Greenwoodauthor=I.+Tubert-Brohmanauthor=S.+Bhatauthor=R.+A.+Friesner&title=Docking+performance+of+the+glide+program+as+evaluated+on+the+Astex+and+DUD+datasets%3A+a+complete+set+of+glide+SP+results+and+selected+results+for+a+new+scoring+function+integrating+WaterMap+and+glide&doi=10.1007%2Fs10822-012-9575-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Docking performance of the glide program as evaluated on the Astex and DUD datasets: a complete set of glide SP results and selected results for a new scoring function integrating WaterMap and glide</span></div><div class="casAuthors">Repasky, Matthew P.; Murphy, Robert B.; Banks, Jay L.; Greenwood, Jeremy R.; Tubert-Brohman, Ivan; Bhat, Sathesh; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">787-799</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Glide SP mode enrichment results for two prepns. of the DUD dataset and native ligand docking RMSDs for two prepns. of the Astex dataset are presented.  Following a best-practices prepn. scheme, an av. RMSD of 1.140 Å for native ligand docking with Glide SP is computed.  Following the same best-practices prepn. scheme for the DUD dataset an av. area under the ROC curve (AUC) of 0.80 and av. early enrichment via the ROC (0.1 %) metric of 0.12 were obsd. 74 and 56 % of the 39 best-practices prepd. targets showed AUC over 0.7 and 0.8, resp.  Av. AUC was greater than 0.7 for all best-practices protein families demonstrating consistent enrichment performance across a broad range of proteins and ligand chemotypes.  In both Astex and DUD datasets, docking performance is significantly improved employing a best-practices prepn. scheme over using minimally-prepd. structures from the PDB.  Enrichment results for WScore, a new scoring function and sampling methodol. integrating WaterMap and Glide, are presented for four DUD targets, hivrt, hsp90, cdk2, and fxa.  WScore performance in early enrichment is consistently strong and all systems examd. show AUC > 0.9 and superior early enrichment to DUD best-practices Glide SP results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHCCMQs2lTrLVg90H21EOLACvtfcHk0li8C1yFjU4D2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVelu7nI&md5=9eb2c6feb24177c81bb5c06b947893fc</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2Fs10822-012-9575-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-012-9575-9%26sid%3Dliteratum%253Aachs%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DTubert-Brohman%26aufirst%3DI.%26aulast%3DBhat%26aufirst%3DS.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DDocking%2520performance%2520of%2520the%2520glide%2520program%2520as%2520evaluated%2520on%2520the%2520Astex%2520and%2520DUD%2520datasets%253A%2520a%2520complete%2520set%2520of%2520glide%2520SP%2520results%2520and%2520selected%2520results%2520for%2520a%2520new%2520scoring%2520function%2520integrating%2520WaterMap%2520and%2520glide%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2012%26volume%3D26%26spage%3D787%26epage%3D799%26doi%3D10.1007%2Fs10822-012-9575-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span> <span> </span><span class="NLM_article-title">Accurate calculation of relative binding free energies between ligands with different net charges</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">6346</span>– <span class="NLM_lpage">6358</span>, <span class="refDoi"> DOI: 10.1021/acs.jctc.8b00825</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.8b00825" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVarurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=6346-6358&author=W.+Chenauthor=Y.+Dengauthor=E.+Russellauthor=Y.+Wuauthor=R.+Abelauthor=L.+Wang&title=Accurate+calculation+of+relative+binding+free+energies+between+ligands+with+different+net+charges&doi=10.1021%2Facs.jctc.8b00825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Accurate Calculation of Relative Binding Free Energies between Ligands with Different Net Charges</span></div><div class="casAuthors">Chen, Wei; Deng, Yuqing; Russell, Ellery; Wu, Yujie; Abel, Robert; Wang, Lingle</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6346-6358</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In drug discovery programs, modifications that change the net charge of the ligands are often considered to improve the binding potency and soly., or to address other ADME/Tox problems.  Accurate calcn. of the binding free-energy changes assocd. with charge-changing perturbations remains a great challenge of central importance in computational drug discovery.  The finite size effects assocd. with periodic boundary condition and lattice summation employed in common mol. dynamics simulations introduce artifacts in the electrostatic potential energy calcns., which need to be carefully handled for accurate free-energy calcns. between systems with different net charges.  The salts in the buffer soln. of exptl. binding affinity assays also have a strong effect on the binding free energies between charged species, which further complicates the modeling of the charge-changing perturbations.  Here, we extend our free-energy perturbation (FEP) algorithm, which has been extensively applied to many drug discovery programs for relative binding free-energy calcns. between ligands with the same net charge (charge-conserving perturbation), to enable charge-changing perturbations.  We have investigated three different approaches to correct the finite size effects and tested them on 10 protein targets and 31 charge-changing perturbations.  We have found that all three methods are able to successfully eliminate the box-size dependence of calcd. binding free energies assocd. with brute force FEP.  Moreover, inclusion of salts matching the ionic strength of exptl. buffer soln. significantly improves the calcd. binding free energies.  For ligands with multiple possible protonation states, we applied the pKa correction to account for the ionization equil. of the ligands and the results are significantly improved.  Finally, the calcd. binding free energies from these methods agree with each other, and also agree well with the exptl. results.  The root-mean-square error between the calcd. binding free energies and exptl. data is 1.1 kcal/mol, which is on par with the accuracy of charge-conserving perturbations.  We anticipate that the outstanding accuracy demonstrated here across a broad range of target classes may have significant implications for drug discovery projects, where charge-changing modifications must be considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPN1nqGGUR9rVg90H21EOLACvtfcHk0li8C1yFjU4D2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVarurjL&md5=bc0f54d3836f2525f90164e4b6b38b25</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.8b00825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.8b00825%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DRussell%26aufirst%3DE.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26atitle%3DAccurate%2520calculation%2520of%2520relative%2520binding%2520free%2520energies%2520between%2520ligands%2520with%2520different%2520net%2520charges%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2018%26volume%3D14%26spage%3D6346%26epage%3D6358%26doi%3D10.1021%2Facs.jctc.8b00825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinbrecher, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlgren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krilov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, W.</span></span> <span> </span><span class="NLM_article-title">Accurate binding free energy predictions in fragment optimization</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2411</span>– <span class="NLM_lpage">2420</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.5b00538</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.5b00538" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1eku7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=2411-2420&author=T.+B.+Steinbrecherauthor=M.+Dahlgrenauthor=D.+Cappelauthor=T.+Linauthor=L.+Wangauthor=G.+Krilovauthor=R.+Abelauthor=R.+Friesnerauthor=W.+Sherman&title=Accurate+binding+free+energy+predictions+in+fragment+optimization&doi=10.1021%2Facs.jcim.5b00538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Accurate Binding Free Energy Predictions in Fragment Optimization</span></div><div class="casAuthors">Steinbrecher, Thomas B.; Dahlgren, Markus; Cappel, Daniel; Lin, Teng; Wang, Lingle; Krilov, Goran; Abel, Robert; Friesner, Richard; Sherman, Woody</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2411-2420</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Predicting protein-ligand binding free energies is a central aim of computational structure-based drug design (SBDD) - improved accuracy in binding free energy predictions could significantly reduce costs and accelerate project timelines in lead discovery and optimization.  The recent development and validation of advanced free energy calcn. methods represents a major step toward this goal.  Accurately predicting the relative binding free energy changes of modifications to ligands is esp. valuable in the field of fragment-based drug design, since fragment screens tend to deliver initial hits of low binding affinity that require multiple rounds of synthesis to gain the requisite potency for a project.  A free energy perturbation protocol, FEP+, which was previously validated on drug-like lead compds., is suitable for the calcn. of relative binding strengths of fragment-sized compds. as well.  The authors study several pharmaceutically relevant targets with a total of >90 fragments and find that the FEP+ methodol., which uses explicit solvent mol. dynamics and physics-based scoring with no parameters adjusted, can accurately predict relative fragment binding affinities.  The calcns. afford R2-values on av. >0.5 compared to exptl. data and root-mean-square errors of ∼1.1 kcal/mol overall, demonstrating significant improvements over the docking and MM-GBSA methods tested in this work and indicating that FEP+ has the requisite predictive power to impact fragment-based affinity optimization projects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2OM1KfoQE4bVg90H21EOLACvtfcHk0li8C1yFjU4D2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1eku7%252FI&md5=116425dcc073d2907c888555e9061aa8</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.5b00538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.5b00538%26sid%3Dliteratum%253Aachs%26aulast%3DSteinbrecher%26aufirst%3DT.%2BB.%26aulast%3DDahlgren%26aufirst%3DM.%26aulast%3DCappel%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DKrilov%26aufirst%3DG.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%26aulast%3DSherman%26aufirst%3DW.%26atitle%3DAccurate%2520binding%2520free%2520energy%2520predictions%2520in%2520fragment%2520optimization%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26spage%3D2411%26epage%3D2420%26doi%3D10.1021%2Facs.jcim.5b00538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, B. J.</span></span> <span> </span><span class="NLM_article-title">Efficient sampling of puckering states of monosaccharides through replica exchange with solute tempering and bond softening</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>149</i></span>, <span class="NLM_elocation-id">072306</span> <span class="refDoi"> DOI: 10.1063/1.5024389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1063%2F1.5024389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=30134707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptlamtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2018&author=L.+Wangauthor=B.+J.+Berne&title=Efficient+sampling+of+puckering+states+of+monosaccharides+through+replica+exchange+with+solute+tempering+and+bond+softening&doi=10.1063%2F1.5024389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient sampling of puckering states of monosaccharides through replica exchange with solute tempering and bond softening</span></div><div class="casAuthors">Wang, Lingle; Berne, B. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">072306/1-072306/10</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    
            (<span class="NLM_cas:orgname">American Institute of Physics</span>)
        </div><div class="casAbstract">A mol.-level understanding of the structure, dynamics, and reactivity of carbohydrates is fundamental to the understanding of a range of key biol. processes.  The six-membered pyranose ring, a central component of biol. monosaccharides and carbohydrates, has many different puckering conformations, and the conformational free energy landscape of these biol. important monosaccharides remains elusive.  The puckering conformations of monosaccharides are sepd. by high energy barriers, which pose a great challenge for the complete sampling of these important conformations and accurate modeling of these systems.  While metadynamics or umbrella sampling methods have been used to study the conformational space of monosaccharides, these methods might be difficult to generalize to other complex ring systems with more degrees of freedom.  In this paper, the authors introduce a new enhanced sampling method for the rapid sampling over high energy barriers that combines the previously developed enhanced sampling method REST (replica exchange with solute tempering) with a bond softening (BOS) scheme that makes a chem. bond in the ring weaker as one ascends the replica ladder.  The authors call this new method replica exchange with solute tempering and bond softening (REST/BOS).  The authors demonstrate the superior sampling efficiency of REST/BOS over other commonly used enhanced sampling methods, including temp. replica exchange method and REST.  The conformational free energy landscape of four biol. important monosaccharides, namely, α-glucose, β-glucose, β-mannose, and β-xylose, is studied using REST/BOS, and results are compared with previous exptl. and theor. studies.  (c) 2018 American Institute of Physics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy9zuewHjbd7Vg90H21EOLACvtfcHk0ljOYwWFzPnJ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptlamtrk%253D&md5=a5ad01e503c19c821c92c97da477583f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1063%2F1.5024389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.5024389%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBerne%26aufirst%3DB.%2BJ.%26atitle%3DEfficient%2520sampling%2520of%2520puckering%2520states%2520of%2520monosaccharides%2520through%2520replica%2520exchange%2520with%2520solute%2520tempering%2520and%2520bond%2520softening%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D2018%26volume%3D149%26doi%3D10.1063%2F1.5024389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damm, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maple, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reboul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupyan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlgren, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaus, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerutti, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krilov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">OPLS3: A force field providing broad coverage of drug-like small molecules and proteins</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1021/acs.jctc.5b00864</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.5b00864" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=281-296&author=E.+Harderauthor=W.+Dammauthor=J.+Mapleauthor=C.+Wuauthor=M.+Reboulauthor=J.+Y.+Xiangauthor=L.+Wangauthor=D.+Lupyanauthor=M.+K.+Dahlgrenauthor=J.+L.+Knightauthor=J.+W.+Kausauthor=D.+S.+Ceruttiauthor=G.+Krilovauthor=W.+L.+Jorgensenauthor=R.+Abelauthor=R.+A.+Friesner&title=OPLS3%3A+A+force+field+providing+broad+coverage+of+drug-like+small+molecules+and+proteins&doi=10.1021%2Facs.jctc.5b00864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins</span></div><div class="casAuthors">Harder, Edward; Damm, Wolfgang; Maple, Jon; Wu, Chuanjie; Reboul, Mark; Xiang, Jin Yu; Wang, Lingle; Lupyan, Dmitry; Dahlgren, Markus K.; Knight, Jennifer L.; Kaus, Joseph W.; Cerutti, David S.; Krilov, Goran; Jorgensen, William L.; Abel, Robert; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">281-296</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The parametrization and validation of the OPLS3 force field for small mols. and proteins are reported.  Enhancements with respect to the previous version (OPLS2.1) include the addn. of off-atom charge sites to represent halogen bonding and aryl nitrogen lone pairs as well as a complete refit of peptide dihedral parameters to better model the native structure of proteins.  To adequately cover medicinal chem. space, OPLS3 employs over an order of magnitude more ref. data and assocd. parameter types relative to other commonly used small mol. force fields (e.g., MMFF and OPLS_2005).  As a consequence, OPLS3 achieves a high level of accuracy across performance benchmarks that assess small mol. conformational propensities and solvation.  The newly fitted peptide dihedrals lead to significant improvements in the representation of secondary structure elements in simulated peptides and native structure stability over a no. of proteins.  Together, the improvements made to both the small mol. and protein force field lead to a high level of accuracy in predicting protein-ligand binding measured over a wide range of targets and ligands (less than 1 kcal/mol RMS error) representing a 30% improvement over earlier variants of the OPLS force field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY_jrOhcBRgrVg90H21EOLACvtfcHk0ljOYwWFzPnJ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE&md5=42663f8cfa84b80a67132bbb13b9b7ce</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.5b00864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.5b00864%26sid%3Dliteratum%253Aachs%26aulast%3DHarder%26aufirst%3DE.%26aulast%3DDamm%26aufirst%3DW.%26aulast%3DMaple%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DReboul%26aufirst%3DM.%26aulast%3DXiang%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLupyan%26aufirst%3DD.%26aulast%3DDahlgren%26aufirst%3DM.%2BK.%26aulast%3DKnight%26aufirst%3DJ.%2BL.%26aulast%3DKaus%26aufirst%3DJ.%2BW.%26aulast%3DCerutti%26aufirst%3DD.%2BS.%26aulast%3DKrilov%26aufirst%3DG.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DOPLS3%253A%2520A%2520force%2520field%2520providing%2520broad%2520coverage%2520of%2520drug-like%2520small%2520molecules%2520and%2520proteins%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2016%26volume%3D12%26spage%3D281%26epage%3D296%26doi%3D10.1021%2Facs.jctc.5b00864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damm, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reboul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlgren, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harder, E. D.</span></span> <span> </span><span class="NLM_article-title">OPLS3e: Extending force field coverage for drug-like small molecules</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1863</span>– <span class="NLM_lpage">1874</span>, <span class="refDoi"> DOI: 10.1021/acs.jctc.8b01026</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.8b01026" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFKlsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=1863-1874&author=K.+Roosauthor=C.+Wuauthor=W.+Dammauthor=M.+Reboulauthor=J.+M.+Stevensonauthor=C.+Luauthor=M.+K.+Dahlgrenauthor=S.+Mondalauthor=W.+Chenauthor=L.+Wangauthor=R.+Abelauthor=R.+A.+Friesnerauthor=E.+D.+Harder&title=OPLS3e%3A+Extending+force+field+coverage+for+drug-like+small+molecules&doi=10.1021%2Facs.jctc.8b01026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">OPLS3e: Extending Force Field Coverage for Drug-Like Small Molecules</span></div><div class="casAuthors">Roos, Katarina; Wu, Chuanjie; Damm, Wolfgang; Reboul, Mark; Stevenson, James M.; Lu, Chao; Dahlgren, Markus K.; Mondal, Sayan; Chen, Wei; Wang, Lingle; Abel, Robert; Friesner, Richard A.; Harder, Edward D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1863-1874</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Building upon the OPLS3 force field we report on an enhanced model, OPLS3e, that further extends its coverage of medicinally relevant chem. space by addressing limitations in chemotype transferability.  OPLS3e accomplishes this by incorporating new parameter types that recognize moieties with greater chem. specificity and integrating an on-the-fly parametrization approach to the assignment of partial charges.  As a consequence, OPLS3e leads to greater accuracy against performance benchmarks that assess small mol. conformational propensities, solvation, and protein-ligand binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWzxgqjMQBLLVg90H21EOLACvtfcHk0ljOYwWFzPnJ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFKlsrs%253D&md5=5c91547ddc0c975f9616cfba56a5454f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.8b01026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.8b01026%26sid%3Dliteratum%253Aachs%26aulast%3DRoos%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DDamm%26aufirst%3DW.%26aulast%3DReboul%26aufirst%3DM.%26aulast%3DStevenson%26aufirst%3DJ.%2BM.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DDahlgren%26aufirst%3DM.%2BK.%26aulast%3DMondal%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DHarder%26aufirst%3DE.%2BD.%26atitle%3DOPLS3e%253A%2520Extending%2520force%2520field%2520coverage%2520for%2520drug-like%2520small%2520molecules%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2019%26volume%3D15%26spage%3D1863%26epage%3D1874%26doi%3D10.1021%2Facs.jctc.8b01026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krilov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupyan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlgren, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbrecher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damm, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murcko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span> <span> </span><span class="NLM_article-title">Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">2695</span>– <span class="NLM_lpage">2703</span>, <span class="refDoi"> DOI: 10.1021/ja512751q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja512751q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2iuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=2695-2703&author=L.+Wangauthor=Y.+Wuauthor=Y.+Dengauthor=B.+Kimauthor=L.+Pierceauthor=G.+Krilovauthor=D.+Lupyanauthor=S.+Robinsonauthor=M.+K.+Dahlgrenauthor=J.+Greenwoodauthor=D.+L.+Romeroauthor=C.+Masseauthor=J.+L.+Knightauthor=T.+Steinbrecherauthor=T.+Beumingauthor=W.+Dammauthor=E.+Harderauthor=W.+Shermanauthor=M.+Brewerauthor=R.+Westerauthor=M.+Murckoauthor=L.+Fryeauthor=R.+Faridauthor=T.+Linauthor=D.+L.+Mobleyauthor=W.+L.+Jorgensenauthor=B.+J.+Berneauthor=R.+A.+Friesnerauthor=R.+Abel&title=Accurate+and+reliable+prediction+of+relative+ligand+binding+potency+in+prospective+drug+discovery+by+way+of+a+modern+free-energy+calculation+protocol+and+force+field&doi=10.1021%2Fja512751q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Accurate and Reliable Prediction of Relative Ligand Binding Potency in Prospective Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and Force Field</span></div><div class="casAuthors">Wang, Lingle; Wu, Yujie; Deng, Yuqing; Kim, Byungchan; Pierce, Levi; Krilov, Goran; Lupyan, Dmitry; Robinson, Shaughnessy; Dahlgren, Markus K.; Greenwood, Jeremy; Romero, Donna L.; Masse, Craig; Knight, Jennifer L.; Steinbrecher, Thomas; Beuming, Thijs; Damm, Wolfgang; Harder, Ed; Sherman, Woody; Brewer, Mark; Wester, Ron; Murcko, Mark; Frye, Leah; Farid, Ramy; Lin, Teng; Mobley, David L.; Jorgensen, William L.; Berne, Bruce J.; Friesner, Richard A.; Abel, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2695-2703</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing tight-binding ligands is a primary objective of small-mol. drug discovery.  Over the past few decades, free-energy calcns. have benefited from improved force fields and sampling algorithms, as well as the advent of low-cost parallel computing.  However, it has proven to be challenging to reliably achieve the level of accuracy that would be needed to guide lead optimization (∼5× in binding affinity) for a wide range of ligands and protein targets.  Not surprisingly, widespread com. application of free-energy simulations has been limited due to the lack of large-scale validation coupled with the tech. challenges traditionally assocd. with running these types of calcns.  Here, we report an approach that achieves an unprecedented level of accuracy across a broad range of target classes and ligands, with retrospective results encompassing 200 ligands and a wide variety of chem. perturbations, many of which involve significant changes in ligand chem. structures.  In addn., we have applied the method in prospective drug discovery projects and found a significant improvement in the quality of the compds. synthesized that have been predicted to be potent.  Compds. predicted to be potent by this approach have a substantial redn. in false positives relative to compds. synthesized on the basis of other computational or medicinal chem. approaches.  Furthermore, the results are consistent with those obtained from our retrospective studies, demonstrating the robustness and broad range of applicability of this approach, which can be used to drive decisions in lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor9UtXEyLPpLVg90H21EOLACvtfcHk0lgUX2YL4nUwbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2iuro%253D&md5=37a4f4a6c085f47ed531342643b6c33b</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fja512751q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja512751q%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DB.%26aulast%3DPierce%26aufirst%3DL.%26aulast%3DKrilov%26aufirst%3DG.%26aulast%3DLupyan%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DDahlgren%26aufirst%3DM.%2BK.%26aulast%3DGreenwood%26aufirst%3DJ.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DMasse%26aufirst%3DC.%26aulast%3DKnight%26aufirst%3DJ.%2BL.%26aulast%3DSteinbrecher%26aufirst%3DT.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DDamm%26aufirst%3DW.%26aulast%3DHarder%26aufirst%3DE.%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DBrewer%26aufirst%3DM.%26aulast%3DWester%26aufirst%3DR.%26aulast%3DMurcko%26aufirst%3DM.%26aulast%3DFrye%26aufirst%3DL.%26aulast%3DFarid%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DMobley%26aufirst%3DD.%2BL.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DBerne%26aufirst%3DB.%2BJ.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DAbel%26aufirst%3DR.%26atitle%3DAccurate%2520and%2520reliable%2520prediction%2520of%2520relative%2520ligand%2520binding%2520potency%2520in%2520prospective%2520drug%2520discovery%2520by%2520way%2520of%2520a%2520modern%2520free-energy%2520calculation%2520protocol%2520and%2520force%2520field%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D2695%26epage%3D2703%26doi%3D10.1021%2Fja512751q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, K. J.</span>; <span class="NLM_string-name">Chow, E.</span>; <span class="NLM_string-name">Xu, H.</span>; <span class="NLM_string-name">Dror, R. O.</span>; <span class="NLM_string-name">Eastwood, M. P.</span>; <span class="NLM_string-name">Gregersen, B. A.</span>; <span class="NLM_string-name">Klepeis, J. L.</span>; <span class="NLM_string-name">Kolossvary, I.</span>; <span class="NLM_string-name">Moraes, M. A.</span>; <span class="NLM_string-name">Sacerdoti, F. D.</span>; <span class="NLM_string-name">Salmon, J. K.</span>; <span class="NLM_string-name">Shan, Y.</span>; <span class="NLM_string-name">Shaw, D. E.</span></span> In  <i>Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters</i>, Proceedings of the ACM/IEEE Conference on Supercomputing (SC06), <span class="NLM_publisher-loc">Tampa, Florida</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=K.+J.+Bowers&author=E.+Chow&author=H.+Xu&author=R.+O.+Dror&author=M.+P.+Eastwood&author=B.+A.+Gregersen&author=J.+L.+Klepeis&author=I.+Kolossvary&author=M.+A.+Moraes&author=F.+D.+Sacerdoti&author=J.+K.+Salmon&author=Y.+Shan&author=D.+E.+Shaw&title=Scalable+Algorithms+for+Molecular+Dynamics+Simulations+on+Commodity+Clusters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBowers%26aufirst%3DK.%2BJ.%26jtitle%3DScalable%2520Algorithms%2520for%2520Molecular%2520Dynamics%2520Simulations%2520on%2520Commodity%2520Clusters%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez-Díaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garuti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargallo-Viola, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span> <span> </span><span class="NLM_article-title">Quantitative measurement of Plasmodium-infected erythrocytes in murine models of malaria by flow cytometry using bidimensional assessment of SYTO-16 fluorescence</span>. <i>Cytometry, Part A</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>75A</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1002/cyto.a.20647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1002%2Fcyto.a.20647" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75A&publication_year=2009&pages=225-235&author=M.+B.+Jim%C3%A9nez-D%C3%ADazauthor=T.+Muletauthor=V.+Gomezauthor=S.+Vieraauthor=A.+Alvarezauthor=H.+Garutiauthor=Y.+Vazquezauthor=A.+Fernandezauthor=J.+Ibanezauthor=M.+Jimenezauthor=D.+Gargallo-Violaauthor=I.+Angulo-Barturen&title=Quantitative+measurement+of+Plasmodium-infected+erythrocytes+in+murine+models+of+malaria+by+flow+cytometry+using+bidimensional+assessment+of+SYTO-16+fluorescence&doi=10.1002%2Fcyto.a.20647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fcyto.a.20647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcyto.a.20647%26sid%3Dliteratum%253Aachs%26aulast%3DJim%25C3%25A9nez-D%25C3%25ADaz%26aufirst%3DM.%2BB.%26aulast%3DMulet%26aufirst%3DT.%26aulast%3DGomez%26aufirst%3DV.%26aulast%3DViera%26aufirst%3DS.%26aulast%3DAlvarez%26aufirst%3DA.%26aulast%3DGaruti%26aufirst%3DH.%26aulast%3DVazquez%26aufirst%3DY.%26aulast%3DFernandez%26aufirst%3DA.%26aulast%3DIbanez%26aufirst%3DJ.%26aulast%3DJimenez%26aufirst%3DM.%26aulast%3DGargallo-Viola%26aufirst%3DD.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26atitle%3DQuantitative%2520measurement%2520of%2520Plasmodium-infected%2520erythrocytes%2520in%2520murine%2520models%2520of%2520malaria%2520by%2520flow%2520cytometry%2520using%2520bidimensional%2520assessment%2520of%2520SYTO-16%2520fluorescence%26jtitle%3DCytometry%252C%2520Part%2520A%26date%3D2009%26volume%3D75A%26spage%3D225%26epage%3D235%26doi%3D10.1002%2Fcyto.a.20647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez-Díaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magan-Marchal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garuti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Gil, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraile, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Bustos, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span> <span> </span><span class="NLM_article-title">A new in vivo screening paradigm to accelerate antimalarial drug discovery</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e66967</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0066967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=10.1371%2Fjournal.pone.0066967" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=23825598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2qtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=M.+B.+Jim%C3%A9nez-D%C3%ADazauthor=S.+Vieraauthor=J.+Ibanezauthor=T.+Muletauthor=N.+Magan-Marchalauthor=H.+Garutiauthor=V.+Gomezauthor=L.+Cortes-Gilauthor=A.+Martinezauthor=S.+Ferrerauthor=M.+T.+Fraileauthor=F.+Calderonauthor=E.+Fernandezauthor=L.+D.+Shultzauthor=D.+Leroyauthor=D.+M.+Wilsonauthor=J.+F.+Garcia-Bustosauthor=F.+J.+Gamoauthor=I.+Angulo-Barturen&title=A+new+in+vivo+screening+paradigm+to+accelerate+antimalarial+drug+discovery&doi=10.1371%2Fjournal.pone.0066967"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">A new in vivo screening paradigm to accelerate antimalarial drug discovery</span></div><div class="casAuthors">Jimenez-Diaz, Maria Belen; Viera, Sara; Ibanez, Javier; Mulet, Teresa; Magan-Marchal, Noemi; Garuti, Helen; Gomez, Vanessa; Cortes-Gil, Lorena; Martiez, Antonio; Ferrer, Santiago; Fraile, Maria Teresa; Caldero, Felix; Fernandez, Esther; Shultz, Leonard D.; Leroy, Didier; Wilson, David M.; Garcia-Bustos, Jose Francisco; Gamo, Francisco Javier; Angulo-Barturen, Inigo</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e66967</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The emergence of resistance to available antimalarials requires the urgent development of new medicines.  The recent disclosure of several thousand compds. active in vitro against the erythrocyte stage of Plasmodium falciparum has been a major breakthrough, though converting these hits into new medicines challenges current strategies.  A new in vivo screening concept was evaluated as a strategy to increase the speed and efficiency of drug discovery projects in malaria.  The new in vivo screening concept was developed based on human disease parameters, i.e. parasitemia in the peripheral blood of patients on hospital admission and parasite redn. ratio (PRR), which were allometrically down-scaled into P. berghei-infected mice.  Mice with an initial parasitemia (P0) of 1.5% were treated orally for two consecutive days and parasitemia measured 24 h after the second dose.  The assay was optimized for detection of compds. able to stop parasite replication (PRR = 1) or induce parasite clearance (PRR >1) with statistical power >99% using only two mice per exptl. group.  In the P. berghei in vivo screening assay, the PRR of a set of eleven antimalarials with different mechanisms of action correlated with human-equiv. data.  Subsequently, 590 compds. from the Tres Cantos Antimalarial Set with activity in vitro against P. falciparum were tested at 50 mg/kg (orally) in an assay format that allowed the evaluation of hundreds of compds. per mo.  The rate of compds. with detectable efficacy was 11.2% and about one third of active compds. showed in vivo efficacy comparable with the most potent antimalarials used clin.  High-throughput, high-content in vivo screening could rapidly select new compds., dramatically speeding up the discovery of new antimalarial medicines.  A global multilateral collaborative project aimed at screening the significant chem. diversity within the antimalarial in vitro hits described in the literature is a feasible task.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXKzdqs7h8k7Vg90H21EOLACvtfcHk0lh_vrWlg1ROYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2qtbjJ&md5=35d24cc0f14f22be828f36714752ac78</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0066967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0066967%26sid%3Dliteratum%253Aachs%26aulast%3DJim%25C3%25A9nez-D%25C3%25ADaz%26aufirst%3DM.%2BB.%26aulast%3DViera%26aufirst%3DS.%26aulast%3DIbanez%26aufirst%3DJ.%26aulast%3DMulet%26aufirst%3DT.%26aulast%3DMagan-Marchal%26aufirst%3DN.%26aulast%3DGaruti%26aufirst%3DH.%26aulast%3DGomez%26aufirst%3DV.%26aulast%3DCortes-Gil%26aufirst%3DL.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DFraile%26aufirst%3DM.%2BT.%26aulast%3DCalderon%26aufirst%3DF.%26aulast%3DFernandez%26aufirst%3DE.%26aulast%3DShultz%26aufirst%3DL.%2BD.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DGarcia-Bustos%26aufirst%3DJ.%2BF.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26atitle%3DA%2520new%2520in%2520vivo%2520screening%2520paradigm%2520to%2520accelerate%2520antimalarial%2520drug%2520discovery%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0066967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaieda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mototani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanzaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terauchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchikawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kori, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel, highly potent, and selective matrix metalloproteinase (mmp)-13 inhibitors with a 1,2,4-triazol-3-yl moiety as a zinc binding group using a structure-based design approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2nurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=608-626&author=H.+Naraauthor=A.+Kaiedaauthor=K.+Satoauthor=T.+Naitoauthor=H.+Mototaniauthor=H.+Okiauthor=Y.+Yamamotoauthor=H.+Kunoauthor=T.+Santouauthor=N.+Kanzakiauthor=J.+Terauchiauthor=O.+Uchikawaauthor=M.+Kori&title=Discovery+of+novel%2C+highly+potent%2C+and+selective+matrix+metalloproteinase+%28mmp%29-13+inhibitors+with+a+1%2C2%2C4-triazol-3-yl+moiety+as+a+zinc+binding+group+using+a+structure-based+design+approach&doi=10.1021%2Facs.jmedchem.6b01007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach</span></div><div class="casAuthors">Nara, Hiroshi; Kaieda, Akira; Sato, Kenjiro; Naito, Takako; Mototani, Hideyuki; Oki, Hideyuki; Yamamoto, Yoshio; Kuno, Haruhiko; Santou, Takashi; Kanzaki, Naoyuki; Terauchi, Jun; Uchikawa, Osamu; Kori, Masakuni</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">608-626</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of a superposition study of x-ray crystal structures of complexes of quinazoline deriv. I and triazole deriv. II with matrix metalloproteinase (MMP)-13 catalytic domain, a novel series of fused pyrimidine compds. which possess a 1,2,4-triazol-3-yl group as a zinc binding group (ZBG) was designed.  Among the herein described and evaluated compds., 5-(3-fluorophenyl)-4-oxo-N-{3-[2-[1H-1,2,4-triazol-3-yloxy]ethoxy]benzyl}-3,4-dihydrothieno[2,3-d]-pyrimidine-2-carboxamide (31f) exhibited excellent potency for MMP-13 (IC50 = 0.036 nM) and selectivities (greater than 1500-fold) over other MMPs (MMP-1, 2, 3, 7, 8, 9, 10, and 14) and tumor necrosis factor-α converting enzyme (TACE).  Furthermore, the inhibitor was shown to protect bovine nasal cartilage explants against degrdn. induced by interleukin-1 and oncostatin M.  In this article, the authors report the discovery of extremely potent, highly selective, and orally bioavailable fused pyrimidine derivs. that possess a 1,2,4-triazol-3-yl group as a novel ZBG for selective MMP-13 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ8Gj9214XrLVg90H21EOLACvtfcHk0lh_vrWlg1ROYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2nurvE&md5=2965566ea0c85df0bc5f806ef5650627</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01007%26sid%3Dliteratum%253Aachs%26aulast%3DNara%26aufirst%3DH.%26aulast%3DKaieda%26aufirst%3DA.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DNaito%26aufirst%3DT.%26aulast%3DMototani%26aufirst%3DH.%26aulast%3DOki%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKuno%26aufirst%3DH.%26aulast%3DSantou%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DTerauchi%26aufirst%3DJ.%26aulast%3DUchikawa%26aufirst%3DO.%26aulast%3DKori%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520novel%252C%2520highly%2520potent%252C%2520and%2520selective%2520matrix%2520metalloproteinase%2520%2528mmp%2529-13%2520inhibitors%2520with%2520a%25201%252C2%252C4-triazol-3-yl%2520moiety%2520as%2520a%2520zinc%2520binding%2520group%2520using%2520a%2520structure-based%2520design%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D608%26epage%3D626%26doi%3D10.1021%2Facs.jmedchem.6b01007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanaya, N. I. T.</span>; <span class="NLM_string-name">Muto, R.</span>; <span class="NLM_string-name">Watanabe, T.</span>; <span class="NLM_string-name">Ochiai, Y.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1-(3-pyridyl or 3-pyridazinyl)-5-heterocyclylpyrazole derivatives as platelet aggregation inhibitors</span>. <span class="NLM_patent">WO2006014005 20060209A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=N.+I.+T.+Kanaya&author=R.+Muto&author=T.+Watanabe&author=Y.+Ochiai&title=Preparation+of+1-%283-pyridyl+or+3-pyridazinyl%29-5-heterocyclylpyrazole+derivatives+as+platelet+aggregation+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKanaya%26aufirst%3DN.%2BI.%2BT.%26atitle%3DPreparation%2520of%25201-%25283-pyridyl%2520or%25203-pyridazinyl%2529-5-heterocyclylpyrazole%2520derivatives%2520as%2520platelet%2520aggregation%2520inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KZ4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KZ4','PDB','7KZ4'); return false;">PDB: 7KZ4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LOK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LOK','PDB','7LOK'); return false;">PDB: 7LOK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYY','PDB','7KYY'); return false;">PDB: 7KYY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYV','PDB','7KYV'); return false;">PDB: 7KYV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RX0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RX0','PDB','4RX0'); return false;">PDB: 4RX0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I65" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I65','PDB','3I65'); return false;">PDB: 3I65</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VTN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VTN','PDB','6VTN'); return false;">PDB: 6VTN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VTY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VTY','PDB','6VTY'); return false;">PDB: 6VTY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O8A" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3O8A','PDB','3O8A'); return false;">PDB: 3O8A</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYK','PDB','7KYK'); return false;">PDB: 7KYK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KZY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KZY','PDB','7KZY'); return false;">PDB: 7KZY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LO1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LO1','PDB','7LO1'); return false;">PDB: 7LO1</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i371"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00173">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_33542"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00173?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00173</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Supporting information methods; supporting information Schemes S1–S10; FEP+ predictions for previously reported<a class="ref ref20" href="javascript:void(0);">(20)</a> Pyrrole-based DHODH inhibitors (Table S1); FEP+ predictions for compounds reported in this publication (Table S2); X-ray data collection and refinement statistics for the structures of PfDHODH bound to select pyrroles (Table S3); <i>In vitro</i> metabolism and kinetic solubility data (Table S4A); Caco-2 permeability studies for carboxamide pyrazoles <b>47</b> and <b>84</b> (Table S4B); mouse PK data after (IV) and oral (PO) dosing for <b>84</b>, <b>88</b>, and <b>154</b> (Table S5); species selectivity and preliminary safety analysis (Table S6); summary of <i>P. falciparum</i> EC<sub>50</sub> values on Dd2 wild-type and DHODH inhibitor (<b>1</b> and <b>26</b>) selected resistant cell lines (Table S7A); steady-state kinetic analysis of recombinant C276F and C276Y mutant <i>Pf</i>DHODH versus <b>26</b> and <b>79</b> (Table S7B); EC<sub>50</sub> determination of 79-resistant Dd2 and 3D7 parasites (Table S8A); list of genes included in the CNV region of <b>79</b> Dd2-resistant parasites (Table S8B); list of genes included in the CNV region of <b>79</b> 3D7-resistant parasites (Table S8C); metrics of whole-genome sequencing of <b>79</b>-resistant parasites and their parental lines (Table S8D); SCID mouse efficacy studies on <b>33</b> and <b>36</b> (conducted at Swiss TPH) (Table S9); SCID mouse efficacy studies on <b>1, 79</b> and <b>99</b> (conducted at TAD) (Table S10); comparison of exposure for SCID mouse versus normal mouse (Table S11); electron density for <i>Pf</i>DHODH coinhibitor structures showing the Fo-Fc map of the bound inhibitors prior to refinement (Figure S1); X-ray structures of <i>Pf</i>DHODH (green) bound to <b>56</b>, <b>86, 81</b>, and <b>18</b> (Figure S2); FEP+ predictions correlated to measured IC<sub>50</sub> values on <i>Pf</i>DHODH (Figure S3); mouse and rat PK profiles for <b>36</b> showing concentrations <b>33</b> as a metabolite (Figure S4); Uganda <i>P. falciparum</i> field isolates. Scatterplots and Spearman Correlations (Figure S5); tolerance phenotype of C276F and C276Y mutant clones versus <b>26</b> and <b>79</b> (Figure S6); SCID mouse efficacy study of <b>33</b> and <b>36</b> showing parasitemia and drug blood concentrations over time (Figure S7); SCID mouse efficacy study of <b>99</b> showing parasitemia and drug blood concentrations over time (Figure S8); NMR and LCMS data for key compounds (<b>26</b>, <b>33</b>, <b>36</b>, <b>79</b>, and <b>99</b>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular Formula Strings Excel Spread sheet (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_001.pdf">jm1c00173_si_001.pdf (4.59 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00173/suppl_file/jm1c00173_si_002.csv">jm1c00173_si_002.csv (12.41 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last"><b>PDB coordinates</b>. The coordinates for the structure of <i>Pf</i>DHODH bound to <b>18, 56, 127, 79, 81, 86</b>, and <b>47</b> have been submitted to the Protein Data Bank (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYK">7KYK</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYV">7KYV</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KYY">7KYY</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KZ4">7KZ4</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KZY">7KZY</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LO1">7LO1</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LOK">7LOK</a>, respectively). The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00173&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-9%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00173%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00173" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a4c284f3f1975","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
